PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FRANK, E; WINKLEBY, MA; FORTMANN, SP; ROCKHILL, B; FARQUHAR, JW				FRANK, E; WINKLEBY, MA; FORTMANN, SP; ROCKHILL, B; FARQUHAR, JW			IMPROVED CHOLESTEROL-RELATED KNOWLEDGE AND BEHAVIOR AND PLASMA-CHOLESTEROL LEVELS IN ADULTS DURING THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STANFORD 5-CITY PROJECT; COMMUNITY-HEALTH EDUCATION; 2 NATIONAL SURVEYS; HEART-DISEASE; RISK-FACTORS; SOCIAL-CLASS; PERSPECTIVE; PHYSICIAN	Objectives.-To determine whether cholesterol-related knowledge and behavior and plasma cholesterol levels were stable until the inception of large-scale national interventions in the middle to late 1980s, whether they subsequently improved, and whether these levels varied by subgroups. Design, Setting, and Participants.-Data were collected from 4173 adults aged 25 through 74 years in the two control cities (San Luis Obispo and Modesto, Calif) of the Stanford Five-City Project. Five separate, community-based surveys were conducted in 1979-1980, 1981-1982, 1983-1984, 1985-1986, and 1989-1990. Results.-Cholesterol-related knowledge and behavior and plasma cholesterol levels improved (P=.0001) in both cities after the early 1980s. Those who were more educated, female, older, or nonsmokers had significantly higher knowledge and behavior scores, and those who were younger, more educated, or normotensive had significantly lower plasma cholesterol levels. Conclusion.-Improvements in this population's cholesterol-related knowledge and behavior and plasma cholesterol levels began in 1985-1986, suggesting that the extensive cholesterol interventions that began in the middle 1980s in the United States created positive cholesterol-related changes at the community level.	STANFORD UNIV, SCH MED, STANFORD CTR RES DIS PREVENT, 1000 WELCH RD, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT MED, PALO ALTO, CA 94304 USA	Stanford University; Stanford University				Frank, Erica/0000-0001-7159-5417	NHLBI NIH HHS [5T32-HL-07034, 1R01-HL-21906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034, R01HL021906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; MCKIBBEN Bill, 1989, END NATURE; NIKNIAN M, 1991, AM J PUBLIC HEALTH, V81, P203, DOI 10.2105/AJPH.81.2.205; Olien C. N., 1983, MASS COMMUNICATION R, V4, P455; RIFKIN J, 1992, BEEF RISE FALL CATTL; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; TAYLOR CB, 1991, AM J EPIDEMIOL, V134, P235, DOI 10.1093/oxfordjournals.aje.a116077; WILLIAMS F, 1977, J COMMUN, V27, P95, DOI 10.1111/j.1460-2466.1977.tb01803.x; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; WINKLEBY MA, IN PRESS HISP J BEHA; 1974, US DHEW NIH75628 PUB, P1	23	44	44	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1566	1572		10.1001/jama.268.12.1566	http://dx.doi.org/10.1001/jama.268.12.1566			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518111				2022-12-24	WOS:A1992JN25600027
J	VINCENT, GM; TIMOTHY, KW; LEPPERT, M; KEATING, M				VINCENT, GM; TIMOTHY, KW; LEPPERT, M; KEATING, M			THE SPECTRUM OF SYMPTOMS AND QT INTERVALS IN CARRIERS OF THE GENE FOR THE LONG-QT SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-RATE; LINKAGE	Background. The familial long-QT syndrome is characterized by a prolonged QT interval on the electro-cardiogram, ventricular arrhythmias, and sudden death. It is not certain, however, that the length of the QT interval is a sensitive or a specific diagnostic criterion. Recently, we identified genetic markers on chromosome 11 that distinguished between carriers and noncarriers of the gene for the long-QT syndrome in three families. In this study, we compared the clinical features of carriers and noncarriers and assessed the diagnostic accuracy of the QT interval. Methods. We obtained medical histories and electro-cardiograms from 199 family members. OT intervals corrected for heart rate (QT(c)) were determined independently by two blinded investigators. Carriers of the long-QT gene (83 subjects) and noncarriers (1 16 subjects) were distinguished by genetic-linkage analysis. Results. Fifty-two of the carriers of the long-QT gene (63 percent) had a history of syncope, whereas four 5 percent had a history of aborted sudden death. The QT(c) intervals of the gene carriers ranged from 0.41 to 0.59 second (mean, 0.49). By contrast, the QT(c) intervals of the noncarriers ranged from 0.38 to 0.47 second (mean, 0.42). On average, carriers of the gene for the long-QT syndrome had longer QT(c) intervals than noncarriers, but there was substantial overlap (in 126 of the 199 subjects, or 63 percent). The use of a QT(c) interval above 0.44 second as a diagnostic criterion resulted in 22 misclassifications among the 199 family members (11 percent). QT(c) intervals of 0.47 second or longer in males and 0.48 second or longer in females were completely predictive but resulted in false negative diagnoses in 40 percent of the males and 20 percent of the females. Conclusions. In families affected by the long-QT syndrome, measurement of the QT(c) interval may not permit an accurate diagnosis. DNA markers make it possible to make a genetic diagnosis in some families, but not all gene carriers have symptoms.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	VINCENT, GM (corresponding author), UNIV UTAH,LATTER DAY ST HOSP,HLTH SCI CTR,DEPT MED,SALT LAKE CITY,UT 84143, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Hashiba K, 1987, Heart Vessels Suppl, V2, P47; HASHIBA K, 1978, JPN CIRC J, V42, P1133, DOI 10.1253/jcj.42.1133; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LIPMAN BS, 1973, CLIN SCALAR ELECTROC, P670; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; MOSS AJ, 1987, JAMA-J AM MED ASSOC, V257, P487; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; VINCENT GM, 1991, AM J CARDIOL, V68, P498, DOI 10.1016/0002-9149(91)90785-J; VINCENT GM, 1986, AM HEART J, V112, P61, DOI 10.1016/0002-8703(86)90678-2; VINCENT GM, 1989, CLIN ASPECTS VENTRIC, P411; VINCENT GM, 1989, CIRCULATION S2, V80, P654; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEINSTEIN MV, 1980, CLIN DECISION ANAL, P79; WEINTRAUB RG, 1990, J AM COLL CARDIOL, V16, P674, DOI 10.1016/0735-1097(90)90359-W; Zar JH., 1999, BIOSTAT ANAL	23	487	498	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					846	852		10.1056/NEJM199209173271204	http://dx.doi.org/10.1056/NEJM199209173271204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508244	Bronze			2022-12-24	WOS:A1992JN12000004
J	ROTHE, M; PEHL, M; TAUBERT, H; JACKLE, H				ROTHE, M; PEHL, M; TAUBERT, H; JACKLE, H			LOSS OF GENE-FUNCTION THROUGH RAPID MITOTIC-CYCLES IN THE DROSOPHILA EMBRYO	NATURE			English	Article							PATTERN; KNIRPS; SEGMENTATION; SUPERFAMILY	THE early developmental period in Drosophila is characterized by rapid mitotic divisions, when the body pattern becomes organized by a cascade of segmentation gene activity1,2. During this process localized expression of the gap gene knirps (kni) is required to establish abdomen segmentation3,4. The knirps-related gene (knrl) encodes a kni-homologous nuclear hormone receptor-like protein5,6 and shares the spatial patterns of kni expression. The two genes differ with respect to the size of their transcription units; kni contains 1 kilobase and knrl 19 kilobases of intron sequences. The consequence of this difference in intron size is that knrl cannot substitute for kni segmentation function, although it gains this ability when expressed from an intronless transgene. Here we show that the length of mitotic cycles provides a physiological barrier to transcript size, and is therefore a significant factor in controlling developmental gene activity during short 'phenocritical' periods. The required coordination of cycle length and gene size provides severe constraints towards the evolution of rapid development.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,W-3400 GOTTINGEN,GERMANY	Max Planck Society								AKAM M, 1987, DEVELOPMENT, V101, P1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; EDGAR B, 1990, CELL, V52, P469; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1989, DEVELOPMENT, V107, P1; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1985, THESIS U TUBINGEN; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1989, DEVELOPMENT, V107, P133; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	20	120	121	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					156	159		10.1038/359156a0	http://dx.doi.org/10.1038/359156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522901				2022-12-24	WOS:A1992JM49400056
J	STEWART, CL; KASPAR, P; BRUNET, LJ; BHATT, H; GADI, I; KONTGEN, F; ABBONDANZO, SJ				STEWART, CL; KASPAR, P; BRUNET, LJ; BHATT, H; GADI, I; KONTGEN, F; ABBONDANZO, SJ			BLASTOCYST IMPLANTATION DEPENDS ON MATERNAL EXPRESSION OF LEUKEMIA INHIBITORY FACTOR	NATURE			English	Article							COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; PREIMPLANTATION DEVELOPMENT; PROTO-ONCOGENE; FACTOR LIF; MURINE; GENES; CSF-1; INTERLEUKIN-6; CYTOKINES	A CRITICAL point during mammalian pregnancy is the implantation of the blastocyst when the embryo attaches to the wall of the uterus. The autonomously developing preimplantation embryo then becomes dependent on the maternal environment for its continued development. Little is known about the regulation of implantation, except that a complex interaction between peptide and steroid hormones synchronizes the preparation of the uterus for implantation with the development of the embryo. Whether the implantation event is under maternal or embryonic control is also unclear (reviewed in refs 1, 2). We have previously shown that a cytokine, leukaemia inhibitory factor (LIF), is expressed in the uterine endometrial glands specifically on the fourth day of pregnancy3. This burst of expression is under maternal control and always precedes implantation of the blastocyst. Here we report that transient expression of LIF in mice is essential for implantation. Females lacking a functional LIF gene are fertile, but their blastocysts fail to implant and do not develop. The blastocysts, however, are viable and, when transferred to wild-type pseudopregnant recipients, they can implant and develop to term.	INST MOLEC GENET, PRAGUE 6, CZECHOSLOVAKIA; ROCHE BIOMED LABS INC, RARITAN, NJ USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES, BASEL NEW TECHNOL, CH-4002 BASEL, SWITZERLAND	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Roche Holding	STEWART, CL (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT CELL & DEV BIOL, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.		Kaspar, Petr/G-5864-2014; Kaspar, Petr/J-1705-2014					BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, NEW BIOL, V4, P61; HILTON DJ, 1991, J CELL PHYSIOL, V148, P430, DOI 10.1002/jcp.1041480315; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hodgen G.D., 1988, P1995; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KOENTGEN F, 1992, THESIS U FREIBOURG G; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MURRAY R, 1990, MOL CELL BIOL, V10, P4953, DOI 10.1128/MCB.10.9.4953; PAMPFER S, 1991, BIOESSAYS, V13, P535, DOI 10.1002/bies.950131007; POLALRD JW, 1987, NATURE, V390, P484; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL J, 1990, J BIOL CHEM, V265, P8833; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; TARTAKOVSKY B, 1991, DEV BIOL, V146, P345, DOI 10.1016/0012-1606(91)90236-V; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Weitlauf H.M., 1988, P231; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZJILSTRA M, 1990, NATURE, V344, P742	31	1673	1767	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					76	79		10.1038/359076a0	http://dx.doi.org/10.1038/359076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522892				2022-12-24	WOS:A1992JL66200058
J	SHARPE, M; HAWTON, K; SEAGROATT, V; PASVOL, G				SHARPE, M; HAWTON, K; SEAGROATT, V; PASVOL, G			FOLLOW-UP OF PATIENTS PRESENTING WITH FATIGUE TO AN INFECTIOUS-DISEASES CLINIC	BRITISH MEDICAL JOURNAL			English	Article							POSTVIRAL FATIGUE; HOSPITAL ANXIETY; DEPRESSION SCALE	Objectives-To determine the symptomatic and functional status during follow up of patients referred to hospital with unexplained fatigue and to identify patient variables associated with persistent functional impairment. Design-Follow up by postal questionnaire six weeks to four years (median 1 year) after initial clinical assessment of patients referred to hospital during 1984-8. Setting-Infectious diseases outpatient clinic in a teaching hospital. Patients-200 consecutive patients with fatigue of uncertain cause for at least six weeks; 177 fulfilled the inclusion criteria. Main outcome measures-Findings at initial assessment; current symptoms, beliefs about the cause of illness, coping behaviours emotional disorder, social variables including membership of self help organisations, and degrees of recovery and functional impairment from questionnaire responses. Results-144 (81%) patients returned completed questionnaires. Initial assessment did not indicate the cause of fatigue, other than preceding infection. The proportion of patients with functional impairment was significantly smaller with longer follow up (33% (11/33) at two to four years, 73% (29/40) at six weeks to six months; chi-2 for trend = 12.5, df=1; p<0.05). Functional impairment was significantly associated with belief in a viral cause of the illness (odds ratio=3-9; 95% confidence interval 1.5 to 9.9), limiting exercise (3.2; 1.5 to 6.6), avoiding alcohol (4.5; 1.8 to 11.3), changing or leaving employment (3.1; 1.4 to 6.9), belonging to a self help organisation (7.8; 2.5 to 23.9), and current emotional disorder (4.4; 2.0 to 9.3). Conclusions-Short term prognosis for recovery of function was poor but improved with time. Most patients had made a functional recovery by two years after initial clinic attendance. Impaired functioning was more likely with certain patient characteristics. Prospective studies are required to clarify whether these associations are the consequences of a more disabling illness or indicate factors contributing to impaired function.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Oxford; University of Oxford	SHARPE, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.		Pasvol, Geoffrey/B-7113-2009	sharpe, michael/0000-0002-6474-9980				BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; DOWSETT EG, 1991, POSTGRAD MED J, V66, P526; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LANDAY A, 1991, LANCET, V338, P701; LANE TJ, 1990, AM J MED SCI, V299, P313, DOI 10.1097/00000441-199005000-00005; LEWIS G, 1990, BRIT J PSYCHIAT, V157, P860, DOI 10.1192/bjp.157.6.860; MANU P, 1989, J AFFECT DISORDERS, V17, P165, DOI 10.1016/0165-0327(89)90039-6; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; Millon C, 1989, PSYCHOL HEALTH, V3, P131; Nelson E, 1987, Fam Pract Res J, V6, P175; NIXON DF, 1987, J CLIN PATHOL, V40, P673, DOI 10.1136/jcp.40.6.673; SHARPE M, 1991, BRIT MED BULL, V47, P989, DOI 10.1093/oxfordjournals.bmb.a072525; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; VALDINI A, 1989, FAM PRACT, V6, P286, DOI 10.1093/fampra/6.4.286; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1989, J ROY COLL GEN PRACT, V39, P26; YOUSEF GE, 1988, LANCET, V1, P146; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	148	149	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					147	152		10.1136/bmj.305.6846.147	http://dx.doi.org/10.1136/bmj.305.6846.147			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515828	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JF06300020
J	AMIGORENA, S; BONNEROT, C; DRAKE, JR; CHOQUET, D; HUNZIKER, W; GUILLET, JG; WEBSTER, P; SAUTES, C; MELLMAN, I; FRIDMAN, WH				AMIGORENA, S; BONNEROT, C; DRAKE, JR; CHOQUET, D; HUNZIKER, W; GUILLET, JG; WEBSTER, P; SAUTES, C; MELLMAN, I; FRIDMAN, WH			CYTOPLASMIC DOMAIN HETEROGENEITY AND FUNCTIONS OF IGG FC-RECEPTORS IN LYMPHOCYTES-B	SCIENCE			English	Article							REPRESSOR CI PROTEIN; N-TERMINAL DOMAIN; LAMBDA-REPRESSOR; MONOCLONAL-ANTIBODIES; DIFFERENT HAPLOTYPES; IA MOLECULES; T RESPONSE; ANTIGEN; IMMUNOGLOBULIN; CELLS	B lymphocytes and macrophages express closely related immunoglobulin G (IgG) Fc receptors (Fc-gamma-RII) that differ only in the structures of their cytoplasmic domains. Because of cell type-specific alternative messenger RNA splicing, B-cell Fc-gamma-RII contains an insertion of 47 amino acids that participates in determining receptor function in these cells. Transfection of an Fc-gamma-RII-negative B-cell line with complementary DNA's encoding the two splice products and various receptor mutants indicated that the insertion was responsible for preventing both Fc-gamma-RII-mediated endocytosis and Fc-gamma-RII-mediated antigen presentation. The insertion was not required for Fc-gamma-RII to modulate surface immunoglobulin-triggered B-cell activation. Instead, regulation of activation involved a region of the cytoplasmic domain common to both the lymphocyte and macrophage receptor isoforms. In contrast, the insertion did contribute to the formation of caps in response to receptor cross-linking, consistent with suggestions that the lymphocyte but not macrophage form of the receptor can associate with the detergent-insoluble cytoskeleton.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; INST CURIE,INSERM,U255,IMMUNOL CELLULAIRE & CLIN LAB,F-75005 PARIS,FRANCE; INST PASTEUR,INSERM,NEUROBIOL CELLULAIRE LAB,U261,F-75724 PARIS 15,FRANCE; INST COCHIN GENET MOLEC,INTERACT PROT LAB,URA 228,F-75014 PARIS,FRANCE	Yale University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Choquet, Daniel/E-4203-2013; Choquet, Daniel/GOJ-8825-2022; Mellman, Ira/ABG-5896-2020; Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022; Choquet, Daniel/K-7893-2018	Choquet, Daniel/0000-0003-4726-9763; Hunziker, Walter/0000-0002-5265-4933; Choquet, Daniel/0000-0003-4726-9763; sautes-fridman, catherine/0000-0003-1735-8722; fridman, wolf herman/0000-0002-1332-0973; Webster, Paul/0000-0002-1980-6931; Amigorena, Sebastian/0000-0001-8583-8416				AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; BREYER RM, 1989, J BIOL CHEM, V264, P13348; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; DICKLER HB, 1981, J EXP MED, V153, P1329, DOI 10.1084/jem.153.5.1329; DRAKE JR, 1989, J IMMUNOL, V143, P1768; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1986, P NATL ACAD SCI USA, V83, P6980, DOI 10.1073/pnas.83.18.6980; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; JONES B, 1986, J IMMUNOL, V136, P348; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; LAI MZ, 1987, J IMMUNOL, V139, P3973; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEWIS VA, 1986, NATURE, V324, P372, DOI 10.1038/324372a0; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Mellman I, 1990, Semin Immunol, V2, P229; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROOSNEK E, 1991, J EXP MED, V173, P487, DOI 10.1084/jem.173.2.487; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; WILSON HA, 1989, J IMMUNOL, V138, P1712	33	413	438	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1808	1812		10.1126/science.1535455	http://dx.doi.org/10.1126/science.1535455			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1535455				2022-12-24	WOS:A1992JA43400033
J	POLLENZ, RS; CHEN, TLL; TRIVINOSLAGOS, L; CHISHOLM, RL				POLLENZ, RS; CHEN, TLL; TRIVINOSLAGOS, L; CHISHOLM, RL			THE DICTYOSTELIUM ESSENTIAL LIGHT CHAIN IS REQUIRED FOR MYOSIN FUNCTION	CELL			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY-CHAIN; SCALLOP MYOSIN; HOMOLOGOUS RECOMBINATION; ACANTHAMOEBA MYOSIN; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; THICK FILAMENTS; ANTISENSE RNA; BINDING-SITES	A Dictyostelium mutant (7-11) that expresses less than 0.5% of wild-type levels of the myosin essential light chain (EMLC) has been created by overexpression of antisense RNA. Cells from 7-11 contain wild-type levels of the myosin heavy chain (MHC) and regulatory light chain (RMLC). Myosin isolated from 7-11 cells consists of the MHC with the RMLC associated in reduced stoichiometry, and binds to purified actin in an ATP-sensitive fashion. Purified 7-11 myosin displays calcium-activated ATPase activity with a V(max) about 15%-25% of that of wild type, and a K(m) for ATP of 27 +/- 5-mu-M versus 83 +/- 30-mu-M for wild type. At actin concentrations as high as 17-mu-M, 7-11 myosin displays greatly reduced actin-activated ATPase activity. Phenotypically, 7-11 cells resemble MHC mutants, growing poorly in suspension and becoming large and multinucleate. When starved for multicellular development, 7-11 cells take several hours longer than wild-type cells to aggregate. Although multicellular aggregates eventually form, they fail to develop further. The cells are also unable to cap receptors in response to Con A treatment. Since cells expressing the EMLC are phenotypically similar to MHC null mutants, the EMLC appears necessary for myosin function, at least in part because it is required for normal actin-activated ATPase activity.			POLLENZ, RS (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611, USA.		Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM39264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1987, J CELL BIOL, V105, P2999, DOI 10.1083/jcb.105.6.2999; DREIZEN P, 1970, BIOCHEMISTRY-US, V9, P1688, DOI 10.1021/bi00810a006; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FREDERIKSEN DW, 1968, BIOCHEMISTRY-US, V7, P3935, DOI 10.1021/bi00851a022; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; FUKUI Y, 1987, METHOD CELL BIOL, P347; GERSHMAN LC, 1970, BIOCHEMISTRY-US, V9, P1677, DOI 10.1021/bi00810a005; GERSHMAN LC, 1969, J MOL BIOL, V44, P2726; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HARDWICKE PMD, 1983, NATURE, V301, P478, DOI 10.1038/301478a0; HARDWICKE PMD, 1982, J MOL BIOL, V156, P141, DOI 10.1016/0022-2836(82)90463-6; HASEGAWA Y, 1990, J BIOCHEM-TOKYO, V108, P909, DOI 10.1093/oxfordjournals.jbchem.a123313; HOPKINSON SB, 1989, MOL CELL BIOL, V9, P4170, DOI 10.1128/MCB.9.10.4170; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; IZANT JG, 1989, CELL MOTIL CYTOSKEL, V14, P81, DOI 10.1002/cm.970140117; JACKSON AP, 1986, FEBS LETT, V197, P154, DOI 10.1016/0014-5793(86)80317-9; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KIEHART DP, 1984, J CELL BIOL, V99, P1024, DOI 10.1083/jcb.99.3.1024; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; OHALLORAN TJ, 1990, J CELL BIOL, V110, P63, DOI 10.1083/jcb.110.1.63; OKAMOTO Y, 1980, J BIOCHEM-TOKYO, V87, P167, DOI 10.1093/oxfordjournals.jbchem.a132722; OKAMOTO Y, 1986, NATURE, V324, P78, DOI 10.1038/324078a0; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLENZ RS, 1991, CELL MOTIL CYTOSKEL, V20, P83, DOI 10.1002/cm.970200202; REES DD, 1981, J BIOL CHEM, V256, P357; REINES D, 1985, J BIOL CHEM, V260, P4248; SELLERS JR, 1984, J BIOL CHEM, V259, P4203; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; SIVARAMAKRISHNAN M, 1982, J BIOL CHEM, V257, P1102; SPUDICH JA, 1989, CELL REGUL, V1, P1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SZENTKIRALYI EM, 1984, J MUSCLE RES CELL M, V5, P147, DOI 10.1007/BF00712153; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; Taylor D L, 1979, Int Rev Cytol, V56, P57, DOI 10.1016/S0074-7696(08)61821-5; TOKUNAGA M, 1987, J MOL BIOL, V194, P245, DOI 10.1016/0022-2836(87)90372-X; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VARNUM B, 1984, J CELL BIOL, V99, P1151, DOI 10.1083/jcb.99.3.1151; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; WEEDS AG, 1967, BIOCHEM J, V105, pC25, DOI 10.1042/bj1050025C; WEEDS AG, 1969, NATURE, V322, P1362; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	80	68	68	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					951	962		10.1016/0092-8674(92)90614-I	http://dx.doi.org/10.1016/0092-8674(92)90614-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1535025				2022-12-24	WOS:A1992HY79200007
J	LI, Y; BOLLAG, G; CLARK, R; STEVENS, J; CONROY, L; FULTS, D; WARD, K; FRIEDMAN, E; SAMOWITZ, W; ROBERTSON, M; BRADLEY, P; MCCORMICK, F; WHITE, R; CAWTHON, R				LI, Y; BOLLAG, G; CLARK, R; STEVENS, J; CONROY, L; FULTS, D; WARD, K; FRIEDMAN, E; SAMOWITZ, W; ROBERTSON, M; BRADLEY, P; MCCORMICK, F; WHITE, R; CAWTHON, R			SOMATIC MUTATIONS IN THE NEUROFIBROMATOSIS-1 GENE IN HUMAN TUMORS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; THYROID CARCINOMA-CELLS; RAS ONCOGENES; TYPE-1 GENE; POINT MUTATIONS; GAP; DIFFERENTIATION; EXPRESSION; TRANSFORMATION; CHILDHOOD	The neurofibromatosis 1 (NF1) gene product, neurofibromin, contains a GTPase-activating protein (GAP)-related domain, or NF1 GRD, that is able to down-regulate p21ras by stimulating its intrinsic GTPase. Since p21ras-GTP is a major regulator of growth and differentiation, mutant neurofibromins resulting from somatic mutations in the NF1 gene might interfere with ras signaling pathways and contribute to the development of tumors. We describe an amino acid substitution in the NF1 GRD, altering Lys-1423, that has occurred in three tumor types: colon adenocarcinoma, myelodysplastic syndrome, and anaplastic astrocytoma, and in one family with neurofibromatosis 1. The GAP activity of the mutant NF1 GRD is 200- to 400-fold lower than that of wild type, whereas binding affinity is unaffected. Thus, germline mutations in NF1 that cause neurofibromatosis 1 can also occur in somatic cells and contribute to the development of sporadic tumors, including tumors not associated with neurofibromatosis 1.	UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT NEUROSURG,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,HUMAN MOLEC BIOL & GENET PROGRAM,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT OBSTET & GYNECOL,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DNA DIAGNOST LAB,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84112; CHIRON CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608; KAROLINSKA INST,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Novartis; Karolinska Institutet	LI, Y (corresponding author), UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLATT J, 1986, CANCER, V57, P1225, DOI 10.1002/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Cohen B H, 1989, Oncology (Williston Park), V3, P23; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; KIBIRIGE MS, 1989, PEDIATR HEMAT ONCOL, V6, P319, DOI 10.3109/08880018909034303; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LYONS J, 1988, BLOOD, V71, P1707; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADUA RA, 1988, LEUKEMIA, V2, P503; PETTY EM, 1991, NUCLEIC ACIDS RES, V19, P690, DOI 10.1093/nar/19.3.690; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YOKOTA J, 1988, ONCOGENE, V3, P471	37	310	320	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					275	281		10.1016/0092-8674(92)90408-5	http://dx.doi.org/10.1016/0092-8674(92)90408-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568247				2022-12-24	WOS:A1992HQ18300007
J	FLYNN, JT; BANCALARI, E; SNYDER, ES; GOLDBERG, RN; FEUER, W; CASSADY, J; SCHIFFMAN, J; FELDMAN, HI; BACHYNSKI, B; BUCKLEY, E; ROBERTS, J; GILLINGS, D				FLYNN, JT; BANCALARI, E; SNYDER, ES; GOLDBERG, RN; FEUER, W; CASSADY, J; SCHIFFMAN, J; FELDMAN, HI; BACHYNSKI, B; BUCKLEY, E; ROBERTS, J; GILLINGS, D			A COHORT STUDY OF TRANSCUTANEOUS OXYGEN-TENSION AND THE INCIDENCE AND SEVERITY OF RETINOPATHY OF PREMATURITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETROLENTAL-FIBROPLASIA	Background. Retinopathy of prematurity is a disease affecting the blood vessels of the retina in premature infants that may result in scarring, retinal detachment, and loss of vision. An association between this condition and the exposure of premature infants to supplemental oxygen has been postulated, but the relation between retinopathy of prematurity and blood oxygen levels has not been defined. The purpose of this study of a cohort of preterm infants was to correlate the incidence and severity of retinopathy of prematurity with the duration of exposure to different ranges of oxygen tension as measured by transcutaneous monitoring (tcPO2). Methods. One hundred one premature infants (birth weight, 500 to 1300 g) requiring supplemental oxygen had continuous monitoring of tcPO2. The number of hours during which the tCPO2 was 80 mm Hg or higher was tabulated for each infant during the first four weeks of life. Results. There was a significant association between the amount of time that the tCPO2 was greater-than-or-equal-to 80 mm Hg and the incidence and severity of retinopathy of prematurity. The odds ratio for each 12-hour period in which the tcPO2 was greater-than-or-equal-to 80 mm Hg was 1.9 (95 percent confidence interval, 1.2 to 3.0) after adjustment for the following factors: birth weight less-than-or-equal-to 1300 g (odds ratio, 2.3 [95 percent confidence interval, 1.6 to 3.4]), five-minute Apgar score of 7 or less (odds ratio, 7.2 [95 percent confidence interval, 2.5 to 21]), and exposure to inspired oxygen at a fractional concentration greater-than-or-equal-to 0.4 (odds ratio, 1.0 [95 percent confidence interval, 0.97 to 1.05]). The association was stronger for tcPO2 values of greater-than-or-equal-to 80 mm Hg occurring from the second through the fourth week of life; during this period, the adjusted odds ratio for a 12-hour period of such exposure was 3.1 (95 percent confidence interval, 1.6 to 6.1). Conclusions. This study supports an association between the incidence and severity of retinopathy of prematurity and the duration of exposure to arterial oxygen levels of 80 mm Hg or higher, measured transcutaneously.	UNIV MIAMI,SCH MED,DEPT PEDIAT,DIV NEONATOL,MIAMI,FL 33152; UNIV PENN,SCH MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; UNIV N CAROLINA,SCH MED,SCH PUBL HLTH,DEPT BIOSTAT,CHAPEL HILL,NC 27514	University of Miami; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FLYNN, JT (corresponding author), BASCOM PALMER EYE INST,DEPT OPHTHALMOL,POB 016880,MIAMI,FL 33101, USA.				NATIONAL EYE INSTITUTE [P30EY002180, R01EY003513] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY03513, 3P0 EY 02180] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGRESTI A, 1984, ANAL ORDINAL CATEGOR, P104; BANCALARI E, 1987, PEDIATRICS, V79, P663; Flynn J T, 1983, Trans Am Ophthalmol Soc, V81, P549; FLYNN JT, 1987, OPHTHALMOLOGY, V94, P620; FLYNN JT, 1987, OPHTHALMOLOGY, V94, P630; FLYNN JT, 1977, ARCH OPHTHALMOL-CHIC, V95, P217, DOI 10.1001/archopht.1977.04450020019002; FLYNN JT, 1975, A GRAEF ARCH KLIN EX, V195, P101, DOI 10.1007/BF00417113; FLYNN JT, 1981, RETINOPATHY PREMATUR, P247; GIBSON DL, 1990, PEDIATRICS, V86, P405; KINSEY VE, 1977, PEDIATRICS, V60, P655; KINSEY VE, 1956, ARCH OPHTHALMOL-CHIC, V56, P481, DOI 10.1001/archopht.1956.00930040489001; KUSHNER BJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P29, DOI 10.1001/archopht.1977.04450010031002; LANMAN JT, 1954, JAMA-J AM MED ASSOC, V155, P223, DOI 10.1001/jama.1954.03690210001001; LUCEY JF, 1984, PEDIATRICS, V73, P82; McCullagh P, 1989, GEN LINEAR MODELS, P151; PATZ A, 1952, AM J OPHTHALMOL, V35, P1248, DOI 10.1016/0002-9394(52)91140-9; QUINN GE, 1982, AM J OPHTHALMOL, V94, P744, DOI 10.1016/0002-9394(82)90298-7; REESE AB, 1953, AM J OPHTHALMOL, V36, P1333; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; Tanabe Y, 1972, Nippon Ganka Gakkai Zasshi, V76, P260; UEMURA Y, 1977, JPN J OPHTHALMOL, V21, P366; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; YU VYH, 1982, ARCH DIS CHILD, V57, P247, DOI 10.1136/adc.57.4.247; 1987, ARCH OPHTHALMOL-CHIC, V105, P1498; 1988, GUIDELINES PERINATAL, P246; 1984, ARCH OPHTHALMOL-CHIC, V102, P1130	26	198	210	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1050	1054		10.1056/NEJM199204163261603	http://dx.doi.org/10.1056/NEJM199204163261603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549150				2022-12-24	WOS:A1992HN73800003
J	HILDEBRANDT, M; NELLEN, W				HILDEBRANDT, M; NELLEN, W			DIFFERENTIAL ANTISENSE TRANSCRIPTION FROM THE DICTYOSTELIUM EB4 GENE LOCUS - IMPLICATIONS ON ANTISENSE-MEDIATED REGULATION OF MESSENGER-RNA STABILITY	CELL			English	Article							3' UNTRANSLATED REGION; REVERSE TRANSCRIPTION; GROWTH-FACTOR; CYCLIC-AMP; DISCOIDEUM; EXPRESSION; TRANSFORMATION; CELLS; IDENTIFICATION; POLYMERASE	The 2.2 kb mRNA of the Dictyostelium discoideum prespore gene EB4-PSV is constitutively transcribed during growth and development, but the message is only accumulated when cells form aggregates and establish the prespore-prestalk pattern. Disruption of the pattern by mechanical disaggregation results in a rapid loss of the mRNA, while transcription remains nearly unchanged. In early development and after disaggregation, when the mRNA is unstable, a 1.8 kb antisense transcript originating from the same gene locus is detected. This RNA has apparently no coding capacity and is transcriptionally regulated by a promoter located within the translated region of the gene. Excess transcription of antisense RNA in vegetative cells and after disaggregation suggests its involvement in the control of mRNA stability. In agreement with this assumption, the inhibition of RNA synthesis during disaggregation prevents destabilization of the mRNA. This stability regulation of an endogenous mRNA is reminiscent of the loss of specific mRNAs in cells transformed with antisense constructs.			HILDEBRANDT, M (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.							ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; AMARA JF, 1987, MOL CELL BIOL, V7, P4585, DOI 10.1128/MCB.7.12.4585; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; CANNON M, 1990, PLANT MOL BIOL, V15, P39, DOI 10.1007/BF00017722; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HARLAND R, 1988, DEVELOPMENT, V102, P837; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HILDEBRANDT M, 1991, DEV BIOL, V144, P212, DOI 10.1016/0012-1606(91)90492-L; HILDEBRANDT M, 1991, BIOCHEM BIOPH RES CO, V181, P884, DOI 10.1016/0006-291X(91)91273-F; HILDEBRANDT M, 1991, DEV GENET, V12, P163, DOI 10.1002/dvg.1020120125; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LOOMIS WF, 1991, GENE REGULATION BIOL, P197; MANGIAROTTI G, 1989, BIOCHEM SOC SYMP, V55, P77; MANGIAROTTI G, 1989, DEVELOPMENT, V106, P473; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1982, DEV BIOL, V98, P82; MANIAK M, 1990, NUCLEIC ACIDS RES, V18, P5375, DOI 10.1093/nar/18.18.5375; MANIAK M, 1989, ANAL BIOCHEM, V176, P78, DOI 10.1016/0003-2697(89)90275-3; MANROW RE, 1988, MOL CELL BIOL, V8, P4088, DOI 10.1128/MCB.8.10.4088; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MAY T, 1991, MECH DEVELOP, V33, P147, DOI 10.1016/0925-4773(91)90081-G; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; OKANO H, 1988, EMBO J, V7, P3407, DOI 10.1002/j.1460-2075.1988.tb03214.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TSE WT, 1990, GENE, V88, P293, DOI 10.1016/0378-1119(90)90047-U; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x	48	123	123	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					197	204		10.1016/0092-8674(92)90130-5	http://dx.doi.org/10.1016/0092-8674(92)90130-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555240				2022-12-24	WOS:A1992HM44500018
J	BERGELSON, JM; SHEPLEY, MP; CHAN, BMC; HEMLER, ME; FINBERG, RW				BERGELSON, JM; SHEPLEY, MP; CHAN, BMC; HEMLER, ME; FINBERG, RW			IDENTIFICATION OF THE INTEGRIN VLA-2 AS A RECEPTOR FOR ECHOVIRUS-1	SCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; RHINOVIRUS RECEPTOR; COLLAGEN RECEPTOR; CELLULAR RECEPTOR; LAMININ RECEPTOR; HELA-CELLS; T-CELLS; POLIOVIRUS; PROTEIN; FIBRONECTIN	Cell surface receptors for echovirus, a common human pathogen, were identified with monoclonal antibodies that protected susceptible cells from infection with echovirus 1. These monoclonal antibodies, which prevented virus attachment to specific receptor sites, recognized the alpha and beta-subunits of the integrin VLA-2 (alpha-2-beta-1), a receptor for collagen and laminin. RD rhabdomyosarcoma cells expressed little VLA-2, did not bind to S-35-labeled virus, and resisted infection until transfected with complementary DNA encoding the alpha-2 subunit of VLA-2. Thus, integrins, adhesion receptors important in interactions between cells and with the extracellular matrix, can mediate virus attachment and infection.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BERGELSON, JM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, INFECT DIS LAB, BOSTON, MA 02115 USA.		Finberg, Robert W/E-3323-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20382] Funding Source: Medline; NIGMS NIH HHS [GM 38903] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, UNPUB; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHERRY J, 1983, INFECTIOUS DISEASE F, pCH7; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CROWELL RL, 1983, COMPR VIROL, V18, P1; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MELNICK JL, 1990, VIROLOGY, pCH21; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MODLIN JF, 1988, PEDIATR INFECT DIS J, V7, P311, DOI 10.1097/00006454-198805000-00002; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SHEPLEY MP, 1988, P NATL ACAD SCI USA, V85, P7743, DOI 10.1073/pnas.85.20.7743; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; TYLER KL, 1990, VIROLOGY, pCH10; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	38	250	259	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1992	255	5052					1718	1720		10.1126/science.1553561	http://dx.doi.org/10.1126/science.1553561			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553561				2022-12-24	WOS:A1992HK81200043
J	OBRIEN, T; KELLY, M; SAUNDERS, C				OBRIEN, T; KELLY, M; SAUNDERS, C			MOTOR-NEURON DISEASE - A HOSPICE PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and evaluate the management of patients with motor neurone disease from the perspective of a hospice. Design - Retrospective analysis of hospice medical and nursing notes. Setting - Established 62 bed teaching and research hospice. Subjects - 124 patients with motor neurone disease cared for by the hospice between january 1980 and November 1990. Main outcome measures - Patient profile; functional status; symptom control and use of opioids; insight; mode and management of death. Results - 124 patients (67 women, 57 men) had a mean age 63.9 years. The median length of admission was 61.5 days (range 1 to 2147). 84 patients (68%) were aware of their diagnosis and its implications when first seen by a hospice doctor. Functionally, the patients were very dependent. Symptoms such as pain, dyspnoea, and insomnia were major problems that responded well to opioids. Many patients were noted to deteriorate "suddenly," and in 58% of cases death occurred within 24 hours of this deterioration. When dying, 106 patients (94%) were peaceful and settled. 101 patients (89%) received opioids during this dying period. No patient choked to death. Conclusions - Although motor neurone disease is an uncommon disorder, many of its symptoms occur commonly in medical practice and must be actively treated. Opioids are both safe and effective for such treatment. The term choking is both inaccurate and inappropriate in describing the cause of death in motor neurone disease and its use should be abandoned.	ST CHRISTOPHERS HOSPICE,LONDON SE26 6DZ,ENGLAND									COCHRANE GM, 1987, MANAGEMENT MOTOR NEU; GAWEL MJ, 1989, CLIN REHABILITATION, V3, P309; Hillel A D, 1987, Adv Exp Med Biol, V209, P201; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; KONDO K, 1984, RES PROGR MOTOR NEUR, P20; Mulder D W, 1987, Adv Exp Med Biol, V209, P325; MULDER DW, 1976, MAYO CLIN PROC, V51, P537; NEWRICK PG, 1984, BRIT MED J, V289, P539, DOI 10.1136/bmj.289.6444.539; NEWRICK PG, 1985, J NEUROL NEUROSUR PS, V48, P838, DOI 10.1136/jnnp.48.8.838; Norris F H, 1989, Rinsho Shinkeigaku, V29, P1485; NORRIS FH, 1985, BRIT MED J, V291, P259, DOI 10.1136/bmj.291.6490.259; OLIVER D, 1989, MOTOR NEURONE DISEAS; Rose F C, 1987, Adv Exp Med Biol, V209, P167; ROSIN A J, 1976, Age and Ageing, V5, P37, DOI 10.1093/ageing/5.1.37; ROWLAND LP, 1980, DIAGNOSIS TREATMENT, P7; Saunders C., 1981, HOSPICE LIVING IDEA, P126; Schiffer D, 1987, Adv Exp Med Biol, V209, P255; SMITH RA, 1980, DIAGNOSIS TREATMENT, P241; 1989, CHURCHILLS MED DICT; 1986, CANCER PAIN RELIEF	20	101	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					471	473		10.1136/bmj.304.6825.471	http://dx.doi.org/10.1136/bmj.304.6825.471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547416	Green Published, Bronze			2022-12-24	WOS:A1992HF55500019
J	ARMSTRONG, AM; MOLYNEUX, E				ARMSTRONG, AM; MOLYNEUX, E			GLASS INJURIES TO CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP,DEPT ACCIDENT & EMERGENCY,LIVERPOOL L12 2AP,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								BAKER MD, 1990, AM J DIS CHILD, V144, P87, DOI 10.1001/archpedi.1990.02150250097042; BELL D, 1984, ARCH DIS CHILD, V59, P672, DOI 10.1136/adc.59.7.672; HAYES M, 1991, CHILD SAFETY REV, P4	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					360	360		10.1136/bmj.304.6823.360	http://dx.doi.org/10.1136/bmj.304.6823.360			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540735	Bronze, Green Published			2022-12-24	WOS:A1992HD38700026
J	LAUER, MS; LEVY, D; ANDERSON, KM; PLEHN, JF				LAUER, MS; LEVY, D; ANDERSON, KM; PLEHN, JF			IS THERE A RELATIONSHIP BETWEEN EXERCISE SYSTOLIC BLOOD-PRESSURE RESPONSE AND LEFT-VENTRICULAR MASS - THE FRAMINGHAM HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD PRESSURE; EXERCISE TEST; ECHOCARDIOGRAPHY; HEART ENLARGEMENT; VENTRICULAR FUNCTION, LEFT	RISK-FACTORS; HYPERTROPHY; DISEASE; ECHOCARDIOGRAPHY; HYPERTENSION; SIZE; AGE; MEN	Objective: To assess the association between an exaggerated exercise systolic blood pressure response and the occurrence of left ventricular hypertrophy in healthy, normotensive individuals. Design: Cross-sectional survey using M-mode echocardiography to measure left ventricular mass and to detect left ventricular hypertrophy. Setting: The Framingham Heart Study. Subjects: Eight-hundred sixty men and 1118 women were studied who were free of cardiovascular or pulmonary disease, who were not taking any antihypertensive or cardiovascular medications, and who successfully achieved at least 90% of their age-predicted maximum heart rate during a monitored exercise treadmill test. All subjects had normal baseline and exercise electrocardiograms. Measurements and Main Results: Men with a peak exercise systolic blood pressure of 210 or more and women with a peak exercise systolic blood pressure of 190 or more were considered to have an "exaggerated" blood pressure response; 122 men and 67 women met these criteria. Subjects with an exaggerated exercise systolic blood pressure response had 10% higher left ventricular mass than those with a normal exercise systolic blood pressure response (in men: 115 +/- 25 compared with 105 +/- 24 g/m, P < 0.001; in women: 86 +/- 22 compared with 73 +/- 16 g/m, P < 0.001); they also had a higher prevalence of left ventricular hypertrophy (in men: odds ratio, 1.34, 95% Cl, 1.00 to 1.80; in women: odds ratio, 2.12, Cl, 1.48 to 3.03). After adjusting for age, resting systolic blood pressure, and body mass index, however, subjects with an exaggerated exercise systolic blood pressure response had only 5% higher left ventricular mass (in men: 111 +/- 2.1 compared with 106 +/- 0.8 g/m, P = 0.02; in women: 80 +/- 1.8 compared with 74 +/- 0.4 g/m, P = 0.002), and they no longer had a statistically increased prevalence of left ventricular hypertrophy (in men: odds ratio, 1.21, Cl, 0.87 to 1.67; in women: odds ratio, 1.30, Cl, 0.84 to 2.01). Conclusions: The apparent relation between exercise systolic blood pressure response and left ventricular mass is confounded by age, resting systolic blood pressure, and body mass; the degree of confounding is such that the biologic significance of this relationship should be questioned.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Framingham Heart Study; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Lauer, Michael S/L-9656-2013	Levy, Daniel/0000-0003-1843-8724; Lauer, Michael S/0000-0002-9217-8177	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038, HL07374] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; DANNENBERG AL, 1989, AM J CARDIOL, V64, P1066, DOI 10.1016/0002-9149(89)90816-3; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1990, ANN INTERN MED, V112, P157, DOI 10.7326/0003-4819-112-3-157; DLIN RA, 1983, AM HEART J, V106, P316, DOI 10.1016/0002-8703(83)90198-9; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; ELLESTAD MH, 1986, STRESS TESTING PRINC, P472; FAGARD R, 1991, HYPERTENSION, V17, P574, DOI 10.1161/01.HYP.17.4.574; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; GARDIN JM, 1987, HYPERTENSION, V9, P36; GOTTDIENER JS, 1990, ANN INTERN MED, V112, P161, DOI 10.7326/0003-4819-112-3-161; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; Kannel W B, 1978, Ann N Y Acad Sci, V304, P128, DOI 10.1111/j.1749-6632.1978.tb25585.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SHEFFIELD LT, 1988, HEART DISEASE TXB CA, P237; SHEFFIELD LT, 1988, HEART DISEASE TXB CA, P227; VANDENBOSSCHE JL, 1984, J AM COLL CARDIOL, V4, P1195, DOI 10.1016/S0735-1097(84)80138-2; WILSON NV, 1981, PREV MED, V10, P62, DOI 10.1016/0091-7435(81)90006-2	31	144	153	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					203	210		10.7326/0003-4819-116-3-203	http://dx.doi.org/10.7326/0003-4819-116-3-203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1530806				2022-12-24	WOS:A1992HB35600005
J	BETZ, WJ; BEWICK, GS				BETZ, WJ; BEWICK, GS			OPTICAL ANALYSIS OF SYNAPTIC VESICLE RECYCLING AT THE FROG NEUROMUSCULAR-JUNCTION	SCIENCE			English	Article							SYNAPSIN-I; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; NERVE-TERMINALS; PROTEIN; ACETYLCHOLINE; MEMBRANE; EXOCYTOSIS	The fluorescent dyes FM1-43 and RH414 label motor nerve terminals in an activity-dependent fashion that involves dye uptake by synaptic vesicles that are recycling. This allows optical monitoring of vesicle recycling in living nerve terminals to determine how recycled vesicles reenter the vesicle pool. The results suggest that recycled vesicles mix with the pool morphologically and functionally. One complete cycle of release of transmitter, recycling of a vesicle, and rerelease of transmitter appears to take about 1 minute.			BETZ, WJ (corresponding author), UNIV COLORADO, SCH MED, DEPT PHYSIOL, DENVER, CO 80262 USA.		Bewick, Guy/AAL-8214-2021	Bewick, Guy/0000-0001-8266-7797	NINDS NIH HHS [NS23466, NS10207] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010207, R01NS023466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARKER LA, 1972, BIOCHEM J, V130, P1063, DOI 10.1042/bj1301063; BETZ W J, 1991, Society for Neuroscience Abstracts, V17, P1157; BETZ W J, 1990, Society for Neuroscience Abstracts, V16, P53; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; CECCARELLI B, 1972, J CELL BIOL, V54, P30, DOI 10.1083/jcb.54.1.30; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; COLLIER B, 1969, CAN J PHYSIOL PHARM, V47, P127, DOI 10.1139/y69-023; HEUSER JE, 1989, Q J EXP PHYSIOL CMS, V74, P1051, DOI 10.1113/expphysiol.1989.sp003333; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; ISRAEL M, 1990, J NEUROCHEM, V55, P1758, DOI 10.1111/j.1471-4159.1990.tb04966.x; ISRAEL M, 1986, P NATL ACAD SCI USA, V83, P9226, DOI 10.1073/pnas.83.23.9226; KOPIN IJ, 1968, J PHARMACOL EXP THER, V161, P271; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; POTTER LT, 1970, J PHYSIOL-LONDON, V206, P145, DOI 10.1113/jphysiol.1970.sp009003; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; TARELLI FT, 1990, PROG BRAIN RES, V84, P83; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VALTORTA F, 1988, NEUROSCIENCE, V24, P593, DOI 10.1016/0306-4522(88)90353-3; WHITTAKER VP, 1990, PROG BRAIN RES, V84, P419; WHITTAKER VP, 1987, ANN NY ACAD SCI, V493, P77, DOI 10.1111/j.1749-6632.1987.tb27185.x; ZIMMERMANN H, 1989, CELL BIOL INT REP, V13, P993, DOI 10.1016/0309-1651(89)90015-5; ZIMMERMANN H, 1979, NEUROSCIENCE, V4, P1773, DOI 10.1016/0306-4522(79)90058-7; ZIMMERMANN H, 1988, HDB EXPT PHARM, V86, P349	27	638	646	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	1992	255	5041					200	203		10.1126/science.1553547	http://dx.doi.org/10.1126/science.1553547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553547				2022-12-24	WOS:A1992GY70400037
J	SHAH, P; DHURJON, L; METCALFE, T; GIBSON, JM				SHAH, P; DHURJON, L; METCALFE, T; GIBSON, JM			LESSON OF THE WEEK - ACUTE ANGLE CLOSURE GLAUCOMA ASSOCIATED WITH NEBULIZED IPRATROPIUM BROMIDE AND SALBUTAMOL	BRITISH MEDICAL JOURNAL			English	Article									E BIRMINGHAM DIST GEN HOSP,DEPT OPHTHALMOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; GEN INFIRM,DEPT OPHTHALMOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary				Gibson, Jonathan M/0000-0002-9281-5244				GRAY RH, 1990, HOSPITAL UPDATE, V16, P446; KALRA L, 1988, CHEST, V93, P739, DOI 10.1378/chest.93.4.739; MALANI JT, 1982, NEW ZEAL MED J, V95, P749; PACKE GE, 1984, LANCET, V2, P691	4	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					40	41		10.1136/bmj.304.6818.40	http://dx.doi.org/10.1136/bmj.304.6818.40			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1531182	Bronze, Green Published			2022-12-24	WOS:A1992GY90900035
J	CHAPMAN, AB; RUBINSTEIN, D; HUGHES, R; STEARS, JC; EARNEST, MP; JOHNSON, AM; GABOW, PA; KAEHNY, WD				CHAPMAN, AB; RUBINSTEIN, D; HUGHES, R; STEARS, JC; EARNEST, MP; JOHNSON, AM; GABOW, PA; KAEHNY, WD			INTRACRANIAL ANEURYSMS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; RISK-FACTORS; DIAGNOSIS	Background and Methods. Intracranial aneurysms are a feature of autosomal dominant polycystic kidney disease, but their prevalence is uncertain. We studied 92 subjects with autosomal dominant polycystic kidney disease who had no symptoms or signs of any neurologic disorder. To determine the prevalence of intracranial aneurysms, we performed high-resolution computed tomography (CT) in 60 subjects, four-vessel cerebral angiography in 21, and both procedures in 11. Results. Four of the 88 subjects in whom the radiologic studies were successfully completed had intracranial aneurysms (4 percent; 95 percent confidence interval, 0.1 to 9 percent), as compared with the prevalence of 1 percent reported for an angiographic study of the general population. Three of the four subjects had multiple aneurysms. Seven subjects for whom the results of CT studies were suspicious underwent cerebral angiography: two had aneurysms, and five had normal vascular structures that accounted for the suspicious results of tomography. Four subjects who had normal CT imaging studies also had normal angiographic examinations. Eight of the 32 subjects who underwent angiography (25 percent) had transient complications, as compared with 22 of 220 control subjects (10 percent) who did not have polycystic kidney disease (P<0.05). We could not identify any risk factor in these subjects that was related to the occurrence of aneurysm. Conclusions. Asymptomatic intracranial aneurysms appear to be more frequent in people with polycystic kidney disease than in the general population, although our 95 percent confidence interval includes the possibility of no difference. Because cerebral angiography is associated with increased morbidity in people with polycystic kidney disease, we recommend high-resolution CT as a screening test.	UNIV HOSP DENVER, DENVER, CO USA; DEPT VET AFFAIRS MED CTR, DENVER, CO USA; DENVER GEN HOSP, DENVER, CO 80204 USA; UNIV COLORADO, SCH MED, DEPT MED, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT RADIOL, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT NEUROL, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Hospital; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Johnson, Anne/0000-0003-1330-7100	NCRR NIH HHS [MO-RR00051] Funding Source: Medline; NIDDK NIH HHS [DK34039] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOSTARUA GJ, 1978, ARCH NEUROL-CHICAGO, V35, P675, DOI 10.1001/archneur.1978.00500340051010; ASKUPMARK E, 1950, ACTA MED SCAND, V138, P15; ATKINSON JLD, 1989, J NEUROSURG, V70, P551, DOI 10.3171/jns.1989.70.4.0551; BIGELOW NH, 1953, AM J MED SCI, V225, P485, DOI 10.1097/00000441-195305000-00004; Braasch WF, 1933, SURG GYNECOL OBSTET, V57, P467; BROWN R A P, 1951, Glasgow Med J, V32, P333; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DELAMONTE SM, 1985, AM J MED, V78, P957, DOI 10.1016/0002-9343(85)90218-9; DITLEFSEN EML, 1960, ACTA MED SCAND, V168, P51; Dunger R, 1904, BEITR PATHOL ANAT AL, V35, P445; EADIE MJ, 1964, J NEUROL SCI, V1, P501, DOI 10.1016/0022-510X(64)90170-4; EARNEST MP, 1987, STROKE, V18, P292; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; GABOW PA, 1990, HEPATOLOGY, V11, P1033, DOI 10.1002/hep.1840110619; HASSLER OVE, 1959, ACTA PATHOL ET MICROBIOL SCAND, V46, P305; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; ISHIBASHI A, 1981, JPN J NEPHROL, V23, P1003; JAIN KK, 1974, ACTA NEUROCHIR, V30, P129, DOI 10.1007/BF01405761; KOBAYASHI H, 1984, SURG NEUROL, V21, P258, DOI 10.1016/0090-3019(84)90198-8; LEVEY AS, 1983, NEW ENGL J MED, V308, P986, DOI 10.1056/NEJM198304283081702; MATSUMURA M, 1986, ACTA NEUROCHIR, V79, P94, DOI 10.1007/BF01407451; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; SALTZMAN GF, 1959, ACTA RADIOL, V51, P415, DOI 10.3109/00016925909171114; SCHMID UD, 1987, NEURORADIOLOGY, V29, P152, DOI 10.1007/BF00327540; TABONE J, 1949, CR HEBD ACAD SCI, V229, P471; TORRES VE, 1990, J AM SOC NEPHROL, V1, P84; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488	28	240	248	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					916	920		10.1056/NEJM199209243271303	http://dx.doi.org/10.1056/NEJM199209243271303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1513348				2022-12-24	WOS:A1992JP01400003
J	SEABRA, MC; BROWN, MS; SLAUGHTER, CA; SUDHOF, TC; GOLDSTEIN, JL				SEABRA, MC; BROWN, MS; SLAUGHTER, CA; SUDHOF, TC; GOLDSTEIN, JL			PURIFICATION OF COMPONENT-A OF RAB GERANYLGERANYL TRANSFERASE - POSSIBLE IDENTITY WITH THE CHOROIDEREMIA GENE-PRODUCT	CELL			English	Article							GTP-BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; SYNAPTIC VESICLES; PEPTIDE-BINDING; ALPHA-SUBUNIT; FARNESYLTRANSFERASE; CLONING; EXPRESSION; DEPENDENCE	Rab geranylgeranyl transferase (GG transferase) from rat brain contains two components, A and B. Component B comprises polypeptides of 60 and 38 kd. Here we report the purification of component A, a single 95 kd polypeptide. The holoenzyme attaches H-3-geranyl-geranyl to cysteines in two GTP-binding proteins, Rab3A and Rab1A. The reaction is abolished when both cysteines in the COOH-terminal CysCys sequence of Rab1A are mutated to serines. The mutant protein inhibits transfer of H-3-geranylgeranyl to wild-type Rab1A and Rab3A, suggesting that the enzyme recognizes conserved sequences distinct from the COOH-terminus. Six peptides from rat component A show striking similarity to the product of the defective gene in choroideremia, an X-linked retinal degeneration disease. The choroideremia protein resembles Rab3A GDI, which binds Rab3A. We hypothesize that component A binds conserved sequences in Rab and that component B transfers geranylgeranyl. A defect in this reaction may cause choroideremia.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HECKENLIVELY JR, 1988, CHOROIDEREMIA RETINI, P176; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	34	258	261	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1049	1057		10.1016/0092-8674(92)90253-9	http://dx.doi.org/10.1016/0092-8674(92)90253-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525821				2022-12-24	WOS:A1992JN78100018
J	TAKEMOTO, S; TERASAKI, PI; CECKA, JM; CHO, YW; GJERTSON, DW				TAKEMOTO, S; TERASAKI, PI; CECKA, JM; CHO, YW; GJERTSON, DW			SURVIVAL OF NATIONALLY SHARED, HLA-MATCHED KIDNEY-TRANSPLANTS FROM CADAVERIC DONORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANTATION; BENEFITS	Background. The importance of HLA histocompatibility typing to the outcome of transplantation of cadaveric kidneys has been controversial. Four years ago, a prospective trial began in all U.S. transplantation centers to determine whether the results of transplantation would improve with the nationwide shipment of kidneys from cadaveric donors to waiting patients undergoing dialysis when there was a match at the HLA-A, B, and DR loci. Methods. A total of 1386 cadaveric kidneys were shipped from 108 organ centers to 198 transplantation centers and distributed among HLA-matched recipients, 1004 of whom were receiving a first transplant and 382 of whom were receiving a subsequent transplant. Graft survival in these recipients was compared with that in 22,188 recipients of first transplants and 3950 recipients of subsequent transplants whose HLA antigens differed from those of the donor. Results. The rate of graft survival at one year in recipients of HLA-matched first transplants was 88 percent, as compared with 79 percent in the recipients of mismatched grafts (P<0.001). The estimated half-life of the kidney after the first year was 17.3 years for matched grafts, as compared with 7.8 years for mismatched grafts (P = 0.003). Among paired kidneys from 470 donors, one-year graft survival was 87 percent in the recipients of matched first grafts, as compared with 80 percent in the recipients of the contralateral kidneys, who did not have HLA matches with the donors. In donors and recipients matched for the more highly defined split Class I and Class II HLA antigens, the rate of graft survival after one year was as high as 90 percent. Conclusions. The collaborative renal-transplantation program for HLA matching of donors and recipients yielded an increased rate of one-year graft survival and an estimated half-life for matched grafts twice that for mismatched grafts. An increased role for HLA matching in kidney allocation is therefore indicated.			TAKEMOTO, S (corresponding author), UNIV CALIF LOS ANGELES,DEPT SURG,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024, USA.							Cho Y W, 1988, Clin Transpl, P277; CICCIARELLI J, 1987, TRANSPLANTATION, V43, P636, DOI 10.1097/00007890-198705000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; Dixon W. J., 1990, BMDP STATISTICAL SOF; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; Lau M, 1991, Clin Transpl, P385; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; OPELZ G, 1988, LANCET, V2, P61; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; Persijn G G, 1988, Clin Transpl, P237; SANFILIPPO F, 1984, NEW ENGL J MED, V311, P358, DOI 10.1056/NEJM198408093110603; STARZL TE, 1987, JAMA-J AM MED ASSOC, V57, P3073; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033; TERASAKI PI, 1991, KIDNEY INT, V39, P557, DOI 10.1038/ki.1991.64; TERASAKI PI, 1990, CLIN TRANSPLANTS 199, P585	17	184	187	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					834	839		10.1056/NEJM199209173271202	http://dx.doi.org/10.1056/NEJM199209173271202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508242	Bronze			2022-12-24	WOS:A1992JN12000002
J	DELSAL, G; RUARO, ME; PHILIPSON, L; SCHNEIDER, C				DELSAL, G; RUARO, ME; PHILIPSON, L; SCHNEIDER, C			THE GROWTH ARREST-SPECIFIC GENE, GAS1, IS INVOLVED IN GROWTH SUPPRESSION	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN TRANSFERRIN RECEPTOR; LARGE TUMOR-ANTIGEN; MESSENGER-RNA; CELL-CYCLE; 3T3 CELLS; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS	This report describes the structure of the mRNA, the protein product, and the growth-regulating activity of one of the growth arrest-specific genes, gas1. From the predicted amino acid sequence, in vitro translation of gas1 mRNA, and immunofluorescence of cells in culture, it appears that the gas1 protein is an integral plasma membrane protein whose expression is linked to growth arrest. When gas1 is overexpressed from a constitutive promoter in quiescent cells, the serum-induced transition from the G0 to the S phase of the cell cycle is inhibited without affecting the normal early serum response. Ectopic expression of the gas1 gene by microinjection in normal and transformed NIH 3T3 cell lines with the notable exception of SV40-transformed 3T3 cells leads to inhibition of DNA synthesis. Thus, gas1 appears to be one component of a negative circuit that governs growth suppression. Its effect is, however, abolished in SV40-transformed cells.	EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	DELSAL, G (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, CONSORTIUM INTERUNIV BIOTECHNOL LABS, AREA SCI PK, 99 PADRICIANO, I-34012 TRIESTE, ITALY.			DEL SAL, GIANNINO/0000-0003-2185-6003				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIGNAMI M, 1988, ONCOGENE, V2, P509; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; Harris H., 1970, CELL FUSION; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEDL T, 1984, J CELL BIOL, V99, P155, DOI 10.1083/jcb.99.1.155; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Schneider C, 1991, CURR OPIN CELL BIOL, V3, P276, DOI 10.1016/0955-0674(91)90152-O; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	72	248	257	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					595	607		10.1016/0092-8674(92)90429-G	http://dx.doi.org/10.1016/0092-8674(92)90429-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505026				2022-12-24	WOS:A1992JJ88600009
J	PFAFFLE, RW; DIMATTIA, GE; PARKS, JS; BROWN, MR; WIT, JM; JANSEN, M; VANDERNAT, H; VANDENBRANDE, JL; ROSENFELD, MG; INGRAHAM, HA				PFAFFLE, RW; DIMATTIA, GE; PARKS, JS; BROWN, MR; WIT, JM; JANSEN, M; VANDERNAT, H; VANDENBRANDE, JL; ROSENFELD, MG; INGRAHAM, HA			MUTATION OF THE POU-SPECIFIC DOMAIN OF PIT-1 AND HYPOPITUITARISM WITHOUT PITUITARY HYPOPLASIA	SCIENCE			English	Article							THYROID STIMULATING HORMONE; TRANSCRIPTION FACTOR; GROWTH-HORMONE; GENE-EXPRESSION; DNA-BINDING; PROLACTIN; PROTEIN	A point mutation in the POU-specific portion of the human gene that encodes the tissue-specific POU-domain transcription factor, Pit-1, results in hypopituitarism, with deficiencies of growth hormone, prolactin, and thyroid-stimulating hormone. In two unrelated Dutch families, a mutation in Pit-1 that altered an alanine in the first putative alpha-helix of the POU-specific domain to proline was observed. This mutation generated a protein capable of binding to DNA response elements but unable to effectively activate its known target genes, growth hormone and prolactin. The phenotype of the affected individuals suggests that the mutant Pit-1 protein is competent to initiate other programs of gene activation required for normal proliferation of somatotrope, lactotrope, and thyrotrope cell types. Thus, a mutation in the POU-specific domain of Pit- 1 has a selective effect on a subset of Pit-1 target genes.	EMORY UNIV,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,2040 RIDGEWOOD DR,ATLANTA,GA 30322; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV UTRECHT,DEPT PEDIAT,UTRECHT,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,VIROL LAB,BILTHOVEN,NETHERLANDS	Emory University; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utrecht University; Netherlands National Institute for Public Health & the Environment			Parks, John/F-8570-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477] Funding Source: NIH RePORTER; NICHD NIH HHS [HD2697, HD24960] Funding Source: Medline; NIDDK NIH HHS [NIDDK 18477] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1991, ENDOCRINE SOC ANN M; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DIMATTIA GE, UNPUB; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LEW AM, 1991, NUCLEIC ACIDS RES, V19, P6329, DOI 10.1093/nar/19.22.6329; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ROGOL AD, 1976, J PEDIATR-US, V88, P953, DOI 10.1016/S0022-3476(76)81048-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56; VANBUULOFFERS SC, 1984, THESIS U UTRECHT; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WINTER JSD, 1974, J CLIN ENDOCR METAB, V39, P356, DOI 10.1210/jcem-39-2-356; WIT JM, 1989, HORM RES, V32, P170, DOI 10.1159/000181284; YOSHIMOTO M, 1990, ACTA PAEDIATR SCAND, V79, P1247	23	378	387	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1118	1121		10.1126/science.257.5073.1118	http://dx.doi.org/10.1126/science.257.5073.1118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509263				2022-12-24	WOS:A1992JJ88400033
J	SHAANAN, B; GRONENBORN, AM; COHEN, GH; GILLILAND, GL; VEERAPANDIAN, B; DAVIES, DR; CLORE, GM				SHAANAN, B; GRONENBORN, AM; COHEN, GH; GILLILAND, GL; VEERAPANDIAN, B; DAVIES, DR; CLORE, GM			COMBINING EXPERIMENTAL INFORMATION FROM CRYSTAL AND SOLUTION STUDIES - JOINT X-RAY AND NMR REFINEMENT	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTERPROTON DISTANCE RESTRAINTS; AMYLASE INHIBITOR TENDAMISTAT; MOLECULAR-DYNAMICS; SINGLE-CRYSTALS; R-FACTOR; PROTEINS; INTERLEUKIN-1-BETA; DIFFRACTION; RESOLUTION	Joint refinement of macromolecules against crystallographic and nuclear magnetic resonance (NMR) observations is presented as a way of combining experimental information from the two methods. The model of interleukin-1-beta derived by the joint x-ray and NMR refinement is shown to be consistent with the experimental observations of both methods and to have crystallographic R value and geometrical parameters that are of the same quality as or better than those of models obtained by conventional crystallographic studies. The few NMR observations that are violated by the model serve as an indicator for genuine differences between the crystal and solution structures. The joint x-ray-NMR refinement can resolve structural ambiguities encountered in studies of multidomain proteins, in which low- to medium-resolution diffraction data can be complemented by higher resolution NMR data obtained for the individual domains.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892; NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,SHADY GROVE,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of Standards & Technology (NIST) - USA			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018; Shaanan, Boaz/F-1202-2012	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Shaanan, Boaz/0000-0001-8925-4362; Gronenborn, Angela M/0000-0001-9072-3525				BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BILLETER M, 1989, J MOL BIOL, V206, P677, DOI 10.1016/0022-2836(89)90575-5; BRAUN W, 1989, J MOL BIOL, V206, P669, DOI 10.1016/0022-2836(89)90574-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P1049, DOI 10.1126/science.235.4792.1049; BRUNGER AT, 1987, PROTEIN ENG, V1, P399, DOI 10.1093/protein/1.5.399; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 21; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, J MOL BIOL, V221, P47, DOI 10.1016/0022-2836(91)90802-D; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2316; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOCH JC, 1991, COMPUTATIONAL ASPECT, P57; HOLAK TA, 1989, J MOL BIOL, V210, P649, DOI 10.1016/0022-2836(89)90138-1; JACK A, 1978, ACTA CRYSTALLOGR A, V34, P931, DOI 10.1107/S0567739478001904; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WLODAWER A, 1982, ACTA CRYSTALLOGR A, V38, P239, DOI 10.1107/S0567739482000527; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719	25	60	62	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					961	964		10.1126/science.1502561	http://dx.doi.org/10.1126/science.1502561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502561				2022-12-24	WOS:A1992JH82700034
J	CLINTON, JJ				CLINTON, JJ			ACUTE PAIN MANAGEMENT CAN BE IMPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,OFF FORUM,SUITE 401,2101 E JEFFERSON ST,ROCKVILLE,MD 20852, USA.							1987, PAIN, V30, P69; 1989, ANESTHESIOL CLIN N A, V7, P1	2	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2580	2580		10.1001/jama.267.19.2580	http://dx.doi.org/10.1001/jama.267.19.2580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573734				2022-12-24	WOS:A1992HT82300004
J	DOLE, VP				DOLE, VP			HAZARDS OF PROCESS REGULATIONS - THE EXAMPLE OF METHADONE-MAINTENANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DOLE, VP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							WEBSTERS 9TH NEW COL	1	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2234	2235		10.1001/jama.267.16.2234	http://dx.doi.org/10.1001/jama.267.16.2234			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556800				2022-12-24	WOS:A1992HN84100036
J	DONOGHUE, MJ; MORRISVALERO, R; JOHNSON, YR; MERLIE, JP; SANES, JR				DONOGHUE, MJ; MORRISVALERO, R; JOHNSON, YR; MERLIE, JP; SANES, JR			MAMMALIAN MUSCLE-CELLS BEAR A CELL-AUTONOMOUS, HERITABLE MEMORY OF THEIR ROSTROCAUDAL POSITION	CELL			English	Article							MYOSIN HEAVY-CHAIN; DIFFERENT SEGMENTAL LEVELS; SKELETAL-MUSCLES; SELECTIVE REINNERVATION; MONOCLONAL-ANTIBODY; PATTERN-FORMATION; SATELLITE CELLS; MYOGENIC CELLS; RE-INNERVATION; NERVOUS-SYSTEM	We previously documented a > 100-fold rostrocaudal gradient of chloramphenicol acetyltransferase (CAT) expression in the muscles of adult mice that bear a myosin light chain-CAT transgene: successively more caudal muscles express successively higher levels of CAT. Here we studied the development and maintenance of this positional information in vitro. CAT levels reflect the rostrocaudal positions of the muscles from which the cells are derived in cultures established from adult muscles, in clones derived from individual adult myogenic (satellite) cells, in cultures prepared from embryonic myoblasts, and in cell lines derived by retrovirus-mediated transfer of an oncogene to satellite cells. Our results suggest that myoblasts bear a positional memory that is established in embryos, retained in adults, cell autonomous, heritable, stable to transformation, and accessible to study in clonal cell lines.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	DONOGHUE, MJ (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BENNETT MR, 1984, J NEUROSCI, V4, P2204; BIXBY JL, 1979, BRAIN RES, V169, P275, DOI 10.1016/0006-8993(79)91030-8; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; BROWN MC, 1983, NATURE, V304, P741, DOI 10.1038/304741a0; COSSU G, 1983, DEV BIOL, V98, P520, DOI 10.1016/0012-1606(83)90382-2; COSSU G, 1980, CELL DIFFER DEV, V9, P357, DOI 10.1016/0045-6039(80)90035-4; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DUSTERHOFT S, 1990, DIFFERENTIATION, V45, P185, DOI 10.1111/j.1432-0436.1990.tb00472.x; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; GAMBKE B, 1984, J BIOL CHEM, V259, P2092; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORZA L, 1990, J HISTOCHEM CYTOCHEM, V38, P257, DOI 10.1177/38.2.2137154; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREENE E.C., 1963, AM PHILOS SOC, V2, P227; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HAUSCHKA SD, 1974, DEV BIOL, V37, P329, DOI 10.1016/0012-1606(74)90153-5; HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P177; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KONIGSBERG I, 1961, P NATL ACAD SCI USA, V47, P1868, DOI 10.1073/pnas.47.11.1868; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Langley J N, 1895, J Physiol, V18, P280; LASKOWSKI MB, 1988, J NEUROSCI, V8, P3094; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PURVES D, 1981, J PHYSIOL-LONDON, V313, P49, DOI 10.1113/jphysiol.1981.sp013650; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, HDB MIKROSKOPISCHEN, V11; SENNI MI, 1986, DIFFERENTIATION, V32, P181, DOI 10.1111/j.1432-0436.1986.tb00571.x; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; STREHLER EE, 1985, MOL CELL BIOL, V5, P3168, DOI 10.1128/MCB.5.11.3168; SUZUE T, 1990, NEURON, V5, P421, DOI 10.1016/0896-6273(90)90081-P; SWETT JE, 1970, AM J PHYSIOL, V219, P762, DOI 10.1152/ajplegacy.1970.219.3.762; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; THOMPSON WJ, 1990, J NEUROBIOL, V21, P212, DOI 10.1002/neu.480210114; TRISLER D, 1990, J EXP BIOL, V153, P11; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	58	82	83	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					67	77		10.1016/0092-8674(92)90119-W	http://dx.doi.org/10.1016/0092-8674(92)90119-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555243				2022-12-24	WOS:A1992HM44500007
J	BARZILAY, J; WARRAM, JH; RAND, LI; PFEIFER, MA; KROLEWSKI, AS				BARZILAY, J; WARRAM, JH; RAND, LI; PFEIFER, MA; KROLEWSKI, AS			RISK FOR CARDIOVASCULAR AUTONOMIC NEUROPATHY IS ASSOCIATED WITH THE HLA-DR3/4 PHENOTYPE IN TYPE-I DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS, INSULIN-DEPENDENT; DIABETIC NEUROPATHIES; CARDIOVASCULAR DISEASES; HLA-DR ANTIGENS	SUBCUTANEOUS INSULIN INFUSION; HEART-RATE-VARIABILITY; METABOLIC CONTROL; NERVE FUNCTION; TRANSPLANTATION; RETINOPATHY; NEPHROPATHY; PREVALENCE; EXPERIENCE; TESTS	Objective: To identify risk factors for the development of cardiovascular autonomic neuropathy in patients with juvenile-onset type I diabetes mellitus. Design: Cross-sectional examination of an inception cohort 15 to 21 years after the onset of diabetes. Setting: Outpatient diabetes clinic. Patients: Seventy-nine patients with type I diabetes who experienced onset of disease before 21 years of age and who were followed for 15 to 21 years. Measurements: Autonomic nerve function was evaluated in all patients using deep breathing and tilt tests. On the basis of these tests, an index of cardiovascular autonomic neuropathy was derived and patients were classified as having intact, mildly impaired, or significantly impaired autonomic function. Results: The group with significantly impaired function had a higher mean hemoglobin A1 at the time of examination than the group without impairment, yet the groups did not differ regarding glycemic control during the first decade of diabetes. The HLA-DR3/4 phenotype was present in more than 50% of the patients with significant autonomic dysfunction and conferred relative odds of 6.2 (95% CI, 1.7 to 23.3) for the development of autonomic neuropathy when compared with other HLA-DR phenotypes. Sex, percent ideal body weight, and smoking did not have a statistically significant effect on the development of autonomic neuropathy. Conclusions: The development of cardiovascular autonomic neuropathy in type I diabetes mellitus is strongly associated with the HLA-DR3/4 phenotype. Thus, genetic predisposition may play an important role in the development of this complication.	JOSLIN DIABET CTR, DIV RES, EPIDEMIOL & GENET SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA; HUMANA HOSP, LEXINGTON, KY USA	Harvard University; Joslin Diabetes Center, Inc.					NATIONAL EYE INSTITUTE [R01EY002636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02636] Funding Source: Medline; NIDDK NIH HHS [DK-41526] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPENZELLER O, 1965, J NEUROL NEUROSUR PS, V28, P510, DOI 10.1136/jnnp.28.6.510; BECKER W, 1979, J AUTONOM NERV SYST, V1, P53, DOI 10.1016/0165-1838(79)90005-5; BERGSTROM B, 1987, ACTA MED SCAND, V222, P147; BODANSKY HJ, 1982, DIABETES, V31, P70, DOI 10.2337/diabetes.31.1.70; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; BRODOWS RG, 1986, DIABETES CARE, V9, P189, DOI 10.2337/diacare.9.2.189; BROWN FM, 1989, DIABETES, V38, P938, DOI 10.2337/diabetes.38.7.938; CICMIR I, 1983, DIABETOLOGIA, V25, P147; DORNAN TL, 1982, DIABETES, V31, P226, DOI 10.2337/diabetes.31.3.226; DUCHEN LW, 1980, ANN INTERN MED, V92, P301, DOI 10.7326/0003-4819-92-2-301; DUNN PJ, 1979, METABOLISM, V28, P777, DOI 10.1016/0026-0495(79)90185-9; DYRBERG T, 1981, DIABETOLOGIA, V20, P190; EWING DJ, 1986, DIABETES CARE, V9, P648, DOI 10.2337/diacare.9.6.648; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; FEDELE D, 1985, HORM METAB RES, V17, P410, DOI 10.1055/s-2007-1013560; GAMBARDELLA S, 1983, J ENDOCRINOL INVEST, V6, P363, DOI 10.1007/BF03347617; GILBEY SG, 1988, DIABETIC MED, V5, P845, DOI 10.1111/j.1464-5491.1988.tb01122.x; GILBEY SG, 1986, DIABETIC MED, V3, P241, DOI 10.1111/j.1464-5491.1986.tb00753.x; GUY RJC, 1984, BRIT MED J, V289, P343, DOI 10.1136/bmj.289.6441.343; HILSTED J, 1979, ACTA MED SCAND, V205, P385; HILSTED J, 1982, DIABETES, V31, P730, DOI 10.2337/diab.31.8.730; JAKOBSEN J, 1988, DIABETES, V37, P452, DOI 10.2337/diabetes.37.4.452; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KROLEWSKI AS, 1992, IN PRESS DIABETES, V41; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; MCCLUSKEY J, 1983, DIABETOLOGIA, V24, P162; OBRIEN IAD, 1986, Q J MED, V61, P957; PFEIFER MA, 1984, DIABETES CARE, V7, P447, DOI 10.2337/diacare.7.5.447; PFEIFER MA, 1982, DIABETES, V31, P339, DOI 10.2337/diabetes.31.4.339; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; ROY TM, 1989, AM J MED, V87, P382; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SCHMIDT RE, 1983, DIABETES, V32, P532, DOI 10.2337/diabetes.32.6.532; SMITH SA, 1986, DIABETIC MED, V3, P330; SOLDERS G, 1987, LANCET, V2, P1232; SUNDKVIST G, 1981, DIABETES CARE, V4, P529, DOI 10.2337/diacare.4.5.529; VIBERTI GC, 1982, LANCET, V1, P1430; WIELING W, 1983, DIABETOLOGIA, V24, P422, DOI 10.1007/BF00257340; YOUNG RJ, 1983, DIABETES, V32, P142, DOI 10.2337/diabetes.32.2.142; ZACHARY A, 1981, AACHT LABORATORY MAN; ZHANG WX, 1990, DIABETES, V39, P613, DOI 10.2337/diabetes.39.5.613	42	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					544	549		10.7326/0003-4819-116-7-544	http://dx.doi.org/10.7326/0003-4819-116-7-544			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543308				2022-12-24	WOS:A1992HL25800004
J	BUSCH, AE; VARNUM, MD; NORTH, RA; ADELMAN, JP				BUSCH, AE; VARNUM, MD; NORTH, RA; ADELMAN, JP			AN AMINO-ACID MUTATION IN A POTASSIUM CHANNEL THAT PREVENTS INHIBITION BY PROTEIN-KINASE-C	SCIENCE			English	Article							K+-CHANNEL; MEMBRANE-PROTEIN; XENOPUS OOCYTES; ION CHANNELS; RAT UTERUS; PHOSPHORYLATION; MODULATION; CLONING; HEART; EXPRESSION	A slowly activating, voltage-dependent potassium channel protein cloned from rat kidney was expressed in Xenopus oocytes. Two activators of protein kinase C, 1-oleoyl-2-acetyl-rac-glycerol and phorbol 12,13-didecanoate, inhibited the current. This inhibition was blocked by the kinase inhibitor staurosporine. Inhibition of the current was not seen in channels in which Ser103 was replaced by Ala, although other properties of the current were unchanged. These results indicate that inhibition of the potassium current results from direct phosphorylation of the channel subunit protein at Ser103.			BUSCH, AE (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022		NIDA NIH HHS [DA03160] Funding Source: Medline; NINDS NIH HHS [NS28504] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003160, R37DA003160] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BUSCH AE, IN PRESS J PHYSL LON; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HURST RS, 1991, MOL PHARMACOL, V40, P572; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; MORAN O, 1991, FEBS LETT, V279, P256, DOI 10.1016/0014-5793(91)80162-V; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PEROZO E, 1990, NEURON, V5, P685, DOI 10.1016/0896-6273(90)90222-2; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; SHEARMAN MS, 1989, PHARMACOL REV, V41, P212; SULLIVAN SK, 1990, P NATL ACAD SCI USA, V87, P4553, DOI 10.1073/pnas.87.12.4553; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TANIYAMA K, 1991, FEBS LETT, V278, P222, DOI 10.1016/0014-5793(91)80121-I; TOHSE N, 1987, AM J PHYSIOL, V253, pH1321, DOI 10.1152/ajpheart.1987.253.5.H1321; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575	26	88	91	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1705	1707		10.1126/science.1553557	http://dx.doi.org/10.1126/science.1553557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553557				2022-12-24	WOS:A1992HK81200038
J	TARLETON, RL; KOLLER, BH; LATOUR, A; POSTAN, M				TARLETON, RL; KOLLER, BH; LATOUR, A; POSTAN, M			SUSCEPTIBILITY OF BETA-2-MICROGLOBULIN-DEFICIENT MICE TO TRYPANOSOMA-CRUZI INFECTION	NATURE			English	Article							CD8+ T-CELLS; SUPPRESSOR CELLS; RESISTANCE; DEFICIENT; INCREASES	THE beta-2-microglobulin (beta-2m) protein associates with the products of the class I major histocompatibility (MHC) loci; this combination functions in the thymic development of and antigen presentation to CD8+ T cells. Mice in which the beta-2m gene has been disrupted by homologous recombination fail to express class I MHC gene products, and therefore lack CD8+ T cells and measurable cytotoxic T-cell responses 1,2. However, beta-2m- mice appear to have normal development of both CD4+ alpha/beta-T-cell receptor (TCR+) and gamma/delta-TCR+ T cells and are not overtly more susceptible than beta-2-m+ mice to potential environmental agents of infection 1,2 or to experimental viral infection 3. Here we show that beta-2m- mice suffer high parasitaemias and early death when infected with the obligate cytoplasmic protozoan parasite Trypanosoma cruzi. Despite this increased susceptibility, the beta-2m- mice are more responsive than their beta-2m+ littermates in terms of lymphokine production, making higher levels of both interleukin-2 and interferon-gamma in response to mitogen stimulation. In addition, the beta-2m- mice show essentially no inflammatory response in parasite-infected tissues. These results confirm previous experiments on mice depleted of CD8+ cells using antibody treatment 4 in demonstrating the importance of CD8+ T cells in immune protection in T. cruzi infection. They also implicate CD8+ T cells and/or class I MHC molecules in regulation of lymphokine production and recruitment of inflammatory cells.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	TARLETON, RL (corresponding author), UNIV GEORGIA,DEPT ZOOL,ATHENS,GA 30602, USA.		Tarleton, Rick/AES-8572-2022	Tarleton, Rick/0000-0002-9589-5243				ANDRADE ZA, 1983, CIBA F SYMP, V99, P214; ARAUJO FG, 1989, INFECT IMMUN, V57, P2246, DOI 10.1128/IAI.57.7.2246-2248.1989; BELTZ LA, 1989, INT J PARASITOL, V19, P555, DOI 10.1016/0020-7519(89)90086-6; CUNNINGHAM DS, 1978, INFECT IMMUN, V22, P155, DOI 10.1128/IAI.22.1.155-160.1978; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Krettli A. U., 1984, Memorias do Instituto Oswaldo Cruz, V79, P59, DOI 10.1590/S0074-02761984000500013; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MINOPRIO P, 1991, RES IMMUNOL, V142, P137, DOI 10.1016/0923-2494(91)90024-D; NABORS GS, 1991, J IMMUNOL, V146, P3591; POSTAN M, 1986, T ROY SOC TROP MED H, V80, P50, DOI 10.1016/0035-9203(86)90193-8; RAMOS C, 1979, J IMMUNOL, V122, P1243; RIBEIRODOSSANTOS R, 1991, RES IMMUNOL, V142, P134, DOI 10.1016/0923-2494(91)90023-C; ROTTENBERG M, 1988, SCAND J IMMUNOL, V28, P573, DOI 10.1111/j.1365-3083.1988.tb01489.x; RUSSO M, 1988, ANN INST PASTEUR IMM, V139, P225, DOI 10.1016/0769-2625(88)90136-5; Santos-Buch C. A., 1985, Immunology and pathogenesis of trypanosomiasis, P145; SCOTT MT, 1981, IMMUNOLOGY, V44, P409; TARLETON RL, 1988, J IMMUNOL, V140, P2769; TARLETON RL, 1990, J IMMUNOL, V144, P717; TRISCHMANN TM, 1983, J IMMUNOL, V130, P1953; YOUNESCHENNOUFI AB, 1988, T ROY SOC TROP MED H, V82, P84, DOI 10.1016/0035-9203(88)90271-4; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	23	328	332	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					338	340		10.1038/356338a0	http://dx.doi.org/10.1038/356338a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549177				2022-12-24	WOS:A1992HK79400064
J	OTTE, AP; MOON, RT				OTTE, AP; MOON, RT			PROTEIN-KINASE-C ISOZYMES HAVE DISTINCT ROLES IN NEURAL INDUCTION AND COMPETENCE IN XENOPUS	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYOS; EXPRESSION; LAEVIS; GENES; RNA; DIFFERENTIATION; ACTIVATION; ECTODERM; ANTERIOR	The restricted ability of embryonic tissue to respond to inductive signals is controlled by a poorly understood phenomenon, termed competence. In Xenopus, dorsal ectoderm is more competent than ventral ectoderm to become induced to neural tissue. We tested whether the Xenopus protein kinase C (PKC) isozymes-alpha and beta have a role in neural induction and competence. We found that PKC-alpha is predominantly localized in dorsal ectoderm, whereas PKC-beta is uniformly distributed. Overexpression of PKC-beta conveys a higher propensity for neural differentiation to both dorsal and ventral ectoderm, but their difference in competence remains. However, ectopic expression of PKC-alpha elevates the level of neural competence of ventral ectoderm to that of dorsal ectoderm. These data indicate that different PKC isozymes have distinct roles in mediating both neural induction and competence.			OTTE, AP (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837] Funding Source: NIH RePORTER; NIAMS NIH HHS [K04 AR 1837] Funding Source: Medline; NICHD NIH HHS [R01 HD 2 7525] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Chen K H, 1988, Second Messengers Phosphoproteins, V12, P251; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DAVIDS M, 1988, ROUX ARCH DEV BIOL, V197, P339, DOI 10.1007/BF00375953; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GURDON JB, 1989, DEVELOPMENT, V105, P27; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1987, J BIOL CHEM, V262, P15714; JONES EA, 1989, DEVELOPMENT, V107, P785; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LAFLAMME SE, 1988, GENE DEV, V2, P853, DOI 10.1101/gad.2.7.853; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Moon R. T., 1989, TECHNIQUE, V1, P76; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OTTE AP, 1990, DEVELOPMENT, V110, P461; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; OTTE AP, 1988, NATURE, V334, P618, DOI 10.1038/334618a0; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SHARPE CR, 1988, DEVELOPMENT, V103, P269; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SHARPE CR, 1989, DEVELOPMENT, V107, P710; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Smith JC, 1989, CURR OPIN CELL BIOL, V1, P1061, DOI 10.1016/S0955-0674(89)80051-1; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WALKER JM, 1990, J BIOL CHEM, V265, P8016	45	106	107	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1021	1029		10.1016/0092-8674(92)90074-M	http://dx.doi.org/10.1016/0092-8674(92)90074-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547501				2022-12-24	WOS:A1992HK67400006
J	FARRELL, M; STRANG, J				FARRELL, M; STRANG, J			MEDICINE IN EUROPE .11. ALCOHOL AND DRUGS	BRITISH MEDICAL JOURNAL			English	Article									BETHLEM ROYAL & MAUDSLEY HOSP,DRUG DEPENDENCE CLIN RES & TREATMENT UNIT,BECKENHAM BR3 3BX,ENGLAND	South London & Maudsley NHS Trust	FARRELL, M (corresponding author), INST PSYCHIAT,NATL ADDICT CTR,LONDON SE5 8AF,ENGLAND.		Farrell, Michael P/A-4769-2012; Strang, John/H-5460-2011	Farrell, Michael P/0000-0001-7008-8130; Strang, John/0000-0002-5413-2725				Bruun K., 1975, ALCOHOL CONTROL POLI; FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; HARDING T, 1990, HIV AIDS EUROPEAN PR; LEROY B, 1991, COMMUNITY 12 DRUG DE; MCGUINESS AJ, 1991, ALCOHOL TAXATION EUR; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; Stimson G., 1987, LAND FIT HEROIN; WALDEGRAVE W, 1992, BRIT MED J, V304, P56, DOI 10.1136/bmj.304.6818.56-c; WALSH D, 1982, WHO17 PUBL HLTH EUR; 1987, MULTICITY STUDY DRUG; 1986, ALCOHOL OUR FAVOURIT; 1990, STATISTICAL HDB; 1990, OFFICIAL J EUROPEAN, V33, P12; 1991, 30 EUR CTR EP MON AI; 1981, ALCOHOL REDUCING HAR	15	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					489	491		10.1136/bmj.304.6825.489	http://dx.doi.org/10.1136/bmj.304.6825.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547425	Green Published, Bronze			2022-12-24	WOS:A1992HF55500028
J	CAO, L; FAHA, B; DEMBSKI, M; TSAI, LH; HARLOW, E; DYSON, N				CAO, L; FAHA, B; DEMBSKI, M; TSAI, LH; HARLOW, E; DYSON, N			INDEPENDENT BINDING OF THE RETINOBLASTOMA PROTEIN AND P107 TO THE TRANSCRIPTION FACTOR E2F	NATURE			English	Article							LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; POLYACRYLAMIDE GELS; SV40; TRANSFORMATION; REGIONS; CELLS	THE cellular protein p107 and the retinoblastoma protein (pRB) have many features in common. Most strikingly, they contain homologous protein domains that mediate interaction with the oncoproteins of several small DNA tumour viruses, including adenovirus E1A and SV40 large-T antigen 1-9. In cells that do not contain these viral oncoproteins, pRB interacts with the cellular transcription factor E2F (refs 10-12) or a related protein termed DRTF1 (ref. 13). E2F associates with a form of pRB that is found primarily in G1 cells 10. It seems that the E2F-pRB complex dissociates near the G1-S boundary before the initiation of S phase, releasing free E2F and apparently, stimulating the ability of E2F to activate transcription 14. Cells that express E1A have no or little pRB-E2F complex, presumably because of the association of E1A with pRB 10,15. During S phase, E2F forms a second complex that contains cyclin A but apparently lacks pRB 1-5. Here, we report that p107 is found in the cyclin A/E2F complex and that this complex also contains p33cdk2. These observations suggest that p107 and pRB cooperate in the regulation of E2F activity, each affecting different stages of the cell cycle. Thus, by binding to pRB and p107, E1A and large-T antigen target two distinct aspects of E2F regulation.	MASSACHUSETTS GEN HOSP CANC CTR, BLDG 149, 13TH ST, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital			Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, IN PRESS SCIENCE; FAHA B, IN PRESS SCIENCE; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, IN PRESS GENES DEV; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYERSON M, IN PRESS COLD SPRING, V58; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	35	386	394	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					176	179		10.1038/355176a0	http://dx.doi.org/10.1038/355176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1530885				2022-12-24	WOS:A1992GY62900063
J	FAHA, B; EWEN, ME; TSAI, LH; LIVINGSTON, DM; HARLOW, E				FAHA, B; EWEN, ME; TSAI, LH; LIVINGSTON, DM; HARLOW, E			INTERACTION BETWEEN HUMAN CYCLIN-A AND ADENOVIRUS E1A-ASSOCIATED P107 PROTEIN	SCIENCE			English	Article							LARGE T-ANTIGEN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; E1A PROTEINS; BINDING; COMPLEXES; REGIONS; PRODUCT; GENE	The products of the adenovirus early region IA (EIA) gene are potent oncoproteins when tested in standard transformation and immortalization assays. Many of the changes induced by EIA may be due to its interaction with cellular proteins. Four of these cellular proteins are the retinoblastoma protein (pRB), p107, cyclin A, and p33cdk2. The pRB and p107 proteins are structurally related and have several characteristics in common, including that they both bind to the SV40 large T oncoprotein as well as to E1A. Cyclin A and p33cdk2 are thought to function in the control of the cell cycle. They bind to one another, forming a kinase that closely resembles the cell cycle-regulating complexes containing p34cdc2. Cyclin A is now shown to bind to p107 in the absence of E1A. The association of p107 with cyclin A suggests a direct link between cell cycle control and the function of p107.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FAHA, B (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA.				NCI NIH HHS [CA 13106, CA 55339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DYSON N, UNPUB; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, UNPUB; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU Q, IN PRESS MOL CELL BI; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, UNPUB	30	220	223	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1992	255	5040					87	90		10.1126/science.1532458	http://dx.doi.org/10.1126/science.1532458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532458				2022-12-24	WOS:A1992GX79100044
J	BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J				BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J			A STRATEGY FOR DELIVERING PEPTIDES INTO THE CENTRAL-NERVOUS-SYSTEM BY SEQUENTIAL METABOLISM	SCIENCE			English	Article							BLOOD-BRAIN-BARRIER; RAT-BRAIN; ENKEPHALIN; AMINOPEPTIDASE	Most peptides do not enter the central nervous system because of their hydrophilic character and the presence of peptidolytic enzymes in the lipoidal blood-brain barrier. To achieve brain delivery of a peptide conjugate, an opioid peptide (enkephalin) was placed in a molecular environment that disguises its peptide nature and provides biolabile, lipophilic functions to penetrate the blood-brain barrier by passive transport. The strategy also incorporates a 1,4-dihydrotrigonellinate targetor that undergoes an enzymatically mediated oxidation to a hydrophilic, membrane-impermeable trigonellinate salt. The polar targetor-peptide conjugate that is trapped behind the lipoidal blood-brain barrier is deposited in the central nervous system. Analgesia was observed with "packaged" enkephalin but not with the unmodified peptide or lipophilic peptide precursors.			BODOR, N (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL PHARM,CTR DRUG DISCOVERY,GAINESVILLE,FL 32610, USA.			Prokai, Laszlo/0000-0002-4559-3458	NIA NIH HHS [1 PO AG10485] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010485] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BODOR N, 1983, SCIENCE, V221, P65, DOI 10.1126/science.6857264; Bodor N., 1983, PHARMACOL THERAPEUT, V19, P337; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; GIBSON AM, 1989, NEUROPEPTIDES, V13, P259, DOI 10.1016/0143-4179(89)90079-6; GORENSTEIN C, 1980, PROC R SOC SER B-BIO, V210, P123, DOI 10.1098/rspb.1980.0123; HAMBROOK JM, 1976, NATURE, V262, P782, DOI 10.1038/262782a0; HERSH LB, 1987, PEPTIDES, V8, P523, DOI 10.1016/0196-9781(87)90019-2; HOEK JB, 1988, BIOCHEM J, V254, P1; ITO F, 1984, MOL CELL ENDOCRINOL, V36, P165, DOI 10.1016/0303-7207(84)90032-7; McKelvy J.F., 1983, P117; NEUWELT EA, 1984, FED PROC, V43, P214; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; PARDRIDGE WM, 1981, ENDOCRINOLOGY, V109, P1138, DOI 10.1210/endo-109-4-1138; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PARDRIDGE WM, 1991, PEPTIDE DRUG DELIVER, P244; POPLACK DG, 1981, NEUROBIOLOGY CEREBRO, P561; TSUZUKI N, 1991, BIOCHEM PHARMACOL, V41, pR5, DOI 10.1016/0006-2952(91)90616-D	18	128	139	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1698	1700		10.1126/science.1529356	http://dx.doi.org/10.1126/science.1529356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529356				2022-12-24	WOS:A1992JN50100035
J	HOWEY, J				HOWEY, J			AIDS CARE CURRICULUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1227	1227		10.1001/jama.268.10.1227	http://dx.doi.org/10.1001/jama.268.10.1227			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507360				2022-12-24	WOS:A1992JL60800001
J	SIMONS, M; EDELMAN, ER; DEKEYSER, JL; LANGER, R; ROSENBERG, RD				SIMONS, M; EDELMAN, ER; DEKEYSER, JL; LANGER, R; ROSENBERG, RD			ANTISENSE C-MYB OLIGONUCLEOTIDES INHIBIT INTIMAL ARTERIAL SMOOTH-MUSCLE CELL ACCUMULATION INVIVO	NATURE			English	Article							FIBROBLAST GROWTH-FACTOR; VASCULAR INJURY; PROLIFERATION; HEPARIN; ANGIOPLASTY; EXPRESSION; ANTIBODY	SYNTHETIC antisense oligonucleotides have been used to dissect gene function in vitro. Technical difficulties prevented the use of this approach for investigating the effect of gene products in vivo. Here we report the use of local delivery of antisense c-myb oligonucleotide to suppress intimal accumulation of rat carotid arterial smooth muscle cells. Our results suggest that antisense oligonucleotides can be used to define the in vivo biological role of specific macromolecules in the blood vessel wall and could potentially serve as a new class of therapeutic agents for cardiovascular disorders.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DIV HLTH SCI TECHNOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1983, LAB INVEST, V49, P327; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; DILLEY RJ, 1987, ATHEROSCLEROSIS, V63, P99, DOI 10.1016/0021-9150(87)90109-2; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JONASSON L, 1988, P NATL ACAD SCI USA, V85, P2303, DOI 10.1073/pnas.85.7.2303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PUKAC LA, 1991, AM J PATHOL, V139, P1501; REILLY CF, 1989, J BIOL CHEM, V264, P6990; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0	24	680	821	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					67	70		10.1038/359067a0	http://dx.doi.org/10.1038/359067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522889				2022-12-24	WOS:A1992JL66200055
J	MEADOR, WE; MEANS, AR; QUIOCHO, FA				MEADOR, WE; MEANS, AR; QUIOCHO, FA			TARGET ENZYME RECOGNITION BY CALMODULIN - 2.4-ANGSTROM STRUCTURE OF A CALMODULIN-PEPTIDE COMPLEX	SCIENCE			English	Article							LIGHT-CHAIN KINASE; BINDING DOMAIN; CENTRAL HELIX; TROPONIN-C; MYOSIN; ACTIVATION; SEQUENCE; SITE	The crystal structure of calcium-bound calmodulin (Ca2+-CaM) bound to a peptide analog of the CaM-binding region of chicken smooth muscle myosin light chain kinase has been determined and refined to a resolution of 2.4 angstroms (angstrom). The structure is compact and has the shape of an ellipsoid (axial ratio approximately 2:1). The bound CaM forms a tunnel diagonal to its long axis that engulfs the helical peptide, with the hydrophobic regions of CaM melded into a single area that closely covers the hydrophobic side of the peptide. There is a remarkably high pseudo-twofold symmetry between the closely associated domains. The central helix of the native CaM is unwound and expanded into a bend between residues 73 and 77. About 185 contacts (<4 angstrom) are formed between CaM and the peptide, with van der Waals contacts comprising approximately 80% of this total.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Duke University								BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRUNGER AT, 1990, XPLOR VERSION 2 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHATTOPADHYAYA R, IN PRESS J MOL BIOL; COX JA, 1985, J BIOL CHEM, V260, P2527; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; LUKAS TS, 1988, COLD SPRING HARB SYM, V63, P185; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, P501; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Seeholzer S.H., 1987, CALCIUM BINDING PROT, P360; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TOROK K, 1992, BIOCHEMISTRY-US, V31, P3452, DOI 10.1021/bi00128a020; VANBERKUM MF, 1990, J BIOL CHEM, V265, P3950; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VORHERR T, 1992, EUR J BIOCHEM, V204, P931, DOI 10.1111/j.1432-1033.1992.tb16714.x; VORHERR T, 1990, BIOCHEMISTRY, V29	38	978	985	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1251	1255		10.1126/science.1519061	http://dx.doi.org/10.1126/science.1519061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519061				2022-12-24	WOS:A1992JL05000025
J	TIESZEN, ME; GRUENBERG, JC				TIESZEN, ME; GRUENBERG, JC			A QUANTITATIVE, QUALITATIVE, AND CRITICAL-ASSESSMENT OF SURGICAL WASTE - SURGEONS VENTURE THROUGH THE TRASH CAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To quantitatively and qualitatively evaluate the surgical waste produced from several common surgical procedures, define categories of waste that might be readily separated for alternative disposal practices or substitution, and determine the change in surgical waste output that elimination or alternative handling methods may effect. Design.-A case series evaluating the surgical waste from five types of surgical procedures including operations of the back, heart, abdomen, hip and knee, and herniorrhaphies, prospectively identified and allocated at the availability of the investigator. Setting.-A single tertiary community teaching hospital. Outcome Measures.-Weight, volume, and percentage of disposable linen, paper, and plastic plus miscellaneous material from surgical waste with a later subset separating plastics from miscellaneous items to completely identify all categories Results.-Surgical waste weighing 610.5 lb (274.7 kg) and occupying 171.6 cu ft (5.1 m3) from 27 cases was examined. Disposable linens accounted for 39% of the weight; paper, 7%; plastic, 26%; and miscellaneous waste, 27%. By volume, disposable linen and paper accounted for 69%; plastic, 23%; and miscellaneous waste, 7%. Disposable linen, paper, and recyclable plastic accounted for 73% +/- 7% (mean +/- SD) by weight and 93% +/- 4% by volume of total surgical waste. Conclusion.-Nationally, annual surgical waste from these five procedures weighs 5.1 X 10(7) lb (2.3 X 10(7) kg) and occupies 1.4 X 10(7) cu ft (4.0 X 10(5) m3). By using reusable linen products and engaging in recycling methods currently available and feasible, we estimate that weight reductions of 73% and volume reductions of 93% in surgical waste are possible.	SAGINAW COOPERAT HOSP INC, DEPT SURG, 1000 HOUGHTON, SAGINAW, MI 48602 USA									Burks J, 1988, Hosp Mater Manage Q, V9, P17; CHADZYNSKI L, 1990, MICH MED, V89, P17; DANCER JW, 1991, MICHIGAN HOSP, V27, P4; Dutlinger B, 1987, J Healthc Mater Manage, V5, P61; Fay M F, 1990, AORN J, V51, P1493, DOI 10.1016/S0001-2092(07)66899-9; GRAVES EJ, 1991, VITAL HLTH STAT 13, V107; GROSSMAN D, 1990, DISCOVER        0411, P36; KUNES E, 1988, OMNI             FEB, P40; KUNES E, 1988, OMNI             FEB, P92; MATHIAS JM, 1990, OR MANAGER, V6, P9; Patterson P, 1990, OR Manager, V6, P8; PATTERSON P, 1990, OR MANAGER, V6, P8; PATTERSON P, 1990, OR MANAGER, V6, P6; RATHJE WL, 1991, NATIONAL GEOGRAP MAY, P117; RUTALA WA, 1989, JAMA-J AM MED ASSOC, V262, P1635, DOI 10.1001/jama.262.12.1635; WAGNER M, 1990, MOD HEALTHCARE, V20, P46; 1985, HOSP PURCHASING NEWS, V9, P14; 1989, JAMA-J AM MED ASSOC, V262, P1669; 1987, MMWR S, V36, pS2; 1985, HOSP PURCHASING NEWS, V9, P26; 1988, INVESTIGATION SOURCE	21	46	47	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2765	2768		10.1001/jama.267.20.2765	http://dx.doi.org/10.1001/jama.267.20.2765			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578596				2022-12-24	WOS:A1992HV26500024
J	SPOLSKY, CM; PHILLIPS, CA; UZZELL, T				SPOLSKY, CM; PHILLIPS, CA; UZZELL, T			ANTIQUITY OF CLONAL SALAMANDER LINEAGES REVEALED BY MITOCHONDRIAL-DNA	NATURE			English	Article							LIZARDS GENUS CNEMIDOPHORUS; RELATIVE AGE; ORIGIN; EVOLUTION; COMPLEX; FISHES	THE existence of clonally reproducing vertebrates has often served as a foil in attempts to explain the near-ubiquity of sexual reproduction in eukaryotes, but the absence of recombination, with its attendant limitation of new genotypes to those produced through mutations, restricts the adaptive ability of clonal organisms 1-3. It has been argued, therefore, that clonal vertebrate taxa have short lifespans 4-14. Variation in mitochondrial DNA (mtDNA) within clonal populations is interpreted instead as reflecting multiple, although limited, independent hybridization events 8-13,15. On the basis of an analysis of an average of 373 nucleotide pairs, we report here that the mtDNA of clonal, hybrid, gynogenetic mole salamanders (Ambystoma, Ambystomatidae) differs by 5% or more from mtDNA of their closest possible sexual relatives (A. jeffersonianum, A. laterale and A. texanum). Assuming usual rates of mtDNA divergence, these lineages have persisted for about 5 million years, far longer than estimated for other clonal vertebrate populations. The low mtDNA variability in the clonal lineages suggests that they have undergone population reductions during the Pleistocene.			SPOLSKY, CM (corresponding author), UNIV ILLINOIS, DEPT ECOL ETHOL & EVOLUT, URBANA, IL 61801 USA.							AVISE JC, 1987, MOL BIOL EVOL, V4, P514; Bell G., 1982, MASTERPIECE NATURE; Bogart James P., 1989, New York State Museum Bulletin, V466, P170; BROWER AVZ, 1991, EVOLUTION, V45, P1281, DOI [10.2307/2409734, 10.1111/j.1558-5646.1991.tb04393.x]; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CLANTON WESLEY, 1934, OCC PAPERS MUS ZOOL UNIV MICH, V290, P1; DENSMORE LD, 1989, EVOLUTION, V43, P969, DOI 10.1111/j.1558-5646.1989.tb02543.x; DENSMORE LD, 1989, EVOLUTION, V43, P943, DOI 10.1111/j.1558-5646.1989.tb02541.x; ECHELLE AA, 1989, EVOLUTION, V43, P984, DOI 10.1111/j.1558-5646.1989.tb02544.x; Felsenstein J., 1984, P169; Goddard KA, 1989, EVOLUTION ECOLOGY UN, V466, P268; KRAUS F, 1990, P NATL ACAD SCI USA, V87, P2235, DOI 10.1073/pnas.87.6.2235; Lowcock Leslie Anthony, 1989, New York State Museum Bulletin, V466, P180; MACGREGOR HC, 1964, SCIENCE, V143, P1043, DOI 10.1126/science.143.3610.1043; Maynard Smith J., 1978, EVOLUTION SEX; MINTON SHERMAN A., 1954, HERPETOLOGICA, V10, P173; MORITZ C, IN PRESS GENETICA; MORITZ C, 1989, B NEW YORK STATE MUS, V466, P87; MORITZ CC, 1989, EVOLUTION, V43, P958, DOI 10.1111/j.1558-5646.1989.tb02542.x; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; QUATTRO JM, 1991, GENETICS, V127, P391; SHELDON FH, 1987, MOL BIOL EVOL, V4, P56; SHIELDS GF, 1987, J MOL EVOL, V24, P212, DOI 10.1007/BF02111234; SPOLSKY C, 1986, MOL BIOL EVOL, V3, P44; SPOLSKY CM, IN PRESS EVOLUTION; UZZELL TM, 1967, EVOLUTION, V21, P345, DOI 10.1111/j.1558-5646.1967.tb00163.x; UZZELL TM, 1964, COPEIA, P247; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WRIGHT JW, 1983, HERPETOLOGICA, V39, P410	29	91	97	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1992	356	6371					706	708		10.1038/356706a0	http://dx.doi.org/10.1038/356706a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570013				2022-12-24	WOS:A1992HQ14600058
J	KIM, SH				KIM, SH			BETA-RIBBON - A NEW DNA RECOGNITION MOTIF	SCIENCE			English	Editorial Material							BINDING; PROTEIN; RNA; MODEL		UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	KIM, SH (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.							BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; SOMERS W, UNPUB; SOMERS WS, 1990, THESIS U LEEDS UK; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WARRANT RW, 1978, NATURE, V271, P130, DOI 10.1038/271130a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	12	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1217	1218		10.1126/science.1546321	http://dx.doi.org/10.1126/science.1546321			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546321				2022-12-24	WOS:A1992HG67700031
J	ALBRIGHT, TD				ALBRIGHT, TD			FORM-CUE INVARIANT MOTION PROCESSING IN PRIMATE VISUAL-CORTEX	SCIENCE			English	Article							SUPERIOR TEMPORAL SULCUS; STRIATE PROJECTION ZONE; AREA MT; TOPOGRAPHIC ORGANIZATION; FUNCTIONAL-PROPERTIES; RECEPTIVE-FIELDS; MACAQUE MONKEY; HUMAN-VISION; SIMPLE CELLS; PERCEPTION	The direction and rate at which an object moves are normally not correlated with the manifold physical cues (for example, brightness and texture) that enable it to be seen. As befits its goals, human perception of visual motion largely evades this diversity of cues for image form; direction and rate of motion are perceived (with few exceptions) in a fashion that does not depend on the physical characteristics of the object. The middle temporal visual area of the primate cerebral cortex contains many neurons that respond selectively to motion in a particular direction and is an integral part of the neural substrate for perception of motion. When stimulated with moving patterns characterized by one of three very diverse cues for form, many middle temporal neurons exhibited similar directional tuning. This lack of sensitivity for figural cue characteristics may allow the uniform perception of motion of objects having a broad spectrum of physical cues.			ALBRIGHT, TD (corresponding author), SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ALBRIGHT T D, 1987, Society for Neuroscience Abstracts, V13, P1626; ALBRIGHT T D, 1989, Society for Neuroscience Abstracts, V15, P323; ALBRIGHT TD, 1989, VISUAL NEUROSCI, V2, P177, DOI 10.1017/S0952523800012037; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ANDERSON CH, 1985, SPIE P INTELL ROBOTS, V579, P71; BATSCHELET E, 1965, STATISTICAL METHODS; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; CHARLES E R, 1989, Investigative Ophthalmology and Visual Science, V30, P427; CHAUDHURI A, UNPUB; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; DOBKINS KR, 1991, INVEST OPHTH VIS SCI, V32, P823; FAHLE M, 1981, PROC R SOC SER B-BIO, V213, P451, DOI 10.1098/rspb.1981.0075; GATTASS R, 1981, J NEUROPHYSIOL, V46, P621, DOI 10.1152/jn.1981.46.3.621; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KELLY DH, 1972, VISION RES, V12, P89, DOI 10.1016/0042-6989(72)90139-3; LELKENS AMM, 1984, VISION RES, V24, P1083, DOI 10.1016/0042-6989(84)90086-5; LEVINSON E, 1975, J PHYSIOL-LONDON, V250, P347, DOI 10.1113/jphysiol.1975.sp011058; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MOVSHON J A, 1991, Society for Neuroscience Abstracts, V17, P524; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; PANTLE A, 1974, VISION RES, V14, P1229, DOI 10.1016/0042-6989(74)90221-1; PANTLE A, 1986, Investigative Ophthalmology and Visual Science, V27, P141; PETERSIK JT, 1978, PERCEPTION, V7, P371, DOI 10.1068/p070371; POLLEN DA, 1981, SCIENCE, V212, P1409, DOI 10.1126/science.7233231; RAMACHAN.VS, 1973, VISION RES, V13, P1399, DOI 10.1016/0042-6989(73)90219-8; Reichardt W, 1961, SENS COMMUN, P303; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; SAITO H, 1989, EXP BRAIN RES, V75, P1; SCHILLER PH, 1976, J NEUROPHYSIOL, V39, P1288, DOI 10.1152/jn.1976.39.6.1288; SPERLING G, 1976, BEHAV RES METH INSTR, V8, P144, DOI 10.3758/BF03201762; STONER GR, IN PRESS VISION RES; UNGERLEIDER LG, 1979, J COMP NEUROL, V188, P347, DOI 10.1002/cne.901880302; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VICTOR JD, 1990, VISION RES, V30, P289, DOI 10.1016/0042-6989(90)90044-L; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	38	261	263	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1992	255	5048					1141	1143		10.1126/science.1546317	http://dx.doi.org/10.1126/science.1546317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546317				2022-12-24	WOS:A1992HF63200046
J	ATTAYA, M; JAMESON, S; MARTINEZ, CK; HERMEL, E; ALDRICH, C; FORMAN, J; LINDAHL, KF; BEVAN, MJ; MONACO, JJ				ATTAYA, M; JAMESON, S; MARTINEZ, CK; HERMEL, E; ALDRICH, C; FORMAN, J; LINDAHL, KF; BEVAN, MJ; MONACO, JJ			HAM-2 CORRECTS THE CLASS-I ANTIGEN-PROCESSING DEFECT IN RMA-S CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; VIRAL PEPTIDES; LYMPHOCYTES-T; MHC; MOLECULES; REGION; GENE; DETERMINANT; EXPRESSION	THE murine major histocompatibility complex (MHC) contains two genes (Ham-1 and Ham-2) that encode members of a super-family of ATP-dependent transport proteins 1,2. These genes are believed to mediate the transport of peptide antigen from the cytoplasm into the lumen of the endoplasmic reticulum for binding by MHC class I molecules. Evidence for such a function has come from the rescue of class I surface expression by a cloned copy of the human homologue of Ham-1, PSF-1, in a human cell line that is defective in antigen processing 3. A mutant murine cell line, RMA-S, has an identical antigen-processing-defective phenotype 4,5. Here we show that expression of a cloned copy of the Ham-2 gene in RMA-S cells results in recovery of the ability to process and present class I-restricted antigens to cytotoxic T lymphocytes, and in partial recovery of class I surface expression. Processing defects for classical (H-2 K and D) and non-classical (Qa1 and HMT) class I molecules are corrected by Ham-2. These data indicate that both MHC-linked transporter genes are probably required for class I antigen processing, and that the functional transporter in this pathway may consist of a Ham-1/Ham-2 heterodimer.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GRAD IMMUNOL PROGRAM,DALLAS,TX 75235	Virginia Commonwealth University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146				ALDRICH CJ, 1988, IMMUNOGENETICS, V28, P334, DOI 10.1007/BF00364232; CARBONE FR, 1988, J EXP MED, V167, P1767, DOI 10.1084/jem.167.6.1767; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HERMEL E, 1991, INT IMMUNOL, V3, P407, DOI 10.1093/intimm/3.4.407; HOSKEN NA, 1989, J IMMUNOL, V142, P1079; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HOSKEN NA, IN PRESS J EXP MED; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LINDAHL KF, 1986, J EXP MED, V163, P334, DOI 10.1084/jem.163.2.334; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MONACO J, IN PRESS J IMMUN RES; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TADA N, 1980, IMMUNOGENETICS, V11, P441, DOI 10.1007/BF01567813; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0	31	296	302	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					647	649		10.1038/355647a0	http://dx.doi.org/10.1038/355647a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538753				2022-12-24	WOS:A1992HD54700059
J	VANDERSLUIJS, P; HULL, M; WEBSTER, P; MALE, P; GOUD, B; MELLMAN, I				VANDERSLUIJS, P; HULL, M; WEBSTER, P; MALE, P; GOUD, B; MELLMAN, I			THE SMALL GTP-BINDING PROTEIN RAB4 CONTROLS AN EARLY SORTING EVENT ON THE ENDOCYTIC PATHWAY	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SEMLIKI FOREST VIRUS; TRANSFERRIN RECEPTOR; MDCK CELLS; K562 CELLS; VESICULAR TRANSPORT; PLASMA-MEMBRANE; EARLY ENDOSOMES; DOMAIN; SECRETION	rab4 is a ras-like GTP-binding protein that associates with early endosomes in a cell cycle-dependent fashion. To determine its role during endocytosis, we generated stable cell lines that overexpressed mutant or wild-type rab4. By measuring endocytosis, transport to lysosomes, and recycling, we found that overexpression of wild-type rab4 had differential effects on the endocytic pathway. Although initial rates of internalization and degradation were not inhibited, the transfectants exhibited a 3-fold decrease in fluid phase endocytosis as well as an alteration in transferrin receptor (Tfn-R) recycling. Wild-type rab4 caused a re-distribution of Tfn-R's from endosomes to the plasma membrane. It also blocked iron discharge by preventing the delivery of Tfn to acidic early endosomes, instead causing Tfn accumulation in a population of nonacidic vesicles and tubules. rab4 thus appears to control the function or formation of endosomes involved in recycling.	INST PASTEUR,F-75724 PARIS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VANDERSLUIJS, P (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.		Goud, Bruno/GWC-4807-2022; Mellman, Ira/ABG-5896-2020	Webster, Paul/0000-0002-1980-6931				BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENFERT C, 1991, J CELL BIOL, V114, P663; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; STEIN BS, 1984, J BIOL CHEM, V259, P4762; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANDERSLUIJS P, 1992, IN PRESS EMBO J; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEISSMAN AM, 1986, J CELL BIOL, V102, P951, DOI 10.1083/jcb.102.3.951; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	56	531	536	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					729	740		10.1016/0092-8674(92)90307-X	http://dx.doi.org/10.1016/0092-8674(92)90307-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516131				2022-12-24	WOS:A1992JL66300005
J	SCHLICK, T; OLSON, WK				SCHLICK, T; OLSON, WK			TREFOIL KNOTTING REVEALED BY MOLECULAR-DYNAMICS SIMULATIONS OF SUPERCOILED DNA	SCIENCE			English	Article							CONFORMATIONAL CHANGE; CIRCULAR DNAS; B-DNA; TOPOISOMERASES; RECOMBINATION; GYRASE; COMPLEX; PBR322; MUTANT; SCHEME	Computer simulations of the supercoiling of DNA, largely limited to stochastic search techniques, can offer important information to complement analytical models and experimental data. Through association of an energy function, minimum-energy supercoiled conformations, fluctuations about these states, and interconversions among forms may be sought. In theory, the observation of such large-scale conformational changes is possible, but modeling and numerical considerations limit the picture obtained in practice. A new computational approach is reported that combines an idealized elastic energy model, a compact B-spline representation of circular duplex DNA, and deterministic minimization and molecular dynamics algorithms. A trefoil knotting result, made possible by a large time-step dynamics scheme, is described. The simulated strand passage supports and details a supercoiled-directed knotting mechanism. This process may be associated with collective bending and twisting motions involved in supercoiling propagation and interwound branching. The results also demonstrate the potential effectiveness of the Langevin/implicit-Euler dynamics scheme for studying biomolecular folding and reactions over biologically interesting time scales.	NYU, COURANT INST MATH SCI, NEW YORK, NY 10012 USA; RUTGERS STATE UNIV, WRIGHT RIEMAN LABS, DEPT CHEM, NEW BRUNSWICK, NJ 08903 USA	New York University; Rutgers State University New Brunswick	SCHLICK, T (corresponding author), NYU, DEPT CHEM, 251 MERCER ST, NEW YORK, NY 10012 USA.			Schlick, Tamar/0000-0002-2392-2062	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034809] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34809] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; Bartels RH, 1987, INTRO SPLINES USE CO; BAUER WR, 1980, SCI AM, V243, P118; BENHAM CJ, 1989, PHYS REV A, V39, P2852; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; Dahlquist G., 1974, NUMERICAL METHODS; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; Frank-Kamenetskii M. D., 1981, Soviet Physics - Uspekhi, V24, P679, DOI 10.1070/PU1981v024n08ABEH004835; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAO MH, 1989, BIOPOLYMERS, V28, P873, DOI 10.1002/bip.360280407; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LANDAU LD, 1975, THEORY ELASTICITY, pCH2; LEBRET M, 1979, BIOPOLYMERS, V18, P1709, DOI 10.1002/bip.1979.360180710; LEBRET M, 1984, BIOPOLYMERS, V23, P1835, DOI 10.1002/bip.360231004; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; Love A.E.H., 1944, TREATISE MATH THEORY; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; McCammon JA., 1987, DYNAMICS PROTEINS NU; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; NYBERG A, IN PRESS CHEM PHYS L; NYBERG AM, 1991, J CHEM PHYS, V95, P4986, DOI 10.1063/1.461715; OLSON WK, 1991, METHODS ENZYMOLOGY M, V203, P403; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PESKIN CS, 1989, COMMUN PUR APPL MATH, V42, P1001, DOI 10.1002/cpa.3160420706; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; SCHLICK T, 1989, COMMUN PUR APPL MATH, V42, P1141, DOI 10.1002/cpa.3160420807; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SCHLICK T, 1992, ACM T MATH SOFTWARE, V18, P46, DOI 10.1145/128745.150973; SCHLICK T, 1987, J COMPUT CHEM, V8, P1025, DOI 10.1002/jcc.540080711; SCHLICK T, 1991, J CHEM PHYS, V94, P2118, DOI 10.1063/1.459935; SHISHIDO K, 1989, NUCLEIC ACIDS RES, V17, P9749, DOI 10.1093/nar/17.23.9749; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; SUMNERS DW, 1990, MATH INTELL, V12, P71, DOI 10.1007/BF03024022; TAN RKZ, 1991, THEORETICAL BIOCH MO, V1, P125; TELEMAN O, 1986, J COMPUT CHEM, V7, P58, DOI 10.1002/jcc.540070108; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; TIMSIT Y, 1991, J MOL BIOL, V221, P919, DOI 10.1016/0022-2836(91)80184-V; TUCKERMAN ME, 1991, J CHEM PHYS, V94, P1465, DOI 10.1063/1.460004; VANGUNSTEREN WF, 1980, MOL PHYS, V40, P1015, DOI 10.1080/00268978000102101; VINOGRAD J, 1966, J GEN PHYSIOL, V49, P103, DOI 10.1085/jgp.49.6.103; WANG JC, 1982, SCI AM, V247, P94, DOI 10.1038/scientificamerican0782-94; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1986, CYCLIC POLYM, P225; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WHITE JH, 1989, MATH METHODS DNA SEQ, pCH9; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	58	89	90	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1110	1115		10.1126/science.257.5073.1110	http://dx.doi.org/10.1126/science.257.5073.1110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509261				2022-12-24	WOS:A1992JJ88400031
J	SELLERS, TA; KUSHI, LH; POTTER, JD; KAYE, SA; NELSON, CL; MCGOVERN, PG; FOLSOM, AR				SELLERS, TA; KUSHI, LH; POTTER, JD; KAYE, SA; NELSON, CL; MCGOVERN, PG; FOLSOM, AR			EFFECT OF FAMILY HISTORY, BODY-FAT DISTRIBUTION, AND REPRODUCTIVE FACTORS ON THE RISK OF POSTMENOPAUSAL BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; GENETIC EPIDEMIOLOGY; BOUND ESTRADIOL; HORMONE LEVELS; WOMEN; ESTROGEN; DISEASE; OBESITY; AGE; RECEPTORS	Background. A family history of breast cancer reflects shared cultural factors, genetic predisposition, or both. There is evidence that the estimated risk associated with a family history of breast cancer increases multiplicatively in combination with other risk factors. We examined the combined effect of family history and anthropometric and reproductive factors on the risk of breast cancer in postmenopausal women. Methods. Using data from a prospective cohort study, we studied 37,105 women 55 to 69 years of age to determine whether known risk factors for breast cancer are modified by a reported family history at the time of entry into the study. Results. During the first four years of follow-up, 493 new breast cancers were diagnosed. The association of the waist-to-hip ratio (the circumference of the waist divided by that of the hips) with the risk of breast cancer was limited predominantly to women with a family history of breast cancer; the age-adjusted relative risk of breast cancer for the women above the fourth quintile for waist-to-hip ratio as compared with those below the first quintile was 3.2 in women with a family history of breast cancer and 1.2 for women without such a family history. An interaction was observed between a family history of breast cancer and the number of live-born children; the protective effect of higher parity was observed primarily among women with a family history of breast cancer. Similarly, the age-adjusted relative risk of breast cancer associated with a late age at first pregnancy (i.e., greater-than-or-equal-to 30 years) was 5.8 for women with a family history of breast cancer and 2.0 for women without such a family history. Conclusions. The increase in the risk of breast cancer associated with a high waist-to-hip ratio, low parity, or greater age at first pregnancy is more pronounced among women with a family history of breast cancer. These findings suggest etiologic differences between familial breast cancer and the sporadic form.	UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	SELLERS, TA (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55455 USA.			Kushi, Lawrence/0000-0001-9136-1175; Potter, John/0000-0001-5439-1500	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742, T32 CA099607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1972, J NATL CANCER I, V48, P1029; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDRIEU N, 1989, INT J CANCER, V44, P415, DOI 10.1002/ijc.2910440306; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BEGG L, 1987, GENET EPIDEMIOL, V4, P233, DOI 10.1002/gepi.1370040402; BOUCHARD C, 1988, INT J OBESITY, V12, P205; Breslow NE, 1987, STATISTICAL METHODS, P1; BRINTON LA, 1982, J NATL CANCER I, V69, P817; BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H; BULBROOK RD, 1978, EUR J CANCER, V14, P1369, DOI 10.1016/0014-2964(78)90120-2; Byrne C, 1991, Epidemiology, V2, P276, DOI 10.1097/00001648-199107000-00007; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FAREWELL VT, 1977, CANCER, V40, P931, DOI 10.1002/1097-0142(197708)40:2<931::AID-CNCR2820400251>3.0.CO;2-Y; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; FISHMAN J, 1983, CANCER RES, V43, P1884; FISHMAN J, 1979, SCIENCE, V204, P1089, DOI 10.1126/science.451553; FOEKENS JA, 1989, CANCER, V63, P2139, DOI 10.1002/1097-0142(19890601)63:11<2139::AID-CNCR2820631112>3.0.CO;2-D; FOLSOM AR, 1989, CANCER RES, V49, P6828; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; GO RCP, 1983, J NATL CANCER I, V71, P455; GOLDSTEIN AM, 1989, CLIN GENET, V36, P100; GREENLAND S, 1988, SCAND J WORK ENV HEA, V14, P125, DOI 10.5271/sjweh.1945; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON BE, 1975, NEW ENGL J MED, V293, P790, DOI 10.1056/NEJM197510162931602; HENDERSON BE, 1988, CANCER RES, V48, P246; INGRAM DM, 1990, BRIT J CANCER, V61, P303, DOI 10.1038/bjc.1990.57; KAYE SA, 1991, INT J EPIDEMIOL, V20, P151, DOI 10.1093/ije/20.1.151; KELSEY JL, 1988, CANCER RES, V48, P5615; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; KING MC, 1980, SCIENCE, V208, P406, DOI 10.1126/science.7367867; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; LUBIN F, 1985, AM J EPIDEMIOL, V122, P579, DOI 10.1093/oxfordjournals.aje.a114137; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; MOORE JW, 1987, BRIT J CANCER, V56, P661, DOI 10.1038/bjc.1987.262; MORGAN RW, 1978, J NATL CANCER I, V60, P965, DOI 10.1093/jnci/60.5.965; MORRIS RD, 1991, AM J PUBLIC HEALTH, V81, P507, DOI 10.2105/AJPH.81.4.507; NAROD SA, 1991, LANCET, V338, P82; OTA DM, 1986, CANCER, V57, P558, DOI 10.1002/1097-0142(19860201)57:3<558::AID-CNCR2820570326>3.0.CO;2-1; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PEKONEN F, 1988, CANCER RES, V48, P1343; PIKE MC, 1977, J NATL CANCER I, V59, P1351, DOI 10.1093/jnci/59.5.1351; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; REED MJ, 1983, CANCER RES, V43, P3940; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHNEIDER NR, 1983, AM J HUM GENET, V35, P454; SCHWARTZ AG, 1985, JNCI-J NATL CANCER I, V75, P665; SELBY JV, 1989, HUM BIOL, V61, P179; SKOLNICK M H, 1984, Genetic Epidemiology, V1, P363, DOI 10.1002/gepi.1370010408; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; WILSON AF, 1986, GENET EPIDEMIOL, P87; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065; 1985, SAS USERS GUIDE STAT	65	223	224	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1323	1329		10.1056/NEJM199205143262004	http://dx.doi.org/10.1056/NEJM199205143262004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1565145				2022-12-24	WOS:A1992HT80300004
J	COHEN, DI; TANI, Y; TIAN, H; BOONE, E; SAMELSON, LE; LANE, HC				COHEN, DI; TANI, Y; TIAN, H; BOONE, E; SAMELSON, LE; LANE, HC			PARTICIPATION OF TYROSINE PHOSPHORYLATION IN THE CYTOPATHIC EFFECT OF HUMAN-IMMUNODEFICIENCY-VIRUS .1.	SCIENCE			English	Article							T-CELL RECEPTOR; PROTEIN-KINASE; HTLV-III/LAV; SYNCYTIUM FORMATION; ANTIGEN RECEPTOR; HERBIMYCIN-A; ACTIVATION; CD4; INHIBITION; RETROVIRUS	Protein tyrosine phosphorylation is a common mechanism of signaling in pathways that regulate T cell receptor-mediated cell activation, cell proliferation, and the cell cycle. Because human immunodeficiency virus (HIV) is thought to affect normal cell signaling, tyrosine phosphorylation may be associated with HIV cytopathicity. In both HIV-infected cells and transfected cells that stably express HIV envelope glycoproteins undergoing HIVgp41-induced cell fusion, a 30-kilodalton protein was phosphorylated on tyrosine with kinetics similar to those of syncytium formation and cell death. When tyrosine phosphorylation was inhibited by the protein tyrosine kinase inhibitor herbimycin A, envelope-mediated syncytium formation was coordinately reduced. These studies show that specific intracellular signals, which apparently participate in cytopathicity, are generated by HIV and suggest strategies by which the fusion process might be interrupted.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	COHEN, DI (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.							DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOWDA D, 1988, J IMMUNOL, V142, P773; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, J IMMUNOL, V144, P647; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245; TANI Y, 1987, P NATL ACAD SCI USA, V84, P4831; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WILEY RL, 1988, J VIROL, V62, P139; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	41	105	109	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					542	545		10.1126/science.1570514	http://dx.doi.org/10.1126/science.1570514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1570514				2022-12-24	WOS:A1992HQ18700070
J	SANDERS, SL; WHITFIELD, KM; VOGEL, JP; ROSE, MD; SCHEKMAN, RW				SANDERS, SL; WHITFIELD, KM; VOGEL, JP; ROSE, MD; SCHEKMAN, RW			SEC61P AND BIP DIRECTLY FACILITATE POLYPEPTIDE TRANSLOCATION INTO THE ER	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; YEAST ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE PROTEIN; CHAIN BINDING-PROTEIN; COLI PLASMA-MEMBRANE; PREPRO-ALPHA-FACTOR; CELL-FREE SYSTEM; ESCHERICHIA-COLI; SECRETORY PROTEINS; SACCHAROMYCES-CEREVISIAE	Secretory proteins are segregated from cytosolic proteins by their translocation into the endoplasmic reticulum (ER). A modified secretory protein trapped during translocation across the ER membrane can be cross-linked to two previously identified proteins, Sec61p and BiP (Kar2p). The dependence of this cross-linking upon proteins and small molecules was examined. Mutations in SEC62 and SEC63 decrease the ability of Sec61p to be cross-linked to the secretory polypeptide trapped in translocation. ATP is also required for interaction of Sec61p with the secretory protein. Three kar2 alleles display defective translocation in vitro. Two of these alleles also decrease the ability of Sec61p to be cross-linked to the secretory protein. The third allele, while exhibiting a severe translocation defect, does not affect the interaction of Sec61p with the secretory protein. These results suggest that Sec61p is directly involved in translocation and that BiP acts at two stages of the translocation cycle.	PRINCETON UNIV, DEPT MOLEC BIOL, LEWIS THOMAS LAB, PRINCETON, NJ 08544 USA	Princeton University	SANDERS, SL (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED RES INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Rose, Mark/0000-0003-1112-4765	NIGMS NIH HHS [R01 GM037739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; Sambrook J., 1989, MOL CLONING LAB MANU; SANZ P, 1988, EMBO J, V7, P3553, DOI 10.1002/j.1460-2075.1988.tb03232.x; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHAUER I, 1985, J CELL BIOL, V100, P1664, DOI 10.1083/jcb.100.5.1664; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCOTT JH, 1980, J BACTERIOL, V142, P414, DOI 10.1128/JB.142.2.414-423.1980; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	61	325	326	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					353	365		10.1016/0092-8674(92)90415-9	http://dx.doi.org/10.1016/0092-8674(92)90415-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568250				2022-12-24	WOS:A1992HQ18300014
J	WEISSMANN, P; CHIN, MT; MOSS, AJ				WEISSMANN, P; CHIN, MT; MOSS, AJ			CARDIAC TACHYPACING FOR SEVERE REFRACTORY IDIOPATHIC ORTHOSTATIC HYPOTENSION	ANNALS OF INTERNAL MEDICINE			English	Note						HYPOTENSION; BRADYCARDIA; CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL		Idiopathic orthostatic hypotension can be a disabling disorder. Conventional medical therapy has included various attempts to expand total fluid volume and to enhance arterial and venous vasoconstriction. We report five patients (one previously reported) with this disorder, all with fixed bradycardia and disabling symptoms, refractory to conventional therapy including fluorocortisone and salt loading. These patients received pacemakers in an attempt to correct their fixed bradycardia. In four cases, improved standing blood pressure was documented, and patients noted improvement in symptoms, maintained for at least 1 year. Cardiac tachypacing is useful adjunct therapy in patients with severe, refractory idiopathic orthostatic hypotension and fixed bradycardia.	UNIV ROCHESTER, MED CTR,SCH MED & DENT,225 CRITTENDEN BLVD, RM 123 HWH, ROCHESTER, NY 14642 USA	University of Rochester			Weissmann, Peter/L-1074-2019					Bradbury S, 1925, AM HEART J, V1, P73, DOI 10.1016/S0002-8703(25)90007-5; BREVETTI G, 1981, AM HEART J, V102, P938, DOI 10.1016/0002-8703(81)90049-1; GOLDBERG MR, 1980, NEW ENGL J MED, V303, P885; KRISTINSSON A, 1983, ACTA MED SCAND, V214, P79; MOSS AJ, 1980, NEW ENGL J MED, V302, P1456, DOI 10.1056/NEJM198006263022606; ONROT J, 1986, AM J MED, V80, P454, DOI 10.1016/0002-9343(86)90720-5; ROBERTSON D, 1985, MOD CONC CARDIOV DIS, V54, P7; SHY GM, 1960, ARCH NEUROL-CHICAGO, V2, P511, DOI 10.1001/archneur.1960.03840110025004; ZIEGLER MG, 1977, NEW ENGL J MED, V296, P293, DOI 10.1056/NEJM197702102960601; 1987, LANCET, V1, P19	10	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					650	651		10.7326/0003-4819-116-8-650	http://dx.doi.org/10.7326/0003-4819-116-8-650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546865				2022-12-24	WOS:A1992HN84400007
J	BALEJA, JD; MARMORSTEIN, R; HARRISON, SC; WAGNER, G				BALEJA, JD; MARMORSTEIN, R; HARRISON, SC; WAGNER, G			SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF CD2-GAL4 FROM SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							REGULATORY PROTEIN; GAL4 PROTEIN; YEAST; COORDINATION	THE GAL4 protein activates transcription of the genes required for galactose utilization in Saccharomyces cerevisiae 1. The protein, consisting of 881 amino acids, is dimeric when bound to one of the approximately twofold symmetrical DNA sites present in the galactose upstream activating sequence (UAS(G)) 2-5. Here we use two-dimensional NMR spectroscopy to determine the structure of an amino-terminal fragment of GAL4 (residues 1-65). This fragment, a monomer in solution, binds as a dimer specifically to UAS(G)-containing DNA. Residues 9-40 form a well defined, compact globular cluster, whereas residues 1-8 and 41-66 show considerable conformational mobility in the absence of DNA. The compact domain contains a motif in which six cysteines, located on two symmetrically related helix/extended strand units connected by a long loop, coordinate two central zinc ions, forming a bimetal-thiolate cluster 6-11. The zincs were replaced by NMR-active Cd-113 in most of our work and structural parameters are therefore derived from the Cd2-protein. The structure obtained for the GAL4 DNA-binding domain represents a novel DNA-binding motif. Essentially the same conformation is observed for the compact domain in solution using NMR techniques as was seen for the central core of the N-terminal fragment bound to DNA using crystallographic techniques 12. Thus, the core of the DNA-binding domain changes little upon binding DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University								ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GADHAVI PL, 1990, FEBS LETT, V276, P49, DOI 10.1016/0014-5793(90)80504-C; GADHAVI PL, 1991, FEBS LETT, V281, P223, DOI 10.1016/0014-5793(91)80398-M; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HYBERTS SG, IN PRESS PROTEIN SCI; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; MARMORSTEIN R, IN PRESS NATURE; MONTELIONE GT, 1989, J MAGN RESON, V82, P198, DOI 10.1016/0022-2364(89)90183-2; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; POVEY JF, 1990, FEBS LETT, V266, P142, DOI 10.1016/0014-5793(90)81525-S; SERIKAWA Y, 1990, PROTEIN ENG, V3, P267, DOI 10.1093/protein/3.4.267; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; Wuthrich K., 1986, NMR PROTEINS NUCL AC	26	124	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					450	453		10.1038/356450a0	http://dx.doi.org/10.1038/356450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557130				2022-12-24	WOS:A1992HL83000070
J	THAKKER, Y; WOODS, S				THAKKER, Y; WOODS, S			STORAGE OF VACCINES IN THE COMMUNITY - WEAK LINK IN THE COLD CHAIN	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess quality of storage of vaccines in the community. Design - Questionnaire survey of general practices and child health clinics, and monitoring of storage temperatures of selected refrigerators. Setting - Central Manchester and Bradford health districts. Subjects - 45 general practices and five child health clinics, of which 40 (80%) responded. Eight practices were selected for refrigeration monitoring. Main outcome measures - Adherence to Department of Health guidelines for vaccine storage, temperature range to which vaccines were exposed over two weeks. Results - Of the 40 respondents, only 16 were aware of the appropriate storage conditions for the vaccines; eight had minimum and maximum thermometers but only one of these was monitored daily. In six of the eight practices selected for monitoring of refrigeration temperatures the vaccines were exposed to either subzero temperatures (three fridges) or temperatures up to 16-degrees-C (three). Two of these were specialised drug storage refrigerators with an incorporated thermostat and external temperature gauges. Conclusion - Vaccines were exposed to temperatures that may reduce their potency. Safe storage of vaccines in the clinics cannot be ensured without adhering to the recommended guidelines. Provision of adequate equipment and training for staff in maintaining the "cold chain" and the use and care of equipment are important components of a successful immunisation programme.	DYNELEY HOUSE,SKIPTON,ENGLAND		THAKKER, Y (corresponding author), PINDERFIELDS HOSP,ROWAN HOUSE,WAKEFIELD WF1 4DG,ENGLAND.							HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; LONGLAND P, 1989, PHARM J, V4, P584; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MCLEAN AA, 1982, ANN INTERN MED, V97, P451, DOI 10.7326/0003-4819-97-3-451_1; SOKHEY J, 1988, VACCINE, V6, P12, DOI 10.1016/0264-410X(88)90006-0; 1980, WKLY EPIDEMIOL REC, V55, P385; 1990, WKLY EPIDEMIOL REC, V65, P181; 1989, EXPANDED PROGRAMME I; 1990, IMMUNISATION INFECTI; 1980, WKLY EPIDEMIOL REC, V55, P396; 1990, PRACTICAL IMMUNISATI, P6; 1990, MANUFACTURERS RECOMM	12	49	62	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					756	758		10.1136/bmj.304.6829.756	http://dx.doi.org/10.1136/bmj.304.6829.756			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571683	Bronze, Green Published			2022-12-24	WOS:A1992HK80000023
J	VONHIPPEL, PH; YAGER, TD				VONHIPPEL, PH; YAGER, TD			THE ELONGATION-TERMINATION DECISION IN TRANSCRIPTION	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CHAIN ELONGATION; FACTOR-RHO; KINETICS	At any template position, the decision to extend the transcript by one residue or to release the nascent RNA represents a kinetic competition between elongation and termination pathways. This competition is discussed in terms of alternative Eyring transition state barriers; changes in termination efficiency correspond to small changes in the relative heights of these barriers. Elongation complexes are stable at nonterminator positions; a model is presented to explain the destabilization of these complexes at intrinsic termination sites. Functionally analogous effects can operate at rho-dependent terminators. Mechanisms for modulation of termination efficiency by regulatory proteins are described.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	VONHIPPEL, PH (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; GILL SC, 1990, BIOPHYS CHEM, V37, P239; JIN D, IN PRESS P NATL ACAD; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; WHELAN WL, UNPUB; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YAGER TD, UNPUB; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	15	85	85	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					809	812		10.1126/science.1536005	http://dx.doi.org/10.1126/science.1536005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536005				2022-12-24	WOS:A1992HD54800026
J	SETTLEMAN, J; ALBRIGHT, CF; FOSTER, LC; WEINBERG, RA				SETTLEMAN, J; ALBRIGHT, CF; FOSTER, LC; WEINBERG, RA			ASSOCIATION BETWEEN GTPASE ACTIVATORS FOR RHO AND RAS FAMILIES	NATURE			English	Article							ESCHERICHIA-COLI; TYROSINE KINASES; BINDING PROTEINS; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; RAS-P21; PRODUCT; GENE; SITE	THE ras-related low-molecular-mass GTPases participate in signal transduction involving a variety of cellular functions, including cell-cycle progression, cellular differentiation, cytoskeletal organization, protein transport and secretion1-2. The cycling of these proteins between GTP-bound and GDP-bound states is partially controlled by GTPase activating proteins (GAPs) which stimulate the intrinsic GTP-hydrolysing activity of specific GTPases1-6. The ras GTPase-activating protein (Ras-GAP) forms a complex with a second protein, p190 (M(r) 190,000), in growth-factor stimulated and tyrosine-kinase transformed cells7,8. At its carboxy-terminal end, p190 contains a region that is conserved in the breakpoint cluster region, n-chimaerin, and Rho-GAP9. Each of these three proteins exhibits GAP activity for at least one member of the rho family of small GTPases10. We have tested recombinant p190 protein for GAP activity on GTPases of the ras, rho and rab families, and show here that p190 can function as a GAP specifically for members of the rho family. Consequently, the formation of a complex between Ras-GAP and p190 in growth-factor stimulated cells may allow the coupling of signalling pathways that involve ras and rho GTPases.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	SETTLEMAN, J (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FRECH M, 1990, J BIOL CHEM, V265, P6353; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1990, J BIOL CHEM, V265, P5990; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	30	298	303	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					153	154		10.1038/359153a0	http://dx.doi.org/10.1038/359153a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522900				2022-12-24	WOS:A1992JM49400054
J	AHISSAR, E; VAADIA, E; AHISSAR, M; BERGMAN, H; ARIELI, A; ABELES, M				AHISSAR, E; VAADIA, E; AHISSAR, M; BERGMAN, H; ARIELI, A; ABELES, M			DEPENDENCE OF CORTICAL PLASTICITY ON CORRELATED ACTIVITY OF SINGLE NEURONS AND ON BEHAVIORAL CONTEXT	SCIENCE			English	Article							LONG-TERM POTENTIATION; VISUAL-CORTEX; HEBBIAN SYNAPSES; MECHANISMS; CONNECTIVITY; HIPPOCAMPUS; DEPRESSION; POSTULATE; MEMORY; SLICES	It has not been possible to analyze the cellular mechanisms underlying learning in behaving mammals because of the difficulties in recording intracellularly from awake animals. Therefore, in the present study of neuronal plasticity in behaving monkeys, the net effect of a single neuron on another neuron (the "functional connection") was evaluated by cross-correlating the times of firing of the two neurons. When two neurons were induced to fire together within a short time window, the functional connection between them was potentiated, and when simultaneous firing was prevented, the connection was depressed. These modifications were strongly dependent on the behavioral context of the stimuli that induced them. The results indicate that changes in the temporal contingency between neurons are often necessary, but not sufficient, for cortical plasticity in the adult monkey: behavioral relevance is required.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT PHYSIOL, IL-91010 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Vaadia, Eilon/E-9347-2011	Ahissar, Merav/0000-0001-7694-8111				ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; AOU SJ, 1992, J NEUROSCI, V12, P560; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BARANYI A, 1991, NEUROSCIENCE, V42, P321, DOI 10.1016/0306-4522(91)90378-2; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BOWER GH, 1981, THEOR LEARN, P21; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CAREW TJ, 1984, J NEUROSCI, V4, P1217; DIPRISCO GV, 1984, PROG NEUROBIOL, V22, P89, DOI 10.1016/0301-0082(84)90021-2; Dudai Y., 1989, NEUROBIOLOGY MEMORY; FARLEY J, 1985, ANNU REV PSYCHOL, V36, P419; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FROSTIG RD, 1983, BRAIN RES, V272, P211, DOI 10.1016/0006-8993(83)90567-X; GREUEL JM, 1988, SCIENCE, V242, P74, DOI 10.1126/science.2902687; GROSSBERG S, 1976, BIOL CYBERN, V23, P121, DOI 10.1007/BF00344744; GROSSBERG S, 1988, NEURAL NETWORKS NATU, P405; Hebb DO, 1949, ORG BEHAVIOR, P62; KANDEL ER, 1968, PHYSIOL REV, V48, P65, DOI 10.1152/physrev.1968.48.1.65; Kandel ER., 1976, CELLULAR BASIS BEHAV; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KLOPF H, 1989, NEURAL MODELS PLASTI, P104; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; Mackintosh N. J, 1983, CONDITIONING ASS LEA; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; STANTON PK, 1985, J NEUROSCI, V5, P2169; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; THORNDIKE EL, 1965, ANIMAL INTELLIGENCE, P244; VAADIA E, 1991, NEURONAL COOPERATIVI; von der Malsburg C, 1973, Kybernetik, V14, P85; Weinberger N. M., 1990, LEARNING COMPUTATION, P91	41	273	276	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1412	1415		10.1126/science.1529342	http://dx.doi.org/10.1126/science.1529342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529342				2022-12-24	WOS:A1992JL61200038
J	KANG, SM; BEVERLY, B; TRAN, AC; BRORSON, K; SCHWARTZ, RH; LENARDO, MJ				KANG, SM; BEVERLY, B; TRAN, AC; BRORSON, K; SCHWARTZ, RH; LENARDO, MJ			TRANSACTIVATION BY AP-1 IS A MOLECULAR TARGET OF T-CELL CLONAL ANERGY	SCIENCE			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; HUMAN IL-2 GENE; INTERLEUKIN-2 GENE; CYCLOSPORINE-A; COSTIMULATORY SIGNAL; ANTIGEN RECEPTOR; SELF-TOLERANCE; ACTIVATION; EXPRESSION; ENHANCER	Anergy is a mechanism of T lymphocyte tolerance induced by antigen receptor stimulation in the absence of co-stimulation. Anergic T cells were shown to have a defect in antigen-induced transcription of the interleukin-2 gene. Analysis of the promoter indicated that the transcription factor AP-1 and its corresponding cis element were specifically down-regulated. Exposure of anergic T cells to interleukin-2 restored both antigen responsiveness and activity of the AP-1 element.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BEVERLY B, IN PRESS MOL MECHANI; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRORSON KA, 1991, J IMMUNOL, V147, P3601; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FORSDYKE DR, 1968, LANCET, V1, P281; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FUGITA T, 1986, CELL, V46, P401; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, IN PRESS INT REV CYT; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HECHT TT, 1983, J IMMUNOL, V131, P1049; HUBBARD SC, 1986, P NATL ACAD SCI USA, V83, P1852, DOI 10.1073/pnas.83.6.1852; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Kang S.-G., UNPUB; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LENARDO M, UNPUB; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1989, J IMMUNOL, V142, P2617; NOSSAL GJV, 1980, P NATL ACAD SCI USA, V77, P16026; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; QUILL H, 1987, J IMMUNOL, V138, P3704; RADLER-POHL A, 1990, New Biologist, V2, P566; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SHIBUYA H, 1989, INT IMMUNOL, V1, P143; SITKOVSKY MV, 1982, J IMMUNOL, V129, P1372; TOMONARI K, 1985, CELL IMMUNOL, V96, P147, DOI 10.1016/0008-8749(85)90347-8; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS TM, 1988, J IMMUNOL, V141, P662	79	336	357	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1134	1138		10.1126/science.257.5073.1134	http://dx.doi.org/10.1126/science.257.5073.1134			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509265				2022-12-24	WOS:A1992JJ88400038
J	RAMIREZ, LC; ARAUZPACHECO, C; LACKNER, C; ALBRIGHT, G; ADAMS, BV; RASKIN, P				RAMIREZ, LC; ARAUZPACHECO, C; LACKNER, C; ALBRIGHT, G; ADAMS, BV; RASKIN, P			LIPOPROTEIN (A) LEVELS IN DIABETES-MELLITUS - RELATIONSHIP TO METABOLIC CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; ATHEROSCLEROSIS; HEMOGLOBIN-A, GLYCOSYLATED; LIPOPROTEINS	LOW-DENSITY LIPOPROTEINS; CORONARY-ARTERY DISEASE; APOLIPOPROTEIN-B; HEART-DISEASE; LP(A); ATHEROSCLEROSIS; PLASMA; RISK; INFARCTION; LIPIDS	Objective: To determine the influence of diabetes control on serum lipoprotein (a) concentrations. Setting: Diabetes clinic of a large metropolitan public hospital, with primary- and secondary-care patients. Design: A cross-sectional study. Comparisons of lipoprotein (a) concentrations were made between a normal control group, a group of diabetic patients with glycated hemoglobin (HbA1c) less than 8.0%, and a group of diabetic patients with HbA1c of 8.0% or higher. Patients: Ninety-five normal controls and 93 diabetic subjects (49 with insulin-dependent diabetes mellitus and 44 with noninsulin-dependent diabetes mellitus). Results: Sixty diabetic subjects with HbA1c levels of 8.0% or higher had higher (25 mg/dL) median levels of lipoprotein (a) when compared with either 93 normal controls (8.8 mg/dL) or 33 diabetic patients with HbA1c less than 8.0% (7.5 mg/dL) (P = 0.008 and P = 0.012, respectively). A similar pattern of distribution of lipoprotein (a) levels according to degree of metabolic control was seen in patients with insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus. No difference in the lipoprotein (a) distribution was noted between diabetic men and women. No correlation was observed between lipoprotein (a) levels and total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. Conclusion. Lipoprotein (a) levels are elevated in poorly controlled diabetic patients. Increased levels of lipoprotein (a) may be a contributing factor to the high risk for atherosclerosis observed in diabetic patients.	UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED, 5323 HARRY HINES BLVD,G5222, DALLAS, TX 75235 USA; GENESCREEN LAB, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCRR NIH HHS [M01RR006331] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMER LO, 1980, ACTA ENDOCRINOL-COP, V94, P53; BEACH KW, 1980, DIABETES, V29, P882, DOI 10.2337/diabetes.29.11.882; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P162; DAHLEN G, 1975, CLIN GENET, V7, P334; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAVIDOFF P, 1989, DIABETES S2, V38, pA70; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; DUNN FL, 1984, METABOLISM, V33, P117, DOI 10.1016/0026-0495(84)90122-7; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GENSINI GF, 1979, THROMB HAEMOSTASIS, V42, P983; GREENFIELD MS, 1982, ARCH INTERN MED, V142, P1498, DOI 10.1001/archinte.142.8.1498; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HAFFNER SM, 1991, DIABETES CARE, V14, P302, DOI 10.2337/diacare.14.4.302; HOWARD BV, 1987, J LIPID RES, V28, P613; KANNEL WB, 1982, DIABETES MELLITUS OB, P735; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; LEVITSKY LL, 1991, DIABETES CARE, V14, P283, DOI 10.2337/diacare.14.4.283; LORENZI M, 1984, DIABETOLOGIA, V26, P218; LUFKIN EG, 1979, METABOLISM, V28, P63, DOI 10.1016/0026-0495(79)90169-0; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NATHAN DM, 1984, CLIN CHEM, V30, P813; PYKE DA, 1979, DIABETOLOGIA, V17, P333, DOI 10.1007/BF01236266; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROTTER JI, 1990, DIABETES MELLITUS TH, P378; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHONFELD G, 1974, DIABETES, V23, P827, DOI 10.2337/diab.23.10.827; STEINBRECHER UP, 1984, DIABETES, V33, P130, DOI 10.2337/diabetes.33.2.130; STOLAR MW, 1988, METABOLISM, V37, P1, DOI 10.1016/0026-0495(88)90180-1; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; 1974, NIH DHEW753628 PUBL	38	110	110	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					42	47		10.7326/0003-4819-117-1-42	http://dx.doi.org/10.7326/0003-4819-117-1-42			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1534477				2022-12-24	WOS:A1992JA43500007
J	CHALE, SS; SWAI, ABM; MUJINJA, PGM; MCLARTY, DG				CHALE, SS; SWAI, ABM; MUJINJA, PGM; MCLARTY, DG			MUST DIABETES BE A FATAL DISEASE IN AFRICA - STUDY OF COSTS OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							TROPICAL AFRICA; TANZANIA; HEALTH	Objective - To estimate the costs of diagnosis and treatment of diabetes in Tanzania. Design - Costs estimated from the reported and recorded experience of patients with newly presenting diabetes in 1989-90 and of diabetic patients first seen in 1981-2. Setting - Muhimbili Medical Centre, Dar es Salaam. Subjects-464 patients (315 men and 149 women). 262 patients diagnosed during 1 September 1989-31 August 1990 (group 1) and 202 during 1 June 1981-31 August 1982 (group 2). Results-The average annual direct cost of diabetes care in 1989-90 was $287 for a patient requiring insulin and $103 for a patient not requiring insulin. Purchase of insulin accounted for 68.2% ($156) of the average annual outpatient costs for patients requiring insulin. For patients not requiring insulin the cost of oral hypoglycaemic drugs and treatment of chronic complications and infections accounted for 42.5% ($29.3) and 48.8% ($33.7) of costs respectively. Cost of outpatient care of diabetic patients for the whole of Tanzania was estimated at $2.7 m, $875 128 (32.2%) of which was for insulin. Doctors' and nurses' costs accounted for 0.2% of total costs of outpatient care. The annual direct inpatient care costs were estimated at $1.25m. Around 0.2% of the Tanzanian population aged 15 years and over used the equivalent of 8% of the total government health expenditure, which was $47 408 382. Conclusion - Diabetes places a severe strain on the limited resources of developing countries. If African patients with diabetes have to pay for their treatment most will be unable to do so and will die.	MUHIMBILI MED CTR,DEPT BEHAV SCI,DAR ES SALAAM,TANZANIA		CHALE, SS (corresponding author), MUHIMBILI MED CTR,DEPT MED,POB 65001,DAR ES SALAAM,TANZANIA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; CORRIGAN CB, 1987, E AFR MED J, V64, P772; Enthoven A., 1984, HLTH DIS, P335; FOX NA, 1988, DIRECT INDIRECT COST; JOHNSON B, 1983, ACTA MED SCAND S, V671, P19; LAING W, 1989, DIABETES MODEL HLTH, P32; MCLARTY DG, 1989, LANCET, V1, P871; MCLARTY DG, 1990, BRIT MED J, V300, P1107, DOI 10.1136/bmj.300.6732.1107; ROLFE M, 1989, J ROY COLL PHYS LOND, V23, P255; SCOTT RS, 1985, DIABETES CARE, V8, P43, DOI 10.2337/diacare.8.1.43; SWAI ABM, 1990, BMJ-BRIT MED J, V300, P1103, DOI 10.1136/bmj.300.6732.1103; TRIOMPHE A, 1988, HEALTH POLICY, V9, P39, DOI 10.1016/0168-8510(88)90116-9; Vaughan P., 1989, Health Policy and Planning, V4, P97, DOI 10.1093/heapol/4.2.97; 1991, WHO FEATURES, P1; 1990, HALI YA UCHUMI WA TA; 1989, UNITED REPUBLIC TANZ	16	49	49	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1215	1218		10.1136/bmj.304.6836.1215	http://dx.doi.org/10.1136/bmj.304.6836.1215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515790	Green Published, Bronze			2022-12-24	WOS:A1992HT96400020
J	GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE				GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE			LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						TESTICULAR NEOPLASMS; CARDIOVASCULAR DISEASES; CISPLATIN; HYPERCHOLESTEROLEMIA	GERM-CELL TUMORS; COMBINATION CHEMOTHERAPY; DENSITY LIPOPROTEIN; RAYNAUDS-PHENOMENON; SERUM-CHOLESTEROL; RENAL-FUNCTION; CISPLATIN; VINBLASTINE; BLEOMYCIN; TOXICITY	. Objective: To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured. . Design: Cohort study. . Setting: Referral center. . Patients: Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who received cisplatin-containing chemotherapy between 1978 and 1985. . Measurements: Serum cholesterol and high-density lipoprotein (HDL) levels, body mass index (BMI), blood pressure, kidney function, and hormonal status were monitored during follow-up after chemotherapy (median follow-up, 88 months; range, 56 to 143 months). The BMI and cholesterol values obtained 4 to 6 years after chemotherapy were compared with values from a sample of healthy, age-matched Dutch men; the cholesterol level was also compared with that of 31 patients treated with orchidectomy for stage I disease. . Results: The mean cholesterol level in patients at the start of chemotherapy was 3.96 +/- 0.98 mmol/L [153 +/- 38 mg/dL], increasing 4 to 6 years later to 6.12 +/- 1.20 mmol/L [237 +/- 46 mg/dL] (P < 0.001); 49 of 57 patients had an elevated low-density lipoprotein (LDL) cholesterol level (> 3.4 mmol/L [130 mg/dL]), with a mean level of 4.47 +/- 1.05 mmol/L [173 +/- 41 mg/dL]. Compared with a sample of healthy Dutch men, the chemotherapy group had an elevated cholesterol level (P < 0.05). At 4 to 6 years, the mean HDL cholesterol level was 0.76 +/- 0.18 mmol/L [29 +/- 7 mg/dL], which was low compared with that of the healthy Dutch men (P < 0.05). The mean BMI for all patients was 2.8% higher than expected 4 to 6 years after chemotherapy (P < 0.01) but was not higher than expected 7 to 10 years after chemotherapy. . Conclusions: In addition to other known late side effects of chemotherapy in patients with testicular cancer, hypercholesterolemia and overweight might represent risk factors for cardiovascular disease in such patients, especially in those who are younger.	UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV MED ONCOL, OOSTERSINGEL 59, 9713 EZ GRONINGEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, BILTHOVEN, NETHERLANDS	University of Groningen; Netherlands National Institute for Public Health & the Environment			Kromhout, Daan/A-8566-2014	Gietema, Jourik/0000-0003-0629-7354; de Vries, Elisabeth/0000-0002-8949-7425				ADOUE D, 1984, ANN INTERN MED, V100, P770, DOI 10.7326/0003-4819-100-5-770_2; ALBERS JJ, 1978, CLIN CHEM, V24, P853; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BOYER M, 1990, J CLIN ONCOL, V8, P21, DOI 10.1200/JCO.1990.8.1.21; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; DOLL DC, 1986, ANN INTERN MED, V105, P48, DOI 10.7326/0003-4819-105-1-48; EDWARDS GS, 1979, CANCER TREAT REP, V63, P551; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; FOSSA SD, 1986, CANCER, V58, P2600, DOI 10.1002/1097-0142(19861215)58:12<2600::AID-CNCR2820581208>3.0.CO;2-D; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG H, 1982, ANN INTERN MED, V96, P311, DOI 10.7326/0003-4819-96-3-311; HANSEN SW, 1990, J CLIN ONCOL, V8, P1695, DOI 10.1200/JCO.1990.8.10.1695; HANSEN SW, 1988, J CLIN ONCOL, V6, P1728, DOI 10.1200/JCO.1988.6.11.1728; HENRIKSSON P, 1990, LANCET, V336, P1178; KROMHOUT D, 1989, 528901002 NAT I PUBL; LEITNER SP, 1986, J CLIN ONCOL, V4, P1500, DOI 10.1200/JCO.1986.4.10.1500; LEJONC JL, 1980, LANCET, V2, P692; MEIJER S, 1983, CANCER, V51, P2035, DOI 10.1002/1097-0142(19830601)51:11<2035::AID-CNCR2820511113>3.0.CO;2-8; MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297; NYDEGGER UE, 1972, CANCER RES, V32, P1756; OPPENHEIM DS, 1989, ANN INTERN MED, V111, P288, DOI 10.7326/0003-4819-111-4-288; ROOKUS MA, 1987, HUM BIOL, V59, P599; ROTH BJ, 1988, J CLIN ONCOL, V6, P1239, DOI 10.1200/JCO.1988.6.8.1239; SAMUELS BL, 1987, INT J ANDROL, V10, P363, DOI 10.1111/j.1365-2605.1987.tb00204.x; SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; STOTER G, 1989, J CLIN ONCOL, V7, P1099, DOI 10.1200/JCO.1989.7.8.1099; STUART NSA, 1990, BRIT J CANCER, V61, P479, DOI 10.1038/bjc.1990.106; SUBAR M, 1986, CANCER TREAT REP, V70, P690; VANBARNEVELD PWC, 1984, AM REV RESPIR DIS, V130, P1078; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; VOGELZANG NJ, 1981, ANN INTERN MED, V95, P288, DOI 10.7326/0003-4819-95-3-288; VOGELZANG NJ, 1980, CANCER TREAT REP, V64, P1159; WILLEMSE PHB, 1983, INT J ANDROL, V6, P497, DOI 10.1111/j.1365-2605.1983.tb00341.x; 1988, ACH INTERN MED, V148, P36	36	82	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					709	715		10.7326/0003-4819-116-9-709	http://dx.doi.org/10.7326/0003-4819-116-9-709			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558341				2022-12-24	WOS:A1992HQ62300002
J	WALLACE, DC				WALLACE, DC			MITOCHONDRIAL GENETICS - A PARADIGM FOR AGING AND DEGENERATIVE DISEASES	SCIENCE			English	Article							KEARNS-SAYRE SYNDROME; HEREDITARY OPTIC NEUROPATHY; OXIDATIVE-PHOSPHORYLATION; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; ELECTRON-TRANSPORT; DNA MUTATIONS; COMPLEX-I; DELETIONS; SEQUENCE	Studies of diseases caused by mitochondrial DNA mutations suggest that a variety of degenerative processes may be associated with defects in oxidative phosphorylation (OXPHOS). Application of this hypothesis has provided new insights into such diverse clinical problems as ischemic heart disease, late-onset diabetes, Parkinson's disease, Alzheimer's disease, and aging.			WALLACE, DC (corresponding author), EMORY UNIV, SCH MED, DEPT GENET & MOLEC MED, ATLANTA, GA 30322 USA.				NHLBI NIH HHS [HL45572] Funding Source: Medline; NIGMS NIH HHS [GM46915] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; BROWN MD, 1992, GENETICS, V130, P163; BROWN MD, 1991, AM J HUM GENET, V49, P183; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CORMIER V, 1991, AM J HUM GENET, V48, P643; CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DORNER G, 1975, ENDOKRINOLOGIE, V66, P225; DORNER G, 1987, EXP CLIN ENDOCRINOL, V89, P84; FREINKEL N, 1986, HORM METAB RES, V18, P427, DOI 10.1055/s-2007-1012338; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HAINES JL, 1991, AM J HUM GENET, V48, P1021; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOWELL N, 1991, AM J HUM GENET, V48, P935; HOWELL N, 1991, AM J HUM GENET, V49, P939; HUOPONEN K, 1991, AM J HUM GENET, V48, P1147; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V; JOHNSON WG, 1991, NEUROLOGY, V41, P82, DOI 10.1212/WNL.41.5_Suppl_2.82; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LESTIENNE P, 1988, LANCET, V1, P885; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LOTT MT, 1990, AM J OPHTHALMOL, V109, P625, DOI 10.1016/S0002-9394(14)72429-8; MCSHANE MA, 1991, AM J HUM GENET, V48, P39; MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509; MORAES CT, 1991, AM J HUM GENET, V48, P492; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MYERS RH, 1985, AM J HUM GENET, V37, P511; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; NEWMAN NJ, 1990, AM J OPHTHALMOL, V109, P726, DOI 10.1016/S0002-9394(14)72445-6; NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PARKER WD, 1990, NEUROLOGY, V40, P1231, DOI 10.1212/WNL.40.8.1231; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; POULTON J, 1989, LANCET, V1, P236; ROTIG A, 1988, LANCET, V2, P567; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, 1991, REV NEUROL-FRANCE, V147, P431; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; SINGER TP, 1987, J NEUROCHEM, V49, P1, DOI 10.1111/j.1471-4159.1987.tb03384.x; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Wallace D C, 1987, Birth Defects Orig Artic Ser, V23, P137; WALLACE DC, 1986, AM J HUM GENET, V38, P461; WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X; WALLACE DC, 1986, HOSP PRACT, V21, P77; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1991, CYTOGENET CELL GENET, V58, P1103, DOI 10.1159/000133724; WALLACE DC, IN PRESS ANN NEUROL; WELSH N, 1991, DIABETOLOGIA, V34, P626, DOI 10.1007/BF00400991; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YOUSUFZAI SYK, 1982, FEBS LETT, V137, P205, DOI 10.1016/0014-5793(82)80350-5; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	84	1126	1154	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					628	632		10.1126/science.1533953	http://dx.doi.org/10.1126/science.1533953			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1533953				2022-12-24	WOS:A1992HR18500023
J	REID, RC; SHAPLEY, RM				REID, RC; SHAPLEY, RM			SPATIAL STRUCTURE OF CONE INPUTS TO RECEPTIVE-FIELDS IN PRIMATE LATERAL GENICULATE-NUCLEUS	NATURE			English	Article							RETINAL GANGLION-CELLS; SENSITIVITY; CAT	HUMAN colour vision depends on three classes of cone photoreceptors, those sensitive to short (S), medium (M) or long (L) wavelengths, and on how signals from these cones are combined by neurons in the retina and brain. Macaque monkey colour vision is similar to human, and the receptive fields of macaque visual neurons have been used as an animal model of human colour processing 1. P retinal ganglion cells and parvocellular neurons are colour-selective neurons in macaque retina and lateral geniculate nucleus. Interactions between cone signals feeding into these neurons are still unclear. On the basis of experimental results with chromatic adaptation, excitatory and inhibitory inputs from L and M cones onto P cells (and parvocellular neurons) were thought to be quite specific 2,3 (Fig. 1a). But these experiments with spatially diffuse adaptation did not rule out the 'mixed-surround' hypothesis: that there might be one cone-specific mechanism, the receptive field centre, and a surround mechanism connected to all cone types indiscriminately (Fig. 1e). Recent work has tended to support the mixed-surround hypothesis 4-8. We report here the development of new stimuli to measure spatial maps of the linear L-, M- and S-cone inputs to test the hypothesis definitively. Our measurements contradict the mixed-surround hypothesis and imply cone specificity in both centre and surround.	NYU,CTR NEURAL SCI,NEW YORK,NY 10003	New York University								[Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; CITRON MC, 1981, J NEUROPHYSIOL, V46, P1161, DOI 10.1152/jn.1981.46.6.1161; DEMONASTERIO FM, 1975, J PHYSIOL-LONDON, V251, P167, DOI 10.1113/jphysiol.1975.sp011086; DEVALOIS RL, 1974, VISION RES, V14, P53, DOI 10.1016/0042-6989(74)90116-3; ESTEVEZ O, 1982, VISION RES, V22, P681, DOI 10.1016/0042-6989(82)90104-3; GASKA J P, 1989, Society for Neuroscience Abstracts, V15, P1056; GIELEN CCAM, 1982, BIOL CYBERN, V44, P211, DOI 10.1007/BF00344277; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; HUBEL D, 1991, COLD SPRING HARB SYM, V55, P643; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KAPLAN E, 1986, P NATL ACAD SCI USA, V83, P2755, DOI 10.1073/pnas.83.8.2755; KAPLAN E, 1984, EXP BRAIN RES, V55, P111; LEE BB, 1989, J PHYSIOL-LONDON, V414, P223, DOI 10.1113/jphysiol.1989.sp017685; MILKMAN N, 1980, BEHAV RES METH INSTR, V12, P283, DOI 10.3758/BF03201667; PAULUS W, 1983, VISION RES, V23, P529, DOI 10.1016/0042-6989(83)90128-1; REID C, 1989, SOC NEUR ABSTR, V15, P323; REID C, 1990, INVEST OPHTHALMOL S, V31, P429; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; SUTTER EE, 1992, SIAM J COMPUT, V20, P686; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	25	194	194	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					716	718		10.1038/356716a0	http://dx.doi.org/10.1038/356716a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570016				2022-12-24	WOS:A1992HQ14600062
J	DENMAN, SJ; BURTON, JR				DENMAN, SJ; BURTON, JR			FLUID INTAKE AND URINARY-TRACT INFECTION IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DENMAN, SJ (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,BALTIMORE,MD 21218, USA.							ANDRIOLE VT, 1968, J LAB CLIN MED, V71, P1; FRIEDMAN SA, 1970, J UROLOGY, V105, P428; Kaye D, 1975, Urol Clin North Am, V2, P407; LONERGAN ET, 1988, GERIATRICS, V43, P23; NUNEZ JFM, 1987, RENAL FUNCTION DISEA, P84; WHELTON A, 1978, JOHNS HOPKINS MED J, V142, P8	6	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2245	&		10.1001/jama.267.16.2245	http://dx.doi.org/10.1001/jama.267.16.2245			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556802				2022-12-24	WOS:A1992HN84100040
J	SUTER, PM; SCHUTZ, Y; JEQUIER, E				SUTER, PM; SCHUTZ, Y; JEQUIER, E			THE EFFECT OF ETHANOL ON FAT STORAGE IN HEALTHY-SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIDDLE-AGED MEN; ALCOHOL-CONSUMPTION; NUTRIENT INTAKE; ENERGY-EXPENDITURE; INDIRECT CALORIMETRY; RESPIRATION CHAMBER; UNITED-STATES; METABOLISM; OVERWEIGHT; OBESITY	Background. Ethanol can account for up to 10 percent of the energy intake of persons who consume moderate amounts of ethanol. Its effect on energy metabolism, however, is not known. Methods. We studied the effect ot ethanol on 24-hour substrate-oxidation rates in eight normal men during two 48-hour sessions in an indirect-calorimetry chamber. In each session, the first 24 hours served as the control period. On the second day of one session, an additional 25 percent of the total energy requirement was added as ethanol (mean [+/- SD], 96 +/- 4 g per day); during the other session, 25 percent of the total energy requirement was replaced by ethanol, which was isocalorically substituted for lipids and carbohydrates. Results. Both the addition of ethanol and the isocaloric substitution of ethanol for other foods reduced 24-hour lipid oxidation. The respective mean (+/- SE) decreases were 49.4 +/- 6.7 and 44.1 +/- 9.3 g per day (i.e., reductions of 36 +/- 3 percent and 31 +/- 7 percent from the oxidation rate during the control day; P < 0.001 and P < 0.0025). This effect occurred only during the daytime period (8:30 a.m. to 11:30 p.m.), when ethanol was consumed and metabolized. Neither the addition of ethanol to the diet nor the isocaloric substitution of ethanol for other foods significantly altered the oxidation of carbohydrate or protein. Both regimens including ethanol produced an increase in 24-hour energy expenditure (7 +/- 1 percent with the addition of ethanol, P < 0.001; 4 +/- 1 percent with the substitution of ethanol for other energy sources, P < 0.025). Conclusions. Ethanol, either added to the diet or substituted for other foods, increases 24-hour energy expenditure and decreases lipid oxidation. Habitual consumption of ethanol in excess of energy needs probably favors lipid storage and weight gain.			SUTER, PM (corresponding author), UNIV LAUSANNE,FAC MED,INST PHYSIOL,7 RUE BUGNON,CH-1005 LAUSANNE,SWITZERLAND.							AKANJI AO, 1990, AM J CLIN NUTR, V51, P112, DOI 10.1093/ajcn/51.1.112; BAECKE JAH, 1983, INT J OBESITY, V7, P13; BEBB HT, 1971, AM J CLIN NUTR, V24, P1042; BLOCK G, 1985, AM J EPIDEMIOL, V122, P27, DOI 10.1093/oxfordjournals.aje.a114084; BURSZTEIN S, 1989, ENERGY METABOLISM; CAMARGO CA, 1987, J AM COLL NUTR, V6, P271; CONTALDO F, 1989, METABOLISM, V38, P166, DOI 10.1016/0026-0495(89)90257-6; CROUT J. RICHARD, 1961, STANDARD METHODS CLIN CHEM, V3, P62; Denney R C, 1984, Contemp Issues Clin Biochem, V1, P51; DENNIS BH, 1985, AM J CLIN NUTR, V41, P312, DOI 10.1093/ajcn/41.5.1103; FRAYN KN, 1990, METABOLISM, V39, P958, DOI 10.1016/0026-0495(90)90308-Y; GRUCHOW HW, 1985, AM J CLIN NUTR, V42, P289, DOI 10.1093/ajcn/42.2.289; JEQUIER E, 1987, ANNU REV NUTR, V7, P187, DOI 10.1146/annurev.nu.07.070187.001155; JEQUIER E, 1983, AM J CLIN NUTR, V38, P989, DOI 10.1093/ajcn/38.6.989; JONES BR, 1982, AM J CLIN NUTR, V35, P135, DOI 10.1093/ajcn/35.1.135; KLUTHE R, 1985, ANN INTERN MED, V103, P1037, DOI 10.7326/0003-4819-103-6-1037; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P295, DOI 10.1093/ajcn/37.2.295; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P287, DOI 10.1093/ajcn/37.2.287; KROMHOUT D, 1990, AM J CLIN NUTR, V51, P123, DOI 10.1093/ajcn/51.1.123; LIEBER CS, 1966, J CLIN INVEST, V45, P1400, DOI 10.1172/JCI105448; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; LIEBER CS, 1982, MED DISORDERS ALCOHO; LIEBER CS, 1985, ACTA MED SCAND S, V703, P11; LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; MCDONALD JT, 1976, AM J CLIN NUTR, V29, P1093, DOI 10.1093/ajcn/29.10.1093; MEZEY E, 1985, FED PROC, V44, P134; MILLAR WJ, 1987, AM J PUBLIC HEALTH, V77, P38, DOI 10.2105/AJPH.77.1.38; NACE EP, 1984, ANNU REV MED, V35, P293, DOI 10.1146/annurev.me.35.020184.001453; PIROLA RC, 1972, PHARMACOLOGY, V7, P185, DOI 10.1159/000136288; PIROLA RC, 1976, AM J CLIN NUTR, V29, P90, DOI 10.1093/ajcn/29.1.90; REINUS JF, 1989, METABOLISM, V38, P125, DOI 10.1016/0026-0495(89)90251-5; SCHUTZ Y, 1982, INT J OBESITY, V6, P23; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399, DOI 10.1152/ajpendo.1990.258.3.E399; SKUTCHES CL, 1983, KIDNEY INT, V23, P57, DOI 10.1038/ki.1983.11; SUTHERLAND WHF, 1980, AM J CLIN NUTR, V33, P2581, DOI 10.1093/ajcn/33.12.2581; THOMSON M, 1988, AM J CLIN NUTR, V47, P139, DOI 10.1093/ajcn/47.1.139; WEATHERALL R, 1988, EUR J CLIN NUTR, V42, P221; WINDHAM CT, 1983, J AM DIET ASSOC, V82, P364; YKIJARVINEN H, 1988, AM J PHYSIOL, V254, pE175, DOI 10.1152/ajpendo.1988.254.2.E175	41	165	168	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					983	987		10.1056/NEJM199204093261503	http://dx.doi.org/10.1056/NEJM199204093261503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545851	Green Published			2022-12-24	WOS:A1992HM28500003
J	GIESE, K; COX, J; GROSSCHEDL, R				GIESE, K; COX, J; GROSSCHEDL, R			THE HMG DOMAIN OF LYMPHOID ENHANCER FACTOR-I BENDS DNA AND FACILITATES ASSEMBLY OF FUNCTIONAL NUCLEOPROTEIN STRUCTURES	CELL			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; SEX-DETERMINING REGION; HISTONE-LIKE PROTEINS; RECEPTOR-ALPHA LOCUS; ECO RI ENDONUCLEASE; COLI IHF PROTEIN; TRANSCRIPTION FACTOR; ATTACHMENT SITE; GENE-REGULATION	The high mobility group (HMG) domain is a DNA-binding motif that is associated with several eukaryotic regulatory proteins, including the lymphoid enhancer-binding factor LEF-1 and the testis-determining factor SRY. Here, we provide evidence that DNA binding by the HMG domain of LEF-1 involves primarily minor groove contacts and induces a bend of approximately 130-degrees in the DNA helix. Bending was also found to accompany sequence-specific DNA binding by the SRY-HMG domain. Examining possible regulatory roles of HMG domain-induced DNA bends, we found that LEF-1 can function in a manner similar to bacterial integration host factor and facilitate communication between widely separated protein-binding sites in a recombination assay. Together with the previous observation that LEF-1 by itself is unable to augment basal promoter activity, these data suggest that HMG domain proteins can serve as "architectural" elements in the assembly of higher-order nucleoprotein structures.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	GIESE, K (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143, USA.							DEVARGAS LM, 1989, SCIENCE, V244, P1457; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN S, 1990, STRUCTURE METHODS, V2, P51; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; HOCHSCHILD A, 1990, DNA TOPOLOGY ITS BIO; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; LU AL, 1981, J BIOL CHEM, V256, P3200; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Ptashne M., 1986, A GENETIC SWITCH; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANHODLE KE, 1989, CHROMATIN; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x	64	608	617	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					185	195		10.1016/0092-8674(92)90129-Z	http://dx.doi.org/10.1016/0092-8674(92)90129-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555239				2022-12-24	WOS:A1992HM44500017
J	SPERLING, RS; STRATTON, P; OSULLIVAN, MJ; BOYER, P; WATTS, DH; LAMBERT, JS; HAMMILL, H; LIVINGSTON, EG; GLOEB, DJ; MINKOFF, H; FOX, HE				SPERLING, RS; STRATTON, P; OSULLIVAN, MJ; BOYER, P; WATTS, DH; LAMBERT, JS; HAMMILL, H; LIVINGSTON, EG; GLOEB, DJ; MINKOFF, H; FOX, HE			A SURVEY OF ZIDOVUDINE USE IN PREGNANT-WOMEN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; AZT	Background and Methods. The expanding indications for zidovudine treatment make it important to elucidate the safety and toxicity of this drug for pregnant women and their fetuses. We asked pediatricians and obstetricians at the AIDS (acquired immunodeficiency syndrome) Clinical Trials Units to report information about pregnant women infected with the human immunodeficiency virus who were continuing their pregnancies and had received, or were receiving, zidovudine during gestation. Results. Reports of 43 women were received from 17 institutions. Doses of zidovudine ranged from 300 to 1200 mg per day, and 24 women took the drug for at least two trimesters. There were two reported instances of maternal toxicity (one gastrointestinal and one hematologic). No teratogenic abnormalities occurred in the 12 infants with first-trimester exposure to zidovudine. All the infants, including two sets of twins, were born alive. The 38 singleton infants born at term for whom birth weights were reported had a mean birth weight of 3287 +/- 670 g; two cases of intrauterine growth retardation were reported among the infants delivered at term. Hemoglobin values, which were available for 31 newborns, ranged from 7.0 to 12.4 mmol per liter (11.2 to 20 g per deciliter); 3 of the 7 newborns with hemoglobin values of less than 8.4 mmol per liter (13.5 g per deciliter) were born prematurely. Conclusions. Zidovudine was well tolerated by the pregnant women and was apparently not associated with malformations in the newborns, premature birth, or fetal distress. No pattern of hematologic toxicity was observed in the newborns, but the anemia and growth retardation seen in a minority of the infants could, in part, have resulted from their mothers' treatment with zidovudine.	NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,MIAMI,FL 33152; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV WASHINGTON,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; UNIV ROCHESTER,MED CTR,DEPT MED,ROCHESTER,NY 14642; BAYLOR COLL MED,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT OBSTET & GYNECOL,DURHAM,NC 27710; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY 10461; SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY; COLUMBIA PRESBYTERIAN MED CTR,DEPT OBSTET & GYNECOL,NEW YORK,NY 10032	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Miami; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle; University of Rochester; Baylor College of Medicine; Duke University; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University; NewYork-Presbyterian Hospital	SPERLING, RS (corresponding author), MT SINAI MED CTR,DEPT OBSTET GYNECOL & REPROD SCI,BOX 1173,1 GUSTAVE LEVY PL,NEW YORK,NY 10029, USA.		Livingston, Elizabeth/AAQ-8879-2021	Livingston, Elizabeth/0000-0003-1642-5516; lambert, john/0000-0001-5404-2415	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027667] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-27667] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARZILAI A, 1990, PEDIATR INFECT DIS J, V9, P931, DOI 10.1097/00006454-199012000-00018; CREASY RK, 1991, NEW ENGL J MED, V325, P727, DOI 10.1056/NEJM199109053251009; DEWOLF F, 1988, LANCET, V1, P373; FERRAZIN A, 1991, 7 INT C AIDS FLOR; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GILLET JY, 1989, LANCET, V2, P269; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LOPEZANAYA A, 1991, J ACQ IMMUN DEF SYND, V4, P64; MACDONALD MG, 1991, J ACQ IMMUN DEF SYND, V4, P100; OSKI FA, 1982, HEMATOLOGIC PROBLEMS, V4, P1; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PRITCHARD JA, 1985, WILLIAMS OBSTETRICS, P747; TOLTZIS P, 1991, J INFECT DIS, V163, P1212, DOI 10.1093/infdis/163.6.1212; VISCARELLO R R, 1991, American Journal of Obstetrics and Gynecology, V164, P248; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WATTS DH, 1991, J INFECT DIS, V163, P226, DOI 10.1093/infdis/163.2.226; 1990, AM J MED, V89, P335	18	92	92	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					857	861		10.1056/NEJM199203263261303	http://dx.doi.org/10.1056/NEJM199203263261303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542322				2022-12-24	WOS:A1992HK52300003
J	BAKER, D; SOHL, JL; AGARD, DA				BAKER, D; SOHL, JL; AGARD, DA			A PROTEIN-FOLDING REACTION UNDER KINETIC CONTROL	NATURE			English	Article							ALPHA-LYTIC PROTEASE; PRO-REGION; STATE	SYNTHESIS of alpha-lytic protease is as a precursor containing a 166 amino-acid pro region 1 transiently required for the correct folding of the protease domain 2-4. By omitting the pro region in an in vitro refolding reaction we trapped an inactive, but folding competent state (I) having an expanded radius yet native-like secondary structure. The I state is stable for weeks at physiological pH in the absence of denaturant, but rapidly folds to the active, native state on addition of the pro region as a separate polypeptide chain. The mechanism of action of the pro region is distinct from that of the chaperonins 5,6: rather than reducing the rate of off-pathway reactions, the pro region accelerates the rate-limiting step on the folding pathway by more than 10 7. Because both the I and native states are stable under identical conditions with no detectable interconversion, the folding of alpha-lytic protease must be under kinetic and not thermodynamic control.	UNIV CALIF SAN FRANCISCO,BIOPHYS GRAD GRP,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BAKER, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217				BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DILL KA, 1989, BIOCHEMISTRY-US, V29, P133; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FUJINAGA M, 1985, J MOL BIOL, V183, P479; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; KETTNER CA, 1988, BIOCHEMISTRY-US, V27, P7682, DOI 10.1021/bi00420a017; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUNDROT CE, 1988, PROTEINS, V3, P71; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; ROCHE RS, 1984, BIOCHEMISTRY-US, V23, P1888; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9	18	298	303	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					263	265		10.1038/356263a0	http://dx.doi.org/10.1038/356263a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552947				2022-12-24	WOS:A1992HJ94400066
J	BRAAKMAN, I; HELENIUS, J; HELENIUS, A				BRAAKMAN, I; HELENIUS, J; HELENIUS, A			ROLE OF ATP AND DISULFIDE BONDS DURING PROTEIN FOLDING IN THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							CHAIN BINDING-PROTEIN; GLUCOSE-REGULATED PROTEINS; VIRUS-G PROTEIN; HEAT-SHOCK; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; ASSOCIATION; CELLS; GLYCOPROTEINS; DEPLETION	BEING topologically equivalent to the extracellular space, the lumen of the endoplasmic reticulum (ER) provides a unique folding environment for newly synthesized proteins. Unlike other compartments in the cell where folding occurs, the ER is oxidizing and therefore can promote the formation of disulphide bonds 1. The reducing agent dithiothreitol, when added to living cells, inhibits disulphide formation with profound effects on folding 2. Taking advantage of this effect, we demonstrate here that folding of influenza haemagglutinin is energy dependent. Metabolic energy is required to support the correct folding and disulphide bond formation in this well characterized viral glycoprotein, to rescue misfolded proteins from disulphide-linked aggregates, and to maintain the oxidized protein in its folded and oligomerization-competent state.			BRAAKMAN, I (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Braakman, Ineke/0000-0003-1592-4364				BALCH WE, 1986, J BIOL CHEM, V261, P4681; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, IN PRESS EMBO J; CLAIRMONT C A, 1991, Journal of Cell Biology, V115, p255A; CLARKE BL, 1985, J BIOL CHEM, V260, P128; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Gething M J, 1990, Semin Cell Biol, V1, P65; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6	30	256	260	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					260	262		10.1038/356260a0	http://dx.doi.org/10.1038/356260a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552946				2022-12-24	WOS:A1992HJ94400065
J	GEARING, DP; COMEAU, MR; FRIEND, DJ; GIMPEL, SD; THUT, CJ; MCGOURTY, J; BRASHER, KK; KING, JA; GILLIS, S; MOSLEY, B; ZIEGLER, SF; COSMAN, D				GEARING, DP; COMEAU, MR; FRIEND, DJ; GIMPEL, SD; THUT, CJ; MCGOURTY, J; BRASHER, KK; KING, JA; GILLIS, S; MOSLEY, B; ZIEGLER, SF; COSMAN, D			THE IL-6 SIGNAL TRANSDUCER, GP130 - AN ONCOSTATIN-M RECEPTOR AND AFFINITY CONVERTER FOR THE LIF RECEPTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA INHIBITORY FACTOR; EXPRESSION CLONING; MOLECULAR-CLONING; CELLS; DIFFERENTIATION; BINDING	Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) are multifunctional cytokines with many similar activities. LIF is structurally and functionally related to another cytokine, Oncostatin M (OSM), that binds to the high-affinity LIF receptor but not to the low-affinity LIF receptor. A complementary DNA was isolated that encodes the high-affinity converting subunit of the LIF receptor. The converter conferred high-affinity binding of both LIF and OSM when expressed with the low-affinity LIF receptor and is identical to the signal transducing subunit of the IL-6 receptor, gp130. The gp130 subunit alone confers low-affinity binding of OSM when expressed in COS-7 cells. This receptor system resembles the high-affinity receptors for granulocyte-macrophage colony-stimulating factor, IL-3, and IL-5, which share a common subunit.			GEARING, DP (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							BAUMANN H, 1988, J BIOL CHEM, V263, P17390; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1991, ANN NY ACAD SCI, V628, P9, DOI 10.1111/j.1749-6632.1991.tb17218.x; GEARING DP, 1991, CELL, V66, P175; GEARING DP, UNPUB; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMIDA M, 1990, FEBS LETT, V268, P261, DOI 10.1016/0014-5793(90)81023-H; YAMAMOTOYAMAGUCHI Y, 1986, EXP CELL RES, V164, P97, DOI 10.1016/0014-4827(86)90457-X; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	32	868	903	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1434	1437		10.1126/science.1542794	http://dx.doi.org/10.1126/science.1542794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542794				2022-12-24	WOS:A1992HH74400057
J	TANG, DC; DEVIT, M; JOHNSTON, SA				TANG, DC; DEVIT, M; JOHNSTON, SA			GENETIC IMMUNIZATION IS A SIMPLE METHOD FOR ELICITING AN IMMUNE-RESPONSE	NATURE			English	Article								To produce an immune reaction against a foreign protein usually requires purification of that protein, which is then injected into an animal. The isolation of enough pure protein is time-consuming and sometimes difficult. Here we report that such a response can also be elicited by introducing the gene encoding a protein directly into the skin of mice. This is achieved using a hand-held form of the biolistic system 1-4 which can propel DNA-coated gold microprojectiles directly into cells in the living animal 3,5,6. Genetic immunization may be time- and labour-saving in producing antibodies and may offer a unique method for vaccination.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ARMALEO D, 1990, CURR GENET, V17, P97, DOI 10.1007/BF00312852; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; JOHNSTON SA, 1991, IN VITRO CELL DEV, V27, P11; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; SANFORD J C, 1991, Technique (Philadelphia), V3, P3; SANFORD JC, 1987, PARTICLE SCI TECHNOL, V5, P27, DOI DOI 10.1080/02726358708904533; SANFORD JC, IN PRESS METH ENZYM; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726	8	1234	1612	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					152	154		10.1038/356152a0	http://dx.doi.org/10.1038/356152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545867				2022-12-24	WOS:A1992HH73100059
J	GRIFFITHS, M; USHERWOOD, MM; REGINALD, PW				GRIFFITHS, M; USHERWOOD, MM; REGINALD, PW			ANTENATAL TEACHING OF THE USE OF SEAT BELTS IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article									WEXHAM PK HOSP,DEPT OBSTET,SLOUGH SL2 4HL,BERKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT OBSTET,AYLESBURY,BUCKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT GYNAECOL,AYLESBURY,BUCKS,ENGLAND; WEXHAM PK HOSP,DEPT GYNAECOL,SLOUGH SL2 4HL,BERKS,ENGLAND				Griffiths, Malcolm/C-5918-2009	Griffiths, Malcolm/0000-0001-6910-2249				GRIFFITHS M, 1991, BRIT J OBSTET GYNAEC, V98, P320, DOI 10.1111/j.1471-0528.1991.tb13402.x; HERBERT DC, 1982, MED J AUSTRALIA, V2, P115; ROTHENBERGER D, 1978, J TRAUMA, V18, P173, DOI 10.1097/00005373-197803000-00004	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					614	614		10.1136/bmj.304.6827.614	http://dx.doi.org/10.1136/bmj.304.6827.614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559091	Bronze, Green Published			2022-12-24	WOS:A1992HH73300024
J	RANISH, JA; LANE, WS; HAHN, S				RANISH, JA; LANE, WS; HAHN, S			ISOLATION OF 2 GENES THAT ENCODE SUBUNITS OF THE YEAST TRANSCRIPTION FACTOR-IIA	SCIENCE			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; INITIATION; ACTIVATION	The yeast transcription factor IIA (TFIIA), a component of the basal transcription machinery of RNA polymerase II and implicated in vitro in regulation of basal transcription, is composed of two subunits of 32 and 13.5 kilodaltons. The genes that encode these subunits, termed TOA1 and TOA2, respectively, were cloned. Neither gene shares obvious sequence similarity with the other or with any other previously identified genes. The recombinant factor bound to a TATA binding protein-DNA complex and complemented yeast and mammalian in vitro transcription systems depleted of TFIIA. Both the TOA1 and TOA2 genes are essential for growth of yeast.	HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University	RANISH, JA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURKE C, 1990, NUCLEIC ACIDS RES, V18, P3611, DOI 10.1093/nar/18.12.3611; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1991, J BIOL CHEM, V266, P1900; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLANAGAN PM, 1991, J BIOL CHEM, V266, P436; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RANISH JA, UNPUB; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	27	119	126	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1127	1129		10.1126/science.1546313	http://dx.doi.org/10.1126/science.1546313			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546313				2022-12-24	WOS:A1992HF63200041
J	ELLINGTON, AD; SZOSTAK, JW				ELLINGTON, AD; SZOSTAK, JW			SELECTION INVITRO OF SINGLE-STRANDED-DNA MOLECULES THAT FOLD INTO SPECIFIC LIGAND-BINDING STRUCTURES	NATURE			English	Article							EVOLUTION; POLYMERASE	WE have isolated a set of ligand-binding DNA sequences from a large pool of random sequence DNAs by selection and amplification in vitro, using similar methods to those described for the isolation of ligand-binding RNAs 1. The ligand-DNA interactions are both sequence- and ligand-specific, and are dependent on proper folding of the single-stranded DNA. Some ligands led to the isolation of more DNA sequences than RNA sequences, and vice versa. Analysis of individual sequences reveals that ligand binding is DNA-specific; RNAs of identical sequence could not interact with the same ligands. Ligand-binding DNAs might be more suitable than RNAs as potential pharmacological reagents 2-4 because of the greater stability of DNA. The apparent primacy of RNA in the early evolution of life 5-7 may have been due to its availability rather than to its functional superiority.			ELLINGTON, AD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ABELSON J, 1990, SCIENCE, V249, P488, DOI 10.1126/science.1696394; ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; ELLINGTON A, 1987, CURRENT PROTOCOLS MO; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Orgel L.E., 1971, PREBIOTIC BIOCH EVOL, P89; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892	12	619	729	16	223	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					850	852		10.1038/355850a0	http://dx.doi.org/10.1038/355850a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538766				2022-12-24	WOS:A1992HF63600064
J	YEW, N; MELLINI, ML; VANDEWOUDE, GF				YEW, N; MELLINI, ML; VANDEWOUDE, GF			MEIOTIC INITIATION BY THE MOS PROTEIN IN XENOPUS	NATURE			English	Article							ONCOGENE PRODUCT; CELL-CYCLE; CYTOPLASMIC FACTOR; OOCYTE MATURATION; KINASE-ACTIVITY; EGGS	WHEN fully grown Xenopus oocytes are stimulated by progesterone, a period of protein synthesis is necessary for maturation 1. Synthesis of the mos proto-oncogene product, pp39mos, is necessary for the activation of M-phase promoting factor (MPF) in meiosis I (ref. 2). On the basis that mos is translated de novo on hormonal stimulation of Xenopus oocytes 3 and that injecting mos RNA into oocytes induces their maturation 3,4, we have proposed that the mos protein is a candidate initiator of oocyte maturation, needed to trigger the conversion of precursor MPF into its active form 1-3. To determine whether mos is the only protein required for initiating maturation, we have produced a soluble, active recombinant mos protein and injected it into Xenopus oocytes. We report here that in the absence of protein synthesis that mos protein efficiently induces germinal vesicle breakdown and the activation of MPF. The oocytes, however, do not proceed into meiosis II. Thus, the mos protein fulfills the requirements of an initiator protein, but the synthesis of one or more additional proteins may be necessary to complete oocyte maturation.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP INC,PROT ISOLAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YEW, N (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP INC,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702, USA.							ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1989, DEVELOPMENT, V107, P685; WALLACE RA, 1978, P NATL ACAD SCI USA, V75, P5534, DOI 10.1073/pnas.75.11.5534; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	23	223	223	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					649	652		10.1038/355649a0	http://dx.doi.org/10.1038/355649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1531698				2022-12-24	WOS:A1992HD54700060
J	SCHOUTEN, EG; DEKKER, JM; POOL, J; KOK, FJ; SIMOONS, ML				SCHOUTEN, EG; DEKKER, JM; POOL, J; KOK, FJ; SIMOONS, ML			WELL SHAPED ST SEGMENT AND RISK OF CARDIOVASCULAR MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							SUDDEN-DEATH; MEN; ELECTROCARDIOGRAM; PROGNOSIS	Objective - To investigate the prognostic value of frequently occurring slight variations in the ST segment for cardiovascular mortality in healthy subjects. Design - Follow up study of mortality in relation to variations in ST segment level in a cohort over the 28 years from 1953 to 1981. A case-cohort sampling design was applied to limit the number of electrocardiograms that had to be coded by hand. Setting - General health examination carried out in 1953 of civil servants in Amsterdam and assessment of subsequent mortality. Subjects - Apparently healthy civil servants aged 40 to 65 years: 1583 men and 1508 women. Main outcome measures - Relative risk of variations in ST segment level for mortality from all causes, cardiovascular disease, and coronary heart disease. Results - In men the multivariate relative risks of 15 year mortality from cardiovascular disease and coronary heart disease of slight ST elevation at 80 ms past the J point (compared with isoelectric ST segment) were 0.5 (95% confidence interval 0.3 to 0.9) and 0.4 (0.2 to 0.8), respectively. As expected, ST segment depression (> 0.25 mm) was associated with increased risk: 1.9 (1.1 to 3.0) and 2.2 (1.2 to 3.9), respectively. In women associations were weaker. The full 28 year period showed a similar pattern of somewhat weaker associations for men; among women, however, no predictive value was apparent. Conclusion - These results are empirical evidence for the intuitive opinion among doctors that a curved, upward sloping ST segment, resulting in slight ST elevation at 80 ms, indicates low risk compared with the isoelectric flat, stretched ST segment.	ERASMUS UNIV,CTR THORAX,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	SCHOUTEN, EG (corresponding author), AGR UNIV WAGENINGEN,DEPT EPIDEMIOL & PUBL HLTH,POB 238,6700 AE WAGENINGEN,NETHERLANDS.							[Anonymous], 1985, THEORETICAL EPIDEMIO; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; BRUCE RA, 1988, CIRCULATION, V77, P897, DOI 10.1161/01.CIR.77.4.897; BRUCE RA, 1978, HEART ARTERIES VEINS; ELLESTAD MH, 1980, STRESS TESTING PRINC, P95; FORTUIN NJ, 1979, AM J MED, V49, P459; GREENLAND S, 1986, STAT MED, V5, P579, DOI 10.1002/sim.4780050605; KAGAN A, 1989, AM J EPIDEMIOL, V130, P268, DOI 10.1093/oxfordjournals.aje.a115333; KREGER BE, 1987, AM HEART J, V113, P377, DOI 10.1016/0002-8703(87)90281-X; LIAO YL, 1988, J AM COLL CARDIOL, V12, P1494, DOI 10.1016/S0735-1097(88)80016-0; MIETTINEN OS, 1985, J CHRON DIS, V38, P543, DOI 10.1016/0021-9681(85)90039-6; MIETTINEN OS, 1982, SCAND J WORK ENV H S, V1, P7; OSTRANDER LD, 1970, AM J CARDIOL, V25, P325, DOI 10.1016/S0002-9149(70)80010-8; Prineas R., 1982, MINNESOTA CODE MANUA; QUYYUMI AA, 1983, BRIT HEART J, V50, P460; RABKIN SW, 1982, BRIT HEART J, V47, P546; Reunanen A, 1978, Adv Cardiol, V21, P310; ROSE G, 1978, BRIT HEART J, V40, P636; VANDENBROUCKE JP, 1984, AM J EPIDEMIOL, V119, P742, DOI 10.1093/oxfordjournals.aje.a113795; VANDERHEIDE RM, 1959, THESIS U AMSTERDAM; 1977, MANUAL INT STATISTIC, V1	21	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					356	359		10.1136/bmj.304.6823.356	http://dx.doi.org/10.1136/bmj.304.6823.356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540733	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992HD38700024
J	MAYEDA, A; KRAINER, AR				MAYEDA, A; KRAINER, AR			REGULATION OF ALTERNATIVE PRE-MESSENGER-RNA SPLICING BY HNRNP-A1 AND SPLICING FACTOR-SF2	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; TRANSFORMED HUMAN-CELLS; SITE SELECTION; BINDING PROTEINS; CORE PROTEINS; HELA-CELLS; PACKAGING PROTEINS; COMPLEX PROTEIN-A1; GENE-EXPRESSION; INVITRO	When messenger RNA precursors (pre-mRNAs) containing alternative 5' splice sites are spliced in vitro, the relative concentrations of the heterogeneous ribonucleoprotein (hnRNP) A1 and the essential splicing factor SF2 precisely determine which 5' splice site is selected. In general, an excess of hnRNP A1 favors distal 5' splice sites, whereas an excess of SF2 results in utilization of proximal 5' splice sites. The regulation of these antagonistic activities may play an important role in the tissue-specific and developmental control of gene expression by alternative splicing.			MAYEDA, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501				ACHESON NH, 1980, DNA TUMOR VIRUSES, P125; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AST G, 1991, EMBO J, V10, P425, DOI 10.1002/j.1460-2075.1991.tb07964.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CELIS JE, 1986, FEBS LETT, V194, P101, DOI 10.1016/0014-5793(86)80059-X; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CONWAY GC, 1989, MOL CELL BIOL, V9, P5273, DOI 10.1128/MCB.9.12.5273; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DEKOCH IG, 1981, MECHANISMS LYMPHOCYT, P222; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GATTONI R, 1991, GENE DEV, V5, P1847, DOI 10.1101/gad.5.10.1847; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; KARN J, 1977, J BIOL CHEM, V252, P7307; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1987, J BIOL CHEM, V262, P17126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LESTOURGEON WM, 1977, COLD SPRING HARB SYM, V42, P885, DOI 10.1101/SQB.1978.042.01.090; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MANLEY JL, 1986, CANCER CELL, V4, P259; MAYEDA A, 1988, MOL CELL BIOL, V8, P4484, DOI 10.1128/MCB.8.10.4484; MAYEDA A, 1992, IN PRESS P NATL ACAD; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; MERRILL BM, 1990, EUKARYOTIC NUCLEUS M, V2, P579; MUNROE SH, 1992, IN PRESS P NATL ACAD; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERKINS KK, 1986, P NATL ACAD SCI USA, V83, P887, DOI 10.1073/pnas.83.4.887; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUBY SW, 1991, TRENDS GENET, V7, P79; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WILK HE, 1985, EUR J BIOCHEM, V146, P71, DOI 10.1111/j.1432-1033.1985.tb08621.x; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	84	661	664	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					365	375		10.1016/0092-8674(92)90477-T	http://dx.doi.org/10.1016/0092-8674(92)90477-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1531115				2022-12-24	WOS:A1992HB35300015
J	KIM, B; LITTLE, JW				KIM, B; LITTLE, JW			DIMERIZATION OF A SPECIFIC DNA-BINDING PROTEIN ON THE DNA	SCIENCE			English	Article							LEXA REPRESSOR; ESCHERICHIA-COLI; TERMINAL DOMAIN; TRANSCRIPTION; CONTACTS; GCN4; RECA; FOS	Many specific DNA-binding proteins bind to sites with dyad symmetry, and the bound form of the protein is a dimer. For some proteins, dimers form in solution and bind to DNA. LexA repressor of Escherichia coli has been used to test an alternative binding model in which two monomers bind sequentially. This model predicts that a repressor monomer should bind with high specificity to an isolated operator half-site. Monomer binding to a half-site was observed. A second monomer bound to an intact operator far more tightly than the first monomer; this cooperativity arose from protein-protein contacts.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721	University of Arizona	KIM, B (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024178] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24178] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRENT RP, UNPUB; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; Fersht A, 1985, ENZYME STRUCTURE MEC, P56; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GOLEMIS EA, COMMUNICATION; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HURSTEL S, 1986, EMBO J, V5, P793, DOI 10.1002/j.1460-2075.1986.tb04283.x; HURSTEL S, 1988, EMBO J, V7, P269, DOI 10.1002/j.1460-2075.1988.tb02809.x; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LYONS D, UNPUB; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAUER RT, 1990, NATURE, V347, P514, DOI 10.1038/347514b0; SCHNARR M, 1988, FEBS LETT, V234, P56, DOI 10.1016/0014-5793(88)81302-4; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; THLIVERIS AT, 1991, BIOCHIMIE, V73, P449, DOI 10.1016/0300-9084(91)90112-E; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WERTMAN KF, 1985, J BACTERIOL, V163, P376, DOI 10.1128/JB.163.1.376-384.1985; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	35	125	129	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					203	206		10.1126/science.1553548	http://dx.doi.org/10.1126/science.1553548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553548				2022-12-24	WOS:A1992GY70400038
J	RAYCHAUDHURI, D; PARK, JT				RAYCHAUDHURI, D; PARK, JT			ESCHERICHIA-COLI CELL-DIVISION GENE FTSZ ENCODES A NOVEL GTP-BINDING PROTEIN	NATURE			English	Article							BUD SITE SELECTION; MOLECULAR CHARACTERIZATION; BIOCHEMICAL-PROPERTIES; YEAST; SEQUENCE; MEMBRANE; PRODUCT; SUPERFAMILY; MUTATIONS; MUTANTS	ESCHERICHIA COLI divides by forming a septum across the middle of the cell. The biochemical mechanism underlying this process is unknown. Genetic evidence suggests that of all the fts (filamentation temperature sensitive) genes1,2 involved in E. coli cell division, ftsZ plays a central role at the earliest known step of septation3-5. Here we show that FtsZ protein binds GTP in vitro using unusual sequence elements6-8. In contrast, such binding to the product of the conditional-lethal ftsZ84 allele is impaired. purified FtsZ displays a Mg2+-dependent GTPase activity which is markedly reduced in the FtsZ84 protein. FtsZ copurifies with near stoichiometric amounts of noncovalently-bound GDP, implying the presence of a GTPase cycle in vivo, similar to that known for signal-transducing GTP-binding proteins8,9. We also show that a small fraction of FtsZ exists as a distinct membrane-associated species that binds GTP. The membrane association of FtsZ and the known ability of GTPases to act as molecular switches8,9 implicate FtsZ in a GTP-activated signal transduction pathway that may regulate the start of septation in E. coli.			RAYCHAUDHURI, D (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111, USA.							BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEALL B, 1991, J BACTERIOL, V173, P5822; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORTON JC, 1987, J BACTERIOL, V169, P1; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DONACHIE WD, 1984, MICROBIAL DEV, P27; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1986, J BIOL CHEM, V261, P963; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LUTKENHAUS J, 1990, TRENDS GENET, V6, P22, DOI 10.1016/0168-9525(90)90045-8; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; POE M, 1985, J BIOL CHEM, V260, P3906; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SNYDER JA, 1976, ANNU REV BIOCHEM, V45, P699, DOI 10.1146/annurev.bi.45.070176.003411; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TASCHNER PEM, 1988, J BACTERIOL, V170, P1533, DOI 10.1128/jb.170.4.1533-1540.1988; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; YI QM, 1985, GENE, V36, P241	38	355	365	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					251	254		10.1038/359251a0	http://dx.doi.org/10.1038/359251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528267				2022-12-24	WOS:A1992JN94400066
J	POWE, NR; GRIFFITHS, RI; DELISSOVOY, G; ANDERSON, GF; WATSON, AJ; GREER, JW; HERBERT, RJ; EGGERS, PW; MILAM, RA; WHELTON, PK				POWE, NR; GRIFFITHS, RI; DELISSOVOY, G; ANDERSON, GF; WATSON, AJ; GREER, JW; HERBERT, RJ; EGGERS, PW; MILAM, RA; WHELTON, PK			ACCESS TO RECOMBINANT ERYTHROPOIETIN BY MEDICARE-ENTITLED DIALYSIS PATIENTS IN THE 1ST YEAR AFTER FDA APPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMODIALYSIS-PATIENTS; HEART-DISEASE; MASSACHUSETTS; CAPACITY; THERAPY; QUALITY; WHITES; TRIAL; COST; LIFE	Objective.-Examine access to recombinant human erythropoietin (rHuEPO) by dialysis-dependent end-stage renal disease (ESRD) patients during the first year after FDA approval for use in clinical practice and Medicare coverage. Design.-Longitudinal and cross-sectional claims data analyses. Setting.-All US providers of outpatient dialysis treatment. Patients.-126 201 Medicare-entitled dialysis patients (almost-equal-to 93% of all US dialysis patients). Outcome Measures.-Percentage of patients who received rHuEPO, odds of receiving rHuEPO according to patient characteristics, and cost of rHuEPO to Medicare. Results.-One year after FDA approval, 52% of all dialysis and 60% of in-center hemodialysis patients who regularly had Medicare-paid dialysis services received rHuEPO at a monthly cost to Medicare of $19 million (18% of Medicare ESRD out-patient expenditures and 6% of all ESRD program expenditures). Blacks were less likely than whites to receive rHuEPO (odds ratio, 0.88; 95% confidence interval, 0.86 to 0.91). Home peritoneal and hemodialysis patients were less likely than in-center hemodialysis patients to receive rHuEPO (odds ratios, 0.17 and 0.22, respectively; 95% confidence intervals, 0.16 to 0.17 and 0.20 to 0.24, respectively). Use of rHuEPO varied across geographic regions. The odds of receiving rHuEPO were lower for patients of male vs female sex, of ages 35 through 64 years vs less than 35 years and greater than 65 years, with a longer history of ESRD, with polycystic kidney disease vs other causes of ESRD, and receiving care in nonprofit vs for-profit facilities. First-month hematocrits were slightly higher (1.2 percentage points) for patients starting rHuEPO in the 12th month than in the first month after FDA approval. Conclusions.-With prompt insurance coverage, the majority of Medicare-entitled dialysis patients received rHuEPO following widespread availability. Factors that may not be related to clinical need (race, setting of care, and geography) possibly influenced early patient access. More attention should be paid to monitoring the appropriate use of high-cost biotechnologic therapy.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS PROGRAM MED TECHNOL & PRACTICE ASSESSMENT,BALTIMORE,MD; WELCH CTR PREVENT CLIN RES & EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS HLTH INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DIV NEPHROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD 21218; US HLTH CARE FINANCING ADM,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	POWE, NR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INTERNAL MED,ROOM 8061,1830 E MONUMENT ST,BALTIMORE,MD 21205, USA.							AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Bunn H. F., 1991, HARRISONS PRINCIPLES, P344; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DOOLITTLE RF, 1991, NEW ENGL J MED, V324, P1360, DOI 10.1056/NEJM199105093241910; EIEENBERG JM, 1986, DOCTORS DECISIONS CO, P5; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GOTCH FA, 1990, AM J KIDNEY DIS, V15, P511, DOI 10.1016/S0272-6386(12)70369-4; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LAUPACIS A, 1990, SEMIN NEPHROL, V10, P11; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; Rettig RA, 1991, KIDNEY FAILURE FEDER; ROBERTSON HT, 1990, AM J KIDNEY DIS, V15, P325, DOI 10.1016/S0272-6386(12)80079-5; SISK JE, 1991, JAMA-J AM MED ASSOC, V266, P247, DOI 10.1001/jama.266.2.247; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; WATSON AJ, 1989, SEMIN NEPHROL, V9, P30; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; [No title captured]; 1990, 03272 HLTH CAR FIN A; 1992, 03319 HLTH CAR FIN A; 1991, AM J KIDNEY DIS S2, V18, P96	26	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1434	1440		10.1001/jama.268.11.1434	http://dx.doi.org/10.1001/jama.268.11.1434			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512912				2022-12-24	WOS:A1992JM84900026
J	APPLEBY, MW; GROSS, JA; COOKE, MP; LEVIN, SD; QIAN, X; PERLMUTTER, RM				APPLEBY, MW; GROSS, JA; COOKE, MP; LEVIN, SD; QIAN, X; PERLMUTTER, RM			DEFECTIVE T-CELL RECEPTOR SIGNALING IN MICE LACKING THE THYMIC ISOFORM OF P59(FYN)	CELL			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CLONAL DELETION; CD4 RECEPTOR; PHOSPHORYLATION; ACTIVATION; P56LCK; STIMULATION; TRANSDUCTION	Considerable evidence supports the hypothesis that the nonreceptor protein tyrosine kinase p59fyn participates in signal transduction from the T cell receptor (TCR). To examine this hypothesis in detail, we have produced mice that lack the thymic isoform of p59fyn but retain expression of the brain isoform of the protein. fynT(null) mice exhibit a remarkably specific lymphoid defect: thymocytes are refractile to stimulation through the TCR with mitogen or antigen, while peripheral T cells, following what appears to be a normal maturation sequence, reacquire significant signaling capabilities. These data confirm that p59fynT plays a pivotal role in TCR signal transduction and demonstrate that additional developmentally regulated signaling components also contribute to TCR-induced lymphocyte activation.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	APPLEBY, MW (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195, USA.				NATIONAL CANCER INSTITUTE [T32CA009537, R01CA045682] Funding Source: NIH RePORTER; NCI NIH HHS [CA09537, CA45682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, IN PRESS MECHANISMS, V4; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	44	507	520	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					751	763		10.1016/0092-8674(92)90309-Z	http://dx.doi.org/10.1016/0092-8674(92)90309-Z			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516132				2022-12-24	WOS:A1992JL66300007
J	LIU, YJ; PETER, D; ROGHANI, A; SCHULDINER, S; PRIVE, GG; EISENBERG, D; BRECHA, N; EDWARDS, RH				LIU, YJ; PETER, D; ROGHANI, A; SCHULDINER, S; PRIVE, GG; EISENBERG, D; BRECHA, N; EDWARDS, RH			A CDNA THAT SUPPRESSES MPP+ TOXICITY ENCODES A VESICULAR AMINE TRANSPORTER	CELL			English	Article							ORGAN SYNAPTIC VESICLES; GAMMA-AMINOBUTYRIC ACID; CHROMAFFIN GRANULES; PARKINSONS-DISEASE; ESCHERICHIA-COLI; RAT-BRAIN; RESERPINE BINDING; NEUROTOXIN 1-METHYL-4-PHENYLPYRIDINIUM; DIHYDROTETRABENAZINE BINDING; TETRACYCLINE-RESISTANCE	Classical neurotransmitters are transported into synaptic vesicles so that their release can be regulated by neural activity. In addition, the vesicular transport of biogenic amines modulates susceptibility to N-methyl-4-phenylpyridinium (MPP+), the active metabolite of the neurotoxin N-methyl-1,2,3,6-tetrahydropyridine that produces a model of Parkinson's disease. Taking advantage of selection in MPP+, we have used gene transfer followed by plasmid rescue to identify a cDNA clone that encodes a vesicular amine transporter. The sequence predicts a novel mammalian protein with 12 transmembrane domains and homology to a class of bacterial drug resistance transporters. We have detected messenger RNA transcripts for this transporter only in the adrenal gland. Monoamine cell populations in the brain stem express a distinct but highly related protein.	HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL; VET ADM MED CTR BRENTWOOD,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT ANAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST EXTRATERR PHYS,DEPT CELL BIOL & MED,LOS ANGELES,CA 90024	Hebrew University of Jerusalem; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LIU, YJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT NEUROL,LOS ANGELES,CA 90024, USA.		Schuldiner, Shimon/F-7628-2012; Liu, Yongjian/J-7852-2018	Schuldiner, Shimon/0000-0002-4874-6237; Prive, Gilbert/0000-0002-0712-4319	NATIONAL EYE INSTITUTE [R01EY004067] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY004067] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DC, 1983, MOL PHARMACOL, V24, P48; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARLSON MD, 1989, J BIOL CHEM, V264, P7369; CARLSSON A, 1963, ACTA PHYSL SCAND S, V215, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN H, 1990, J NEUROCHEM, V54, P1142, DOI 10.1111/j.1471-4159.1990.tb01941.x; COHEN G, 1990, J NEURAL TRANSM-SUPP, V32, P229; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Frize E.D., 1954, NEW ENGL J MED, V251, P1006; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Hokfelt T., 1984, CLASSICAL NEUROTRANS, V2, P277; ISAMBERT MF, 1992, BIOCHEMISTRY-US, V31, P1980, DOI 10.1021/bi00122a012; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; KNIGGE KM, 1977, BRAIN RES, V120, P393, DOI 10.1016/0006-8993(77)90394-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, SCIENCE, V225, P1480, DOI 10.1126/science.6332378; LIU Y, 1992, IN PRESS P NATL ACAD, V89; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; NAITO S, 1983, J BIOL CHEM, V258, P696; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; RAMSAY RR, 1986, J BIOL CHEM, V261, P7585; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; REINHARD JF, 1987, P NATL ACAD SCI USA, V84, P8160, DOI 10.1073/pnas.84.22.8160; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SNYDER SH, 1986, MPTP NEUROTOXIN PROD, P191; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; STERNINI C, 1989, GASTROENTEROLOGY, V97, P348, DOI 10.1016/0016-5085(89)90070-X; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; TANNER CM, 1990, NEUROLOGY, V40, P17; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VINCENT MS, 1991, MOL PHARMACOL, V40, P889; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; [No title captured]; 1989, NEW ENGL J MED, V321, P1364	85	527	543	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					539	551		10.1016/0092-8674(92)90425-C	http://dx.doi.org/10.1016/0092-8674(92)90425-C			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505023				2022-12-24	WOS:A1992JJ88600005
J	EISENBERG, RS				EISENBERG, RS			GENES, PATENTS, AND PRODUCT DEVELOPMENT	SCIENCE			English	Article								In the past year,the National Institutes of Health (NIH) has filed patent applications on more than 2750 partial complementary DNA sequences of unknown function. The rationale for the filings-that patent protection may be necessary to ensure that private firms are willing to invest in developing related products-rests on two premises: first, that NIH may obtain patent rights that will offer effective product monopolies to licensee firms, and second, that unless NIH obtains these rights now, firms will be unable to obtain a comparable degree of exclusivity by other means, such as by obtaining patents on their own subsequent innovations. Neither premise is clearly wrong, although both are subject to doubt in view of statements from industry representatives that the NIH patenting strategy will deter rather than promote product development.			EISENBERG, RS (corresponding author), UNIV MICHIGAN,SCH LAW,ANN ARBOR,MI 48109, USA.							Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; HEALY B, 1992, MAY PUBL M FED COORD; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; MOSSINGHOFF GJ, 1992, COMMUNICATION   0528; 1991, POSITION PAPER PATEN; 1992, IBA POSITION PAPER R	7	46	46	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					903	908		10.1126/science.1502556	http://dx.doi.org/10.1126/science.1502556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JH827	1502556				2022-12-24	WOS:A1992JH82700021
J	LOLAIT, SJ; OCARROLL, AM; MCBRIDE, OW; KONIG, M; MOREL, A; BROWNSTEIN, MJ				LOLAIT, SJ; OCARROLL, AM; MCBRIDE, OW; KONIG, M; MOREL, A; BROWNSTEIN, MJ			CLONING AND CHARACTERIZATION OF A VASOPRESSIN V2 RECEPTOR AND POSSIBLE LINK TO NEPHROGENIC DIABETES-INSIPIDUS	NATURE			English	Article							ARGININE-VASOPRESSIN; MESSENGER-RNAS; BINDING-SITES; LOCALIZATION; DNA; AMPLIFICATION; ANTAGONISTS; EXPRESSION; PRIMER; POTENT	THE antidiuretic effect of arginine vasopressin (AVP) is mediated by renal-type (V2) receptors linked to adenylyl cyclase 1. We report here the cloning of the rat kidney V2 AVP receptor complementary DNA that encodes a 370-amino-acid protein with a transmembrane topography characteristic of G protein-coupled receptors, and with similarity to the V1a (hepatic) AVP receptor 2 in its seven membrane-spanning domains. Expression of the cloned cDNA in mammalian cells showed specific ligand binding and activity characteristic of the native V2 AVP receptor. The receptor messenger RNA is detected only in the kidney. The human V2 receptor gene has been localized to the long arm of the X chromosome close to the locus for nephrogenic diabetes insipidus, an X-linked recessive disorder characterized by renal resistance to the antidiuretic action of AVP 3-6.	NIMH,CELL BIOL LAB,BLDG 36,ROOM 3A-17,BETHESDA,MD 20892; GRP NEUROBIOCHIM CELLULAIRE & MOLEC,F-75006 PARIS,FRANCE; NCI,CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Morel, Alain/AAU-7496-2021; Lolait, Stephen/AAG-4483-2020; Brownstein, Michael/B-8609-2009	morel, alain/0000-0003-0125-1883				ANTONI FA, 1984, NEUROPEPTIDES, V4, P413, DOI 10.1016/0143-4179(84)90116-1; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BODE HH, 1969, NEW ENGL J MED, V280, P750, DOI 10.1056/NEJM196904032801404; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DORSA DM, 1983, PEPTIDES, V4, P699, DOI 10.1016/0196-9781(83)90021-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOLMES MC, 1985, NEUROENDOCRINOLOGY, V117, P421; JANS DA, 1990, J BIOL CHEM, V265, P15379; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIRK CJ, 1977, FEBS LETT, V83, P267, DOI 10.1016/0014-5793(77)81020-X; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KNOERS N, 1988, HUM GENET, V80, P31, DOI 10.1007/BF00451451; KONIG M, 1991, Molecular and Cellular Neuroscience, V2, P331, DOI 10.1016/1044-7431(91)90063-T; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MANNING M, 1984, J MED CHEM, V27, P423, DOI 10.1021/jm00370a002; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; OLSEN AS, 1981, MOL CELL BIOL, V1, P439, DOI 10.1128/MCB.1.5.439; PHILLIPS PA, 1990, ENDOCRINOLOGY, V126, P1478, DOI 10.1210/endo-126-3-1478; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827; YOUNG WS, 1987, NEUROENDOCRINOLOGY, V46, P439	28	487	493	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					336	339		10.1038/357336a0	http://dx.doi.org/10.1038/357336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534150				2022-12-24	WOS:A1992HW13200050
J	JOHNSON, WG; BRENNAN, TA; NEWHOUSE, JP; LEAPE, LL; LAWTHERS, AG; HIATT, HH; WEILER, PC				JOHNSON, WG; BRENNAN, TA; NEWHOUSE, JP; LEAPE, LL; LAWTHERS, AG; HIATT, HH; WEILER, PC			THE ECONOMIC CONSEQUENCES OF MEDICAL INJURIES - IMPLICATIONS FOR A NO-FAULT INSURANCE PLAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORT	Background. - There has been little research into the actual economic consequences of medical injuries. This inhibits informed discussion of alternatives to malpractice litigation. For example, the cost of no-fault medical accident insurance has been thought to be prohibitive. Method. - As part of a comprehensive analysis of medical injury and litigation, we interviewed a random sample of 794 individuals who had suffered medical adverse events in New York hospitals in 1984 and used their responses to calculate the cost of injuries. We then estimated the costs of a simulated no-fault insurance program that would operate as a second payer to direct insurance sources and would compensate for all financial losses attributed to medical injury. Results. - The estimated costs that would be paid by a simulated no-fault program were $161 million for medical care, $276 million for lost wages, and $441 million in lost household production, or a total of $878 million in 1989 dollars for the cohort of patients who were injured in 1984. Conclusion. - Although our estimate does not include administrative costs, it nonetheless indicates that a no-fault program would not be notably costlier than the more than $1 billion New York physicians now spend annually on malpractice insurance.	BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University	JOHNSON, WG (corresponding author), ARIZONA STATE UNIV,COLL BUSINESS,SCH HLTH ADM & POLICY,TEMPE,AZ 85287, USA.		Newhouse, Joseph/AGJ-5632-2022					[Anonymous], 1986, COSTS COMPENSATION P; BERKOWITZ M, 1990, EC CONSEQUENCES TRAU; BOMBAUGH RL, 1971, COLUMBIA LAW REV, V71, P207, DOI 10.2307/1121170; BOVBJERG RR, 1989, NORTHWEST U LAW REV, V83, P908; BRENNAN TA, 1990, CLIN RES, V35, P551; DOUGLASS J, 1990, J FORENSIC EC, V4, P25, DOI DOI 10.5085/0898-5510-4.1.25; FELDSTEIN M, 1978, BROOKINGS PAPERS EC, V1, P1; HENSLER DR, 1991, R3999HHSICJ RAND COR; JOHNSON WG, 1984, IND LABOR RELAT REV, V37, P529, DOI 10.2307/2523670; JOHNSON WG, 1979, RES REPORT US INTERD; JOHNSON WG, 1984, MILBANK Q, V61, P177; Kakalik James S., 1988, COSTS COMPENSATION P; LAMBRINOS J, 1985, J RISK INSUR, V52, P464, DOI 10.2307/252781; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MANNE H, 1985, MED MALPRACTICE POLI; PRIEST GL, 1987, YALE LAW J, V96, P1521, DOI 10.2307/796494; RICE DP, 1990, EC COSTS ALCOHOL DRU; SCHWARTZ A, 1988, YALE LAW J, V97, P353, DOI 10.2307/796411; SCHWARTZ WB, 1978, NEW ENGL J MED, V298, P1282, DOI 10.1056/NEJM197806082982304; Viscusi W. Kip, 1988, INTL REV L EC, V8, P203, DOI DOI 10.1016/0144-8188(88)90006-3; WALKER KE, 1976, TIME USE MEASURE HOU; WEILER PC, 1991, MED MALPRACTICE TRIA; 1987, MED EC          1005; 1985, MED EC          1007; 1965, REPORTING HOSPITALIZ; 1986, WORK LIFE ESTIMATES; 1986, MED EC          1006; 1989, AVERAGE CHARGES HOME; 1980, VITAL STATISTICS US; 1985, EMPLOYEE BENEFITS 19; 1988, MED EC          1003; 1990, PATIENTS DOCTORS LAW; 1982, US BUREAU CENSUS P60, V139	33	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2487	2492		10.1001/jama.267.18.2487	http://dx.doi.org/10.1001/jama.267.18.2487			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573726				2022-12-24	WOS:A1992HT06800028
J	ROSENBLUM, L; DARROW, W; WITTE, J; COHEN, J; FRENCH, J; GILL, PS; POTTERAT, J; SIKES, K; REICH, R; HADLER, S				ROSENBLUM, L; DARROW, W; WITTE, J; COHEN, J; FRENCH, J; GILL, PS; POTTERAT, J; SIKES, K; REICH, R; HADLER, S			SEXUAL PRACTICES IN THE TRANSMISSION OF HEPATITIS-B VIRUS AND PREVALENCE OF HEPATITIS-DELTA VIRUS-INFECTION IN FEMALE PROSTITUTES IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HOMOSEXUAL MEN; SALIVA; ANTIGEN; SEMEN; NONOXYNOL-9; OUTBREAK; CONTACTS; MARKERS	Objective.- To evaluate heterosexual transmission of hepatitis B virus (HBV) and the prevalence of hepatitis delta virus (HDV) infection in female prostitutes. Design.-Survey. Setting. - Sexually transmitted disease clinics, drug treatment programs, detention centers, and/or outreach efforts in eight areas in the United States. Participants. - A total of 1368 female prostitutes 18 years of age or older. Outcome Measures. - Seropositivity for HBV and HDV infection. Results. - The overall prevalence of past or present HBV infection was 56%: 74% in women who were injecting-drug users (IDUs), 38% in women reporting no history of injecting-drug use (non-IDUs), 51% in whites, 55% in blacks, and 67% in Hispanics. Of 21 HBV carrier IDUs, 21% had HDV infection; of 18 HBV carrier non-IDUs, 6% had HDV infection. In non-IDUs (49%), risk factors for HBV infection were a history of having penile-anal intercourse (odds ratio [OR], 3.1; 95% confidence limits [CL], 1.3, 7.3) and seropositivity for syphilis and human immunodeficiency virus (HIV) infection. In IDUs, factors associated with an increased risk of infection, in addition to behaviors related to injecting-drug use, were the number of lifetime sexual partners, having sexual partners from groups at high risk for HBV infection, and seropositivity for syphilis and HIV infection; spermicide and/or diaphragm use was associated with a markedly decreased risk of HBV infection among blacks (OR, 0.1; 95% CL, 0.03, 0.4) and Hispanics (OR, 0.2; 95% CL, 0.06, 0.9). Conclusion. - This is the first study to suggest that having anal intercourse and failing to use vaginal contraceptives may facilitate transmission of HBV to women. Our data support guidelines that recommend hepatitis B vaccination for prostitutes and persons with a history of sexually transmitted diseases or multiple sexual partners.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; FLORIDA DEPT HLTH & REHAB SERV,TALLAHASSEE,FL; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; NEW JERSEY DEPT HLTH,TRENTON,NJ; UNIV SO CALIF,LOS ANGELES,CA 90089; EL PASO CTY DEPT HLTH & ENVIRONM,COLORADO SPRINGS,CO; GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; CLARK CTY HLTH DIST,LAS VEGAS,NV	Centers for Disease Control & Prevention - USA; Florida Department of Health; University of California System; University of California San Francisco; New Jersey Department of Health & Senior Services; University of Southern California	ROSENBLUM, L (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH,ATLANTA,GA 30333, USA.		Potterat, John J/B-4680-2009					ALTER HJ, 1977, INFECT IMMUN, V16, P928, DOI 10.1128/IAI.16.3.928-933.1977; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ALTER MJ, 1986, JAMA-J AM MED ASSOC, V256, P1307, DOI 10.1001/jama.256.10.1307; BADDOUR LM, 1988, SEX TRANSM DIS, V15, P174, DOI 10.1097/00007435-198807000-00014; COHEN C, 1990, AIDS 2ND DECADE, P253; Darrow William, 1990, AIDS DRUGS PROSTITUT, P18; DAVISON F, 1987, J HEPATOL, V4, P37, DOI 10.1016/S0168-8278(87)80007-7; DECOCK KM, 1988, WESTERN J MED, V148, P307; FIELDS HA, 1986, J CLIN IMMUNOASSAY, V9, P128; GOVINDARAJAN S, 1983, GASTROENTEROLOGY, V85, P160; HEATHCOT.J, 1974, LANCET, V1, P71; HERSH T, 1971, NEW ENGL J MED, V285, P1363, DOI 10.1056/NEJM197112092852408; HICKS DR, 1985, LANCET, V2, P1422; KOFF RS, 1977, GASTROENTEROLOGY, V72, P297; KREISS J, 1989, 5TH P INT C AIDS MON, P36; LETTAU LA, 1987, NEW ENGL J MED, V317, P1256, DOI 10.1056/NEJM198711123172004; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MUSHAWAR IK, 1984, VIRAL HEPATITIS LIVE, P617; NIRUTHISARD S, 1991, 7TH P INT C AIDS FLO, P317; NORTH BB, 1990, HETEROSEXUAL TRANSMI, P273; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PETERSEN NJ, 1982, ANN INTERN MED, V96, P170; PONZETTO A, 1984, HEPATOLOGY, V4, P1111, DOI 10.1002/hep.1840040603; REDEKER AG, 1975, NEW ENGL J MED, V293, P1055; ROSENBERG M, 1987, JAMA-J AM MED ASSOC, V258, P2308; ROSENBLUM LS, 1990, J INFECT DIS, V161, P407, DOI 10.1093/infdis/161.3.407; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SCOTT RM, 1980, J INFECT DIS, V142, P67, DOI 10.1093/infdis/142.1.67; SINGH B, 1976, AM J OBSTET GYNECOL, V126, P422, DOI 10.1016/0002-9378(76)90630-X; SOLOMON RE, 1988, ANN INTERN MED, V108, P51, DOI 10.7326/0003-4819-108-1-51; VOELLER B, 1991, ARCH SEX BEHAV, V20, P233, DOI 10.1007/BF01541846; WEISFUSE IB, 1989, HEPATOLOGY, V9, P872, DOI 10.1002/hep.1840090614; WRIGHT RA, 1975, JAMA-J AM MED ASSOC, V232, P717, DOI 10.1001/jama.232.7.717; 1991, MMWR SRR13, V40, P1; 1985, SAS USERS GUIDE STAT, P171	36	55	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2477	2481		10.1001/jama.267.18.2477	http://dx.doi.org/10.1001/jama.267.18.2477			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573724				2022-12-24	WOS:A1992HT06800026
J	AMIRI, P; LOCKSLEY, RM; PARSLOW, TG; SADICK, M; RECTOR, E; RITTER, D; MCKERROW, JH				AMIRI, P; LOCKSLEY, RM; PARSLOW, TG; SADICK, M; RECTOR, E; RITTER, D; MCKERROW, JH			TUMOR-NECROSIS-FACTOR-ALPHA RESTORES GRANULOMAS AND INDUCES PARASITE EGG-LAYING IN SCHISTOSOME-INFECTED SCID MICE	NATURE			English	Article							LYT2+ SPLENIC CELLS; NUDE-MICE; MANSONI EGGS; ATHYMIC MICE; RECONSTITUTION; ANTIGEN; IMMUNOPATHOLOGY; PATHOLOGY; FIBROSIS; ANTIBODY	SCHISTOSOMIASIS (bilharzia) is a parasitic disease caused by several species of schistosome worms (blood flukes). The key pathogenic event in this disease is the formation of granulomas around schistosome eggs trapped in portal venules of the liver 1-9. Granulomas are a distinctive form of chronic inflammation characterized by localized aggregation of activated macrophages around an inciting stimulus 10. Each granuloma evolves to form a fibrous scar; in schistosomiasis, the result is widespread hepatic fibrosis and portal hypertension. To identify the specific immune signal molecules necessary for granuloma formation, we studied schistosome infections in severe combined immunodeficient (SCID) mice, which have normal macrophages but lack functional B or T lymphocytes 11,12. Here we report that the immunoregulatory cytokine tumour necrosis factor-alpha is necessary and sufficient to reconstitute granuloma formation in schistosome-infected SCID mice. Moreover, we find that the parasitic worms require tumour necrosis factor-alpha for egg-laying and for excretion of eggs from the host. The implication of this latter result is that the parasite has adapted so successfully to its host that it uses a host-derived immunoregulatory protein as a signal for replication and transmission.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,ANAT PATHOL SERV 113B,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BYRAM JE, 1977, AM J TROP MED HYG, V26, P944, DOI 10.4269/ajtmh.1977.26.944; BYRAM JE, 1979, AM J TROP MED HYG, V28, P274, DOI 10.4269/ajtmh.1979.28.274; CHEEVER AW, 1985, PARASITE IMMUNOL, V7, P387, DOI 10.1111/j.1365-3024.1985.tb00085.x; CHEEVER AW, 1989, AM J TROP MED HYG, V40, P66, DOI 10.4269/ajtmh.1989.40.66; CHENSUE SW, 1989, J IMMUNOL, V142, P1281; CUSTER RP, 1985, AM J PATHOL, V120, P464; DOENHOFF MJ, 1985, DEV BIOL STAND, V62, P63; DOENHOFF MJ, 1986, T ROY SOC TROP MED H, V80, P503, DOI 10.1016/0035-9203(86)90126-4; DOUGHTY BL, 1982, J IMMUNOL, V128, P37; DUVALL RH, 1967, AM J TROP MED HYG, V16, P483, DOI 10.4269/ajtmh.1967.16.483; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; JAATTELA M, 1991, LAB INVEST, V64, P724; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; MATHEW RC, 1986, INFECT IMMUN, V54, P820, DOI 10.1128/IAI.54.3.820-826.1986; MCGEE HJ, 1984, NATURE, V308, P667, DOI 10.1038/308667a0; OLDS GR, 1989, J INFECT DIS, V159, P798, DOI 10.1093/infdis/159.4.798; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PERRIN PJ, 1988, J IMMUNOL, V141, P1714; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; PRAKASH S, 1990, J IMMUNOL, V144, P317; ROBBINS SL, 1984, PATHOLOGIC BASIS DIS, P64	24	422	441	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					604	607		10.1038/356604a0	http://dx.doi.org/10.1038/356604a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560843				2022-12-24	WOS:A1992HP03100049
J	SCHNOLZER, M; KENT, SBH				SCHNOLZER, M; KENT, SBH			CONSTRUCTING PROTEINS BY DOVETAILING UNPROTECTED SYNTHETIC PEPTIDES - BACKBONE-ENGINEERED HIV PROTEASE	SCIENCE			English	Article							VIRUS TYPE-1 PROTEASE; ASPARTIC PROTEINASES; CRYSTAL-STRUCTURE; MUTAGENESIS; RESOLUTION; INHIBITOR; COMPLEX; HOMOLOGY	Backbone-engineered HIV-1 protease was prepared by a total chemical synthesis approach that combines the act of joining two peptides with the generation of an analog structure. Unprotected synthetic peptide segments corresponding to the two halves of the HIV-1 protease monomer polypeptide chain were joined cleanly and in high yield through unique mutually reactive functional groups, one on each segment. Ligation was performed in 6 molar guanidine hydrochloride, thus circumventing limited solubility of protected peptide segments, the principal problem of the classical approach to the chemical synthesis of proteins. The resulting fully active HIV-1 protease analog contained a thioester replacement for the natural peptide bond between Gly51-Gly52 in each of the two active site flaps, a region known to be highly sensitive to mutational changes of amino acid side chains.	Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BACA M, 1992, PEPTIDES, P732; BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAYER E, 1991, ANGEW CHEM INT EDIT, V30, P113, DOI 10.1002/anie.199101133; BLAKE J, 1986, INT J PEPT PROT RES, V27, P191; CARTER P, 1986, BIOCHEM J, V237, P1; CHENG HC, 1991, INT J PEPT PROT RES, V38, P70; Epton R., 1990, INNOVATION PERSPECTI, P11; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KENT SBH, 1991, PEPTIDES 1990, P169; KENT SBH, 1989, VIRAL PROTEINASES TH, P223; KENT SBH, IN PRESS INNOVATION; KIYAMA S, 1984, INT J PEPT PROT RES, V23, P174; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KOPPENHOEFER B, 1985, ORG SYNTH, V64, P230; LAPATTO P, 1989, NATURE, V342, P299; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OFFORD R, 1991, PROTEIN ENG, V4, P709, DOI 10.1093/protein/4.7.709; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; SASAKI T, 1991, J ORG CHEM, V56, P3159, DOI 10.1021/jo00009a043; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHNOLZER M, UNPUB; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMASHIRO D, 1988, INT J PEPT PROT RES, V31, P322	36	296	405	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					221	225		10.1126/science.1566069	http://dx.doi.org/10.1126/science.1566069			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566069				2022-12-24	WOS:A1992HM89600029
J	LECKBAND, DE; ISRAELACHVILI, JN; SCHMITT, FJ; KNOLL, W				LECKBAND, DE; ISRAELACHVILI, JN; SCHMITT, FJ; KNOLL, W			LONG-RANGE ATTRACTION AND MOLECULAR-REARRANGEMENTS IN RECEPTOR-LIGAND INTERACTIONS	SCIENCE			English	Article							STREPTAVIDIN; MONOLAYERS; SURFACES; PROTEIN	A surface force apparatus was used to measure a long-range attractive protein-ligand force at separations D < 85 angstroms. This force may effectively "steer" ligand trajectories, resulting in a greater than 27-fold enhancement of the association rate. A much stronger specific attraction is measured at contact (D < 4 angstroms). A sevenfold increase in intermembrane adhesion resulted from increased lateral mobility of the receptors and molecular rearrangements in membranes above the solid-fluid transition temperature.	MAX PLANCK INST POLYMER RES,W-6500 MAINZ,GERMANY	Max Planck Society	LECKBAND, DE (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106, USA.				NIGMS NIH HHS [GM13300] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON SA, 1985, BIOPOLYMERS, V24, P1323, DOI 10.1002/bip.360240717; BAYER EA, 1990, METHOD ENZYMOL, V184, P49; BELL G, 1988, PHYSICAL BASIS CELL, pCH10; BERRY RS, 1980, PHYSICAL CHEM, P1160; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; BONGRAND P, 1984, CELL SURFACE DYNAMIC, pCH14; CEVC G, 1984, PHOSPHOLIPID BILAYER, P242; CHRISTENSON HK, 1988, SCIENCE, V239, P390, DOI 10.1126/science.239.4838.390; CLAESSON PM, 1990, J COLLOID INTERF SCI, V136, P541, DOI 10.1016/0021-9797(90)90400-I; CREIGHTON TE, 1989, PROTEINS, P340; EVANS EA, 1985, BIOPHYS J, V48, P185, DOI 10.1016/S0006-3495(85)83771-1; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, pCH11; LECKBAND D, UNPUB; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MARRA J, 1985, BIOCHEMISTRY-US, V24, P4608, DOI 10.1021/bi00338a020; MARRA J, 1986, METHOD ENZYMOL, V127, P353; METZLER DE, 1977, BIOCHEMISTRY-US, P433; SLAYTON P, 1990, BIOCHEMISTRY-US, V29, P7381; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387; WIEGEL FW, 1984, CELL SURFACE DYNAMIC, pCH5	24	121	124	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1419	1421		10.1126/science.1542789	http://dx.doi.org/10.1126/science.1542789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542789				2022-12-24	WOS:A1992HH74400050
J	KITAMURA, D; RAJEWSKY, K				KITAMURA, D; RAJEWSKY, K			TARGETED DISRUPTION OF MU-CHAIN MEMBRANE EXON CAUSES LOSS OF HEAVY-CHAIN ALLELIC EXCLUSION	NATURE			English	Article							PRE-B-CELLS; GENE REARRANGEMENT; IMMUNOGLOBULIN-MU; ANTIBODY; RECOMBINATION; INHIBITION; ACTIVATION; EXPRESSION; GENERATION; MATURATION	BURNET'S clonal selection theory 1 suggests that each B lymphocyte is committed to a single antibody specificity. This is achieved by a programme of somatic rearrangements of the gene segments encoding antibody variable (V) regions, in the course of B-cell development 2,3 . Evidence from immunoglobulin-transgenic mice and immunoglobulin-gene-transfected transformed pre-B cells suggests that the membrane form of the immunoglobulin heavy (H) chain of class-mu (mu-m), expressed from a rearranged H-chain (IgH) locus, may signal allelic exclusion of the homologous IgH locus in the cell 4-6 and initiation of light (L)-chain gene rearrangement in the Ig-kappa loci 6. We report here that targeted disruption of the membrane exon of the mu-chain indeed results in the loss of H-chain allelic exclusion. But, some kappa-chain gene rearrangement is still observed in the absence of mu-m expression.	UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY	University of Cologne								ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BURNET FM, 1959, CLONAL SELECTION THE; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; Coffman R L, 1982, Immunol Rev, V69, P5; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GAUSE A, 1987, EUR J IMMUNOL, V17, P981, DOI 10.1002/eji.1830170714; GRUTZMANN R, 1981, THESIS U COLOGNE; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1847; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KARASUYAMA H, 1990, J EXP MED, V172, P962; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KOHLER G, 1980, P NATL ACAD SCI-BIOL, V77, P2197, DOI 10.1073/pnas.77.4.2197; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MCHEYZERWILLIAMS MG, 1989, J IMMUNOL METHODS, V119, P9, DOI 10.1016/0022-1759(89)90375-X; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; TONEGAWA S, 1983, NATURE, V302, P79; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	34	335	352	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					154	156		10.1038/356154a0	http://dx.doi.org/10.1038/356154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545868				2022-12-24	WOS:A1992HH73100060
J	BAILEY, IS; KARRAN, SE; TOYN, K; BROUGH, P; RANABOLDO, C; KARRAN, SJ				BAILEY, IS; KARRAN, SE; TOYN, K; BROUGH, P; RANABOLDO, C; KARRAN, SJ			COMMUNITY SURVEILLANCE OF COMPLICATIONS AFTER HERNIA SURGERY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the effect of a programme of postoperative community surveillance on the rate of detection of wound complications after operation for inguinal hernia. Design - Prospective audit of wound complications including complications recorded in case notes and those discovered by community surveillance. Setting - Academic surgical unit of three consultant surgeons. Patients - 510 patients undergoing elective inguinal hernia repair between June 1985 and August 1989. Results - The wound infection rate recorded in the hospital notes was 3% compared with 9% when additional information was obtained from community surveillance. Wound complications were detected in 143 (28%) patients by community surveillance compared with a complication rate of 7% in the case records for the same patients. Conclusions - Wound complications are common after clean surgery in patients discharged home early. Complication rates are a reflection not only of the standards of surgical practice but also the rigour with which they are sought. Before national comparative audit data are published the method of collection must be standardised. For short stay surgery this should include meaningful community surveillance.	UNIV SOUTHAMPTON,ROYAL S HAMPSHIRE HOSP,SURG UNIT,SOUTHAMPTON SO9 4PE,ENGLAND	University of Southampton								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; Buck N, 1987, REPORT CONFIDENTIAL; CRUSE P, 1980, CONTROVERSIES SURGIC, P327; 1989, WORKING PATIENTS; 1964, ANN SURG S, V160, P1; 1960, LANCET, V2, P659	6	146	149	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					469	471		10.1136/bmj.304.6825.469	http://dx.doi.org/10.1136/bmj.304.6825.469			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547415	Bronze, Green Published			2022-12-24	WOS:A1992HF55500018
J	MOWRY, KL; MELTON, DA				MOWRY, KL; MELTON, DA			VEGETAL MESSENGER-RNA LOCALIZATION DIRECTED BY A 340-NT RNA SEQUENCE ELEMENT IN XENOPUS OOCYTES	SCIENCE			English	Article							BICOID RNA; DROSOPHILA; VG1; LAEVIS; EGGS; IDENTIFICATION; TRANSLOCATION; TRANSCRIPTION; PROTEIN; POLE	Contained within a single cell, the fertilized egg, is information that will ultimately specify the entire organism. During early embryonic cleavages, cells acquire distinct fates and their differences in developmental potential might be explained by localization of informational molecules in the egg. The mechanisms by which Vg1 RNA, a maternal mRNA, is translocated to the vegetal pole of Xenopus oocytes may indicate how developmental signals are localized. Data presented here show that a 340-nucleotide localization signal present in the 3' untranslated region of Vg1 RNA is sufficient to direct RNA localization to the vegetal pole.			MOWRY, KL (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Mowry, Kimberly/0000-0002-4126-2889	NIGMS NIH HHS [GM 32921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; JAMRICH M, 1984, EMBO J, V3, P1939, DOI 10.1002/j.1460-2075.1984.tb02073.x; KIM J, 1991, CELL, V66, P23; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; MOWRY KL, 1988, UNPUB, V7, P1749; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Sambrook J., 1989, MOL CLONING LAB MANU; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1985, COLD SPRING HARB SYM, V50, P21, DOI 10.1101/SQB.1985.050.01.005; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	26	229	233	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					991	994		10.1126/science.1546297	http://dx.doi.org/10.1126/science.1546297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546297				2022-12-24	WOS:A1992HE60500043
J	ORMEJOHNSON, WH				ORMEJOHNSON, WH			NITROGENASE STRUCTURE - WHERE TO NOW	SCIENCE			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; MOFE PROTEIN; CLUSTERS; METAL; SITE				ORMEJOHNSON, WH (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; CHRISTOU G, 1982, J AM CHEM SOC, V104, P2820, DOI 10.1021/ja00374a021; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; DEAN DR, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P95; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GRESSHOFF PM, 1990, NITROGEN FIXATION AC; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOLM RH, 1977, IRON SULFUR PROTEINS, V3, P206; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HUGHES DL, 1988, NITROGEN FIXATION 10, P66; Jolly W. L., 1964, INORGANIC CHEM NITRO; KAUL BB, 1990, J AM CHEM SOC, V112, P2002, DOI 10.1021/ja00161a058; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LOWE DJ, 1984, BIOCHEM J, V24, P887; LOWE DJ, 1984, BIOCHEM J, V224, P909; MAY HD, 1990, NITROGEN FIXATION AC, P162; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; SCHROCK RR, 1991, J AM CHEM SOC, V113, P725, DOI 10.1021/ja00002a079; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SURERUS KK, IN PRESS J AM CHEM S; THORNELEY RNF, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P103; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; WINK DA, 1989, BIOCHEMISTRY-US, V28, P9407, DOI 10.1021/bi00450a024; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; 1979, AMMONIA	33	70	72	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1639	1640		10.1126/science.1529351	http://dx.doi.org/10.1126/science.1529351			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529351				2022-12-24	WOS:A1992JN50100018
J	INGLESE, J; KOCH, WJ; CARON, MG; LEFKOWITZ, RJ				INGLESE, J; KOCH, WJ; CARON, MG; LEFKOWITZ, RJ			ISOPRENYLATION IN REGULATION OF SIGNAL TRANSDUCTION BY G-PROTEIN-COUPLED RECEPTOR KINASES	NATURE			English	Article							GAMMA SUBUNITS CONTAIN; RAS PROTEINS; TRANSLOCATION; FARNESYL; FAMILY; CELLS; ACID; P21	RHODOPSIN kinase1 and beta-adrenergic receptor kinase (beta-ARK)2 are related members of a serine/threonine kinase family that specifically initiate deactivation of G-protein-coupled receptors. After stimulus-mediated receptor activation, these cytoplasmic kinases translocate to the plasma membrane3,4. Here we show that the molecular basis for this event involves a class of unsaturated lipids called isoprenoids. Covalent modification in vivo of rhodopsin kinase by a 15-C (farnesyl) isoprenoid5 enables the kinase to anchor to photon-activated rhodopsin. Mutations that alter or eliminate the isoprenoid, fully disable light-specific Rhodopsin kinase translocation. Other receptor kinases (such as beta-ARK), which lack an intrinsic lipid, are activated6 on exposure to brain beta-gamma-subunits of the signal-transducing G proteins, the gamma-subunit of which bears a 20-C (geranylgeranyl) isoprenoid7,8. Using chimaeric beta-ARKs that undergo isoprenylation in vitro, we demonstrate that membrane association and activation of these kinases can occur in the absence of beta-gamma. These results indicate that rhodopsin kinase (by means of an integral isoprenoid) and beta-ARK (through its association with beta-gamma) both rely on the function of isoprenyl moieties for their translocation and activity, illustrating distinct, though related, modes of biological regulation of receptor function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021					ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, IN PRESS J NEUROSCI; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, NATURE, V322, P869; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; COX AD, IN PRESS CRIT REV ON; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PITCHER J, IN PRESS SCIENCE; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	26	269	274	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					147	150		10.1038/359147a0	http://dx.doi.org/10.1038/359147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522899				2022-12-24	WOS:A1992JM49400052
J	ONORATO, IM; WASSILAK, SG; MEADE, B				ONORATO, IM; WASSILAK, SG; MEADE, B			EFFICACY OF WHOLE-CELL PERTUSSIS-VACCINE IN PRESCHOOL-CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTECTIVE EFFICACY; HOUSEHOLD EXPOSURE; DIPHTHERIA; ANTIBODY; DTP	Objective.-To evaluate the efficacy of currently used whole-cell pertussis vaccines. Design.-Active surveillance to detect pertussis cases in Baltimore, Md, Denver, Colo, and Milwaukee, Wis, and investigation of secondary attack rates in 347 household contacts, aged 1 through 4 years, to estimate vaccine efficacy. Outcome Measure.-Vaccine efficacy was estimated using different case definitions for pertussis. Results.-Vaccine efficacy was 64%, 81%, and 95% for case definitions of mild cough, paroxysmal cough, and severe clinical illness, respectively. Requiring laboratory confirmation increased efficacy to 95% to 98% for culture-positive children and to 77% to 95% for culture- or serology-confirmed cases, depending on disease severity. Vaccine efficacy for typical paroxysmal cough increased from 44% for one diphtheria, tetanus, and pertussis vaccine dose to 80% for four or more doses. Conclusions.-The trend toward increasing vaccine efficacy with different case definitions may be due to improved efficacy in preventing severe illness and to case definitions that are more specific for pertussis. Whole-cell pertussis vaccine was highly effective in preventing pertussis in preschool children exposed to infection within their households. Direct side-by-side efficacy studies of whole-cell vaccine and the recently licensed acellular vaccine will be necessary to assure that comparable protection is afforded by the new vaccines if they are to be used for immunization of infants.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014	US Food & Drug Administration (FDA)	ONORATO, IM (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,TECH INFORMAT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333, USA.							[Anonymous], 1988, LANCET, Vi, P955; BEGG RC, 1984, NEW ZEAL MED J, V97, P408; BLACKWELDER WC, 1991, AM J DIS CHILD, V145, P1285, DOI 10.1001/archpedi.1991.02160110077024; BLENNOW M, 1988, BRIT MED J, V296, P1570, DOI 10.1136/bmj.296.6636.1570; BLUMBERG DA, 1990, J PEDIATR-US, V117, P46, DOI 10.1016/S0022-3476(05)82442-4; CODY CL, 1981, PEDIATRICS, V68, P650; COUTLER HL, 1985, SHOT DARK; FINE PEM, 1987, REV INFECT DIS, V9, P866; FINE PEM, 1988, INT J EPIDEMIOL, V17, P635, DOI 10.1093/ije/17.3.635; HINMAN AR, 1984, PUBLIC HEALTH REP, V99, P255; HOLLANDER HO, 1991, J INFECT DIS, V163, P1046; Howson CP, 1991, ADVERSE EFFECTS PERT; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MEADE BD, 1990, DHHS PUBLICATION, P322; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; REGAN J, 1977, J CLIN MICROBIOL, V6, P303; STORSAETER J, 1990, VACCINE, V8, P457, DOI 10.1016/0264-410X(90)90246-I; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1992, MMWR, V41, P1; 1984, WEEKLY EPIDEMIOL REC, V59, P26; 1984, MMWR, V33, P573; 1991, MMWR, V40, P1; 1991, ANN NEUROL, V29, P458	26	79	83	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2745	2749		10.1001/jama.267.20.2745	http://dx.doi.org/10.1001/jama.267.20.2745			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578592				2022-12-24	WOS:A1992HV26500020
J	SAID, G; GOULONGOEAU, C; SLAMA, G; TCHOBROUTSKY, G				SAID, G; GOULONGOEAU, C; SLAMA, G; TCHOBROUTSKY, G			SEVERE EARLY-ONSET POLYNEUROPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS - A CLINICAL AND PATHOLOGICAL-STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROPATHY; DEGENERATION; PATHOGENESIS; PAINFUL	Background and Methods. The pathophysiologic features of diabetic neuropathy, a common and disabling long-term complication of diabetes mellitus, are poorly understood. We studied five patients, 22 to 34 years old, in whom an uncommonly severe symmetric polyneuropathy developed soon after the onset of insulin-dependent diabetes. Their autonomic function and nerve conduction were studied, and sural-nerve biopsy specimens were examined by light and electron microscopy. Other causes of neuropathy were carefully excluded. Results. Four patients had autonomic dysfunction with postural hypotension, fainting, diarrhea, and Argyll Robertson pupils and peripheral neuropathy with loss of sensation of pain and changes in temperature that followed a pattern suggestive of a length-dependent degeneration of nerve fibers. In contrast, the fifth patient had muscle weakness and atrophy of limb extremities, with "glove and stocking" sensory loss, but little autonomic dysfunction. In the biopsy specimens of sural nerves, the mean (+/- SD) density of myelinated fibers was reduced to 20 +/- 14 percent of that measured in five control patients, and the density of unmyelinated fibers was reduced to 6 +/- 4 percent of that in the controls. Regenerating fibers accounted for 38 +/- 11 percent of the myelinated axons. Abnormalities of the myelin sheath affected 33 +/- 21 percent of the isolated fibers, and axonal degeneration 11 +/- 8 percent. Dying-back fibers, a characteristic of the centripetal degeneration of peripheral axons, were also identified. The dying-back process progressed at the rate of a few hundred micrometers per day. Conclusions. Early-onset symptomatic polyneuropathy in patients with diabetes mellitus is characterized by the loss of both myelinated and unmyelinated nerve fibers. Spontaneous axonal regeneration is remarkably frequent, even when neuropathy is severe.	UNIV PARIS 11,HOP BICETRE,SERV NEUROL,PARIS,FRANCE; HOP HOTEL DIEU,SERV DIABETOL,F-75181 PARIS 04,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite								ALI Z, 1989, J NEUROL NEUROSUR PS, V52, P94, DOI 10.1136/jnnp.52.1.94; AZERAD E, 1961, PRESSE MED, V69, P1419; BEHSE F, 1990, ACTA NEUROL SCAND  S, V82, P3; BRITLAND ST, 1990, DIABETES, V39, P898, DOI 10.2337/diabetes.39.8.898; BROWN MJ, 1976, ARCH NEUROL-CHICAGO, V33, P164, DOI 10.1001/archneur.1976.00500030020004; CORNIL V, 1907, MANUEL HISTOLOGIE PA, V3, P527; Dieulafoy G., 1906, CLIN MED HOTEL DIEU, P130; DYCK P J, 1987, P223; DYCK PJ, 1986, ANN NEUROL, V19, P425, DOI 10.1002/ana.410190503; EWING D J, 1987, P66; FAGERBERG SE, 1963, ACTA MED SCAND, V174, P711; FUJIMURA H, 1991, BRAIN, V114, P1929, DOI 10.1093/brain/114.4.1929; GREENE DA, 1987, NEW ENGL J MED, V316, P599; JAMAL GA, 1987, MUSCLE NERVE, V10, P537, DOI 10.1002/mus.880100608; JOHNSON PC, 1986, ANN NEUROL, V19, P450, DOI 10.1002/ana.410190505; KING RHM, 1989, NEUROPATH APPL NEURO, V15, P339, DOI 10.1111/j.1365-2990.1989.tb01234.x; LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867; MCINTYRE AK, 1980, PHYSL PERIPHERAL NER, P41; MELTON LJ, 1987, DIABETIC NEUROPATHY, P27; PARKHOUSE N, 1988, NEW ENGL J MED, V318, P1306, DOI 10.1056/NEJM198805193182005; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; Sabin T.D., 1978, PHYSL PATHOBIOLOGY A, P431; SAID G, 1984, NEUROLOGY, V34, P1025, DOI 10.1212/WNL.34.8.1025; SAID G, 1983, BRAIN, V106, P791, DOI 10.1093/brain/106.4.791; SIDENIUS P, 1987, P260; THOMAS PK, 1984, PERIPHERAL NEUROPATH, P1773; VERGELY P, 1893, GAZ HEBD MED CHIR, V32, P376	28	111	111	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1257	1263		10.1056/NEJM199205073261905	http://dx.doi.org/10.1056/NEJM199205073261905			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560802				2022-12-24	WOS:A1992HR44700005
J	VIONNET, N; STOFFEL, M; TAKEDA, J; YASUDA, K; BELL, GI; ZOUALI, H; LESAGE, S; VELHO, G; IRIS, F; PASSA, P; FROGUEL, P; COHEN, D				VIONNET, N; STOFFEL, M; TAKEDA, J; YASUDA, K; BELL, GI; ZOUALI, H; LESAGE, S; VELHO, G; IRIS, F; PASSA, P; FROGUEL, P; COHEN, D			NONSENSE MUTATION IN THE GLUCOKINASE GENE CAUSES EARLY-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							DNA; POLYMORPHISMS; POLYMERASE	MATURITY-ONSET diabetes of the young (MODY) is a form of non-insulin-dependent (type 2) diabetes mellitus (NIDDM) which is characterized by an early age at onset and an autosomal dominant mode of inheritance 1. Except for these features, the clinical characteristics of patients with MODY are similar to those with the more common late-onset form(s) of NIDDM. Previously 2 we observed tight linkage between DNA polymorphisms in the glucokinase gene on the short arm of chromosome 7 and NIDDM in a cohort of sixteen French families having MODY. Glucokinase is an enzyme that catalyses the formation of glucose-6-phosphate from glucose and may be involved in the regulation of insulin secretion and integration of hepatic intermediary metabolism 3. Because the glucokinase gene was a candidate for the site of the genetic lesion in these families, we scanned this gene for mutations. Here we report the identification of a nonsense mutation in the gene encoding glucokinase and its linkage with early-onset diabetes in one family. To our knowledge, this result is the first evidence implicating a mutation in a gene involved in glucose metabolism in the pathogenesis of NIDDM.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM,5841 S MARYLAND AVE,MC1028,CHICAGO,IL 60637; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-91000 EVRY,FRANCE; UNIV CHICAGO,DEPT MOLEC BIOL & MED,CHICAGO,IL 60637; GENETHON,F-91000 EVRY,FRANCE	Howard Hughes Medical Institute; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Chicago			Velho, Gilberto/Q-6724-2017; FROGUEL, Philippe/O-6799-2017; Vionnet, Nathalie/N-6302-2017	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784; Stoffel, Markus/0000-0003-1304-5817				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875	12	569	594	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					721	722		10.1038/356721a0	http://dx.doi.org/10.1038/356721a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570017				2022-12-24	WOS:A1992HQ14600064
J	MUSCH, A; WIEDMANN, M; RAPOPORT, TA				MUSCH, A; WIEDMANN, M; RAPOPORT, TA			YEAST SEC PROTEINS INTERACT WITH POLYPEPTIDES TRAVERSING THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							PREPRO-ALPHA-FACTOR; POST-TRANSLATIONAL TRANSLOCATION; CELL-FREE SYSTEM; SIGNAL SEQUENCE; NASCENT POLYPEPTIDES; SECRETORY PROTEINS; FACTOR INVITRO; IMPORT; COMPONENT; INSERTION	We show by photocross-linking that nascent secretory proteins, during their passage through the endoplasmic reticulum membrane of S. cerevisiae, are in physical contact with Sec61p and Sec62p, two genetically identified membrane proteins that are essential for in vivo translocation. Sec61p seems to be in continuous contact, whereas Sec62p is involved only transiently. Translocation comprises both ATP-dependent and -independent phases of interaction with the Sec proteins. The results suggest a direct role of the Sec proteins in translocation.			MUSCH, A (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,O-1115 BERLIN,GERMANY.							ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, IN PRESS CELL, V69; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STIRLING CJ, 1992, IN PRESS MOL BIOL CE; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WIEDMANN M, 1988, EMBO J, V7, P1763, DOI 10.1002/j.1460-2075.1988.tb03006.x	41	111	112	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					343	352		10.1016/0092-8674(92)90414-8	http://dx.doi.org/10.1016/0092-8674(92)90414-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568249				2022-12-24	WOS:A1992HQ18300013
J	PINNER, RW; SCHUCHAT, A; SWAMINATHAN, B; HAYES, PS; DEAVER, KA; WEAVER, RE; PLIKAYTIS, BD; REEVES, M; BROOME, CV; WENGER, JD				PINNER, RW; SCHUCHAT, A; SWAMINATHAN, B; HAYES, PS; DEAVER, KA; WEAVER, RE; PLIKAYTIS, BD; REEVES, M; BROOME, CV; WENGER, JD			ROLE OF FOODS IN SPORADIC LISTERIOSIS .2. MICROBIOLOGIC AND EPIDEMIOLOGIC INVESTIGATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; MONOCYTOGENES; MEDIA; MILK	Objective. - To evaluate the role of foods in sporadic listeriosis. Design. - Microbiologic survey of foods collected from refrigerators of patients with listeriosis identified through active laboratory-based surveillance. Patient and food Listeria monocytogenes isolates were subtyped to identify foods contaminated with the same strain of L monocytogenes that caused illness in the patient; samples of these foods were obtained from the retail source. Setting. - Multistate population-based study conducted between 1988 and 1990. Results. - Listeria monocytogenes grew from at least one food specimen in the refrigerators of 79 (64%) of 1 23 listeriosis patients; 11 % of more than 2000 food specimens collected in the study contained L monocytogenes. Twenty-six (33%) of 79 refrigerators with foods that grew L monocytogenes contained at least one food isolate of the same strain as that in the corresponding patient, a frequency much higher than would be expected by chance (P < .001). Multivariate analysis showed that of the food specimens that grew L monocytogenes, foods that were ready-to-eat, foods that grew L monocytogenes by a direct-plating method (a measure of the level of contamination), and foods that contained serotype 4b isolates were independently associated with an increased likelihood of containing the patient-matching strain. Conclusion. - We identified specific food and L monocytogenes isolate characteristics-ready-to-eat foods, foods containing higher concentrations of L monocytogenes, and foods containing serotype 4b-which were associated with disease-causing strains. These results can provide guidance to industry and regulatory agencies in developing strategies to prevent listeriosis.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,BIOSTAT & INFORMAT BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	PINNER, RW (corresponding author), CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		BIBB WF, 1989, INT J FOOD MICROBIOL, V8, P233, DOI 10.1016/0168-1605(89)90018-4; BILLE J, 1990, FOODBORNE LISTERIOSI, P71; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GILBERT R, 1990, P INT C LISTERIA FOO, P82; HAYES PS, 1991, APPL ENVIRON MICROB, V57, P2109, DOI 10.1128/AEM.57.8.2109-2113.1991; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOVETT J, 1987, J FOOD PROTECT, V50, P188, DOI 10.4315/0362-028X-50.3.188; MCCLAIN D, 1988, J ASSOC OFF ANA CHEM, V71, P679; MCLAUCHLIN J, 1990, PHLS MICROBIOL DIGES, V3, P54; PIFFARETTI JC, 1989, P NATL ACAD SCI USA, V86, P3818, DOI 10.1073/pnas.86.10.3818; RIEDO FX, 1990, 30TH INT C ANT AG CH, P248; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SCHWARTZ B, 1988, LANCET, V2, P779; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SWAMINATHAN B, 1988, J ASSOC OFF ANA CHEM, V71, P664; VANNETTEN P, 1989, INT J FOOD MICROBIOL, V8, P299, DOI 10.1016/0168-1605(89)90001-9; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1988, B WORLD HEALTH ORGAN, V66, P421	21	187	197	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2046	2050		10.1001/jama.267.15.2046	http://dx.doi.org/10.1001/jama.267.15.2046			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552640				2022-12-24	WOS:A1992HM65000029
J	BEEMAN, RW; FRIESEN, KS; DENELL, RE				BEEMAN, RW; FRIESEN, KS; DENELL, RE			MATERNAL-EFFECT SELFISH GENES IN FLOUR BEETLES	SCIENCE			English	Article							YELLOW MONKEY FLOWER; DROSOPHILA-MELANOGASTER; FEMALE STERILITY; HYBRIDS; POPULATIONS; CHROMOSOME; GENETICS; GENOME	A previously unknown class of dominant, maternal-effect lethal M factors was found to be widespread in natural populations of the flour beetle, Tribolium castaneum, collected on several continents. Such factors are integrated into the host chromosomes at variable locations and show the remarkable property of self-selection by maternal-effect lethality to all hatchlings that do not inherit a copy of the factor itself. Offspring are rescued by either paternally or maternally inherited copies. The M-bearing chromosome is thereby perpetuated at the expense of its non-M homolog. M factors that map to different regions of the genome do not rescue one another's maternal-effect lethality. Factors expressing these properties are predicted to spread in a population, even in the absence of any additional selective advantage. Similar factors also occur in the related species T. confusum.	KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506	Kansas State University	BEEMAN, RW (corresponding author), USDA ARS,N CENT REG,US GRAIN MKT RES LAB,1515 COLL AVE,MANHATTAN,KS 66502, USA.			Friesen, Kenlee/0000-0003-1211-3953				BEEMAN RW, 1986, J HERED, V77, P451, DOI 10.1093/oxfordjournals.jhered.a110279; BEEMAN RW, 1990, J ECON ENTOMOL, V83, P1745, DOI 10.1093/jee/83.5.1745; BEEMAN RW, UNPUB; CHRISTIE P, 1987, EVOLUTION, V41, P571, DOI 10.1111/j.1558-5646.1987.tb05827.x; CHRISTIE P, 1984, J HERED, V75, P510, DOI 10.1093/oxfordjournals.jhered.a110004; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; HUTTER P, 1990, GENETICS, V124, P909; KIDWELL MG, 1977, GENETICS, V86, P813; NUR U, 1988, SCIENCE, V240, P512, DOI 10.1126/science.3358129; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; ORR HA, 1989, EVOLUTION, V43, P180, DOI 10.1111/j.1558-5646.1989.tb04216.x; ORR HA, 1987, GENETICS, V116, P555; PICARD G, 1978, BIOL CELLULAIRE, V31, P235; WADE MR, COMMUNICATION	14	135	141	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					89	92		10.1126/science.1566060	http://dx.doi.org/10.1126/science.1566060			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566060				2022-12-24	WOS:A1992HL82200032
J	ROBINSON, MS; KREIS, TE				ROBINSON, MS; KREIS, TE			RECRUITMENT OF COAT PROTEINS ONTO GOLGI MEMBRANES IN INTACT AND PERMEABILIZED CELLS - EFFECTS OF BREFELDIN-A AND G-PROTEIN ACTIVATORS	CELL			English	Article							MONOCLONAL-ANTIBODIES; UNCOATING ATPASE; CLATHRIN; TRANSPORT; STACK; PITS; PURIFICATION; ADAPTORS; VESICLES; BINDING	Brefeldin A (BFA) causes a rapid redistribution of coat proteins (e.g., gamma-adaptin) associated with the clathrin-coated vesicles that bud from the trans-Golgi network (TGN), while the clathrin-coated vesicles that bud from the plasma membrane are unaffected. Gamma-Adaptin redistributes with the same kinetics as beta-COP, a coat protein associated with the non-clathrin-coated vesicles that bud from the Golgi complex. Upon removal of BFA, however, gamma-adaptin recovers its perinuclear distribution more rapidly. Redistribution of both proteins can be prevented by pretreating cells with AIF4-. Recruitment of adaptors from the cytosol onto the TGN membrane has been reconstituted in a permeabilized cell system and is increased by addition of GTP-gamma-S and blocked by addition of BFA. These results suggest a role for G proteins in the control of the clathrin-coated vesicle cycle at the TGN and further extend the similarities between clathrin-coated vesicles and non-clathrin-coated vesicles.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	ROBINSON, MS (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; DAVOUST J, 1991, P AM I PHYSICS, V226, P385; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, IN PRESS SCIENCE; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KIRCHHAUSEN T, 1991, IN PRESS J BIOL CHEM; KREIS TE, 1979, P NATL ACAD SCI USA, V76, P3414; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SERAFINI T, 1991, NATURE, V349, P215; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	40	333	335	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					129	138		10.1016/0092-8674(92)90124-U	http://dx.doi.org/10.1016/0092-8674(92)90124-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555237				2022-12-24	WOS:A1992HM44500012
J	SOSIN, DM; SACKS, JJ				SOSIN, DM; SACKS, JJ			MOTORCYCLE HELMET-USE LAWS AND HEAD-INJURY PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FATALITIES	Objective. - To rebut criticism of a previous study of motorcycle helmet-use laws through reanalysis with improved measures of exposure, stratification for regional differences in crash risk, and addressing of total motorcycle-related mortality and the grounds for targeting motorcyclists for helmet-use laws. Design. - Death certificate-based correlational study of motorcycle-related deaths and motorcycle helmet-use laws. Population Studied. - United States resident deaths from 1979 through 1986. Results. - Regardless of the denominator used (resident population, motorcycle registrations, or motorcycle crashes), states with full helmet-use laws had consistently lower head injury-associated death rates than states without such laws, even when stratified by region. Total motorcycle-related mortality, however, was similar between law groups. On a registration or crash basis, motorcyclists who died in crashes had a fivefold to sixfold higher risk of head injury than those who died using any other type of motor vehicle. Conclusion. - Full helmet-use laws were consistently associated with lower rates of head injury-associated death. While disagreement remains on the acceptability of the legislative approach, the scientific basis for motorcycle helmet-use laws as a head injury prevention tool appears sound.	CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, DIV INJURY CONTROL, ATLANTA, GA 30333 USA; CTR DIS CONTROL, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ADAMS JGU, 1983, ENVIRON PLANN C, V1, P193, DOI 10.1068/c010193; BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Cairns H, 1943, BMJ-BRIT MED J, V1943, P591, DOI 10.1136/bmj.1.4297.591; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; HURT HH, 1981, USC TSC811 U SO CAL; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; LUNA GK, 1981, WESTERN J MED, V135, P89; MCSWAIN NE, 1984, J TRAUMA, V24, P233, DOI 10.1097/00005373-198403000-00009; SCOTT RE, 1983, UMTRI8389 U MICH TRA; SHARP D, 1991, EASYRIDERS, V45, P34; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; WATSON GS, 1981, AM J PUBLIC HEALTH, V71, P297, DOI 10.2105/AJPH.71.3.297; 1980, MOTORCYCLE STATISTIC; DOT HS806438 US DEP; 1980, DOT HS805312 US DEP; 1985, DOT HS806867 US DEP; 1991, AM MOTORCYCLIST, V45, P34; 1988, DOT HS807296 US DEP	19	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1649	1651		10.1001/jama.267.12.1649	http://dx.doi.org/10.1001/jama.267.12.1649			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542175				2022-12-24	WOS:A1992HJ59700033
J	SELVIN, PR; COOK, DN; PON, NG; BAUER, WR; KLEIN, MP; HEARST, JE				SELVIN, PR; COOK, DN; PON, NG; BAUER, WR; KLEIN, MP; HEARST, JE			TORSIONAL RIGIDITY OF POSITIVELY AND NEGATIVELY SUPERCOILED DNA	SCIENCE			English	Article							FLUORESCENCE DEPOLARIZATION; ESCHERICHIA-COLI; DEPENDENCE; PROTEIN; MACROMOLECULES; REQUIREMENT; DYNAMICS; REPEAT	Time-correlated single-photon counting of intercalated ethidium bromide was used to measure the torsion constants of positively supercoiled, relaxed, ana negatively supercoiled pBR322 DNA, which range in superhelix density from +0.042 to -0.123. DNA behaves as coupled, nonlinear torsional pendulums under superhelical stress, and the anharmonic term in the Hamiltonian is approximately 15 percent for root-mean-square fluctuations in twist at room temperature. At the level of secondary structure, positively supercoiled DNA is significantly more flexible than negatively supercoiled DNA. These results exclude certain models that account for differential binding affinity of proteins to positively and negatively supercoiled DNA.	UNIV CALIF BERKELEY,DEPT PHYS,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794	University of California System; University of California Berkeley; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	SELVIN, PR (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CHEM BIODYNAM LAB,BERKELEY,CA 94720, USA.				FDA HHS [FD 8R1 GM 41911A-03-NF-03/92] Funding Source: Medline	FDA HHS		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ALLISON SA, 1979, CHEM PHYS, V41, P35, DOI 10.1016/0301-0104(79)80131-7; ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BAUER W, 1970, Journal of Molecular Biology, V47, P419, DOI 10.1016/0022-2836(70)90312-8; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FUJIMOTO BS, 1990, NATURE, V344, P175, DOI 10.1038/344175a0; HAHN S, 1986, J MOL BIOL, V188, P355, DOI 10.1016/0022-2836(86)90160-9; HOGAN M, 1979, BIOCHEMISTRY-US, V18, P280, DOI 10.1021/bi00569a007; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; HUNT NG, IN PRESS J CHEM PHYS; HURST JE, IN PRESS J CHEM PHYS; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; LIDE DR, 1990, CRC HDB CHEM PHYSICS; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILLAR DP, 1982, J CHEM PHYS, V76, P2080, DOI 10.1063/1.443182; SELVIN PR, 1990, THESIS U CALIFORNIA; SHIBATA JH, 1984, BIOCHEMISTRY-US, V23, P1188, DOI 10.1021/bi00301a025; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SONG L, 1990, J MOL BIOL, V214, P307, DOI 10.1016/0022-2836(90)90163-G; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; THOMAS JC, 1983, BIOCHEMISTRY-US, V22, P6194, DOI 10.1021/bi00295a024; WU PG, 1988, BIOCHEMISTRY-US, V27, P8128, DOI 10.1021/bi00421a023	30	59	59	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					82	85		10.1126/science.1553534	http://dx.doi.org/10.1126/science.1553534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553534				2022-12-24	WOS:A1992GX79100042
J	PROPST, T; PROPST, A; DIETZE, O; JUDMAIER, G; BRAUNSTEINER, H; VOGEL, W				PROPST, T; PROPST, A; DIETZE, O; JUDMAIER, G; BRAUNSTEINER, H; VOGEL, W			HIGH PREVALENCE OF VIRAL-INFECTION IN ADULTS WITH HOMOZYGOUS AND HETEROZYGOUS ALPHA(1)-ANTITRYPSIN DEFICIENCY AND CHRONIC LIVER-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ALPHA-1-ANTITRYPSIN; HEPATITIS, CHRONIC ACTIVE; LIVER CIRRHOSIS; HEPATITIS ANTIBODIES; HEPATITIS-C VIRUS	HEPATITIS-C VIRUS; ALPHA-ANTITRYPSIN DEFICIENCY; CHRONIC ACTIVE HEPATITIS; ALPHA-1-ANTITRYPSIN DEFICIENCY; MALIGNANT HEPATOMA; CYTO-TOXICITY; CIRRHOSIS; ANTIBODIES; EMPHYSEMA; PROTEIN	Objective: To determine the prevalence of chronic liver disease in adults with homozygous (Pi ZZ) and heterozygous (Pi Z) alpha1-antitrypsin deficiency and to assess the presence of other possible risk factors for the development of chronic active hepatitis and cirrhosis of the liver in these patients. Design: Cross-sectional study. Setting: A referral-based university hospital. Patients: Consecutive patients (164) with the Pi ZZ and Pi Z phenotype with and without chronic liver disease. Measurements: The presence of antibody to hepatitis C virus (anti-HCV) was determined using an assay incorporating synthetic peptide antigen from capsid protein (United Biomedical [UBI] assay) and a second-generation enzyme immunoassay (Abbott test); the presence of antibody to hepatitis B virus (anti-HBV) was determined using radioimmunoassays incorporating hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg); assays for antinuclear antibody and antimitochondrial antibody (M2 subtype) were also done, and alcohol abuse was assessed by history. Results: Among patients with cirrhosis (32%), 62% were anti-HCV positive by the Abbott test (P = 0.006), and 41% were anti-HCV positive by the UBI assay (P = 0.007). Thirty-three percent of patients with cirrhosis had hepatitis B virus (HBV) infection (P = 0.01); 41% had a history of alcoholism; and 12% had features of autoimmune liver disease. Only five patients (9%) with cirrhosis had no other risk factor for chronic liver disease. Among patients with chronic active hepatitis (7%), 80% were anti-HCV positive by the Abbott test (P = 0.002), and 75% were anti-HCV positive by the UBI assay (P < 0.001). Thirty percent of patients with chronic active hepatitis had HBV infection (P = 0.023); 18% had autoimmune hepatitis; and 8% abused alcohol. Only two patients (17%) had no additional risk factor for the development of chronic active hepatitis. Among patients with steatosis of the liver (48%), 5% were anti-HCV positive by the Abbott test, and none were anti-HCV positive by the UBI assay; 18% had serologic evidence of past HBV infection, and 28% abused alcohol. Among patients without chronic liver disease (13%), no viral infection could be found; 9% were alcoholics. Conclusions: Chronic liver disease in patients with alpha1-antitrypsin deficiency is associated with a high prevalence of viral infection; this infection, rather than alpha1-antitrypsin deficiency alone, may be the cause of the liver disease in such patients.	UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT PATHOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck	PROPST, T (corresponding author), UNIV HOSP INNSBRUCK, DEPT INTERNAL MED, ANICHSTR 35, A-6020 INNSBRUCK, AUSTRIA.							ADES EW, 1982, SCAND J IMMUNOL, V15, P109, DOI 10.1111/j.1365-3083.1982.tb00628.x; BRANTLY M, 1988, SCIENCE, V242, P1700, DOI 10.1126/science.2904702; BREIT SN, 1985, CLIN IMMUNOL IMMUNOP, V35, P363, DOI 10.1016/0090-1229(85)90097-2; BRILLANTI S, 1989, LANCET, V2, P1390; CARLSON J, 1985, SCAND J GASTROENTERO, V20, P835, DOI 10.3109/00365528509088831; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; COX DW, 1980, HUM GENET, V53, P429, DOI 10.1007/BF00287070; CRELL RW, 1979, ESSAYS MED BIOCH, V4, P83; ERIKSSON S, 1974, ACTA MED SCAND, V195, P451; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; FATTOVICH G, 1989, LANCET, V2, P797; FISHER RL, 1976, GASTROENTEROLOGY, V71, P646; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GELLER SA, 1990, HEPATOLOGY, V12, P40, DOI 10.1002/hep.1840120108; HODGES JR, 1981, NEW ENGL J MED, V304, P557, DOI 10.1056/NEJM198103053041001; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; HUDIG D, 1981, J IMMUNOL, V126, P1569; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MORIN T, 1975, LANCET, V1, P250; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; ROGET M, 1990, HEPATOLOGY, V11, P333, DOI 10.1002/hep.1840110234; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SCHROEDER WT, 1985, AM J HUM GENET, V37, P868; SHARP HL, 1971, J LAB CLIN MED, V78, P1012; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SHARP HL, 1982, SEMIN LIVER DIS, V2, P314, DOI 10.1055/s-2008-1040718; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	31	81	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					641	645		10.7326/0003-4819-117-8-641	http://dx.doi.org/10.7326/0003-4819-117-8-641			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530195				2022-12-24	WOS:A1992JR86100003
J	BILOUS, RW; MURTY, G; PARKINSON, DB; THAKKER, RV; COULTHARD, MG; BURN, J; MATHIAS, D; KENDALLTAYLOR, P				BILOUS, RW; MURTY, G; PARKINSON, DB; THAKKER, RV; COULTHARD, MG; BURN, J; MATHIAS, D; KENDALLTAYLOR, P			AUTOSOMAL DOMINANT FAMILIAL HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN PARATHYROID-HORMONE; IDIOPATHIC HYPOPARATHYROIDISM; RECESSIVE INHERITANCE; GENE; NEPHROPATHY		UNIV NEWCASTLE UPON TYNE,DEPT EAR NOSE & THROAT SURG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PAEDIAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT HUMAN GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; MRC,CLIN RES CTR,DIV MOLEC MED,HARROW HA1 3UJ,MIDDX,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Medical Research Council Clinical Trials Unit				Thakker, Rajesh/0000-0002-1438-3220; Burn, John/0000-0002-9823-2322				AHN TG, 1986, MEDICINE, V65, P73, DOI 10.1097/00005792-198603000-00001; AHONEN P, 1985, CLIN GENET, V27, P535, DOI 10.1111/j.1399-0004.1985.tb02037.x; Albright F, 1929, J CLIN INVEST, V7, P183, DOI 10.1172/JCI100224; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; BARAKAT AY, 1977, J PEDIATR-US, V91, P61, DOI 10.1016/S0022-3476(77)80445-9; BOONSTRA CE, 1965, ANN INTERN MED, V63, P468, DOI 10.7326/0003-4819-63-3-468; BRONSKY D, 1968, J CLIN ENDOCR METAB, V28, P61, DOI 10.1210/jcem-28-1-61; CHU HY, 1964, CHINESE MED J-PEKING, V83, P723; COUNAHAN R, 1976, ARCH DIS CHILD, V51, P875, DOI 10.1136/adc.51.11.875; DAHLBERG PJ, 1983, AM J MED GENET, V16, P99, DOI 10.1002/ajmg.1320160115; DECAMPO C, 1988, J ENDOCRINOL INVEST, V11, P91, DOI 10.1007/BF03350111; EDWARDS BD, 1989, J MED GENET, V26, P289, DOI 10.1136/jmg.26.5.289; ELLIS HA, 1969, PEDIATRICS, V44, P225; GEERTINGER P, 1967, PEDIATRICS, V39, P43; GEERTINGER P, 1969, ACTA PATHOL MIC SC, V75, P270; HUNTER AGW, 1981, J MED GENET, V18, P431, DOI 10.1136/jmg.18.6.431; IKEDA K, 1987, LARYNGOSCOPE, V97, P1075; KRUSE K, 1987, EUR J PEDIATR, V146, P373, DOI 10.1007/BF00444941; KUNSTADTER RH, 1963, AM J DIS CHILD, V105, P499, DOI 10.1001/archpedi.1963.02080040501014; LEHNHARDT E, 1986, CLIN ASPECTS INNER E, P57; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCELDUFF A, 1989, AUST NZ J MED, V19, P22, DOI 10.1111/j.1445-5994.1989.tb01668.x; MILLER M J, 1972, Henry Ford Hospital Medical Journal, V20, P3; NAYLOR SL, 1983, SOMAT CELL GENET, V9, P609, DOI 10.1007/BF01574261; NUSYNOWITZ ML, 1976, MEDICINE, V55, P105, DOI 10.1097/00005792-197603000-00001; PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592-149; PEDEN VH, 1960, AM J HUM GENET, V12, P323; PHILIPSON B, 1978, ACTA MED SCAND, V203, P223; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAO SD, 1981, ANN INTERN MED, V95, P655, DOI 10.7326/0003-4819-95-5-655_1; RICHTER PL, 1968, NEUROLOGY, V18, P75, DOI 10.1212/WNL.18.1_Part_1.75; SHAW NJ, 1991, ARCH DIS CHILD, V66, P1191, DOI 10.1136/adc.66.10.1191; THAKKER RV, 1990, J CLIN INVEST, V86, P40, DOI 10.1172/JCI114712; VALDESDAPENA MA, 1971, ACTA PATH MICRO IM A, VA 79, P228; WEIDAUER H, 1981, ARCH OTO-RHINO-LARYN, V231, P677, DOI 10.1007/BF00501699; WHYTE MP, 1981, J PEDIATR-US, V99, P608, DOI 10.1016/S0022-3476(81)80272-7; WINTER WE, 1983, J PEDIATR-US, V103, P387, DOI 10.1016/S0022-3476(83)80408-9; YUMITA S, 1986, TOHOKU J EXP MED, V148, P135, DOI 10.1620/tjem.148.135	38	118	121	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1069	1074		10.1056/NEJM199210083271506	http://dx.doi.org/10.1056/NEJM199210083271506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522843				2022-12-24	WOS:A1992JR32100006
J	GESTELAND, RF; WEISS, RB; ATKINS, JF				GESTELAND, RF; WEISS, RB; ATKINS, JF			RECODING - REPROGRAMMED GENETIC DECODING	SCIENCE			English	Article							POLYMERASE-III HOLOENZYME; RELEASE FACTOR-II; ESCHERICHIA-COLI; READING FRAME; GAMMA-SUBUNIT; MESSENGER-RNA; SELENOCYSTEINE; CODON; PSEUDOKNOT; PEPTIDE		UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	GESTELAND, RF (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112, USA.			Atkins, John/0000-0001-7933-0165				ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HILL KE, 1991, J BIOL CHEM, V266, P10050; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; MATSUFUJI S, UNPUB; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	20	159	162	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1640	1641		10.1126/science.1529352	http://dx.doi.org/10.1126/science.1529352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529352				2022-12-24	WOS:A1992JN50100019
J	HOLDEN, C				HOLDEN, C			CRIME CONFERENCE - BACK TO THE DRAWING BOARD, SAYS NIH	SCIENCE			English	Editorial Material																		WALTERS R, 1992, SCIENCE, V257, P739	1	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1474	1474		10.1126/science.1523404	http://dx.doi.org/10.1126/science.1523404			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523404				2022-12-24	WOS:A1992JM57000012
J	WALENT, JH; PORTER, BW; MARTIN, TFJ				WALENT, JH; PORTER, BW; MARTIN, TFJ			A NOVEL 145-KD BRAIN CYTOSOLIC PROTEIN RECONSTITUTES CA2+-REGULATED SECRETION IN PERMEABLE NEUROENDOCRINE CELLS	CELL			English	Article							SEMI-INTACT CELLS; KINASE-C; VESICULAR TRANSPORT; MEMBRANE-FUSION; GOLGI-COMPLEX; MAST-CELLS; PC12 CELLS; EXOCYTOSIS; PURIFICATION; COMPONENTS	The regulated secretory pathway is activated by elevated cytoplasmic Ca2+; however, the components mediating Ca2+ regulation have not been identified. In semi-intact neuroendocrine cells, Ca2+-activated secretion is ATP- and cytosol protein-dependent. We have identified a novel brain protein, p145, as a cytosolic factor that reconstitutes Ca2+-activated secretion in two neuroendocrine cell types. The protein is a dimer of 145 kd subunits, exhibits Ca2+-dependent interaction with a hydrophobic matrix, and binds phospholipid vesicles, suggesting a membrane-associated function. A p145-specific antibody inhibits the reconstitution of Ca2+-activated secretion by cytosol, indicating an essential role for p145. The restricted expression of p145 in tissues exhibiting a regulated secretory pathway suggests a key role for this protein in the transduction of Ca2+ signals into vectorial membrane fusion events.			WALENT, JH (corresponding author), UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706, USA.				NIDDK NIH HHS [DK 40428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; AUNIS D, 1988, J EXP BIOL, V139, P253; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FRICKER LD, 1990, NEUROENDOCRINOLOGY, V51, P658, DOI 10.1159/000125407; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY JC, 1992, IN PRESS J CELL BIOL; KOFFER A, 1989, J CELL SCI, V94, P585; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; Miller SG, 1990, CURR OPIN CELL BIOL, V2, P642, DOI 10.1016/0955-0674(90)90105-N; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; OBENDORF D, 1988, NEUROSCIENCE, V25, P343, DOI 10.1016/0306-4522(88)90030-9; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; ROSSIER J, 1989, ANAL BIOCHEM, V178, P27, DOI 10.1016/0003-2697(89)90350-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	37	237	241	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					765	775		10.1016/0092-8674(92)90310-9	http://dx.doi.org/10.1016/0092-8674(92)90310-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516133				2022-12-24	WOS:A1992JL66300008
J	GARDNER, JM; NAKATSU, Y; GONDO, Y; LEE, S; LYON, MF; KING, RA; BRILLIANT, MH				GARDNER, JM; NAKATSU, Y; GONDO, Y; LEE, S; LYON, MF; KING, RA; BRILLIANT, MH			THE MOUSE PINK-EYED DILUTION GENE - ASSOCIATION WITH HUMAN PRADER-WILLI AND ANGELMAN SYNDROMES	SCIENCE			English	Article							PARENTAL ORIGIN; CDNA CLONES; P-LOCUS; HYPOPIGMENTATION; IDENTIFICATION; DELETION; MUTANTS; ABNORMALITIES; CHROMOSOME-7; EXPRESSION	Complementary DNA clones from the pink-eyed dilution (p) locus of mouse chromosome 7 were isolated from murine melanoma and melanocyte libraries. The transcript from this gene is missing or altered in six independent mutant alleles of the p locus, suggesting that disruption of this gene results in the hypopigmentation phenotype that defines mutant p alleles. Characterization of the human homolog revealed that it is localized to human chromosome 15 at q11.2-q12, a region associated with Prader-Willi and Angelman syndromes, suggesting that altered expression of this gene may be responsible for the hypopigmentation phenotype exhibited by certain individuals with these disorders.	FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111; MRC,RADIOBIOL UNIT,DIDCOT 0X11 0RD,OXON,ENGLAND; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Fox Chase Cancer Center; University of Minnesota System; University of Minnesota Twin Cities			Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489; Nakatsu, Yoshimichi/0000-0001-7408-7071	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM022167, R01GM043840] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM43840, GM22167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APKARIAN P, 1989, DOC OPHTHALMOL, V71, P355, DOI 10.1007/BF00152762; BRAY GA, 1983, MEDICINE, V62, P59, DOI 10.1097/00005792-198303000-00001; BRILLIANT MH, 1992, MAMM GENOME, V3, P187, DOI 10.1007/BF00355717; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; BRILLIANT MH, UNPUB; BUTLER MG, 1989, AM J HUM GENET, V45, P140; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; CREEL DJ, 1986, NEW ENGL J MED, V314, P1606, DOI 10.1056/NEJM198606193142503; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P4408, DOI 10.1073/pnas.83.12.4408; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GONDO Y, UNPUB; Green MC., 1989, GENETIC VARIANTS STR, P12; HAMABE J, 1991, AM J MED GENET, V41, P54, DOI 10.1002/ajmg.1320410116; HEARING VJ, 1973, J ULTRA MOL STRUCT R, V43, P88, DOI 10.1016/S0022-5320(73)90072-5; HITTNER HM, 1982, AM J OPHTHALMOL, V94, P328, DOI 10.1016/0002-9394(82)90358-0; HUNT DM, 1971, J EMBRYOL EXP MORPH, V26, P111; JOHNSON DR, 1975, J REPROD FERTIL, V42, P51, DOI 10.1530/jrf.0.0420051; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LARUE L, 1990, SOMAT CELL MOLEC GEN, V16, P361, DOI 10.1007/BF01232464; LYON MF, IN PRESS P NATL ACAD; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MARKERT CL, 1956, GENETICS, V41, P429; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MELVOLD RW, 1974, GENET RES, V23, P319, DOI 10.1017/S0016672300014956; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS RJS, 1977, MOUSE NEWS LETT, V57, P18; PHILLIPS RJS, 1977, MOUSE NEWS LETT, V56, P38; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; RUSSELL ES, 1949, GENETICS, V34, P146; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVERS WK, 1979, COAT COLORS MICE, P90; STEPHENSON DA, 1985, J EMBRYOL EXP MORPH, V87, P65; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WAGSTAFF J, 1991, GENOMICS, V11, P1071, DOI 10.1016/0888-7543(91)90034-C; WALLIS CE, 1989, J MED GENET, V26, P337, DOI 10.1136/jmg.26.5.337; WIESNER GL, 1987, AM J HUM GENET, V40, P431; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WOLFE HG, 1963, 11TH P INT C GEN, P251	50	198	200	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1121	1124		10.1126/science.257.5073.1121	http://dx.doi.org/10.1126/science.257.5073.1121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509264				2022-12-24	WOS:A1992JJ88400034
J	LEE, DK; MARANTZ, PR; DEVEREUX, RB; KLIGFIELD, P; ALDERMAN, MH				LEE, DK; MARANTZ, PR; DEVEREUX, RB; KLIGFIELD, P; ALDERMAN, MH			LEFT-VENTRICULAR HYPERTROPHY IN BLACK-AND-WHITE HYPERTENSIVES - STANDARD ELECTROCARDIOGRAPHIC CRITERIA OVERESTIMATE RACIAL-DIFFERENCES IN PREVALENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ECHOCARDIOGRAPHIC DETERMINATION; CARDIAC ANATOMY; BLOOD-PRESSURE; WORK SITE; MASS; RISK; SENSITIVITY; VALIDATION; MORTALITY	Objective.-To assess racial differences in the accuracy of standard electrocardiographic (ECG) criteria in the diagnosis of left ventricular hypertrophy (LVH). Design.-The sensitivity and specificity of standard ECG criteria were compared in blacks and whites using echocardiographic LVH as the reference standard. Setting.-Eight worksite-based hypertension clinics in New York, NY. Patients.-A sample of 122 black and 148 white hypertensive patients. Results.-The prevalence of ECG-LVH was two to six times higher in blacks than in whites, depending on the criteria used (range, 6% to 24% in blacks vs 1% to 7% in whites; P=.0005 to .19 for black-white comparisons). The difference in prevalence of ECG-LVH, however, was less striking and did not attain statistical significance (26% in blacks and 20% in whites; P >.2). The sensitivity of the ECG was low (range, 3% to 17%) and did not differ significantly between the two races for any of the conventional criteria; specificity, however, was lower in blacks for all criteria (range, 73% to 94% vs 95% to 100% for whites; P=.0001 to .09). The predictive value of a positive ECG was consistently, although not significantly, lower in the black subjects. Black race was the strongest independent predictor of decreased ECG specificity in multiple logistic regression analysis that also considered age, gender, body mass index, left ventricular mass index, and smoking. Conclusions.-Commonly used ECG criteria for the detection of LVH have a poor sensitivity in both black and white hypertensives and a lower specificity in blacks than in whites; this may lead to a greater number of false-positive diagnoses in black patients, as well as to an overestimation of black-white difference in LVH prevalence.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, ROOM 1301, BRONX, NY 10461 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, DIV CARDIOL, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Cornell University; NewYork-Presbyterian Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P50 HL-18323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BARTEL A, 1971, ARCH INTERN MED, V128, P929, DOI 10.1001/archinte.128.6.929; BEAGLEHOLE R, 1975, J CHRON DIS, V28, P549, DOI 10.1016/0021-9681(75)90061-2; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; CARR AA, 1985, HYPERTENSION, V7, P948, DOI 10.1161/01.HYP.7.6.948; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V67, P907, DOI 10.1161/01.CIR.67.4.907; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; Fleiss JL, 1981, STAT METHODS RATES P; Gubner R, 1943, ARCH INTERN MED, V72, P196, DOI 10.1001/archinte.1943.00210080052005; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; HOLT JH, 1978, CIRCULATION, V57, P1129, DOI 10.1161/01.CIR.57.6.1129; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LEE DK, 1991, AM J HYPERTENS, V4, pA19; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MENSAH G A, 1991, Journal of the American College of Cardiology, V17, p71A; MUNROFAURE AD, 1979, BMJ-BRIT MED J, V1, P1944; MURPHY ML, 1985, AM J CARDIOL, V55, P545, DOI 10.1016/0002-9149(85)90244-9; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; OKIN PM, 1992, J ELECTROCARDIOL, V25, P111, DOI 10.1016/0022-0736(92)90115-G; Prineas R., 1982, MINNESOTA CODE MANUA; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391; REICHEK N, 1982, AM HEART J, V103, P202, DOI 10.1016/0002-8703(82)90493-8; ROMAN MJ, 1987, J AM COLL CARDIOL, V9, P500, DOI 10.1016/S0735-1097(87)80041-4; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; ROMHILT DW, 1969, CIRCULATION, V40, P185, DOI 10.1161/01.CIR.40.2.185; Savage D D, 1979, J Natl Med Assoc, V71, P709; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; TYROLER HA, 1984, AM HEART J, V108, P658, DOI 10.1016/0002-8703(84)90651-3; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WOYTHALER JN, 1983, J AM COLL CARDIOL, V2, P305, DOI 10.1016/S0735-1097(83)80167-3; 1985, HYPERTENSION, V7, P105; [No title captured]	51	103	104	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3294	3299		10.1001/jama.267.24.3294	http://dx.doi.org/10.1001/jama.267.24.3294			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1534587				2022-12-24	WOS:A1992HY94400027
J	SIMON, TL; STEHLING, L				SIMON, TL; STEHLING, L			INDICATIONS FOR AUTOLOGOUS TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SIMON, TL (corresponding author), UNITED BLOOD SERV,SCOTTSDALE,AZ, USA.							AuBuchon J P, 1989, Transfus Med Rev, V3, P290, DOI 10.1016/S0887-7963(89)70089-4; CREGAN P, 1991, TRANSFUSION, V31, P172, DOI 10.1046/j.1537-2995.1991.31291142950.x; 1988, JAMA-J AM MED ASSOC, V260, P2700	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573760				2022-12-24	WOS:A1992HT82300039
J	CIESIELSKI, C; MARIANOS, D; OU, CY; DUMBAUGH, R; WITTE, J; BERKELMAN, R; GOOCH, B; MYERS, G; LUO, CC; SCHOCHETMAN, G; HOWELL, J; LASCH, A; BELL, K; ECONOMOU, N; SCOTT, B; FURMAN, L; CURRAN, J; JAFFE, H				CIESIELSKI, C; MARIANOS, D; OU, CY; DUMBAUGH, R; WITTE, J; BERKELMAN, R; GOOCH, B; MYERS, G; LUO, CC; SCHOCHETMAN, G; HOWELL, J; LASCH, A; BELL, K; ECONOMOU, N; SCOTT, B; FURMAN, L; CURRAN, J; JAFFE, H			TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS IN A DENTAL PRACTICE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HEALTH PERSONNEL; INFECTION CONTROL; DENTISTS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HEPATITIS-B TRANSMISSION; ORAL SURGEON; OUTBREAK; TYPE-1; AIDS; PROFESSIONALS; INFECTION; BLOOD; RISK	Objective: To determine if patients of a dentist with the acquired immunodeficiency syndrome (AIDS) became infected with human immunodeficiency virus (HIV) during their dental care and, if so, to identify possible mechanisms of transmission. Design: Retrospective epidemiologic follow-up of the dentist, his office practice, and his former patients. Setting: The practice of a dentist with AIDS in Florida. Participants: A dentist with AIDS, his health care providers and employees, and former patients of the dentist, including eight HIV-infected patients. Measurements: Identification of risks for HIV transmission (if present), degree of genetic relatedness of the viruses, and identification of infection control and other office practices. Results: Five of the eight HIV-infected patients had no confirmed exposures to HIV other than the dental practice and were infected with HIV strains that were closely related to those of the dentist. Each of the five had invasive dental procedures, done by the dentist after he was diagnosed with AIDS. Four of these five patients shared visit days (P > 0.2). Breaches in infection control and other dental office practices to explain these transmissions could not be identified. Conclusion: Although the specific incident that resulted in HIV transmission to these patients remains uncertain, the epidemiologic evidence supports direct dentist-to-patient transmission rather than a patient-to-patient route.	CTR DIS CONTROL, NATL CTR PREVENT SERV, DIV ORAL HLTH, ATLANTA, GA 30333 USA; FLORIDA DEPT HLTH & REHAB SERV, W PALM BEACH, FL 33401 USA; FLORIDA DEPT HLTH & REHAB SERV, TALLAHASSEE, FL 32301 USA; UNIV CALIF LOS ALAMOS SCI LAB, LOS ALAMOS, NM 87545 USA	Centers for Disease Control & Prevention - USA; Florida Department of Health; Florida Department of Health; United States Department of Energy (DOE); Los Alamos National Laboratory	CIESIELSKI, C (corresponding author), CTR DIS CONTROL, DIV HIV AIDS, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							AHTONE J, 1983, J AM DENT ASSOC, V106, P219, DOI 10.14219/jada.archive.1983.0416; ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BURGER H, 1990, VACCINES 90, P255; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; CARL M, 1982, LANCET, V1, P731; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; Comer R W, 1991, J Dent Educ, V55, P187; COUTINHO RA, 1982, LANCET, V1, P345; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; FLOWER AJE, 1990, 1990 INT S VIR HEP L, P94; FLYNN NM, 1987, WESTERN J MED, V146, P439; GOODMAN RA, 1982, ANN INTERN MED, V96, P119, DOI 10.7326/0003-4819-96-1-119_1; GROB PJ, 1981, LANCET, V2, P1218; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LEVIN ML, 1974, JAMA-J AM MED ASSOC, V228, P1139, DOI 10.1001/jama.228.9.1139; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MATHE AA, 1980, LANCET, V1, P16; MILLER RG, 1988, AIDS NERVOUS SYSTEM, P65; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; MYERS G, 1990, HUMAN RETROVIRUSES A; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU CY, 1992, IN PRESS SCIENCE, P255; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; REINGOLD AL, 1982, J INFECT DIS, V145, P262, DOI 10.1093/infdis/145.2.262; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945, DOI 10.1001/archneur.1988.00520330023005; WELCH J, 1989, LANCET, V1, P205; 1987, J HOSP INFECT, V9, P34; 1988, REPORT PRESIDENTIAL, P33; 1987, MMWR, V36, P132; 1987, MMWR, V36, P1; 1986, MMWR, V35, P221; 1990, MMWR, V39, P489; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	49	183	187	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					798	805		10.7326/0003-4819-116-10-798	http://dx.doi.org/10.7326/0003-4819-116-10-798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567094				2022-12-24	WOS:A1992HT80200003
J	BUNTINX, F; KNOTTNERUS, JA; CREBOLDER, HFJM; ESSED, GGM; SCHOUTEN, H				BUNTINX, F; KNOTTNERUS, JA; CREBOLDER, HFJM; ESSED, GGM; SCHOUTEN, H			RELATION BETWEEN QUALITY OF CERVICAL SMEARS AND PROBABILITY OF ABNORMAL RESULTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIMBURG,DEPT GYNAECOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT MED STAT,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Hasselt University	BUNTINX, F (corresponding author), UNIV LIMBURG,DEPT GEN PRACTICE,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Buntinx, Frank/E-4950-2011; Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					BUNTINX F, 1991, ACTA CYTOL, V35, P64; MITCHELL H, 1991, LANCET, V337, P265, DOI 10.1016/0140-6736(91)90870-U; STEINER C, 1989, ACTA CYTOL, V33, P471; VOOIJS GP, 1988, NEW FRONTIERS CYTOLO, P412; ZUNA RE, 1984, POSTGRAD MED, V76, P36, DOI 10.1080/00325481.1984.11698775	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1224	1224		10.1136/bmj.304.6836.1224	http://dx.doi.org/10.1136/bmj.304.6836.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515793	Bronze, Green Published			2022-12-24	WOS:A1992HT96400024
J	WINDERICKX, J; LINDSEY, DT; SANOCKI, E; TELLER, DY; MOTULSKY, AG; DEEB, SS				WINDERICKX, J; LINDSEY, DT; SANOCKI, E; TELLER, DY; MOTULSKY, AG; DEEB, SS			POLYMORPHISM IN RED PHOTOPIGMENT UNDERLIES VARIATION IN COLOR MATCHING	NATURE			English	Article							MOLECULAR-GENETICS; VISION; PIGMENTS; CONE	GENETIC variation of human senses within the normal range probably exists but usually cannot be investigated in detail for lack of appropriate methods. The study of subtle perceptual differences in red-green colour vision is feasible since both photopigment genotypes and psychophysical phenotypes can be assessed by sophisticated techniques. Red-green colour vision in humans is mediated by two different visual pigments: red (long-wavelength sensitive) and green (middle-wavelength sensitive). The apoproteins of these highly homologous photopigments are encoded by genes on the X chromosome 1. Colour matches of males with normal colour vision fall into two main groups that appear to be transmitted by X-linked inheritance 2-6. This difference in colour matching is likely to reflect small variations in the absorption maxima of visual pigments 7-11, suggesting the presence of two common variants of the red and/or green visual pigments that differ in spectral positioning 5,6. We report that a common single amino-acid polymorphism (62% Ser, 38% Ala) at residue 180 of the X-linked red visual pigment explains the finding of two major groups in the distribution of colour matching among males with normal colour vision.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHYSIOL BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ALPERN M, 1979, J PHYSIOL-LONDON, V288, P85; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; EISNER A, 1981, J OPT SOC AM, V71, P705, DOI 10.1364/JOSA.71.000705; EISNER AE, 1987, J OPT SOC AM, V4, pP123; LUTZE M, 1990, VISION RES, V30, P149, DOI 10.1016/0042-6989(90)90134-7; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POKORNY J, 1989, DOC OPHTHALMOL, V52, P512; SMITH VC, 1976, VISION RES, V16, P1087, DOI 10.1016/0042-6989(76)90247-9; Stiles W. S., 1959, OPT ACTA, V6, P1, DOI [DOI 10.1080/713826267, 10.1080/713826267]; WAALER GHM, 1967, NATURE, V215, P406, DOI 10.1038/215406a0	20	159	161	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					431	433		10.1038/356431a0	http://dx.doi.org/10.1038/356431a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557123				2022-12-24	WOS:A1992HL83000062
J	RICHARD, EA; LISMAN, JE				RICHARD, EA; LISMAN, JE			RHODOPSIN INACTIVATION IS A MODULATED PROCESS IN LIMULUS PHOTORECEPTORS	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; PHOSPHODIESTERASE ACTIVATION; 48-KDA PROTEIN; PHOSPHORYLATION; MEMBRANES; ARRESTIN; DROSOPHILA; LIGHT; METARHODOPSIN; HOMOLOG	MANY G-protein-coupled receptors are only transiently active because an inactivation process stops the receptor from activating G protein molecules 1-3. Although this inactivated has been investigated in vitro, the real kinetics of the process can only be obtained from intact cells. Here we describe a method for measuring the inactivation of rhodopsin in intact photoreceptors and the application of this method to the ultraviolet rhodopsin of Limulus median eye 4. The results show that the inactivation process is very rapid (< 150 ms) and occurs well before the peak of the receptor potential. We have also investigated whether the inactivation process can itself be modulated. Our results show that light-adaptation accelerates inactivation by about 10-fold, providing evidence that G-protein-mediated transduction can be modulated at this first stage.			RICHARD, EA (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							AZUMA K, 1975, BIOCHIM BIOPHYS ACTA, V393, P520, DOI 10.1016/0005-2795(75)90079-3; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; HAGINS WA, 1967, SCIENCE, V157, P813, DOI 10.1126/science.157.3790.813; HAMDORF K, 1980, NATURE, V283, P859, DOI 10.1038/283859a0; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KAHANA A, 1990, BIOL B A, V179, P230; KIRSCHFELD K, 1978, Z NATURFORSCH C, V33, P1009; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LEVINE E, 1987, J GEN PHYSIOL, V90, P575, DOI 10.1085/jgp.90.4.575; LEVINE H, 1991, MECH DEVELOP, V33, P19; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LISMAN J, 1985, J GEN PHYSIOL, V85, P171, DOI 10.1085/jgp.85.2.171; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NOLTE J, 1972, J GEN PHYSIOL, V59, P167, DOI 10.1085/jgp.59.2.167; PAULSEN R, 1984, J COMP PHYSIOL, V155, P39, DOI 10.1007/BF00610929; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; TOKUNAGA F, 1975, FEBS LETT, V55, P229, DOI 10.1016/0014-5793(75)80998-7; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671	24	24	24	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					336	338		10.1038/356336a0	http://dx.doi.org/10.1038/356336a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549176				2022-12-24	WOS:A1992HK79400063
J	HARRIS, ME; HAJDUK, SL				HARRIS, ME; HAJDUK, SL			KINETOPLASTID RNA EDITING - INVITRO FORMATION OF CYTOCHROME-B GRNA-MESSENGER RNA CHIMERAS FROM SYNTHETIC SUBSTRATE RNAS	CELL			English	Article							TRYPANOSOMA-BRUCEI; SUBUNIT-III; GUIDE RNAS; MITOCHONDRIA; DNA; TRANSCRIPTS; OXIDASE; NUCLEOTIDES; INFORMATION; POLYMERASE	RNA editing in the kinetoplastid Trypanosoma brucei results in the addition and deletion of uridine residues within several mitochondrial mRNAs. The site and number of uridines added appears to be directed by small (approximately 70 nt) guide RNAs (gRNAs), which can base pair to the edited sequences. We examined reactions involving synthetic cytochrome b (CYb) gRNA and pre-edited mRNA in vitro. A major product of the in vitro reaction is a chimeric RNA molecule containing both gRNA and mRNA sequences. Formation of the CYb gRNA-mRNA chimera was specific, since such molecules did not accumulate when either the gRNA or mRNA was substituted with control RNAs. The reaction required a free 3' hydroxyl on the gRNA and was unaffected by capping of the gRNA's 5' end. Direct RNA sequencing indicated that the CYb gRNA is covalently linked via its 3' poly(U) tail to one of the editing sites on the CYb mRNA. These results suggest that the U's added during editing are donated by the poly(U) tail of a gRNA via a chimeric gRNA-mRNA intermediate.	UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	HARRIS, ME (corresponding author), UNIV ALABAMA, SCH MED, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, P30AI027767, R21AI021401] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21401, P30 AI27767] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	24	66	66	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1091	1099		10.1016/0092-8674(92)90080-V	http://dx.doi.org/10.1016/0092-8674(92)90080-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547505				2022-12-24	WOS:A1992HK67400012
J	SCHLESINGER, Y; GRANOFF, DM				SCHLESINGER, Y; GRANOFF, DM			AVIDITY AND BACTERICIDAL ACTIVITY OF ANTIBODY ELICITED BY DIFFERENT HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTER-MEMBRANE-PROTEIN; HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE; MONOCLONAL-ANTIBODIES; FUNCTIONAL-ACTIVITY; INFANTS; AFFINITY; IMMUNIZATION; SERUM	Objective. - Antibody avidity is a measure of the functional affinity of serum antibody to bind to antigen. In this study, we compared the avidity of antibodies elicited by vaccination with three Haemophilus influenzae type b (Hib) conjugate vaccines and investigated the relationship between antibody avidity and the ability of antibody to activate complement-mediated bactericidal activity. Design. - A convenience sample of 171 postvaccination serum samples with more than 0.5-mu-g/mL of anticapsular antibody, the minimum concentration required for measurement of avidity. The serum samples were obtained from infants participating in immunogenicity trials with Hib capsular polysaccharide (PRP) conjugated to meningococcal outer membrane protein complex (PRP-OMPC) or to tetanus toxoid (PRP-T), or PRP oligomers conjugated to a nontoxic mutant diphtheria toxin, CRM197 (Oligo-CRM). Patients. - Healthy infants recruited in private practices. Primary Outcome Measures. - Avidity of vaccine-induced serum anticapsular antibody and serum bactericidal titers. Results. - In infants vaccinated at 2, 4, and 6 months of age, Oligo-CRM evoked antibody of higher avidity than PRP-OMPC (P < .001). The mean avidity of antibody elicited by PRP-T was intermediate, being lower than Oligo-CRM (P < .02) but higher than PRP-OMPC (P = .001). Also, after one dose, 18-month-old infants given Oligo-CRM had higher avidity antibodies compared with those given PRP-OMPC P < .001). Half of the infants in both age groups who were given Oligo-CRM developed antibody avidity of 2.50 nM-1 or greater, whereas more than two thirds of the infants given PRP-OMPC had avidity values of 1.25 nM-1 or less. Antibodies with avidity of 1.25 nM-1 or less were, on average, 6.6-fold less active in assays of complement-mediated bactericidal activity than antibodies with avidity of 2.50 nM-1 or greater (P < .001). Conclusions. - Oligo-CRM and PRP-T conjugate vaccines elicit higher avidity antibody than PRP-OMPC, and high-avidity antibody is more potent than low-avidity antibody in serum bactericidal assays. Consideration should be given to including measurement of antibody avidity in assessment of new vaccines since avidity may affect the ability of serum antibody to confer protection against disease.	WASHINGTON UNIV,SCH MED,MALLINCK DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842, R01AI017962] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 17962, AI21842] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLSTEDT S, 1974, INT ARCH ALLER A IMM, V46, P470, DOI 10.1159/000231150; AMIR J, 1990, PEDIATR RES, V27, P358, DOI 10.1203/00006450-199004000-00008; ANDERSON P, 1987, J INFECT DIS, V156, P582, DOI 10.1093/infdis/156.4.583; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; EINHORN MS, 1986, LANCET, V2, P299; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; GRANOFF DM, 1991, 31ST P INT C ANT AG; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GRISWOLD WR, 1989, J INFECT DIS, V159, P1083, DOI 10.1093/infdis/159.6.1083; HETHERINGTON SV, 1990, J INFECT DIS, V162, P1185, DOI 10.1093/infdis/162.5.1185; HOLMES SJ, 1991, J PEDIATR-US, V118, P364, DOI 10.1016/S0022-3476(05)82148-1; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; JOHNSON ND, 1981, NATURE, V291, P29; KAYHTY H, 1983, J INFECT DIS, V147, P1100; MADORE DV, 1990, PEDIATRICS, V85, P331; MUSHER D, 1986, J INFECT DIS, V154, P935, DOI 10.1093/infdis/154.6.935; OTTERNESS I, 1982, ANTIBODY TOOL, P97; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; PERSSON MAA, 1988, J IMMUNOL, V140, P3875; PINCUS SH, 1988, J IMMUNOL, V140, P2779; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; STEIN HE, IN PRESS J INFECT DI; WEINBERG GA, 1986, J IMMUNOL, V136, P4232	28	185	191	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1489	1494		10.1001/jama.267.11.1489	http://dx.doi.org/10.1001/jama.267.11.1489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538539				2022-12-24	WOS:A1992HH48800029
J	MALVIN, GM; WOOD, SC				MALVIN, GM; WOOD, SC			BEHAVIORAL HYPOTHERMIA AND SURVIVAL OF HYPOXIC PROTOZOANS PARAMECIUM-CAUDATUM	SCIENCE			English	Article								Hypoxia has been shown to elicit behavioral hypothermia in a number of different metazoan species, all with nervous systems. The protozoan, Paramecium caudatum, has no nervous system and was not expected to display behavioral hypothermia. However, this species was also found to select a lower temperature in a thermal gradient under hypoxic conditions. This response proved to be beneficial as survival of hypoxic paramecia was greatly increased at lower temperatures. This unicellular species may provide a useful model to investigate the cellular and molecular basis of adaptive thermoregulatory behavior.			MALVIN, GM (corresponding author), LOVELACE FDN MED EDUC & RES,OXYGEN TRANSPORT PROGRAM,2425 RIDGECREST SE,ALBUQUERQUE,NM 87108, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038942, R01HL040537, R01HL038942] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38942, HL-40537] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Kitching JA, 1939, BIOL BULL-US, V77, P339, DOI 10.2307/1537643; MENDELSSOHN M, 1995, PFLUGERS ARCH GES PH, V60, P1; WOOD SC, 1991, ANNU REV PHYSIOL, V53, P71, DOI 10.1146/annurev.physiol.53.1.71; WOOD SC, 1991, STRATEGIES PHYSL ADA, P295	4	53	53	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1423	1425		10.1126/science.1542790	http://dx.doi.org/10.1126/science.1542790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542790				2022-12-24	WOS:A1992HH74400052
J	MILES, SA; MARTINEZMAZA, O; REZAI, A; MAGPANTAY, L; KISHIMOTO, T; NAKAMURA, S; RADKA, SF; LINSLEY, PS				MILES, SA; MARTINEZMAZA, O; REZAI, A; MAGPANTAY, L; KISHIMOTO, T; NAKAMURA, S; RADKA, SF; LINSLEY, PS			ONCOSTATIN-M AS A POTENT MITOGEN FOR AIDS-KAPOSIS SARCOMA DERIVED CELLS	SCIENCE			English	Article							IMMUNODEFICIENCY SYNDROME AIDS; LONG-TERM CULTURE; GROWTH-REGULATOR	Oncostatin M, a cytokine produced by activated lymphoid cells, regulates the growth and differentiation of a number of tumor and normal cells. In contrast to its effects on normal endothelia and aortic smooth muscle cell cultures, Oncostatin M was a potent mitogen for cells derived from acquired immunodeficiency syndrome-related Kaposi's sarcoma (AIDS-KS). After exposure to Oncostatin M, AIDS-KS cells assumed a spindle morphology, had an increased ability to proliferate in soft agar, and secreted increased amounts of interleukin-6. Oncostatin M RNA and immunoreactive Oncostatin M protein were found in AIDS-KS-derived cell isolates. These results suggest that Oncostatin M may play a role in the pathogenesis of AIDS-KS.	UNIV CALIF LOS ANGELES,CTR CARE,LOS ANGELES,CA 90024; HUNTINGTON MEM HOSP,INST MOLEC MED & TECHNOL,PASADENA,CA 91105; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; OSAKA UNIV,SCH MED,DEPT MED 3,OSAKA,JAPAN; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90089	University of California System; University of California Los Angeles; University of Southern California; Huntington Memorial Hospital; Bristol-Myers Squibb; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Osaka University; University of Southern California	MILES, SA (corresponding author), UNIV CALIF LOS ANGELES,CTR AIDS,ROOM BH-412,CHS 179317,LOS ANGELES,CA 90024, USA.		Martinez-Maza, Otoniel/B-2667-2009; Kishimoto, Tadamitsu/C-8470-2009	Martinez-Maza, Otoniel/0000-0003-1364-0675; 	NATIONAL CANCER INSTITUTE [K04CA001588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01588] Funding Source: Medline; NIAID NIH HHS [AI27660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMANN AJ, 1987, J CLIN IMMUNOL, V7, P481, DOI 10.1007/BF00915059; BERMAN MA, 1987, CLIN IMMUNOL IMMUNOP, V42, P133, DOI 10.1016/0090-1229(87)90180-2; BROWN TJ, 1991, J IMMUNOL, V147, P2175; BROWN TJ, 1987, J IMMUNOL, V139, P2977; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; LAUBENSTEIN LJ, 1984, J CLIN ONCOL, V2, P1115, DOI 10.1200/JCO.1984.2.10.1115; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MILES SA, UNPUB; MITSUYASU RT, 1988, BLOOD REV, V2, P222, DOI 10.1016/0268-960X(88)90011-2; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; VOLBERDING P, 1989, AIDS, P345; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	18	269	281	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1432	1434		10.1126/science.1542793	http://dx.doi.org/10.1126/science.1542793			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542793				2022-12-24	WOS:A1992HH74400056
J	BERLOT, CH; BOURNE, HR				BERLOT, CH; BOURNE, HR			IDENTIFICATION OF EFFECTOR-ACTIVATING RESIDUES OF GS-ALPHA	CELL			English	Article							GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; PERTUSSIS TOXIN; SCANNING MUTAGENESIS; CRYSTAL-STRUCTURE; RAS; SUBUNIT; GENE; CDNA	The heterotrimeric G proteins transduce extracellular signals by interacting with specific intracellular effectors. We have used a scanning mutagenesis approach to identify amino acids of alpha(s), the alpha-subunit of G(s), that determine the specificity of its interaction with its effector, adenylyl cyclase. In a subunit chimeras, residues 236-356 of alpha(s) comprise the shortest linear stretch that is required for activation of adenylyl cyclase. Within these 121 residues, we identified four clusters of residues in which substitutions prevented effector activation. Mutations in three of these regions did not affect alpha-subunit expression or the GTP-induced conformational change. The identified alpha(s) residues in the NH2-terminal half of the 121-residue region endowed the cognate alpha(i2) segment with the ability to activate effector, while those in the COOH-terminal half did not. In a three-dimensional G-alpha model, based on the structure of p21ras the effector-activating residues of alpha(s) form a surface on the membrane-facing side of the molecule; this surface includes a region that changes conformation upon binding GTP.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BERLOT, CH (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA.							Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1991, J BIOL CHEM, V266, P16226; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARIS S, 1987, J BIOL CHEM, V262, P1970; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443	52	174	190	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					911	922		10.1016/0092-8674(92)90034-A	http://dx.doi.org/10.1016/0092-8674(92)90034-A			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547491				2022-12-24	WOS:A1992HH74800010
J	MURRAY, EA; RAUSCH, DM; LENDVAY, J; SHARER, LR; EIDEN, LE				MURRAY, EA; RAUSCH, DM; LENDVAY, J; SHARER, LR; EIDEN, LE			COGNITIVE AND MOTOR IMPAIRMENTS ASSOCIATED WITH SIV INFECTION IN RHESUS-MONKEYS	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; VIRUS-INFECTION; MEMORY	Cognitive and motor deficits are now recognized as significant clinical features of infection with the human immunodeficiency virus (HIV). Juvenile rhesus macaques infected with simian immunodeficiency virus (SIV) were found to exhibit cognitive and motor deficits characteristic of HIV infection. Impairment on a motor skill task was the most reliable indicator of infection. Various cognitive impairments were also evident. These deficits were related to SIV infection of the brain but not to inflammatory lesions at a particular locus. The results suggest that the SIV-infected rhesus macaque is a valuable model for understanding the cause of HIV-associated central nervous system dysfunction and for developing a treatment.	NIMH,CELL BIOL LAB,MOLEC & CELLULAR NEUROBIOL UNIT,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT LAB MED & PATHOL,NEWARK,NJ 07103	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Rutgers State University New Brunswick; Rutgers State University Medical Center	MURRAY, EA (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1E104,BETHESDA,MD 20892, USA.		Murray, Elisabeth A./X-2051-2019	Eiden, Lee/0000-0001-7524-944X; Murray, Elisabeth/0000-0003-1450-1642				ASANUMA H, 1984, J NEUROPHYSIOL, V52, P212, DOI 10.1152/jn.1984.52.2.212; BASKIN GB, 1986, J NATL CANCER I, V77, P127; DESROSIERS RC, 1987, REV INFECT DIS, V9, P438; GOETHE KE, 1989, ARCH NEUROL-CHICAGO, V46, P129, DOI 10.1001/archneur.1989.00520380029008; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MILLER EN, 1990, NEUROLOGY, V40, P197, DOI 10.1212/WNL.40.2.197; MISHKIN M, 1987, SCI AM, V256, P80, DOI 10.1038/scientificamerican0687-80; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; OSTLE B, 1963, STAT RES, P98; PERDICES M, 1989, ANN NEUROL, V25, P460, DOI 10.1002/ana.410250507; PRICE RW, 1988, ANN NEUROL, V23, pS27, DOI 10.1002/ana.410230711; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SHARER LR, 1988, ANN NEUROL, V23, pS108, DOI 10.1002/ana.410230727; SHARER LR, 1991, J MED PRIMATOL, V20, P211; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; TROSS S, 1988, AIDS, V2, P81, DOI 10.1097/00002030-198804000-00002; WARD JM, 1987, AM J PATHOL, V127, P199; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILKIE FL, 1990, ARCH NEUROL-CHICAGO, V47, P433, DOI 10.1001/archneur.1990.00530040085022; 1984, Q J EXP PSYCHOL-B, V36, P173	21	154	156	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1246	1249		10.1126/science.1546323	http://dx.doi.org/10.1126/science.1546323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546323				2022-12-24	WOS:A1992HG67700040
J	SHINKAI, Y; RATHBUN, G; LAM, KP; OLTZ, EM; STEWART, V; MENDELSOHN, M; CHARRON, J; DATTA, M; YOUNG, F; STALL, AM; ALT, FW				SHINKAI, Y; RATHBUN, G; LAM, KP; OLTZ, EM; STEWART, V; MENDELSOHN, M; CHARRON, J; DATTA, M; YOUNG, F; STALL, AM; ALT, FW			RAG-2-DEFICIENT MICE LACK MATURE LYMPHOCYTES OWING TO INABILITY TO INITIATE V(D)J REARRANGEMENT	CELL			English	Article							PRE-B-CELLS; COMBINED IMMUNE-DEFICIENCY; REGION GENE SEGMENTS; SCID MICE; ANTIGEN RECEPTOR; VARIABLE REGION; RECOMBINATION ACTIVITY; JOINING SIGNALS; EXPRESSION; DEFECT	We have generated mice that carry a germline mutation in which a large portion of the RAG-2 coding region is deleted. Homozygous mutants are viable but fail to produce mature B or T lymphocytes. Very immature lymphoid cells were present in primary lymphoid organs of mutant animals as defined by surface marker analyses and Abelson murine leukemia virus (A-MuLV) transformation assays. However, these cells did not rearrange their immunoglobulin or T cell receptor loci. Lack of V(D)J recombination activity in mutant pre-B cell lines could be restored by introduction of a functional RAG-2 expression vector. Therefore, loss of RAG-2 function in vivo results in total inability to initiate V(D)J rearrangement, leading to a novel severe combined immune deficient (SCID) phenotype. Because the SCID phenotype was the only obvious abnormality detected in RAG-2 mutant mice, RAG-2 function and V(D)J recombinase activity, per se, are not required for development of cells other than lymphocytes.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University			Shinkai, Yoichi/N-3909-2014; Charron, Jean/A-9792-2013; Lam, Kong-Peng/G-5374-2012	Shinkai, Yoichi/0000-0002-6051-2484; Charron, Jean/0000-0002-5133-0056; Lam, Kong-Peng/0000-0002-1316-4333	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT F W, 1991, Current Biology, V1, P3, DOI 10.1016/0960-9822(91)90108-9; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; FULOP GM, 1988, CELL IMMUNOL, V113, P192, DOI 10.1016/0008-8749(88)90017-2; GEHA RS, 1992, IN PRESS PRIMARY IMM; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; PARKS DR, 1986, HDB EXPT IMMUNOLOGY; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SILVERSTONE AE, 1978, DIFFERENTIATION NORM, P433; SIU G, 1984, NATURE, V311, P344, DOI 10.1038/311344a0; YANCOPOULOS GD, 1990, P NATL ACAD SCI USA, V87, P5759, DOI 10.1073/pnas.87.15.5759; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	50	2209	2300	2	73	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					855	867		10.1016/0092-8674(92)90029-C	http://dx.doi.org/10.1016/0092-8674(92)90029-C			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547487				2022-12-24	WOS:A1992HH74800005
J	SULLIVAN, SL; GOTTESMAN, ME				SULLIVAN, SL; GOTTESMAN, ME			REQUIREMENT FOR ESCHERICHIA-COLI NUSG PROTEIN IN FACTOR-DEPENDENT TRANSCRIPTION TERMINATION	CELL			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; ANTITERMINATION PROTEIN; GENE-EXPRESSION; FACTOR-RHO; SEQUENCE; OPERON; RECOGNITION; MUTATIONS	The 21 kd NusG protein is essential for E. coli viability. Cells depleted for NusG were defective for factor-dependent transcription termination. Rho-induced polarity in the gal operon and the Rho-dependent lambda-tR1 and lambda-tL1 terminators were suppressed in NusG-deficient cells. NusG depletion inactivated the phage HK022 Nun termination factor. In contrast, the factor-independent lambda-tl terminator was fully active in NusG-depleted cells and could be suppressed by phage lambda-N function.			SULLIVAN, SL (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ADHYA S, 1968, GENETICS, V62, P231; ALIFANO P, 1991, CELL, V64, P553; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; DECROMBR.B, 1973, NATURE-NEW BIOL, V241, P260, DOI 10.1038/newbio241260a0; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; Miller J.H., 1972, EXPT MOL GENETICS; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; OPPENHEIM AB, 1982, J MOL BIOL, V158, P327, DOI 10.1016/0022-2836(82)90201-7; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REYES O, 1976, J BACTERIOL, V126, P1108, DOI 10.1128/JB.126.3.1108-1112.1976; REYNOLDS R, 1992, IN PRESS J MOL BIOL; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; Silhavy T.J., 1984, EXPT GENE FUSIONS; SULLIVAN SL, 1992, IN PRESS J BACTERIOL, V174; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241	33	160	162	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					989	994		10.1016/0092-8674(92)90041-A	http://dx.doi.org/10.1016/0092-8674(92)90041-A			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547498				2022-12-24	WOS:A1992HH74800017
J	LUTHY, R; BOWIE, JU; EISENBERG, D				LUTHY, R; BOWIE, JU; EISENBERG, D			ASSESSMENT OF PROTEIN MODELS WITH 3-DIMENSIONAL PROFILES	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING; RECOGNITION; RESOLUTION; RUBISCO; DOMAINS; ENERGY; DESIGN	As methods for determining protein three-dimensional (3D) structure develop, a continuing problem is how to verify that the final protein model is correct. The revision of several protein models to correct errors 1-6 has prompted the development of new criteria for judging the validity of X-ray 7-9 and NMR 10,11 structures, as well as the formation of energetic 12-14 and empirical methods 15,16 to evaluate the correctness of protein models. The challenge is to distinguish between a mistraced or wrongly folded model, and one that is basically correct, but not adequately refined. We show that an effective test of the accuracy of a 3D protein model is a comparison of the model to its own amino-acid sequence, using a 3D profile 16, computed from the atomic coordinates of the structure 3D profiles of correct protein structures match their own sequences with high scores. In contrast, 3D profiles for protein models known to be wrong score poorly. An incorrectly modelled segment in an otherwise correct structure can be identified by examining the profile score in a moving-window scan. The accuracy of a protein model can be assessed by its 3D profile, regardless of whether the model has been derived by X-ray, NMR or computational procedures.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BAUMANN G, 1989, PROTEIN ENG, V2, P329, DOI 10.1093/protein/2.5.329; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1983, FED PROC, V42, P2592; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; GOSH D, 1982, J MOL BIOL, V158, P73; HENDLICH M, 1990, J MOL BIOL, V216, P167, DOI 10.1016/S0022-2836(05)80068-3; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LEBIODA L, 1989, J BIOL CHEM, V264, P3685; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; NAVIA M, 1989, NATURE, V347, P615; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; NOVOTNY J, 1988, PROTEINS, V4, P19, DOI 10.1002/prot.340040105; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; Peitsch M C, 1990, New Biol, V2, P197; RAGHUNATHAN G, 1990, PROTEINS, V8, P213, DOI 10.1002/prot.340080304; STENKAMP RE, 1978, ACTA CRYSTALLOGR B, V38, P784; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	30	2467	2542	6	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					83	85		10.1038/356083a0	http://dx.doi.org/10.1038/356083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538787				2022-12-24	WOS:A1992HG60200063
J	ADAMS, MD; DUBNICK, M; KERLAVAGE, AR; MORENO, R; KELLEY, JM; UTTERBACK, TR; NAGLE, JW; FIELDS, C; VENTER, JC				ADAMS, MD; DUBNICK, M; KERLAVAGE, AR; MORENO, R; KELLEY, JM; UTTERBACK, TR; NAGLE, JW; FIELDS, C; VENTER, JC			SEQUENCE IDENTIFICATION OF 2,375 HUMAN BRAIN GENES	NATURE			English	Article							CDNA CLONING; PROTEIN	WE recently described a new approach for the rapid characterization of expressed genes by partial DNA sequencing to generate 'expressed sequence tags' 1. From a set of 600 human brain complementary DNA clones, 348 were informative nuclear-encoded messenger RNAs. We have now partially sequenced 2,672 new, independent cDNA clones isolated from four human brain cDNA libraries to generate 2,375 expressed sequence tags to nuclear-encoded genes. These sequences, together with 348 brain expressed sequence tags from our previous study, comprise more than 2,500 new human genes and 870,769 base pairs of DNA sequence. These data represent an approximate doubling of the number of human genes identified by DNA sequencing and may represent as many as 5% of the genes in the human genome.	NINCDS,RECEPTOR BIOCHEM & MOLEC BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Kerlavage, Anthony/0000-0002-3954-9653; Fields, Chris/0000-0002-4812-0744				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKER WC, 1991, NUCLEIC ACIDS RES, V19, P2231, DOI 10.1093/nar/19.suppl.2231; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CASERO RA, 1991, J BIOL CHEM, V266, P810; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; GALAU G, 1977, ARCH BIOCHEM BIOPHYS, V197, P584; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; PAULSON KE, 1985, NATURE, V316, P3259; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; RUBENSTEIN J, NUCLEIC ACIDS RES, V18, P4833; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	19	742	823	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					632	634		10.1038/355632a0	http://dx.doi.org/10.1038/355632a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538749				2022-12-24	WOS:A1992HD54700053
J	DOOLEY, SW; VILLARINO, ME; LAWRENCE, M; SALINAS, L; AMIL, S; RULLAN, JV; JARVIS, WR; BLOCH, AB; CAUTHEN, GM				DOOLEY, SW; VILLARINO, ME; LAWRENCE, M; SALINAS, L; AMIL, S; RULLAN, JV; JARVIS, WR; BLOCH, AB; CAUTHEN, GM			NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS IN A HOSPITAL UNIT FOR HIV-INFECTED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							EPIDEMIC	Objective. - To assess nosocomial transmission of tuberculosis (TB). Design. - A historical cohort study of hospitalized patients with the human immunodeficiency virus (HIV) and a purified protein derivative (PPD) tuberculin skin test survey of health care workers (HCWs). Setting. - A large public teaching hospital in San Juan, Puerto Rico. Patients. - For the cohort study, a case patient was defined as any patient in the HIV unit at the hospital who developed culture-positive TB from 31 days or more after admission through December 31, 1989. For the PPD survey, of 1420 HCWs from the hospital, 908 agreed to participate and had sufficient data for analysis. Main Outcome Measures. - For the cohort study, to compare the risk of developing active TB among patients who were exposed to hospital roommates with infectious TB and the risk among nonexposed patients. For the HCW PPD survey, to determine the prevalence of and risk factors for tuberculous infection. Results. - Eight of 48 (9.7/10 000 person-days) exposed case patients vs four of 192 (0.8/10 000 person-days) nonexposed case patients developed active TB (relative risk [RR] = 11; 95% confidence interval [Cl], 2.3, 50.3). Positive PPDs (greater-than-or-equal-to 10 mm of induration) in HCWs were associated with older age (P = .0001) and with history of community TB exposure (P = .0002). In a multivariable logistic model that adjusted for these variables, HIV unit nurses (nine of 19) and nurses in the internal medicine ward (45 of 90) had a higher proportion of positive PPDs than the reference group (clerical personnel on other floors: 35 of 188, P = .0005). Conclusions. - These data suggest that patient-to-patient transmission of TB in HIV units can occur and that HCWs are at risk of acquiring TB infection.	HOSPITAL MUNICIPAL,SAN JUAN,PR; CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	DOOLEY, SW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,MAILSTOP E-10,ATLANTA,GA 30333, USA.							CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; Kent PT, 1985, GUIDE LEVEL 3 LAB; 1985, SAS USERS GUIDE STAT; 1991, MMWR, V40, P585; 1990, MMWR, V39, P1	10	197	203	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2632	2634		10.1001/jama.267.19.2632	http://dx.doi.org/10.1001/jama.267.19.2632			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573751				2022-12-24	WOS:A1992HT82300031
J	YEW, PR; BERK, AJ				YEW, PR; BERK, AJ			INHIBITION OF P53 TRANSACTIVATION REQUIRED FOR TRANSFORMATION BY ADENOVIRUS EARLY 1B-PROTEIN	NATURE			English	Article							E1B-58KD TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; CELLULAR P53; VIRAL-DNA; CELLS; PROTEIN; LOCALIZATION; ASSOCIATION; ACTIVATION; EXPRESSION	THE cellular phosphoprotein p53 inhibits progression through the mammalian cell cycle 1,2. Both p53 alleles are frequently mutated in human tumours 3,4, indicating that p53 is a tumour suppressor. Recent studies have suggested that p53 functions as a transcriptional activator 5-8, but the significance of this activity in cell-cycle control has not been established. The adenovirus 2 (Ad2) early 1B (E1B) 55K protein binds to p53 in transformed cells 9 and contributes to oncogenic transformation by Ad2 (refs 10-12). Here we report that mutants of E1B 55K and wild-type Ad12 E1B 54K proteins show a strong correlation between their ability to inhibit p53-mediated transcriptional activation and their ability to cooperate with adenovirus E1A protein in the transformation of primary cells. These results indicate that p53 probably inhibits cell cycling by functioning as a transcription factor.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	YEW, PR (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024, USA.		BERK, ARNOLD/AAF-7052-2020					BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BYRD PJ, 1988, VIROLOGY, V163, P155, DOI 10.1016/0042-6822(88)90242-5; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAK I, 1986, BIOCHEM CELL BIOL, V64, P256, DOI 10.1139/o86-036; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; OROURKE RW, 1990, ONCOGENE, V5, P1829; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STILLMAN B, 1986, CANCER SURV, V5, P389; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	29	538	558	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					82	85		10.1038/357082a0	http://dx.doi.org/10.1038/357082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1533443				2022-12-24	WOS:A1992HT22900064
J	WETZLER, M; TALPAZ, M; KELLAGHER, MJ; GUTTERMAN, JY; KURZROCK, R				WETZLER, M; TALPAZ, M; KELLAGHER, MJ; GUTTERMAN, JY; KURZROCK, R			MYELOKATHEXIS - NORMALIZATION OF NEUTROPHIL COUNTS AND MORPHOLOGY BY GM-CSF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COLONY-STIMULATING FACTOR; MONOCYTES; ADHESION		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,BOX 41,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Kurzrock, Razelle/AAU-9782-2020	Talpaz, Moshe/0000-0003-3361-3981				BISHOP CR, 1968, J CLIN INVEST, V47, P249, DOI 10.1172/JCI105721; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; KRILL CE, 1964, NEW ENGL J MED, V270, P973, DOI 10.1056/NEJM196405072701902; SISSON SD, 1988, BLOOD, V72, P1368; WETZLER M, 1990, AM J MED, V89, P663, DOI 10.1016/0002-9343(90)90187-I; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	9	29	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2179	2180		10.1001/jama.267.16.2179	http://dx.doi.org/10.1001/jama.267.16.2179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556785				2022-12-24	WOS:A1992HN84100010
J	DECLUE, JE; PAPAGEORGE, AG; FLETCHER, JA; DIEHL, SR; RATNER, N; VASS, WC; LOWY, DR				DECLUE, JE; PAPAGEORGE, AG; FLETCHER, JA; DIEHL, SR; RATNER, N; VASS, WC; LOWY, DR			ABNORMAL REGULATION OF MAMMALIAN P21(RAS) CONTRIBUTES TO MALIGNANT-TUMOR GROWTH IN VONRECKLINGHAUSEN (TYPE-1) NEUROFIBROMATOSIS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; RAS P21; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDE; SCHWANN-CELLS; GENE-PRODUCT; GAP; DOMAIN; MUTATIONS; BINDING	Tumor cell lines derived from malignant schwannomas removed from patients with neurofibromatosis type 1 (NF1) have been examined for the level of expression of NF1 protein. All three NF1 lines examined expressed lower levels of NF1 protein than control cells, and the level in one line was barely detectable. The tumor lines expressed normal levels of p120GAP and p21ras. Although the p21ras proteins isolated from the tumor cells had normal (nonmutant) biochemical properties in vitro, they displayed elevated levels of bound GTP in vivo. The level of total cellular GAP-like activity was reduced in extracts from the tumor line that expresses very little NF1 protein. Introduction of the catalytic region of GAP into this line resulted in morphological reversion and lower in vivo GTP binding by endogenous p21ras. These data implicate NF1 protein as a tumor suppressor gene product that negatively regulates p21ras and define a "positive" growth role for ras activity in NF1 malignancies.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PSYCHIAT, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT HUMAN GENET, RICHMOND, VA 23298 USA; UNIV CINCINNATI, COLL MED, DEPT ANAT & CELL BIOL, CINCINNATI, OH 45267 USA	Harvard University; Brigham & Women's Hospital; Virginia Commonwealth University; Virginia Commonwealth University; University System of Ohio; University of Cincinnati	DECLUE, JE (corresponding author), NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA.			RATNER, NANCY/0000-0001-5030-9354	NCI NIH HHS [CA 16059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, CANCER RES, V51, P712; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DER CJ, 1988, ONCOGENE, V3, P105; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	58	508	518	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					265	273		10.1016/0092-8674(92)90407-4	http://dx.doi.org/10.1016/0092-8674(92)90407-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568246				2022-12-24	WOS:A1992HQ18300006
J	LECHLEITER, JD; CLAPHAM, DE				LECHLEITER, JD; CLAPHAM, DE			MOLECULAR MECHANISMS OF INTRACELLULAR CALCIUM EXCITABILITY IN X-LAEVIS OOCYTES	CELL			English	Article							INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; XENOPUS-OOCYTES; MUSCLE-CELLS; RELEASE; CA-2+; WAVE; PROPAGATION; ACTIVATION; EGGS	Following receptor activation in Xenopus ooctyes, spiral waves of intracellular Ca2+ release were observed. We have identified key molecular elements in the pathway that give rise to Ca2+ excitability. The patterns of Ca2+ release produced by GTP-gamma-S and by inositol 1,4,5-trisphosphate (IP3) are indistinguishable from receptor-induced Ca2+ patterns. The regenerative Ca2+ activity is critically dependent on the presence of IP3 and on the concentration of intracellular Ca2+, but is independent of extracellular Ca2+. Broad regions of the intracellular milieu can be synchronously excited to initiate Ca2+ waves and produce pulsating foci of Ca2+ release. By testing the temperature dependence of wavefront propagation, we provide evidence for an underlying process limited by diffusion, consistent with the elementary theory of excitable media. We propose a model for intracellular Ca2+ signaling in which wave propagation is controlled by IP3-mediated Ca2+ release from internal stores, but is modulated by the cytoplasmic concentration and diffusion of Ca2+.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BERRIDGE M J, 1991, Current Biology, V1, P296, DOI 10.1016/0960-9822(91)90089-F; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLITON C, 1992, IN PRESS J MICROSC; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; DOCKERY JD, 1988, PHYSICA D, V30, P177, DOI 10.1016/0167-2789(88)90105-4; DUPONT G, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P461; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOERSTER P, 1989, P NATL ACAD SCI USA, V86, P6831, DOI 10.1073/pnas.86.18.6831; GIRARD S, 1992, IN PRESS BIOPHYS J; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; GURNEY AM, 1987, P NATL ACAD SCI USA, V84, P3496, DOI 10.1073/pnas.84.10.3496; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; KEENER JP, 1986, SIAM J APPL MATH, V46, P1039, DOI 10.1137/0146062; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MILLER RN, 1981, BIOPHYS J, V34, P227, DOI 10.1016/S0006-3495(81)84847-3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Segel IH, 1976, BIOCH CALCULATIONS; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1991, NEW BIOL, V3, P3; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Winfree A.T., 1987, TIME BREAKS 3 DIMENS; Winfree A. T., 1990, APPL MECH REV, V43, P297; WINFREE AT, 1980, GEOMETRY BIOL TIME, P246; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0; Zykov V. S., 1980, Biophysics, V25, P906	49	335	341	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					283	294		10.1016/0092-8674(92)90409-6	http://dx.doi.org/10.1016/0092-8674(92)90409-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568248				2022-12-24	WOS:A1992HQ18300008
J	MARMORSTEIN, R; CAREY, M; PTASHNE, M; HARRISON, SC				MARMORSTEIN, R; CAREY, M; PTASHNE, M; HARRISON, SC			DNA RECOGNITION BY GAL4 - STRUCTURE OF A PROTEIN DNA COMPLEX	NATURE			English	Article							REQUIRES SEQUENCES ADJACENT; ZINC FINGER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; BINDING DOMAIN; KLUYVEROMYCES-LACTIS; AMINO-ACIDS; MACROMOLECULAR STRUCTURES; ASPERGILLUS-NIDULANS; NUCLEOTIDE-SEQUENCE	A specific DNA complex of the 65-residue, N-terminal fragment of the yeast transcriptional activator, GAL4, has been analysed at 2.7 angstrom resolution by X-ray crystallography. The protein binds as a dimer to a symmetrical 17-base-pair sequence. A small, Zn2+-containing domain recognizes a conserved CCG triplet at each end of the site through direct contacts with the major groove. A short coiled-coil dimerization element imposes 2-fold symmetry. A segment of extended polypeptide chain links the metal-binding module to the dimerization element and specifies the length of the site. The relatively open structure of the complex would allow another protein to bind coordinately with GAL4.	HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute	MARMORSTEIN, R (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.			Carey, Michael/0000-0003-3899-6280				ANDRIANOPOULOS A, 1990, MOL CELL BIOL, V10, P3194, DOI 10.1128/MCB.10.6.3194; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BALZI E, 1987, J BIOL CHEM, V262, P16871; BAUM JA, 1987, MOL CELL BIOL, V7, P1256, DOI 10.1128/MCB.7.3.1256; BERI RK, 1987, NUCLEIC ACIDS RES, V15, P7991, DOI 10.1093/nar/15.19.7991; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR MANUAL; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DICKERSON R E, 1990, P1; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOPPER JE, 1978, P NATL ACAD SCI USA, V75, P2878, DOI 10.1073/pnas.75.6.2878; JOHNSTON M, 1988, GENETICS, V120, P63; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PAN T, 1990, J BIOL CHEM, V265, P21427; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SALMERON JM, 1990, GENETICS, V125, P21; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128; WITTE MM, 1988, MOL CELL BIOL, V8, P3726, DOI 10.1128/MCB.8.9.3726; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WRAY LV, 1987, MOL GEN GENET, V125, P139; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261	63	567	595	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					408	414		10.1038/356408a0	http://dx.doi.org/10.1038/356408a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557122				2022-12-24	WOS:A1992HL83000054
J	SCHOPPA, NE; MCCORMACK, K; TANOUYE, MA; SIGWORTH, FJ				SCHOPPA, NE; MCCORMACK, K; TANOUYE, MA; SIGWORTH, FJ			THE SIZE OF GATING CHARGE IN WILD-TYPE AND MUTANT SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SQUID GIANT-AXON; SODIUM-CHANNEL; K+ CHANNELS; CURRENTS; DROSOPHILA; INACTIVATION; ACTIVATION; CDNA; LOCUS; GENE	The high sensitivity of voltage-gated ion channels to changes in membrane potential implies that the process of channel opening is accompanied by large charge movements. Previous estimates of the total charge displacement, q, have been deduced from the voltage dependence of channel activation and have ranged from 4 to 8 elementary charges (e0). A more direct measurement of q in Drosophila melanogaster Shaker 29-4 potassium channels yields a q value of 12.3 e0. A similar q value is obtained from mutated Shaker channels having reduced voltage sensitivity. These results can be explained by a model for channel activation in which the equilibria of voltage-dependent steps are altered in the mutant channels.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; UNIV CALIF BERKELEY,DEPT ENTOMOL,BERKELEY,CA 94720	Yale University; University of California System; University of California Berkeley								Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; CONTI F, 1984, EUR BIOPHYS J BIOPHY, V11, P137, DOI 10.1007/BF00276629; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IVERSON LE, 1990, J NEUROSCI, V10, P2903; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KEYNES RD, 1974, J PHYSIOL-LONDON, V239, P393, DOI 10.1113/jphysiol.1974.sp010575; KOREN G, 1990, NEURON, V2, P39; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MEVES H, 1974, J PHYSIOL-LONDON, V243, P847, DOI 10.1113/jphysiol.1974.sp010780; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NONNER W, 1975, PFLUEGERS ARCH, V375, P75; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SCHAUF CL, 1986, ION CHANNELS NEURAL, P3; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SPIRES S, 1989, J GEN PHYSIOL, V93, P263, DOI 10.1085/jgp.93.2.263; STRUHMER W, 1991, PFLUEGERS ARCH, V418, P423; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; WHITE MM, 1985, J GEN PHYSIOL, V85, P539, DOI 10.1085/jgp.85.4.539; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	29	371	377	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1712	1715		10.1126/science.1553560	http://dx.doi.org/10.1126/science.1553560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553560				2022-12-24	WOS:A1992HK81200041
J	WEISS, KB; GERGEN, PJ; HODGSON, TA				WEISS, KB; GERGEN, PJ; HODGSON, TA			AN ECONOMIC-EVALUATION OF ASTHMA IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHANGING PATTERNS; CHILDHOOD ASTHMA; HOSPITALIZATION; CHILDREN; MORTALITY; COST	Background. Asthma is a common chronic illness. Recently, increases in morbidity and mortality due to this disease have been reported. We studied the distribution of health care resources used for asthma in order to lay the groundwork for further policy decisions aimed at reducing the economic burden of this disorder. Methods. Estimates of direct medical expenditures and indirect costs (in 1985 dollars) were derived from data available from the National Center for Health Statistics. These cost estimates were projected to 1990 dollars. Results. The cost of illness related to asthma in 1990 was estimated to be $6.2 billion. Inpatient hospital services represented the largest single direct medical expenditure for this chronic condition, approaching $1.6 billion. The value of reduced productivity due to loss of school days represented the largest single indirect cost, approaching $1 billion in 1990. Although asthma is often considered to be a mild chronic illness treatable with ambulatory care, we found that 43 percent of its economic impact was associated with emergency room use, hospitalization, and death. Nearly two thirds of the visits for ambulatory care were to physicians in three primary care specialties - pediatrics, family medicine or general practice, and internal medicine. Conclusions. Potential reductions in the costs related to asthma in the United States may be identified through a closer examination of the effectiveness of care associated with each category of cost. Future health policy efforts to improve the effectiveness of primary care interventions for asthma in the ambulatory setting may reduce the costs of this common illness.	GEORGE WASHINGTON UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,CTR HLTH POLICY RES,WASHINGTON,DC 20052; NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BETHESDA,MD 20892; CTR DIS CONTROL,NATL CTR HLTH STAT,OFF ANAL & EPIDEMIOL,HYATTSVILLE,MD	George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	WEISS, KB (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT HLTH CARE SCI,RM 2B-401,2150 PENN AVE NW,WASHINGTON,DC 20037, USA.		Fahimifar, Sepideh/M-5303-2019					CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; COOPER B, 1976, EC COSTS SELECTED RE; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GONZALEZ ML, 1988, SOCIOECONOMIC CHARAC; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; HODGSON TA, 1984, 4TH P NAT C HUM VAL, P147; HUGHES DM, 1991, PEDIATRICS, V87, P54; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; Rice D P, 1985, Health Care Financ Rev, V7, P61; RICE DP, 1989, CANCER CARE AND COST, P39; Rice DP, 1989, COST INJURY US REPOR; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; VANCE VJ, 1971, ANN ALLERGY, V29, P455; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1983, VITAL HLTH STATIS 10, V154; 1986, VITAL HLTH STATIS 13, V96; 1988, VITAL HLTH STATIST 2, V108; 1985, VITAL HLTH STATIS 13, V91; 1991, NIH910342A NAT ASTH; 1989, PHYSICIANS DESK REFE; 1983, VITAL HLTH STATIS 13, V83; 1987, EMPLOY EARN, V34, P214; 1970, VITAL HLTH STATIST 2, V39; 1986, HOSPITAL STATISTICS; 1983, DHHS PHS832001 PUBL; 1988, DHHS PHS8811012 PUBL; 1989, DRUG TOPICS RED BOOK; 1987, VITAL HLTH STATIS 10, V166; 1987, VITAL HLTH STATIS 13, V99; 1984, VITAL HLTH STATIS 13, V84; 1988, VITAL HLTH STATIS 13, V93; 1989, EMPLOY EARN, V36, P227; 1990, HLTH CARE FINANC REV, V11, P1; 1973, VITAL HLTH STATIST 2, V54; 1980, IOM8002 I MED NAT AC; 1990, SOC SECUR B, V53, P74	41	802	811	0	57	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					862	866		10.1056/NEJM199203263261304	http://dx.doi.org/10.1056/NEJM199203263261304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK523	1542323				2022-12-24	WOS:A1992HK52300004
J	KORNHAUSER, JM; NELSON, DE; MAYO, KE; TAKAHASHI, JS				KORNHAUSER, JM; NELSON, DE; MAYO, KE; TAKAHASHI, JS			REGULATION OF JUN-B MESSENGER-RNA AND AP-1 ACTIVITY BY LIGHT AND A CIRCADIAN CLOCK	SCIENCE			English	Article							TRANSCRIPTION FACTOR AP-1; IMMEDIATE EARLY GENES; C-FOS; SUPRACHIASMATIC NUCLEUS; GROWTH-FACTORS; PROTEIN-SYNTHESIS; NERVOUS-SYSTEM; EXPRESSION; RHYTHMS; ONCOGENE	The suprachiasmatic nuclei (SCN) of the hypothalamus comprise the primary pacemaker responsible for generation of circadian rhythms in mammals. Light stimuli that synchronize this circadian clock induce expression of the c-fos gene in rodent SCN, which suggests a possible role for Fos in circadian entrainment. Appropriate light stimuli also induce the expression of jun-B messenger RNA in the SCN of golden hamsters but only slightly elevate c-jun messenger RNA levels. In addition, tight increases the amount of a protein complex in the SCN that binds specifically to sites on DNA known to mediate regulation by the AP-1 transcription factor. The photic regulation of both jun-B messenger RNA expression and AP-1 binding activity is dependent on circadian phase: only tight stimuli that shift behavioral rhythms induce jun-B and AP-1 expression. Thus, tight and the circadian pacemaker interact to regulate a specific set of immediate-early genes in the SCN that may participate in entrainment of the circadian clock.	NORTHWESTERN UNIV, INST NEUROSCI, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University			Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878				ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CARD JP, 1984, NEUROSCIENCE, V13, P415, DOI 10.1016/0306-4522(84)90240-9; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; INOUYE ST, 1988, AM J PHYSIOL, V255, pR1055, DOI 10.1152/ajpregu.1988.255.6.R1055; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU X, INPRESS J NEUROSCI; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MOORE RY, 1973, BRAIN RES, V49, P403, DOI 10.1016/0006-8993(73)90431-9; MOORE RY, 1983, FED PROC, V42, P2783; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORSE DS, 1990, TRENDS BIOCHEM SCI, V15, P262, DOI 10.1016/0968-0004(90)90050-L; NAGY F, 1988, GENE DEV, V2, P376, DOI 10.1101/gad.2.4.376; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REA MA, 1989, BRAIN RES BULL, V23, P577, DOI 10.1016/0361-9230(89)90204-9; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; TAKAHASHI JS, 1987, BRAIN RES, V405, P199, DOI 10.1016/0006-8993(87)91010-9; UHL GR, 1986, SCIENCE, V232, P390, DOI 10.1126/science.3961487; WOLLNIK F, 1989, BRAIN RES, V496, P82, DOI 10.1016/0006-8993(89)91053-6; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	52	206	206	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1581	1584		10.1126/science.1549784	http://dx.doi.org/10.1126/science.1549784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549784				2022-12-24	WOS:A1992HJ80900044
J	LEAHY, DJ; AXEL, R; HENDRICKSON, WA				LEAHY, DJ; AXEL, R; HENDRICKSON, WA			CRYSTAL-STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T-CELL CORECEPTOR CD8 AT 2.6 A-RESOLUTION	CELL			English	Article							BENCE-JONES PROTEIN; SURFACE-ANTIGEN T8; CLASS-I MOLECULES; 3-DIMENSIONAL STRUCTURE; MHC CLASS; CRYSTALLOGRAPHIC REFINEMENT; 2.0-A RESOLUTION; ALPHA-3 DOMAIN; LYMPHOCYTES-T; KINASE P56LCK	A secreted fragment of the extracellular portion of human CD8-alpha has been expressed in CHO cells, and a deglycosylated and proteolyzed form of this fragment has been crystallized. We report here the crystal structure of this fragment as refined at 2.6 angstrom resolution. The structure was solved by molecular replacement using a superposition of ten variable domains from immunoglobulin light chains as the search model. Only the N-terminal 114 amino acids of CD8-alpha are visible in the electron density maps. The domain formed by these residues possesses a fold typical of immunoglobulin variable domains and associates to form F(v)-Like homodimers.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	LEAHY, DJ (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076	PHS HHS [5-31294-3600] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BILDERBACK D, 1988, NUCL INSTRUM METH A, V266, P636, DOI 10.1016/0168-9002(88)90457-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLITHE DL, 1989, ENDOCRINOLOGY, V125, P2267, DOI 10.1210/endo-125-5-2267; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, XPLOR MANUAL; CHANG CH, 1985, BIOCHEMISTRY-US, V24, P4890, DOI 10.1021/bi00339a025; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; Clare Speakman J., 1972, STRUCTURE BONDING, P141; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUREY W, 1983, J MOL BIOL, V167, P661, DOI 10.1016/S0022-2836(83)80104-1; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MACPHERSON A, 1982, PREPARATION ANAL PRO, P94; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PETERS D, 1981, J MOL STRUCT, V85, P107; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SNOW PM, 1984, J IMMUNOL, V133, P2058; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1985, EUR J IMMUNOL, V15, P529, DOI 10.1002/eji.1830150520; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	74	254	265	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1145	1162		10.1016/0092-8674(92)90085-Q	http://dx.doi.org/10.1016/0092-8674(92)90085-Q			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547508				2022-12-24	WOS:A1992HK67400017
J	GUTHRIE, S; MUCHAMORE, I; KUROIWA, A; MARSHALL, H; KRUMLAUF, R; LUMSDEN, A				GUTHRIE, S; MUCHAMORE, I; KUROIWA, A; MARSHALL, H; KRUMLAUF, R; LUMSDEN, A			NEUROECTODERMAL AUTONOMY OF HOX-2.9 EXPRESSION REVEALED BY RHOMBOMERE TRANSPOSITIONS	NATURE			English	Article							CHICK HINDBRAIN; MOUSE HINDBRAIN; HOMEOTIC GENES; DROSOPHILA; SEGMENTATION; ANTERIOR; XENOPUS; ORGANIZATION; INDUCTION; PROTEIN	INVOLVEMENT of the Hox genes in regional specifications of the vertebrate body axis is suggested by sequence similarity with the homeotic selector genes of Drosophila, the conservation of a collinear relationship between genomic organization and site of expression, and mutational analysis 1-5. Subdivision of vertebrate embryo hindbrain neuroepithelium into lineage compartments 6 (rhombomeres 7,8) underlies segmental patterning of neuronal differentiation 9. The rhombomere boundaries delimit domains of expression of Hox genes 10-12, presumed to be determinants of rhombomere phenotype, suggesting that Hox genes confer positional value 13; the formation of rhombomere 4 (r4) is followed by strong expression of Hox-2.9 within its confines 14. If the Hox genes are determinants, their expression should be autonomous from the developmental stage at which regional commitment becomes fixed and irreversible. We have transplanted the future r4 region (from state-9-chick embryos) into the more anterior position of r2 and probed for Hox-2.9 transcripts. We report here that Hox-2.9 was expressed in the ectopic r4 as strongly as in the normal r4, whereas reciprocal grafts of future r2 to r4 position did not express Hox-2.9. The phenotype of ectopic rhombomeres developed according to their original position, as demonstrated by retrograde tracing of efferent cranial nerve nuclei. As early as stage-9 - (six somites), both Hox-2.9 expression and segment identity are autonomous in the chick embryo hindbrain, independent both of position in the neuroepithelium and of signals from the underlying mesoderm 15.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,MRC,LONDON SE1 9RT,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; TOHOKU UNIV,DEPT CELL BIOL,SENDAI,MIYAGI 980,JAPAN	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; MRC National Institute for Medical Research; Tohoku University			Lumsden, Andrew/C-5146-2009; Guthrie, Sarah C/C-5727-2009; Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Kuroiwa, Atsushi/0000-0001-7710-4041; Muchamore, Ian/0000-0003-2121-1539				AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ALTABA ARI, 1990, DEVELOPMENT, V108, P595; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Graper L, 1913, ARCH MIKROSK ANAT, V83, P371; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HOLTFRETER J, 1936, W ROUX ARCH ENT MECH, V134, P446; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1991, DEVELOPMENT, V111, P35; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	27	153	155	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					157	159		10.1038/356157a0	http://dx.doi.org/10.1038/356157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545869				2022-12-24	WOS:A1992HH73100061
J	GORDON, CR; SPITZER, O; SHUPAK, A; DOWECK, I				GORDON, CR; SPITZER, O; SHUPAK, A; DOWECK, I			SURVEY OF MAL DE DEBARQUEMENT	BRITISH MEDICAL JOURNAL			English	Article											GORDON, CR (corresponding author), ISRAEL NAVAL HYPERBAR INST,MOT SICKNESS & HUMAN PERFORMANCE LAB,POB 8040,IL-31080 HAIFA,ISRAEL.			Gordon, Carlos/0000-0003-1576-214X; Doweck, Ilana/0000-0002-1065-0299				BROWN JJ, 1987, AM J OTOLARYNG, V8, P219, DOI 10.1016/S0196-0709(87)80007-8; Irwin J., 1881, LANCET, V118, P907, DOI DOI 10.1016/S0140-6736(02)38129-7; Reason JT., 1975, MOTION SICKNESS; WIKER SF, 1979, AVIAT SPACE ENVIR MD, V50, P1046; WIKER SF, 1979, CGD2979 US DEP TRANS	5	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					544	544		10.1136/bmj.304.6826.544	http://dx.doi.org/10.1136/bmj.304.6826.544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559057	Green Published, Bronze			2022-12-24	WOS:A1992HG59900020
J	DAWES, MG; GREEN, J; ASHURST, H				DAWES, MG; GREEN, J; ASHURST, H			FOR DEBATE - ROUTINE WEIGHING IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; MATERNAL WEIGHT; GAIN; WOMEN; TERM		NATL PERINATAL EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Oxford				Dawes, Martin/0000-0003-3624-2477				ABRAMS BF, 1986, AM J OBSTET GYNECOL, V154, P503, DOI 10.1016/0002-9378(86)90591-0; ALTMAN DG, 1989, EFFECTIVE CARE PREGN, V1, P411; BILLEWICZ NZ, 1970, BR J PREV SOC MED, V24, P97; Campbell DM, 1983, NUTR PREGNANCY, P243; CEDERLOF R, 1970, ACTA PSYCHIAT SCAND, V219, P47; Chalmers I, 1989, EFFECTIVE CARE PREGN, P1465; DAWES MG, 1991, BRIT J OBSTET GYNAEC, V98, P189, DOI 10.1111/j.1471-0528.1991.tb13367.x; DAWES MG, 1991, BRIT J OBSTET GYNAEC, V98, P195, DOI 10.1111/j.1471-0528.1991.tb13368.x; GREEN J, 1989, EFFECTIVE CARE PREGN, V1, P281; GREENE GW, 1988, OBSTET GYNECOL, V71, P702; HAIEK L, 1989, J ADOLESCENT HEALTH, V10, P16, DOI 10.1016/0197-0070(89)90041-7; HERINGA M, 1988, EUR J OBSTET GYN R B, V28, P7; HYTTEN FE, 1979, J HUM NUTR, V33, P461; Hytten FE, 1980, CLIN PHYSL OBSTET, P193; LORIS P, 1985, J AM DIET ASSOC, V85, P1296; MACINTYRE S, 1983, SOCIOLOGY FOOD EATIN, P57; MOHIDE P, 1989, EFFECTIVE CARE PREGN, V1, P6; MOLLER B, 1989, BRIT J OBSTET GYNAEC, V96, P158, DOI 10.1111/j.1471-0528.1989.tb01655.x; NEWCOMBE RG, 1982, J EPIDEMIOL COMMUN H, V36, P306, DOI 10.1136/jech.36.4.306; ORR RD, 1979, J AM DIET ASSOC, V75, P126; ORSTEAD C, 1985, J AM DIET ASSOC, V85, P40; PALMER JL, 1985, J AM DIET ASSOC, V85, P946; REDMAN CWG, 1988, LANCET, V1, P809; ROOKUS MA, 1987, INT J OBESITY, V11, P609; SAMRA JS, 1988, LANCET, V2, P1420; SEIDMAN DS, 1989, OBSTET GYNECOL, V74, P240; TAFFEL SM, 1986, AM J PUBLIC HEALTH, V76, P1396, DOI 10.2105/AJPH.76.12.1396; THOMSON AM, 1957, BMJ-BRIT MED J, V1, P243, DOI 10.1136/bmj.1.5013.243; WALLENBURG HCS, 1989, EFFECTIVE CARE PREGN, V1, P382	29	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					487	489		10.1136/bmj.304.6825.487	http://dx.doi.org/10.1136/bmj.304.6825.487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547424	Green Published, Bronze			2022-12-24	WOS:A1992HF55500027
J	IZUMI, Y; CLIFFORD, DB; ZORUMSKI, CF				IZUMI, Y; CLIFFORD, DB; ZORUMSKI, CF			INHIBITION OF LONG-TERM POTENTIATION BY NMDA-MEDIATED NITRIC-OXIDE RELEASE	SCIENCE			English	Article							RAT HIPPOCAMPUS; L-ARGININE; INTERCELLULAR MESSENGER; SYNAPTIC TRANSMISSION; RECEPTOR ACTIVATION; RELAXING FACTOR; AMINO-ACIDS; INDUCTION; BRAIN; ENHANCEMENT	Activation of N-methyl-D-aspartate (NMDA) receptors before tetanic stimulation blocks long-term potentiation (LTP) in the CA1 region of the hippocampus. This NMDA-mediated inhibition of LTP can be reversed by the nitric oxide (NO) inhibitors L-N(G)-monomethyl-arginine or hemoglobin and mimicked by sodium nitroprusside. These results indicate that the timing of NO release relative to high-frequency activation of CA1 synapses may be an important determinant of LTP generation and suggest that NO may play a positive or negative modulatory role in LTP depending on prior events at the tetanized synapse and the ambient concentration of excitatory amino acids.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	IZUMI, Y (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000964, R01MH045493, R29MH045493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [AG05681] Funding Source: Medline; NIMH NIH HHS [MH00964, MH45493] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; ERRINGTON ML, 1987, NEUROSCIENCE, V20, P279, DOI 10.1016/0306-4522(87)90019-4; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IZUMI Y, 1992, NEUROSCI LETT, V135, P227, DOI 10.1016/0304-3940(92)90442-A; IZUMI Y, 1992, NEUROSCI LETT, V137, P245, DOI 10.1016/0304-3940(92)90414-3; IZUMI Y, UNPUB; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARTIN W, 1986, BRIT J PHARMACOL, V89, P563, DOI 10.1111/j.1476-5381.1986.tb11157.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; van Sande M, 1970, J Neurochem, V17, P125	33	217	219	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1273	1276		10.1126/science.1519065	http://dx.doi.org/10.1126/science.1519065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519065				2022-12-24	WOS:A1992JL05000032
J	KILEY, TD				KILEY, TD			PATENTS ON RANDOM COMPLEMENTARY-DNA FRAGMENTS	SCIENCE			English	Article								The proposal by the National Institutes of Health (NIH) to patent products resulting merely from sequencing the human genome is a mistake: at worst, it is wrong in patent law; at best, it relies on deficiencies in law concerning what is "useful" as a requirement for patents. The proposal is symptomatic of a problem besieging biotechnology-attempts to control the raw material of scientific experimentation before research has determined the practical value of such material-that needs curing on many fronts. Corrective measures are proposed for adoption by the Executive branch, the Congress, and the courts.										ROBERTS L, 1991, SCIENCE, V254, P184, DOI 10.1126/science.1925568; ROBERTS L, 1991, SCIENCE, V254, P1104, DOI 10.1126/science.1957160; USDIN S, 1992, BIOWORLD TODAY, V3, P1	3	26	26	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					915	918		10.1126/science.1502558	http://dx.doi.org/10.1126/science.1502558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502558				2022-12-24	WOS:A1992JH82700023
J	LEE, SH; EWERT, DP; FREDERICK, PD; MASCOLA, L				LEE, SH; EWERT, DP; FREDERICK, PD; MASCOLA, L			RESURGENCE OF CONGENITAL-RUBELLA SYNDROME IN THE 1990S - REPORT ON MISSED OPPORTUNITIES AND FAILED PREVENTION POLICIES AMONG WOMEN OF CHILDBEARING AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; IMMUNIZATION; PROGRAM; VACCINATION	Objective. - To assess previous missed opportunities for rubella screening and vaccination of women delivering infants with congenital rubella syndrome and to discuss prevention strategies. Design. - Descriptive analysis of data collected through interviews and review of medical records. Population Studied. - Twenty-one women who delivered infants with congenital rubella syndrome in four Southern California counties from January 1, 1990, through January 8, 1991. Results. - Twelve (57%) of the women had a total of 22 known missed opportunities for rubella screening or vaccination. Of the 22 missed opportunities, three (14%) were missed screenings at the time of marriage, two (9%) were missed screenings during previous pregnancies, five (23%) were missed screenings during induced abortions, and 12 (55%) were missed opportunities for vaccination postpartum or after induced abortions. Nine (43%) of the women had no known missed opportunities for rubella screening or vaccination. Of 12 women educated in California, only four (33%) were subject to the 1982 California school rubella immunization requirement. Conclusions. - Congenital rubella syndrome could have been prevented in more than half of the infants born to these women if missed opportunities for rubella testing and/or vaccination had not occurred. Because premarital rubella testing and school immunization requirements do not ensure that all women of childbearing age are immune to rubella, physicians and hospitals should establish procedures for postpartum rubella vaccination of susceptible women. Family planning and abortion clinics should implement routine rubella testing and follow-up vaccination of susceptible women.	LOS ANGELES CTY DEPT HLTH SERV,ACUTE COMMUNICABLE DIS CONTROL UNIT,ROOM 231,313 N FIGUEROA ST,LOS ANGELES,CA 90012; CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,LOS ANGELES,CA					Frederick, Paul/0000-0002-7936-5488				ANTHONY N, 1977, AM J PUBLIC HEALTH, V67, P763, DOI 10.2105/AJPH.67.8.763; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; DALES LG, 1981, WESTERN J MED, V135, P266; GRILLNER L, 1973, SCAND J INFECT DIS, V5, P237, DOI 10.3109/inf.1973.5.issue-4.01; KAPLAN KM, 1990, AM J DIS CHILD, V144, P118, DOI 10.1001/archpedi.1990.02150250130050; KLEIN EB, 1980, J PEDIATR-US, V97, P774, DOI 10.1016/S0022-3476(80)80264-2; LANDES RD, 1980, J PEDIATR-US, V97, P465, DOI 10.1016/S0022-3476(80)80207-1; LOSONSKY GA, 1982, J INFECT DIS, V145, P661, DOI 10.1093/infdis/145.2.661; NELSON DB, 1982, AM J PUBLIC HEALTH, V72, P710, DOI 10.2105/AJPH.72.7.710; ORENSTEIN WA, 1984, JAMA-J AM MED ASSOC, V251, P1988, DOI 10.1001/jama.251.15.1988; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; PREBLUD SR, 1986, J INFECT DIS, V154, P367, DOI 10.1093/infdis/154.2.367; ROBERTSON SE, 1987, AM J PUBLIC HEALTH, V77, P1347, DOI 10.2105/AJPH.77.10.1347; SERDULA MK, 1986, PUBLIC HEALTH REP, V101, P329; SEWELL CM, 1986, AM J PUBLIC HEALTH, V76, P1250, DOI 10.2105/AJPH.76.10.1250; SHLIAN DM, 1978, JAMA-J AM MED ASSOC, V240, P662, DOI 10.1001/jama.240.7.662; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1986, J INFECT DIS, V154, P368, DOI 10.1093/infdis/154.2.368; VOGT RL, 1985, AM J PUBLIC HEALTH, V75, P1088, DOI 10.2105/AJPH.75.9.1088; 1985, MMWR, V34, P228; 1985, MMWR, V34, P65; 1986, MMWR, V35, P779; 1986, MMWR, V35, P770; 1990, MMWR, V39, P32; 1990, MMWR, V39, P1; 1991, MMWR, V40, P93	26	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2616	2620		10.1001/jama.267.19.2616	http://dx.doi.org/10.1001/jama.267.19.2616			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573748				2022-12-24	WOS:A1992HT82300027
J	WORMALD, RPL; WRIGHT, LA; COURTNEY, P; BEAUMONT, B; HAINES, AP				WORMALD, RPL; WRIGHT, LA; COURTNEY, P; BEAUMONT, B; HAINES, AP			VISUAL PROBLEMS IN THE ELDERLY POPULATION AND IMPLICATIONS FOR SERVICES	BRITISH MEDICAL JOURNAL			English	Article							EYE DISEASE; PREVALENCE	Objective - To determine the prevalence of visual disability and common eye disease among elderly people in inner London. Design - Cross sectional random sample survey. Setting - Inner London health centre. Subjects - Random sample of people aged 65 and over taken from practice's computerised age-sex register. Main outcome measures - Presenting binocular Snellen 6 m distance acuity and best monocular 3 m Sonksen-Silver acuity to classify prevalence of blindness by World Health Organisation criteria (less than 3/60 in better eye) and American criteria for legal blindness (better eye equal to 6/60 or less) and of low vision by WHO criteria (best acuity 6/18) and visual impairment by American criteria (less than 6/12 or 20/40 but greater than 6/60 or 20/200 in better eye). Principal cause of visual loss by diagnosis, referral indication by cause to hospital eye service, and proportion of cases known to primary care. Results - 207 of 288 (72%) eligible people were examined. 17 (8%) housebound subjects were examined at home. The prevalence of blindness was 1% by WHO criteria and 3.9% by American criteria. The prevalence of low vision (WHO criteria) was 7.7%. The prevalence of visual impairment (American criteria) was 10.6%. Cataract accounted for 75% of cases of low vision. Only eight out of 16 patients with low vision were known by their general practitioner to have an eye problem. 56 subjects (27%) would probably have benefited from refraction. Comparisons with studies in the United States and Finland suggested higher rates in this sample, mainly due to the prevalence of disabling cataract. Conclusion - There seems to be a considerable amount of undetected ocular disease in elderly people in the community.	INST OPHTHALMOL,DEPT PREVENT MED,LONDON EC1V 9EJ,ENGLAND; WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND	University of London; University College London; University of London; University College London				Haines, Andy/0000-0002-8053-4605				BRENNAN ME, 1973, BRIT J PREV SOC MED, V27, P154; CULLINAN TR, 1977, 28 HLTH SERV RES UN; FREER CB, 1990, BRIT MED J, V300, P1447, DOI 10.1136/bmj.300.6737.1447; GARDNER S, 1989, CONFIDENCE INTERVAL; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; HAKKINEN L, 1984, SCAND J SOC MED S, V35; HITCHINGS RA, 1989, BRIT MED J, V298, P1126, DOI 10.1136/bmj.298.6681.1126; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3; PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191; SANDERSON D, 1986, CANADIAN NURSE   FEB, P19; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; 1988, 1 OFF POP CENS SURV; 1980, SURV OPHTHALMOL S, V24, P335	14	116	118	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1226	1229		10.1136/bmj.304.6836.1226	http://dx.doi.org/10.1136/bmj.304.6836.1226			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515797	Green Published, Bronze			2022-12-24	WOS:A1992HT96400028
J	MAKELA, TP; KOSKINEN, PJ; VASTRIK, I; ALITALO, K				MAKELA, TP; KOSKINEN, PJ; VASTRIK, I; ALITALO, K			ALTERNATIVE FORMS OF MAX AS ENHANCERS OR SUPPRESSORS OF MYC-RAS COTRANSFORMATION	SCIENCE			English	Article							DNA-BINDING; EMBRYO FIBROBLASTS; PROTEINS; TRANSCRIPTION; EXPRESSION; ONCOGENES; PROBES; CELLS; MOTIF; DIMER	Max is a basic-helix-loop-helix-leucine zipper protein capable of forming sequence-specific DNA binding complexes with Myc proteins. An alternatively spliced messenger RNA has been identified that encodes a form of Max truncated at the COOH-terminus. This DELTA-Max protein retained the ability to bind to the CACGTG motif in a complex with c-Myc but lacks the nuclear localization signal and the putative regulatory domain of Max. When tested in a myc-ras cotransformation assay in rat embryo fibroblasts, Max suppressed, whereas DELTA-Max enhanced, transformation. Thus, the maxgene may encode both a negative and a positive regulator of c-Myc function.	UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, DEPT PATHOL, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki			Koskinen, Päivi J/G-8939-2014; Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009; Vastrik, Imre/C-2690-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; 				ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; EVAN GI, 1988, CURR TOP MICROBIOL, V141, P189; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TE, UNPUB; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLAN JL, 1987, P NATL ACAD SCI USA, V84, P5311, DOI 10.1073/pnas.84.15.5311; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAKSELA K, 1990, J CELL BIOCHEM, V42, P153, DOI 10.1002/jcb.240420306; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WINQVIST R, 1984, EMBO J, V3, P2947, DOI 10.1002/j.1460-2075.1984.tb02237.x; ZIFF EB, COMMUNICATION	29	137	142	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					373	377		10.1126/science.256.5055.373	http://dx.doi.org/10.1126/science.256.5055.373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566084				2022-12-24	WOS:A1992HP03200035
J	VU, ET; KRASNE, FB				VU, ET; KRASNE, FB			EVIDENCE FOR A COMPUTATIONAL DISTINCTION BETWEEN PROXIMAL AND DISTAL NEURONAL INHIBITION	SCIENCE			English	Article							ESCAPE BEHAVIOR; DENDRITES; CRAYFISH; CELLS	Most neurons have inhibitory synapses both "proximally" near the spike-initiating zone and "distally" on dendrites. Although distal inhibition is thought to be an adaptation for selective inhibition of particular dendritic branches, another important distinction exists between proximal and distal inhibition. Proximal inhibition can attenuate excitatory input absolutely so that no amount of excitation causes firing. Distal inhibition, however, inhibits relatively; any amount of it can be overcome by sufficient excitation. These properties are used as predicted in the circuit-mediating crayfish escape behavior. Many neuronal computations require relative inhibition. This could partly account for the ubiquity of distal inhibition.	UNIV CALIF LOS ANGELES,DEPT PSYCHOL,NEUROSCI PROGRAM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								EDEWAYEDWARDS DH, 1991, J NEUROSCI, V11, P2117; FUJITA Y, 1979, BRAIN RES, V175, P59, DOI 10.1016/0006-8993(79)90514-6; JACK JJB, 1975, ELECTRIC CURRENT FLO, P197; KOCH C, 1986, TRENDS NEUROSCI, V9, P204, DOI 10.1016/0166-2236(86)90060-3; KRASNE FB, 1969, J EXP BIOL, V50, P29; KRASNE FB, 1988, J NEUROSCI, V8, P3703; KRASNE FB, 1975, J EXP BIOL, V63, P433; LLINAS R, 1971, J NEUROPHYSIOL, V34, P532, DOI 10.1152/jn.1971.34.4.532; LLINAS R, 1975, ADV NEUROL, V12, P1; McClelland J. L., 1986, PARALLEL DISTRIBUTED, V2; MORI K, 1984, J NEUROSCI, V4, P2291; Rall W, 1964, NEURAL THEORY MODELI, P73; ROBERTS A, 1968, J EXP BIOL, V48, P545; Shepherd GM, 1990, SYNAPTIC ORG BRAIN, P439; TERZUOLO CA, 1968, STRUCTURE FUNCTION I, P261; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; WINE JJ, 1972, J EXP BIOL, V56, P1	17	82	88	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1710	1712		10.1126/science.1553559	http://dx.doi.org/10.1126/science.1553559			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553559				2022-12-24	WOS:A1992HK81200040
J	SUCHETA, A; ACKRELL, BAC; COCHRAN, B; ARMSTRONG, FA				SUCHETA, A; ACKRELL, BAC; COCHRAN, B; ARMSTRONG, FA			DIODE-LIKE BEHAVIOR OF A MITOCHONDRIAL ELECTRON-TRANSPORT ENZYME	NATURE			English	Article							SUCCINATE-DEHYDROGENASE	IN mitochondria, electrons derived from the oxidation of succinate by the tricarboxylic acid cycle enzyme succinate-ubiquinone oxido-reductase are transferred directly to the quinone pool. Here we provide evidence that the soluble form of this enzyme (succinate dehydrogenase) behaves as a diode that essentially allows electron flow in one direction only. The gating effect is observed when electrons are exchanged rapidly and directly between fully active succinate dehydrogenase and a graphite electrode. Turnover is therefore measured under conditions of continuously variable electrochemical potential. The otherwise rapid and efficient reduction of fumarate (the reverse reaction) is severely retarded as the driving force (overpotential) is increased. Such behaviour can arise if a rate-limiting chemical step like substrate binding or product release depends on the oxidation state of a redox group on the enzyme. The observation provides, for a biological electron-transport system, a simple demonstration of directionality that is enforced by kinetics as opposed to that which is assumed from thermodynamics.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,DIV MOLEC BIOL,SAN FRANCISCO,CA 94143; VET ADM MED CTR,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SUCHETA, A (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ARMSTRONG FA, 1990, STRUCT BOND, V72, P137; BARD AJ, 1980, ELECTROCHEMICAL METH, pCH8; BEINERT H, 1977, ARCH BIOCHEM BIOPHYS, V182, P95, DOI 10.1016/0003-9861(77)90287-9; COLLMAN JP, 1986, J AM CHEM SOC, V108, P7847, DOI 10.1021/ja00284a067; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; MACKENROTH DR, 1984, ILLUSTRATED ENCY SOL, pCH1; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; SINGER TP, 1973, ADV ENZYMOL RAMB, V37, P189; ZEIJLEMAKER WP, 1968, BIOCHIM BIOPHYS ACTA, V178, P213	10	170	170	4	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					361	362		10.1038/356361a0	http://dx.doi.org/10.1038/356361a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549182				2022-12-24	WOS:A1992HK79400072
J	FROGUEL, P; VAXILLAIRE, M; SUN, F; VELHO, G; ZOUALI, H; BUTEL, MO; LESAGE, S; VIONNET, N; CLEMENT, K; FOUGEROUSSE, F; TANIZAWA, Y; WEISSENBACH, J; BECKMANN, JS; LATHROP, GM; PASSA, P; PERMUTT, MA; COHEN, D				FROGUEL, P; VAXILLAIRE, M; SUN, F; VELHO, G; ZOUALI, H; BUTEL, MO; LESAGE, S; VIONNET, N; CLEMENT, K; FOUGEROUSSE, F; TANIZAWA, Y; WEISSENBACH, J; BECKMANN, JS; LATHROP, GM; PASSA, P; PERMUTT, MA; COHEN, D			CLOSE LINKAGE OF GLUCOKINASE LOCUS ON CHROMOSOME-7P TO EARLY-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							YOUNG; GLUCOSE; GENE; MODY	NON-INSULIN-DEPENDENT diabetes mellitus (NIDDM) is a major health problem, affecting 5% of the world population. Genetic factors are important in NIDDM, but the mechanisms leading to glucose intolerance are unknown 1,2. Genetic linkage has been investigated in multigeneration families to localize, and ultimately identify, the gene(s) predisposing to NIDDM. Here we report linkage between the glucokinase locus on chromosome 7p and diabetes in 16 French families with maturity-onset diabetes of the young, a form of NIDDM characterized by monogenic autosomal dominant transmission and early age of onset 3. Statistical evidence of genetic heterogeneity was significant, with an estimated 45-95% of the 16 families showing linkage to glucokinase. Because glucokinase is a key enzyme of blood glucose homeostasis 4, these results are evidence that a gene involved in glucose metabolism could be implicated in the pathogenesis of NIDDM.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; GENETHON,F-91000 EVRY,FRANCE; INST PASTEUR,CNRS,F-75724 PARIS 15,FRANCE; INSERM,U358,F-75010 PARIS,FRANCE; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL)	FROGUEL, P (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Clément, karine/R-1120-2017; Beckmann, Jacques S/A-9772-2008; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017; Vionnet, Nathalie/N-6302-2017	Beckmann, Jacques S/0000-0002-9741-1900; FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X; 				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHANSON P, 1991, J MED SCI, V7, P336; DEFRONZO RA, 1988, DIABETES, V37, P6667; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1991, DIABETOLOGIA, V34, P685, DOI 10.1007/BF00401001; FROGUEL P, 1991, NUCLEIC ACIDS RES, V19, P5799, DOI 10.1093/nar/19.20.5799; FROGUEL P, 1991, NUCLEIC ACIDS RES, V19, P3754, DOI 10.1093/nar/19.13.3754-a; HAZAN J, IN PRESS J GENOMICS; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATSUTANI A, 1990, DIABETES, V39, P534; MEGLASSON MA, 1984, AM J PHYSIOL, V246, P1; MISHRA SK, 1992, GENOMICS, V12, P326, DOI 10.1016/0888-7543(92)90381-2; ORAHILLY S, 1988, DIABETOLOGIA, V31, P792; RAHILLY SO, 1988, DIABETOLOGIA, V31, P407; RAHILLY SO, 1988, DIAB MED, V5, P224; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; TURNER RC, 1983, DIABETOLOGIA, V24, P404; TZALL S, 1989, AM J HUM GENET, V44, P864; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; [No title captured]	27	527	556	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					162	164		10.1038/356162a0	http://dx.doi.org/10.1038/356162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545870				2022-12-24	WOS:A1992HH73100063
J	PORTER, DG				PORTER, DG			ETHICAL SCORES FOR ANIMAL-EXPERIMENTS	NATURE			English	Editorial Material											PORTER, DG (corresponding author), UNIV GUELPH,DEPT BIOMED SCI,GUELPH N1G 2W1,ONTARIO,CANADA.							MANN MD, 1991, LAB ANIM SCI, V41, P6; MCLAUGHLIN RM, 1990, ANIMAL RESEARCH, ANIMAL RIGHTS, ANIMAL LEGISLATION, P11; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; PRENTICE ED, 1990, INVEST RADIOL, V25, P271, DOI 10.1097/00004424-199003000-00012; SHARPE R, 1989, CRUEL DECEPTION USE; 1983, SCI PROCEDURES LIVIN; 1990, ANIMALS, V24, P97	7	85	86	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					101	102		10.1038/356101a0	http://dx.doi.org/10.1038/356101a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH731	1545854				2022-12-24	WOS:A1992HH73100021
J	SMITH, FW; FEIGON, J				SMITH, FW; FEIGON, J			QUADRUPLEX STRUCTURE OF OXYTRICHA TELOMERIC DNA OLIGONUCLEOTIDES	NATURE			English	Article							PROTON RESONANCES; H-1-NMR SPECTRA; NMR; ASSIGNMENT; FRAGMENT; SPECTROSCOPY; PHASE	THE telomeres of most eukaryotes contain a repeating G-rich sequence with the consensus d(T/A)1-4G1-8, of which 12-16 bases form a 3' single-strand overhang beyond the telomeric duplex 1. It has been proposed that these G-rich oligonucleotides associate to form four-stranded structures from one 2-4, two 2,5 or four 6,7 individual strands and that these structures may be relevant in vivo. The proposed structures contain Hoogsteen base-paired G-quartets, precedent for which has been in the literature for many years 8. Here we use H-1 NMR spectroscopy to study the conformations of the DNA oligonucleotides d(G4T4G4) (Oxy-1.5) and d(G4T4G4T4G4T4G4) (Oxy-3.5) which contain the Oxytricha telomere repeat (T4G4). We find that these molecules fold to form a symmetrical bimolecular and an intramolecular quadruplex, respectively. Both structures have four G-quartets formed from nucleotides that are alternately syn and anti along each strand. This arrangement differs from earlier models in which the strands are alternately all syn or all anti 2,3,5 . The T4 loops in Oxy-1.5 are on opposite ends of the quadruplex and loop diagonally across the G-quartet, resulting in adjacent strands being alternately parallel and antiparallel.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BORZO M, 1978, CR ACAD SCI C CHIM, V287, P475; BRUNGER AT, 1990, MANUAL, P1; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DELEEUW FAAM, 1983, J COMPUT CHEM, V4, P428, DOI 10.1002/jcc.540040319; FEIGON J, 1984, NUCLEIC ACIDS RES, V12, P1243, DOI 10.1093/nar/12.2.1243; FEIGON J, IN PRESS DNA STRUCTU; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; KINTANAR A, 1987, NUCLEIC ACIDS RES, V15, P5845, DOI 10.1093/nar/15.14.5845; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PATEL DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1413, DOI 10.1073/pnas.79.5.1413; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	27	534	572	1	84	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					164	168		10.1038/356164a0	http://dx.doi.org/10.1038/356164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545871				2022-12-24	WOS:A1992HH73100064
J	KEYES, LN; CLINE, TW; SCHEDL, P				KEYES, LN; CLINE, TW; SCHEDL, P			THE PRIMARY SEX DETERMINATION SIGNAL OF DROSOPHILA ACTS AT THE LEVEL OF TRANSCRIPTION	CELL			English	Article							DOSAGE COMPENSATION; DETERMINATION GENE; X-CHROMOSOME; LETHAL GENE; MELANOGASTER; ELEMENT; DAUGHTERLESS; SEQUENCE; PROTEINS; BINDING	For Drosophila, the choice between male and female development is made by the switch gene, Sxl, in response to the X:A ratio. Once Sxl is turned on in females, it actively maintains the determined state, independent of the X:A signal, by a positive autoregulatory feedback loop in which Sxl proteins direct the female-specific splicing of Sxl transcripts. In this paper we have investigated the mechanism controlling pathway initiation. Our results suggest a two-step model for the initial activation of Sxl in females. In the first step, a special class of Sxl mRNAs is expressed in female embryos from an early promoter that responds to the genes signaling the X:A ratio. The proteins produced from these early mRNAs then initiate the autoregulatory loop by directing the female-specific processing of transcripts from the late Sxl promoter.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KEYES, LN (corresponding author), PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA.							BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLINE TW, 1986, GENETICS, V114, P345; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GERGEN JP, 1987, GENETICS, V117, P477; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LYTTLE TW, 1989, GENETICS, V121, P751; MAINE EM, 1985, COLD SPRING HARB SYM, V50, P595, DOI 10.1101/SQB.1985.050.01.072; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; WALKER ES, 1989, GENETICS, V122, P81	41	190	195	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					933	943		10.1016/0092-8674(92)90036-C	http://dx.doi.org/10.1016/0092-8674(92)90036-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547493				2022-12-24	WOS:A1992HH74800012
J	WHITE, JG; SOUTHGATE, E; THOMSON, JN				WHITE, JG; SOUTHGATE, E; THOMSON, JN			MUTATIONS IN THE CAENORHABDITIS-ELEGANS UNC-4 GENE ALTER THE SYNAPTIC INPUT TO VENTRAL CORD MOTOR NEURONS	NATURE			English	Article							DROSOPHILA; NEMATODE	IDENTIFICATION of the genes orchestrating neurogenesis would greatly enhance our understanding of this process. Genes have been identified that specify neuron type (for example cut 1 and numb 2 in Drosophila and mec-3 in Caenorhabditis elegans 3) and process guidance (for example, unc-5, unc-6 and unc-40 in C. elegans 4 and the fas-1 gene of Drosophila 5). We sought genes defining synaptic specificity by identifying mutations that alter synaptic connectivity in the motor circuitry in the nematode C. elegans. We used electron microscopy of serial sections 6 to reconstruct the ventral nerve-cords of uncoordinated (unc) mutants 7,8 that have distinctive locomotory choreographies. Here we describe the phenotype of mutations in the unc-4 gene in which a locomotory defect is correlated with specific changes in synaptic input to a subset of the excitatory VA motor neurons, normally used in reverse locomotion. The circuitry alterations do not arise because of the inaccessibility of the appropriate synaptic partners, but are a consequence of changes in synaptic specificity. The VA motor neurons with altered synaptic inputs are all lineal sisters of VB motor neurons; the VA motor neurons without VB sisters have essentially the same synaptic inputs as in wild-type animals. The normal function of the wild-type allele of unc-4 may thus be to invoke the appropriate synaptic specificities to VA motor neurons produced in particular developmental contexts.			WHITE, JG (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DURBIN R, 1987, THESIS CAMBRIDGE U; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; HEDGECOCK EM, 1990, NEURON, V2, P61; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI	14	106	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					838	841		10.1038/355838a0	http://dx.doi.org/10.1038/355838a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538764				2022-12-24	WOS:A1992HF63600060
J	HECHT, SR; BERGER, M				HECHT, SR; BERGER, M			RIGHT-SIDED ENDOCARDITIS IN INTRAVENOUS-DRUG-USERS - PROGNOSTIC FEATURES IN 102 EPISODES	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS, BACTERIAL; SUBSTANCE ABUSE, INTRAVENOUS; STAPHYLOCOCCUS-AUREUS; PULMONARY VALVE; TRICUSPID VALVE	TRICUSPID-VALVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS ENDOCARDITIS; ACTIVE INFECTIVE ENDOCARDITIS; VEGETATION SIZE; ECHOCARDIOGRAPHIC FINDINGS; PROSTHETIC REPLACEMENT; CLINICAL IMPLICATIONS; COMBINATION THERAPY; ADDICTS; DIAGNOSIS	Objective: To describe the clinical, laboratory, and echocardiographic findings in a large group of patients with right-sided endocarditis and to determine whether any of these findings is predictive of prognosis. Design: Retrospective survey of medical records to evaluate the course of hospitalization with follow-up on 6-month survival. Review of two-dimensional echocardiograms by an observer blinded to clinical information. Setting: Large, metropolitan, voluntary hospital. Patients: One hundred twenty-one intravenous drug users with clinical and bacteriologic evidence of 132 episodes of endocarditis. The presence ot a right-sided valvular vegetation detected by two-dimensional echocardiography was required for entry into the study. Measurements and Results: Staphylococcus aureus was the most common infecting organism (82%, 108 of 132). Vegetations involved the tricuspid valve in 127 episodes, the pulmonic in 4, and both in 1; they ranged in size from 0.4 to 4.3 cm (mean, 1.5 +/- 0.7 cm). Vegetations greater than 1.0 cm were present in 106 cases (80%). Among patients with isolated native right-sided endocarditis who reached a definite end point in treatment, mortality was 7% (7 of 98). Vegetations greater than 2.0 cm were associated with a significantly higher mortality compared with vegetations of 2.0 cm or less (33% compared with 1.3%, P < 0.001). Conclusions: Overall, right-sided endocarditis has a favorable prognosis. Although complications and prolonged fever are common, most cases respond to medical therapy. Our findings suggest that vegetation size may be an important predictor of outcome and that vegetations greater than 2.0 cm are associated with increased mortality.	CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	HECHT, SR (corresponding author), BETH ISRAEL MED CTR, 1ST AVE & 16TH ST, NEW YORK, NY 10003 USA.							ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; ANDY JJ, 1977, AM J CARDIOL, V40, P17, DOI 10.1016/0002-9149(77)90094-7; ARBULU A, 1981, J THORAC CARDIOV SUR, V82, P684; BARBOUR DJ, 1986, AM J CARDIOL, V57, P475, DOI 10.1016/0002-9149(86)90776-9; BAYER AS, 1988, CHEST, V93, P247, DOI 10.1378/chest.93.2.247; BERGER M, 1984, AM HEART J, V107, P391, DOI 10.1016/0002-8703(84)90393-4; BERGER M, 1980, CIRCULATION, V61, P855, DOI 10.1161/01.CIR.61.4.855; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHAN PK, 1989, AM HEART J, V117, P1140, DOI 10.1016/0002-8703(89)90874-0; DINUBILE M, 1987, AM J MED, V82, P811, DOI 10.1016/0002-9343(87)90019-2; GINZTON LE, 1982, AM J CARDIOL, V49, P1853, DOI 10.1016/0002-9149(82)90202-8; HUBBELL G, 1981, AM HEART J, V102, P85, DOI 10.1016/0002-8703(81)90418-X; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; LEVINE DP, 1986, REV INFECT DIS, V8, P374; LUTAS EM, 1986, AM HEART J, V112, P107, DOI 10.1016/0002-8703(86)90687-3; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; RACKLEY CE, 1990, HEART ARTERIES VEINS, P855; REISBERG BE, 1979, PROG CARDIOVASC DIS, V22, P193, DOI 10.1016/0033-0620(79)90023-9; ROBBINS MJ, 1986, AM J MED, V80, P165, DOI 10.1016/0002-9343(86)90004-5; ROBIN E, 1975, AM J CARDIOL, V35, P481, DOI 10.1016/0002-9149(75)90830-9; SANABRIA TJ, 1990, ARCH INTERN MED, V150, P1305, DOI 10.1001/archinte.150.6.1305; SHEIKH MU, 1979, AM J MED, V66, P283, DOI 10.1016/0002-9343(79)90546-1; SHENOY MM, 1984, AM J CARDIOL, V54, P1374, DOI 10.1016/S0002-9149(84)80106-X; SHIVELY BK, 1991, J AM COLL CARDIOL, V18, P391, DOI 10.1016/0735-1097(91)90591-V; SKEHAN JD, 1988, BRIT HEART J, V59, P62; STAFFORD A, 1979, AM J CARDIOL, V44, P754, DOI 10.1016/0002-9149(79)90298-4; STAFFORD WJ, 1985, BRIT HEART J, V53, P310; STEWART JA, 1980, CIRCULATION, V61, P374, DOI 10.1161/01.CIR.61.2.374; TAAMS MA, 1990, BRIT HEART J, V63, P109; WONG D, 1983, ARCH INTERN MED, V143, P1874, DOI 10.1001/archinte.143.10.1874; YEE ES, 1988, J THORAC CARDIOV SUR, V96, P133	34	182	190	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					560	566		10.7326/0003-4819-117-7-560	http://dx.doi.org/10.7326/0003-4819-117-7-560			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524330				2022-12-24	WOS:A1992JQ22600003
J	BELLANNECHANTELOT, C; LACROIX, B; OUGEN, P; BILLAULT, A; BEAUFILS, S; BERTRAND, S; GEORGES, I; GLIBERT, F; GROS, I; LUCOTTE, G; SUSINI, L; CODANI, JJ; GESNOUIN, P; POOK, S; VAYSSEIX, G; LUKUO, J; RIED, T; WARD, D; CHUMAKOV, I; LEPASLIER, D; BARILLOT, E; COHEN, D				BELLANNECHANTELOT, C; LACROIX, B; OUGEN, P; BILLAULT, A; BEAUFILS, S; BERTRAND, S; GEORGES, I; GLIBERT, F; GROS, I; LUCOTTE, G; SUSINI, L; CODANI, JJ; GESNOUIN, P; POOK, S; VAYSSEIX, G; LUKUO, J; RIED, T; WARD, D; CHUMAKOV, I; LEPASLIER, D; BARILLOT, E; COHEN, D			MAPPING THE WHOLE HUMAN GENOME BY FINGERPRINTING YEAST ARTIFICIAL CHROMOSOMES	CELL			English	Article							PHYSICAL MAP; CAENORHABDITIS-ELEGANS; DNA; CONSTRUCTION; SEQUENCE; STRATEGY; LIBRARY; CLONES; HYBRIDIZATION; GENES	Physical mapping of the human genome has until now been envisioned through single chromosome strategies. We demonstrate that by using large insert yeast artificial chromosomes (YACs) a whole genome approach becomes feasible. YACs (22,000) of 810 kb mean size (5 genome equivalents) have been fingerprinted to obtain individual patterns of restriction fragments detected by a LINE-1 (L1) probe. More than 1000 contigs were assembled. Ten randomly chosen contigs were validated by metaphase chromosome fluorescence in situ hybridization, as well as by analyzing the inter-Alu PCR patterns of their constituent YACs. We estimate that 15% to 20% of the human genome, mainly the L1-rich regions, is already covered with contigs larger than 3 Mb.	GENETHON, F-91000 EVRY, FRANCE; INST NATL RECH INFORMAT & AUTOMAT, F-78153 LE CHESNAY, FRANCE; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	Yale University; Yale University	BELLANNECHANTELOT, C (corresponding author), CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE.		susini, laurent/N-7913-2019; Susini, Laurent/O-4227-2016	Susini, Laurent/0000-0002-5164-2770; Le Paslier, Denis/0000-0003-4335-9956; BARILLOT, Emmanuel/0000-0003-2724-2002				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; ARNOLD N, 1992, IN PRESS TECHNIQUES; BALDING DJ, 1991, B MATH BIOL, V53, P853, DOI 10.1016/S0092-8240(05)80411-2; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BELLANNECHANTELOT C, 1991, NUCLEIC ACIDS RES, V19, P505, DOI 10.1093/nar/19.3.505; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANGIANO G, 1990, NUCLEIC ACIDS RES, V18, P5077, DOI 10.1093/nar/18.17.5077; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COLLEAUX L, 1992, YEAST, V8, P325, DOI 10.1002/yea.320080410; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CRAIG AG, 1990, NUCLEIC ACIDS RES, V18, P2653; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORENBERG JR, 1992, TRENDS BIOTECHNOL, V10, P27, DOI 10.1016/0167-7799(92)90163-P; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LACROIX B, 1992, IN PRESS WORLD SCI; LANDER E S, 1988, Genomics, V2, P231; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; MONTANARO V, 1991, AM J HUM GENET, V48, P183; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; SHAFITZAGARDO B, 1982, NUCLEIC ACIDS RES, V10, P3175, DOI 10.1093/nar/10.10.3175; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609	33	169	175	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					1059	1068		10.1016/0092-8674(92)90254-A	http://dx.doi.org/10.1016/0092-8674(92)90254-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525822				2022-12-24	WOS:A1992JN78100019
J	GEORGIADIS, MM; KOMIYA, H; CHAKRABARTI, P; WOO, D; KORNUC, JJ; REES, DC				GEORGIADIS, MM; KOMIYA, H; CHAKRABARTI, P; WOO, D; KORNUC, JJ; REES, DC			CRYSTALLOGRAPHIC STRUCTURE OF THE NITROGENASE IRON PROTEIN FROM AZOTOBACTER-VINELANDII	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; MAGNESIUM ADENOSINE 5'-TRIPHOSPHATE; ELECTRON-PARAMAGNETIC RESONANCE; CLOSTRIDIUM-PASTEURIANUM; FE-PROTEIN; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-BINDING; MACROMOLECULAR CRYSTALLOGRAPHY; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURE	The nitrogenase enzyme system catalyzes the ATP (adenosine triphosphate)-dependent reduction of dinitrogen to ammonia during the process of nitrogen fixation. Nitrogenase consists of two proteins: the iron (Fe)-protein, which couples hydrolysis of ATP to electron transfer, and the molybdenum-iron (MoFe)-protein, which contains the dinitrogen binding site. In order to address the role of ATP in nitrogen fixation, the crystal structure of the nitrogenase Fe-protein from Azotobacter vinelandii has been determined at 2.9 angstrom (angstrom) resolution. Fe-protein is a dimer of two identical subunits that coordinate a single 4Fe:4S cluster. Each subunit folds as a single alpha/beta-type domain, which together symmetrically ligate the surface exposed 4Fe:4S cluster through two cysteines from each subunit. A single bound ADP (adenosine diphosphate) molecule is located in the interface region between the two subunits. Because the phosphate groups of this nucleotide are approximately 20 angstrom from the 4Fe:4S cluster, it is unlikely that ATP hydrolysis and electron transfer are directly coupled. Instead, it appears that interactions between the nucleotide and cluster sites must be indirectly coupled by allosteric changes occurring at the subunit interface. The coupling between protein conformation and nucleotide hydrolysis in Fe-protein exhibits general similarities to the H-Ras p21 and recA proteins that have been recently characterized structurally. The Fe-protein structure may be relevant to the functioning of other biochemical energy-transducing systems containing two nucleotide-binding sites, including membrane transport proteins.	CALTECH,DEPT CHEM & CHEM ENGN,147-75CH,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM45162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM045162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BETHGE PH, CCP4 DAR LAB PROJ; Bishop P. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P71; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURKE DG, UNPUB; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CORK C, 1985, METHOD ENZYMOL, V114, P452; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DAESCH G, 1968, J BACTERIOL, V96, P346, DOI 10.1128/JB.96.2.346-351.1968; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEITS TL, 1989, J BIOL CHEM, V264, P6619; DRENTH J, 1975, J BIOL CHEM, V250, P5268; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; GAVINI N, 1992, IN PRESS J BIOL CHEM; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GEORGIADIS M, UNPUB; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAUSINGER RP, 1982, J BIOL CHEM, V257, P2483; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JACOBSON MR, 1990, J BIOL CHEM, V265, P19429; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; MEYER J, 1988, BIOCHEMISTRY-US, V27, P6150, DOI 10.1021/bi00416a048; MORGAN TV, 1986, FEBS LETT, V206, P4, DOI 10.1016/0014-5793(86)81329-1; MORGAN TV, 1990, BIOCHEMISTRY-US, V29, P3077, DOI 10.1021/bi00464a026; MURRELL SA, 1988, BIOCHEM J, V251, P609, DOI 10.1042/bj2510609; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; REES DC, 1983, J BIOL CHEM, V258, P2733; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SIMPSON FB, 1984, SCIENCE, V224, P1095, DOI 10.1126/science.6585956; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAL S, 1991, J BIOL CHEM, V266, P10654; TANAKA M, 1977, J BIOL CHEM, V252, P7093; TANAKA M, 1977, J BIOL CHEM, V252, P7089; TANAKA M, 1977, J BIOL CHEM, V252, P7081; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1992, PHILOS T R SOC B, V336, P73, DOI 10.1098/rstb.1992.0046; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER GA, 1973, BIOCHEM BIOPH RES CO, V53, P904, DOI 10.1016/0006-291X(73)90177-0; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG ZC, 1985, BIOCHEMISTRY-US, V24, P214, DOI 10.1021/bi00322a031; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT GD, 1985, BIOCHEMISTRY-US, V24, P7226, DOI 10.1021/bi00346a031; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, IN PRESS SCIENCE; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	91	572	586	2	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1653	1659		10.1126/science.1529353	http://dx.doi.org/10.1126/science.1529353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529353				2022-12-24	WOS:A1992JN50100022
J	DELATTRE, O; ZUCMAN, J; PLOUGASTEL, B; DESMAZE, C; MELOT, T; PETER, M; KOVAR, H; JOUBERT, I; DEJONG, P; ROULEAU, G; AURIAS, A; THOMAS, G				DELATTRE, O; ZUCMAN, J; PLOUGASTEL, B; DESMAZE, C; MELOT, T; PETER, M; KOVAR, H; JOUBERT, I; DEJONG, P; ROULEAU, G; AURIAS, A; THOMAS, G			GENE FUSION WITH AN ETS DNA-BINDING DOMAIN CAUSED BY CHROMOSOME-TRANSLOCATION IN HUMAN TUMORS	NATURE			English	Article							EWINGS-SARCOMA; RECIPROCAL TRANSLOCATION; MYXOID CHONDROSARCOMA; PROTEINS; ERYTHROLEUKEMIA; REARRANGEMENTS; CONSISTENCY; T(11-22); VIRUS	EWING'S sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11; 22) (q24; q12) chromosome translocation1-8, the breakpoints of which have recently been cloned9. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation9. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE; ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA; MCGILL UNIV,CTR RECH NEUROSCI,MONTREAL H3G 1A4,QUEBEC,CANADA; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550; INST CURIE,CNRS,URA 620,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Saint Anna Children's Hospital; McGill University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			j, zucman-rossi/AAV-3594-2021; zucman-rossi, Jessica/B-5098-2009; Plougastel-Douglas, Beatrice/Q-3186-2019	j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; Plougastel-Douglas, Beatrice/0000-0002-6389-561X; delattre, olivier/0000-0002-8730-2276; Desmaze, Chantal/0000-0003-0777-8854; Kovar, Heinrich/0000-0001-6873-9109				AURIAS A, 1983, NEW ENGL J MED, V309, P496; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CAVAZZANA AO, 1988, ADV NEUROBLASTOMA RE, V2, P463; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DECHADAREVIAN JP, 1984, NEW ENGL J MED, V311, P1702; DOUGLASS EC, 1986, J NATL CANCER I, V77, P1211; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR A, 1990, J BIOL CHEM, V265, P17094; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; SHEN WPV, 1990, CANCER GENET CYTOGEN, V45, P207, DOI 10.1016/0165-4608(90)90084-N; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10173; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VIGFUSSON NV, 1986, CANCER GENET CYTOGEN, V22, P211, DOI 10.1016/0165-4608(86)90157-3; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WHANGPENG J, 1987, CANCER GENET CYTOGEN, V29, P155, DOI 10.1016/0165-4608(87)90043-4; ZUCMAN J, IN PRESS GENES CHROM	34	1477	1508	6	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					162	165		10.1038/359162a0	http://dx.doi.org/10.1038/359162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522903				2022-12-24	WOS:A1992JM49400058
J	COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP				COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP			PRESCRIPTION DRUG DIVERSION CONTROL AND MEDICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CATCHMENT-AREA SITES; UNITED-STATES; CHRONIC PAIN; BENZODIAZEPINES; ABUSE; PREVALENCE; DEPRESSION; DISORDER; PROGRAM; QUALITY	Concern about the role of prescription drug diversion in drug abuse has led to demands for more stringent regulation and for better ways to detect prescription drug diversion. Advances in technology now allow point-of-sale computer systems to report prescriptions filled by pharmacies to state agencies rapidly and possibly more economically. However, the advantages of more comprehensive control systems must be balanced against their possible effects on medical practice and patient care. Our limited knowledge about prescription drug diversion and the impact of diversion control systems on medical practice is summarized. Needed research is outlined together with the components of a diversion control program that balances reducing drug diversion with minimizing adverse effects on medical practice and patient care. We stress the need for broadly defined practice parameters and peer review by medical experts thoroughly familiar with the complexities of medical practice.	NIDA,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)								ADAMS EH, 1991, NEW YORK STATE J MED, V91, P337; AMBRE JJ, 1991, MAY NAT I DRUG AB TE; BAIRD WP, 1990, BALANCING RESPONSE P, P65; BALTER MB, 1992, J PSYCHOACTIVE DRUGS, V24, P63, DOI 10.1080/02791072.1992.10471620; BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; BATTEN HL, 1991, DRUG SERVICES RES SO; BERINA LF, 1985, AM J HOSP PHARM, V42, P857, DOI 10.1093/ajhp/42.4.857; Burton B T, 1991, NIDA Res Monogr, V115, P47; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; CLEELAND CS, 1989, ADV PAIN RES THER, P81; COLE JO, 1990, J PSYCHIAT RES, V24, P135, DOI 10.1016/0022-3956(90)90045-R; DAHL J, 1991, MAY NAT I DRUG AB TE; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; DUBE CE, 1990, CURRICULUM PRIMARY C; EDWARDS CC, 1972, FED REG         0815, V37, P16503; FARNSWORTH P, 1990, BALANCING RESPONSE P, P103; FDA Drug Bulletin, 1982, FDA DRUG B, V12, P4; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; GARVEY MJ, 1986, AM J PSYCHIAT, V143, P1601; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; Green J, 1989, PAIN MANAGE, V2, P241; HAISLIP GR, 1982, SUBST ABUS, V4, P4; HASH BM, 1984, J CLIN PSYCHOPHARM, V4, P298, DOI 10.1097/00004714-198410000-00022; HECHTMAN L, 1984, AM J ORTHOPSYCHIAT, V54, P415, DOI 10.1111/j.1939-0025.1984.tb01507.x; HILL CS, 1987, JAMA-J AM MED ASSOC, V257, P2081; HOLLISTER AS, 1991, SCIENCE, V252, P11, DOI 10.1126/science.252.5002.11-a; HOLLISTER AS, 1990, SUBST ABUSE, V11, P69; HORGAN C, 1991, REV PRESCRIPTION DRU; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; IRVINE GD, 1991, METHAMPHETAMINE ABUS, P33; Joranson D E, 1990, J Pain Symptom Manage, V5, pS12; JORANSON DE, 1992, B J MED LICENSURE DI, V79, P15; KALES A, 1983, J CLIN PSYCHOPHARM, V3, P140, DOI 10.1097/00004714-198304000-00038; KLEIN LE, 1981, J MED EDUC, V56, P504; LEVIN AA, 1992, JAMA-J AM MED ASSOC, V268, P473, DOI 10.1001/jama.268.4.473; LONEY J, 1988, ADOLESCENT DRUG ABUS, P19; LURIE P, 1992, JAMA-J AM MED ASSOC, V268, P472; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; Mellinger Glen, 1981, EPIDEMIOLOGICAL IMPA, P117; MORGAN JP, 1986, AM OPIOPHOBIA CUSTOM, P163; NAGY A, 1987, ACTA PSYCHIAT SCAND, V765, P47; Nemeroff C B, 1990, N C Med J, V51, P240; PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1; PISCOPO JA, 1991, MAY NAT I DRUG AB TE; PORTENOY R, 1990, J PAIN SYMPTOM MA S1, V5, P546; PORTER J, 1980, NEW ENGL J MED, V302, P123; PROTTAS J, 1991, MAY NAT I DRUG AB TE; PUDER KS, 1988, AM J DRUG ALCOHOL AB, V14, P463, DOI 10.3109/00952998809001564; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RICHARD BW, 1988, J CLIN PHARMACOL, V28, P395, DOI 10.1002/j.1552-4604.1988.tb05747.x; RICKELS K, 1972, CLIN PHARMACOL THER, V13, P595; RICKELS K, 1991, MAY NAT I DRUG AB TE; ROCK N, 1991, MAY AM AC CHILD AD P; SALZMAN C, 1991, NOV NIH CONS DEV C D; Sanders J H Jr, 1989, N C Med J, V50, P105; SATEL SL, 1989, J CLIN PSYCHIAT, V50, P241; SCHWARTZ HI, 1991, GEN HOSP PSYCHIAT, V13, P219, DOI 10.1016/0163-8343(91)90122-D; SCHWEIZER E, 1990, ARCH GEN PSYCHIAT, V47, P908; SHADER RI, 1991, J CLIN PHARMACOL, V31, P781, DOI 10.1002/j.1552-4604.1991.tb01910.x; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SIGLER KA, 1984, AM J HOSP PHARM, V41, P108, DOI 10.1093/ajhp/41.1.108; SMITH MC, 1983, SOC MED CONFLICTING, P259; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; TEMIN P, 1981, DRUGS HLTH, P173; TENNANT FS, 1983, POSTGRAD MED, V73, P81, DOI 10.1080/00325481.1983.11698315; UHLENHUTH EH, 1988, J CLIN PSYCHOPHARM, V8, P161; UHLENHUTH EH, 1987, CURR MED RES OPIN, V765, P47; UNGERLEIDER JT, 1980, ARCH GEN PSYCHIAT, V37, P106; WEBB CE, 1991, MAY NAT I DRUG AB TE; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; Weissman D E, 1991, Wis Med J, V90, P671; WILFORD BB, 1991, J PSYCHOACTIVE DRUGS, V23, P343, DOI 10.1080/02791072.1991.10471605; WILFORD BB, 1983, NEW ENGL J MED, V308, P1457; WOLFE SM, 1990, HLTH LETT, V6, P6; WOODS JH, 1991, LANCET, V337, P295, DOI 10.1016/0140-6736(91)90902-2; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539; 1991, US DHHS ADM901839 PU; 1985, FED REG         1018, V50, P42184; 1991, J AM ACAD CHILD ADOL, V30, P1; 1991, US DHHS ADM911732 PU; 1982, GAOGGD832 GEN ACC OF; 1978, GAOGGD7822 GEN ACC O; 1990, PLAN CURB PRESCRIPTI; 1986, FED REG         0513, V51, P17476; 1992, OHIO STATE BOARD FEB, V13, P3; 1992, J NIH RES, V4, P27; 1990, EPIDEMIOL NOTES, V5, P1; 1990, BENZODIAZEPINE DEPEN; 1992, GAOHRD92115 GEN ACC	93	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1306	1310		10.1001/jama.268.10.1306	http://dx.doi.org/10.1001/jama.268.10.1306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL608	1507377				2022-12-24	WOS:A1992JL60800032
J	LEGERSKI, R; PETERSON, C				LEGERSKI, R; PETERSON, C			EXPRESSION CLONING OF A HUMAN DNA-REPAIR GENE INVOLVED IN XERODERMA-PIGMENTOSUM GROUP-C	NATURE			English	Article							HIGH-EFFICIENCY TRANSFORMATION; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; EXCISION REPAIR; RAD4 GENE; CELLS; COMPLEMENTATION; MUTANTS; DEFECT	XERODERMA pigmentosum (XP) is a rare human autosomal recessive disease characterized by solar sensitivity, high predisposition for developing cancers on areas exposed to sunlight, and, in some cases, neurological abnormalities1,2. XP cells are defective in DNA repair3, and complementation of this defect has been used to identify eight genetic groups (A-G and variant)4. We have developed a simple, highly efficient complementary DNA expression system for use in human cells5. Here we use this system to isolate a cDNA clone that restores the ultraviolet sensitivity and unscheduled DNA synthesis of XP-C cells to normal levels. The XP-C complementing clone XPCC encodes a highly hydrophilic protein which is composed of a predicted 823 amino acids and shares limited homology with the product of the yeast DNA repair gene RAD4. The XPCC transcript is undetectable by northern blotting in most XP-C cell lines examined.			LEGERSKI, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLEAVER JE, 1975, REV GENET, V26, P365; COUTO LB, 1989, J BACTERIOL, V171, P1862, DOI 10.1128/jb.171.4.1862-1869.1989; DAYAGROSJEAN L, 1987, MUTAT RES, V183, P185, DOI 10.1016/0167-8817(87)90061-7; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; GIETZ RD, 1988, GENE, V74, P535, DOI 10.1016/0378-1119(88)90186-2; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEGERSKI RJ, 1984, P NATL ACAD SCI-BIOL, V81, P5676, DOI 10.1073/pnas.81.18.5676; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STORMO GD, 1987, NUCLEIC ACID PROTEIN, P231; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WEBER CA, 1988, MOL CELL BIOL, V8, P1137, DOI 10.1128/MCB.8.3.1137; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	25	208	211	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					70	73		10.1038/359070a0	http://dx.doi.org/10.1038/359070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522891				2022-12-24	WOS:A1992JL66200056
J	LOUIE, GV; BROWNLIE, PD; LAMBERT, R; COOPER, JB; BLUNDELL, TL; WOOD, SP; WARREN, MJ; WOODCOCK, SC; JORDAN, PM				LOUIE, GV; BROWNLIE, PD; LAMBERT, R; COOPER, JB; BLUNDELL, TL; WOOD, SP; WARREN, MJ; WOODCOCK, SC; JORDAN, PM			STRUCTURE OF PORPHOBILINOGEN DEAMINASE REVEALS A FLEXIBLE MULTIDOMAIN POLYMERASE WITH A SINGLE CATALYTIC SITE	NATURE			English	Article							HYDROXYMETHYLBILANE SYNTHASE; DIPYRROMETHANE COFACTOR; RESOLUTION STRUCTURE; NUCLEOTIDE-SEQUENCE; SUBSTRATE BINDING; ARGININE RESIDUES; 2.3-A RESOLUTION; ACTIVE-TRANSPORT; PROTEIN; REFINEMENT	The three-domain structure of porphobilinogen deaminase, a key enzyme in the biosynthetic pathway of tetrapyrroles, has been defined by X-ray analysis at 1.9 angstrom resolution. Two of the domains structurally resemble the transferrins and periplasmic binding proteins. The dipyrromethane cofactor is covalently linked to domain 3 but is bound by extensive salt-bridges and hydrogen-bonds within the cleft between domains 1 and 2, at a position corresponding to the binding sites for small-molecule ligands in the analogous proteins. The X-ray structure and results from site-directed mutagenesis provide evidence for a single catalytic site. Interdomain flexibility may aid elongation of the polypyrrole product in the active-site cleft of the enzyme.	UNIV LONDON BIRKBECK COLL, IMPERIAL CANC RES FUND, STRUCT MOLEC BIOL UNIT, LONDON WC1E 7HX, ENGLAND; UNIV LONDON, QUEEN MARY & WESTFIELD COLL, SCH BIOL SCI, LONDON E1 4NS, ENGLAND	Cancer Research UK; University of London; Birkbeck University London; University of London; Queen Mary University London	LOUIE, GV (corresponding author), UNIV LONDON BIRKBECK COLL, DEPT CRISTALLOG, MOLEC BIOL LAB, MALET ST, LONDON WC1E 7HX, ENGLAND.		Wood, Stephen P/B-1438-2009	Warren, Martin/0000-0002-6028-6456				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DELFAU MH, 1990, J CLIN INVEST, V86, P1511, DOI 10.1172/JCI114869; EVANS SV, IN PRESS J MOL GRAPH; HADENER A, 1990, BIOCHEM J, V271, P487; HANEEF I, 1985, ACTA CRYSTALLOGR A, V41, P426, DOI 10.1107/S0108767385000915; HART GJ, 1987, J CHEM SOC CHEM COMM, P1762, DOI 10.1039/c39870001762; JONES C, 1984, J CHEM SOC PERK T 1, P2625, DOI 10.1039/p19840002625; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Jordan P.M., 1991, NEW COMPREHENSIVE BI, V19, P1, DOI DOI 10.1016/S0167-7306(08)60108-8; JORDAN PM, 1987, FEBS LETT, V225, P87, DOI 10.1016/0014-5793(87)81136-5; JORDAN PM, 1992, J MOL BIOL, V224, P269, DOI 10.1016/0022-2836(92)90590-G; JORDAN PM, 1991, BIOCHEM J, V280, P445, DOI 10.1042/bj2800445; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; LANDER M, 1991, BIOCHEM J, V275, P447, DOI 10.1042/bj2750447; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MAUZERALL D, 1960, J AM CHEM SOC, V82, P2605, DOI 10.1021/ja01495a053; MGONE CS, IN PRESS HUM GENET; PETRICEK M, 1990, J BACTERIOL, V172, P2250, DOI 10.1128/jb.172.5.2250-2258.1990; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; RAICH N, 1986, NUCLEIC ACIDS RES, V14, P5955, DOI 10.1093/nar/14.15.5955; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SCHAUDER JR, 1987, J CHEM SOC CHEM COMM, P436, DOI 10.1039/c39870000436; SCOTT AI, 1989, FEBS LETT, V242, P319, DOI 10.1016/0014-5793(89)80493-4; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STUBNICER AC, 1988, NUCLEIC ACIDS RES, V16, P3102, DOI 10.1093/nar/16.7.3102; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; THOMAS SD, 1986, NUCLEIC ACIDS RES, V14, P6215, DOI 10.1093/nar/14.15.6215; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARREN MJ, 1988, BIOCHEMISTRY-US, V27, P9020, DOI 10.1021/bi00425a021	38	177	181	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					33	39		10.1038/359033a0	http://dx.doi.org/10.1038/359033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522882				2022-12-24	WOS:A1992JL66200044
J	DICKINSON, LA; JOH, T; KOHWI, Y; KOHWISHIGEMATSU, T				DICKINSON, LA; JOH, T; KOHWI, Y; KOHWISHIGEMATSU, T			A TISSUE-SPECIFIC MAR/SAR DNA-BINDING PROTEIN WITH UNUSUAL BINDING-SITE RECOGNITION	CELL			English	Article							SCAFFOLD-ATTACHED REGIONS; CHROMOSOMAL LOOP ANCHORAGE; BETA-GLOBIN GENE; ESCHERICHIA-COLI; TOPOISOMERASE-II; NUCLEAR SCAFFOLD; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; CONSENSUS SEQUENCE; CRYSTAL-STRUCTURE	A human cDNA was cloned that encodes a DNA-binding protein (SATB1) that is expressed predominantly in thymus and binds selectively to the nuclear matrix/scaffold-associating DNAs (MARs/SARs). Missing nucleoside experiments showed that SATB1 selectively binds in a special AT-rich sequence context where one strand consists of mixed A's, T's, and C's, excluding G's (ATC sequences). When this feature is destroyed by mutation, SATB1 binding is greatly reduced even if the direct contact sequence remains intact. Conjunctional SATB1-binding sequences become stably unpaired in supercoiled DNA. Specific mutations that diminish the unwinding potential greatly reduce SATB1 binding. However, SATB1 does not bind single-stranded DNA. Chemical interference assays show that SATB1 binds along the minor groove with very little contact with the bases. This suggests that SATB1 recognizes the ATC sequence indirectly through the altered sugar-phosphate backbone structure present in the double-stranded DNA.			DICKINSON, LA (corresponding author), LA JOLLA CANC RES FDN,LA JOLLA,CA 92037, USA.				NCI NIH HHS [R01 CA51377, R01 CA39681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039681, R01CA051377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROTHERTON T, 1991, BIOCHEMISTRY-US, V30, P5845, DOI 10.1021/bi00238a006; BROWN DG, 1990, EMBO J, V9, P1329, DOI 10.1002/j.1460-2075.1990.tb08242.x; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEDOROFF NV, 1978, CELL, V13, P701, DOI 10.1016/0092-8674(78)90220-9; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOFMANN MC, 1989, CANCER RES, V49, P4696; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOCHETKOV N K, 1971, Tetrahedron Letters, V22, P1993; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOO HS, 1987, BIOCHEMISTRY-US, V26, P3745, DOI 10.1021/bi00386a070; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STOCKHAUS J, 1987, NUCLEIC ACIDS RES, V15, P3479, DOI 10.1093/nar/15.8.3479; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	77	448	489	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					631	645		10.1016/0092-8674(92)90432-C	http://dx.doi.org/10.1016/0092-8674(92)90432-C			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505028				2022-12-24	WOS:A1992JJ88600012
J	CARTWRIGHT, K; REILLY, S; WHITE, D; STUART, J				CARTWRIGHT, K; REILLY, S; WHITE, D; STUART, J			EARLY TREATMENT WITH PARENTERAL PENICILLIN IN MENINGOCOCCAL DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS; ANTIBIOTICS; ASSOCIATION; INFECTIONS; ENDOTOXIN; CHILDHOOD; SERUM	Objective-To measure the effect of parenteral antibiotics given before admission to hospital on mortality and on bacteriological investigations in meningococcal disease. Design-Retrospective review of hospital notes and laboratory and public health medicine department records. Setting-Three health districts in south west England. Subjects-Patients with meningococcal disease in Gloucester district presenting between 1 January 1982 and 31 December 1991 (n=190); patients with meningococcal disease in Plymouth (n=118) and Bath (n=73) districts presenting between 1 January 1988 and 31 December 1991 (total=381). Main outcome measure-Number of deaths from meningococcal disease. Results-Parenteral antibiotic given by general practitioners was associated with a substantial reduction in mortality (from 9% to 5%; relative risk 0.6, 95% confidence interval 0.2 to 1.5); patients with a rash were more likely to be given parenteral antibiotics, and mortality was further reduced (from 12% to 5%; 0.5, 0.2 to 1.4). In a district where such treatment was regularly encouraged its use increased from 5% to 40% of cases over 10 years (p=0.00001). Treatment with parenteral antibiotics before admission made isolation of meningococci from blood and cerebrospinal fluid less likely but did not affect nasopharyngeal cultures. Conclusions-General practitioners should carry benzylpenicillin in their emergency bags at all times and should administer it promptly, preferably intravenously, whenever meningococcal disease is suspected, unless the patient has had an anaphylactic reaction to penicillin. Specimens for culture should include a nasopharyngeal swab.	DERRIFORD HOSP, PUBL HLTH LAB, PLYMOUTH PL6 8DH, ENGLAND; ROYAL UNITED HOSP, PUBL HLTH LAB, BATH BA1 3NG, ENGLAND; GLOUCESTER HLTH AUTHOR, COMMUNICABLE DIS CONTROL, GLOUCESTER GL1 1LY, ENGLAND	Derriford Hospital	CARTWRIGHT, K (corresponding author), GLOUCESTERSHIRE ROYAL HOSP, PUBL HLTH LAB, GLOUCESTER GL1 3NN, ENGLAND.							ABBOTT JD, 1985, J INFECTION, V11, P241, DOI 10.1016/S0163-4453(85)93294-3; ABRAMSON JS, 1985, J INFECT DIS, V151, P370, DOI 10.1093/infdis/151.2.370; ANDERSEN BM, 1980, ACTA PATH MICRO IM B, V88, P231; BANKS HS, 1948, LANCET, V252, P677, DOI 10.1016/S0140-6736(48)91113-1; BANKS HS, 1948, LANCET, V255, P635; BAXTER P, 1988, LANCET, V1, P1166; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CARTWRIGHT KAV, 1986, LANCET, V2, P558; CARTWRIGHT KAV, 1990, J CLIN PATHOL, V43, P438, DOI 10.1136/jcp.43.5.438-a; CONVERSE GM, 1973, J PEDIATR-US, V83, P220, DOI 10.1016/S0022-3476(73)80479-2; Dean A. G., 1990, EPI INFO VERSION 5 W; DEVOE IW, 1982, MICROBIOL REV, V46, P162, DOI 10.1128/MMBR.46.2.162-190.1982; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FALLON RJ, 1984, J HYG-CAMBRIDGE, V93, P167, DOI 10.1017/S0022172400064688; GEDDE-DAHL T W, 1990, NIPH (National Institute of Public Health) Annals (Oslo), V13, P45; GOLDACRE MJ, 1977, ARCH DIS CHILD, V52, P501, DOI 10.1136/adc.52.6.501; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; JARVIS CW, 1972, CLIN PEDIATR, V11, P201, DOI 10.1177/000992287201100406; Jones D M, 1992, Commun Dis Rep CDR Rev, V2, pR61; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; Lieberman J M, 1990, Infect Dis Clin North Am, V4, P703; MELLADO MC, 1991, EPIDEMIOL INFECT, V106, P283, DOI 10.1017/S0950268800048421; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; OAKLEY JR, 1979, BRIT MED J, V2, P468, DOI 10.1136/bmj.2.6188.468; ONG ELC, 1988, BRIT MED J, V297, P901, DOI 10.1136/bmj.297.6653.901; SIPPEL JE, 1990, J CLIN PATHOL, V43, P610, DOI 10.1136/jcp.43.7.610-c; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; STEPHENS DS, 1991, REV INFECT DIS, V13, P22; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TALAN DA, 1988, REV INFECT DIS, V10, P365; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; 1990, IMMUNISATION INFECTI, P166; 1974, LANCET, V1, P55; 1988, MENINGOCOCCAL INFECT; 1989, DRUG THER B, V27, P17	42	205	207	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1992	305	6846					143	147		10.1136/bmj.305.6846.143	http://dx.doi.org/10.1136/bmj.305.6846.143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515827	Bronze, Green Submitted, Green Published			2022-12-24	WOS:A1992JF06300019
J	KRUMHOLZ, HM; DOUGLAS, PS; LAUER, MS; PASTERNAK, RC				KRUMHOLZ, HM; DOUGLAS, PS; LAUER, MS; PASTERNAK, RC			SELECTION OF PATIENTS FOR CORONARY ANGIOGRAPHY AND CORONARY REVASCULARIZATION EARLY AFTER MYOCARDIAL-INFARCTION - IS THERE EVIDENCE FOR A GENDER BIAS	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; SEX FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; WOMENS HEALTH; SELECTION BIAS	ARTERY BYPASS-SURGERY; WOMEN; MORTALITY; SEX; DISEASE; MEN	Objective: To determine whether a gender bias exists in the selection of patients for diagnostic and therapeutic cardiovascular procedures early after myocardial infarction. Design: A retrospective cohort study. Setting: A community-based tertiary care teaching hospital. Patients: A total of 2473 consecutive patients with a principal discharge diagnosis of acute myocardial infarction and a peak creatine kinase MB fraction of at least 4%. Measurements: Comparison of men and women regarding the frequency with which they underwent various cardiac procedures. Results: Women had coronary angiography during hospitalization for myocardial infarction much less frequently than men (odds ratio, 0.55; 95% Cl, 0.46 to 0.65), but the age-adjusted rates were similar in women and men (odds ratio, 0.91; Cl, 0.75 to 1.12). An abnormal ejection fraction (< 50%) was equally frequent in women and men who underwent left ventriculography (odds ratio, 0.85; Cl, 0.56 to 1.30). Among patients who had coronary angiography, women had a significantly lower rate of severe coronary artery disease, defined as either a left main stenosis of more than 50%, three-vessel disease, or two-vessel disease with a proximal left anterior descending stenosis of more than 70% (odds ratio, 0.67; Cl, 0.48 to 0.93). When adjustments were made for age, women had percutaneous transluminal coronary angioplasty as often as men (odds ratio, 1.16; Cl, 0.83 to 1.62) but had coronary artery bypass graft surgery significantly less frequently (odds ratio, 0.58; Cl, 0.37 to 0.91). When adjustments were made for age and the severity of coronary artery disease, the difference in rates was of borderline significance (odds ratio, 0.65; Cl, 0.41 to 1.01). Conclusions: No evidence of a difference in the rate of coronary angiography early after myocardial infarction between women and men was found after age adjustment. Among patients who have cardiac catheterization early after myocardial infarction, women and men are equally likely to have angioplasty, but women are less likely than men to have coronary artery bypass surgery.	MASSACHUSETTS GEN HOSP, CELL BIOL UNIT, 32 FRUIT ST, BOSTON, MA 02114 USA; BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; LAHEY CLIN FDN, MED CTR, CARDIOL SECT, BURLINGTON, MA 01805 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Lahey Hospital & Medical Center			Lauer, Michael S/L-9656-2013; , Harlan/AAI-2875-2020	Lauer, Michael S/0000-0002-9217-8177; Douglas, Pamela/0000-0001-9876-4049	NHLBI NIH HHS [HL-07374] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; KENNEDY RH, 1982, NEW ENGL J MED, V307, P986, DOI 10.1056/NEJM198210143071605; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; ZIR LM, 1976, CIRCULATION, V53, P627, DOI 10.1161/01.CIR.53.4.627	22	252	256	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					785	790		10.7326/0003-4819-116-10-785	http://dx.doi.org/10.7326/0003-4819-116-10-785			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567092				2022-12-24	WOS:A1992HT80200001
J	KIPREOS, ET; WANG, JYJ				KIPREOS, ET; WANG, JYJ			CELL-CYCLE REGULATED BINDING OF C-ABL TYROSINE KINASE TO DNA	SCIENCE			English	Article							PROTEIN	The proto-oncogene c-abl encodes a protein tyrosine kinase that is localized in the cytoplasm and the nucleus. The large carboxyl-terminal segment of c-Abl was found to contain a DNA-binding domain that was necessary for the association of c-Abl with chromatin. The DNA-binding activity of c-Abl was lost during mitosis when the carboxyl-terminal segment became phosphorylated. In vitro phosphorylation of the DNA-binding domain by cdc2 kinase abolished DNA binding. Homozygous mutant mice expressing a c-Abl tyrosine kinase without the DNA-binding domain have been reported to die of multiple defects at birth. Thus, binding of the c-Abl tyrosine kinase to DNA may be essential to its biological function.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01 CA043054, CA 43054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hancock R, 1977, Methods Cell Biol, V15, P127, DOI 10.1016/S0091-679X(08)60213-7; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1984, CELL, V36, P349; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233	12	195	202	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					382	385		10.1126/science.256.5055.382	http://dx.doi.org/10.1126/science.256.5055.382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566087				2022-12-24	WOS:A1992HP03200038
J	NARAYANAN, R; KLEMENT, JF; RUBEN, SM; HIGGINS, KA; ROSEN, CA				NARAYANAN, R; KLEMENT, JF; RUBEN, SM; HIGGINS, KA; ROSEN, CA			IDENTIFICATION OF A NATURALLY-OCCURRING TRANSFORMING VARIANT OF THE P65 SUBUNIT OF NF-KAPPA-B	SCIENCE			English	Article							ENHANCER-BINDING-PROTEIN; REL ONCOGENE ENCODES; THYMIDINE KINASE; CELL-LINES; GENE; EXPRESSION; NUCLEAR; TRANSACTIVATION; LYMPHOPOIESIS; HOMOLOGY	Transcription factor NF-kappa-B comprises two proteins, p50 and p65, that have sequence similarity to the v-rel oncogene. In primary hematopoietic cell populations an alternatively spliced form of NF-kappa-B p65 mRNA was observed that encoded a protein designated p65-DELTA. Expression of the p65-DELTA cDNA in Rat-1 fibroblasts resulted in focus formation, anchorage-independent growth in soft agar, and tumor formation in athymic nude mice, effects not obtained with expression of p65 or a p65-DELTA mutant that contains a disruption within the transcriptional activation domain. Thus, p65-DELTA, which associated weakly and interfered with DNA binding by p65, may sequester an essential limiting regulatory factor or factors required for NF-kappa-B function.	ROCHE INST MOLEC BIOL, DEPT GENE REGULAT, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA	Roche Holding				Narayanan, Ramaswamy/0000-0001-9346-9083				BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COLLINS LS, 1987, J IMMUNOL, V138, P1082; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HENDERSON AJ, 1990, J IMMUNOL, V145, P423; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ITO E, 1990, ONCOGENE, V5, P1755; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENT J, UNPUB; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; NARAYANAN R, 1989, EXP HEMATOL, V17, P832; NARAYANAN RB, UNPUB; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUBEN SM, 1992, MOL CELL BIOL, V12, P144; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; THEILEN GH, 1966, J NATL CANCER I, V37, P731; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	30	83	85	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					367	370		10.1126/science.256.5055.367	http://dx.doi.org/10.1126/science.256.5055.367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566083				2022-12-24	WOS:A1992HP03200033
J	SCHWARTZ, DA; LANDAS, SK; LASSISE, DL; BURMEISTER, LF; HUNNINGHAKE, GW; MERCHANT, JA				SCHWARTZ, DA; LANDAS, SK; LASSISE, DL; BURMEISTER, LF; HUNNINGHAKE, GW; MERCHANT, JA			AIRWAY INJURY IN SWINE CONFINEMENT WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						AGRICULTURAL WORKERS DISEASES; AGROCHEMICALS; SWINE; ASTHMA; BRONCHITIS; OCCUPATIONAL MEDICINE	COTTON DUST; RESPIRATORY SYMPTOMS; INHALED ENDOTOXIN; LUNG-FUNCTION; BUILDINGS; EXPOSURE; FARMERS; ASTHMA	Objective: To determine whether work-related respiratory symptoms are indicative of underlying lung disease among swine confinement workers and, if so, to identify whether respiratory changes were more indicative of airway or of interstitial lung injury. Design: Nested case-control study within a population-based longitudinal study. Setting: University hospital. Participants: Study participants were randomly selected from a group of 207 swine confinement workers followed longitudinally. Of these, 43 workers with respiratory symptoms were identified, and 31 were randomly selected for inclusion in this study. Three control groups (swine confinement workers, neighbor farmers, and blue collar workers) without work-related respiratory symptoms were frequency-matched by age, sex, and smoking status to the symptomatic swine confinement workers. Measurements: Spirometry and lung volumes, diffusing capacity of carbon monoxide, chest radiograph, methacholine airway challenge, and bronchoalveolar lavage were done. An endobronchial biopsy was done in the last 27 participants evaluated. Results: Although spirometric measures of airflow were similar between the symptomatic swine confinement workers and the three control groups, swine confinement cases were found to have significant elevations in residual volume (126.5 +/- 28.2 L) when compared to swine confinement controls (115.4 +/- 38.4 L; P less-than-or-equal-to 0.05), neighborhood farmer controls (101.1 +/- 29.4 L; P less-than-or-equal-to 0.005), and blue collar controls (106.4 +/- 30.4 L; P less-than-or-equal-to 0.05). Swine confinement cases also had an enhanced airway response to inhaled methacholine and had thickening of the epithelial basement membrane of the lobar bronchi. No parenchymal injury was observed in the swine confinement cases. Conclusions: Our findings suggest that swine confinement workers who have work-related respiratory symptoms are at risk for airway, but not parenchymal, lung injury, and that spirometry may not accurately reflect the extent of airway injury.	UNIV IOWA, COLL MED, DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	SCHWARTZ, DA (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, DIV PULM DIS, IOWA CITY, IA 52242 USA.				NHLBI NIH HHS [HL-37121] Funding Source: Medline; NIEHS NIH HHS [ES-00203] Funding Source: Medline; NIOSH CDC HHS [OH-00093] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [K01OH000093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1080/15298668791385507; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CASTELLAN RM, 1984, ANN INTERN MED, V101, P157, DOI 10.7326/0003-4819-101-2-157; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DONHAM K, 1989, BRIT J IND MED, V46, P31; DONHAM KJ, 1984, AM J IND MED, V5, P367, DOI 10.1002/ajim.4700050505; DONHAM KJ, 1984, ARCH ENVIRON HEALTH, V39, P96, DOI 10.1080/00039896.1984.10545842; DONHAM KJ, 1986, AM IND HYG ASSOC J, V47, P404, DOI 10.1080/15298668691389955; DONHAM KJ, 1986, AM J IND MED, V10, P294, DOI 10.1002/ajim.4700100318; DOSMAN JA, 1988, J OCCUP ENVIRON MED, V30, P715; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904; HOLNESS DL, 1987, AM J IND MED, V11, P571, DOI 10.1002/ajim.4700110509; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; ROCHE WR, 1989, LANCET, V1, P520; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; SCHWARTZ DA, 1987, OCCUP MED, V2, P297; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; VANGANSE WF, 1972, AM REV RESPIR DIS, V105, P30; VONESSEN SG, 1988, AM REV RESPIR DIS, V138, P921, DOI 10.1164/ajrccm/138.4.921; ZAVALA D, 1983, RECENT ADV RESPIRATO, V3, P21	32	61	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					630	635		10.7326/0003-4819-116-8-630	http://dx.doi.org/10.7326/0003-4819-116-8-630			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546862				2022-12-24	WOS:A1992HN84400004
J	PALAZZO, RE; VAISBERG, E; COLE, RW; RIEDER, CL				PALAZZO, RE; VAISBERG, E; COLE, RW; RIEDER, CL			CENTRIOLE DUPLICATION IN LYSATES OF SPISULA-SOLIDISSIMA OOCYTES	SCIENCE			English	Article							SURF CLAM; CELL-CYCLE; EGGS; CENTROSOMES; REPRODUCTION	A cell-free system has been developed that executes centriole duplication. Surf clam (Spisula solidissima) oocytes, arrested at late prophase of meiosis I, do not contain centrioles, centrosomes, or asters. Serial section high-voltage electron microscopy (HVEM) of asters and spindles isolated from potassium chloride-activated oocytes indicates that within 4 minutes oocytes assemble a single centriole that is duplicated by 15 minutes when assembly of the first meiotic spindle is complete. A mixture of lysates from unactivated oocytes and potassium chloride-activated oocytes induces centriole formation and duplication. Astral microtubule content in these lysate mixtures increases with time.	ACAD SCI USSR,PROT RES INST,MOSCOW V-71,USSR; WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	PALAZZO, RE (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01219] Funding Source: Medline; PHS HHS [R01-40198, R01-43264] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN RD, 1953, BIOL BULL, V105, P213, DOI 10.2307/1538639; Bornens M., 1984, MEMBRANE STRUCTURE F, P99; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; DIRKSEN ER, 1991, BIOL CELL, V72, P31, DOI 10.1016/0248-4900(91)90075-X; Fulton C, 1971, ORIGIN CONTINUITY CE, P170; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; KLOTZ C, 1990, J CELL BIOL, V110, P405, DOI 10.1083/jcb.110.2.405; KURIYAMA R, 1986, DEV BIOL, V114, P151, DOI 10.1016/0012-1606(86)90391-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGO F J, 1970, Journal of Ultrastructure Research, V33, P495, DOI 10.1016/S0022-5320(70)90177-2; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; PALAZZO RE, 1988, ZOOL SCI, V5, P603; REBHUN LI, 1959, BIOL BULL, V117, P518, DOI 10.2307/1538865; RIEDER CL, 1985, J ELECTRON MICR TECH, V2, P11, DOI 10.1002/jemt.1060020103; SACHS MI, 1971, J ULTRA MOL STRUCT R, V36, P806, DOI 10.1016/S0022-5320(71)90032-3; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1990, ADV CELL BIOL, V3, P221; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; WEISENBERG RC, 1975, J CELL BIOL, V64, P146, DOI 10.1083/jcb.64.1.146; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN	22	89	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					219	221		10.1126/science.1566068	http://dx.doi.org/10.1126/science.1566068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566068				2022-12-24	WOS:A1992HM89600028
J	SIDRANSKY, D; TOKINO, T; HAMILTON, SR; KINZLER, KW; LEVIN, B; FROST, P; VOGELSTEIN, B				SIDRANSKY, D; TOKINO, T; HAMILTON, SR; KINZLER, KW; LEVIN, B; FROST, P; VOGELSTEIN, B			IDENTIFICATION OF RAS ONCOGENE MUTATIONS IN THE STOOL OF PATIENTS WITH CURABLE COLORECTAL TUMORS	SCIENCE			English	Article							FLOW-CYTOMETRIC DNA; RECTAL ADENOCARCINOMAS; NATURAL-HISTORY; GENE-MUTATIONS; CANCER; COLON; TUMORIGENESIS; PROLIFERATION; PREVENTION; EVOLUTION	Colorectal (CR) tumors are usually curable if detected before metastasis. Because genetic alterations are associated with the development of these tumors, mutant genes may be found in the stool of individuals with CR neoplasms. The stools of nine patients whose tumors contained mutations of K-ras were analyzed. In eight of the nine cases, the ras mutations were detectable in DNA purified from the stool. These patients included those with benign and malignant neoplasms from proximal and distal colonic epithelium. Thus, colorectal tumors can be detected by a noninvasive method based on the molecular pathogenesis of the disease.	JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21231; MD ANDERSON HOSP,DEPT CELL BIOL,HOUSTON,TX 77054; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,GASTROINTESTINAL ONCOL SECT,HOUSTON,TX 77030; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Tokino, Takashi/AAI-9887-2021		NCI NIH HHS [CA35494, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, R01CA035494, R37CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BEART RW, 1991, TXB CLIN ONCOLOGY, P213; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; COOPER JN, 1991, NEW ENGL J MED, V326, P136; COPELAND EM, 1968, AM J SURG, V116, P875, DOI 10.1016/0002-9610(68)90458-3; DECOSSE JJ, 1991, NEW ENGL J MED, V326, P134; DELATTRE P, 1989, LANCET, V335, P353; DUKES CE, 1958, BRIT J CANCER, V12, P309, DOI 10.1038/bjc.1958.37; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EISENBERG B, 1982, CANCER, V49, P1131, DOI 10.1002/1097-0142(19820315)49:6<1131::AID-CNCR2820490611>3.0.CO;2-T; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRINNELL RS, 1950, ANN SURG, V2, P494; HAMMARBERG C, 1986, ACTA ONCOL, V25, P45, DOI 10.3109/02841868609136377; KNOERNSCHILD H E, 1963, Surg Forum, V14, P137; LIPKIN M, 1988, CANCER RES, V48, P235; LIPKIN M, 1963, J CLIN INVEST, V42, P767, DOI 10.1172/JCI104769; MACDONALD WC, 1964, GASTROENTEROLOGY, V46, P405; MEHL LE, 1991, J SURG ONCOL, V47, P243, DOI 10.1002/jso.2930470409; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MORSON BC, 1974, CANCER, V34, P845, DOI 10.1002/1097-0142(197409)34:3+<845::AID-CNCR2820340710>3.0.CO;2-H; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; QUIRKE P, 1987, J PATHOL, V151, P285, DOI 10.1002/path.1711510408; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICH T, 1983, CANCER-AM CANCER SOC, V52, P1317, DOI 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6; Rosenberg SA., CANC PRINCIPLES PRAC, Ved, P895; SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TRIBUKAIT B, 1983, ACTA PATH MICRO IM A, V91, P89; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELIN S, 1963, AMER J ROENTGENOL RA, V90, P673; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	46	668	749	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					102	105		10.1126/science.1566048	http://dx.doi.org/10.1126/science.1566048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566048				2022-12-24	WOS:A1992HL82200037
J	JURIVICH, DA; SISTONEN, L; KROES, RA; MORIMOTO, RI				JURIVICH, DA; SISTONEN, L; KROES, RA; MORIMOTO, RI			EFFECT OF SODIUM-SALICYLATE ON THE HUMAN HEAT-SHOCK RESPONSE	SCIENCE			English	Article							AMINO-ACID-ANALOGS; ASPIRIN-LIKE DRUGS; DNA-BINDING; TRANSCRIPTION FACTOR; HUMAN-CELLS; PROTEIN; SEQUENCE; INHIBITION; EXPRESSION; ACTIVATION	Sodium salicylate, an anti-inflammatory agent, was examined for its effects on the heat shock response in cultured human cells. Salicylate activation of DNA binding by the heat shock transcription factor (HSF) was comparable to activation attained during heat shock. However, sodium salicylate did not induce heat shock gene transcription even though the HSF was bound in vivo to the heat shock elements upstream of the heat shock protein 70 (Hsp 70) gene. These results reveal that activation of the heat shock transcriptional response is a multistep process. Modulation of extracellular pH augments sensitivity to salicylate-induced activation of HSF.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT MED,EVANSTON,IL 60208	Northwestern University; Northwestern University			Kroes, Roger A/B-7620-2009	Sistonen, Lea/0000-0003-1341-2867	NIA NIH HHS [AG00509] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ADRIAN C, 1957, J PHARMACOL EXP THER, V120, P540; AMICI C, UNPUB; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGGS GA, 1987, P NATL ACAD SCI USA, V84, P1417, DOI 10.1073/pnas.84.5.1417; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; JAMES MJ, 1990, J RHEUMATOL, V17, P579; JAMES MJ, 1990, J RHEUMATOL, V17, P529; JURIVICH D, UNPUB; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KUBO T, 1985, ARTHRITIS RHEUM, V28, P1140, DOI 10.1002/art.1780281010; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P21; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OHNO K, 1988, J BIOL CHEM, V263, P19764; Ritossa F, 1963, DROSOPHILA INFORMATI, V37, P122, DOI 10.1016/0014-4827(64)90147-8; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SARGENT CA, 1989, P NATL ACAD SCI USA, V86, P1968, DOI 10.1073/pnas.86.6.1968; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WATOWICH SS, 1990, THESIS NW U EVANSTON; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	42	343	357	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1243	1245		10.1126/science.1546322	http://dx.doi.org/10.1126/science.1546322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546322				2022-12-24	WOS:A1992HG67700039
J	CURTIN, JJ; SAMPSON, MA				CURTIN, JJ; SAMPSON, MA			NEED FOR OPEN ACCESS NON-SCREENING MAMMOGRAPHY IN A HOSPITAL WITH A SPECIALIST BREAST CLINIC SERVICE	BRITISH MEDICAL JOURNAL			English	Article							ASPIRATION CYTOLOGY; FALSE ALARMS; CANCER; DIAGNOSIS; ACCURACY; WOMEN	Objective - Assessment of open access non-screening mammography in a hospital with a breast clinic. Design - Retrospective analysis of patients sent for first mammogram to our open access service by general practitioners and breast clinic in the year April 1989 to March 1990. Setting - District general hospital serving 200 000 people before the introduction of breast screening. Subjects - 361 symptomatic women referred directly by general practitioners and 226 women referred by the breast clinic for first, non-screening mammograms. Main outcome measures - Radiographic reports on all patients. Final diagnosis in patients reported as having possible or probable neoplasm. Results - Of the women referred directly by general practitioners one (0.2%) was reported as showing probable malignancy (later histologically confirmed) and 15 (4%) as showing possible malignancy (on follow up none had proved malignancy). Of the women referred by the breast clinic 38 (17%) were reported as showing probable malignancy (all had confirmed carcinomas) and 35 (15%) as showing possible malignancy (19 (54%) had proved malignancy). 18 of the proved malignancies were in women under 50 years old, 26 were in women over 64 years, and 14 were in women of screening age. 54 (93%) of the 58 patients with proved breast cancer and an abnormal mammogram had a discrete breast lump. Conclusions - General practitioners accurately divided women into low and high risk groups, resulting in few abnormalities being detected in patients referred directly for mammography. This suggests that an open access non-screening mammography service for general practitioners is unnecessary in an area with a specialist breast clinic. The large proportion of cancers in women outside of screening age emphasises the need for such clinics.			CURTIN, JJ (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,DEPT RADIOL,HARROW HA1 3UJ,MIDDX,ENGLAND.			Sampson, Madeleine/0000-0003-1265-5103				ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; BAINES CJ, 1986, RADIOLOGY, V160, P295, DOI 10.1148/radiology.160.2.3523590; BANERJEE AK, 1988, LANCET, V2, P336; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; DEVITT JE, 1989, LANCET, V2, P1257; DIXON JM, 1983, LANCET, V2, P564; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; EDEIKEN S, 1988, CANCER, V61, P263, DOI 10.1002/1097-0142(19880115)61:2<263::AID-CNCR2820610211>3.0.CO;2-Z; EGELI RA, 1979, CANCER-AM CANCER SOC, V43, P878, DOI 10.1002/1097-0142(197903)43:3<878::AID-CNCR2820430315>3.0.CO;2-K; GARSTIN WIH, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90125-O; HANSELL DM, 1988, CLIN RADIOL, V39, P150; MANN BD, 1983, ARCH SURG-CHICAGO, V118, P23; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; SMALLWOOD J, 1985, BRIT J SURG, V72, P841, DOI 10.1002/bjs.1800721022; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; WALLIS MG, 1991, CLIN RADIOL, V44, P13, DOI 10.1016/S0009-9260(05)80218-1; YELLAND A, 1991, BRIT MED J, V302, P618, DOI 10.1136/bmj.302.6777.618; 1988, LANCET, V2, P411	18	10	10	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					549	551		10.1136/bmj.304.6826.549	http://dx.doi.org/10.1136/bmj.304.6826.549			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559063	Green Published, Bronze			2022-12-24	WOS:A1992HG59900027
J	FRANCKLYN, C; SHI, JP; SCHIMMEL, P				FRANCKLYN, C; SHI, JP; SCHIMMEL, P			OVERLAPPING NUCLEOTIDE DETERMINANTS FOR SPECIFIC AMINOACYLATION OF RNA MICROHELICES	SCIENCE			English	Article							MOLECULAR RECOGNITION; SYNTHETASE; IDENTITY; PARAMETERS; PAIR; END; POLYMERASE; GENES; SITE; BASE	A seven-base pair microhelix that recapitulates a glycine transfer RNA (tRNA) acceptor helix can be specifically aminoacylated with glycine. A single base pair and the single-stranded discriminator base near the attachment site are essential for aminoacylation. These nucleotide sequence elements, and those in microhelices that can be charged with histidine and alanine, occur in the same positions and therefore overlap. Studies on a systematic set of sequence variants showed that no microhelix could be charged with more than one amino acid. Also, none of the three cognate aminoacyl-tRNA synthetases (aaRSs) gave a detectable amount of aminoacylation of the CCA trinucleotide that is common to the 3' ends of all tRNAs, showing that the specific acceptor stem nucleotide bases confer aminoacylation. An analysis of the relative contributions of these microhelices to overall tRNA recognition indicates that their interaction with aaRSs constitutes a substantial part of the recognition of the whole tRNAs.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					PHS HHS [15539] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARBON J, 1974, J MOL BIOL, V85, P371, DOI 10.1016/0022-2836(74)90439-2; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; FERSHT A, 1977, ENZYME STRUCTURE MEC, P33; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMES GC, 1982, ENZYME CATALYSIS REG, P76; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROBERTS JW, 1974, NATURE, V250, P412, DOI 10.1038/250412a0; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1989, BIOCHEMISTRY-US, V29, P361; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; TOTH MJ, 1990, J BIOL CHEM, V265, P1005	38	130	131	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1992	255	5048					1121	1125		10.1126/science.1546312	http://dx.doi.org/10.1126/science.1546312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546312				2022-12-24	WOS:A1992HF63200039
J	JONES, KP; BAIN, DJG; MIDDLETON, M; MULLEE, MA				JONES, KP; BAIN, DJG; MIDDLETON, M; MULLEE, MA			CORRELATES OF ASTHMA MORBIDITY IN PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							PRESSURIZED AEROSOL INHALERS; PEAK EXPIRATORY FLOW; GENERAL-PRACTICE; INTERNATIONAL TRENDS; MANAGEMENT; MORTALITY; PATIENT; PREVALENCE; EDUCATION; CHILDREN	Objectives - To explore the morbidity of patients diagnosed as asthmatic in general practice, to examine the determinants of this morbidity, and to derive a simple morbidity screening tool for use in primary care. Design - Patient interviews, lung function measurements, and data extraction from general practice case notes. Subjects - 300 asthmatic patients aged 5 to 65 years randomly selected from the repeat prescribing registers of three general practices in the Southampton area. Main outcome measures - Reported morbidity using a calculated index based on three questions (Are you in a wheezy or asthmatic condition at least once per week; Have you had time off work or school in the past year because of your asthma; Do you suffer from attacks of wheezing during the night?); mean forced expiratory volume in one second and mean peak expiratory flow (over a seven day period); diurnal variation in peak flow; and the relation of the morbidity index to lung function. Results - Mean forced expiratory volume in one second was 67% predicted (SD 18.4), mean peak expiratory flow was 80% predicted (SD 18.9), and mean diurnal variation was 10% (SD 7.7). 76 subjects were classified as having low morbidity, 95 medium, and 125 high. The morbidity index was significantly associated with forced expiratory volume in one second, mean peak expiratory flow rate, and diurnal variation (p < 0.05); it was not significantly associated with inhaler technique or use of prophylaxis. Conclusions - There was a large burden of persisting morbidity across all ages of patients diagnosed as asthmatic in the three well resourced practices studied. The use of the morbidity index may help to target the asthmatic patients needing more attention by concentrating on those reporting medium to high morbidity.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	JONES, KP (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,FAC MED,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6SY,ENGLAND.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BOSANQUET N, 1988, BRIT MED J, V296, P1576, DOI 10.1136/bmj.296.6636.1576; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; EVANS R, 1987, CHEST S, V91, P65; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; GONAWARDENA KA, 1987, THORAX, V42, P689; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HILTON S, 1982, J ROY SOC MED, V75, P625; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; HILTON S, 1986, LANCET, V1, P26; HOLGATE ST, 1988, Q J MED, V66, P5; HORN CR, 1989, RESP MED, V83, P71, DOI 10.1016/S0954-6111(89)80063-0; HORSLEY MG, 1988, J CLIN PHARM THER, V13, P139, DOI 10.1111/j.1365-2710.1988.tb00170.x; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JENKINSON D, 1988, BRIT MED J, V297, P267, DOI 10.1136/bmj.297.6643.267; JONES K, 1989, J ROY COLL GEN PRACT, V39, P254; Jones K, 1989, UPDATE, V38, P1399; JONES KP, 1990, BRIT MED J, V300, P1629, DOI 10.1136/bmj.300.6740.1629; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NEVILLE R, 1990, PRACTITIONER, V234, P417; NORUSIS MJ, 1983, SPSSX INTRO STATISTI; NORUSIS MJ, 1989, SPSS GUIDE DATA ANAL; PEDERSEN S, 1986, ALLERGY, V41, P118, DOI 10.1111/j.1398-9995.1986.tb00287.x; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; 1989, LANCET, V2, P199; 1982, BMJ, V285, P1251	36	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					361	364		10.1136/bmj.304.6823.361	http://dx.doi.org/10.1136/bmj.304.6823.361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540736	Bronze, Green Published			2022-12-24	WOS:A1992HD38700027
J	BROWN, DA; ROSE, JK				BROWN, DA; ROSE, JK			SORTING OF GPI-ANCHORED PROTEINS TO GLYCOLIPID-ENRICHED MEMBRANE SUBDOMAINS DURING TRANSPORT TO THE APICAL CELL-SURFACE	CELL			English	Article							POLARIZED EPITHELIAL-CELLS; VESICULAR STOMATITIS-VIRUS; GLYCOSYL-PHOSPHATIDYLINOSITOL; PLASMA-MEMBRANE; TRYPANOSOMA-BRUCEI; MDCK CELLS; INTRACELLULAR-TRANSPORT; CHOLERA-TOXIN; ORGANIZATION; GLYCOPROTEINS	We show that a protein with a glycosylphosphatidyl inositol (GPI) anchor can be recovered from lysates of epithelial cells in a low density, detergent-insoluble form. Under these conditions, the protein is associated with detergent-resistant sheets and vesicles that contain other GPI-anchored proteins and are enriched in glycosphingolipids, but do not contain a basolateral marker protein. The protein is recovered in this complex only after it has been transported to the Golgi complex, suggesting that protein-sphingolipid microdomains form in the Golgi apparatus and plasma membrane and supporting the model proposed by Simons and colleagues for sorting of certain membrane proteins to the apical surface after intracellular association with glycosphingolipids.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University; Yale University					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; PHS HHS [A124345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APGAR JR, 1986, J CELL BIOL, V103, P351, DOI 10.1083/jcb.103.2.351; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BERGER J, 1987, P NATL ACAD SCI USA, V84, P4885, DOI 10.1073/pnas.84.14.4885; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; DOERING TL, 1990, J BIOL CHEM, V265, P611; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LETARTEMUIRHEAD M, 1974, BIOCHEM J, V143, P51, DOI 10.1042/bj1430051; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MACALA LJ, 1983, J LIPID RES, V24, P1243; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MENON AK, 1988, J BIOL CHEM, V263, P1970; MESCHER MF, 1981, NATURE, V289, P139, DOI 10.1038/289139a0; MESCHER MF, 1986, ADV EXP MED, V184, P387; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; NICHOLS GE, 1988, J LIPID RES, V29, P1205; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1982, CELL, V30, P753, DOI 10.1016/0092-8674(82)90280-X; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; STREULI CH, 1981, EXP CELL RES, V136, P247, DOI 10.1016/0014-4827(81)90002-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THIELE HG, 1986, IMMUNOLOGY, V59, P195; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VITETTA ES, 1973, EUR J IMMUNOL, V3, P446, DOI 10.1002/eji.1830030714; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	54	2575	2628	3	157	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					533	544		10.1016/0092-8674(92)90189-J	http://dx.doi.org/10.1016/0092-8674(92)90189-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1531449				2022-12-24	WOS:A1992HD39800013
J	DEVOS, AM; ULTSCH, M; KOSSIAKOFF, AA				DEVOS, AM; ULTSCH, M; KOSSIAKOFF, AA			HUMAN GROWTH-HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR - CRYSTAL-STRUCTURE OF THE COMPLEX	SCIENCE			English	Article							X-RAY-DIFFRACTION; MACROMOLECULAR CRYSTALLOGRAPHY; SCANNING MUTAGENESIS; PROLACTIN RECEPTOR; HUMAN CD4; BINDING; SUPERFAMILY; RESOLUTION; FRAGMENT; DETECTOR	Binding of human growth hormone (hGH) to its receptor is required for regulation of normal human growth and development. Examination of the 2.8 angstrom crystal structure of the complex between the hormone and the extracellular domain of its receptor (hGHbp) showed that the complex consists of one molecule of growth hormone per two molecules of receptor. The hormone is a four-helix bundle with an unusual topology. The binding protein contains two distinct domains, similar in some respects to immunoglobulin domains. The relative orientation of these domains differs from that found between constant and variable domains in immunoglobulin Fab fragments. Both hGHbp domains contribute residues that participate in hGH binding. In the complex both receptors donate essentially the same residues to interact with the hormone, even though the two binding sites on hGH have no structural similarity. Generally, the hormone-receptor interfaces match those identified by previous mutational analyses. In addition to the hormone-receptor interfaces, there is also a substantial contact surface between the carboxyl-terminal domains of the receptors. The relative extents of the contact areas support a sequential mechanism for dimerization that may be crucial for signal transduction.			DEVOS, AM (corresponding author), GENENTECH INC, DEPT PROT ENGN, 460 POINT SAN BRUNO BLVD, SAN FRANCISCO, CA 94080 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEWLEY TA, 1984, ARCH BIOCHEM BIOPHYS, V233, P219, DOI 10.1016/0003-9861(84)90620-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLARK RD, UNPUB; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1990, J BIOL CHEM, V265, P3111; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MULKERRIN MG, UNPUB; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; STEIGEMANN W, 1974, THESIS TU MUNCHEN; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULTSCH M, IN PRESS J MOL BIOL; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	2072	2635	1	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1992	255	5042					306	312		10.1126/science.1549776	http://dx.doi.org/10.1126/science.1549776			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549776				2022-12-24	WOS:A1992GZ69500035
J	MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC				MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC			THE 3-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROM RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC	CELL			English	Article							I HISTOCOMPATIBILITY ANTIGENS; SELF-PEPTIDES; HLA-A; ALPHA-3 DOMAIN; ANKYLOSING-SPONDYLITIS; LYMPHOCYTES-T; MOLECULES; RECOGNITION; PROTEIN; SITE	Cell surface complexes of class I MHC molecules and bound peptide antigens serve as specific recognition elements controlling the cytotoxic immune response. The 2.1 angstrom structure of the human class I MHC molecule HLA-B27 provides a detailed composite image of a co-crystallized collection of HLA-B27-bound peptides, indicating that they share a common main-chain structure and length. It also permits direct visualization of the conservation of arginine as an "anchor" side chain at the second peptide position, which is bound in a potentially HLA-B27-specific pocket and may therefore have a role in the association of HLA-B27 with several diseases. Tight peptide binding to class I MHC molecules appears to result from the extensive contacts found at the ends of the cleft between peptide main-chain atoms and conserved MHC side chains, which also involve the peptide in stabilizing the three-dimensional fold of HLA-B27. The concentration of binding interactions at the peptide termini permits extensive sequence (and probably some length) variability in the center of the peptide, where it is exposed for T cell recognition.	HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute	MADDEN, DR (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLU M, 1990, THESIS HARVARD U CAM; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, X PLOR; BUXTON SE, 1992, J EXP MED, V175, P809, DOI 10.1084/jem.175.3.809; CALVO V, 1990, J IMMUNOL, V144, P4038; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOO SY, 1991, J IMMUNOL, V147, P174; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DECASTRO JAL, 1984, METHOD ENZYMOL, V108, P582; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EZQUERRA A, 1985, BIOCHEMISTRY-US, V24, P1733, DOI 10.1021/bi00328a025; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FREMONT DH, 1992, IN PRESS SCIENCE; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GORGA JC, 1992, PROTEINS, V12, P87, DOI 10.1002/prot.340120110; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HEDRICK PW, 1991, P NATL ACAD SCI USA, V88, P5897, DOI 10.1073/pnas.88.13.5897; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERMANS J, 1974, ACTA CRYSTALLOGR A, VA 30, P730, DOI 10.1107/S056773947400180X; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; HUET SH, 1990, INT IMMUNOL, V4, P311; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Johnson CK, 1965, 3794 ONRL; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KHAN MA, 1987, ANKYLOSING SPONDYLIT, V1, P23; KRISHNA S, 1992, NATURE, V357, P164, DOI 10.1038/357164a0; LATRON F, 1992, IN PRESS SCIENCE; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOPEZ D, 1992, J IMMUNOL, V148, P996; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MATSUMURA M, 1992, IN PRESS SCIENCE; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULZ GE, 1979, PRINCIPALS PROTEIN S, P3; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VILLADANGOS JA, 1992, J IMMUNOL, V149, P505; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZHANG W, 1992, IN PRESS P NATL ACAD	75	643	663	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1035	1048		10.1016/0092-8674(92)90252-8	http://dx.doi.org/10.1016/0092-8674(92)90252-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525820				2022-12-24	WOS:A1992JN78100017
J	FAHS, MC; MANDELBLATT, J; SCHECHTER, C; MULLER, C				FAHS, MC; MANDELBLATT, J; SCHECHTER, C; MULLER, C			COST-EFFECTIVENESS OF CERVICAL-CANCER SCREENING FOR THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						CERVIX NEOPLASMS; COST-BENEFIT ANALYSIS; VAGINAL SMEARS; MASS SCREENING; MEDICARE	PREVENTIVE HEALTH-CARE; PNEUMOCOCCAL IMMUNIZATION; NATIONAL TRENDS; FOLLOW-UP; WOMEN; CYTOLOGY; SMEARS; VACCINATION; MAMMOGRAPHY; PHYSICIANS	Objective: To analyze the costs and benefits of alternate cervical cancer screening schedules among elderly women. Setting: Population-based screening programs. Design: A Markov model predicts the outcomes of periodic screening, diagnosis, and treatment for cervical cancer among women from 65 to 109 years of age. Patients: A hypothetical cohort of one million 65-year-old women, representative of the U.S. population. Measurements: The costs and yields of screening. Results: Triennial screening reduced mortality from cervical cancer among the elderly by 74% at a cost of $2254 per year of life saved. Annual screening increased costs to $7345 per year of life saved; less frequent schedules yielded lower costs but decreased savings in life. These results were most sensitive to the quality of the Papanicolaou smear and the characteristics of the women using the benefit. If the sensitivity of the Papanicolaou smear was reduced from a baseline estimate of 75% to 50% and the specificity was decreased to 87% from 95%, the cost effectiveness ratio increased by nearly $7000 per year of life saved. If triennial screening is targeted to women who have not had regular screening, the program will save money as well as years of life; however, screening women who have been screened regularly is considerably less efficient, increasing costs to $33 572 per year of life saved. Conclusion: The success of the new Medicare benefit depends substantially on physicians assuring that their elderly patients, particularly women without regular prior screening, obtain high quality Papanicolaou smears. The data also show that after a woman 65 years of age or older has a history of regular negative smears, screening is inefficient and can cease.	MEM SLOAN KETTERING CANC CTR, DEPT EPIDEMIOL & BIOSTAT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	FAHS, MC (corresponding author), MT SINAI MED CTR, DEPT COMMUNITY MED, BOX 1043, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.				PHS HHS [J3-4130.0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAQUET C, 1987, MILBANK Q, V65, P322, DOI 10.2307/3349994; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BEILBY JOW, 1982, OBSTET GYNECOL, V60, P46; BERGET A, 1977, DAN MED BULL, V24, P26; BOYES DA, 1982, CLIN INVEST MED, V5, P1; CAMPION MJ, 1986, LANCET, V2, P237; CELENTANO DD, 1989, PREV MED, V18, P411, DOI 10.1016/0091-7435(89)90001-7; CELENTANO DD, 1982, PREV MED, V11, P454, DOI 10.1016/0091-7435(82)90048-2; CHRISTOPHERSON WM, 1969, CANCER-AM CANCER SOC, V24, P64, DOI 10.1002/1097-0142(196907)24:1<64::AID-CNCR2820240108>3.0.CO;2-Y; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; COPPLESON LW, 1975, AM J OBSTET GYNECOL, V122, P127, DOI 10.1016/0002-9378(75)90627-4; CREASMAN WT, 1981, GYNECOL ONCOL, V12, pS306, DOI 10.1016/0090-8258(81)90084-6; DAVIS JR, 1981, ACTA CYTOL, V25, P533; DICKINSON L, 1972, MAYO CLIN PROC, V47, P534; DUNN JE, 1959, J NATL CANCER I, V23, P507; DUNN JE, 1981, AM J OBSTET GYNECOL, V139, P868, DOI 10.1016/0002-9378(81)90951-0; EDDY D, 1987, BREAST CANCER SCREEN; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FAHS MC, 1991, WOMEN POPULATION AGI, P1; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FIDLER H. K., 1968, J OBSTET GYNAECOL BRIT COMMONW, V75, P392; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; FOX CH, 1967, AM J OBSTET GYNECOL, V99, P960, DOI 10.1016/0002-9378(67)90251-7; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; GAY JD, 1985, ACTA CYTOL, V29, P1043; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; HARLAN LC, 1991, AM J PUBLIC HEALTH, V81, P885, DOI 10.2105/AJPH.81.7.885; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HUSAIN OAN, 1974, J CLIN PATHOL, V27, P935, DOI 10.1136/jcp.27.12.935; HUSAIN OAN, 1984, BRIT MED J, V289, P50, DOI 10.1136/bmj.289.6436.50; KASHGARI.M, 1970, AM J EPIDEMIOL, V92, P211, DOI 10.1093/oxfordjournals.aje.a121201; KINLEN LJ, 1978, LANCET, V2, P463; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; MACCORMAC L, 1988, MED J AUSTRALIA, V149, P530, DOI 10.5694/j.1326-5377.1988.tb120761.x; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MAMON JA, 1990, PREV MED, V19, P363, DOI 10.1016/0091-7435(90)90036-J; MANDELBLATT J, 1991, AM J OBSTET GYNECOL, V164, P644, DOI 10.1016/S0002-9378(11)80040-2; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; MCPHEE SJ, 1987, AM J PUBLIC HEALTH, V77, P780, DOI 10.2105/AJPH.77.7.780; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MILLER AB, 1991, CAN MED ASSOC J, V145, P1301; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; MULLER C, 1990, COSTS EFFECTIVENESS; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NELSON JH, 1989, CA-CANCER J CLIN, V39, P157, DOI 10.3322/canjclin.39.3.157; PETERSEN O, 1956, AM J OBSTET GYNECOL, V72, P1063, DOI 10.1016/0002-9378(56)90072-2; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; RIOTTON G, 1986, COMMUNICATION   0306; ROBERTSON JH, 1988, RISK CERVICAL CANCER; RYLANDER E, 1977, ACTA OBSTET GYN SCAN, V56, P115, DOI 10.3109/00016347709158352; SCHWARTZ B, 1990, JAMA-J AM MED ASSOC, V264, P1154; SILVERBERG E, 1984, CA-CANCER J CLIN, V34, P7; SPRIGGS AI, 1977, BRIT MED J, V1, P1516; STAUB JJ, 1976, NEW ENGL J MED, V294, P223; STENKVIST B, 1984, JAMA-J AM MED ASSOC, V252, P1423, DOI 10.1001/jama.252.11.1423; STERN E, 1959, CANCER, V12, P933, DOI 10.1002/1097-0142(195909/10)12:5<933::AID-CNCR2820120513>3.0.CO;2-2; Stern E, 1969, Obstet Gynecol Surv, V24, P711, DOI 10.1097/00006254-196907001-00005; WEISMAN CS, 1989, PUBLIC HEALTH REP, V104, P209; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1987, NATIONAL HOSPITAL DI; 1989, GUIDE CLIN PREVENTIV, P26; 1990, JAMA-J AM MED ASSOC, V264, P54; 1985, CHEM ABSTR, V35, P197; 1976, VITAL STATISTICS US, V2; 1989, WASHINGTON REPORT, V7, P1; 1985, CANCER INCIDENCE 197; 1976, CAN MED ASSOC J, V114, P1003; 1980, CHEM ABSTR, V30, P215; 1988, PRESS RELEASE; 1981, SO MED J, V74, P87; 1984, VITAL STATISTICS U A, V2; 1991, NCI912789 NIH DIV CA; 1988, 2ND P C STAT ART QUA	77	110	111	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					520	527		10.7326/0003-4819-117-6-520	http://dx.doi.org/10.7326/0003-4819-117-6-520			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503355				2022-12-24	WOS:A1992JN25700012
J	VOGELMANN, AM; ACKERMAN, TP; TURCO, RP				VOGELMANN, AM; ACKERMAN, TP; TURCO, RP			ENHANCEMENTS IN BIOLOGICALLY EFFECTIVE ULTRAVIOLET-RADIATION FOLLOWING VOLCANIC-ERUPTIONS	NATURE			English	Article							HETEROGENEOUS CHEMISTRY; PALMER-STATION; EL-CHICHON; OZONE; ANTARCTICA; SKIN	AEROSOLS injected into the stratosphere by large volcanic eruptions may induce ozone destruction through processes including heterogeneous chemical reactions. The effect of ozone reductions on surface ultraviolet irradiation is not obvious, however, because aerosols also increase the reflection of sunlight. Here we use a radiative transfer model to estimate the changes in biologically effective ultraviolet radiation (UV-BE) at the Earth's surface produced by the El Chichon (1982) and Mount Pinatubo (1991) eruptions. We find that in both cases surface UV-BE intensity can increase because the effect of ozone depletion outweighs the increased scattering.	UNIV CALIF LOS ANGELES,DEPT ATMOSPHER SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	VOGELMANN, AM (corresponding author), PENN STATE UNIV,DEPT METEOROL,UNIV PK,PA 16802, USA.		Vogelmann, Andrew M/M-8779-2014	Vogelmann, Andrew M/0000-0003-1918-5423				ACKERMAN TP, 1976, J APPL METEOROL, V15, P28, DOI 10.1175/1520-0450(1976)015<0028:IRTIPA>2.0.CO;2; ANGELL JK, 1985, MON WEATHER REV, V113, P641, DOI 10.1175/1520-0493(1985)113<0641:GBASEF>2.0.CO;2; ANGELL JK, 1988, J APPL METEOROL, V27, P91, DOI 10.1175/1520-0450(1988)027<0091:AUTOTV>2.0.CO;2; BERGER DS, 1976, PHOTOCHEM PHOTOBIOL, V24, P587, DOI 10.1111/j.1751-1097.1976.tb06877.x; BLUMTHALER M, 1988, PHOTOCHEM PHOTOBIOL, V48, P85, DOI 10.1111/j.1751-1097.1988.tb02790.x; BLUTH GJS, 1992, GEOPHYS RES LETT, V19, P151, DOI 10.1029/91GL02792; BOJKOV RD, 1987, MON WEATHER REV, V115, P2187, DOI 10.1175/1520-0493(1987)115<2187:TAAIOD>2.0.CO;2; BRASSEUR GP, 1990, NATURE, V348, P626, DOI 10.1038/348626a0; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; CHANDRA S, 1991, GEOPHYS RES LETT, V18, P2277, DOI 10.1029/91GL02779; COOHILL TP, 1991, IMPACT GLOBAL CLIMAT; CUZZI JN, 1982, J ATMOS SCI, V39, P917, DOI 10.1175/1520-0469(1982)039<0917:TDFSAF>2.0.CO;2; FREDERICK JE, 1988, PHOTOCHEM PHOTOBIOL, V47, P571, DOI 10.1111/j.1751-1097.1988.tb08846.x; Goody R., 1964, ATMOSPHERIC RAD, V1; HOFMANN DJ, 1989, J GEOPHYS RES-ATMOS, V94, P5029, DOI 10.1029/JD094iD04p05029; HOFMANN DJ, 1987, REV GEOPHYS, V25, P743, DOI 10.1029/RG025i004p00743; Hunter J. R., 1982, ROLE SOLAR ULTRAVIOL, P459; LUBIN D, 1989, GEOPHYS RES LETT, V16, P783, DOI 10.1029/GL016i008p00783; LUBIN D, 1990, J GEOPHYS RES-ATMOS, V95, P13883, DOI 10.1029/JD095iD09p13883; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P37, DOI 10.1029/91GL02954; McCormick M. P., 1984, GEOFISICA INT, V23, P187; MICHELANGELI DV, 1989, J GEOPHYS RES-ATMOS, V94, P18429, DOI 10.1029/JD094iD15p18429; MICHELANGELI DV, 1992, J GEOPHYS RES-ATMOS, V97, P865, DOI 10.1029/91JD01308; MOLINA LT, 1986, J GEOPHYS RES-ATMOS, V91, P14501, DOI 10.1029/JD091iD13p14501; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PINTO JP, 1989, J GEOPHYS RES-ATMOS, V94, P11165, DOI 10.1029/JD094iD08p11165; PRATHER M, 1992, J GEOPHYS RES-ATMOS, V97, P10187, DOI 10.1029/92JD00845; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHETTLE EP, 1979, ADA085951; SMITH RC, 1992, SCIENCE, V255, P952, DOI 10.1126/science.1546292; STAMNES K, 1990, GEOPHYS RES LETT, V17, P2181, DOI 10.1029/GL017i012p02181; TERAMURA AH, 1987, AM J BOT, V74, P975, DOI 10.2307/2443936; TOON OB, 1976, J APPL METEOROL, V15, P225, DOI 10.1175/1520-0450(1976)015<0225:AGAMOA>2.0.CO;2; TURCO RP, 1992, BER BUNSEN PHYS CHEM, V96, P323, DOI 10.1002/bbpc.19920960319; VALERO FPJ, 1992, GEOPHYS RES LETT, V19, P163, DOI 10.1029/92GL00074; Worrest R, 1982, ROLE SOLAR ULTRAVIOL, V7, P429; 1991, ENV EFFECTS OZONE DE; 1986, 16 WORLD MET ORG REP, V1; 1976, NOAAST761562 US STAN	39	34	34	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					47	49		10.1038/359047a0	http://dx.doi.org/10.1038/359047a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522884				2022-12-24	WOS:A1992JL66200048
J	TROTTER, Y; CELEBRINI, S; STRICANNE, B; THORPE, S; IMBERT, M				TROTTER, Y; CELEBRINI, S; STRICANNE, B; THORPE, S; IMBERT, M			MODULATION OF NEURAL STEREOSCOPIC PROCESSING IN PRIMATE AREA-V1 BY THE VIEWING DISTANCE	SCIENCE			English	Article							BINOCULAR INTERACTION; VISUAL-CORTEX; PERCEPTION; DISPARITIES; STRIATE; NEURONS; MONKEY; LIGHT	Accurate binocular depth perception requires information about both stereopsis (relative depth) and distance (absolute depth). It is unclear how these two types of information are integrated in the visual system. In alert, behaving monkeys the responsiveness of a large majority of neurons in the primary visual cortex (area V1) was modulated by the viewing distance. This phenomenon affected particularly disparity-related activity and background activity and was not dependent on the pattern of retinal stimulation. Therefore, extraretinal factors, probably related to ocular vergence or accommodation, or both, can affect processing early in the visual pathway. Such modulations could be useful for (i) judging true distance and (ii) scaling retinal disparity to give information about three-dimensional shape.			TROTTER, Y (corresponding author), UNIV PARIS 06,INST NEUROSCI,NEUROSCI VIS LAB,9 QUAI ST BERNARD,F-75230 PARIS 05,FRANCE.		THORPE, Simon J/A-5661-2008; celebrini, simona/H-2169-2011; Trotter, Yves/G-7333-2011	THORPE, Simon J/0000-0003-4997-3367; 				ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; CUMMING BG, 1991, NATURE, V349, P411, DOI 10.1038/349411a0; FOLEY JM, 1980, PSYCHOL REV, V87, P411, DOI 10.1037/0033-295X.87.5.411; GAUTHIER GM, 1990, SCIENCE, V249, P58, DOI 10.1126/science.2367852; GNADT JW, 1991, SOC NEUR ABSTR, V2, P1113; JOSHUA DE, 1970, EXP BRAIN RES, V10, P389, DOI 10.1007/BF02324766; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; LEHKY SR, 1990, COLD SPRING HARB SYM, V55, P765; MAZZONI P, 1991, P NATL ACAD SCI USA, V88, P4433, DOI 10.1073/pnas.88.10.4433; MORRISON JD, 1984, PERCEPTION, V13, P555, DOI 10.1068/p130555; NIKARA T, 1968, EXP BRAIN RES, V6, P353; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; Wheatstone C., 1838, 18 CONTRIBUTIONS PHY, P371	17	112	112	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1279	1281		10.1126/science.1519066	http://dx.doi.org/10.1126/science.1519066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519066				2022-12-24	WOS:A1992JL05000034
J	KUZNETSOV, SA; LANGFORD, GM; WEISS, DG				KUZNETSOV, SA; LANGFORD, GM; WEISS, DG			ACTIN-DEPENDENT ORGANELLE MOVEMENT IN SQUID AXOPLASM	NATURE			English	Article							FAST AXONAL-TRANSPORT; INHIBITION; MECHANISM; MICROFILAMENTS; MICROTUBULES; FILAMENTS; MOTILITY; VANADATE; PROTEIN; KINESIN	STUDIES of organelle movement in axoplasm extruded from the squid giant axon have led to the basic discoveries of microtubule-dependent organelle motility 1-3 and the characterization of the microtubule-based motor proteins kinesin and cytoplasmic dynein 4,5. Rapid organelle movement in higher animal cells, especially in neurons, is considered to be microtubule-based. The role of actin filaments, which are also abundant in axonal cytoplasm 6,7, has remained unclear. The inhibition of organelle movement in axoplasm by actin-binding proteins 8-11 such as DNase I, gelsolin and synapsin I has been attributed to their ability to disorganize the microtubule domains where most of the actin-filaments are located 7. Here we provide evidence of a new type of organelle movement in squid axoplasm which is independent of both microtubules and microtubule-based motors. This movement is ATP-dependent, unidirectional, actin-dependent, and probably generated by a myosin-like motor. These results demonstrate that an actomyosin-like mechanism can be directly involved in the generation of rapid organelle transport in nerve cells.	TECH UNIV MUNICH,INST ZOOL,W-8046 GARCHING,GERMANY; DARTMOUTH COLL,DEPT BIOL SCI,HANOVER,NH 03755; MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT MOLEC BIOL,MOSCOW 119899,USSR	Technical University of Munich; Dartmouth College; Lomonosov Moscow State University	KUZNETSOV, SA (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.			Langford, George/0000-0001-9737-2182; Weiss, Dieter G./0000-0002-1789-2995				ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; BRADY ST, 1984, NATURE, V310, P56, DOI 10.1038/310056a0; CALDWELL PC, 1960, J PHYSIOL-LONDON, V152, P561, DOI 10.1113/jphysiol.1960.sp006509; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; GIBBONS IR, 1978, P NATL ACAD SCI USA, V75, P2220, DOI 10.1073/pnas.75.5.2220; GILBERT SP, 1989, J CELL BIOL, V109, P2379, DOI 10.1083/jcb.109.5.2379; GOLDBERG DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7448, DOI 10.1073/pnas.77.12.7448; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; ISENBERG G, 1980, BRAIN RES, V194, P588, DOI 10.1016/0006-8993(80)91247-0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MCGUINNESS TL, 1989, J NEUROSCI, V9, P4138; MORRIS JR, 1984, J CELL BIOL, V98, P2064, DOI 10.1083/jcb.98.6.2064; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SMITH SJ, 1990, EUR J BIOCHEM, V193, P69, DOI 10.1111/j.1432-1033.1990.tb19305.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WEISS D G, 1989, P221; WEISS DG, 1988, CELL MOTIL CYTOSKEL, V10, P285, DOI 10.1002/cm.970100133; WEISS DG, 1986, J CELL SCI S, V5, P1; WEST JJ, 1967, J BIOL CHEM, V242, P1140; WEST JJ, 1967, BIOCHEM BIOPH RES CO, V29, P611, DOI 10.1016/0006-291X(67)90530-X; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	29	324	325	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					722	725		10.1038/356722a0	http://dx.doi.org/10.1038/356722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570018				2022-12-24	WOS:A1992HQ14600065
J	BARRY, CE; HAYES, SF; HACKSTADT, T				BARRY, CE; HAYES, SF; HACKSTADT, T			NUCLEOID CONDENSATION IN ESCHERICHIA-COLI THAT EXPRESS A CHLAMYDIAL HISTONE HOMOLOG	SCIENCE			English	Article							GENE-EXPRESSION; PSEUDOMONAS-AERUGINOSA; DNA; PROTEIN; TRACHOMATIS; VIRULENCE; BACTERIA; CYCLE; H1	Chlamydial cell types are adapted for either extracellular survival or intracellular growth. In the transcriptionally inert elementary bodies, the chromosome is densely compacted; in metabolically active reticulate bodies, the chromatin is loosely organized. Condensation of the chlamydial nucleoid occurs concomitant with expression of proteins homologous to eukaryotic histone H1. When the Chlamydia trachomatis 18-kilodalton histone homolog Hcl is expressed in Escherichia coli, a condensed nucleoid structure similar to that of chlamydiae is observed with both light and electron microscopy. These results support a role for Hc1 in condensation of the chlamydial nucleoid.	NIAID, ROCKY MT LABS, INTRACELLULAR PARASITES LAB, HAMILTON, MT 59840 USA; NIAID, ROCKY MT LABS, VECTORS & PATHOGENS LAB, STRUCT PATHOBIOL SECT, HAMILTON, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Hackstadt, Ted/0000-0003-1367-5528				ARNDTJOVIN DJ, 1989, METHOD CELL BIOL, V30, P417; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; COSTERTON JW, 1976, CAN J MICROBIOL, V22, P16, DOI 10.1139/m76-003; DERETIC V, 1990, J BACTERIOL, V172, P5544, DOI 10.1128/jb.172.10.5544-5554.1990; DERETIC V, 1991, MOL MICROBIOL, V5, P1577, DOI 10.1111/j.1365-2958.1991.tb01903.x; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HACKSTADT T, 1991, J BACTERIOL, V173, P7046, DOI 10.1128/jb.173.21.7046-7049.1991; HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; KATO J, 1990, P NATL ACAD SCI USA, V87, P2887, DOI 10.1073/pnas.87.8.2887; Larsson L.-I., 1988, IMMUNOCYTOCHEMISTRY; MANAFI M, 1991, MICROBIOL REV, V55, P335, DOI 10.1128/MMBR.55.3.335-348.1991; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NEWHALL WJ, 1987, INFECT IMMUN, V55, P162, DOI 10.1128/IAI.55.1.162-168.1987; PERARA E, 1990, CHLAMYDIAL INFECTION, P44; PETTIJOHN DE, 1982, CELL, V30, P667, DOI 10.1016/0092-8674(82)90269-0; PINCUS SH, 1990, J EXP MED, V172, P745, DOI 10.1084/jem.172.3.745; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; ROBINSON EN, 1984, INFECT IMMUN, V46, P361, DOI 10.1128/IAI.46.2.361-366.1984; SCHACHTER J, 1988, CURR TOP MICROBIOL, V138, P109; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SJASTAD K, 1982, J GEN MICROBIOL, V128, P3037; SOLBRIG MV, 1990, MOL MICROBIOL, V4, P1535, DOI 10.1111/j.1365-2958.1990.tb02064.x; STONINGT.OG, 1971, P NATL ACAD SCI USA, V68, P6, DOI 10.1073/pnas.68.1.6; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAO S, 1991, J BACTERIOL, V173, P2818, DOI 10.1128/JB.173.9.2818-2822.1991; WAGAR EA, 1988, INFECT IMMUN, V56, P1678, DOI 10.1128/IAI.56.7.1678-1684.1988	35	96	99	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					377	379		10.1126/science.256.5055.377	http://dx.doi.org/10.1126/science.256.5055.377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566085				2022-12-24	WOS:A1992HP03200036
J	BOICE, JD; HARVEY, EB; BLETTNER, M; STOVALL, M; FLANNERY, JT				BOICE, JD; HARVEY, EB; BLETTNER, M; STOVALL, M; FLANNERY, JT			CANCER IN THE CONTRALATERAL BREAST AFTER RADIOTHERAPY FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIATION-THERAPY; IRRADIATION; RISK; SURGERY; CERVIX; WOMEN	Background. Patients with breast cancer have a threefold increase in the risk that a second breast cancer will develop. Radiation treatment for the initial cancer can result in moderately high doses to the contralateral breast, possibly contributing to this heightened risk. Methods. We conducted a case-control study in a cohort of 41,109 women diagnosed with breast cancer between 1935 and 1982 in Connecticut. We reviewed the medical records of 655 women in whom a second breast cancer developed five or more years after the initial tumor and compared their radiation exposure with that of 1189 matched controls from the cohort who did not have a second cancer. The dose of radiation to the contralateral breast was estimated from the original radiotherapy records. Among the exposed women, the average radiation dose to the contralateral breast was 2.82 Gy (maximum, 7.10). Results. Overall, 23 percent of the women who had a second breast cancer and 20 percent of the controls had received radiotherapy (relative risk of a second breast cancer associated with radiotherapy, 1.19). Among women who survived for at least 10 years, radiation treatment was associated with a small but marginally significant elevation in the risk of a second breast cancer (relative risk, 1.33); the risk increased significantly with the dose of radiation. An increase in risk in association with radiotherapy was evident only among women who were under 45 years of age when they were treated (relative risk, 1.59) and not among older women (relative risk, 1.01). Conclusions. Radiotherapy for breast cancer contributes little to the already high risk of a second cancer in the opposite breast. Fewer than 3 percent of all second breast cancers in this study could be attributed to previous radiation treatment; the risk, however, was significantly increased among women who underwent irradiation at a relatively young age (< 45 years). Radiation exposure after the age of 45 entails little, if any, risk of radiation-induced breast cancer.	CONNECTICUT TUMOR REGISTRY,HARTFORD,CT; UNIV TEXAS,CTR CANC,HOUSTON,TX 77025	University of Texas System	BOICE, JD (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EXECUT PLAZA N,RM 408,6130 EXECUT BLVD,ROCKVILLE,MD 20852, USA.				NCI NIH HHS [N01-CP0-5609, N01-CP8-5604, N01-CP9-5614] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085604, N01CP005609, N01CP095614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BARAL E, 1977, CANCER, V40, P2905, DOI 10.1002/1097-0142(197712)40:6<2905::AID-CNCR2820400621>3.0.CO;2-Y; BASCO VE, 1985, BRIT J CANCER, V52, P319, DOI 10.1038/bjc.1985.196; BOICE JD, 1989, INT J CANCER, V44, P7, DOI 10.1002/ijc.2910440103; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BURNS PE, 1984, CAN MED ASSOC J, V130, P881; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FRAASS BA, 1985, INT J RADIAT ONCOL, V11, P485, DOI 10.1016/0360-3016(85)90179-8; HANKEY BF, 1983, J NATL CANCER I, V70, P797; HARRIS JR, 1990, CANCER-AM CANCER SOC, V66, P1427, DOI 10.1002/1097-0142(19900915)66:14+<1427::AID-CNCR2820661420>3.0.CO;2-W; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON IC, 1989, CANCER PRINCIPLES PR, V2, P1197; HORN PL, 1988, CANCER-AM CANCER SOC, V62, P412, DOI 10.1002/1097-0142(19880715)62:2<412::AID-CNCR2820620228>3.0.CO;2-3; KURTZ JM, 1988, INT J RADIAT ONCOL, V15, P277, DOI 10.1016/S0360-3016(98)90005-0; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MCCREDIE JA, 1975, CANCER, V35, P1472, DOI 10.1002/1097-0142(197505)35:5<1472::AID-CNCR2820350536>3.0.CO;2-M; MELLINK WAM, 1991, CANCER-AM CANCER SOC, V67, P1844, DOI 10.1002/1097-0142(19910401)67:7<1844::AID-CNCR2820670705>3.0.CO;2-W; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MONTAGUE ED, 1984, CANCER, V53, P700, DOI 10.1002/1097-0142(19840201)53:3+<700::AID-CNCR2820531318>3.0.CO;2-2; PARKER RG, 1989, AM J CLIN ONCOL-CANC, V12, P213, DOI 10.1097/00000421-198906000-00007; SCHELL SR, 1982, CANCER, V50, P1191, DOI 10.1002/1097-0142(19820915)50:6<1191::AID-CNCR2820500628>3.0.CO;2-F; SHELLABARGER CJ, 1986, RAD CARCINOGENESIS, P169; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; TERCILLA O, 1989, INT J RADIAT ONCOL, V17, P205, DOI 10.1016/0360-3016(89)90390-8; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518; ZUCALI R, 1987, EUR J SURG ONCOL, V13, P413; 1991, JAMA-J AM MED ASSOC, V265, P391	29	316	320	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					781	785		10.1056/NEJM199203193261201	http://dx.doi.org/10.1056/NEJM199203193261201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538720				2022-12-24	WOS:A1992HJ59200001
J	CORINA, DP; VAID, J; BELLUGI, U				CORINA, DP; VAID, J; BELLUGI, U			THE LINGUISTIC BASIS OF LEFT-HEMISPHERE SPECIALIZATION	SCIENCE			English	Article								In humans the two cerebral hemispheres of the brain are functionally specialized with the left hemisphere predominantly mediating language skills. The basis of this lateralization has been proposed to be differential localization of the linguistic, the motoric, or the symbolic properties of language. To distinguish among these possibilities, lateralization of spoken language, signed language, and nonlinguistic gesture have been compared in deaf and hearing individuals. This analysis, plus additional clinical findings, support a linguistic basis of left hemisphere specialization.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; TEXAS A&M UNIV SYST,COLLEGE STN,TX 77843	Salk Institute; Texas A&M University System; Texas A&M University College Station			Hsu, Oscar LiJen/C-3754-2009		NICHD NIH HHS [HD12349] Funding Source: Medline; NIDCD NIH HHS [DC00146, DC00201] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012349] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELLUGI U, 1980, SIGNED SPOKEN LANGUA, P115; BELLUGI U, 1989, TRENDS NEUROSCI, V12, P10; BROWN J, 1977, MIND BRAIN CONSCIOUS; Brown J. W., 1991, SELF PROCESS; CORINA DP, 1989, INVEST PSYCHOL, V7, P31; CORINA DP, IN PRESS BRAIN LANG; GREEN A, 1990, BRAIN LANG, V39, P107, DOI 10.1016/0093-934X(90)90007-4; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; KIMURA D, 1976, STUDIES NEUROLINGUIS, P145; KIMURA D, 1989, READINGS ENCY NEUROS; KINSBOURNE M, 1971, Q J EXP PSYCHOL, V23, P34; Kinsbourne M., 1978, ATTENTION PERFORM, VVII, P345; Klima E. S., 1988, SIGNS LANGUAGE; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; Padden CarolA., 1983, INTERACTION MORPHOLO; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Stokoe W. C., 1965, DICT AM SIGN LANGUAG; Supalla T.R., 1982, THESIS U SAN DIEGO S; [No title captured]	20	61	61	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1258	1260		10.1126/science.1546327	http://dx.doi.org/10.1126/science.1546327			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG677	1546327	Green Submitted			2022-12-24	WOS:A1992HG67700044
J	PANKRATZ, MJ; BUSCH, M; HOCH, M; SEIFERT, E; JACKLE, H				PANKRATZ, MJ; BUSCH, M; HOCH, M; SEIFERT, E; JACKLE, H			SPATIAL CONTROL OF THE GAP GENE KNIRPS IN THE DROSOPHILA EMBRYO BY POSTERIOR MORPHOGEN SYSTEM	SCIENCE			English	Article							HEAD DEVELOPMENT; HUNCHBACK; PATTERN; KRUPPEL; SEGMENTATION; EXPRESSION; ANTERIOR; INFORMATION; POLARITY; GRADIENT	The gap genes of Drosophila are the first zygotic genes to respond to the maternal positional signals and establish the body pattern along the anterior-posterior axis. The gap gene knirps, required for patterning in the posterior region of the embryo, can be activated throughout the wild-type embryo and is normally repressed from the anterior and posterior sides. These results provide direct molecular evidence that the posterior morphogen system interacts in a fundamentally different manner than do hunchback and bicoid, which are responsible for anterior pattern formation.	INST GENET & MIKROBIOL, W-8000 MUNICH 19, GERMANY		PANKRATZ, MJ (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ENTWICKLUNGSBIOL ABT, W-3400 GOTTINGEN, GERMANY.							AKAM M, 1987, DEVELOPMENT, V101, P1; ANDERSON DT, 1972, DEV SYSTEMS INSECTS, V2; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; ELDON ED, 1991, DEVELOPMENT, V111, P367; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1989, DEVELOPMENT, V107, P651; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOCH M, UNPUB; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1991, DEVELOPMENT, V112, P679; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PANKRATZ MJ, UNPUB; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; ROTHE M, UNPUB; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1983, DEV EVOLUTION; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	40	67	67	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					986	989		10.1126/science.1546296	http://dx.doi.org/10.1126/science.1546296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546296				2022-12-24	WOS:A1992HE60500041
J	CUNNINGHAM, CC; GORLIN, JB; KWIATKOWSKI, DJ; HARTWIG, JH; JANMEY, PA; BYERS, HR; STOSSEL, TP				CUNNINGHAM, CC; GORLIN, JB; KWIATKOWSKI, DJ; HARTWIG, JH; JANMEY, PA; BYERS, HR; STOSSEL, TP			ACTIN-BINDING PROTEIN REQUIREMENT FOR CORTICAL STABILITY AND EFFICIENT LOCOMOTION	SCIENCE			English	Article							DICTYOSTELIUM MUTANT; HUMAN-PLATELETS; ALPHA-ACTININ; MEMBRANE; ASSOCIATION; MACROPHAGES; HEPATOCYTES; GELATION; LINKING; FILAMIN	Three unrelated tumor cell lines derived from human malignant melanomas lack actin-binding protein (ABP), which cross-links actin filaments in vitro and connects these filaments to plasma membrane glycoproteins. The ABP-deficient cells have impaired locomotion and display circumferential blebbing of the plasma membrane. Expression of A.BP in one of the lines after transfection restored translocational motility and reduced membrane blebbing. These findings establish that ABP functions to stabilize cortical actin in vivo and is required for efficient cell locomotion.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CHILDRENS HOSP,DEPT HEMATOL ONCOL,DIV PEDIAT ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	CUNNINGHAM, CC (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL 19429] Funding Source: Medline; NIAID NIH HHS [AI 08051] Funding Source: Medline; NIAMS NIH HHS [AR 38910] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; BYERS HR, 1991, AM J PATHOL, V139, P423; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES WA, 1977, J CELL BIOL, V75, P941, DOI 10.1083/jcb.75.3.941; Eicke H.-F., 1990, PHYSICAL NETWORKS PO, P169; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HARTWIG JH, 1991, LUNG SCI F, P141; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; LUBYPHELPS K, 1988, ANNU REV BIOPHYS BIO, V17, P369; MESLAND DAM, 1981, EXP CELL RES, V135, P431, DOI 10.1016/0014-4827(81)90184-1; MORROW J, 1985, BIOCHIM BIOPHYS ACTA, V830, P147; NARVANEN O, 1987, FEBS LETT, V224, P156, DOI 10.1016/0014-5793(87)80440-4; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHLEICHER M, 1988, J CELL SCI, V90, P59; Stossel T.P., 1987, P131; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1984, J CELL BIOL, V99, pS15, DOI 10.1083/jcb.99.1.15s; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WEISS E, 1973, BEITR PATHOL, V150, P345	30	490	500	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					325	327		10.1126/science.1549777	http://dx.doi.org/10.1126/science.1549777			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549777				2022-12-24	WOS:A1992GZ69500040
J	BLENDON, RJ; SZALAY, US; KNOX, RA				BLENDON, RJ; SZALAY, US; KNOX, RA			SHOULD PHYSICIANS AID THEIR PATIENTS IN DYING - THE PUBLIC PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115, USA.							KENT C, 1991, MED HLTH        1202, V45, pA2; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WOOD F, 1990, AM PROFILE OPINIONS, P627; 1991, AM VIEW ANGING RESUL; 1989, PHYSICIAN PUBLIC ATT; 1991, NY TIMES        1107, pB14; 1990, GENERAL SOCIAL SURVE	9	181	182	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2658	2662		10.1001/jama.267.19.2658	http://dx.doi.org/10.1001/jama.267.19.2658			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573758				2022-12-24	WOS:A1992HT82300038
J	STRUHL, G; JOHNSTON, P; LAWRENCE, PA				STRUHL, G; JOHNSTON, P; LAWRENCE, PA			CONTROL OF DROSOPHILA BODY PATTERN BY THE HUNCHBACK MORPHOGEN GRADIENT	CELL			English	Article							KRUPPEL GENE-EXPRESSION; FUSHI-TARAZU; SEGMENTATION GENE; GAP GENE; ABDOMINAL SEGMENTATION; SPATIAL EXPRESSION; HEAD DEVELOPMENT; BICOID PROTEIN; MATERNAL GENE; EMBRYO	Most of the thoracic and abdominal segments of Drosophila are specified early in embryogenesis by the overlapping activities of the hunchback (hb), Kruppel, knirps, and giant gap genes. The orderly expression of these genes depends on two maternal determinants: bicoid, which activates hb transcription anteriorly, and nanos, which blocks translation of hb transcripts posteriorly. Here we provide evidence that the resulting gradient of hb protein dictates where the Kruppel, knirps, and giant genes are expressed by providing a series of concentration thresholds that regulate each gene independently. Thus, hb protein functions as a classical morphogen, triggering several distinct responses as a function of its graded distribution.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology	STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT GENET & DEV, NEW YORK, NY 10032 USA.			Lawrence, Peter/0000-0002-9554-8268				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; Dalcq A, 1938, FORM CAUSALITY EARLY; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1968, 12TH P INT C GEN, V2, P96; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY D, 1988, DROS INF SERV, V68; LINDSLEY DL, 1985, DROS INF SERV, V62; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; Sander K, 1975, Ciba Found Symp, V0, P241; Sander Klaus, 1959, Wilhelm Roux Arch Entwickl Mech Org, V151, P430, DOI 10.1007/BF00573355; Sander Klaus, 1960, Wilhelm Roux Arch Entwickl Mech Org, V151, P660, DOI 10.1007/BF00577816; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1989, CIBA F SYMP, V144, P65; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; von Ubisch L, 1953, ENTWICKLUNGSPROBLEME; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8	63	229	232	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					237	249		10.1016/0092-8674(92)90405-2	http://dx.doi.org/10.1016/0092-8674(92)90405-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568245				2022-12-24	WOS:A1992HQ18300004
J	GILL, TM				GILL, TM			WHAT HAVE I DONE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						RESUSCITATION; HEART ARREST; ETHICS, MEDICAL		This short tale deals with a timely subject of general concern to internists and to most clinicians-that awful moment of hesitation when embarking on the urgent resuscitation of a patient whose previous health status is unknown. The exhilaration of a successful effort is supplanted by the dismay of a dismal outcome.			GILL, TM (corresponding author), YALE UNIV, SCH MED, RM IE-61 SHM, POB 3333, NEW HAVEN, CT 06510 USA.			Gill, Thomas/0000-0002-6450-0368				MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					691	691		10.7326/0003-4819-116-8-691	http://dx.doi.org/10.7326/0003-4819-116-8-691			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546871				2022-12-24	WOS:A1992HN84400014
J	PRENTICE, MB; FLOWER, AJE; MORGAN, GM; NICHOLSON, KG; RANA, B; FIRMIN, RK; MITCHELL, CJ				PRENTICE, MB; FLOWER, AJE; MORGAN, GM; NICHOLSON, KG; RANA, B; FIRMIN, RK; MITCHELL, CJ			INFECTION WITH HEPATITIS-B VIRUS AFTER OPEN-HEART-SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HOST DEFENSE FUNCTIONS; CARDIOPULMONARY BYPASS; HUMAN-BEINGS; TRANSMISSION; STAFF; FEATURES; ANTIGEN; HBSAG; SERUM		LEICESTER ROYAL INFIRM,LEICESTER PUBL HLTH LAB,LEICESTER LE1 5WW,ENGLAND; LEICESTERSHIRE AREA HLTH AUTHOR,PUBL HLTH MED,LEICESTER LE1 6TY,ENGLAND; GROBY RD HOSP,INFECT DIS,LEICESTER LE3 9QE,ENGLAND; GROBY RD HOSP,CARDIOTHORAC SURG,LEICESTER LE3 9QE,ENGLAND	University of Leicester			Prentice, Michael/AAE-7246-2019	Prentice, Michael/0000-0003-1117-2388				ALEXANDER GJM, 1987, LANCET, V2, P66; BARKER LF, 1971, J AMER MED ASSOC, V216, P1970, DOI 10.1001/jama.216.12.1970; BERRIDGE DC, 1990, BRIT J SURG, V77, P585, DOI 10.1002/bjs.1800770540; CLEE WB, 1987, BMJ-BRIT MED J, V295, P530, DOI 10.1136/bmj.295.6597.530; COBB J, 1987, BRIT MED J, V294, P1667, DOI 10.1136/bmj.294.6588.1667; COUTINHO RA, 1982, LANCET, V1, P345; FRATER RWM, 1990, AIDS SURGERY, P121; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HARRISON TJ, 1985, BRIT MED J, V290, P663, DOI 10.1136/bmj.290.6469.663; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HOFMANN H, 1988, INFECTION, V16, P171, DOI 10.1007/BF01644095; HOSIE KB, 1988, LANCET, V2, P1500; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; POLAKOFF S, 1986, BRIT MED J, V293, P33, DOI 10.1136/bmj.293.6538.33; SIM AJW, 1988, BRIT MED J, V296, P80, DOI 10.1136/bmj.296.6615.80; SMEDIRA N, 1989, ADV TRAUMA, V4, P67; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; VANVELZENBLAD H, 1985, ANN THORAC SURG, V39, P212, DOI 10.1016/S0003-4975(10)62581-7; VANVELZENBLAD H, 1985, ANN THORAC SURG, V39, P207, DOI 10.1016/S0003-4975(10)62578-7; WELCH J, 1989, LANCET, V1, P205; YELLOWLESS H, 1981, GUIDANCE HEPATITIS B; 1985, MMWR, V34, P73; 1991, BMJ, V303, P184; 1990, IMMUNISATION INFECTI; 1983, HOSPITAL INPATIENT E	26	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					761	764		10.1136/bmj.304.6829.761	http://dx.doi.org/10.1136/bmj.304.6829.761			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571684	Green Published, Bronze			2022-12-24	WOS:A1992HK80000025
J	WANG, YC; FROST, BJ				WANG, YC; FROST, BJ			TIME TO COLLISION IS SIGNALED BY NEURONS IN THE NUCLEUS ROTUNDUS OF PIGEONS	NATURE			English	Article							MOTION; FLIES	THROUGHOUT the animal kingdom, the sight of a rapidly approaching object usually signals danger and elicits an escape response 1-6. Gibson 7 suggested that the symmetrical expansion of an object's image (looming) is the critical variable determining that the object is on a collision course with the observer. Similarly, large expanding flow-fields like those produced by locomotion may precipitate manoeuvres such as turning or landing 8,9. From such observations it has been shown that the optic flow parameter, tau, which specifies time to contact with the approaching object best fits the behavioural data 10,11. We describe a subpopulation of neurons in the nucleus rotundus of the pigeon brain that respond selectively to objects moving on a collision course towards the bird. These neurons give their maximum response at a constant time before contact occurs, even when the size of the stimulus or its velocity is varied widely. We propose that these neurons are signalling the time to collision of approaching objects.	QUEENS UNIV,DEPT PHYSIOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada								BORST A, 1988, NATURWISSENSCHAFTEN, V75, P265, DOI 10.1007/BF00378023; COGGSHALL JC, 1972, J EXP BIOL, V57, P401; DEAN P, 1989, TRENDS NEUROSCI, V12, P137, DOI 10.1016/0166-2236(89)90052-0; FROST BJ, 1990, VISION RES, V30, P1677, DOI 10.1016/0042-6989(90)90152-B; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; Gibson J. J, 1979, ECOLOGICAL APPROACH; HAYES WN, 1967, ANIM BEHAV, V15, P102, DOI 10.1016/S0003-3472(67)80018-6; HILTON SH, 1982, J EXP BIOL, V100, P158; LEE DN, 1981, NATURE, V293, P293, DOI 10.1038/293293a0; Loeb G. E., 1986, ELECTROMYOGRAPHY EXP; MARTINOYA C, 1990, BIOL CYBERN, V63, P127, DOI 10.1007/BF00203035; REVZIN AM, 1970, BRAIN BEHAV EVOLUT, V3, P195; SCHIFF W, 1962, SCIENCE, V136, P982, DOI 10.1126/science.136.3520.982; SCHIFF W, 1965, PSYCHOL MONOGR, V79; SWANSTON MT, 1986, PERCEPT PSYCHOPHYS, V39, P309, DOI 10.3758/BF03202998; WAGNER H, 1982, NATURE, V297, P147, DOI 10.1038/297147a0	16	217	221	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					236	238		10.1038/356236a0	http://dx.doi.org/10.1038/356236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552942				2022-12-24	WOS:A1992HJ94400056
J	BALDI, MI; MATTOCCIA, E; BUFARDECI, E; FABBRI, S; TOCCHINIVALENTINI, GP				BALDI, MI; MATTOCCIA, E; BUFARDECI, E; FABBRI, S; TOCCHINIVALENTINI, GP			PARTICIPATION OF THE INTRON IN THE REACTION CATALYZED BY THE XENOPUS TRANSFER-RNA SPLICING ENDONUCLEASE	SCIENCE			English	Article							YEAST TRANSFER-RNA; INTERVENING SEQUENCES; TRANSCRIPTION; PRECURSORS; SECONDARY; SUBSTRATE; EXCISION; LAEVIS; PROBES; GENE	Introns have generally been assumed to be passive in the transfer RNA splicing reaction. Experiments have now been done showing that the endonuclease is able to cut a precursor provided that a base in the single-stranded loop of the intron can pair with the base of the 5' exon situated at the position that immediately follows the anticodon stem (position 33 in the yeast tRNA isoacceptor pre-tRNA3Leu, position 32 in yeast pre-tRNA(Phe). The elucidation of the role of the intron reveals that in addition to the conserved bases, there are positions in the mature domain which, although not necessarily occupied by the same base in all pre-tRNA's, nevertheless have a fundamental role in the splicing reaction. These positions are termed cardinal positions.	CNR,INST CELL BIOL,VIALE MARX 43,I-00137 ROME,ITALY; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; ENICHEM,DIPARTIMENTO BIOTECHNOL,I-00015 MONTEROTONDO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Chicago								BALDI MI, 1986, CELL, V47, P965, DOI 10.1016/0092-8674(86)90811-1; DZEKELY E, 1988, J BIOL CHEM, V263, P13839; FAHNESTOCK SR, 1972, P NATL ACAD SCI USA, V69, P363, DOI 10.1073/pnas.69.2.363; GANDINIATTARDI D, 1989, METHOD ENZYMOL, V181, P510; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; JOHNSON JD, 1980, P NATL ACAD SCI-BIOL, V77, P2564, DOI 10.1073/pnas.77.5.2564; LEE MC, 1985, J BIOL CHEM, V260, P3108; MATTOCCIA E, 1983, CELL, V32, P67, DOI 10.1016/0092-8674(83)90497-X; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; ULBRICH N, 1978, J BIOL CHEM, V253, P9049; WICKENS MP, 1987, CELL, V51, P339, DOI 10.1016/0092-8674(87)90629-5; WREDE P, 1979, J BIOL CHEM, V254, P9608	20	66	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1404	1408		10.1126/science.1542788	http://dx.doi.org/10.1126/science.1542788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542788				2022-12-24	WOS:A1992HH74400045
J	MARGOLIS, B; HU, P; KATZAV, S; LI, W; OLIVER, JM; ULLRICH, A; WEISS, A; SCHLESSINGER, J				MARGOLIS, B; HU, P; KATZAV, S; LI, W; OLIVER, JM; ULLRICH, A; WEISS, A; SCHLESSINGER, J			TYROSINE PHOSPHORYLATION OF VAV PROTOONCOGENE PRODUCT CONTAINING SH2 DOMAIN AND TRANSCRIPTION FACTOR MOTIFS	NATURE			English	Article							PHOSPHOLIPASE C-II; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; RECEPTOR; CELLS; PROTEINS; RELEASE; BINDING; PDGF	ACTIVATION of receptor-linked and cytoplasmic protein tyrosine kinases is crucial in the control of normal and abnormal cell growth and differentiation 1,2. Some substrates of protein tyrosine kinases such as phospholipase C-gamma and ras GTPase-activating protein (GAP) contain sequences homologous to the src protein domains SH2 and SH3 (refs 3-9). The proto-oncogene Vav is expressed in haematopoietic cells and its product Vav contains sequence motifs commonly found in transcription factors, such as helix-loop-helix, leucine-zipper and zinc-finger motifs and nuclear localization signals 10-12, as well as a single SH2 and two SH3 domains. Here we show that stimulation of T-cell antigen receptor on normal human peripheral blood lymphocytes or on human leukaemic T cells, and the crosslinking of IgE receptors on rat basophilic leukaemia cells, both promote the phosphorylation of tyrosine residues in Vav. Moreover, activation of the receptor for epidermal growth factor leads to marked tyrosine phosphorylation of Vav in cells transiently expressing vav, and Vav associates with the receptor through its SH2 domain. We propose that vav encodes a new class of substrates whose tyrosine phosphorylation may provide a mechanism for direct signal transduction linking receptors at the cell surface to transcriptional control.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV NEW MEXICO, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DIV RHEUMATOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	St Jude Children's Research Hospital; University of New Mexico; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco	MARGOLIS, B (corresponding author), NYU MED CTR, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA.		Hu, Patrick/I-2902-2019	Hu, Patrick/0000-0002-5611-8062				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLEN J, 1991, CELL GROWTH DIFFER, V2, P365; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN DR, 1990, CELL, V61, P121; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OLIVER JM, 1988, PROG ALLERGY, V42, P195; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUH PG, 1988, J BIOL CHEM, V263, P14497; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	37	381	389	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					71	74		10.1038/356071a0	http://dx.doi.org/10.1038/356071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1531699				2022-12-24	WOS:A1992HG60200059
J	YEDNOCK, TA; CANNON, C; FRITZ, LC; SANCHEZMADRID, F; STEINMAN, L; KARIN, N				YEDNOCK, TA; CANNON, C; FRITZ, LC; SANCHEZMADRID, F; STEINMAN, L; KARIN, N			PREVENTION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY ANTIBODIES AGAINST ALPHA-4-BETA-1 INTEGRIN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULES; HOMING RECEPTORS; CELL-ADHESION; LYMPHOCYTE-T; ANTIGEN; ENDOTHELIUM; BINDING; DEMYELINATION	EXPERIMENTAL autoimmune encephalomyelitis (EAE) is an inflammatory condition of the central nervous system with similarities to multiple sclerosis 1,2. In both diseases circulating leukocytes penetrate the blood-brain barrier and damage myelin, resulting in impaired nerve conduction and paralysis 3-5 . We sought to identify the adhesion receptors that mediate the attachment of circulating leukocytes to inflamed brain endothelium in EAE, because this interaction is the first step in leukocyte entry into the central nervous system. Using an in vitro adhesion assay on tissue sections, we found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels. Binding was inhibited by antibodies against the integrin molecule alpha-4-beta-1, but not by antibodies against numerous other adhesion receptors. When tested in vivo, anti-alpha-4 integrin effectively prevented the accumulation of leukocytes in the central nervous system and the development of EAE. Thus, therapies designed to interfere with alpha-4-beta-1 integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.	UNIV AUTONOMA MADRID,MADRID 34,SPAIN; STANFORD UNIV,STANFORD,CA 94305	Autonomous University of Madrid; Stanford University	YEDNOCK, TA (corresponding author), ATHENA NEUROSCI,S SAN FRANCISCO,CA, USA.		Sanchez-Madrid, Francisco/M-7889-2016	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Steinman, Lawrence/0000-0002-2437-2250				ALVORD EC, 1984, EXPT ALLERGIC ENCEPH, P1; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BRISCOE DM, 1991, TRANSPLANTATION, V51, P537; CANNELLA B, 1990, J EXP MED, V172, P1521, DOI 10.1084/jem.172.5.1521; CHIN YH, 1990, J IMMUNOL, V145, P3669; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KOCH AE, 1991, LAB INVEST, V64, P313; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PATERSON PY, 1976, TXB IMMUNOPATHOLOGY, P179; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RAINE CS, 1990, LAB INVEST, V63, P476; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; TRAUGOTT U, 1986, CELL IMMUNOL, V99, P395, DOI 10.1016/0008-8749(86)90248-0; WILCOX CE, 1990, J NEUROIMMUNOL, V30, P43, DOI 10.1016/0165-5728(90)90051-N; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	30	1476	1618	2	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					63	66		10.1038/356063a0	http://dx.doi.org/10.1038/356063a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538783				2022-12-24	WOS:A1992HG60200056
J	HAGLER, J; SHUMAN, S				HAGLER, J; SHUMAN, S			A FREEZE-FRAME VIEW OF EUKARYOTIC TRANSCRIPTION DURING ELONGATION AND CAPPING OF NASCENT MESSENGER-RNA	SCIENCE			English	Article							VACCINIA VIRUS; POLYMERASE; PURIFICATION; GUANYLYLTRANSFERASE; TERMINATION; INVITRO	Ribonuclease footprinting of nascent messenger RNA within ternary complexes of vaccinia RNA polymerase revealed an RNA binding site that encompasses an 18-nucleotide RNA segment. The dimensions of the binding site did not change as the polymerase moved along the template. Capping of the 5' end of the RNA was cotranscriptional and was confined to nascent chains 31 nucleotides or greater in length. Purified capping enzyme formed a binary complex with RNA polymerase in solution in the absence of nucleic acid. These findings suggest a mechanism for cotranscriptional establishment of messenger RNA identity in eukaryotes.			HAGLER, J (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; HAGLER J, UNPUB; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LUO Y, 1991, J BIOL CHEM, V266, P13303; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MOSS B, 1991, J BIOL CHEM, V266, P1355; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SPENCER E, 1980, J BIOL CHEM, V255, P5388; VENKATESAN S, 1980, J BIOL CHEM, V255, P903	20	82	82	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					983	986		10.1126/science.1546295	http://dx.doi.org/10.1126/science.1546295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546295				2022-12-24	WOS:A1992HE60500040
J	KELLY, A; POWIS, SH; KERR, LA; MOCKRIDGE, I; ELLIOTT, T; BASTIN, J; UCHANSKAZIEGLER, B; ZIEGLER, A; TROWSDALE, J; TOWNSEND, A				KELLY, A; POWIS, SH; KERR, LA; MOCKRIDGE, I; ELLIOTT, T; BASTIN, J; UCHANSKAZIEGLER, B; ZIEGLER, A; TROWSDALE, J; TOWNSEND, A			ASSEMBLY AND FUNCTION OF THE 2 ABC TRANSPORTER PROTEINS ENCODED IN THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	NATURE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-II REGION; HLA-B ANTIGENS; MONOCLONAL-ANTIBODY; INFLUENZA NUCLEOPROTEIN; MULTIDRUG RESISTANCE; MOLECULAR ANALYSIS; CYSTIC-FIBROSIS; HEAVY-CHAINS; MHC	PRESENTATION Of Cytoplasmic antigens to class I-restricted cytotoxic T cells implied the existence of a specialized peptide transporter 1-3 (reviewed in ref. 4). For most class I heavy chains, association with peptides of the appropriate length is required for stable assembly with beta-2-microglobulin 5-11. Mutant cells RMA-S (ref. 12) and .174/T2 (refs 13, 14) neither assemble stable class I molecules nor present intracellular antigens, and we have suggested that they have lost a function required for the transport of short peptides from the cytosol to the endoplasmic reticulum 5-7. The genetic defect in .174 has been localized to a large deletion in the class II region of the major histocompatibility complex 6,15,16, within which two genes (RING4 and RING11) have been identified that code for 'ABC' (ATP-binding cassette) transporters 15,17-21. We report here that the protein products of these two genes assemble to form a complex. Defects in either protein result in the formation of unstable class I molecules and loss of presentation of intracellular antigens. The molecular defect in a new mutant, BM36.1, is shown to be in the ATP-binding domain of the RING11/PSF2 protein. This is in contrast to the mutant .134 (ref. 15), which lacks the RING4/PSF1 protein.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,INST EXPTL ONKOL & TRANSPLANTAT MED,W-1000 BERLIN 19,GERMANY	University of Oxford; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	KELLY, A (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Townsend, Alain/0000-0002-3702-0107				BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PARHAM P, 1979, J IMMUNOL, V123, P342; POWIS SH, IN PRESS P NATN ACAD; RADKA SF, 1982, J IMMUNOL, V128, P2804; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SMITH MEF, 1989, P NATL ACAD SCI USA, V86, P5557, DOI 10.1073/pnas.86.14.5557; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPRING B, 1985, IMMUNOGENETICS, V21, P277, DOI 10.1007/BF00375380; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VOLZ A, IN PRESS CYTOGENET C; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; ZIEGLER A, 1985, IMMUNOBIOLOGY, V169, P455, DOI 10.1016/S0171-2985(85)80001-2	33	403	407	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					641	644		10.1038/355641a0	http://dx.doi.org/10.1038/355641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538751				2022-12-24	WOS:A1992HD54700057
J	ZAMORE, PD; PATTON, JG; GREEN, MR				ZAMORE, PD; PATTON, JG; GREEN, MR			CLONING AND DOMAIN-STRUCTURE OF THE MAMMALIAN SPLICING FACTOR U2AF	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; DROSOPHILA-MELANOGASTER; SNRNP BINDING; 70K PROTEIN; RNA; GENE; PURIFICATION; EXPRESSION; INTRONS; IDENTIFICATION	A complementary DNA clone encoding the large subunit of the essential mammalian pre-messenger RNA splicing component U2 snRNP auxiliary factor (U2AF65) has been isolated and expressed in vitro. It contains two functional domains: a sequence-specific RNA-binding region composed of three ribonucleoprotein-consensus sequence domains, and an arginine/serine-rich motif necessary for splicing but not for binding to pre-mRNA.	HARVARD UNIV, SCH MED, MOLEC & CELLULAR PHYSIOL LAB, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	ZAMORE, PD (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; VOELKER RA, 1991, MOL CELL BIOL, V11, P894, DOI 10.1128/MCB.11.2.894; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	39	499	507	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1992	355	6361					609	614		10.1038/355609a0	http://dx.doi.org/10.1038/355609a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538748				2022-12-24	WOS:A1992HD54700043
J	DAVIES, K				DAVIES, K			MULLING OVER MOUSE MODELS	NATURE			English	Editorial Material																		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; COLLINS FS, 1992, NATURE, V358, P708, DOI 10.1038/358708a0; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; GASCHEN PP, 1992, J NEUROL SCI, V110, P149; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Morell Robert, 1992, Human Molecular Genetics, V1, P243, DOI 10.1093/hmg/1.4.243; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56	13	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					86	86		10.1038/359086a0	http://dx.doi.org/10.1038/359086a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522893	Bronze			2022-12-24	WOS:A1992JL66200062
J	SHIBUYA, H; YONEYAMA, M; NINOMIYATSUJI, J; MATSUMOTO, K; TANIGUCHI, T				SHIBUYA, H; YONEYAMA, M; NINOMIYATSUJI, J; MATSUMOTO, K; TANIGUCHI, T			IL-2 AND EGF RECEPTORS STIMULATE THE HEMATOPOIETIC-CELL CYCLE VIA DIFFERENT SIGNALING PATHWAYS - DEMONSTRATION OF A NOVEL ROLE FOR C-MYC	CELL			English	Article							BETA-CHAIN; MESSENGER-RNA; ERYTHROPOIETIN RECEPTOR; GROWTH-FACTORS; T-CELLS; V-ABL; GENE; ONCOGENE; LINE; EXPRESSION	Stimulation via cytokine receptors such as IL-2 and IL-3 receptors, but not by the EGF receptor (EGFR), induces cells of the BAF-B03 hematopoietic cell line to transit the cell cycle. We demonstrate that the IL-2 receptor beta-chain (IL-2R-beta) is linked to at least two intracellular signaling pathways. One pathway may involve a protein tyrosine kinase of the src family, which leads to the induction of the c-jun and c-fos genes, among others. A second pathway, involving an as yet unknown mechanism, leads to c-myc gene induction. Stimulation of the EGFR, expressed following transfection of an appropriate recombinant construct, can activate the former, but not the latter, pathway in this cell line and cause the cells to enter S phase but not progress further. This deficiency can be rescued by ectopic expression of the c-myc gene, indicating a novel role for this proto-oncogene in the S to G2/M transition of the cell cycle.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	SHIBUYA, H (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.		Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1992, IN PRESS EUR J BIOCH; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REED JC, 1987, ONCOGENE, V1, P223; ROUSSELMF, 1991, NATURE, V353, P361; RUDEN TV, 1988, EMBO J, V7, P2749; SATO C, 1985, J CELL BIOL, V100, P748, DOI 10.1083/jcb.100.3.748; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TANAKA T, 1991, INT IMMUNOL, V3, P105, DOI 10.1093/intimm/3.1.105; TROUCHE D, 1991, J IMMUNOL, V147, P2398; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUDO M, 1989, J IMMUNOL, V143, P4039; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	261	265	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					57	67		10.1016/0092-8674(92)90533-I	http://dx.doi.org/10.1016/0092-8674(92)90533-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1535827				2022-12-24	WOS:A1992JC95700008
J	MOMAND, J; ZAMBETTI, GP; OLSON, DC; GEORGE, D; LEVINE, AJ				MOMAND, J; ZAMBETTI, GP; OLSON, DC; GEORGE, D; LEVINE, AJ			THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION	CELL			English	Article							CELLULAR TUMOR-ANTIGEN; AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEINS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; MAMMALIAN-CELLS; T-ANTIGEN; GENE	A cellular phosphoprotein with an apparent molecular mass of 90 kd (p90) that forms a complex with both mutant and wild-type p53 protein has been characterized, purified, and identified. The protein was identified as a product of the murine double minute 2 gene (mdm-2). The mdm-2 gene enhances the tumorigenic potential of cells when it is overexpressed and encodes a putative transcription factor. To determine if mdm-2 could modulate p53 transactivation, a p53-responsive element from the muscle creatine kinase gene was employed. A wild-type p53-expressing plasmid enhanced the expression of the p53-responsive element when cotransfected into cells that contain no endogenous p53. When a cosmid expressing mdm-2 was transfected with this p53-expressing plasmid, the transactivation of the p53-responsive element was inhibited. Thus, a product of the mdm-2 oncogene forms a tight complex with the p53 protein, and the mdm-2 oncogene can inhibit p53-mediated transactivation.	UNIV PENN,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania	MOMAND, J (corresponding author), PRINCETON UNIV,LEWIS THOMAS LAB,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Momand, Jamil/F-8154-2012; Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NATIONAL CANCER INSTITUTE [F32CA008771] Funding Source: NIH RePORTER; NCI NIH HHS [CA09258-07, 5 F32 CA08771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAWASAKI E, 1989, AMPLIFICATIONS, P4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, IN PRESS GENES DEV	53	2861	2959	3	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1237	1245		10.1016/0092-8674(92)90644-R	http://dx.doi.org/10.1016/0092-8674(92)90644-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535557				2022-12-24	WOS:A1992JA43100017
J	BICKELL, NA; PIEPER, KS; LEE, KL; MARK, DB; GLOWER, DD; PRYOR, DB; CALIFF, RM				BICKELL, NA; PIEPER, KS; LEE, KL; MARK, DB; GLOWER, DD; PRYOR, DB; CALIFF, RM			REFERRAL PATTERNS FOR CORONARY-ARTERY DISEASE TREATMENT - GENDER BIAS OR GOOD CLINICAL JUDGMENT	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; SELECTION BIAS; SEX FACTORS; CORONARY ARTERY BYPASS; REFERRAL AND CONSULTATION; WOMENS HEALTH	ACUTE MYOCARDIAL-INFARCTION; SEX-DIFFERENCES; BYPASS-SURGERY; PROGNOSTIC PREDICTION; MEDICAL COMPLAINTS; REGRESSION-MODELS; FEMALE PATIENTS; WOMEN; MORTALITY; SURVIVAL	Objective: To determine whether a gender bias exists in referral for coronary bypass graft surgery among patients with catheterization-documented coronary artery disease. Design: Historical cohort study (1969 to 1984). Setting: A referral medical center. Patients: A total of 5795 patients with catheterization-documented coronary artery disease. Measurements: Surgical referral patterns of men and women grouped by risk for cardiac death and by treatment effectiveness. Time trends were evaluated for three periods: 1969 to 1974, 1975 to 1979, and 1980 to 1984. Results: Overall, when no adjustment was made for baseline risk for cardiac death, no statistical difference was found between men and women regarding referral for surgery (46% compared with 44%, respectively). When an adjustment was made for such risk, the male-to-female odds ratio for surgical referral was 1.28 (95% Cl, 1.05 to 1.58) among patients with a low risk for cardiac death. This effect was most evident in the 1980 to 1984 period (odds ratio, 1.73; Cl, 1.29 to 2.31). In the high-risk group, the odds ratio was 0.84 (Cl, 0.68 to 1.04), with little change occurring during the study. Men were more likely to be referred for surgery when surgery offered the least survival benefit relative to medical therapy (odds ratio, 1.29; Cl, 1.08 to 1.54). This effect was most pronounced in the 1980 to 1984 period (odds ratio, 1.63; Cl, 1.27 to 2.10). Conclusions: Women are less likely than men to be referred for coronary bypass graft surgery among patients with a low risk for cardiac death, in whom surgery offers little or no survival benefit over medical treatment. Women are at least as likely as men to be referred for bypass surgery among more symptomatic and more severely diseased patients, in whom surgery offers the greatest survival benefits. These trends were most prominent in the recent years of the study. Based on surgical survival benefits, these referral patterns may represent more appropriate treatment referral for women than men.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University				Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER; AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; CALIFF RM, 1988, CIRCULATION, V78, P185; CALIFF RM, 1972, JR STAT SOC B, V34, P187; COLAMECO S, 1983, J FAM PRACTICE, V16, P1117; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DEVLIN TF, 1986, 11TH P ANN SAS US GR, P646; DOLISZNY KM, 1989, CIRCULATION, V80, P410; EAKER ED, 1987, CORONARY HEART DISEA, P122; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GREER S, 1986, J FAM PRACTICE, V23, P49; HARLAN WR, 1987, CORONARY HEART DISEA, P131; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HIBARD JH, 1984, INT Q COMMUNITY HLTH, V4, P95; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; JONES RH, 1981, CIRCULATION, V64, P586, DOI 10.1161/01.CIR.64.3.586; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; KOSKENVUO M, 1986, SOC SCI MED, V23, P605, DOI 10.1016/0277-9536(86)90154-1; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MCCRANIE EW, 1978, SOC SCI MED-MED SOC, V12, P111, DOI 10.1016/0160-7979(78)90032-2; NATHANSON CA, 1977, SOC SCI MED, V11, P13, DOI 10.1016/0037-7856(77)90141-X; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PRYOR DB, 1984, J CHRON DIS, V37, P521, DOI 10.1016/0021-9681(84)90003-1; PRYOR DB, 1987, CIRCULATION, V76, P13; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; PRYOR DB, 1989, CIRCULATION S2, V80, P409; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; STACK RS, 1988, J AM COLL CARDIOL, V11, P1141, DOI 10.1016/0735-1097(88)90274-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stone CJ, 1985, P STAT COMP SECT AM, P45; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; VERBRUGGE LM, 1987, WOMEN HEALTH, V12, P103, DOI 10.1300/J013v12n02_07; WAGNER PJ, 1988, BEHAVIORAL MED, V6, P9; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; Wallen J, 1979, Women Health, V4, P135, DOI 10.1300/J013v04n02_03; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Wingard DL, 1987, CORONARY HEART DISEA, P99	49	174	174	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					791	797		10.7326/0003-4819-116-10-791	http://dx.doi.org/10.7326/0003-4819-116-10-791			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567093				2022-12-24	WOS:A1992HT80200002
J	JACOBSEN, JR; PRUDENT, JR; KOCHERSPERGER, L; YONKOVICH, S; SCHULTZ, PG				JACOBSEN, JR; PRUDENT, JR; KOCHERSPERGER, L; YONKOVICH, S; SCHULTZ, PG			AN EFFICIENT ANTIBODY-CATALYZED AMINOACYLATION REACTION	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; BINDING-ENERGY	An antibody generated against a neutral phosphonate diester transition-state analog was found to catalyze the aminoacylation of the 3'-hydroxyl group of thymidine with an alanyl ester. A comparison of the apparent second-order rate constant of the antibody-catalyzed reaction [5.4 x 10(4) molar-1 minute-1 (M-1 min-1)] with that of the uncatalyzed reaction (2.6 x 10(-4) M-1 min-1) revealed this to be a remarkably efficient catalyst. Moreover, although the concentration of water (55 M) greatly exceeds that of the secondary alcohol, the antibody selectively catalyzes acyl transfer to thymidine. The antibody exhibits sequential binding, with Michaelis constants of 770-mu-M and 260-mu-M for acyl acceptor and donor, respectively, and a dissociation constant of 240 pM for hapten. This antibody-catalyzed reaction provides increased insight into the requirements for efficient aminoacylation catalysts and may represent a first step toward the generation of "aminoacyl transfer RNA synthetases" with novel specificities.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,DEPT BIOORGAN CHEM,PALO ALTO,CA 94304	University of California System; University of California Berkeley				Prudent, James/0000-0002-8948-1781	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024695] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24695] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1986, TRENDS BIOCHEM SCI, V11, P321, DOI 10.1016/0968-0004(86)90289-6; HALDANE JBS, 1930, ENZYMES, P182; JACKSON DY, IN PRESS ANGEW CHEM; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PECHT I, 1972, J MOL BIOL, V68, P241, DOI 10.1016/0022-2836(72)90211-2; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; STORM DR, 1972, J AM CHEM SOC, V94, P5805, DOI 10.1021/ja00771a045; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120	24	60	61	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					365	367		10.1126/science.256.5055.365	http://dx.doi.org/10.1126/science.256.5055.365			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566082				2022-12-24	WOS:A1992HP03200032
J	MARTINEZ, C; DEGEUS, P; LAUWEREYS, M; MATTHYSSENS, G; CAMBILLAU, C				MARTINEZ, C; DEGEUS, P; LAUWEREYS, M; MATTHYSSENS, G; CAMBILLAU, C			FUSARIUM-SOLANI CUTINASE IS A LIPOLYTIC ENZYME WITH A CATALYTIC SERINE ACCESSIBLE TO SOLVENT	NATURE			English	Article							X-RAY; LIPASE	LIPASES belong to a class of esterases whose activity on triglycerides is greatly enhanced at lipid-water interfaces 1. This phenomenon, called interfacial activation 2, has a structural explanation: a hydrophobic lid, which at rest covers the catalytic site, is displaced on substrate or inhibitor binding, and probably interacts with the lipid matrix 3-6. Fusarium solani pisi cutinase belongs to a group of homologous enzymes of relative molecular mass 22-25K (ref. 7) capable of degrading cutin, the insoluble lipid-polyester matrix covering the surface of plants 7, and hydrolysing triglycerides 7,8. Cutinases differ from classical lipases in that they do not exhibit interfacial activation; they are active on soluble as well as on emulsified triglycerides. Cutinases therefore establish a bridge between esterases and lipases. We report here the three-dimensional structure of a recombinant cutinase from F. solani pisi, expressed in Escherichia coli 9,10. Cutinase is an alpha-beta protein; the active site is composed of the triad Ser 120, His 188 and Asp 175. Unlike other lipases, the catalytic serine is not buried under surface loops, but is accessible to solvent. This could explain why cutinase does not display interfacial activation.	FAC MED NORD,CNRS,LCCMB,F-13326 MARSEILLE 15,FRANCE; CORVAS INT NV,B-9000 GHENT,BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite								ABERGEL C, 1990, J MOL BIOL, V215, P215, DOI 10.1016/S0022-2836(05)80339-0; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; COLLOCH N, 1987, J MOL GRAPHICS, V5, P170; CONNOLLY ML, 1983, SCIENCE, V306, P287; DEGEUS P, Patent No. 894004621; DEREWENDA ZS, IN PRESS BIOCH CELL; ETTINGER WF, 1987, BIOCHEMISTRY-US, V26, P7883, DOI 10.1021/bi00398a052; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kolattukudy PE., 1981, METHODS ENZYMOLOGY, P652; LAUWEREYS M, 1991, LIPASES STRUCTURE ME, V16, P243; LIAO DI, 1990, J BIOL CHEM, V265, P6528; PULLMAN B, 1970, THEOR CHIM ACTA, V18, P344; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	26	349	377	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					615	618		10.1038/356615a0	http://dx.doi.org/10.1038/356615a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560844				2022-12-24	WOS:A1992HP03100053
J	BATES, DW; LEE, TH				BATES, DW; LEE, TH			RAPID CLASSIFICATION OF POSITIVE BLOOD CULTURES - PROSPECTIVE VALIDATION OF A MULTIVARIATE ALGORITHM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDENTIFICATION; ASSOCIATION; BACTEREMIA; SLIME	Objective. - To develop and validate a model predicting whether a positive blood culture represents a true positive or a contaminant in hospitalized patients, using only information available when the initial culture result becomes available. Design. - Prospective cohort study with derivation and validation sets. Setting. - Urban tertiary care hospital. Patients. - Clinical data were collected within 24 hours of the initial culture from a random sample of inpatients who had blood cultures performed, and data from the episodes in which growth was reported were included. There were 219 episodes in the derivation set and 129 episodes in the validation set. Main Outcome Measure. - True bacteremia. Reviewers blinded to potential clinical predictors and initial laboratory results classified 115 (53%) of the episodes in the derivation set and 57 (44%) of the episodes in the validation set as true positives. Results. - Independent multivariate predictors of bacteremia were organism type, days until the blood culture became positive, multiple positive cultures, and clinical risk score. These factors were used to develop a model stratifying patients into four risk groups. In the derivation set's lowest-risk group, 92% (65/71) of positives represented contaminants, and in the highest-risk group, 97% (86/89) of positives represented true positives. In the validation set, the misclassification rates were 14% (8/59) in the low-risk group, and 11% (5/44) in the high-risk group. These two groups together comprised 76% of all episodes. Conclusion. - This model can help clinicians quantify the likelihood that a given positive blood culture represents a true positive when the laboratory first calls, which may be helpful in subsequent decision making.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [1 F32 HS00040-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; DOERN GV, 1982, ANTIMICROB AGENTS CH, V21, P1023, DOI 10.1128/AAC.21.6.1023; EDMISTON CE, 1989, INFECT CONT HOSP EP, V10, P111; EPSTEIN PE, 1990, ANN INTERN MED, V113, P646, DOI 10.7326/0003-4819-113-9-646; HARTZ A, 1986, MED DECIS MAKING, V6, P149, DOI 10.1177/0272989X8600600304; ISHAK MA, 1985, J CLIN MICROBIOL, V22, P1025, DOI 10.1128/JCM.22.6.1025-1029.1985; KOCKA FE, 1975, J INFECT DIS, V131, P456, DOI 10.1093/infdis/131.4.456; KOTILAINEN P, 1990, J CLIN MICROBIOL, V28, P2779, DOI 10.1128/JCM.28.12.2779-2785.1990; MACGREGOR RR, 1972, ARCH INTERN MED, V130, P84, DOI 10.1001/archinte.130.1.84; MADISON BM, 1983, J CLIN MICROBIOL, V18, P722, DOI 10.1128/JCM.18.3.722-724.1983; MOORE DF, 1981, J CLIN MICROBIOL, V13, P934, DOI 10.1128/JCM.13.5.934-939.1981; TRENHOLME GM, 1989, J CLIN MICROBIOL, V27, P1342, DOI 10.1128/JCM.27.6.1342-1345.1989; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35	15	71	73	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1962	1966		10.1001/jama.267.14.1962	http://dx.doi.org/10.1001/jama.267.14.1962			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548830				2022-12-24	WOS:A1992HL67700032
J	WALKER, C; GOLDSWORTHY, TL; WOLF, DC; EVERITT, J				WALKER, C; GOLDSWORTHY, TL; WOLF, DC; EVERITT, J			PREDISPOSITION TO RENAL-CELL CARCINOMA DUE TO ALTERATION OF A CANCER SUSCEPTIBILITY GENE	SCIENCE			English	Article							VONHIPPEL-LINDAU DISEASE; TUMORS; RATS; ADENOCARCINOMAS; IDENTIFICATION; NEOPLASMS; ADENOMAS; LOCUS	A single germ line gene mutation at a tumor susceptibility locus in a rodent model of hereditary human renal cancer caused a 70-fold increase in susceptibility to chemical carcinogenesis. A carcinogen that targeted both renal epithelial and mesenchymal cells caused an increase in tumors of epithelial origin in susceptible animals; the number of carcinogen-induced mesenchymal tumors was unaffected by the presence of the mutation at the susceptibility locus. Thus, this mutation defines a genetic locus for susceptibility to carcinogen-induced tumors and modulation of carcinogen susceptibility by this locus exhibits cell-type specificity.			WALKER, C (corresponding author), CHEM IND INST TOXICOL, POB 12137, RES TRIANGLE PK, NC 27709 USA.			Everitt, Jeffrey/0000-0003-0273-6284				CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; EVERITT J, UNPUB; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FUNAKI K, 1991, CANCER RES, V51, P4415; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HARD G C, 1986, Toxicologic Pathology, V14, P112; HARD GC, 1984, CARCINOGENESIS, V5, P1047, DOI 10.1093/carcin/5.8.1047; JOHANNESSEN JV, 1980, J SUBMICR CYTOL PATH, V12, P463; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1990, GENETIC BASIS FOR CARCINOGENESIS, P15; LAMIELL JM, 1989, MEDICINE, V68, P1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MEADOWS AT, 1988, B CANCER, V75, P125; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OUTZEN HC, 1983, SEMIN ONCOL, V10, P378; RECIO L, 1991, MOL CARCINOGEN, V4, P350, DOI 10.1002/mc.2940040504; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SOLLEVELD H A, 1986, Toxicologic Pathology, V14, P168, DOI 10.1177/019262338601400204; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALKER C, 1991, CANCER RES, V51, P2973; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4; WEINBERG RA, 1989, CIBA F SYMP, V142, P99; ZBAR B, 1989, IMPORTANT ADV ONCOL, V41	33	82	82	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1992	255	5052					1693	1695		10.1126/science.1553556	http://dx.doi.org/10.1126/science.1553556			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553556				2022-12-24	WOS:A1992HK81200033
J	SGANGA, MW; BAUER, CE				SGANGA, MW; BAUER, CE			REGULATORY FACTORS CONTROLLING PHOTOSYNTHETIC REACTION CENTER AND LIGHT-HARVESTING GENE-EXPRESSION IN RHODOBACTER-CAPSULATUS	CELL			English	Article							REACTION CENTER POLYPEPTIDES; RHODOPSEUDOMONAS-CAPSULATA; BACTERIOCHLOROPHYLL BIOSYNTHESIS; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; 3A RESOLUTION; R-CAPSULATA; PUF OPERON; OXYGEN; BACTERIA	Most species of photosynthetic bacteria synthesize their photosynthetic apparatus only under conditions of reduced oxygen tension. To a large extent, this phenomenon is dependent upon anaerobic induction of photosynthesis gene expression. Here we report an example of a regulatory gene, regA, that is involved in transactivating anaerobic expression of the photosynthetic apparatus. We show that RegA is itself responsible for differential induction of light-harvesting and reaction center gene expression relative to operons for photopigment biosynthesis. Surprisingly, strains disrupted for regA were found to retain normal photosynthetic growth capabilities under high light intensities. We further show that photosynthetic growth in the absence of transactivating structural gene expression is a consequence of the superoperonal organization of the photosynthetic gene cluster.			SGANGA, MW (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NIGMS NIH HHS [GM40941, R01 GM040941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, R01GM040941, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; BARANY F, 1985, GENE, V37, P111, DOI 10.1016/0378-1119(85)90263-X; BAUER CE, 1991, MOL GEN GENET, V228, P433, DOI 10.1007/BF00260637; BAUER CE, 1988, J BIOL CHEM, V263, P4820; BAUER CE, 1988, P NATL ACAD SCI USA, V85, P7074, DOI 10.1073/pnas.85.19.7074; BECK J, 1982, Z NATURFORSCH C, V37, P199; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BIEL AJ, 1983, J BACTERIOL, V156, P686, DOI 10.1128/JB.156.2.686-694.1983; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHEN CYA, 1988, CELL, V52, P609, DOI 10.1016/0092-8674(88)90473-4; CLARK WG, 1984, J BACTERIOL, V157, P945, DOI 10.1128/JB.157.3.945-948.1984; Clayton R.K., 1966, PHOTOCHEM PHOTOBIOL, V5, P669, DOI [10.1111/j.1751-1097.1966.tb05813.x, DOI 10.1111/J.1751-1097.1966.TB05813.X]; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DALE RMK, 1987, METHOD ENZYMOL, V155, P204; DAVISON J, 1987, GENE, V51, P275, DOI 10.1016/0378-1119(87)90316-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DREWS G, 1981, ADV MICROB PHYSIOL, V22, P1, DOI 10.1016/S0065-2911(08)60325-2; GEST H, 1983, ARCH MICROBIOL, V136, P11, DOI 10.1007/BF00415602; KLUG G, 1991, P NATL ACAD SCI USA, V88, P1765, DOI 10.1073/pnas.88.5.1765; KLUG G, 1987, EMBO J, V6, P3315; MADIGAN M, 1982, J BACTERIOL, V150, P1422, DOI 10.1128/JB.150.3.1422-1429.1982; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOLNIK PA, 1984, NATURE, V307, P289, DOI 10.1038/307289a0; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WELLINGTON CL, 1991, J BACTERIOL, V173, P2954, DOI 10.1128/JB.173.9.2954-2961.1991; WELLINGTON CL, 1989, GENE, V83, P251, DOI 10.1016/0378-1119(89)90111-X; WELLINGTON CL, 1991, J BACTERIOL, V173, P1432, DOI 10.1128/jb.173.4.1432-1443.1991; WELLINGTON CL, 1992, CAN J MICROBIOL, V38, P20, DOI 10.1139/m92-003; YANG ZY, 1990, J BACTERIOL, V126, P619; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; YOUVAN DC, 1985, P NATL ACAD SCI USA, V82, P58, DOI 10.1073/pnas.82.1.58; ZHU YS, 1986, P NATL ACAD SCI USA, V83, P7613, DOI 10.1073/pnas.83.20.7613; ZHU YS, 1986, J BACTERIOL, V168, P1180, DOI 10.1128/jb.168.3.1180-1188.1986; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	50	154	157	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					945	954		10.1016/0092-8674(92)90037-D	http://dx.doi.org/10.1016/0092-8674(92)90037-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547494				2022-12-24	WOS:A1992HH74800013
J	HOBBS, FDR; CHERRY, RC; FIELDING, JWL; PIKE, L; HOLDER, R				HOBBS, FDR; CHERRY, RC; FIELDING, JWL; PIKE, L; HOLDER, R			ACCEPTABILITY OF OPPORTUNISTIC SCREENING FOR OCCULT GASTROINTESTINAL BLOOD-LOSS	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; CONTROLLED TRIAL; GENERAL-PRACTICE	Objective - To test patient compliance for faecal occult blood testing in suburban and inner city general practice. Design - Prospective opportunistic trial using the Haemoccult test kit. Tests were offered during routine surgery attendance. Setting - Three group general practices in Birmingham. Subjects - All patients aged 40 years or older on the start date who routinely attended surgery during two years. Main outcome measures - Numbers of patients approached for testing and the numbers refusing, accepting, and returning the test kits. Results - Only 26.3% (1230/4677) of the potential target population had been screened within the two years, although 988 (39.3%) of the suburban practice target were screened. However, 55.7% (1230/2207) of patients actually offered a test returned completed kits, with only 6% (133) refusing the kit. 683 (61.6%) patients aged 50-69 returned kits, compared with 343 (54.3%) aged 70 or over and 204 (43.8%) aged 40-49. These differences were significant (p < 0.001). Patients from the inner city practice were significantly less likely to be offered the test than those in suburban practice (242 (11.2%) v 988 (39.9%), p < 0.001) and return the samples (242 (38.8%) v 988 (62.4%), p < 0.001). Patients from the inner city practice were also more likely to refuse the test (78 (12.5%) v 55 (3.5%), p < 0.001). Conclusions - Opportunistic testing for occult faecal blood in asymptomatic patients was reasonably acceptable to patients, especially those in a suburban practice. If the test is shown to reduce mortality from colorectal cancer then formal screening would probably achieve acceptable target rates, especially among patients aged 50-69, who represent the prime risk group.	UNIV BIRMINGHAM,STAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; GREENBANK MED CTR,BIRMINGHAM B28 8BG,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TJ,ENGLAND; BIRMINGHAM FAMILY HLTH SERV AUTHOR,BIRMINGHAM B6 5RQ,ENGLAND	University of Birmingham; University of Birmingham	HOBBS, FDR (corresponding author), UNIV BIRMINGHAM,GEN PRACT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			hobbs, richard/0000-0001-7976-7172				BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BOX V, 1984, PUBLIC HEALTH, V98, P16, DOI 10.1016/S0033-3506(84)80055-4; Farrands P A, 1984, Community Med, V6, P12; FARRANDS PA, 1981, LANCET, V1, P1231; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; GILL PG, 1978, BRIT J SURG, V65, P17, DOI 10.1002/bjs.1800650105; HARDCASTLE JD, 1980, LANCET, V1, P791; HARDCASTLE JD, 1989, LANCET, V1, P1160; HARDCASTLE JD, 1983, LANCET, V2, P1; HOLLIDAY HW, 1979, LANCET, V1, P309; KELLY MH, 1990, GASTROENTEROLOGY TRE; LALLEMAND RC, 1984, BRIT MED J, V288, P31, DOI 10.1136/bmj.288.6410.31; LOVE R, 1981, LANCET, P489; MANT D, 1990, BRIT J GEN PRACT, V40, P423; MANT D, 1990, BMJ, V300, P1318; MCCRAE FA, 1982, GASTROENTEROLOGY, V82, P891; NICHOLS S, 1986, BRIT MED J, V293, P107, DOI 10.1136/bmj.293.6539.107; PAYNE CD, 1987, GLIM SYSTEM RELEASE; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Silman A, 1984, Community Med, V6, P8; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; WEATHERALL DJ, 1983, OXFORD TXB MED, V1; WILSON JMG, 1968, WHO34 PUBL HLTH PAP; 1989, COMPENDIUM HLTH STAT	24	32	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					483	486		10.1136/bmj.304.6825.483	http://dx.doi.org/10.1136/bmj.304.6825.483			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547423	Green Published, Bronze			2022-12-24	WOS:A1992HF55500026
J	KAINZ, M; ROBERTS, J				KAINZ, M; ROBERTS, J			STRUCTURE OF TRANSCRIPTION ELONGATION COMPLEXES INVIVO	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; TERNARY COMPLEXES; PROMOTER DNA; ANTITERMINATION; INITIATION; METHYLATION; MECHANISM; PROTEIN	The opening of duplex DNA in the elongation phase of transcription by Escherichia coli RNA polymerase in vivo was detected at a regulatory site where a prolonged pause in transcription occurs. Single-stranded DNA in the transcription bubble was identified by its reactivity with potassium permanganate (KMnO4). The elongation structure in vivo was similar to that of transcription complexes made in vitro with some differences. The observed reactivity to KMnO4 of the DNA template strand was consistent with the existence of an RNA-DNA hybrid of about 12 nucleotides.			KAINZ, M (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK S, 1987, CELL, V50, P885; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1991, J BACTERIOL, V173, P1554, DOI 10.1128/jb.173.4.1554-1560.1991; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, UNPUB; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; WAGNER LA, 1990, NUCLEIC ACIDS RES, V18, P3529, DOI 10.1093/nar/18.12.3529; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG X, 1988, THESIS CORNELL U; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217	22	90	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					838	841		10.1126/science.1536008	http://dx.doi.org/10.1126/science.1536008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536008				2022-12-24	WOS:A1992HD54800034
J	SOLLNER, T; RASSOW, J; WIEDMANN, M; SCHLOSSMANN, J; KEIL, P; NEUPERT, W; PFANNER, N				SOLLNER, T; RASSOW, J; WIEDMANN, M; SCHLOSSMANN, J; KEIL, P; NEUPERT, W; PFANNER, N			MAPPING OF THE PROTEIN IMPORT MACHINERY IN THE MITOCHONDRIAL OUTER-MEMBRANE BY CROSS-LINKING OF TRANSLOCATION INTERMEDIATES	NATURE			English	Article							PRECURSOR PROTEINS; RECEPTOR; IDENTIFICATION; RECOGNITION; INSERTION; CARRIER; SITE	MITOCHONDRIA Contain a complex machinery for the import of nuclear-encoded proteins 1,2. Receptor proteins exposed on the outer membrane surface are required for the specific binding of precursor proteins to mitochondria, either by binding of cytosolic signal recognition factors or by direct recognition of the precursor polypeptides 1-5. Subsequently, the precursors are inserted into the outer membrane at the general insertion site GIP (general insertion protein) 6-10. Here we report the analysis of receptors and GIP by crosslinking of translocation intermediates and by coimmunoprecipitation. Surface-accumulated precursors were crosslinked to the receptors MOM19 and MOM72, suggesting a direct interaction of preproteins with surface receptors. We identified three novel mitochondrial outer membrane proteins, MOM7, MOM8, and MOM30 that, together with the previously identified MOM38, seem to form the GIP site and are present in the mitochondrial receptor com lex.	UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY; AKAD WISSENSCH DDR, ZENT INST MOLEK BIOL, O-1115 BERLIN, GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016; Pfanner, Nikolaus/AAV-7878-2021	Schlossmann, Jens/0000-0002-2550-6839; 				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, IN PRESS J BIOL CHEM, V267; FONT B, 1991, FEBS LETT, V279, P105, DOI 10.1016/0014-5793(91)80262-2; GILLESPIE LL, 1987, J BIOL CHEM, V262, P7939; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MARTIN J, 1991, J BIOL CHEM, V266, P18051; ONO H, 1990, J BIOCHEM-TOKYO, V107, P840, DOI 10.1093/oxfordjournals.jbchem.a123135; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RASSOW J, IN PRESS FEBS LETT; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SOLLNER T, 1988, FEBS LETT, V229, P25, DOI 10.1016/0014-5793(88)80790-7; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	24	153	156	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					84	87		10.1038/355084a0	http://dx.doi.org/10.1038/355084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1530986	Green Published			2022-12-24	WOS:A1992GY22800057
J	CHRISCHILLES, EA; SEGAR, ET; WALLACE, RB				CHRISCHILLES, EA; SEGAR, ET; WALLACE, RB			SELF-REPORTED ADVERSE DRUG-REACTIONS AND RELATED RESOURCE USE - A STUDY OF COMMUNITY-DWELLING PERSONS 65 YEARS OF AGE AND OLDER	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERSE DRUG REACTION REPORTING SYSTEMS; GERIATRICS; HEALTH RESOURCES; DRUG TOXICITY; HEALTH STATUS	GENERAL-PRACTICE	Objective: To describe the incidence and health resource consequences of self-reported adverse drug reactions (ADRs) and their relation to self-perceived health, number of medications used, and age in a geographically based population 65 years of age and older. Design: A survey of a defined population. Participants: Three thousand, one hundred seventy noninstitutionalized persons 65 years of age and older residing in two Iowa counties. Measurements: Reports of ADRs (elicited using an open-ended questionnaire); names of drugs involved; descriptions of reactions and related health resource use; self-perceived health status (at the first annual follow-up); and number of medications (from the baseline interview). Results: Ten percent (95% Cl, 8.97 to 11.09) of respondents reported one or more ADRs. Three quarters of respondents who reported ADRs contacted a physician. Of these, half indicated that a laboratory test had been ordered, and 7% reported a hospitalization due to the reaction. Advanced age alone was associated with decreased risk in women; a similar trend in men was not statistically significant. However, persons with poorer health status and those who reported the greatest prior use of medications were most likely to report reactions. Conclusions: In this study of noninstitutionalized elderly persons, advanced age did not appear to be associated with increased risk for self-reported ADRs. We could not determine whether the decrease in ADR reports among the oldest respondents represented true diminished ADR occurrence or altered ADR detection and reporting capabilities. When projected to the elderly community-dwelling U.S. population, 2.2 million annual physician visits, 1.1 million laboratory tests, and 146 000 hospitalizations may result from ADRs.			CHRISCHILLES, EA (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA.			Chrischilles, Elizabeth/0000-0002-1843-1955				Campbell W H, 1978, J Community Health, V3, P205, DOI 10.1007/BF01349383; CHRISCHILLES EA, 1989, PHARMACOEPIDEMIOLOGY; CHRISCHILLES EA, 1992, IN PRESS J GERONTOL; CICCOLUNGHI SN, 1975, J CLIN PHARMACOL, V15, P496, DOI 10.1002/j.1552-4604.1975.tb01471.x; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; Colsher Patricia L., 1991, Annals of Epidemiology, V1, P215; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; CURB J D, 1985, American Journal of Preventive Medicine, V1, P36; DOWNING RW, 1970, J CLIN PHARM     SEP, P289; German P S, 1989, J Aging Health, V1, P4, DOI 10.1177/089826438900100102; GRYMONPRE RE, 1988, J AM GERIATR SOC, V36, P1092, DOI 10.1111/j.1532-5415.1988.tb04395.x; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; HELLING DK, 1987, J AM GERIATR SOC, V35, P4, DOI 10.1111/j.1532-5415.1987.tb01312.x; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; HUSKISSON EC, 1974, BRIT MED J, V29, P698; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; IREY NS, 1976, AM J PATHOL, V82, P617; KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247; KELLAWAY GS, 1973, NEW ZEAL MED J, V78, P525; KLEIN LE, 1984, ARCH INTERN MED, V144, P1185, DOI 10.1001/archinte.144.6.1185; KOCH H, 1987, PHS871250 US DEP HLT; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LUMLEY C E, 1986, Pharmaceutical Medicine (London), V1, P205; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTYS CR, 1979, BMJ-BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6199.1194; MCEVOY GK, 1990, AHFS DRUG INFORMATIO; MICHOCKI RJ, 1988, J AM GERIATR SOC, V36, P79, DOI 10.1111/j.1532-5415.1988.tb03439.x; MOELLER J, 1989, PHS893448 US DEP HLT; MULROY R, 1973, BRIT MED J, V2, P407, DOI 10.1136/bmj.2.5863.407; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SMIDT NA, 1972, NEW ZEAL MED J, V76, P397; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART RB, 1971, JOHNS HOPKINS MED J, V129, P319; STEWART RB, 1988, THERAPEUTICS ELDERLY; VENULET J, 1980, INT J CLIN PHARM TH, V18, P381; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1990, PHYSICIANS DESK REFE; 1979, HLTH INTERVIEW SURVE	41	104	106	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					634	640		10.7326/0003-4819-117-8-634	http://dx.doi.org/10.7326/0003-4819-117-8-634			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530194				2022-12-24	WOS:A1992JR86100002
J	GURWITZ, JH; COL, NF; AVORN, J				GURWITZ, JH; COL, NF; AVORN, J			THE EXCLUSION OF THE ELDERLY AND WOMEN FROM CLINICAL-TRIALS IN ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; PROPHYLACTIC LIDOCAINE; MORTALITY; AGE; HYPERTENSION; MORBIDITY; PATTERNS; THERAPY; MEN	Objective.-To determine the extent to which the elderly have been excluded from trials of drug therapies used in the treatment of acute myocardial infarction, to identify factors associated with such exclusions, and to explore the relationship between the exclusion of elderly and the representation of women. Data Sources.-We conducted a systematic search of the English-language literature from January 1960 through September 1991 to identify all relevant studies of specific pharmacotherapies employed in the treatment of acute myocardial infarction. To accomplish this, we searched MEDLINE, major cardiology textbooks, meta-analyses, reviews, editorials, and the bibliographies of all identified articles. Study Selection.-Only trials in which patients were randomly allocated to receive a specific therapeutic regimen or a placebo or nonplacebo control regimen were included for review. Data Extraction.-Studies were abstracted for year of publication, source of support, performance location, drug therapies to which patients were randomized, use of invasive diagnostic tests or therapeutic procedures, exclusion criteria, size and demographic characteristics of the randomized study population, and principal outcome measures. Data Synthesis.-A total of 214 trials met inclusion criteria, involving 150 920 study subjects. Over 60% of trials excluded persons over the age of 75 years. Studies published after 1980 were more likely to have age-based exclusions compared with studies published before 1980 (adjusted odds ratio, 4.92; 95% confidence interval, 2.33 to 10.54). Trials of thrombolytic therapy involving an invasive procedure were more likely to exclude elderly patients compared with other studies (adjusted odds ratio, 2.45; 95% confidence interval, 1.10 to 5.47). Studies with age-based exclusions had a smaller percentage of women compared with those without such exclusions (18% vs 23%; P=.0002), with the mean age of the study population significantly associated with the proportion of women participants (P=.0001, R2=.29). Conclusions.-Age-based exclusions are frequently used in clinical trials of medications used in the treatment of acute myocardial infarction. Such exclusions limit the ability to generalize study findings to the patient population that experiences the most morbidity and mortality from acute myocardial infarction.	HARVARD RES & TRAINING CTR, BOSTON, MA USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA; UNIV MASSACHUSETTS, SCH MED, DEPT FAMILY & COMMUNITY MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP, DIV GERONTOL, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.		Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X	NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER; NIA NIH HHS [KO8 AG00510-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADOLPH RJ, 1990, J AM COLL CARDIOL, V16, P793, DOI 10.1016/S0735-1097(10)80323-7; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1989, GUIDELINE STUDY DRUG; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DOUGLAS PS, 1986, CIRCULATION, V74, P917, DOI 10.1161/01.CIR.74.5.917; DUNN HM, 1985, AM HEART J, V110, P353, DOI 10.1016/0002-8703(85)90156-5; EVEMY KL, 1978, EUR J CARDIOL, V7, P391; FISHER LD, 1989, INT J CARDIOL, V24, P317, DOI 10.1016/0167-5273(89)90011-9; FULTON JP, 1989, VITAL HLTH STAT 10, V167; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GRAVES EJ, 1991, VITAL HLTH STAT, V13; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; KAPANTAIS G, 1989, ADV DATA VITAL HLTH, V172; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; LAKATTA EG, 1982, AM J PHYSIOL, V242, pH927, DOI 10.1152/ajpheart.1982.242.6.H927; LEVEY BA, 1991, CLIN PHARMACOL THER, V50, P641, DOI 10.1038/clpt.1991.201; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; RICH MW, 1992, AM J MED, V92, P7, DOI 10.1016/0002-9343(92)90008-Y; ROSS AM, 1990, J MYO ISCH, V2, P65; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WILHELMSEN L, 1988, EUR HEART J, V9, P207, DOI 10.1093/oxfordjournals.eurheartj.a062484; WILHELMSSON C, 1974, LANCET, V2, P1157; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114; YUSUF S, 1991, AM J CARDIOL, V68, P954, DOI 10.1016/0002-9149(91)90416-I; YUSUF S, 1988, LANCET, V1, P1088; 1991, VITAL STATISTICS U A, V2; 1987, SAS RELEAS 604; 1987, VITAL HLTH STAT, V3; 1990, STATISTICAL ABSTRACT	42	381	388	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1417	1422		10.1001/jama.1992.03490110055029	http://dx.doi.org/10.1001/jama.1992.03490110055029			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512909				2022-12-24	WOS:A1992JM84900023
J	HOULE, D; HOFFMASTER, DK; ASSIMACOPOULOS, S; CHARLESWORTH, B				HOULE, D; HOFFMASTER, DK; ASSIMACOPOULOS, S; CHARLESWORTH, B			THE GENOMIC MUTATION-RATE FOR FITNESS IN DROSOPHILA	NATURE			English	Article							AFFECTING VIABILITY; MELANOGASTER; POPULATIONS; EVOLUTION	THE mutation rate per genome for local affecting fitness is crucial in theories of the evolution of sex and recombination1,2 and of outbreeding mechanisms3. Mutational variation in fitness may also be important in the evolution of mate choice in animals2,4,5. No information is available on the rate at which spontaneous mutations with small effects on fitness arise, although viability (probability of survival to adulthood) has been studied in Drosophila melanogaster6-9. These experiments involved the accumulation of spontaneous mutations in the virtual absence of natural selection, in a set of independently maintained lines with a common origin. The rates of decline in mean and increase in variance among lines permit estimation of limits to the mean number of new mutations arising per generation (U) and the average homozygous effect of a new mutation of minor effect (s)7,9,10. For the second chromosome of D. melanogaster, the value of U is at least 0.17 (ref. 7), and (1 - h)s is less than 0.02, where hs is the average decline in fitness of heterozygotes. As the second chromosome is about 40% of the genome, these data indicate a mutation rate per haploid genome of at least 0.42 for viability. Here we present similar data on the effects of homozygous spontaneous mutations on a measure of fitness in D. melanogaster.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago								ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATEMAN A, 1959, INT J RADIAT BIOL, V2, P170; CARLSSON BG, 1987, ORNIS SCAND, V18, P237, DOI 10.2307/3676890; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lindsley D.L., 1968, GENETIC VARIATIONS D; MUKAI T, 1969, GENETICS, V61, P749; MUKAI T, 1971, GENETICS, V69, P385; MUKAI T, 1972, GENETICS, V72, P335; MUKAI T, 1964, GENETICS, V50, P1; OHNISHI O, 1977, GENETICS, V87, P529; SIMMONS MJ, 1980, GENETICS, V94, P467; Sokal R. R, 1981, BIOMETRY; SVED JA, 1971, GENET RES, V18, P97, DOI 10.1017/S0016672300012453; YOSHIMARU H, 1985, JPN J GENET, V60, P307, DOI 10.1266/jjg.60.307	20	108	108	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					58	60		10.1038/359058a0	http://dx.doi.org/10.1038/359058a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522887				2022-12-24	WOS:A1992JL66200052
J	ADLER, RG				ADLER, RG			GENOME RESEARCH - FULFILLING THE PUBLICS EXPECTATIONS FOR KNOWLEDGE AND COMMERCIALIZATION	SCIENCE			English	Article							BIOTECHNOLOGY; PROJECT; PATENTS	This article provides a historical perspective for the patenting of gene sequences and describes the fundamentals and evolution of patent law. It summarizes federal technology transfer law and policy and assesses the impacts of patenting on academic research. The patentability of gene sequences is then considered along with potential impacts that published sequence data may have on obtaining patent protection for downstream products. Industry's position on gene patenting is summarized and perspectives from the emerging public record on these issues are presented. The article discussing points at which the filing of patent applications and the licensing of patents may be appropriate. It concludes that technology transfer policies for genome research must be adopted carefully so that they remain viable in a time of rapid technological change.			ADLER, RG (corresponding author), NIH,OFF TECHNOL TRANSFER,BETHESDA,MD 20892, USA.			Adler, Reid/0000-0002-4998-4034				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADLER R, 1988, HARVARD J LAW TECH, V1, P1; ADLER R, 1989, AM INTELECT PROP LAW, V16, P287; ADLER RG, 1984, SCIENCE, V224, P357, DOI 10.1126/science.6584975; Beier David, 1991, DENVER U LAW REV, V68, P173; BENT S, 1992, GENET ENG NEWS   JAN, P4; BURRILL GS, 1990, BIOTECH 91 CHANGING, P5; Cohen Stanley N, 1980, US Patent, Patent No. [4,237,224, 4237224]; CURIEN H, 1991, SCIENCE, V254, P1710; Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; FEIT, 1989, J PAT TRADEMARK OFF, V71, P819; GREENLEE LL, 1991, DENVER U LAW REV, V68, P127; HEALY B, 1992, IN PRESS N ENGL J ME; ISRAELSEN N, 1988, AM INTELECT PROP L A, V16, P457; JARJALA DS, 1992, JURIMETRICS, V32, P121; KELLY PD, 1992, BIO-TECHNOL, V10, P52, DOI 10.1038/nbt0192-52; KOSHLAND DE, 1992, SCIENCE, V255, P1189, DOI 10.1126/science.255.5049.1189; MANSFIELD E, 1979, REV EC STATISTIC FEB, P49; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; MOSSINGHOFF GJ, 1992, COMMUNICATION   0528; Pasteur L., 1871, REV SCI; RAINES L, 1992, MAY PUBL M FCCSET CO; RAINES LJ, 1991, ISSUES SCI TECHNOL, V8, P33; Santayana George, 1905, LIFE REASON, VII; Schwaab Richard L., 1987, INTELLECTUAL PROPERT; Solzhenitsyn Aleksandr, 1978, NAT REV, V30; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; WATSON JD, 1981, DNA STORY DOCUMENTAR, pCH16; Winslow Ron, WALL STREET J; 1992, OTATCT527E OFF TECHN; 1991, OTABA495 OFF TECHN A, P203; 1991, REPORT NATIONAL BIOT, P17; 1984, OTAB2218 US C OFF TE; 1988, OTABA373 US C OFF TE, pCH16; 1991, OTABA494 US C OFF TE, P17; 1992, WASHINGTON POST 0501; [No title captured]; 1988, IMPLICATIONS SOC, P91	40	32	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					908	914		10.1126/science.1502557	http://dx.doi.org/10.1126/science.1502557			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JH827	1502557				2022-12-24	WOS:A1992JH82700022
J	GIMBLE, FS; THORNER, J				GIMBLE, FS; THORNER, J			HOMING OF A DNA ENDONUCLEASE GENE BY MEIOTIC GENE CONVERSION IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							SITE-SPECIFIC ENDONUCLEASE; INTRON-ENCODED PROTEINS; DOUBLE-STRAND-BREAK; RIBOSOMAL-RNA GENE; ADENOSINE-TRIPHOSPHATASE; YEAST; SUBUNIT; RECOMBINATION; TRANSCRIPTION; PURIFICATION	An unusual protein splicing reaction joins the N-terminal segment (A) and the C-terminal segment (C) of the 119K primary translation product (ABC) of the yeast VMA1 gene to yield a 69K vacuolar H+-ATPase subunit (AC) and an internal 50K polypeptide (B). This 50K protein is a site-specific DNA endonuclease that shares 34% identity with the homothallic switching endonuclease. The site cleaved by the VMA1-derived endonuclease exists in a VMA1 allele that lacks the derived endonuclease segment of the open reading frame. Cleavage at this site only occurs during meiosis and initiates 'homing', a genetic event that converts a VMA1 allele lacking the endonuclease coding sequence into one that contains it.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, ROOM 401, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Wood, David W/B-2992-2012	THORNER, Jeremy/0000-0002-2583-500X; 				BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BELFORT M, 1990, ANNU REV GENET, V24, P363; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; HENIGENS LAM, 1980, CELL, P185; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JACQUIER A, 1985, CELL, V41, P383, DOI 10.1016/S0092-8674(85)80011-8; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KAWASAKI K, 1991, J BIOL CHEM, V266, P5342; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LEMIEUX B, 1988, MOL GEN GENET, V212, P48, DOI 10.1007/BF00322443; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MURRAY JAH, 1986, EMBO J, V5, P3391, DOI 10.1002/j.1460-2075.1986.tb04655.x; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; NAKAGAWA K, 1988, EUR J BIOCHEM, V171, P23, DOI 10.1111/j.1432-1033.1988.tb13753.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU; SARWAR G, 1985, J FOOD SCI, V50, P353, DOI 10.1111/j.1365-2621.1985.tb13400.x; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Sherman F., 1986, METHODS YEAST GENETI; SHIBATA T, 1984, J BIOL CHEM, V259, P499; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VANARSDELL SW, 1987, TRANSCRIPTIONAL CONT, P325; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WATABE H, 1983, J BIOL CHEM, V258, P4663; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE C, 1992, MOL CELL BIOL, V12, P716, DOI 10.1128/MCB.12.2.716; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; ZINN AR, 1985, CELL, V40, P887, DOI 10.1016/0092-8674(85)90348-4	50	245	252	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1992	357	6376					301	306		10.1038/357301a0	http://dx.doi.org/10.1038/357301a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534148				2022-12-24	WOS:A1992HW13200037
J	WATKINS, H; ROSENZWEIG, A; HWANG, DS; LEVI, T; MCKENNA, W; SEIDMAN, CE; SEIDMAN, JG				WATKINS, H; ROSENZWEIG, A; HWANG, DS; LEVI, T; MCKENNA, W; SEIDMAN, CE; SEIDMAN, JG			CHARACTERISTICS AND PROGNOSTIC IMPLICATIONS OF MYOSIN MISSENSE MUTATIONS IN FAMILIAL HYPERTROPHIC CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAVY-CHAIN GENE; SUDDEN-DEATH; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; MOLECULAR-BASIS; INTERRELATIONS; SEQUENCE; THERAPY; DNA	Background. Familial hypertrophic cardiomyopathy is characterized by a variable degree of myocardial hypertrophy and a wide range of symptoms. Different mutations in the beta-cardiac myosin heavy-chain gene have been identified in three affected families. However, neither the proportion of cases attributable to myosin mutations nor the effects of different mutations on clinical outcome are known. Methods. Using a ribonuclease protection assay, we screened the beta-cardiac myosin heavy-chain genes of probands from 25 unrelated families with familial hypertrophic cardiomyopathy; this assay is a sensitive method for detecting the presence and location of mutations. We further defined the mutations by analyzing their nucleotide sequences. The clinical features of the disease were compared in families with various myosin mutations. Results. Seven mutations in the beta-cardiac myosin heavy-chain gene were identified in 12 of the 25 families. All were missense mutations (i.e., causing the substitution of a single amino acid) clustered in the head and head-rod junction regions of the molecule. Six mutations resulted in a change in the charge of the amino acid. Patients with mutations that changed the charge of the altered amino acid (such as that from arginine to glutamine at nucleotide 403 or from arginine to cysteine at nucleotide 453) had a significantly shorter life expectancy (mean age at death, 33 years), whereas patients with the one mutation that did not produce a change in charge (Val606Met) had nearly normal survival. However, patients with different mutations did not differ appreciably in their clinical manifestations of familial hypertrophic cardiomyopathy. Conclusions. Different missense mutations in the beta-cardiac myosin heavy-chain gene can be identified in approximately 50 percent of families with hypertrophic cardiomyopathy. In those families, a definite genetic diagnosis can be made in all members. Since the location of a mutation or its DNA-sequence alteration (or both) appears to influence survival, we suggest that the precise definition of the disease-causing mutation can provide important prognostic information about affected members.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND; TAICHUNG VET GEN HOSP,DIV CARDIOL,TAICHUNG,TAIWAN; HOWARD HUGHES MED INST,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114	St Georges University London; Taichung Veterans General Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	WATKINS, H (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.		McKenna, William J/C-3243-2008; Rosenzweig, Anthony/AAD-7893-2019	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046320, R29HL041474] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02228, HL-46320, HL-41474] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; Cox D. R., 1984, ANAL SURVIVAL DATA; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P4051, DOI 10.1093/nar/18.13.4051; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P3227, DOI 10.1093/nar/18.11.3227; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KAUFMAN DL, 1990, GENOMICS, V8, P656, DOI 10.1016/0888-7543(90)90252-P; KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE ET, 1980, STATISTICAL METHODS; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; MCKENNA WJ, 1989, DISEASES HEART, P9233; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NEWMAN H, 1985, J AM COLL CARDIOL, V5, P1064, DOI 10.1016/S0735-1097(85)80006-1; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; SOLOMON SD, 1990, AM J HUM GENET, V47, P389; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; YOUSSOUFIAN H, 1988, AM J HUM GENET, V42, P718	36	586	614	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1108	1114		10.1056/NEJM199204233261703	http://dx.doi.org/10.1056/NEJM199204233261703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552912				2022-12-24	WOS:A1992HP80000003
J	TIAN, M; MANIATIS, T				TIAN, M; MANIATIS, T			POSITIVE CONTROL OF PRE-MESSENGER-RNA SPLICING INVITRO	SCIENCE			English	Article							DROSOPHILA DOUBLESEX GENE; SEXUAL-DIFFERENTIATION; U2 SNRNP; BINDING PROTEINS; REGULATORY GENE; MELANOGASTER; IDENTIFICATION; SEQUENCES; TRANSFORMER-2; PURIFICATION	Positive control of the sex-specific alternative splicing of doublesex (dsx) precursor messenger RNA (pre-mRNA) in Drosophila melanogaster involves the activation of a female-specific 3' splice site by the products of the transformer (tra) and transformer-2 (tra-2) genes. The mechanisms of this process were investigated in an in vitro system in which the female-specific 3' splice site could be activated by recombinant Tra or Tra-2 (or both). An exon sequence essential for regulation in vivo was shown to be both necessary and sufficient for activation in vitro. Nuclear proteins in addition to Tra and Tra-2 were found to bind specifically to this exon sequence. Therefore, Tra and Tra-2 may act by promoting the assembly of a multiprotein complex on the exon sequence. This complex may facilitate recognition of the adjacent 3' splice site by the splicing machinery.			TIAN, M (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM42231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERIN M, UNPUB; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RIAN M, UNPUB; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	178	183	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					237	240		10.1126/science.1566072	http://dx.doi.org/10.1126/science.1566072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566072				2022-12-24	WOS:A1992HM89600034
J	WEI, ML; CRESSWELL, P				WEI, ML; CRESSWELL, P			HLA-A2 MOLECULES IN AN ANTIGEN-PROCESSING MUTANT-CELL CONTAIN SIGNAL SEQUENCE-DERIVED PEPTIDES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; MONOCLONAL-ANTIBODIES; EXPRESSION; PROTEIN; ASSOCIATION; TRANSPORT; REGION; GENE	THE mutant human cell line T2 is defective in antigen presentation in the context of class I major histocompatibility complex (MHC) molecules 1,2, and also in that transfected T2 cells show poor surface expression of exogenous human class I (HLA) alleles 3. Both defects are thought to lie in the transport of antigenic peptides derived from cytosolic proteins into the endoplasmic reticulum (ER) 1,2, as peptide-deficient class I molecules might be expected to be either unstable or retained in the ER 4. The products of several mouse class I (H-2) genes, and the endogenous gene HLA-A2 do, however, reach the surface of T2 cells at reasonable levels although they are non-functional 3,5,6. We report here that, as expected, poorly surface-expressed HLA molecules do not significantly bind endogenous peptides. Surprisingly, H-2 molecules expressed in T2 also lack associated peptides, arguing that 'empty' complexes of mouse class I glycoproteins with human beta-2-microglobulin are neither retained in the ER nor unstable. HLA-A2 molecules, however, do bind high levels of a limited set of endogenous peptides. We have sequenced three of these peptides and find that two, a 9-mer and an 11-mer, are derived from a putative signal sequence (of IP-30, an interferon-gamma-inducible protein 7), whereas a third, a 13-mer, is of unknown origin. The unusual length of two of the peptides argues that the 9-mers normally associated with HLA-A2 molecules may be generated before their transport from the cytosol rather than in a pre-Golgi compartment. To our knowledge, this is the first report of the isolation of a fragment of a eukaryotic signal peptide generated in vivo.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Howard Hughes Medical Institute; Yale University; Duke University				Wei, Maria/0000-0002-3568-1921				ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HARMON RC, 1983, IMMUNOGENETICS, V18, P541, DOI 10.1007/BF00364395; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1979, J IMMUNOL, V123, P342; ROCHE PA, 1990, J IMMUNOL, V144, P1849; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213	29	499	508	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					443	446		10.1038/356443a0	http://dx.doi.org/10.1038/356443a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557127				2022-12-24	WOS:A1992HL83000067
J	STRINGER, MD; PLEDGER, G; DRAKE, DP				STRINGER, MD; PLEDGER, G; DRAKE, DP			CHILDHOOD DEATHS FROM INTUSSUSCEPTION IN ENGLAND AND WALES, 1984-9	BRITISH MEDICAL JOURNAL			English	Article							CURRENT MANAGEMENT; DIAGNOSIS; CHILDREN; INFANCY; REFLUX	Objective - To assess the incidence of potentially avoidable factors contributing to death of children with intussusception. Design - Review of children who died with intussusception in England and Wales between 1984 and 1989 from data of the Office of Population Censuses and Surveys, case notes, coroners' records, and necropsy reports. Main outcome measures - Unambiguous objective criteria such as failure to diagnose intussusception within 24 hours of admission. Results - 33 children died of acute intussusception in England and Wales between 1984 and 1989 compared with 67 in the previous six years. Their median age was 7 months (range 2 months to 12 years), and two thirds were boys. Half of the deaths occurred at home or soon after arrival at hospital but 15 patients had surgery. Potentially avoidable factors contributing to death were identified in 20 (61%) children, all but three of whom had ileocolic intussusception. These factors were excessive delay in diagnosis, inadequate intravenous fluid and antibiotic therapy, delay in recognising recurrent or residual intussusception after hydrostatic reduction, and surgical complications. Of the 13 patients in whom no avoidable factors were identified, there were nine of 11 children with isolated small bowel intussusception, who tended to have atypical presentations. Conclusion - Although the mortality from intussusception has declined, there remains ample opportunity for improved management.	NEWCASTLE AREA HLTH AUTHOR,NEWCASTLE TYNE,ENGLAND; HOSP SICK CHILDREN,PEDIAT SURG,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BEASLEY SW, 1988, PEDIATR SURG INT, V3, P135; BEASLEY SW, 1987, AUST NZ J SURG, V57, P11, DOI 10.1111/j.1445-2197.1987.tb01231.x; BRUCE J, 1987, J PEDIATR GASTR NUTR, V6, P663, DOI 10.1097/00005176-198709000-00003; CAMPLING EA, 1990, REPORT NATIONAL CONF; DENNISON WM, 1970, BRIT J SURG, V57, P679, DOI 10.1002/bjs.1800570912; EIN SH, 1971, J PEDIATR SURG, V6, P16, DOI 10.1016/0022-3468(71)90663-4; EIN SH, 1976, J PEDIATR SURG, V11, P563, DOI 10.1016/S0022-3468(76)80013-9; EKLOF O, 1980, PEDIATR RADIOL, V9, P199, DOI 10.1007/BF01092945; FITCH SJ, 1985, GASTROINTEST RADIOL, V10, P181, DOI 10.1007/BF01893098; Goodman R.M., 1983, MALFORMED INFANT CHI; HEDLUND GL, 1990, RADIOLOGY, V174, P187, DOI 10.1148/radiology.174.1.2294546; HICKEY RW, 1990, ANN EMERG MED, V19, P390, DOI 10.1016/S0196-0644(05)82343-1; HUTCHISON IF, 1980, BRIT J SURG, V67, P209, DOI 10.1002/bjs.1800670314; MORRISON B, 1948, BRIT MED J, V1, P776, DOI 10.1136/bmj.1.4555.776; NIXON JR, 1974, J IRISH MED ASSOC, V67, P134; PALDER SB, 1991, J PEDIATR SURG, V26, P271, DOI 10.1016/0022-3468(91)90501-J; PLEDGER HG, 1969, BMJ-BRIT MED J, V4, P466, DOI 10.1136/bmj.4.5681.466; PLEDGER HG, 1987, BMJ-BRIT MED J, V295, P1233, DOI 10.1136/bmj.295.6608.1233; PRACROS JP, 1985, LANCET, V2, P733; RAVITCH MM, 1986, PEDIATR SURG, P868; SPARNON AL, 1984, AUST NZ J SURG, V54, P353; STEYN J, 1961, BMJ-BRIT MED J, V1, P1730, DOI 10.1136/bmj.1.5241.1730; WEST KW, 1987, SURGERY, V102, P704; 1978, HOSPITAL INPATIENT E; 1978, MORTALITY STATISTICS; 1982, HOSPITAL ACTIVITY AN; 1987, HOSPITAL ACTIVITY AN	27	44	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					737	739		10.1136/bmj.304.6829.737	http://dx.doi.org/10.1136/bmj.304.6829.737			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571677	Green Published, Bronze			2022-12-24	WOS:A1992HK80000016
J	LOOKER, D; ABBOTTBROWN, D; COZART, P; DURFEE, S; HOFFMAN, S; MATHEWS, AJ; MILLERROEHRICH, J; SHOEMAKER, S; TRIMBLE, S; FERMI, G; KOMIYAMA, NH; NAGAI, K; STETLER, GL				LOOKER, D; ABBOTTBROWN, D; COZART, P; DURFEE, S; HOFFMAN, S; MATHEWS, AJ; MILLERROEHRICH, J; SHOEMAKER, S; TRIMBLE, S; FERMI, G; KOMIYAMA, NH; NAGAI, K; STETLER, GL			A HUMAN RECOMBINANT HEMOGLOBIN DESIGNED FOR USE AS A BLOOD SUBSTITUTE	NATURE			English	Article							HUMAN-HEMOGLOBIN; ESCHERICHIA-COLI; RESOLUTION; FRAGMENT	THE need to develop a blood substitute is now urgent because of the increasing concern over blood-transmitted viral and bacterial pathogens 1. Cell-free haemoglobin solutions 2,3 and human haemoglobin synthesized in Escherichia coli 4 and Saccharomyces cerevisiae 5 have been investigated as potential oxygen-carrying substitutes for red blood cells. But these haemoglobins cannot be used as a blood substitute because (1) the oxygen affinity in the absence of 2,3-bisphosphoglycerate is too high to allow unloading of enough oxygen in the tissues 6, and (2) they dissociate into alpha-beta dimer 7 that are cleared rapidly by renal filtration 8-10, which can result in long-term kidney damage 7-9. We have produced a human haemoglobin using an expression vector containing one gene encoding a mutant beta-globin with decreased oxygen affinity and one duplicated, tandemly fused alpha-globin gene. Fusion of the two alpha-globin subunits increases the half-life of this haemoglobin molecule in vivo by preventing its dissociation into alpha-beta dimers and therefore also eliminates renal toxicity.	SOMATOGEN INC,5797 CENT AVE,BOULDER,CO 80301; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								ACKERS GK, 1974, P NATL ACAD SCI USA, V71, P4312, DOI 10.1073/pnas.71.11.4312; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRO G P, 1991, Biomaterials Artificial Cells and Immobilization Biotechnology, V19, P357; BUCCI E, 1989, J BIOL CHEM, V264, P6191; BUNN HF, 1969, J EXP MED, V129, P925, DOI 10.1084/jem.129.5.925; BUNN HF, 1969, J EXP MED, V129, P909, DOI 10.1084/jem.129.5.909; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; LEE R, 1989, J SURG RES, V47, P407, DOI 10.1016/0022-4804(89)90092-9; LOEB WF, 1989, CLIN CHEM LABORATORY, P460; MANNING LR, 1991, P NATL ACAD SCI USA, V88, P3329, DOI 10.1073/pnas.88.8.3329; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; MOSS GS, 1984, SURGERY, V95, P249; Mulder AG, 1934, J CELL COMPAR PHYSL, V5, P383, DOI 10.1002/jcp.1030050310; NAGAI K, 1982, J BIOL CHEM, V257, P1622; POOL R, 1990, SCIENCE, V250, P1654; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SNYDER SR, 1987, P NATL ACAD SCI USA, V84, P7280, DOI 10.1073/pnas.84.20.7280; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57	22	265	296	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					258	260		10.1038/356258a0	http://dx.doi.org/10.1038/356258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552945				2022-12-24	WOS:A1992HJ94400064
J	SUTER, U; WELCHER, AA; OZCELIK, T; SNIPES, GJ; KOSARAS, B; FRANCKE, U; BILLINGSGAGLIARDI, S; SIDMAN, RL; SHOOTER, EM				SUTER, U; WELCHER, AA; OZCELIK, T; SNIPES, GJ; KOSARAS, B; FRANCKE, U; BILLINGSGAGLIARDI, S; SIDMAN, RL; SHOOTER, EM			TREMBLER MOUSE CARRIES A POINT MUTATION IN A MYELIN GENE	NATURE			English	Article							HYPOMYELINATION; CHROMOSOME-11; NEUROPATHY; LOCUS; MICE; MAP	THE autosomal dominant trembler mutation 1 (Tr), maps to mouse chromosome 11 (ref. 2) and manifests as a Schwann-cell defect 3 characterized by severe hypomyelination 4 and continuing Schwann-cell proliferation throughout life 5,6. Affected animals move clumsily and develop tremor and transient seizures at a young age. We have recently described a potentially growth-regulating myelin protein, peripheral myelin protein-22 (PMP-22; refs 7,8), which is expressed by Schwann cells and found in peripheral myelin. We now report the assignment of the gene for PMP-22 to mouse chromosome 11. Cloning and sequencing of PMP-22 complementary DNAs from inbred Tr mice reveals a point mutation that substitutes an aspartic acid residue for a glycine in a putative membrane-associated domain of the PMP-22 protein. Our results identify the PMP-22 gene as a likely candidate for the mouse trembler locus and will encourage the search for mutations in the corresponding human gene in pedigrees with hypertrophic neuropathies such as Charcot-Marie-Tooth 9 and Dejerine-Sottas 10 diseases (hereditary motor and sensory neuropathies I and III).	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET & PEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,DIV NEUROGENET,SOUTHBOROUGH,MA 01772; UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01605	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Harvard University; University of Massachusetts System; University of Massachusetts Worcester			Suter, Ueli/A-1624-2010					AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; DAVISSON MT, 1978, CYTOGENET CELL GENET, V22, P552, DOI 10.1159/000131022; DELEON M, 1991, J NEUROSCI RES, V29, P437; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYCK PJ, 1971, MAYO CLIN PROC, V46, P432; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; HENRY EW, 1983, J NEUROPATH EXP NEUR, V42, P688, DOI 10.1097/00005072-198311000-00008; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MCALPINE PJ, 1990, GENOMICS, V7, P408, DOI 10.1016/0888-7543(90)90175-T; MUNKE M, 1986, CYTOGENET CELL GENET, V42, P236, DOI 10.1159/000132284; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; PERKINS CS, 1981, NEUROPATH APPL NEURO, V7, P115, DOI 10.1111/j.1365-2990.1981.tb00081.x; PHAMDINH D, 1991, P NATL ACAD SCI USA, V88, P7562, DOI 10.1073/pnas.88.17.7562; SNIPES GJ, IN PRESS J CELL BIOL; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195	17	380	392	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					241	244		10.1038/356241a0	http://dx.doi.org/10.1038/356241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552943				2022-12-24	WOS:A1992HJ94400058
J	HAGAN, I; YANAGIDA, M				HAGAN, I; YANAGIDA, M			KINESIN-RELATED CUT7 PROTEIN ASSOCIATES WITH MITOTIC AND MEIOTIC SPINDLES IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; NUCLEAR DIVISION; CULTURED-CELLS; DROSOPHILA; GENE; MUTATION; MITOSIS; IDENTIFICATION	SEVERAL mitotic and meiotic gene products are related to the microtubule motor kinesin, providing insight into the molecular basis of the complex motile events responsible for spindle formation and function 1. Of these genes, three have been shown to affect spindle structure when mutated 2-6. The most severe phenotype is seen in Aspergillus nidulans bimC and Schizosaccharomyces pombe cut7 mutants. In both fungi the intranuclear spindle is bipolar, with microtubules that emanate from spindle pole bodies at either pole, interdigitating in a central overlap zone. In bimC and cut7 mutants, microtubule interdigitation does not appear to take place, instead two unconnected half spindles form and chromosome separation fails 2,6,7. Here we report that cut7 protein concentrates on or near the spindle pole bodies throughout mitotic and meiotic nuclear division and associates with mitotic spindle microtubules in a stage-specific manner, associating with the mid-anaphase B midzone. In cut7ts mutants, spindle pole bodies stain but mitotic microtubules do not.			HAGAN, I (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.			Hagan, Iain/0000-0002-5858-9415				AIST JR, 1991, J CELL SCI, V100, P279; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HARLOW E, 1988, ANTIBODIES; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HORIO T, 1991, J CELL SCI, V99, P693; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KIMBLE M, 1983, J CELL SCI, V62, P301; MASUDA H, 1990, J CELL BIOL, V110, P417, DOI 10.1083/jcb.110.2.417; MCCULLY EK, 1971, J CELL SCI, V9, P475; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; ROBINOW CF, 1977, GENETICS, V87, P491; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1986, J CELL SCI, V80, P253; TODA T, 1981, J CELL SCI, V52, P271; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WOODS A, 1989, J CELL SCI, V93, P491; WORDEMAN L, 1989, J CELL SCI, V93, P279; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817	32	222	224	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					74	76		10.1038/356074a0	http://dx.doi.org/10.1038/356074a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538784				2022-12-24	WOS:A1992HG60200060
J	WEGENER, AMK; LETOURNEUR, F; HOEVELER, A; BROCKER, T; LUTON, F; MALISSEN, B				WEGENER, AMK; LETOURNEUR, F; HOEVELER, A; BROCKER, T; LUTON, F; MALISSEN, B			THE T-CELL RECEPTOR/CD3 COMPLEX IS COMPOSED OF AT LEAST 2 AUTONOMOUS TRANSDUCTION MODULES	CELL			English	Article							MEDIATED SIGNAL TRANSDUCTION; NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; TYROSINE PHOSPHORYLATION; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; SUBUNIT INTERACTIONS; TRANSFECTED CELLS; MESSENGER-RNA	Recent studies have demonstrated that the CD3-zeta subunit of the T cell antigen receptor (TCR) complex is involved in signal transduction. However, the function of the remaining invariant subunits, CD3-gamma, -delta, and epsilon, is still poorly understood. To examine their role in TCR function, we have constructed TCR/CD3 complexes devoid of functional zeta-subunit and showed that they are still able to trigger the production of interleukin-2 in response to antigen or superantigen. These data, together with previous results, indicate that the TCR/CD3 complex is composed of at least two parallel transducing units, made of the gamma-delta-epsilon and zeta-chains, respectively, Furthermore, the analysis of partially truncated zeta-chains has led us to individualize a functional domain that may have constituted the building block of most of the transducing subunits associated with antigen receptors and some Fc receptors.			WEGENER, AMK (corresponding author), CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, CASE 906, F-13288 MARSEILLE 9, FRANCE.		Luton, Frederic/N-7673-2017; Malissen, Bernard/AAK-4659-2020	Letourneur, Francois/0000-0003-2232-6127; Malissen, Bernard/0000-0003-1340-9342				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BERNOT A, 1991, P NATL ACAD SCI USA, V88, P2550, DOI 10.1073/pnas.88.6.2550; BILL J, 1989, J EXP MED, V169, P115, DOI 10.1084/jem.169.1.115; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, P NATL ACAD SCI USA, V85, P8623, DOI 10.1073/pnas.85.22.8623; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GILLIS S, 1978, J IMMUNOL, V120, P2027; GODING JW, 1986, HDB EXPT IMMUNOLOGY, V1; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HASER WG, 1987, J EXP MED, V166, P1186, DOI 10.1084/jem.166.4.1186; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRISSANSEN GW, 1987, J IMMUNOL, V138, P3513; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LABIT C, 1984, HYBRIDOMA, V3, P163, DOI 10.1089/hyb.1984.3.163; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1989, IMMUNOGENETICS, V29, P265, DOI 10.1007/BF00717911; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MERCEP M, 1988, J IMMUNOL, V140, P324; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; ORTEGA G, 1986, J IMMUNOL, V137, P3240; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RA C, 1989, J BIOL CHEM, V264, P15323; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; VIVIER E, 1991, J IMMUNOL, V146, P206; VIVIER E, 1991, J IMMUNOL, V146, P1142; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WHITE J, 1989, J IMMUNOL, V143, P1822; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	81	433	444	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					83	95		10.1016/0092-8674(92)90208-T	http://dx.doi.org/10.1016/0092-8674(92)90208-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531041	Green Published			2022-12-24	WOS:A1992GZ58300011
J	GRUENEBERG, DA; NATESAN, S; ALEXANDRE, C; GILMAN, MZ				GRUENEBERG, DA; NATESAN, S; ALEXANDRE, C; GILMAN, MZ			HUMAN AND DROSOPHILA HOMEODOMAIN PROTEINS THAT ENHANCE THE DNA-BINDING ACTIVITY OF SERUM RESPONSE FACTOR	SCIENCE			English	Article							YEAST TRANSCRIPTION ACTIVATOR; TERNARY COMPLEX-FORMATION; C-FOS PROMOTER; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MAT-ALPHA-1 PROTEIN; ANTIRRHINUM-MAJUS; RECOGNITION HELIX; CRYSTAL-STRUCTURE; HOMEOBOX GENES	Cells with distinct developmental histories can respond differentially to identical signals, suggesting that signals are interpreted in a fashion that reflects a cell's identity. How this might occur is suggested by the observation that proteins of the homeodomain family, including a newly identified human protein, enhance the DNA-binding activity of serum response factor, a protein required for the induction of genes by growth and differentiation factors. Interaction with proteins of the serum response factor family may allow homeodomain proteins to specify the transcriptional response to inductive signals. Moreover, because the ability to enhance the binding of serum response factor to DNA resides within the homeodomain but is independent of homeodomain DNA-binding activity, this additional activity of the homeodomain may account for some of the specificity of action of homeodomain proteins in development.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA045642] Funding Source: NIH RePORTER; NCI NIH HHS [CA08968, CA45642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; ATTAR RM, UNPUB; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; CSERJESI P, IN PRESS DEVELOPMENT; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUENEBERG DA, UNPUB; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENIKOFF S, 1990, NUCLEIC ACIDS RES, V18, P2961, DOI 10.1093/nar/18.10.2961; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; JOSTES B, 1991, MECH DEVELOP, V33, P27; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURET J, 1988, J BIOL CHEM, V263, P9149; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OPSTELTEN DJE, 1991, MECH DEVELOP, V34, P29, DOI 10.1016/0925-4773(91)90089-O; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RYAN WE, UNPUB; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SIMON K, UNPUB; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Sprague G F Jr, 1990, Adv Genet, V27, P33; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUHL K, 1982, P NATL ACAD SCI-BIOL, V79, P7385, DOI 10.1073/pnas.79.23.7385; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TREISMAN J, 1989, CELL, V59, P553; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERSHON AK, COMMUNICATION; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	90	299	305	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1089	1095		10.1126/science.257.5073.1089	http://dx.doi.org/10.1126/science.257.5073.1089			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509260				2022-12-24	WOS:A1992JJ88400025
J	HAAF, T; WARBURTON, PE; WILLARD, HF				HAAF, T; WARBURTON, PE; WILLARD, HF			INTEGRATION OF HUMAN ALPHA-SATELLITE DNA INTO SIMIAN CHROMOSOMES - CENTROMERE PROTEIN-BINDING AND DISRUPTION OF NORMAL CHROMOSOME SEGREGATION	CELL			English	Article							DOUBLE MINUTE CHROMOSOMES; SYRIAN-HAMSTER CELLS; ADRENAL-TUMOR CELLS; ANTIGEN CENP-B; MAMMALIAN CHROMOSOMES; GENE AMPLIFICATION; LOCATED BENEATH; Y-CHROMOSOME; CAD GENES; SEQUENCES	Centromeres of mammalian and other complex eukaryotic chromosomes are dominated by one or more classes of satellite DNA. To test the hypothesis that alpha-satellite DNA, the major centromeric satellite of primate chromosomes, is involved in centromere structure and/or function, human alpha-satellite DNA was introduced into African green monkey (AGM) cells. Centromere protein binding was apparent at the sites of integrated human alpha-satellite DNA. In the presence of an AGM centromere on the same chromosome, human alpha-satellite was associated with bridges between the separating sets of chromatids at anaphase and an increased number of lagging chromosomes at meta-phase, both features consistent with the integrated alpha-satellite disrupting normal chromosome segregation. These experiments suggest that alpha-satellite DNA provides the primary sequence information for centromere protein binding and for at least some functional aspect(s) of a mammalian centromere, playing a role either in kinetochore formation or in sister chromatid apposition.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	HAAF, T (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.				NHGRI NIH HHS [HG00107] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERNAT RL, 1991, CELL, V66, P1229, DOI 10.1016/0092-8674(91)90045-Z; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Brinkley B.R., 1989, MITOSIS MOL MECHANIS, P77; BROWN PC, 1981, MOL CELL BIOL, V1, P1077, DOI 10.1128/MCB.1.12.1077; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1991, J CELL SCI, V99, P1; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; FORD JH, 1989, MECHANISMS CHROMOSOM, P231; GEORGE DL, 1982, P NATL ACAD SCI-BIOL, V79, P1597, DOI 10.1073/pnas.79.5.1597; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GRADY DL, 1992, P NATL ACAD SCI USA, V89, P1695, DOI 10.1073/pnas.89.5.1695; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HAAF T, 1988, CANCER GENET CYTOGEN, V30, P73, DOI 10.1016/0165-4608(88)90094-5; HAAF T, 1990, EXP CELL RES, V191, P157, DOI 10.1016/0014-4827(90)90051-B; HAAF T, 1990, CYTOGENET CELL GENET, V53, P40, DOI 10.1159/000132892; HAAF T, 1990, HUM GENET, V85, P486; HAAF T, 1991, P223; HADLACZKY G, 1991, P NATL ACAD SCI USA, V88, P8106, DOI 10.1073/pnas.88.18.8106; HAMKALO BA, 1985, P NATL ACAD SCI USA, V82, P1126, DOI 10.1073/pnas.82.4.1126; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P699, DOI 10.1128/MCB.3.4.699; LIN CC, 1990, CANCER GENET CYTOGEN, V48, P271, DOI 10.1016/0165-4608(90)90131-S; MANUELIDIS L, 1976, NUCLEIC ACIDS RES, V3, P3063, DOI 10.1093/nar/3.11.3063; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Miklos GLG, 1985, MOL EVOLUTIONARY GEN, P241; MOLEBAJER J, 1990, P NATL ACAD SCI USA, V87, P3599, DOI 10.1073/pnas.87.9.3599; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PERETTI D, 1986, HUM GENET, V73, P12, DOI 10.1007/BF00292655; PERUCHO M, 1980, CELL, V22, P9; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PRAZNOVSZKY T, 1991, P NATL ACAD SCI USA, V88, P11042, DOI 10.1073/pnas.88.24.11042; ROSENBERG H, 1978, SCIENCE, V200, P394, DOI 10.1126/science.205944; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1990, FRONTIERS MOL BIOL, P99; STENMAN S, 1975, EXP CELL RES, V90, P87, DOI 10.1016/0014-4827(75)90360-2; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; THERMAN E, 1986, HUM GENET, V72, P191, DOI 10.1007/BF00291876; TYLERSMITH C, 1987, J MOL BIOL, V195, P457, DOI 10.1016/0022-2836(87)90175-6; VISSING H, 1987, NUCLEIC ACIDS RES, V15, P1363, DOI 10.1093/nar/15.4.1363; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WARBURTON PE, 1990, J MOL BIOL, V216, P3, DOI 10.1016/S0022-2836(05)80056-7; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WAYE JS, 1989, P NATL ACAD SCI USA, V86, P6250, DOI 10.1073/pnas.86.16.6250; WAYE JS, 1986, MOL CELL BIOL, V6, P315; WEVRICK R, 1990, MOL CELL BIOL, V10, P6374, DOI 10.1128/MCB.10.12.6374; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1971, SCIENCE, V174, P1200, DOI 10.1126/science.174.4015.1200	66	191	206	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					681	696		10.1016/0092-8674(92)90436-G	http://dx.doi.org/10.1016/0092-8674(92)90436-G			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505032				2022-12-24	WOS:A1992JJ88600016
J	OVERDUIN, M; RIOS, CB; MAYER, BJ; BALTIMORE, D; COWBURN, D				OVERDUIN, M; RIOS, CB; MAYER, BJ; BALTIMORE, D; COWBURN, D			3-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY-2 DOMAIN OF C-ABL	CELL			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN STRUCTURES; SH2 DOMAIN; ACTIVATION; P60C-SRC; BINDING; SITE; GAP	SH2 regions are protein motifs capable of binding target protein sequences that contain a phosphotyrosine. The solution structure of the abl SH2 product, a protein of 109 residues and 12.1 kd, has been determined by multidimensional nuclear magnetic resonance spectroscopy. It is a compact spherical domain with a pair of three-stranded antiparallel beta-sheets and a C-terminal alpha-helix enclosing the hydrophobic core. Three arginines project from a short N-terminal alpha-helix and one beta-sheet into the putative phosphotyrosine-binding site, which lies on a face distal from the termini. Comparison with other SH2 sequences supports a common global fold and mode of phosphotyrosine binding for this family.			OVERDUIN, M (corresponding author), ROCKEFELLER UNIV LABS, NEW YORK, NY 10021 USA.			Overduin, Michael/0000-0002-3114-6585; Cowburn, David/0000-0001-6770-7172	NCI NIH HHS [CA-51462] Funding Source: Medline; NIDDK NIH HHS [DK-20357] Funding Source: Medline; NIGMS NIH HHS [GM-47021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DALEY GQ, 1991, ADV CANCER RES, V57, P151; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, IN PRESS P NATL ACAD; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICK K, 1986, NMR PROTEINS NUCLEIC	29	163	170	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					697	704		10.1016/0092-8674(92)90437-H	http://dx.doi.org/10.1016/0092-8674(92)90437-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505033				2022-12-24	WOS:A1992JJ88600017
J	ECKER, DJ; VICKERS, TA; BRUICE, TW; FREIER, SM; JENISON, RD; MANOHARAN, M; ZOUNES, M				ECKER, DJ; VICKERS, TA; BRUICE, TW; FREIER, SM; JENISON, RD; MANOHARAN, M; ZOUNES, M			PSEUDO HALF-KNOT FORMATION WITH RNA	SCIENCE			English	Article							TAR RNA; BINDING; PROTEIN; SEQUENCE	A pseudo-half-knot can be formed by binding an oligonucleotide asymmetrically to an RNA hairpin loop. This binding motif was used to target the human immunodeficiency virus TAR element, an important viral RNA structure that is the receptor for Tat, the major viral transactivator protein. Oligonucleotides complementary to different halves of the TAR structure bound with greater affinity than molecules designed to bind symmetrically around the hairpin. The pseudo-half-knot-forming oligonucleotides altered the TAR structure so that specific recognition and binding of a Tat-derived peptide was disrupted. This general binding motif may be used to disrupt the structure of regulatory RNA hairpins.			ECKER, DJ (corresponding author), ISIS PHARMACEUT, 2280 FARADAY AVE, CARLSBAD, CA 92008 USA.			Ecker, David/0000-0003-4350-9037				CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; ECKER D, UNPUB ANTISENSE RES; ECKER DJ, UNPUB; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; PUGLISI JD, 1991, ACCOUNTS CHEM RES, V24, P152, DOI 10.1021/ar00005a005; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WITHERELL GW, 1990, BIOCHEMISTRY-US, V29, P11051, DOI 10.1021/bi00502a006	19	89	94	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					958	961		10.1126/science.1502560	http://dx.doi.org/10.1126/science.1502560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502560				2022-12-24	WOS:A1992JH82700033
J	LOCKHART, DJ; KIM, PS				LOCKHART, DJ; KIM, PS			INTERNAL STARK-EFFECT MEASUREMENT OF THE ELECTRIC-FIELD AT THE AMINO TERMINUS OF AN ALPHA-HELIX	SCIENCE			English	Article							DIELECTRIC-CONSTANT; DIPOLE MODEL; PROTEINS; STABILITY; STABILIZATION; RESONANCE; PEPTIDES; ALANINE; CHARGE	The strengths of electrostatic interactions in biological molecules are difficult to calculate or predict because they occur in complicated, inhomogeneous environments. The electric field at the amino terminus of an alpha-helix in water has been determined by measuring the shift in the absorption band for a covalently attached, neutral probe molecule with an electric dipole moment difference between the ground and excited electronic states (an internal Stark effect). The field at the interface between the helix and the solvent is found to be an order of magnitude stronger than expected from the dielectric properties of bulk water. Furthermore, although the total electric dipole moment of the helix increases with length, the electric field at the amino terminus does not.			LOCKHART, DJ (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.							AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FIELDS C G, 1991, Peptide Research, V4, P95; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; GILSON MK, 1985, J MOL BIOL, V183, P503; HEMANT SK, 1991, J AM CHEM SOC, V113, P6062; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; LIFF MI, 1991, J AM CHEM SOC, V113, P1014, DOI 10.1021/ja00003a041; Liptay W., 1974, Excited states. Vol.1, P129; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P664, DOI 10.1021/bi00377a001; LOCKHART DJ, UNPUB; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; NICHOLSON H, 1991, BIOCHEMISTRY-US, V30, P9816, DOI 10.1021/bi00105a002; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; ROHL CA, 1992, BIOCHEMISTRY-US, V31, P1263, DOI 10.1021/bi00120a001; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; Wada A, 1976, Adv Biophys, P1; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	34	189	192	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					947	951		10.1126/science.1502559	http://dx.doi.org/10.1126/science.1502559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502559				2022-12-24	WOS:A1992JH82700030
J	MALLABIABARRENA, A; FRESNO, M; ALARCON, B				MALLABIABARRENA, A; FRESNO, M; ALARCON, B			AN ENDOPLASMIC-RETICULUM RETENTION SIGNAL IN THE CD3-EPSILON CHAIN OF THE T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN RECEPTOR; CD3 COMPLEX; EPSILON-SUBUNITS; DEGRADATION; PROTEINS; LOCALIZATION	ISOLATED polypeptide chains of the T-cell antigen receptor complex are degraded or retained in the endoplasmic reticulum (ER) 1-4. Assembly of the multisubunit complex allows the individual chains to escape retention in the ER and to be expressed on the cell surface. We engineered a series of deletions in the CD3-epsilon subunit of the human T-cell receptor in order to find the sequences responsible for its retention in the ER. Deletion of amino acids 171 to 180 in the cytosolic tail resulted in the cell-surface expression of the isolated chain. This sequence also promotes retention when it is appended to CD4, a plasma membrane protein. Mutagenesis of the 10-amino-acid CD3-epsilon sequence established that the tyrosine and serine residues are important for ER retention. This and other ER retention signals must be hidden when a complete T-cell receptor complex is assembled in order to allow its expression on the cell surface.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, CANTOBLANCO, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Alarcon, Balbino/N-9648-2016; SANZ, MAGDALENA/L-4825-2013	Alarcon, Balbino/0000-0001-7820-1070; SANZ, MAGDALENA/0000-0002-3106-2680; Fresno Escudero, Manuel/0000-0002-9223-5477				ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CARRERA AC, 1987, EUR J IMMUNOL, V17, P179, DOI 10.1002/eji.1830170205; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH RA, 1991, IMMUNOGENETICS, V33, P396, DOI 10.1007/BF00216700; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SALMERON A, 1991, J IMMUNOL, V147, P3047; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	24	66	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					593	596		10.1038/357593a0	http://dx.doi.org/10.1038/357593a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1535117				2022-12-24	WOS:A1992HZ11200055
J	CARSON, JL; KELLEY, MA; DUFF, A; WEG, JG; FULKERSON, WJ; PALEVSKY, HI; SCHWARTZ, JS; THOMPSON, BT; POPOVICH, J; HOBBINS, TE; SPERA, MA; ALAVI, A; TERRIN, ML				CARSON, JL; KELLEY, MA; DUFF, A; WEG, JG; FULKERSON, WJ; PALEVSKY, HI; SCHWARTZ, JS; THOMPSON, BT; POPOVICH, J; HOBBINS, TE; SPERA, MA; ALAVI, A; TERRIN, ML			THE CLINICAL COURSE OF PULMONARY-EMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENOUS THROMBOSIS; LATE PROGNOSIS; FILTER	Background. Pulmonary embolism is a potentially fatal disorder. Information about the outcome of clinically recognized pulmonary embolism is sparse, particularly given that new treatments for more seriously ill patients are now available. Methods. We prospectively followed 399 patients with pulmonary embolism diagnosed by lung scanning and pulmonary angiography, who were enrolled in a multicenter diagnostic trial. We reviewed all hospitalizations, all new investigations of pulmonary embolism, and all deaths among the patients within one year of diagnosis. Results. Of the 399 patients, 375 (94 percent) received treatment for pulmonary embolism, usually conventional anticoagulation. Only 10 patients (2.5 percent) died of pulmonary embolism; 9 of them had clinically suspected recurrent pulmonary embolism. Clinically apparent pulmonary embolism recurred in 33 patients (8.3 percent), of whom 45 percent died during follow-up. Ninety-five patients with pulmonary embolism (23.8 percent) died within one year. The conditions associated with these deaths were cancer (relative risk, 3.8; 95 percent confidence interval, 2.3 to 6.4), left-sided congestive heart failure (relative risk, 2.7; 95 percent confidence interval, 1.5 to 4.6), and chronic lung disease (relative risk, 2.2; 95 percent confidence interval, 1.2 to 4.0). The most frequent causes of death in patients with pulmonary embolism were cancer (in 34.7 percent), infection (22.1 percent), and cardiac disease (16.8 percent). Conclusions. When properly diagnosed and treated, clinically apparent pulmonary embolism was an uncommon cause of death, and it recurred in only a small minority of patients. Most deaths were due to underlying diseases. Patients with pulmonary embolism who had cancer, congestive heart failure, or chronic lung disease had a higher risk of dying within one year than did other patients with pulmonary embolism.	UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT RADIOL, PHILADELPHIA, PA 19104 USA; LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA USA; UNIV MICHIGAN, SCH MED, DEPT MED, ANN ARBOR, MI 48104 USA; DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27706 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA; MARYLAND MED RES INST, BALTIMORE, MD USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Duke University; Harvard University; Massachusetts General Hospital; Henry Ford Health System; Henry Ford Hospital	CARSON, JL (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, DIV GEN INTERNAL MED, NEW BRUNSWICK, NJ 08903 USA.							ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; [Anonymous], 1970, J AMER MED ASSOC, V214, P2163; [Anonymous], 1974, JAMA, V229, P1606; BARRITT DW, 1960, LANCET, V1, P1309; COON WW, 1969, ANN SURG, V170, P559, DOI 10.1097/00000658-196910000-00007; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; GREENFIELD LJ, 1981, ARCH SURG-CHICAGO, V116, P1451; HALL RJC, 1977, BRIT HEART J, V39, P1128; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HAYS WL, 1973, STATISTICS SOCIAL SC, P404; HERMANN RE, 1961, AM J SURG, V102, P19, DOI 10.1016/0002-9610(61)90680-8; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2.37S; KANTER B, 1988, CHEST, V93, P170, DOI 10.1378/chest.93.1.170; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LEE ET, 1980, STATISTICAL METHODS; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MACINTYRE D, 1982, POSTGRAD MED J, V58, P222, DOI 10.1136/pgmj.58.678.222; MONREAL M, 1989, CHEST, V95, P976, DOI 10.1378/chest.95.5.976; MORRELL MT, 1963, BRIT MED J, P830, DOI 10.1136/bmj.2.5361.830; MOSER KM, 1987, ANN INTERN MED, V107, P560, DOI 10.7326/0003-4819-107-4-560; MURPHY ML, 1968, CIRCULATION, V38, P1116, DOI 10.1161/01.CIR.38.6.1116; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PHEAR D, 1960, LANCET, V2, P832; SECKERWALKER RH, 1970, BRIT MED J, V4, P135; Siegel S., 1956, NONPARAMETRIC STAT, P96; SUTTON GC, 1977, BRIT HEART J, V39, P1135; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER AP, 1988, ARCH INTERN MED, V148, P1321, DOI 10.1001/archinte.148.6.1321; 1988, SAS PROCEDURES GUIDE, P441	35	833	868	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1240	1245		10.1056/NEJM199205073261902	http://dx.doi.org/10.1056/NEJM199205073261902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560799				2022-12-24	WOS:A1992HR44700002
J	KIEL, DP; BARON, JA; ANDERSON, JJ; HANNAN, MT; FELSON, DT				KIEL, DP; BARON, JA; ANDERSON, JJ; HANNAN, MT; FELSON, DT			SMOKING ELIMINATES THE PROTECTIVE EFFECT OF ORAL ESTROGENS ON THE RISK FOR HIP FRACTURE AMONG WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; HIP FRACTURES; OSTEOPOROSIS; ESTROGEN REPLACEMENT THERAPY; BONE DENSITY	HORMONE-REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; BONE-MINERAL CONTENT; LIFE-STYLE FACTORS; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; DIETARY CALCIUM; ENDOMETRIAL CARCINOMA; FOREARM FRACTURES; SLENDER SMOKER	. Objective: To determine if the association between smoking and osteoporotic fractures is related to the quantity of cigarettes smoked and to determine if smoking modifies the protection by estrogens. . Design: Cohort study. . Setting: A population-based cohort study, the Framingham Study. . Participants: A total of 2873 women in the Framingham Study followed through examination 19 (1985-1987). . Measurements: All fractures of the proximal femur sustained by women in the Framingham Study from 1948 to 1987 were ascertained. At almost all examinations, available information on cigarette smoking was used to classify women as "ever smokers" compared with "never smokers," and, among "ever smokers," "current" compared with "former smokers." A similar classification for estrogen use was created. Information on potentially confounding variables was taken from each examination, including age, adiposity (weight/height 2), alcohol consumption (ounces per week), and caffeine intake (coffee and tea). . Results: Overall, 207 hip fractures occurred among 34 700 woman-examinations of observation. In the entire cohort, current smoking did not appear to increase hip fracture risk (adjusted odds ratio [AOR], 1.22; 95% Cl, 0.76 to 1.95; P > 0.2). Also overall, current estrogen use appeared to be protective (AOR, 0.38; Cl, 0.12 to 1.21, P = 0.10). Among current smokers, however, estrogen use did not protect against fracture (AOR for current use, 1.26; Cl, 0.29 to 5.45), whereas estrogen was protective in nonsmokers (AOR for current or past use, 0.37; Cl, 0. 1 9 to 0. 75; P = 0.005). . Conclusions: Overall, smoking does not appear to increase the risk for hip fracture in women. Although estrogen replacement protects nonsmokers from fracture, smoking may negate the protective skeletal effects of estrogen replacement therapy.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT MED, HANOVER, NH 03756 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, BOSTON, MA 02118 USA	Brown University; Dartmouth College; Boston Medical Center	KIEL, DP (corresponding author), RHODE ISL HOSP, 593 EDDY ST, PROVIDENCE, RI 02903 USA.			Kiel, Douglas/0000-0001-8474-0310; Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DANIELL HW, 1972, J AMER MED ASSOC, V221, P509, DOI 10.1001/jama.1972.03200180051022; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; Hollo I, 1979, Aktuelle Gerontol, V9, P365; JENSEN GF, 1986, EUR J CLIN INVEST, V16, P239, DOI 10.1111/j.1365-2362.1986.tb01335.x; JENSEN J, 1988, AM J OBSTET GYNECOL, V159, P820, DOI 10.1016/S0002-9378(88)80144-3; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P351; KRALL EA, 1991, J BONE MINER RES, V6, P331; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; KREIGER N, 1986, AM J EPIDEMIOL, V123, P291, DOI 10.1093/oxfordjournals.aje.a114237; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAVECCHIA C, 1991, INT J EPIDEMIOL, V20, P671, DOI 10.1093/ije/20.3.671; LINDSAY R, 1981, OSTEOPOROSIS RECENT, P481; LU AYH, 1972, J BIOL CHEM, V247, P1727; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; MCNAIR P, 1980, MINER ELECTROL METAB, V3, P94; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; ROTHMAN KJ, 1986, EPIDEMIOLOGY, P226; RUNDGREN A, 1984, MECH AGEING DEV, V28, P273, DOI 10.1016/0047-6374(84)90027-7; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SOWERS MR, 1985, AM J CLIN NUTR, V41, P1045, DOI 10.1093/ajcn/41.5.1045; SPARROW D, 1982, ARCH ENVIRON HEALTH, V37, P246, DOI 10.1080/00039896.1982.10667572; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; SUOMINEN H, 1984, AGE AGEING, V13, P273, DOI 10.1093/ageing/13.5.273; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	46	111	116	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					716	721		10.7326/0003-4819-116-9-716	http://dx.doi.org/10.7326/0003-4819-116-9-716			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558342				2022-12-24	WOS:A1992HQ62300003
J	FELSON, DT; ZHANG, YQ; ANTHONY, JM; NAIMARK, A; ANDERSON, JJ				FELSON, DT; ZHANG, YQ; ANTHONY, JM; NAIMARK, A; ANDERSON, JJ			WEIGHT-LOSS REDUCES THE RISK FOR SYMPTOMATIC KNEE OSTEOARTHRITIS IN WOMEN - THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOARTHRITIS; KNEE INJURIES; WEIGHT LOSS; OBESITY	OSTEO-ARTHRITIS; OBESITY	Objective: To evaluate the effect of weight loss in preventing symptomatic knee osteoarthritis in women. Design: Cohort analytic study. Setting: The Framingham Study, based on a sample of a defined population. Patients: Women who participated in the Framingham Knee Osteoarthritis Study (1983 to 1985): Sixty-four out of 796 women studied had recent-onset symptomatic knee osteoarthritis (knee symptoms plus radiographically confirmed osteoarthritis) were compared with women without disease. Measurements: Recalled date of symptom onset was used as the incident date of disease. Historical weight was defined as baseline body mass index up to 12 years before symptom onset. Change in body mass index was assessed at several intervals before the current examination. Odds ratios assessing the association between weight change and knee osteoarthritis were adjusted for age, baseline body mass index, history of previous knee injury, habitual physical activity level, occupational physical labor, smoking status, and attained education. Results: Weight change significantly affected the risk for the development of knee osteoarthritis. For example, a decrease in body mass index of 2 units or more (weight loss, approximately 5.1 kg) over the 10 years before the current examination decreased the odds for developing osteoarthritis by over 50% (odds ratio, 0.46; 95% CI, 0.24 to 0.86; P = 0.02). Among those women with a high risk for osteoarthritis due to elevated baseline body mass index (greater-than-or-equal-to 25), weight loss also decreased the risk (for 2 units of body mass index, odds ratio, 0.41; P = 0.02). Weight gain was associated with a slightly increased risk for osteoarthritis, which was not statistically significant. Conclusion: Weight loss reduces the risk for symptomatic knee osteoarthritis in women.	BOSTON UNIV HOSP, DEPT RADIOL, BOSTON, MA 02218 USA	Boston University	FELSON, DT (corresponding author), BOSTON UNIV, BOSTON CITY HOSP, CTR ARTHRIT, A203, 80 E CONCORD ST, BOSTON, MA 02118 USA.			Zhang, Yuqing/0000-0001-7954-1149; Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHESON RM, 1975, ANN RHEUM DIS, V34, P379, DOI 10.1136/ard.34.5.379; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Ball J, 1963, ATLAS STANDARD RADIO, V2; DAVIS MA, 1988, AM J EPIDEMIOL, V127, P1019, DOI 10.1093/oxfordjournals.aje.a114878; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FELSON DT, 1989, ARTHRITIS RHEUM, V32, P166, DOI 10.1002/anr.1780320209; FELSON DT, 1991, J RHEUMATOL, V18, P1587; HANNAN MT, 1992, IN PRESS J CLIN EPID; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; KELLGREN JH, 1958, ANN RHEUM DIS, V17, P388, DOI 10.1136/ard.17.4.388; LEACH RE, 1973, CLIN ORTHOP RELAT R, V93, P271; TRAUT EF, 1969, J AM GERIATR SOC, V17, P710, DOI 10.1111/j.1532-5415.1969.tb02326.x; VANSAASE JLCM, 1988, J RHEUMATOL, V15, P1152	15	648	686	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					535	539		10.7326/0003-4819-116-7-535	http://dx.doi.org/10.7326/0003-4819-116-7-535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543306				2022-12-24	WOS:A1992HL25800002
J	LANGLOIS, AJ; WEINHOLD, KJ; MATTHEWS, TJ; GREENBERG, ML; BOLOGNESI, DP				LANGLOIS, AJ; WEINHOLD, KJ; MATTHEWS, TJ; GREENBERG, ML; BOLOGNESI, DP			THE ABILITY OF CERTAIN SIV VACCINES TO PROVOKE REACTIONS AGAINST NORMAL-CELLS	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY VIRUS-INFECTION; PROTECTION; ANTIGENS; MACAQUES		DUKE UNIV,MED CTR,CTR AIDS RES,DEPT SURG,DURHAM,NC 27710	Duke University								ANDERSON C, 1991, NATURE, V353, P287, DOI 10.1038/353287b0; AZOCAR J, 1979, CANCER RES, V39, P3388; BOLOGNESI DP, 1970, COMP LEUKEMIA RES 19, P126; BROWN P, 1991, NEW SCI, V21, P14; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; DESROSIERS R, COMMUNICATION; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DESROSIERS RC, 1989, 21ST C AIDS ANN; GARDNER MB, IN PRESS AIDS; GIRARD M P, 1990, AIDS (London), V4, pS143; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; HILLEMAN MR, 1985, J INFECT DIS, V151, P407, DOI 10.1093/infdis/151.3.407; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HU SL, IN PRESS SCIENCE; JAVAHERIAN K, UNPUB P NATL ACAD SC; LANGLOIS AJ, 1991, AIDS RES HUM RETROV, V7, P713, DOI 10.1089/aid.1991.7.713; LINDENMANN J, 1977, VIRUS INFECTION CELL, P291; MADDOX J, 1991, NATURE, V353, P297, DOI 10.1038/353297a0; MONTEFIORE DC, IN PRESS NATURE; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WATANABE M, 1991, P NATL ACAD SCI USA, V88, P4616, DOI 10.1073/pnas.88.11.4616	24	87	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					292	293		10.1126/science.1549775	http://dx.doi.org/10.1126/science.1549775			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549775				2022-12-24	WOS:A1992GZ69500032
J	TRICHOPOULOS, D; MOLLO, F; TOMATIS, L; AGAPITOS, E; DELSEDIME, L; ZAVITSANOS, X; KALANDIDI, A; KATSOUYANNI, K; RIBOLI, E; SARACCI, R				TRICHOPOULOS, D; MOLLO, F; TOMATIS, L; AGAPITOS, E; DELSEDIME, L; ZAVITSANOS, X; KALANDIDI, A; KATSOUYANNI, K; RIBOLI, E; SARACCI, R			ACTIVE AND PASSIVE SMOKING AND PATHOLOGICAL INDICATORS OF LUNG-CANCER RISK IN AN AUTOPSY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIR-POLLUTION; CIGARETTE-SMOKING; TOBACCO-SMOKE; BRONCHIAL EPITHELIUM; SMALL AIRWAYS; COUNTY; ASSOCIATION; EXPOSURE; DISEASE; WOMEN	Objective.-The association between involuntary smoking and lung cancer has been supported by most epidemiologic studies, but a number of authors and interest groups claim that the possibility of bias has not been excluded. Few autopsy-based studies have explored the role of active smoking and other exposures in lung carcinogenesis, and none has been previously done to examine the role of passive smoking. We have undertaken such an autopsy-based study in Athens, Greece. Design.-Lung specimens were taken at autopsy from 400 persons 35 years of age or older, of both genders, who had died within 4 hours from a cause other than respiratory or cancer in Athens or the surrounding area. For each person at least seven tissue blocks were taken from the main and lobar bronchi and at least five blocks from the parenchyma, including an average of about 20 smaller cartilaginous bronchi and membranous bronchioles. The specimens were examined without knowledge of the exposures of the particular subject in Turin, Italy. For 283 (71%) of the subjects the preservation of the bronchial epithelium was satisfactory for pathological examination, and for 206 among them (73%) an interview could be arranged with their next of kin, focusing on smoking habits of the deceased and their spouses, as well as other variables. The interviewers were not aware of the results of the pathological examinations. Main Outcome Measure.-Specimens were examined for basal cell hyperplasia, squamous cell metaplasia, cell atypia, and (in membranous bronchioles and bronchiolo-alveolar airways) mucous cell metaplasia, ie, pathological entities that may be lung cancer risk indicators or epithelial, possibly precancerous, lesions (EPPL). The gland and wall thicknesses were also measured and their ratio calculated (Reid Index). Results.-In comparison with nonsmokers, EPPL values were significantly higher among current smokers and higher, but not significantly so, among former smokers. Furthermore, EPPL values were significantly higher among deceased nonsmoking women married to smokers rather than to nonsmokers. In this set of data neither occupation nor residence was associated with EPPL, but this could be due to the poor correlation of residential history with exposure to air pollution and the lack of adequate standardization of contemporary Greek occupations. The Reid Index was higher among smokers and former smokers in comparison with nonsmokers, among subjects with mainly urban residence in comparison with those with mainly rural residence, and among nonsmoking women married to smokers in comparison with those married to nonsmokers, but none of these differences was statistically significant. Conclusion.-These results provide support to the body of evidence linking passive smoking to lung-cancer, even though they are based on a study methodologically different from those that have previously examined this association.	UNIV ATHENS,SCH MED,DEPT PATHOL,ATHENS,GREECE; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; WHO,INT AGCY RES CANC,LYON,FRANCE; UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10124 TURIN,ITALY	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; World Health Organization; International Agency for Research on Cancer (IARC); University of Turin	TRICHOPOULOS, D (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Katsouyanni, Klea/D-4856-2014	Katsouyanni, Klea/0000-0002-0132-9575; Riboli, Elio/0000-0001-6795-6080				AGAPITOS E, 1991, AUTOPSY EPIDEMIOLOGY, P263; [Anonymous], 1986, IARC MONOGRAPHS EVAL; [Anonymous], 1985, EPIDEMIOLOGY AIR POL; AUERBACH O, 1962, NEW ENGL J MED, V267, P111, DOI 10.1056/NEJM196207192670301; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; AUERBACH O, 1956, CANCER, V9, P76, DOI 10.1002/1097-0142(195601/02)9:1<76::AID-CNCR2820090106>3.0.CO;2-D; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BLOT WJ, 1976, AM J EPIDEMIOL, V103, P539, DOI 10.1093/oxfordjournals.aje.a112258; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; BUFFLER PA, 1988, AM J EPIDEMIOL, V128, P683, DOI 10.1093/oxfordjournals.aje.a115022; CANVOW BW, 1978, ENV HLTH PERSPECT, V22, P17; CARROLL R, 1961, BRIT J CANCER, V15, P215, DOI 10.1038/bjc.1961.27; COSIO MG, 1980, AM REV RESPIR DIS, V122, P265; Cosio MG, 1977, NEW ENGL J MED, V298, P1277; EVERINGHAM R, 1991, TOBACCO LITIGATION A; Field W E, 1966, Br J Dis Chest, V60, P66, DOI 10.1016/S0007-0971(66)80002-5; FORD AB, 1980, ARCH ENVIRON HEALTH, V35, P350; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAMMOND EC, 1980, PREV MED, V9, P206, DOI 10.1016/0091-7435(80)90077-8; HENDERSON BE, 1975, AM J EPIDEMIOL, V101, P477, DOI 10.1093/oxfordjournals.aje.a112118; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; LEE PN, 1987, TOXICOL LETT, V35, P157, DOI 10.1016/0378-4274(87)90102-0; LEE PN, 1987, HUM TOXICOL, V6, P517, DOI 10.1177/096032718700600612; MATANOSKI GM, 1981, ENVIRON RES, V25, P8, DOI 10.1016/0013-9351(81)90076-1; Mollo F, 1981, Pathologica, V73, P185; MULLEN JBM, 1986, AM REV RESPIR DIS, V133, P120, DOI 10.1164/arrd.1986.133.1.120; Pershagen G, 1990, EUROPEAN SCH ONCOLOG, P63; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SARACCI R, 1989, MUTAT RES, V22, P117; SOLOMON MD, 1990, MODERN PATHOL, V3, P684; TANNENBAUM A, 1970, INT J CANCER, V5, P282, DOI 10.1002/ijc.2910050217; THURLBECK WM, 1988, PATHOLOGY LUNG, P529; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TRICHOPOULOS D, 1988, SCAND J SOC MED, V16, P75, DOI 10.1177/140349488801600203; VENA JE, 1982, AM J EPIDEMIOL, V116, P42, DOI 10.1093/oxfordjournals.aje.a113401; VINE MF, 1990, AM J EPIDEMIOL, V131, P781, DOI 10.1093/oxfordjournals.aje.a115569; VUTUC C, 1984, PREV MED, V13, P698, DOI 10.1016/S0091-7435(84)80019-5; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WEINBERG GB, 1982, AM J EPIDEMIOL, V115, P40, DOI 10.1093/oxfordjournals.aje.a113278; WELLS AJ, 1991, AM J EPIDEMIOL, V133, P208, DOI 10.1093/oxfordjournals.aje.a115859; WHIMSTER W F, 1988, Applied Pathology, V6, P241; WRIGHT JL, 1984, AM REV RESPIR DIS, V129, P989; WRIGHT JL, 1985, ARCH PATHOL LAB MED, V109, P163; ZU ZY, 1989, J NATL CANCER I, V81, P1800; 1985, PHS DHHS CDC87839833	50	48	49	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1697	1701		10.1001/jama.268.13.1697	http://dx.doi.org/10.1001/jama.268.13.1697			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527879				2022-12-24	WOS:A1992JQ37600031
J	DEBOER, P; CROSSLEY, R; ROTHFIELD, L				DEBOER, P; CROSSLEY, R; ROTHFIELD, L			THE ESSENTIAL BACTERIAL CELL-DIVISION PROTEIN FTSZ IS A GTPASE	NATURE			English	Article							ESCHERICHIA-COLI; GENE-FTSZ; BACILLUS-SUBTILIS; SEPTATION; CLONING; SITE	CYTOKINESIS defines the last stage in the division cycle, in which cell constriction leads to the formation of daughter cells. The biochemical mechanisms responsible for this process are poorly understood. In bacteria, the ftsZ gene product, FtsZ, is required for cell division1-3,17, playing a prominent role in cytokinesis. The cellular concentration of FtsZ regulates the frequency of division4 and genetic studies have indicated that it is the target of several endogenous division inhibitors5. At the time of onset of septal invagination, the FtsZ protein is recruited from the cytoplasm to the division site, where it assembles into a ring that remains associated with the leading edge of the invaginating septum until septation is completed 6. Here we report that FtsZ specifically binds and hydrolyses GTP. The reaction can be dissociated into a GTP-dependent activation stage that is markedly affected by the concentration of FtsZ, and a hydrolysis stage in which GTP is hydrolysed to GDP. The results indicate that GTP binding and hydrolysis are important in enabling FtsZ to support bacterial cytokinesis, either by facilitating the assembly of the FtsZ ring and/or by catalysing an essential step in the cytokinetic process itself.			DEBOER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA.			de Boer, Piet/0000-0002-5375-6317				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; CARLIER MF, 1989, INT REV CYTOL, V115, P139; DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; HESSE J, 1987, J BIOL CHEM, V262, P15472; LUTKENHAUS JF, 1980, J BACTERIOL, V142, P615, DOI 10.1128/JB.142.2.615-620.1980; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; PLA J, 1991, MOL MICROBIOL, V5, P1681, DOI 10.1111/j.1365-2958.1991.tb01915.x; STERNLICHT H, 1987, FEBS LETT, V214, P226, DOI 10.1016/0014-5793(87)80061-3; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; YI QM, 1985, GENE, V36, P241	17	447	459	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1992	359	6392					254	256		10.1038/359254a0	http://dx.doi.org/10.1038/359254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528268				2022-12-24	WOS:A1992JN94400067
J	HWANG, C; SINSKEY, AJ; LODISH, HF				HWANG, C; SINSKEY, AJ; LODISH, HF			OXIDIZED REDOX STATE OF GLUTATHIONE IN THE ENDOPLASMIC-RETICULUM	SCIENCE			English	Article							PROTEIN-DISULFIDE-ISOMERASE; MICROSOMAL-MEMBRANES; RAT-LIVER; CATALYZED FORMATION; BOND FORMATION; SYSTEM; THIOL; TRANSLOCATION; RIBONUCLEASE; TRANSPORT	The redox state of the endoplasmic reticulum (ER) was measured with the peptide N-Ace-tyl-Asn-Tyr-Thr-Cys-NH2. The peptide diffused across cellular membranes; some became glycosylated and thus trapped within the secretory pathway, and its cysteine residue underwent reversible thiol-disulfide exchanges with the surrounding redox buffer. Glycosylated peptides from cells were disulfide-linked to glutathione, indicating that glutathione is the major redox buffer in the secretory pathway. The redox state of the secretory pathway was more oxidative than that of the cytosol; the ratio of reduced glutathione to the disulfide form (GSH/GSSG) within the secretory pathway ranged from 1:1 to 3:1, whereas the overall cellular GSH/GSSG ratio ranged from 30:1 to 100:1. Cytosolic glutathione was also transported into the lumen of microsomes in a cell-free system. Although how the ER maintains an oxidative environment is not known, these results suggest that the demonstrated preferential transport of GSSG compared to GSH into the ER lumen may contribute to this redox compartmentation.	MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA; MIT, CTR BIOTECH PROC ENGN, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANIYA Y, 1989, ARCH BIOCHEM BIOPHYS, V270, P330, DOI 10.1016/0003-9861(89)90035-0; BANNAI S, 1980, J CELL PHYSIOL, V104, P215, DOI 10.1002/jcp.1041040211; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; COTGREAVE IA, 1989, SULPHUR CONTAINING B, V2, P101; Dolphin D., 1990, GLUTATHIONE CHEM BIO, V3; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HWANG C, UNPUB; ISAACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192, DOI 10.1016/0304-4165(77)90152-0; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; KADERBHAI MA, 1984, BIOCHEM J, V217, P145, DOI 10.1042/bj2170145; KADERBHAI MA, 1985, EUR J BIOCHEM, V153, P167, DOI 10.1111/j.1432-1033.1985.tb09283.x; KOIVU J, 1987, J BIOL CHEM, V262, P6159; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KUROSAWA K, 1990, BIOCHEM BIOPH RES CO, V167, P367, DOI 10.1016/0006-291X(90)91774-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; NILSSON R, 1973, J CELL BIOL, V56, P762, DOI 10.1083/jcb.56.3.762; ONDARZA RN, 1989, BIOSCIENCE REP, V9, P593, DOI 10.1007/BF01119803; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PETERSEN JG, 1974, J BIOL CHEM, V249, P5633; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; Torchinsky Y, 1981, SULFUR PROTEINS; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	40	1598	1635	5	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1496	1502		10.1126/science.1523409	http://dx.doi.org/10.1126/science.1523409			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523409				2022-12-24	WOS:A1992JM57000021
J	LIN, AN; FROST, J; DENG, TL; SMEAL, T; ALALAWI, N; KIKKAWA, U; HUNTER, T; BRENNER, D; KARIN, M				LIN, AN; FROST, J; DENG, TL; SMEAL, T; ALALAWI, N; KIKKAWA, U; HUNTER, T; BRENNER, D; KARIN, M			CASEIN KINASE-II IS A NEGATIVE REGULATOR OF C-JUN DNA-BINDING AND AP-1 ACTIVITY	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; TRANS-ACTING FACTOR; TRANSCRIPTIONAL ACTIVATION; STIMULATE TRANSCRIPTION; PROTO-ONCOGENE; PHOSPHORYLATION; GENE; ELEMENT; SERUM; FIBROBLASTS	c-Jun, a major component of the inducible transcription factor AP-1, is a phosphoprotein. In nonstimulated fibroblasts and epithelial cells, c-Jun is phosphorylated on a cluster of two to three sites abutting its DNA-binding domain. Phosphorylation of these sites inhibits DNA binding, and their dephosphorylation correlates with increased AP-1 activity. We show that two of these sites, Thr-231 and Ser-249, are phosphorylated by casein kinase II (CKII). Substitution of the third site, Ser-243, by Phe interferes with phosphorylation of the inhibitory sites in vivo and by purified CKII in vitro. Microinjection into living cells of synthetic peptides that are specific competitive substrates or inhibitors of CKII results in induction of AP-1 activity and c-Jun expression. Microinjection of CKII supresses induction of AP-1 by either phorbol ester or an inhibitory peptide. These results suggest that one of the roles of CKII, a major nuclear protein kinase with no known functions, is to attenuate AP-1 activity through phosphorylation of c-Jun.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA; SALK INST BIOL RES, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, CTR CANC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego	LIN, AN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.			Frost, Jeffrey/0000-0001-9722-1536; Brenner, David/0000-0003-2573-525X	NATIONAL CANCER INSTITUTE [R01CA039811, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004151, R37ES004151] Funding Source: NIH RePORTER; NCI NIH HHS [CA39811, CA50528] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; DENG T, 1992, IN PRESS P NATL ACAD, V89; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FERAMISCO JR, 1986, MICROINJECTION ORGAN, P40; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIRZLAFF J M, 1989, New Biologist, V1, P44; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GLINEUR C, 1989, ONCOGENE, V4, P1247; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KARIN M, 1991, MOL ASPECTS CELLULAR, V6, P143; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Tooze J, 1980, DNA TUMOR VIRUSES; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANG-YEN H-F, 1990, New Biologist, V2, P351	65	368	374	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					777	789		10.1016/0092-8674(92)90311-Y	http://dx.doi.org/10.1016/0092-8674(92)90311-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516134				2022-12-24	WOS:A1992JL66300009
J	STRAUS, DB; WEISS, A				STRAUS, DB; WEISS, A			GENETIC-EVIDENCE FOR THE INVOLVEMENT OF THE ICK TYROSINE KINASE IN SIGNAL TRANSDUCTION THROUGH THE T-CELL ANTIGEN RECEPTOR	CELL			English	Article							PROTEIN-KINASE; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; SURFACE MOLECULES; CROSS-LINKING; CD4 RECEPTOR; SRC FAMILY; ACTIVATION; P56LCK; PHOSPHORYLATION	Signaling through the T cell antigen receptor (TCR) results both in rapid increases in tyrosine phosphorylation on a number of proteins and in the activation of the phosphatidylinositol pathway. It is not clear how stimulation of the TCR leads to these signaling events. Mutants of the Jurkat T cell line have been previously isolated that fail to show increases in calcium following receptor stimulation. Analysis of one of these mutants, JCaM1, which is defective in the induction of tyrosine phosphorylation, revealed a defect in the expression of functional lck tyrosine kinase. The lack of lck activity was caused in part by a splicing defect. Expression of the lck cDNA in JCaM1 restores the ability of the cell to respond to TCR stimulation. These results indicate that lck is required for normal signal transduction through the TCR.			STRAUS, DB (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANSOTEGUI IJ, 1991, SCAND J IMMUNOL, V33, P375, DOI 10.1111/j.1365-3083.1991.tb01784.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P8613, DOI 10.1073/pnas.85.22.8613; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TESTI R, 1989, J IMMUNOL, V142, P1854; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	57	1009	1046	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					585	593		10.1016/0092-8674(92)90428-F	http://dx.doi.org/10.1016/0092-8674(92)90428-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505025				2022-12-24	WOS:A1992JJ88600008
J	WULCZYN, FG; NAUMANN, M; SCHEIDEREIT, C				WULCZYN, FG; NAUMANN, M; SCHEIDEREIT, C			CANDIDATE PROTOONCOGENE BCL-3 ENCODES A SUBUNIT-SPECIFIC INHIBITOR OF TRANSCRIPTION FACTOR NF-KAPPA-B	NATURE			English	Article							DNA-BINDING PROTEIN; REL-ASSOCIATED PP40; C-REL; GENE; CLONING; DORSAL; PURIFICATION; DROSOPHILA; COMPLEX; MOTIFS	THE NF-kappa-B subunits p50 and p65 and the product of the rel proto-oncogene are members Of a growing class of transcription factors with a unique DNA-binding and dimerization domain1-13. Nuclear transfer of each of these factors is controlled by cytoplasmic inhibitors, and regulated by specific stimuli. The inhibitors I-kappa-B-alpha and -beta and pp40 recognize either p65 or the c-rel protein14-16. We show here that the proto-oncogene bcl-3, believed to be involved in certain human B-cell leukaemias17, encodes a protein that functions as an I-kappa-B-like molecule for native NF-kappa-B but is specific for the p50 subunit. The ankyrin repeat domain of the bcl-3 product is shown to mediate complex formation with NF-kappa-B dimers by contacting the conserved dimerization domain of NF-kappa-B.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society			Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOSH S, 1990, CELL, V62, P1019; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1991, CELL, V64, P439; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	29	214	215	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					597	599		10.1038/358597a0	http://dx.doi.org/10.1038/358597a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501714				2022-12-24	WOS:A1992JH82900064
J	ZHANG, Y; HEYM, B; ALLEN, B; YOUNG, D; COLE, S				ZHANG, Y; HEYM, B; ALLEN, B; YOUNG, D; COLE, S			THE CATALASE PEROXIDASE GENE AND ISONIAZID RESISTANCE OF MYCOBACTERIUM-TUBERCULOSIS	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; EXPRESSION; TRANSFORMATION; SUPEROXIDE; EXTRACTS; CLONING; STRAINS	TUBERCULOSIS is responsible for one in four of all avoidable adult deaths in developing countries1. Increased frequency and accelerated fatality of the disease among individuals infected with human immunodeficiency virus has raised worldwide concern that control programmes may be inadequate2, and the emergence of multidrug-resistant strains of Mycobacterium tuberculosis has resulted in several recent fatal outbreaks in the United States3. Isonicotinic acid hydrazide (isoniazid, INH) forms the core of antituberculosis regimens; however, clinical isolates that are resistant to INH show reduced catalase activity and a relative lack of virulence in guinea-pigs4-7. Here we use mycobacterial genetics8,9 to study the molecular basis of INH resistance. A single M. tuberculosis gene, katG, encoding both catalase and peroxidase, restored sensitivity to INH in a resistant mutant of Mycobacterium smegmatis, and conferred INH susceptibility in some strains of Escherichia coli. Deletion of katG from the chromosome was associated with INH resistance in two patient isolates of M. tuberculosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,LONDON W12 0HS,ENGLAND; INST PASTEUR,GENET MOLEC BACTERIENNE LAB,F-75724 PARIS 15,FRANCE; CHU PITIE SALPETRIERE,SERV BACTERIOL VIROL,F-75634 PARIS 13,FRANCE	Imperial College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	ZHANG, Y (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,TB & RELATED INFECT UNIT,LONDON W12 0HS,ENGLAND.							COHN ML, 1954, AM REV TUBERC PULM, V70, P641; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; HEYM B, IN PRESS RES MICROBI; JACKETT PS, 1978, J GEN MICROBIOL, V104, P37, DOI 10.1099/00221287-104-1-37; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; MITCHISON DA, 1963, J PATHOL BACTERIOL, V86, P377, DOI 10.1002/path.1700860213; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, INFECT IMMUN, V60, P2160, DOI 10.1128/IAI.60.6.2160-2165.1992; ZHANG Y, 1991, MOL MICROBIOL, V5, P381, DOI 10.1111/j.1365-2958.1991.tb02120.x	21	1042	1117	2	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					591	593		10.1038/358591a0	http://dx.doi.org/10.1038/358591a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501713				2022-12-24	WOS:A1992JH82900062
J	HOLLENBERG, M; MANGANO, DT; BROWNER, WS; LONDON, MJ; TUBAU, JF; TATEO, IM				HOLLENBERG, M; MANGANO, DT; BROWNER, WS; LONDON, MJ; TUBAU, JF; TATEO, IM			PREDICTORS OF POSTOPERATIVE MYOCARDIAL-ISCHEMIA IN PATIENTS UNDERGOING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; HEART-DISEASE; ANESTHESIA; FRAMINGHAM; RISK; REINFARCTION; INFARCTION; MORBIDITY; ONSET	Objective.-To identify predictors of postoperative myocardial ischemia in patients scheduled to undergo major noncardiac surgery. Design.-Historical, clinical, laboratory, and physiological data were obtained prospectively before and during surgery to identify potential univariate predictors of postoperative myocardial ischemia, which then were entered into multivariate logistic models. Continuous two-lead electrocardiograms before, during, and after surgery were used to identify episodes of myocardial ischemia. Setting.-Department of Veterans Affairs tertiary care hospital. Patients.-A consecutive sample of 474 men at high risk for or with coronary artery disease who were scheduled to undergo major noncardiac surgery (95% compliance rate). Main Outcome Measure.-Significant variables identified by multivariate logistic models that are associated with postoperative myocardial ischemia. Results.-Five major preoperative predictors of postoperative myocardial ischemia were identified: (1) left ventricular hypertrophy by electrocardiogram; (2) history of hypertension; (3) diabetes mellitus; (4) definite coronary artery disease; and (5) use of digoxin. The risk of postoperative myocardial ischemia increased progressively with the number of predictors present: in 22% of patients with no predictors, in 31% with one predictor, in 46% with two predictors, in 70% with three predictors, and in 77% with four predictors. Conclusion.-Patient subgroups who are at high risk for developing postoperative myocardial ischemia and who might benefit the most from intensive Holter monitoring in the postoperative period now can be identified preoperatively.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	HOLLENBERG, M (corresponding author), DEPT VET AFFAIRS MED CTR, 4150 CLEMENT ST 111C3, SAN FRANCISCO, CA 94121 USA.			Tice, Jeffrey/0000-0002-9857-2028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Cox DR., 1970, ANAL BINARY DATA; DORTIMER AC, 1978, CIRCULATION, V57, P133, DOI 10.1161/01.CIR.57.1.133; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HOLLENBERG M, 1985, AM J CARDIOL, V56, P13, DOI 10.1016/0002-9149(85)90557-0; HOLLENBERG M, 1986, J AM COLL CARDIOL, V7, pA163; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; STRAUER BE, 1985, J CARDIOVASC PHARM, V7, pS62, DOI 10.1097/00005344-198507002-00013; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; VIGORITA VJ, 1980, AM J CARDIOL, V46, P535, DOI 10.1016/0002-9149(80)90500-7; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5; 1979, NOMENCLATURE CRITERI, P94	25	122	129	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					205	209		10.1001/jama.268.2.205	http://dx.doi.org/10.1001/jama.268.2.205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1535109				2022-12-24	WOS:A1992JB27900026
J	MARZUK, PM; TARDIFF, K; SMYTH, D; STAJIC, M; LEON, AC				MARZUK, PM; TARDIFF, K; SMYTH, D; STAJIC, M; LEON, AC			COCAINE USE, RISK-TAKING, AND FATAL RUSSIAN ROULETTE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BEHAVIOR	Objective. - To examine the association between recent cocaine use and risk taking, particularly in the form of playing Russian roulette, a paradigm for extreme risk-taking behavior. Design. - A case-control study. Cases and Controls. - The prevalence of cocaine use among all Russian roulette fatalities (N = l4) was compared with a demographically similar, randomly selected sample (N = 54) of all suicides by handgun during a contemporaneous 4-year period in New York City, NY. Results. - Recent use of cocaine, the most common drug found at autopsy, was detected in 64% of Russian roulette fatalities and in 35% of the control group (P < .05). All Russian roulette fatalities were male and usually young and unemployed. Blacks and Hispanics accounted for 80% of all cases and were overrepresented compared with their numbers in the general population. Conclusion. - In some populations cocaine may be associated with life-threatening risk-taking behaviors.	CORNELL UNIV,MED CTR,COLL MED,DEPT AFRC,NEW YORK,NY 10021; NYU,SCH MED,DEPT FORENS MED,NEW YORK,NY 10003; NEW YORK OFF CHIEF MED EXAMINER,NEW YORK,NY	Cornell University; New York University	MARZUK, PM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PSYCHIAT,1300 YORK AVE,NEW YORK,NY 10021, USA.							ADLAF EM, 1983, DRUG ALCOHOL DEPEN, V11, P287, DOI 10.1016/0376-8716(83)90020-0; AMBRE J, 1988, J ANAL TOXICOL, V34, P53; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; COHEN PA, 1977, PERS SOC PSYCHOL B, V11, P119; COLE P, 1980, STATISTICAL METHODS; DACKIS CA, 1985, NEUROSCI BIOBEHAV RE, V9, P447; FISHBAIN DA, 1987, AM J PSYCHIAT, V144, P563; KOGAN N, 1967, NEW DIR PSYCH, V3, P111; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TEGER AI, 1969, J PERS SOC PSYCHOL, V11, P170, DOI 10.1037/h0027054; WEISS JMA, 1957, PSYCHIATR, V20, P17	12	10	11	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2635	2637						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573752				2022-12-24	WOS:A1992HT82300032
J	MANDELBLATT, JS; WHEAT, ME; MONANE, M; MOSHIEF, RD; HOLLENBERG, JP; TANG, J				MANDELBLATT, JS; WHEAT, ME; MONANE, M; MOSHIEF, RD; HOLLENBERG, JP; TANG, J			BREAST-CANCER SCREENING FOR ELDERLY WOMEN WITH AND WITHOUT COMORBID CONDITIONS - A DECISION-ANALYSIS MODEL	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; MAMMOGRAPHY; GERIATRICS; HEALTH SERVICES FOR THE AGED	PRIMARY-CARE; MORTALITY; MAMMOGRAPHY; AGE; SURVIVAL; PATTERNS; PREVENTION; REDUCTION; DIAGNOSIS; PROJECT	. Objective: To determine whether breast cancer screening extends life for women aged 65 years or more with and without comorbid medical conditions. . Setting: A provider-patient encounter. . Design: A decision analysis of the utility of screening for breast cancer. . Measurements: Clinical examination and mammography among four groups of women aged 65 to 85 or more years: average health, mild hypertension, congestive heart failure, and average-health black women. The effects of screening were estimated using the best quality data available. . Results: Screening saved life at all ages among patients studied. Savings were highest for black women and decreased with increasing age and comorbidity. Screening all average-health women aged 65 or more saved 67 912 years of life. For women who had cancer, screening extended life by 617 days for average-health women between 65 and 69 years of age and 178 days for those aged 85 years or more. Perioperative mortality and test characteristics had little effect on the results. The risks equaled the benefits of screening only when operative mortality was between 27% and 62%. The marginal costs of screening during a routine office visit were $138 and increased with advancing age and decreasing test specificity. Benefits persisted after adjustment for changes in long-term quality of life; however, for women aged 85 years and older (with and without comorbidities), the short-term morbidity of anxiety or discomfort associated with screening may have outweighed the benefits. . Conclusion: No inherent reason exists to impose an upper-age limit for breast cancer screening; however, more data are needed on women's preferences for screening strategies.	MONTEFIORE MED CTR, BRONX, NY 10467 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CABRINI MED CTR, MALVERN, VIC 3140, AUSTRALIA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cabrini Health	MANDELBLATT, JS (corresponding author), MEM SLOAN KETTERING CANC CTR, DIV CANC CONTROL, 1275 YORK AVE, BOX 60, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE ON AGING [K08AG000471] Funding Source: NIH RePORTER; NIA NIH HHS [KO8 AG00471] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON NK, 1991, CANCER, V67, P844, DOI 10.1002/1097-0142(19910201)67:3+<844::AID-CNCR2820671416>3.0.CO;2-B; AARONSON NK, 1991, CANCER, V67, P839, DOI 10.1002/1097-0142(19910201)67:3+<839::AID-CNCR2820671415>3.0.CO;2-0; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ALLEN C, 1986, J AM GERIATR SOC, V34, P637, DOI 10.1111/j.1532-5415.1986.tb04904.x; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK JS, 1990, J AM GERIATR SOC, V38, P168, DOI 10.1111/j.1532-5415.1990.tb03480.x; BLOOM JR, 1991, CANCER, V67, P855, DOI 10.1002/1097-0142(19910201)67:3+<855::AID-CNCR2820671418>3.0.CO;2-1; BURACK RC, 1987, PREV MED, V16, P739, DOI 10.1016/0091-7435(87)90014-4; CARBONE PP, 1983, PERSPECTIVES PREVENT, P63; CELENTANO DD, 1982, PREV MED, V11, P454, DOI 10.1016/0091-7435(82)90048-2; CHAO A, 1987, PREV MED, V16, P710, DOI 10.1016/0091-7435(87)90053-3; DEVITT JE, 1970, CAN MED ASSOC J, V103, P923; EDDY D, 1987, US C OFFICE TECHNOLO; EDDY D, 1990, COSTS EFFECTIVENESS; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENWALD P, 1986, NATL CANCER I MONOGR, V2, P27; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; HERBSMAN H, 1981, CANCER-AM CANCER SOC, V47, P2358, DOI 10.1002/1097-0142(19810515)47:10<2358::AID-CNCR2820471006>3.0.CO;2-K; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; KASSIRER JP, 1976, YALE J BIOL MED, V49, P149; KLEINFELD G, 1963, ANN SURG, V157, P600, DOI 10.1097/00000658-196304000-00016; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MULLER CM, 1990, OTAS SERIES PREVENTI; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; PAUKER SG, 1976, ANN INTERN MED, V85, P8, DOI 10.7326/0003-4819-85-1-8; PLANTE DA, 1986, AM J MED, V80, P1169, DOI 10.1016/0002-9343(86)90680-7; POLEDNAK AP, 1986, CANCER, V58, P807, DOI 10.1002/1097-0142(19860801)58:3<807::AID-CNCR2820580333>3.0.CO;2-X; ROSEN PP, 1985, J SURG ONCOL, V28, P90, DOI 10.1002/jso.2930280204; SHAPIRO S, 1982, AM J PUBLIC HEALTH, V72, P1142, DOI 10.2105/AJPH.72.10.1142; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SINGER RB, 1976, MED RISKS; SONDIK E, 1989, ANN CANCER STATISTIC; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TEMIANKA D, 1989, JAMA-J AM MED ASSOC, V262, P1950, DOI 10.1001/jama.1989.03430140064016; TURNBULL AD, 1978, CLIN BULL, V8, P139; VERBEEK ALM, 1984, LANCET, V1, P1222; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; Weinstein MC, 1980, CLIN DECISION ANAL; WHITE LJ, 1985, ANN INTERN MED, V103, P143, DOI 10.7326/0003-4819-103-1-143; 1981, VITAL STATISTICS US, V2; 1986, SURVEY PUBLIC AWAREN, P1; 1983, CA-CANCER J CLIN, V33, P255; 1989, GUIDE CLIN PREVENTIV, P26; 1990, JAMA-J AM MED ASSOC, V264, P54; 1988, MMWR, V37, P3357; 1973, NIH902789 NCI PHS US; 1987, STUDY WOMENS AWARENE; 1989, JAMA-J AM MED ASSOC, V261, P2535	65	139	138	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					722	730		10.7326/0003-4819-116-9-722	http://dx.doi.org/10.7326/0003-4819-116-9-722			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558343				2022-12-24	WOS:A1992HQ62300004
J	MORIKAWA, K; MATSUMOTO, O; TSUJIMOTO, M; KATAYANAGI, K; ARIYOSHI, M; DOI, T; IKEHARA, M; INAOKA, T; OHTSUKA, E				MORIKAWA, K; MATSUMOTO, O; TSUJIMOTO, M; KATAYANAGI, K; ARIYOSHI, M; DOI, T; IKEHARA, M; INAOKA, T; OHTSUKA, E			X-RAY STRUCTURE OF T4 ENDONUCLEASE-V - AN EXCISION REPAIR ENZYME SPECIFIC FOR A PYRIMIDINE DIMER	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; DNA GLYCOSYLASE; NACL CONCENTRATION; BACTERIOPHAGE-T4; GENE; PURIFICATION; CLEAVAGE; PROTEINS	The x-ray structure of T4 endonuclease V, an enzyme responsible for the first step of a pyrimidine-dimer-specific excision-repair pathway, was determined at a 1.6-angstrom resolution. The enzyme consists of a single compact domain classified into an all-alpha-structure. This single domain has two distinct catalytic activities: it functions as a pyrimidine dimer glycosylase and as an apurinic-apyrimidinic endonuclease. The amino-terminal segment penetrates between two major helices and prevents their direct contact. The refined structure suggests the residues involved in the substrate binding and the catalysis of the glycosylation reaction.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	MORIKAWA, K (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.			Ariyoshi, Mariko/0000-0002-1361-2642				DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; Doi T., UNPUB; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LLOYD RS, 1989, PROTEINS, V6, P128, DOI 10.1002/prot.340060204; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; MONOHARAN M, 1988, J AM CHEM SOC, V110, P2690; MORIKAWA K, 1988, J MOL BIOL, V202, P683, DOI 10.1016/0022-2836(88)90298-7; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; WARNER HR, 1981, J VIROL, V40, P204, DOI 10.1128/JVI.40.1.204-210.1981; YASUDA S, 1970, P NATL ACAD SCI USA, V67, P1839, DOI 10.1073/pnas.67.4.1839	31	117	118	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					523	526		10.1126/science.1575827	http://dx.doi.org/10.1126/science.1575827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1575827				2022-12-24	WOS:A1992HQ18700064
J	NATTINGER, AB; GOTTLIEB, MS; VEUM, J; YAHNKE, D; GOODWIN, JS				NATTINGER, AB; GOTTLIEB, MS; VEUM, J; YAHNKE, D; GOODWIN, JS			GEOGRAPHIC-VARIATION IN THE USE OF BREAST-CONSERVING TREATMENT FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MASTECTOMY; RADIOTHERAPY; CONSENSUS; SERVICES; SURGERY	Background. In the past decade there has been an increase in the use of treatment designed to conserve the breast for women with breast cancer. The extent to which such treatment has been adopted in various regions of the country and whether characteristics of hospitals and patients predict its use are not known, however. Methods. We used national data on Medicare claims for inpatient care provided in 1986 to study 36,982 women 65 to 79 years of age, who had local or regional breast cancer and underwent either mastectomy or breast-conserving treatment (local excision, quadrantectomy, or subtotal mastectomy). Information about the hospitals at which these women were treated was obtained from an American Hospital Association survey. Results. Of the 36,982 women, 12.1 percent had breast-conserving surgery and 87.9 percent had a mastectomy. The frequency of breast-conserving surgery ranged from 3.5 percent to 21.2 percent in various states. The highest rate of use was in the Middle Atlantic states (20.0 percent) and New England (17.2 percent), and the lowest was in the East South Central states (5.9 percent) and the West South Central states (7.3 percent). Breast-conserving treatment was used more often in urban than in rural areas, in teaching hospitals than in nonteaching hospitals, in large hospitals than in small hospitals, and in hospitals with on-site radiation therapy or geriatric services than in others. Most of the geographic variation persisted after adjustment for the characteristics of hospitals and patients for which data were available. Conclusions. There is substantial geographic variation in the use of breast-conserving surgery, which cannot be explained by differences in hospital characteristics. Hospital characteristics that were independently predictive of greater use of breast-conserving surgery were the size of the metropolitan area, the status of the institution as a teaching hospital, and the availability of radiation therapy and geriatric services.	MED COLL WISCONSIN,DEPT BIOSTAT & CLIN EPIDEMIOL,MILWAUKEE,WI 53226; UNIV WISCONSIN,SCH MED,DEPT MED,MILWAUKEE,WI 53201	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee	NATTINGER, AB (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV GEN INTERNAL MED,8700 W WISCONSIN AVE,BOX 135,MILWAUKEE,WI 53226, USA.			Nattinger, Ann/0000-0002-8189-3300	NCI NIH HHS [1-R01-CA54676-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEBER RB, 1987, ARCH INTERN MED, V147, P1543, DOI 10.1001/archinte.147.9.1543; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Harris J. R., 1985, CANCER PRINCIPLES PR, P1119; HARRIS JR, 1985, NEW ENGL J MED, V313, P1365, DOI 10.1056/NEJM198511213132128; HOSMER DW, 1989, APPLIED LOGICAL REGR; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LAU J, 1991, CLIN RES, V39, pA252; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LIBERATI A, 1991, AM J PUBLIC HEALTH, V81, P38, DOI 10.2105/AJPH.81.1.38; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; ROSS LL, 1982, MED CARE, V20, P266; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; 1990, 1990 NIH CONS DEV C, V8; 1990, HCFA0330 HLTH CAR FI; 1987, HOSPITAL STATISTICS	22	468	468	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1102	1107		10.1056/NEJM199204233261702	http://dx.doi.org/10.1056/NEJM199204233261702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552911	Bronze			2022-12-24	WOS:A1992HP80000002
J	JOHANSSON, JE; ADAMI, HO; ANDERSSON, SO; BERGSTROM, R; HOLMBERG, L; KRUSEMO, UB				JOHANSSON, JE; ADAMI, HO; ANDERSSON, SO; BERGSTROM, R; HOLMBERG, L; KRUSEMO, UB			HIGH 10-YEAR SURVIVAL RATE IN PATIENTS WITH EARLY, UNTREATED PROSTATIC-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; CARCINOMA; PROSTATECTOMY	Objective. - To learn about the natural history of untreated, early-stage prostatic cancer. Design. - Cohort study with a mean follow-up of 123 months (range, 81 to 165 months). Setting. - Population-based, regionally well defined. Patients. - A consecutive sample of 223 patients (98% of all eligible) with early-stage (TO-2, NX, MO), initially untreated prostatic cancer. Main Outcome Measures. - Progression-free, disease-specific, and overall survival. Need for palliative and terminal care. Intervention. - Patients with tumor progression were hormonally treated (orchiectomy or estrogens) if they had symptoms. Results. - After complete follow-up, only 19 (8.5%) of the 223 patients had died of prostate cancer and 105 (85%) of a total of 124 deaths were from other causes. The 10-year, disease-specific survival rate was 86.8% (95% confidence interval, 80.7% to 92.9%) and was equally high (87.9%) in a subgroup of 58 patients who met current indications for radical prostatectomy. The progression-free, 10-year survival rate was 53.1% (95% confidence interval, 44.2% to 62.0%). In 50 of 76 patients, local growth provided the only evidence of progression, and endocrine treatment was generally successful in these cases. Following an initial increase, the rate of disease progression and death from prostate cancer decreased during the last years of follow-up. Conclusion. - The low disease-specific mortality rate especially in patients with highly and moderately differentiated tumors, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.	UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, UPPSALA, SWEDEN; UNIV UPPSALA, DEPT STAT, S-75105 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT SURG, UPPSALA, SWEDEN; UNIV UPPSALA, CTR DATA, S-75105 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University; Uppsala University Hospital; Uppsala University	JOHANSSON, JE (corresponding author), OREBRO MED CTR HOSP, DEPT UROL, S-70185 OREBRO, SWEDEN.							ADOLFSSON J, 1990, J UROLOGY, V144, P1404, DOI 10.1016/S0022-5347(17)39754-9; BAGSHAW MA, 1985, CANCER, V55, P2079, DOI 10.1002/1097-0142(19850501)55:9+<2079::AID-CNCR2820551408>3.0.CO;2-X; BAKKE A, 1985, 1985 P FINN UR CLUB, P58; CORRIERE JN, 1970, CANCER, V25, P911, DOI 10.1002/1097-0142(197004)25:4<911::AID-CNCR2820250426>3.0.CO;2-Y; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; GEORGE NJR, 1988, LANCET, V1, P494; GERVASI LA, 1989, J UROLOGY, V142, P332, DOI 10.1016/S0022-5347(17)38748-7; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HANASH KA, 1972, J UROLOGY, V107, P450, DOI 10.1016/S0022-5347(17)61053-X; HANDLEY R, 1988, BRIT J UROL, V62, P249, DOI 10.1111/j.1464-410X.1988.tb04328.x; HOSTETTER AL, 1990, AM J CLIN PATHOL, V94, P693, DOI 10.1093/ajcp/94.6.693; JOHANSSON JE, 1989, LANCET, V1, P799; KARNOFSKY DA, 1946, EVALUATION CHEMOTHER; LARSON A, 1985, SCAND J UROL NEPHROL, P30; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; MIDDLETON RG, 1990, UROL CLIN N AM, V17, P779; MOSKOVITZ B, 1987, UROL INT, V42, P49, DOI 10.1159/000281849; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHMIDT J D, 1976, Urology, V7, P602, DOI 10.1016/0090-4295(76)90085-6; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; WHITMORE WF, 1988, NATL CANCER I MONOGR, V7, P7; 1978, TNM CLASSIFICATION M; 1980, INT HISTOLOGICAL CLA, V22	27	446	451	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2191	2196		10.1001/jama.267.16.2191	http://dx.doi.org/10.1001/jama.267.16.2191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556796				2022-12-24	WOS:A1992HN84100028
J	ORENTLICHER, D				ORENTLICHER, D			THE ILLUSION OF PATIENT CHOICE IN END-OF-LIFE DECISIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRITICALLY ILL; RESUSCITATION; INFORMATION; PREFERENCES; PHYSICIANS; DOCTORS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUNSEL,CHICAGO,IL 60610, USA.							BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; CALLAHAN D, 1983, HASTINGS CENT REP, V20, P22; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KATZ J, 1984, SILENT WORLD DOCTOR, P48; KODISH E, 1991, NEW ENGL J MED, V325, P1349, DOI 10.1056/NEJM199111073251905; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LEVY DR, 1985, PEDIATRICS, V75, P639; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOUISELL DW, 1989, MED MALPRACTICE; MALLOY TR, 1991, AM GERIATRIC SOC AM; MARTEAU TM, 1989, BRIT J SOC PSYCHOL, V28, P89, DOI 10.1111/j.2044-8309.1989.tb00849.x; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WALLACE LM, 1986, SOC SCI MED, V22, P29, DOI 10.1016/0277-9536(86)90305-9; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252; 1987, GUIDELINES TERMINATI, P26; 1982, MAKING HLTH CARE DEC, P1; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1983, DECIDING FOREGO LIFE, P43; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1992, CURRENT OPINIONS 199	35	81	81	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2101	2104		10.1001/jama.267.15.2101	http://dx.doi.org/10.1001/jama.267.15.2101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552646				2022-12-24	WOS:A1992HM65000038
J	ANGUIANO, A; OATES, RD; AMOS, JA; DEAN, M; GERRARD, B; STEWART, C; MAHER, TA; WHITE, MB; MILUNSKY, A				ANGUIANO, A; OATES, RD; AMOS, JA; DEAN, M; GERRARD, B; STEWART, C; MAHER, TA; WHITE, MB; MILUNSKY, A			CONGENITAL BILATERAL ABSENCE OF THE VAS-DEFERENS - A PRIMARILY GENITAL FORM OF CYSTIC-FIBROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; GRADIENT GEL-ELECTROPHORESIS; POLYMORPHIC DNA MARKER; SINGLE-BASE CHANGES; ABNORMAL DISTRIBUTION; POINT MUTATIONS; GENE; IDENTIFICATION; LOCALIZATION; MISMATCHES	Objective. - Almost all males with cystic fibrosis (CF) have absent vasa deferentia. It has been suggested that otherwise healthy males with congenital bilateral absence of the vas deferens (CBAVD), previously considered a distinct genetic entity, have an increased frequency of CF gene mutations. This study examined the genetic commonality of these two disorders. Design. -We typed six common CF gene mutations in 25 patients with CBAVD. Additional rare mutations were sought using single-stranded conformation polymorphisms and direct DNA sequencing. When rare mutations were found, they were sought in a large sample of both CF patients and obligate CF carriers to exclude them as polymorphisms. Setting. - All the patients presented to a male infertility clinic of a teaching hospital. Subjects.-Twenty-five unselected, unrelated azoospermic men with CBAVD, most of them of Northern European ancestry. Results. - Sixteen (64%) of the 25 men with CBAVD had at least one detectable CF mutation, 16 times the expected frequency (P < .001). Moreover, we have thus far determined that three of these 16 men are compound heterozygotes, one of whom has a mutation not previously described. Analyses continue on patients who have yet to yield a detectable mutation. Conclusions. - Some, if not all, otherwise healthy men with CBAVD reflect a newly recognized, primarily genital, phenotype of CF. Prior to sperm aspiration to remedy infertility, CF mutation analysis should be recommended for them and their partners, as well as for their relatives.	BOSTON UNIV, SCH MED, CTR HUMAN GENET, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT UROL, BOSTON, MA 02118 USA; BOSTON UNIV HOSP, BOSTON, MA 02218 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; NCI, VIRAL CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; PROGRAM RESOURCES INC, FREDERICK CANC RES & DEV CTR, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Oates, Robert/0000-0003-2330-6697; Maher, Thomas/0000-0002-6083-9487; Milunsky, Aubrey/0000-0003-2114-4823	OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS JA, 1984, BIOCHIM BIOPHYS ACTA, V782, P247, DOI 10.1016/0167-4781(84)90059-9; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CAMPBELL MF, 1970, UROLOGY, V2, P1573; CHARNY CW, 1965, J UROLOGY, V93, P399, DOI 10.1016/S0022-5347(17)63787-X; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DAVIES K, 1990, NATURE, V348, P110, DOI 10.1038/348110a0; DEAN M, 1991, BIOTECHNIQUES, V10, P332; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DEAN M, 1991, ADV EXP MED BIOL, V290, P45; DENNING CR, 1968, PEDIATRICS, V41, P7; di Sant'Agnese P A, 1968, N Engl J Med, V279, P103, DOI 10.1056/NEJM196807112790213; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; DUMUR V, 1990, LANCET, V335, P1340, DOI 10.1016/0140-6736(90)91216-W; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HOLSCLAW DS, 1971, J UROLOGY, V106, P568, DOI 10.1016/S0022-5347(17)61343-0; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM BS, 1989, AM J HUM GENET, V44, P827; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KLECZKOWSKA A, 1989, CLIN GENET, V35, P268; KNOWLTON RG, 1985, NATURE, V318, P380, DOI 10.1038/318380a0; LAROCHE D, 1991, LANCET, V337, P55, DOI 10.1016/0140-6736(91)93377-L; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LUCOTTE G, 1991, LANCET, V337, P988, DOI 10.1016/0140-6736(91)91634-7; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NELSON RE, 1950, J UROLOGY, V63, P176, DOI 10.1016/S0022-5347(17)68750-0; NG ISL, 1991, HUM GENET, V87, P613; OLSON JR, 1969, J CLIN PATHOL, V22, P725, DOI 10.1136/jcp.22.6.725; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE L, 1991, AM J HUM GENET, V48, P608; PETIT P, 1983, HUM GENET, V64, P303, DOI 10.1007/BF00279418; RIGOT JM, 1991, NEW ENGL J MED, V325, P64; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHELLEN TMCM, 1980, FERTIL STERIL, V34, P401; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TSUI LC, 1985, SCIENCE, V230, P1054, DOI 10.1126/science.2997931; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WAINWRIGHT BJ, 1985, NATURE, V318, P384, DOI 10.1038/318384a0; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	54	428	434	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1794	1797		10.1001/jama.267.13.1794	http://dx.doi.org/10.1001/jama.267.13.1794			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545465				2022-12-24	WOS:A1992HK67200029
J	MCADAMS, AL				MCADAMS, AL			A RIGHT-TO-DIE	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					765	766		10.1136/bmj.304.6829.765	http://dx.doi.org/10.1136/bmj.304.6829.765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571685	Bronze, Green Published			2022-12-24	WOS:A1992HK80000027
J	GHOSH, A; SHATZ, CJ				GHOSH, A; SHATZ, CJ			INVOLVEMENT OF SUBPLATE NEURONS IN THE FORMATION OF OCULAR DOMINANCE COLUMNS	SCIENCE			English	Article							CAT VISUAL-CORTEX; EARLY POSTNATAL-DEVELOPMENT; LONG-TERM POTENTIATION; NMDA RECEPTORS; CORTICAL PLASTICITY; BLOCKADE PREVENTS; CEREBRAL-CORTEX; STRIATE CORTEX; CELLS; AFFERENTS	During development of the mammalian visual system, axon terminals of lateral geniculate nucleus (LGN) neurons, initially intermixed within layer 4 of the visual cortex, gradually segregate according to eye preference to form ocular dominance columns. In addition to LGN axons and layer 4 neurons, subplate neurons may also participate in interactions leading to column formation. Deletion of subplate neurons before the formation of ocular dominance columns prevents the segregation of LGN axons within layer 4. Thus, interactions between LGN axons and layer 4 neurons are not sufficient; subplate neurons are also required for formation of ocular dominance columns in the visual cortex.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University					NATIONAL EYE INSTITUTE [R37EY002858, R01EY002858] Funding Source: NIH RePORTER; NEI NIH HHS [EY02858] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON PA, 1988, J NEUROSCI, V8, P2183; ANTONINI A, 1990, EUR J NEUROSCI, V2, P744, DOI 10.1111/j.1460-9568.1990.tb00465.x; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CHUN JJM, 1989, J NEUROSCI, V9, P1648; CHUN JJM, 1988, J CELL BIOL, V106, P857, DOI 10.1083/jcb.106.3.857; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FOX K, 1989, J NEUROSCI, V9, P2443; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FRIAUF E, 1990, J NEUROSCI, V10, P2601; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; GHOSH A, 1992, J NEUROSCI, V12, P39; Ghosh A., UNPUB; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SHATZ CJ, 1977, BRAIN RES, V131, P103, DOI 10.1016/0006-8993(77)90031-2; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1986, J NEUROSCI, V6, P3655; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; VALVERDE F, 1987, DEV BRAIN RES, V32, P283, DOI 10.1016/0165-3806(87)90108-8; WAHLE P, 1987, J COMP NEUROL, V261, P165, DOI 10.1002/cne.902610202; WIESEL TN, 1974, BRAIN RES, V79, P273, DOI 10.1016/0006-8993(74)90416-8	33	204	205	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1441	1443		10.1126/science.1542795	http://dx.doi.org/10.1126/science.1542795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542795				2022-12-24	WOS:A1992HH74400059
J	TLSTY, TD; WHITE, A; SANCHEZ, J				TLSTY, TD; WHITE, A; SANCHEZ, J			SUPPRESSION OF GENE AMPLIFICATION IN HUMAN CELL HYBRIDS	SCIENCE			English	Article							OUABAIN-RESISTANT; HELA-CELLS; EXPRESSION; TUMORIGENICITY; CHROMOSOME-11; MALIGNANCY; LINES	Gene amplification, one example of genetic instability, is of prognostic and clinical importance in neoplasia. In tumorigenic cells, gene amplification occurs at a very high frequency, whereas in normal diploid fibroblasts the event is undetectable by the clonogenic assay. To investigate genetic control of gene amplification, amplification frequency was measured in hybrids of tumorigenic cells and normal diploid cells. The ability to amplify an endogenous gene behaved as a recessive genetic trait, and control of gene amplification potential segregated independently of tumorigenicity and immortality.			TLSTY, TD (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PATHOL & CURRICULUM GENET,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.							BENEDICT WF, 1984, CANCER RES, V44, P3471; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CHEN P, 1990, CARCINOGENESIS D, P13; DER CJ, 1978, CELL, V15, P1241, DOI 10.1016/0092-8674(78)90050-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FOULDS L, 1975, NEOPLASTIC DEV, V2; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; NICHOLSON GL, 1987, CANCER RES, V47, P1473; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTTO E, 1989, J BIOL CHEM, V264, P3390; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; POSTE G, 1986, CANCER TREAT REP, V70, P183; ROBBINS AR, 1977, BIOCHEMISTRY-US, V16, P5163, DOI 10.1021/bi00642a600; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STARK GR, 1984, ANN REV BIOCH, V37, P705; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, UNPUB; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791	28	71	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1425	1427		10.1126/science.1542791	http://dx.doi.org/10.1126/science.1542791			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542791				2022-12-24	WOS:A1992HH74400053
J	MAHADEVAN, M; TSILFIDIS, C; SABOURIN, L; SHUTLER, G; AMEMIYA, C; JANSEN, G; NEVILLE, C; NARANG, M; BARCELO, J; OHOY, K; LEBLOND, S; EARLEMACDONALD, J; DEJONG, PJ; WIERINGA, B; KORNELUK, RG				MAHADEVAN, M; TSILFIDIS, C; SABOURIN, L; SHUTLER, G; AMEMIYA, C; JANSEN, G; NEVILLE, C; NARANG, M; BARCELO, J; OHOY, K; LEBLOND, S; EARLEMACDONALD, J; DEJONG, PJ; WIERINGA, B; KORNELUK, RG			MYOTONIC-DYSTROPHY MUTATION - AN UNSTABLE CTG REPEAT IN THE 3' UNTRANSLATED REGION OF THE GENE	SCIENCE			English	Article								Myotonic dystrophy (DM) is the most common inherited neuromuscular disease in adults, with a global incidence of 1 in 8000 individuals. DM is an autosomal dominant, multisystemic disorder characterized primarily by myotonia and progressive muscle weakness. Genomic and complementary DNA probes that map to a 10-kilobase Eco RI genomic fragment from human chromosome 19q13.3 have been used to detect a variable length polymorphism in individuals with DM. Increases in the size of the allele in patients with DM are now shown to be due to an increased number of trinucleotide CTG repeats in the 3' untranslated region of a DM candidate gene. An increase in the severity of the disease in successive generations (genetic anticipation) is accompanied by an increase in the number of trinucleotide repeats. Nearly all cases of DM (98 percent or 253 of 258 individuals) displayed expansion of the CTG repeat region. These results suggest that DM is primarily caused by mutations that generate an amplification of a specific CTG repeat.	UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1H 8L1,ONTARIO,CANADA; CHILDRENS HOSP EASTERN ONTARIO,RES INST,OTTAWA K1H 8L1,ONTARIO,CANADA; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Radboud University Nijmegen			Wieringa, Berend/A-5346-2011; Jansen, Gert/HCI-8852-2022	Wieringa, Berend/0000-0001-9192-8020; Jansen, Gert/0000-0002-7524-171X				ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, UNPUB; JANSEN G, IN PRESS GENOMICS; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PENROSE LS, 1948, ANN EUGENIC, V14, P125; SHUTLER G, IN PRESS GENOMICS; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	15	1413	1454	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1253	1255		10.1126/science.1546325	http://dx.doi.org/10.1126/science.1546325			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546325				2022-12-24	WOS:A1992HG67700042
J	SALT, A; NOBLEJAMIESON, G; BARNES, ND; MOWAT, AP; ROLLES, K; JAMIESON, N; JOHNSTON, P; FRIEND, P; CALNE, RY				SALT, A; NOBLEJAMIESON, G; BARNES, ND; MOWAT, AP; ROLLES, K; JAMIESON, N; JOHNSTON, P; FRIEND, P; CALNE, RY			LIVER-TRANSPLANTATION IN 100 CHILDREN - CAMBRIDGE AND KINGS-COLLEGE-HOSPITAL SERIES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CYTOMEGALO-VIRUS DISEASE; BILIARY ATRESIA; EXPERIENCE; REJECTION; GRAFT; THROMBOSIS; DEFICIENCY; SURGERY; KIDNEY; DONOR	Objective - To review the results of the Addenbrooke's and King's College Hospital children's liver transplantation programme. Design - Retrospective analysis of the first 100 children to receive liver grafts at Addenbrooke's Hospital, Cambridge, from December 1983 to March 1990. Setting - Addenbrooke's Hospital, Cambridge, and King's College Hospital, London. Subjects - 153 children assessed for liver transplantation, of whom 22 died before a donor became available and 31 were considered unsuitable. 100 children received grafts, of whom 27 had second grafts. Results - One year actuarial patient survival was 71%, with 57% one year graft survival. In the last two years survival rates had improved considerably, with 86% of patients and 63% of grafts surviving for at least one year. Sixty five children were alive 12 to 86 months after transplantation; 63 were well and leading normal active lives and 56 had entirely normal liver function. Children's growth and development were essentially normal, with many showing remarkable catch up growth. Conclusions - Liver transplantation offers children with terminal liver disease a high chance of a return to full quality life and normal development. Improved surgical and medical care have progressively improved survival. The timing of transplantation is critical but has been constrained particularly by the availability of donors and resources.	ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV LONDON KINGS COLL HOSP, PAEDIAT HEPATOL, LONDON SE5 8RX, ENGLAND; ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Friend, Peter/AAH-6512-2019					ANDREWS WS, 1989, J PEDIATR SURG, V24, P77, DOI 10.1016/S0022-3468(89)80306-9; BISMUTH H, 1984, SURGERY, V95, P367; BROELSCH CE, 1988, TRANSPLANTATION, V45, P519, DOI 10.1097/00007890-198803000-00003; CALNE R, 1987, LIVER TRANSPLANTATIO; CALNE RY, 1976, ANN SURG, V184, P605, DOI 10.1097/00000658-197611000-00012; COULDEN RA, 1990, LANCET, V336, P273, DOI 10.1016/0140-6736(90)91804-J; DEHEMPTINNE B, 1987, TRANSPLANT P, V19, P3317; FOEGH ML, 1990, TRANSPL P, V22, P119; GARTNER JC, 1984, PEDIATRICS, V74, P140; HARPER PL, 1988, LANCET, V2, P924; HUBSCHER SG, 1991, TRANSPL P, V23, P1415; KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7; MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011; MCDONALD JA, 1989, TRANSPLANT P, V21, P3792; MIELIVERGANI G, 1989, LANCET, V1, P421; NOBLEJAMIESON G, 1990, ARCH DIS CHILD, V65, P1217, DOI 10.1136/adc.65.11.1217; OGUMA S, 1989, HEPATOLOGY, V9, P204, DOI 10.1002/hep.1840090207; OHI R, 1990, J PEDIATR SURG, V25, P442, DOI 10.1016/0022-3468(90)90390-U; OTTE JB, 1987, TRANSPLANT P, V19, P3289; PETT S, 1987, TRANSPLANT P, V19, P3256; ROLLES K, 1984, HEPATOLOGY, V4, pS50, DOI 10.1002/hep.1840040715; SALMELA K, 1990, TRANSPLANT P, V22, P238; SALT A, 1990, J CLIN PATHOL, V43, P63, DOI 10.1136/jcp.43.1.63; SAMUEL D, 1989, TRANSPLANT P, V21, P2225; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1979, PEDIATRICS, V63, P825; STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009; STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443; WEIMAR W, 1990, TRANSPLANT P, V22, P229; 1984, HEPATOLOGY S, V4, P107	32	57	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					416	421		10.1136/bmj.304.6824.416	http://dx.doi.org/10.1136/bmj.304.6824.416			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547389	Green Published, Bronze			2022-12-24	WOS:A1992HE38900019
J	ROBINSON, DS; HAMID, Q; YING, S; TSICOPOULOS, A; BARKANS, J; BENTLEY, AM; CORRIGAN, C; DURHAM, SR; KAY, AB				ROBINSON, DS; HAMID, Q; YING, S; TSICOPOULOS, A; BARKANS, J; BENTLEY, AM; CORRIGAN, C; DURHAM, SR; KAY, AB			PREDOMINANT TH2-LIKE BRONCHOALVEOLAR LYMPHOCYTE-T POPULATION IN ATOPIC ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN EOSINOPHILS; PULMONARY SARCOIDOSIS; HUMAN INTERLEUKIN-5; BRONCHIAL BIOPSIES; IMMUNE REGULATION; CELL CLONE; TH2 CLONES; IFN-GAMMA; RELEASE; RNA	Background. In atopic asthma, activated T helper lymphocytes are present in bronchial-biopsy specimens and bronchoalveolar-lavage (BAL) fluid, and their production of cytokines may be important in the pathogenesis of this disorder. Different patterns of cytokine release are characteristic of certain subgroups of T helper cells, termed T(H1) and T(H2), the former mediating delayed-type hypersensitivity and the latter mediating IgE synthesis and eosinophilia. The pattern of cytokine production in atopic asthma is unknown. Methods. We assessed cells obtained by BAL in subjects with mild atopic asthma and in normal control subjects for the expression of messenger RNA (mRNA) for interleukin-2, 3, 4, and 5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma by in situ hybridization with P-32-labeled complementary RNA. Localization of mRNA to BAL T cells was assessed by simultaneous in situ hybridization and immunofluorescence and by in situ hybridization after immunomagnetic enrichment or depletion of T cells. Results. As compared with the control subjects, the subjects with asthma had more BAL cells per 1000 cells that were positive for mRNA for interleukin-2 (P < 0.05), 3 (P < 0.01), 4 (P < 0.001), and 5 (P < 0.001) and GM-CSF (P < 0.001). There was no significant difference between the two groups in the number of cells expressing mRNA for interferon gamma. In the subjects with asthma, mRNA for interleukin-4 and 5 was expressed predominantly by T lymphocytes. Conclusions. Atopic asthma is associated with activation in the bronchi of the interleukin-3, 4, and 5 and GM-CSF gene cluster, a pattern compatible with predominant activation of the T(H2)-like T-cell population.	NATL HEART & LUNG INST,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London			Tsicopoulos, Anne/C-2260-2019	Tsicopoulos, Anne/0000-0002-1579-2763; Bentley, Andrew/0000-0002-6883-9246; Corrigan, Chris/0000-0002-0706-6534				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHANG TL, 1990, J IMMUNOL, V145, P2803; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CORRIGAN CJ, 1988, LANCET, V1, P1129; DELPOZO V, 1990, J IMMUNOL, V144, P3117; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FONG TAT, 1989, J IMMUNOL, V143, P2887; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GIAID A, 1989, HISTOCHEMISTRY, V93, P191, DOI 10.1007/BF00315974; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LEA T, 1985, SCAND J IMMUNOL, V22, P207, DOI 10.1111/j.1365-3083.1985.tb01873.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; ROBINSON DS, 1991, 3RD INT C BRONCH LAV; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SALTINI C, 1986, J CLIN INVEST, V77, P1962, DOI 10.1172/JCI112525; STREET NE, 1990, J IMMUNOL, V144, P1629; SWAIN SL, 1990, J IMMUNOL, V145, P3796; WALKER C, 1991, J IMMUNOL, V146, P1829; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673	38	2526	2606	3	150	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					298	304		10.1056/NEJM199201303260504	http://dx.doi.org/10.1056/NEJM199201303260504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1530827				2022-12-24	WOS:A1992HA99100004
J	DERAY, G; BENHMIDA, M; LEHOANG, P; MAKSUD, P; AUPETIT, B; BAUMELOU, A; JACOBS, C				DERAY, G; BENHMIDA, M; LEHOANG, P; MAKSUD, P; AUPETIT, B; BAUMELOU, A; JACOBS, C			RENAL-FUNCTION AND BLOOD-PRESSURE IN PATIENTS RECEIVING LONG-TERM, LOW-DOSE CYCLOSPORINE THERAPY FOR IDIOPATHIC AUTOIMMUNE UVEITIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYCLOSPORINE; UVEITIS; AUTOIMMUNE DISEASES; KIDNEY DISEASES; HYPERTENSION	GLOMERULAR-FILTRATION RATE; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; INTERSTITIAL NEPHRITIS; TRANSPLANT RECIPIENTS; ANTERIOR UVEITIS; CONTROLLED TRIAL; HYPERTENSION; PLACEBO; NEPHROTOXICITY	Objective: To determine the renal side effects of long-term, low-dose cyclosporine therapy (initial dose, 5 mg/kg body weight per day) in patients with autoimmune idiopathic uveitis. Design: Cohort study with at least 2 years of follow-up. Setting: A teaching hospital in Paris, France (Hospital Pitie-Salpetriere). Patients: Sixteen patients with idiopathic autoimmune uveitis who were normotensive and had normal renal function before treatment. Cyclosporine was administered orally for at least 2 years at an initial dosage of 5 mg/kg body weight per day. Results: After 2 years of treatment, the serum creatinine level increased by 35 +/- 5 mumol/L (0.40 +/- 0.06 mg/dL) (95% Cl, 25 to 46 mumol/L, [73 +/- 4 to 108 +/- 4 mumol/L]). Creatinine clearance decreased significantly from 120 +/- 5 mL/min to 75 +/- 4 mL/min. Glomerular filtration rate decreased from 116 +/- 8 mL/min to 75 +/- 3 mL/min, and effective renal plasma flow decreased from 455 +/- 24 mL/min to 338 +/- 30 mL/min (P < 0.05). Cyclosporine induced a significant increase in serum uric acid, total cholesterol, and serum potassium levels. Blood pressure was normal in all patients before treatment; 81% (95% Cl, 64% to 98%) of these patients developed hypertension after 24 months of treatment. Blood pressure was controlled with a single drug in all but two patients. Conclusions: In patients with healthy native kidneys, long-term cyclosporine therapy, even at a low dose (5 mg/kg per day), is nephrotoxic and is associated with a high incidence of hypertension.			DERAY, G (corresponding author), HOP PITIE, SERV NEPHROL, 83 BLVD HOP, F-75013 PARIS, FRANCE.			Ben Hmida, Mohamed/0000-0002-0997-6136				BENNETT WM, 1988, AM J MED, V85, P131, DOI 10.1016/S0002-9343(88)80330-9; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; COHEN SL, 1989, NEPHROL DIAL TRANSPL, V4, P201, DOI 10.1093/oxfordjournals.ndt.a091856; CURTIS JJ, 1988, AM J MED, V85, P134; DERAY G, 1988, EUR J CLIN PHARMACOL, V34, P601, DOI 10.1007/BF00615224; DERAY G, 1987, LANCET, V1, P158; DERAY G, 1989, CLIN NEPHROL, V32, P47; DIETERLE A, 1988, TRANSPLANT P, V20, P349; DOBRIN RS, 1975, AM J MED, V59, P325, DOI 10.1016/0002-9343(75)90390-3; DOUGADOS M, 1988, ANN RHEUM DIS, V47, P127, DOI 10.1136/ard.47.2.127; GAFTER U, 1986, NEPHRON, V42, P249, DOI 10.1159/000183675; GURECKI J, 1985, TRANSPLANT P, V17, P1997; LAMB FS, 1987, LIFE SCI, V40, P2571, DOI 10.1016/0024-3205(87)90080-4; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; LIN HY, 1989, NEW ENGL J MED, V321, P287, DOI 10.1056/NEJM198908033210504; LUDWIN D, 1988, TRANSPLANT P, V20, P367; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MORGAN BJ, 1989, FASEB J, V3, pA1145; POWLES AV, 1990, BRIT J DERMATOL, V122, P665, DOI 10.1111/j.1365-2133.1990.tb07288.x; RAINE AEG, 1988, NEPHROL DIAL TRANSPL, V3, P458, DOI 10.1093/oxfordjournals.ndt.a091698; RUSSELL CD, 1985, J NUCL MED, V26, P1243; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHMITZSCHUMANN M, 1986, PROG ALLERGY, V38, P436; SINCLAIR NR, 1986, NEW ENGL J MED, V314, P1219; STILLER CR, 1983, NEW ENGL J MED, V309, P809; TAUXE WN, 1982, EUR J NUCL MED, V7, P51; TAUXE WN, 1971, MAYO CLIN PROC, V46, P524; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; TUGWELL P, 1987, J RHEUMATOL, V14, P1108; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; VANRIJTHOVEN AWAM, 1991, J RHEUMATOL, V18, P19; WEIDLE PJ, 1988, DRUG INTEL CLIN PHAR, V22, P443, DOI 10.1177/106002808802200601; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; YOCUM DE, 1988, ANN INTERN MED, V109, P863, DOI 10.7326/0003-4819-109-11-863; ZACHARIAE H, 1990, BRIT J DERMATOL, V122, P677, DOI 10.1111/j.1365-2133.1990.tb07290.x	37	87	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					578	583		10.7326/0003-4819-117-7-578	http://dx.doi.org/10.7326/0003-4819-117-7-578			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524331				2022-12-24	WOS:A1992JQ22600006
J	HOGAN, BLM; THALLER, C; EICHELE, G				HOGAN, BLM; THALLER, C; EICHELE, G			EVIDENCE THAT HENSEN NODE IS A SITE OF RETINOIC ACID SYNTHESIS	NATURE			English	Article							DEVELOPING CHICK LIMB; LOCAL APPLICATION; XENOPUS EMBRYOS; NERVOUS-SYSTEM; MOUSE EMBRYOS; EXPRESSION; PATTERN; GENES; BUD; TRANSFORMATION	HENSEN'S node of amniotes, like the Spemann organizer of amphibians, can induce a second body axis when grafted into a host embryo1. The avian node, as well as several midline structures originating from it (notochord, floor plate), can also induce digit pattern duplications when grafted into the chick wing bud2,3. We report here that the equivalent of Hensen's node from mouse is an effective inducer of digits in the chick wing bud. Tissues anterior and posterior to the node also evoke pattern duplications, but with a significantly lower efficiency. The finding that the murine node operates in an avian wing bud suggests that the same inducing agent(s) function in both primary and secondary embryonic fields and have been conserved during vertebrate evolution. Digit pattern duplications are also evoked by local administration of all-transretinoic acid4,5. This similarity raises the possibility that Hensen's node is a source of retinoic acid. The mouse node is capable of synthesizing retinoic acid from its biosynthetic precursor all-transretinol at a substantially higher rate than either anterior or posterior tissues.	BAYLOR COLL MED,V&M MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Baylor College of Medicine; Vanderbilt University								ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; [Anonymous], 1952, EPIGENETICS BIRDS; CONLON RA, IN PRESS DEVELOPMENT; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GAUNT SJ, 1990, TRENDS GENET, V6, P208; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAWSON KA, 1992, CIBA F SYMP, V165, P3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; Romijn HJ, 1982, DEV BRAIN RES, V2, P583; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SCHOENWOLF GC, 1992, DEV DYNAM, V193, P235, DOI 10.1002/aja.1001930304; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SMITH SM, 1991, DEVELOPMENT, V111, P245; STERN CD, 1979, ANAT EMBRYOL, V156, P319, DOI 10.1007/BF00299630; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUNDIN O, 1992, DEVELOPMENT, V114, P841; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1988, DEVELOPMENT, V103, P473; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0	33	205	206	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					237	241		10.1038/359237a0	http://dx.doi.org/10.1038/359237a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528265				2022-12-24	WOS:A1992JN94400062
J	VANTILBEURGH, H; SARDA, L; VERGER, R; CAMBILLAU, C				VANTILBEURGH, H; SARDA, L; VERGER, R; CAMBILLAU, C			STRUCTURE OF THE PANCREATIC LIPASE PROCOLIPASE COMPLEX	NATURE			English	Article							REFINEMENT; COLIPASE	INTERFACIAL adsorption of pancreatic lipase is strongly dependent on the physical chemical properties of the lipid surface. These properties are affected by amphiphiles such as phospholipids and bile salts. In the presence of such amphiphiles, lipase binding to the interface requires a protein cofactor, colipase1-3. We obtained crystals of the pancreatic lipase-procolipase complex and solved the structure at 3.04 angstrom resolution. Here we describe the structure of procolipase, which essentially consists of three 'fingers' and is topologically comparable to snake toxins4,5. The tips of the fingers contain most of the hydrophobic amino acids and presumably form the interfacial binding site. Lipase binding occurs at the opposite side to this site and involves polar interactions. Determination of the three-dimensional structure of pancreatic lipase has revealed the presence of two domains: an amino-terminal domain, at residues 1-336 containing the active site and a carboxy-terminal domain at residues 337-449 (ref. 6). Procolipase binds exclusively to the C-terminal domain of lipase. No conformational change in the lipase molecule is induced by the binding of procolipase.	FAC ST CHARLES,INST CHIM BIOL,F-13331 MARSEILLE 3,FRANCE; CNRS,CTR BIOCHIM & BIOL MOLEC,F-13402 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	VANTILBEURGH, H (corresponding author), FAC MED NORD,LCCMB,CNRS,F-13326 MARSEILLE 15,FRANCE.							ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; Borgstrom B., 1984, P151; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; COZZONE PJ, 1984, EUR J BIOCHEM, V114, P119; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; ERLANSON C, 1974, BIOCHIM BIOPHYS ACTA, V259, P198; JANIN J, 1990, J BIOL CHEM, V265, P16027; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; RATHELOT J, 1981, BIOCHIMIE, V63, P227, DOI 10.1016/S0300-9084(81)80196-4; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; ROUSSEL A, 1991, SILICON GRAPHICS DIR; SARDA L, 1991, LIPASES STRUCTURE ME, P145; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	18	303	318	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					159	162		10.1038/359159a0	http://dx.doi.org/10.1038/359159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522902				2022-12-24	WOS:A1992JM49400057
J	THORNBERRY, NA; BULL, HG; CALAYCAY, JR; CHAPMAN, KT; HOWARD, AD; KOSTURA, MJ; MILLER, DK; MOLINEAUX, SM; WEIDNER, JR; AUNINS, J; ELLISTON, KO; AYALA, JM; CASANO, FJ; CHIN, J; DING, GJF; EGGER, LA; GAFFNEY, EP; LIMJUCO, G; PALYHA, OC; RAJU, SM; ROLANDO, AM; SALLEY, JP; YAMIN, TT; LEE, TD; SHIVELY, JE; MACCROSS, M; MUMFORD, RA; SCHMIDT, JA; TOCCI, MJ				THORNBERRY, NA; BULL, HG; CALAYCAY, JR; CHAPMAN, KT; HOWARD, AD; KOSTURA, MJ; MILLER, DK; MOLINEAUX, SM; WEIDNER, JR; AUNINS, J; ELLISTON, KO; AYALA, JM; CASANO, FJ; CHIN, J; DING, GJF; EGGER, LA; GAFFNEY, EP; LIMJUCO, G; PALYHA, OC; RAJU, SM; ROLANDO, AM; SALLEY, JP; YAMIN, TT; LEE, TD; SHIVELY, JE; MACCROSS, M; MUMFORD, RA; SCHMIDT, JA; TOCCI, MJ			A NOVEL HETERODIMERIC CYSTEINE PROTEASE IS REQUIRED FOR INTERLEUKIN-1-BETA PROCESSING IN MONOCYTES	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; SEQUENCE-ANALYSIS; MONONUCLEAR-CELLS; PRECURSOR; ENZYME; IDENTIFICATION; PROTEINASES; ACTIVATION; 1-BETA	Interleukin-1-beta (IL-1-beta)-converting enzyme cleaves the IL-1-beta precursor to mature IL-1-beta, an important mediator of inflammation. The identification of the enzyme as a unique cysteine protease and the design of potent peptide aldehyde inhibitors are described. Purification and cloning of the complementary DNA indicates that IL-1-beta-converting enzyme is composed of two nonidentical subunits that are derived from a single proenzyme, possibly by autoproteolysis. Selective inhibition of the enzyme in human blood monocytes blocks production of mature IL-1-beta, indicating that it is a potential therapeutic target.	MERCK SHARP & DOHME LTD, DEPT MOLEC IMMUNOL, POB 2000, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM & MOLEC PATHOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT MED CHEM RES, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM PROC RES & DEV, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOL DATA, RAHWAY, NJ 07065 USA; CITY HOPE NATL MED CTR, BECKMAN RES INT, DUARTE, CA 91010 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; City of Hope; Beckman Research Institute of City of Hope				Elliston, Keith/0000-0002-9110-9233				BAZAN JF, 1989, FEBS LETT, V249, P5, DOI 10.1016/0014-5793(89)80003-1; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BULL HG, 1985, J BIOL CHEM, V260, P2963; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; ITOH N, 1987, J BIOL CHEM, V262, P3132; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LONNEMANN G, 1989, EUR J IMMUNOL, V19, P1531, DOI 10.1002/eji.1830190903; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RICH DH, 1986, PROTEINASE INHIBITOR, P153; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SCHMIDT JA, 1990, PEPTIDE GROWTH FACTO, P473; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHERIDAN RP, IN PRESS PROTEINS; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0	40	2062	2171	3	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1992	356	6372					768	774		10.1038/356768a0	http://dx.doi.org/10.1038/356768a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574116				2022-12-24	WOS:A1992HR18600041
J	SCHUCHAT, A; DEAVER, KA; WENGER, JD; PLIKAYTIS, BD; MASCOLA, L; PINNER, RW; REINGOLD, AL; BROOME, CV				SCHUCHAT, A; DEAVER, KA; WENGER, JD; PLIKAYTIS, BD; MASCOLA, L; PINNER, RW; REINGOLD, AL; BROOME, CV			ROLE OF FOODS IN SPORADIC LISTERIOSIS .1. CASE-CONTROL STUDY OF DIETARY RISK-FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIC LISTERIOSIS; INFECTION; OUTBREAK	Objective. - To identify dietary risk factors for sporadic listeriosis. Design. - Case-control study with blinded telephone interviews. Setting. - Multistate population of 18 million persons, November 1988 through December 1990. Participants. - One hundred sixty-five patients with culture-confirmed listeriosis and 376 control subjects matched for age, health care provider, and immunosuppressive condition. Results. - The annual incidence of invasive listeriosis was 7.4 cases per million population; 23% of the infections were fatal. Cases were more likely than matched controls to have eaten soft cheeses (odds ratio [OR], 2.6; 95% confidence interval [Cl], 1.4 to 4.8; P = .002) or food purchased from store delicatessen counters (OR, 1.6; 95% Cl, 1.0 to 2.5; P = .04); 32% of sporadic disease could be attributed to eating these foods. Sixty-nine percent of cases in men and nonpregnant women occurred in cancer patients, persons with the acquired immunodeficiency syndrome, organ transplant recipients, or those receiving corticosteroid therapy. Among these immunosuppressed patients, eating undercooked chicken also increased the risk of listeriosis (OR, 3.3; 95% Cl, 1.2 to 9.2; P = .02). Conclusions. - Foodborne transmission may account for a substantial portion of sporadic listeriosis. Prevention efforts should include dietary counseling of high-risk patients and continued monitoring of food production.	CTR DIS CONTROL, DIV BACTERIAL & MYCOT DIS, BIOSTAT & INFORMAT BRANCH, ATLANTA, GA 30333 USA; LOS ANGELES CTY DEPT HLTH SERV, BERKELEY, CA USA; UNIV CALIF BERKELEY, DEPT BIOMED & ENVIRONM HLTH SCI, BERKELEY, CA 94720 USA	Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	SCHUCHAT, A (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		BILLE J, 1990, T IND MICR, P71; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1991, AM J EPIDEMIOL, V133, P392, DOI 10.1093/oxfordjournals.aje.a115893; HO JL, 1986, ARCH INTERN MED, V146, P520, DOI 10.1001/archinte.146.3.520; HUMBLE CG, 1984, AM J EPIDEMIOL, V119, P86, DOI 10.1093/oxfordjournals.aje.a113729; Humphrey T. J., 1990, PHLS Microbiology Digest, V7, P57; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MARSHALL J, 1980, AM J EPIDEMIOL, V112, P675, DOI 10.1093/oxfordjournals.aje.a113040; McLauchlin J., 1990, PHLS Microbiology Digest, V7, P54; MILLER JK, 1965, AM J CLIN PATHOL, V43, P248; Morbidity and Mortality Weekly Report (MMWR), 1988, MMWR-MORBID MORTAL W, V37, P764; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; SCHLECH WF, 1990, T IND MICR, P51; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P221; SCHUCHAT A, 1991, P INT C LISTERIA FOO, P69; SCHWARTZ B, 1988, LANCET, V2, P779; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1988, B WORLD HEALTH ORGAN, V66, P421; 1986, SUGI SUPPLEMENTAL LI, P307; 1989, MMWR, V38, P267	22	260	265	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2041	2045		10.1001/jama.267.15.2041	http://dx.doi.org/10.1001/jama.267.15.2041			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552639				2022-12-24	WOS:A1992HM65000028
J	GUSSONI, E; PAVLATH, GK; LANCTOT, AM; SHARMA, KR; MILLER, RG; STEINMAN, L; BLAU, HM				GUSSONI, E; PAVLATH, GK; LANCTOT, AM; SHARMA, KR; MILLER, RG; STEINMAN, L; BLAU, HM			NORMAL DYSTROPHIN TRANSCRIPTS DETECTED IN DUCHENNE MUSCULAR-DYSTROPHY PATIENTS AFTER MYOBLAST TRANSPLANTATION	NATURE			English	Article							MOSAIC EXPRESSION; MUSCLE-FIBERS; GENE; CARRIERS; DELETION; PROTEIN; LOCUS; CDNA	GENE delivery by transplantation of normal myoblasts has been proposed as a treatment of the primary defect, lack of the muscle protein dystrophin, that causes Duchenne muscular dystrophy (DMD), a lethal human muscle degenerative disorder 1,2. To test this possibility, we transplanted normal myoblasts from a father or an unaffected sibling into the muscle of eight boys with DMD, and assessed their production of dystrophin. Three patients with deletions in the dystrophin gene expressed normal dystrophin transcripts in muscle biopsy specimens taken from the transplant site one month after myoblast injection. Using the polymerase chain reaction we established that the dystrophin in these biopsies derived from donor myoblast DNA. These results show that transplanted myoblasts persist and produce dystrophin in muscle fibres of DMD patients.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305; CALIF PACIFIC MED CTR,DIV NEUROMUSCULAR RES,SAN FRANCISCO,CA 94118	Stanford University; Stanford University; California Pacific Medical Center			Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677; Steinman, Lawrence/0000-0002-2437-2250				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ARAHATA K, 1989, NEW ENGL J MED, V320, P138, DOI 10.1056/NEJM198901193200302; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BEGGS AH, 1990, HUM GENET, V86, P45; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BONILLA E, 1988, AM J PATHOL, V133, P440; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHAMBERLAIN JS, 1990, PCR PROTOCOLS GUIDE; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER BJ, 1990, LAB INVEST, V62, P171; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; FORREST SM, 1987, NATURE, V329, P638, DOI 10.1038/329638a0; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUGHES S, 1992, CELL, V68, P1; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; KARPATI G, 1989, AM J PATHOL, V135, P27; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAW PK, 1990, LANCET, V336, P114, DOI 10.1016/0140-6736(90)91628-N; MAN NT, 1990, FEBS LETT, V262, P237, DOI 10.1016/0014-5793(90)80199-S; PANZARA MA, IN PRESS BIOTECHNIQU; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; WATKINS SC, 1989, MUSCLE NERVE, V12, P861, DOI 10.1002/mus.880121013; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096	31	352	377	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					435	438		10.1038/356435a0	http://dx.doi.org/10.1038/356435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557125				2022-12-24	WOS:A1992HL83000064
J	ZEITLYN, S; RAHMAN, AKSM; NIELSEN, BH; GOMES, M; KOFOED, PEL; MAHALANABIS, D				ZEITLYN, S; RAHMAN, AKSM; NIELSEN, BH; GOMES, M; KOFOED, PEL; MAHALANABIS, D			COMPLIANCE WITH DIPHTHERIA, TETANUS, AND PERTUSSIS IMMUNIZATION IN BANGLADESH - FACTORS IDENTIFYING HIGH-RISK GROUPS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To evaluate factors associated with non-compliance with having second vaccination against diphtheria, tetanus, and pertussis in a treatment centre in Dhaka to determine which children were most at risk of not completing immunisation. Design - Cohort study of infants given first dose of the vaccine and followed up six weeks later to ascertain compliance with having second dose. Factors associated with non-compliance were evaluated. Setting - Dhaka treatment centre of the International Centre for Diarrhoeal Disease Research, Bangladesh. Subjects - 136 unimmunised children aged 6 weeks to 23 months who lived within reach of the treatment centre. At time of the six week follow up 16 of the children could not be traced and seven had died. Interventions - All children received their first dose of the vaccine. In each case health education workers had informed the mother about the value of immunisation, and she was given clear instructions to bring the child back after four weeks for the second dose. Main outcome measure - Rate of non-compliance with advice to return child for second vaccination. Results - 46 of 113 children (41%) received the second dose of the vaccine. Factors most closely associated with mothers' failure to comply with the second dose were lack of education and low income. Children whose mothers knew most about immunisation at first interview were more likely to have their second dose. Conclusions - Preventive health care services such as immunisation are appropriately offered in treatment centres, but compliance among children varies with socioeconomic status and mother's education. Further research should be aimed at ways to make health education more effective among uneducated parents.	INT CTR DIARRHOEL DIS RES,CHILD HLTH PROGRAMME,POB 128,DHAKA 1000,BANGLADESH; INT CTR DIARRHOEL DIS RES BANGLADESH,DIV CLIN SCI,DHAKA 1000,BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)								BAIRAGI R, 1980, B WORLD HEALTH ORGAN, V58, P767; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GUPTA AD, 1988, COMMUNICATING IMMUNI; SCHULER SR, 1985, STUD FAMILY PLANN, V16, P260, DOI 10.2307/1966999; 1991, STATE WORLDS CHILDRE, P102; 1989, EXPANDED PROGRAMME I	7	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					606	609		10.1136/bmj.304.6827.606	http://dx.doi.org/10.1136/bmj.304.6827.606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559089	Green Published, Bronze			2022-12-24	WOS:A1992HH73300022
J	ROMEO, C; AMIOT, M; SEED, B				ROMEO, C; AMIOT, M; SEED, B			SEQUENCE REQUIREMENTS FOR INDUCTION OF CYTOLYSIS BY THE T-CELL ANTIGEN/FC RECEPTOR ZETA-CHAIN	CELL			English	Article							NATURAL-KILLER-CELLS; FC-GAMMA-RIII; TRIGGER MOLECULES; CYTO-TOXICITY; TUMOR-CELLS; COMPLEX; EXPRESSION; CD16; RECOGNITION; LYMPHOCYTES	The zeta-chain of the T cell antigen receptor is a dimeric transmembrane protein with a very short extracellular domain and an extended cytoplasmic tail that triggers T cell effector function when aggregated by extracellular stimuli. We have reduced the active site of zeta to an 18 residue motif that can be appended to the intracellular domain of other transmembrane proteins to endow them with receptor-like activity. The compact size of the motif appears to eliminate zeta-mechanisms based on enzymatic activity and suggests that one or at most a few cellular proteins interact with the zeta-intracellular domain to initiate signal transduction. Analysis of individual amino acids within the 18 residue element reveals two phylogenetically conserved tyrosines that are absolutely required for activity and other residues that are less essential but contribute to the efficacy of receptor-directed cytolysis.			ROMEO, C (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.				NIAID NIH HHS [AI27849] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; BREITMEYER JB, 1987, J IMMUNOL, V138, P726; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GRAZIANO RF, 1987, J IMMUNOL, V138, P945; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMUELSON LE, 1985, CELL, V43, P223; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TRENN G, 1989, J IMMUNOL, V142, P3796; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; WEISS A, 1984, J IMMUNOL, V133, P123; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YOUNG JDE, 1987, J EXP MED, V166, P1894, DOI 10.1084/jem.166.6.1894	42	318	331	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					889	897		10.1016/0092-8674(92)90032-8	http://dx.doi.org/10.1016/0092-8674(92)90032-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547489				2022-12-24	WOS:A1992HH74800008
J	COLE, AT; BRUNDELL, S; HUDSON, N; HAWTHORNE, AB; MAHIDA, YR; HAWKEY, CJ				COLE, AT; BRUNDELL, S; HUDSON, N; HAWTHORNE, AB; MAHIDA, YR; HAWKEY, CJ			RANITIDINE, ASPIRIN, FOOD, AND THE STOMACH	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; HAWKEY CJ, 1991, CLIN SCI, V81, P565, DOI 10.1042/cs0810565; SATOH H, 1982, GASTROENTEROLOGY, V83, P210; STEPHENS FO, 1968, DIGESTION, V1, P267, DOI 10.1159/000196864	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					544	545		10.1136/bmj.304.6826.544-a	http://dx.doi.org/10.1136/bmj.304.6826.544-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559058	Green Published, Bronze			2022-12-24	WOS:A1992HG59900021
J	KIM, JS; REES, DC				KIM, JS; REES, DC			STRUCTURAL MODELS FOR THE METAL CENTERS IN THE NITROGENASE MOLYBDENUM-IRON PROTEIN	SCIENCE			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; KLEBSIELLA-PNEUMONIAE NITROGENASE; SUBSTRATE REDUCTION PROPERTIES; CONSERVED CYSTEINE RESIDUES; MOFE PROTEIN; ALPHA-SUBUNIT; FEMO-COFACTOR; BETA-SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; CLUSTER	Structural models for the nitrogenase FeMo-cofactor and P-clusters are proposed based on crystallographic analysis of the nitrogenase molybdenum-iron (MoFe)-protein from Azotobacter vinelandii at 2.7 angstrom resolution. Each center consists of two bridged clusters; the FeMo-cofactor has 4Fe:3S and 1Mo:3Fe:3S clusters bridged by three non-protein ligands, and the P-clusters contain two 4Fe:4S clusters bridged by two cysteine thiol ligands. Six of the seven Fe sites in the FeMo-cofactor appear to have trigonal coordination geometry, including one ligand provided by a bridging group. The remaining Fe site has tetrahedral geometry and is liganded to the side chain of Cys(alpha-275). The Mo site exhibits approximate octahedral coordination geometry and is liganded by three sulfurs in the cofactor, two oxygens from homocitrate, and the imidazole side chain of His(alpha-442). The P-clusters are liganded by six cysteine thiol groups, two which bridge the two clusters, alpha-88 and beta-95, and four which singly coordinate the remaining Fe sites, alpha-62, alpha-154, beta-70, and beta-153. The side chain of Ser(beta-188) may also coordinate one iron. The polypeptide folds of the homologous alpha and beta-subunits surrounding the P-clusters are approximately related by a twofold rotation that may be utilized in the binding interactions between the MoFe-protein and the nitrogenase Fe-protein. Neither the FeMo-cofactor nor the P-clusters are exposed to the surface, suggesting that substrate entry, electron transfer, and product release must involve a carefully regulated sequence of interactions between the MoFe-protein and Fe-protein of nitrogenase.	CALTECH,DIV CHEM & CHEM ENGN 14775CH,PASADENA,CA 91125	California Institute of Technology								ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ARBER JM, 1988, BIOCHEM J, V252, P421, DOI 10.1042/bj2520421; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CHU CTW, 1977, INORG CHEM, V16, P3245, DOI 10.1021/ic50178a052; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DEAN DR, 1990, MOL MICROBIOL, V4, P1505, DOI 10.1111/j.1365-2958.1990.tb02061.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DRENTH J, 1975, J BIOL CHEM, V250, P5268; EIDSNESS MK, 1986, J AM CHEM SOC, V108, P2746, DOI 10.1021/ja00270a039; GEORGIADIS M, UNPUB; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HERSKOVITZ T, 1972, P NATL ACAD SCI USA, V69, P2437, DOI 10.1073/pnas.69.9.2437; Holm R. H., 1985, MOLYBDENUM ENZYMES; HOLMES S, 1990, COMPOS SCI TECHNOL, V38, P1, DOI 10.1016/0266-3538(90)90068-G; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUYNH BH, 1980, BIOCHIM BIOPHYS ACTA, V623, P124, DOI 10.1016/0005-2795(80)90015-X; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KENT HM, 1990, MOL MICROBIOL, V4, P1497, DOI 10.1111/j.1365-2958.1990.tb02060.x; KENT HM, 1989, BIOCHEM J, V264, P257, DOI 10.1042/bj2640257; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; LAMMERS PJ, 1983, P NATL ACAD SCI-BIOL, V80, P4723, DOI 10.1073/pnas.80.15.4723; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LINDAHL PA, 1988, J BIOL CHEM, V263, P19412; LINDAHL PA, 1987, J BIOL CHEM, V262, P12900; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MARCUS RN, 1992, SCIENCE, V256, P1007; MAY HD, 1991, BIOCHEM J, V277, P457, DOI 10.1042/bj2770457; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; POWER PP, 1991, ANGEW CHEM INT EDIT, V30, P330, DOI 10.1002/anie.199103301; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SCOTT DJ, 1990, NITROGEN FIXATION AC, P169; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; SURERUS KK, IN PRESS J AM CHEM S; THOMANN H, 1987, J AM CHEM SOC, V109, P7913, DOI 10.1021/ja00259a067; THOMANN H, 1991, P NATL ACAD SCI USA, V88, P6620, DOI 10.1073/pnas.88.15.6620; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG SZ, 1988, BIOCHEMISTRY-US, V27, P2800, DOI 10.1021/bi00408a021; WEININGER MS, 1982, P NATL ACAD SCI-BIOL, V79, P378, DOI 10.1073/pnas.79.2.378; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4	61	743	769	1	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1677	1682		10.1126/science.1529354	http://dx.doi.org/10.1126/science.1529354			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529354				2022-12-24	WOS:A1992JN50100030
J	NOSE, A; MAHAJAN, VB; GOODMAN, CS				NOSE, A; MAHAJAN, VB; GOODMAN, CS			CONNECTIN - A HOMOPHILIC CELL-ADHESION MOLECULE EXPRESSED ON A SUBSET OF MUSCLES AND THE MOTONEURONS THAT INNERVATE THEM IN DROSOPHILA	CELL			English	Article							MEMBRANE GLYCOPROTEIN-IB; AMINO-ACID SEQUENCE; LEUCINE-RICH ALPHA-2-GLYCOPROTEIN; SELECT APPROPRIATE PATHWAYS; VENTRAL PATTERN-FORMATION; CENTRAL-NERVOUS-SYSTEM; FACTOR-BINDING DOMAIN; GROWTH CONE GUIDANCE; GRASSHOPPER EMBRYO; VONWILLEBRAND-FACTOR	Each abdominal hemisegment in the Drosophila embryo contains a stereotyped array of 30 muscles, each specifically innervated by one or a few motoneurons. We screened 11,000 enhancer trap lines, isolated several expressing beta-galactosidase in small subsets of muscle fibers prior to innervation, and identified two of these as inserts in connectin and Toll, members of the leucine-rich repeat gene family. Connectin contains a signal sequence, ten leucine-rich repeats, and a putative phosphatidylinositol membrane linkage; in S2 cells, connectin can mediate homophilic cell adhesion. Connectin is expressed on the surface of eight muscles, the motoneurons that innervate them, and several glial cells along the pathways leading to them. During synapse formation, the protein localizes to synaptic sites; afterward, it largely disappears. Thus, connectin is a novel cell adhesion molecule whose expression suggests a role in target recognition.			NOSE, A (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.				PHS HHS [18366] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BALL EE, 1985, DEV BIOL, V111, P383, DOI 10.1016/0012-1606(85)90492-0; BALL EE, 1985, J NEUROSCI, V5, P1808; BALL EE, 1985, DEV BIOL, V111, P399, DOI 10.1016/0012-1606(85)90493-2; BALL EE, 1985, DEV BIOL, V111, P417, DOI 10.1016/0012-1606(85)90494-4; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BATE M, 1990, DEVELOPMENT, V110, P791; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASH S, 1992, J NEUROSCI, V12, P2051; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EISEN JS, 1991, NEURON, V6, P767, DOI 10.1016/0896-6273(91)90173-W; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FREDIEU JR, 1989, DEVELOPMENT, V106, P739; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GERTTULA S, 1988, GENETICS, V119, P123; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HANDA M, 1986, J BIOL CHEM, V261, P2579; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P26; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HO RK, 1983, NATURE, V301, P66, DOI 10.1038/301066a0; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cellbio.7.1.505; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANDMESSER LT, 1980, ANNU REV NEUROSCI, V3, P279, DOI 10.1146/annurev.ne.03.030180.001431; LEISS D, 1988, DEVELOPMENT, V104, P525; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PIKE SH, 1990, J NEUROSCI, V10, P44; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	73	269	272	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					553	567		10.1016/0092-8674(92)90426-D	http://dx.doi.org/10.1016/0092-8674(92)90426-D			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505024				2022-12-24	WOS:A1992JJ88600006
J	KEENLYSIDE, RA; HAWKINS, AS; JOHNSON, AM; ADLER, MW				KEENLYSIDE, RA; HAWKINS, AS; JOHNSON, AM; ADLER, MW			FOR DEBATE - ATTITUDES TO TRACING AND NOTIFYING CONTACTS OF PEOPLE WITH HIV-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; PARTNER NOTIFICATION; AIDS				KEENLYSIDE, RA (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON WC1 8AA,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ADLER MW, 1988, BRIT MED J, V296, P1420, DOI 10.1136/bmj.296.6634.1420; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; ERON J J JR, 1990, AIDS (London), V4, pS193; FEINBERG J, 1990, AIDS (London), V4, pS209; GIESECKE J, 1990, LANCET, V336, P508, DOI 10.1016/0140-6736(90)92058-P; GIESECKE J, 1991, LANCET, V338, P1096, DOI 10.1016/0140-6736(91)91962-T; GOSTIN L, 1987, AM J PUBLIC HEALTH, V77, P361, DOI 10.2105/AJPH.77.3.361; JONES JL, 1990, JAMA-J AM MED ASSOC, V264, P1284, DOI 10.1001/jama.264.10.1284; LEEN CLS, 1989, LANCET, V2, P512; MILLER D, 1989, AIDS, V3, pS187, DOI 10.1097/00002030-198901001-00027; OSBORN JE, 1988, NEW ENGL J MED, V318, P444, DOI 10.1056/NEJM198802183180710; POTTERAT JJ, 1989, AM J PUBLIC HEALTH, V29, P874; RAMSTEDT K, 1990, SEX TRANSM DIS, V17, P37, DOI 10.1097/00007435-199017010-00008; RHAME FS, 1989, NEW ENGL J MED, V320, P1249; RUTHERFORD GW, 1988, JAMA-J AM MED ASSOC, V259, P3609, DOI 10.1001/jama.259.24.3609; SESNAN K, 1989, VENEROLOGY, V2, P75; TOOMEY KE, 1989, AIDS, V3, pS57, DOI 10.1097/00002030-198901001-00009; VERNON TM, 1988, JAMA-J AM MED ASSOC, V260, P3274; WYKOFF RF, 1988, JAMA-J AM MED ASSOC, V259, P3563, DOI 10.1001/jama.259.24.3563; 1989, REPORT CONSULTATION; 1980, HDB CONTACT TRACING; 1991, AIDS HIV QUARTERLY S; 1983, MMWR, V37, P393	25	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					165	168		10.1136/bmj.305.6846.165	http://dx.doi.org/10.1136/bmj.305.6846.165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515835	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JF06300029
J	FUH, G; CUNNINGHAM, BC; FUKUNAGA, R; NAGATA, S; GOEDDEL, DV; WELLS, JA				FUH, G; CUNNINGHAM, BC; FUKUNAGA, R; NAGATA, S; GOEDDEL, DV; WELLS, JA			RATIONAL DESIGN OF POTENT ANTAGONISTS TO THE HUMAN GROWTH-HORMONE RECEPTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; PURIFICATION; MUTAGENESIS; SUPERFAMILY; EXPRESSION; PROLACTIN; CLONING; DOMAIN	A hybrid receptor was constructed that contained the extracellular binding domain of the human growth hormone (hGH) receptor linked to the transmembrane and intracellular domains of the murine granulocyte colony-stimulating factor receptor. Addition of hGH to a myeloid leukemia cell line (FDC-P1) that expressed the hybrid receptor caused proliferation of these cells. The mechanism for signal transduction of the hybrid receptor required dimerization because monoclonal antibodies to the hGH receptor were agonists whereas their monovalent fragments were not. Receptor dimerization occurs sequentially-a receptor binds to site 1 on hGH, and then a second receptor molecule binds to site 2 on hGH. On the basis of this sequential mechanism, which may occur in many other cytokine receptors, inactive hGH analogs were designed that were potent antagonists to hGH-induced cell proliferation. Such antagonists could be useful for treating clinical conditions of hGH excess, such as acromegaly.	GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Roche Holding; Genentech; Roche Holding; Genentech			Nagata, Shigekazu/AAG-3203-2019; Fukunaga, Rikiro/CAG-2891-2022; Wells, Jim A/O-9854-2016	Nagata, Shigekazu/0000-0001-9758-8426; 				BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BAS SH, 1991, P NATL ACAD SCI USA, V88, P4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FROHMAN LA, 1991, J CLIN ENDOCR METAB, V72, P1175, DOI 10.1210/jcem-72-6-1175; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, UNPUB; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; ISHIZAKAIKEDA E, UNPUB; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; WELLS JA, IN PRESS RECENT PROG	23	585	652	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1677	1680		10.1126/science.256.5064.1677	http://dx.doi.org/10.1126/science.256.5064.1677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1535167				2022-12-24	WOS:A1992HZ17400044
J	BIRNBAUMER, M; SEIBOLD, A; GILBERT, S; ISHIDO, M; BARBERIS, C; ANTARAMIAN, A; BRABET, P; ROSENTHAL, W				BIRNBAUMER, M; SEIBOLD, A; GILBERT, S; ISHIDO, M; BARBERIS, C; ANTARAMIAN, A; BRABET, P; ROSENTHAL, W			MOLECULAR-CLONING OF THE RECEPTOR FOR HUMAN ANTIDIURETIC-HORMONE	NATURE			English	Article							EXPRESSION; DNA; PROTEIN; PROBES; GENE; CDNA	ANTIDIURESIS, the recovery of water from the lumen of the renal collecting tubule, is regulated by the hypothalamic release of antidiuretic hormone (ADH), which binds to specific receptors on renal collecting tubule cells, stimulates adenylyl cyclase and promotes the cyclic AMP-mediated incorporation of water pores into the luminal surface of these cells 1-3. We report here the isolation of the human ADH receptor gene using a genomic expression cloning approach 4. The gene was used to clone the complementary DNA from a human renal library. The deduced amino-acid sequence of the receptor yields a hydropathy profile characteristic of receptors with seven putative transmembrane regions. This and the comparison with other cloned receptors indicates that the ADH receptor is a member of the superfamily of G-protein-coupled receptors.			BIRNBAUMER, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.		Brabet, Philippe/AAO-8522-2020	Brabet, Philippe/0000-0003-2739-1622				BIRNBAUMER L, 1974, J BIOL CHEM, V249, P7857; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARRIS HW, 1990, AM J PHYSIOL, V258, P237; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; JARD S, 1987, AM J PHYSIOL, V253, P41; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CB, 1989, MOL BIOL INFORM RESO; LEVY FO, IN PRESS J BIOL CHEM; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Michell R H, 1979, Biochem Soc Trans, V7, P861; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	23	480	486	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					333	335		10.1038/357333a0	http://dx.doi.org/10.1038/357333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534149				2022-12-24	WOS:A1992HW13200049
J	GILLMAN, MW; OLIVERIA, SA; MOORE, LL; ELLISON, RC				GILLMAN, MW; OLIVERIA, SA; MOORE, LL; ELLISON, RC			INVERSE ASSOCIATION OF DIETARY CALCIUM WITH SYSTOLIC BLOOD-PRESSURE IN YOUNG-CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSION; CHILDHOOD	Objective.-To investigate the association of dietary calcium with blood pressure in young children. Design.-Cohort. Setting.-General community. Subjects.-Eighty-nine boys and girls, aged 3 to 6 years, from The Framingham Children's Study. Measurements.-During the first year of the study, we derived nutrient data from multiple food diaries (a mean of 9.6 days of recording for each subject). At the beginning of the second year of the study, we obtained anthropometric data and up to five blood pressure readings (mean, 4.5) on each child at a single sitting. Results.-The range of subjects' average daily calcium intake was 4.9 to 19.6 mmol per 4200 kJ, with a mean of 12.8 mmol per 4200 kJ. Subjects' average systolic blood pressure ranged from 73 to 129 mm Hg, with a mean of 95.9 mm Hg; for diastolic blood pressure, the range was 37 to 78 mm Hg, mean 54.6 mm Hg. Multiple linear regression analysis, adjusted for the effects of sex, height, body mass index, and heart rate, showed that for each increment of 2.5 mmol of dietary calcium per 4200 kJ per day, systolic blood pressure was 2.27 mm Hg lower (95% confidence interval, 0.63 to 3.91 mm Hg; P = .008). We found no such association for diastolic blood pressure. Conclusion.-Dietary calcium is inversely related to systolic blood pressure in young children.			GILLMAN, MW (corresponding author), BOSTON UNIV,SCH MED,EVANS SECT PREVENT MED & EPIDEMIOL,B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.			Moore, Lynn/0000-0002-1028-919X; Ellison, Robert Curtis/0000-0002-0582-7467	NHLBI NIH HHS [HL 35653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT BS, 1987, CIRCULATION, V76, P360; [Anonymous], 1987, PEDIATRICS, V79, P1; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; DAHL LK, 1970, P SOC EXP BIOL MED, V133, P1405, DOI 10.3181/00379727-133-34700; DEURENBERG P, 1990, BRIT J NUTR, V63, P293, DOI 10.1079/BJN19900116; ELLISON RC, 1984, AM J EPIDEMIOL, V120, P542, DOI 10.1093/oxfordjournals.aje.a113915; GILLMAN M, 1991, AM J EPIDEMIOL, V134, P730; GILLMAN MW, 1991, PEDIATRICS, V87, P708; JENNER DA, 1988, AM J CLIN NUTR, V47, P1052, DOI 10.1093/ajcn/47.6.1052; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LAUER RM, 1989, PEDIATRICS, V84, P633; LEE D, 1957, AM J CLIN NUTR, V5, P166, DOI 10.1093/ajcn/5.2.166; LIEBMAN M, 1986, HYPERTENSION, V8, P843, DOI 10.1161/01.HYP.8.10.843; MARMOR JK, 1991, J CLIN EPIDEMIOL, V44, P531, DOI 10.1016/0895-4356(91)90216-V; MCCARRON DA, 1989, KIDNEY INT, V35, P717, DOI 10.1038/ki.1989.44; MCCARRON DA, 1991, AM J CLIN NUTR, V54, pS215, DOI 10.1093/ajcn/54.1.215S; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; MOORE LL, 1991, J PEDIATR-US, V118, P215, DOI 10.1016/S0022-3476(05)80485-8; NICKLAS TA, 1990, FOOD SOURCES NUTRIEN; ROSNER B, 1987, AM J EPIDEMIOL, V126, P1115, DOI 10.1093/oxfordjournals.aje.a114750; ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811; SOWERS JR, 1989, J LAB CLIN MED, V114, P338; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WITSCHI J, 1981, J AM DIET ASSOC, V78, P609; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; 1991, NIH912732 US DEP HLT	27	53	54	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2340	2343		10.1001/jama.267.17.2340	http://dx.doi.org/10.1001/jama.267.17.2340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564773				2022-12-24	WOS:A1992HR01500026
J	DOHERTY, P; MOOLENAAR, CECK; ASHTON, SV; MICHALIDES, RJAM; WALSH, FS				DOHERTY, P; MOOLENAAR, CECK; ASHTON, SV; MICHALIDES, RJAM; WALSH, FS			THE VASE EXON DOWN-REGULATES THE NEURITE GROWTH-PROMOTING ACTIVITY OF NCAM-140	NATURE			English	Article							CELL-ADHESION MOLECULE; N-CAM; HOMOPHILIC BINDING; NERVOUS-SYSTEM; MUSCLE; OUTGROWTH; MECHANISM; BRAIN	AXONAL growth, guidance and synapse formation are controlled by receptors on neuronal growth cones that can recognize positive and inhibitory cues in the local microenvironment 1-3 . Four well characterized receptor systems are known that recognize the growth-promoting activities associated with the extracellular matrix and the membranes of cells such as astrocytes, muscle cells and Schwann cells; these are the integrins 4 and the homophilically binding cell adhesion molecules neural-cell adhesion molecule (NCAM), N-cadherin and L1 (refs 5-12). Alternative splicing generates 20-30 isoforms of NCAM and these can also be differentially glycosylated 13. There are two sites where alternative splicing changes the extracellular structure of membrane-bound NCAM and one of these (the MSD1 region) does not obviously affect function 6. Here we report that the variable alternatively spliced exon (VASE) in immunoglobulin domain 4 downregulates the neurite outgrowth-promoting activity of NCAM. The high level of VASE expression in the adult central as compared with peripheral nervous system 21 could contribute to the poor regenerative capacity of the former.	NETHERLANDS CANC INST,DEPT TUMOR BIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	DOHERTY, P (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		Doherty, Patrick/A-8752-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; CHUONG CM, 1984, J NEUROSCI, V4, P2354; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MOOLENAAR CE, IN PRESS INT J CANCE; PATEL K, 1991, BRIT J CANCER, V63, P20; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PREDIGER EA, 1988, P NATL ACAD SCI USA, V85, P9616, DOI 10.1073/pnas.85.24.9616; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271	30	144	146	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					791	793		10.1038/356791a0	http://dx.doi.org/10.1038/356791a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574117				2022-12-24	WOS:A1992HR18600049
J	KONIG, R; HUANG, LY; GERMAIN, RN				KONIG, R; HUANG, LY; GERMAIN, RN			MHC CLASS-II INTERACTION WITH CD4 MEDIATED BY A REGION ANALOGOUS TO THE MHC CLASS-I BINDING-SITE FOR CD8	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL HYBRIDOMA; DIRECTED MUTAGENESIS; SURFACE EXPRESSION; LYMPHOCYTES-T; MOLECULES; ANTIGENS; GENE; RECOGNITION; L3T4	INTERACTIONs between major histocompatibility complex (MHC) molecules and the CD4 or CD8 coreceptors have a major role in intrathymic T-cell selection 1. On mature T cells, each of these two glycoproteins is associated with a class-specific bias in MHC molecule recognition by the T-cell receptor. CD4+ T cells respond to antigen in association with MHC class II molecules and CD8+ T cells respond to antigen in association with MHC class I molecules. Physical interaction between the CD4/MHC class II molecules and CD8/MHC class I molecules has been demonstrated by cell adhesion assay 2-5, and a binding site for CD8 on class I has been identified 6,7. Here we demonstrate that a region of the MHC class II beta-chain beta-2-domain, structurally analogous to the CD8-binding loop in the MHC class I alpha-3 domain, is critical for function with both mouse and human CD4.			KONIG, R (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BETHESDA, MD 20892 USA.		Konig, Rolf/B-3128-2008; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DALBADIEMCFARLAND G, 1982, P NATL ACAD SCI-BIOL, V79, P6409, DOI 10.1073/pnas.79.21.6409; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDING H, 1985, NATURE, V317, P425, DOI 10.1038/317425a0; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LOMBARDI G, 1991, J IMMUNOL, V147, P2034; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RONCHESE F, 1987, J IMMUNOL, V139, P629; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; TRAVERS P, 1984, NATURE, V310, P235, DOI 10.1038/310235a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	37	322	326	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1992	356	6372					796	798		10.1038/356796a0	http://dx.doi.org/10.1038/356796a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574118				2022-12-24	WOS:A1992HR18600051
J	MCCORMICK, MC; BROOKSGUNN, J; WORKMANDANIELS, K; TURNER, J; PECKHAM, GJ				MCCORMICK, MC; BROOKSGUNN, J; WORKMANDANIELS, K; TURNER, J; PECKHAM, GJ			THE HEALTH AND DEVELOPMENTAL STATUS OF VERY-LOW-BIRTH-WEIGHT CHILDREN AT SCHOOL AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL DEMONSTRATION PROGRAM; PATENT DUCTUS-ARTERIOSUS; PERINATAL SERVICES; PREMATURE-INFANTS; BEHAVIOR PROBLEMS; 1000 GRAMS; FOLLOW-UP; REGIONALIZATION; INDOMETHACIN; MULTICENTER	Objective. - To assess the effect of improved survival of increasingly premature infants by examining the outcomes at school age of a large group of children born at different birth weights. Design. - Inception cohort. Setting/Participants. - Participants were selected from two previously studied multisite cohorts: very low-birth-weight (less-than-or-equal-to 1500 g) children referred to participating intensive care units and heavier birth-weight children drawn from a stratified random sample of births in geographically defined regions. Follow-up at 8 to 10 years of age was by a combination of telephone interview and home/clinic visits for 65.1% (1868) of those eligible. Main Outcome Measures. - The presence or absence of 17 specific conditions, limitations in activities of daily living due to health, mental health (affective health, behavior problems), and, for a subset, 10 scores. Results. - Decreasing birth weight was associated with an increased morbidity for all measures except affective health; those with birth weights of 1500 g or less were more likely to experience multiple health problems. Maternal educational attainment did not influence the association of birth weight with morbidity except for IQ among children whose birth weight was above 1000 g, for which socioeconomic disadvantage worsened the status of all children irrespective of birth weight. Conclusions. - Children born at lower birth weights experience increased morbidity at early school age. These results reinforce the importance of postdischarge, early intervention programs to reduce the risk of these later health problems.	HARVARD UNIV,SCH MED,DEPT PEDIAT,JOINT PROGRAM NEONATOL,BOSTON,MA 02115; COLUMBIA UNIV,NEW YORK,NY 10027; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV NEONATOL,PHILADELPHIA,PA	Harvard University; Harvard Medical School; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	MCCORMICK, MC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			McCormmick, Marie/0000-0002-3938-1707	NICHD NIH HHS [N01-HD-5-2928] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052928] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; AYLWARD GP, 1985, J DEV BEHAV PEDIATR, V6, P3; BLAYNEY M, 1991, J PEDIATR-US, V118, P201, DOI 10.1016/S0022-3476(05)80483-4; BUEHLER JW, 1987, PUBLIC HEALTH REP, V102, P151; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; DARLINGTON RB, 1980, SCIENCE, V208, P202, DOI 10.1126/science.208.4440.202; DEAN JA, 1988, EPI INFO VERSION 3; DEGRAW C, 1988, J PEDIATR-US, V113, P971, DOI 10.1016/S0022-3476(88)80565-1; EISEN M, 1984, RAND R2313HEW; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; GOUDY WJ, 1985, J GERONTOL, V40, P358, DOI 10.1093/geronj/40.3.358; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; HOY EA, 1988, INT J BEHAV DEV, V11, P37, DOI 10.1177/016502548801100104; HUNT JV, 1988, PEDIATRICS, V82, P596; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; KLOCKARS AJ, 1986, QUANTITATIVE APPLICA, V61; LASKY RE, 1987, AM J DIS CHILD, V141, P100, DOI 10.1001/archpedi.1987.04460010100037; McCormick M C, 1991, Paediatr Perinat Epidemiol, V5, P410, DOI 10.1111/j.1365-3016.1991.tb00727.x; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCCORMICK MC, 1985, JAMA-J AM MED ASSOC, V253, P799; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; MUTCH LMM, 1989, ARCH DIS CHILD, V64, P1394, DOI 10.1136/adc.64.10_Spec_No.1394; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; OVERPECK MD, 1989, PUBLIC HEALTH REP, V104, P58; PECKHAM GJ, 1984, J PEDIATR-US, V105, P285, DOI 10.1016/S0022-3476(84)80134-1; PETERSON JL, 1986, J MARRIAGE FAM, V48, P295, DOI 10.2307/352397; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; SHONKOFF JP, 1987, PEDIATRICS, V80, P650; TEPLIN SW, 1991, J PEDIATR-US, V118, P768, DOI 10.1016/S0022-3476(05)80045-9; Wechsler DW., 1999, INTELLIGENCE SCALE C; WEGMAN ME, 1989, PEDIATRICS, V84, P943; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1987, HLTH TECHNOLOGY CASE, V38; 1991, J PEDIATR, V118, P761; 1988, SAS STAT USERS GUIDE; 1982, VITAL HLTH STATIS 10, V141	44	240	241	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2204	2208		10.1001/jama.267.16.2204	http://dx.doi.org/10.1001/jama.267.16.2204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HN841	1556798				2022-12-24	WOS:A1992HN84100030
J	HERSH, BS; MARKOWITZ, LE; MAES, EF; FUNKHOUSER, AW; BAUGHMAN, AL; SIROTKIN, BI; HADLER, SC				HERSH, BS; MARKOWITZ, LE; MAES, EF; FUNKHOUSER, AW; BAUGHMAN, AL; SIROTKIN, BI; HADLER, SC			THE GEOGRAPHIC-DISTRIBUTION OF MEASLES IN THE UNITED-STATES, 1980 THROUGH 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGHLY VACCINATED POPULATION; RISK-FACTORS; SCHOOL POPULATION; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; DISEASE; FAILURE; CARE	Objective. - To describe the geographic distribution of measles cases in the United States by county for the 10-year period from 1980 through 1989. Design. - Ecological analysis of national measles surveillance data. Methods. - Measles cases reported to the Morbidity and Mortality Weekly Report from 1980 through 1989 were analyzed. Data from the 1980 and 1990 US censuses were used to produce demographic profiles for each of the 3137 counties. Outcome variables examined included mean annual incidence and number of years reporting measles, with use of Spearman's rank correlation coefficients to examine the association between the demographic and the two outcome variables. Results. - A total of 56 775 measles cases were reported during the decade. Of the nation's 3137 counties, 1690 (53.9%) did not report any cases; only 17 (0.5%) reported measles in all 10 years. Counties reporting measles more frequently during the decade had higher median populations, population densities, and percentage of black and Hispanic populations than those counties reporting less frequently. Population size, Population density, and percentage of Hispanic population were associated with number of years reporting measles and mean annual measles incidence rate. Measles cases in counties reporting measles every year predominately occurred in unvaccinated preschoolers; cases in counties reporting less frequently predominately occurred in vaccinated school-aged children. Conclusions. - This analysis illustrates the focal nature of measles in the United States during the past decade. Most counties have not reported a single case of measles during the entire decade, and only 17 counties reported measles every year. Targeted strategies are needed to improve age-appropriate immunization levels among preschool-aged children living in large inner-city areas.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								Anderson R M, 1984, IMA J Math Appl Med Biol, V1, P233; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; FRANK JA, 1985, AM J DIS CHILD, V139, P881, DOI 10.1001/archpedi.1985.02140110035024; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; GRIFFITH.DA, 1973, J ROY STAT SOC A STA, V136, P441, DOI 10.2307/2344999; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hinman A R, 1980, Epidemiol Rev, V2, P153; HULL HF, 1985, PEDIATRICS, V76, P518; HUTCHINS SS, 1990, AM J EPIDEMIOL, V132, P157, DOI 10.1093/oxfordjournals.aje.a115627; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; ORENSTEIN WA, 1990, PEDIATR CLIN N AM, V37, P709; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; 1991, MMWR, V40, P369; 1990, MMWR, V39, P317; 1990, MMWR, V39, P23; 1991, REPORT COMMITTEE INF, P308; 1990, MMWR, V39, P3; 1988, MMWR, V37, P527; 1990, MMWR, V39, P473; 1989, MMWR, V38, P49; 1989, MMWR, V38, pS9; 1988, MMWR, V38, P601; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1986, MMWR, V35, P213; 1989, MMWR, V38, P591; 1990, MMWR, V39, P361; 1978, MMWR, V27, P391; 1989, 1040RD1 CURR POP P25; 1990, MMWR, V39, P353; 1991, MMWR, V40, P36	36	27	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1936	1941		10.1001/jama.267.14.1936	http://dx.doi.org/10.1001/jama.267.14.1936			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL677	1548826				2022-12-24	WOS:A1992HL67700027
J	RODEWALD, HR; MOINGEON, P; LUCICH, JL; DOSIOU, C; LOPEZ, P; REINHERZ, EL				RODEWALD, HR; MOINGEON, P; LUCICH, JL; DOSIOU, C; LOPEZ, P; REINHERZ, EL			A POPULATION OF EARLY FETAL THYMOCYTES EXPRESSING FC-GAMMA-RII/III CONTAINS PRECURSORS OF LYMPHOCYTES-T AND NATURAL-KILLER-CELLS	CELL			English	Article							AFFINITY IGE RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; BONE-MARROW; ZETA-CHAIN; NK CELLS; DEVELOPMENTAL BIOLOGY; ACTIVATION PATHWAYS; TRANSFECTED CELLS; B-CELLS	We have identified a dominant fetal thymocyte population at day 14.5 of gestation in the mouse that lacks CD4 and CD8 but expresses Fc-gamma-RII/III+ several days prior to acquisition of the T cell receptor (TCR) in vivo. If maintained in a thymic microenvironment, this population of CD4-CD8-TCR-Fc-gamma-RII/III+ thymocytes differentiates first into CD4+CD8+TCR(low)Fc-gamma-RII/III- thymocytes and subsequently CD4+CD8-TCR(high)Fc-gamma-RII/III- and CD4-CD8+TCR(high)Fc-gamma-RII/III mature Ti alpha-beta lineage T cells. However, if removed from the thymus, the CD4-CD8-TCR-Fc-gamma-RII/III+ thymocyte population selectively generates functional natural killer (NK) cells in vivo as well as in vitro. These findings show that a cellular pool of Fc-gamma-RII/III+ precursors gives rise to T and NK lineages in a microenvironment-dependent manner. Moreover, they suggest a hitherto unrecognized role for Fc receptors on primitive T cells.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, FLOW CYTOMETRY FACIL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	RODEWALD, HR (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Lopez, Peter/AAP-7234-2020	Moingeon, Philippe/0000-0002-2380-9983; Lopez, Peter/0000-0002-8587-7148; Dosiou, Chrysoula/0000-0001-6609-5135	NIAID NIH HHS [AI21226, AI 19807] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226, R37AI019807, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACUTO O, 1983, CELL, V34, P717, DOI 10.1016/0092-8674(83)90528-7; ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; ALLISON JP, 1982, J IMMUNOL, V129, P2293; ANDERSON CL, 1974, J EXP MED, V139, P1175, DOI 10.1084/jem.139.5.1175; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; [Anonymous], IMMUNOBIOLOGY NATURA; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1986, J IMMUNOL, V137, P3734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MD, 1966, J EXP MED, V123, P75, DOI 10.1084/jem.123.1.75; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FAURE F, 1990, IMMUNOL TODAY, V11, P108, DOI 10.1016/0167-5699(90)90041-7; FONTAINEPERUS JC, 1981, J IMMUNOL, V126, P2310; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARNIWAGNER BA, 1990, J IMMUNOL, V144, P796; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HACKETT J, 1986, P NATL ACAD SCI USA, V83, P3427, DOI 10.1073/pnas.83.10.3427; HACKETT J, 1985, J IMMUNOL, V134, P3731; HALLER O, 1977, J EXP MED, V145, P1411, DOI 10.1084/jem.145.5.1411; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HERBERMAN RB, 1978, J IMMUNOL, V121, P304; HERBERMAN RB, 1986, ANNU REV IMMUNOL, V4, P651, DOI 10.1146/annurev.iy.04.040186.003251; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HOGAN B, 1986, MANIPULATING MOUSE E, P271; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P7706, DOI 10.1073/pnas.82.22.7706; HORI T, 1991, J IMMUNOL, V146, P2116; HOWARD FD, 1990, P NATL ACAD SCI USA, V87, P7015, DOI 10.1073/pnas.87.18.7015; JOHNSON GD, 1986, HDB EXPT IMMUNOLOGY, V4, P1; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; JOTEREAU F, 1987, J IMMUNOL, V138, P1026; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KOO GC, 1986, J IMMUNOL, V137, P3742; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUZIEL WA, 1991, EUR J IMMUNOL, V21, P1563, DOI 10.1002/eji.1830210635; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOHMANNMATTHES ML, 1979, J IMMUNOL, V123, P1883; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MELLMAN IS, 1980, J EXP MED, V152, P1048, DOI 10.1084/jem.152.4.1048; MICHON JM, 1988, J IMMUNOL, V140, P3660; MILLER JF, 1961, LANCET, V2, P748; MINGARI MC, 1991, J EXP MED, V174, P21, DOI 10.1084/jem.174.1.21; MOINGEON P, 1988, J EXP MED, V168, P2077, DOI 10.1084/jem.168.6.2077; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; NAKANISHI N, 1987, NATURE, V325, P720, DOI 10.1038/325720a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; ORTALDO JR, 1984, ANNU REV IMMUNOL, V2, P359, DOI 10.1146/annurev.iy.02.040184.002043; OWEN JJT, 1969, J EXP MED, V129, P431, DOI 10.1084/jem.129.2.431; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; PETER HH, 1983, J IMMUNOL, V131, P2332; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PHILLIPS JH, 1987, J IMMUNOL, V139, P683; PLUM J, 1990, J IMMUNOL, V144, P3710; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAMSDELL FJ, 1987, J IMMUNOL, V139, P1446; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SKINNER M, 1987, J EXP MED, V165, P1481, DOI 10.1084/jem.165.6.1481; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPANGRUDE GJ, 1988, J EXP MED, V167, P1671, DOI 10.1084/jem.167.5.1671; STOUT RD, 1975, J EXP MED, V142, P611, DOI 10.1084/jem.142.3.611; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YAGITA H, 1989, EUR J IMMUNOL, V19, P2211, DOI 10.1002/eji.1830191206; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	97	275	285	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					139	150		10.1016/0092-8674(92)90125-V	http://dx.doi.org/10.1016/0092-8674(92)90125-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1532536				2022-12-24	WOS:A1992HM44500013
J	JAY, PY; ELSON, EL				JAY, PY; ELSON, EL			SURFACE PARTICLE-TRANSPORT MECHANISM INDEPENDENT OF MYOSIN-II IN DICTYOSTELIUM	NATURE			English	Article							HEAVY-CHAIN; ACTIN; CELLS; DISCOIDEUM; FLOW; LAMELLIPODIA; GENERATION; RECEPTORS; AMEBAE	CELLULAR locomotion Could be driven by the rearward transport of membrane-bound particles observed on motile fibroblasts 1, keratinocytes 2 and neuronal growth cones 3. A force propelling free surface particles backwards could move the cell forwards if the particles were anchored to a rigid substratum. During capping, myosin II ('double-headed' myosin) draws crosslinked membrane proteins to the rear of a cell. The mhcA- mutant of the amoebal stage of the slime mould Dictyostelium discoideum, in which the myosin II gene has been deleted 4, cannot cap surface particles but can crawl along the substratum 5,6. Thus, the mechanism driving capping is not essential for locomotion. We show here that the null mutant is capable of a different type of active rearward transport, independent of myosin II and distinct from capping. The transported particles on mhcA- cells follow parallel paths. In the wild-type Ax2 strain, myosin II causes particles to converge towards a focal point and significantly increases the velocity of transport behind the leading edge of the cell.			JAY, PY (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110, USA.							BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; CARBONI JM, 1985, J CELL BIOL, V100, P1884, DOI 10.1083/jcb.100.6.1884; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; HELLIO R, 1985, J CELL SCI, V79, P327; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MOLDAY R, 1976, J CELL BIOL, V71, P314, DOI 10.1083/jcb.71.1.314; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1991, REV PHYSL, V53, P653; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	18	52	52	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					438	440		10.1038/356438a0	http://dx.doi.org/10.1038/356438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557126				2022-12-24	WOS:A1992HL83000065
J	KUNIN, CM				KUNIN, CM			SURVEILLANCE CULTURES OF THE URINE AND CATHETER PLACEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KUNIN, CM (corresponding author), OHIO STATE UNIV,COLUMBUS,OH 43210, USA.							GIVENS CD, 1980, J UROLOGY, V124, P646, DOI 10.1016/S0022-5347(17)55596-2; HARDING GKM, 1991, ANN INTERN MED, V114, P713, DOI 10.7326/0003-4819-114-9-713; KUNIN CM, 1987, DETECTION PREVENTION, P245; PLATT R, 1982, NEW ENGL J MED, V307, P637, DOI 10.1056/NEJM198209093071101	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542181				2022-12-24	WOS:A1992HJ59700039
J	BLOCK, PC				BLOCK, PC			PERCUTANEOUS MITRAL BALLOON VALVOTOMY BY MEANS OF THE DOUBLE-BALLOON TECHNIQUE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					799	799						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538723				2022-12-24	WOS:A1992HJ59200004
J	CROSS, SJ; EVANS, SA; THOMSON, LF; LEE, HS; JENNINGS, KP; SHIELDS, TG				CROSS, SJ; EVANS, SA; THOMSON, LF; LEE, HS; JENNINGS, KP; SHIELDS, TG			SAFETY OF SUBAQUA DIVING WITH A PATENT FORAMEN OVALE	BRITISH MEDICAL JOURNAL			English	Article							DECOMPRESSION-SICKNESS; DIVERS		ABERDEEN ROYAL INFIRM,HYPERBAR MED UNIT,ABERDEEN AB9 2ZB,SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM,DEPT CARDIOL,ABERDEEN AB9 2ZD,SCOTLAND.							HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; MOON RE, 1989, LANCET, V1, P513; SHUB C, 1976, MAYO CLIN PROC, V51, P81; WILMSHURST PT, 1989, LANCET, V2, P1302	5	33	33	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					481	482		10.1136/bmj.304.6825.481	http://dx.doi.org/10.1136/bmj.304.6825.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547421	Green Published, Bronze			2022-12-24	WOS:A1992HF55500024
J	PIMM, SL; GITTLEMAN, JL				PIMM, SL; GITTLEMAN, JL			BIOLOGICAL DIVERSITY - WHERE IS IT	SCIENCE			English	Editorial Material									UNIV TENNESSEE,GRAD PROGRAM ECOL,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville	PIMM, SL (corresponding author), UNIV TENNESSEE,DEPT ZOOL,KNOXVILLE,TN 37996, USA.							JARVINEN O, 1978, OIKOS, V30, P496, DOI 10.2307/3543345; MARES MA, 1992, SCIENCE, V255, P976, DOI 10.1126/science.255.5047.976; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; RICE B, 1983, VEGETATIO, V52, P129, DOI 10.1007/BF00044988; ROSENZWEIG ML, IN PRESS HIST GEOGRP; SCHALL JJ, 1978, SCIENCE, V201, P679, DOI 10.1126/science.201.4357.679; TOBIN RJ, 1990, EXPENDABLE FUTURE; WALLACE AR, 1876, GEOGRPAHICAL DISTRIB	10	45	49	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					940	940		10.1126/science.1546290	http://dx.doi.org/10.1126/science.1546290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546290				2022-12-24	WOS:A1992HE60500030
J	RISCH, N				RISCH, N			GENETIC-LINKAGE - INTERPRETING LOD SCORES	SCIENCE			English	Editorial Material							FAMILIAL ALZHEIMERS-DISEASE; BREAST-CANCER; ONSET		YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University	RISCH, N (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.				NHGRI NIH HHS [HG00348] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; ELSTON RC, 1975, ANN HUM GENET, V38, P341, DOI 10.1111/j.1469-1809.1975.tb00619.x; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; GOATE AM, 1989, LANCET, V1, P352; GREENBERG DA, 1989, GENET EPIDEMIOL, V6, P259, DOI 10.1002/gepi.1370060145; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL JM, 1989, AM J HUM GENET, V44, P577; MORTON NE, 1955, AM J HUM GENET, V7, P277; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; OTT J, 1985, ANAL HUMAN GENETIC L; RISCH N, 1990, GENET EPIDEMIOL, V7, P3, DOI 10.1002/gepi.1370070103; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1991, AM J HUM GENET, V48, P1058; RISCH N, IN PRESS HUM HERED; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104	22	65	83	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					803	804		10.1126/science.1536004	http://dx.doi.org/10.1126/science.1536004			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536004				2022-12-24	WOS:A1992HD54800025
J	WALD, A; COYLE, MB; CARLSON, LC; THOMPSON, RL; HOOTON, TM				WALD, A; COYLE, MB; CARLSON, LC; THOMPSON, RL; HOOTON, TM			INFECTION WITH A FASTIDIOUS MYCOBACTERIUM RESEMBLING MYCOBACTERIUM-SIMIAE IN 7 PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note								We report the clinical features of seven patients with the acquired immunodeficiency syndrome (AIDS) who were infected with a new, fastidious mycobacterium, and we describe the microbiologic properties of the isolates. All patients but one had had a previous AIDS-defining illness; the median CD4 lymphocyte count was 7/muL. Fevers and wasting were the most common signs and symptoms, followed by abdominal pain and diarrhea. The mycobacterium grew fastidiously on solid media and resembled Mycobacterium simiae on chromatography. We conclude that this mycobacterium infects profoundly immunosuppressed patients with AIDS. The clinical features at presentation are comparable to those reported in patients with disseminated Mycobacterium avium complex infection.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; GRP HLTH COOPERAT PUGET SOUND, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative			Wald, Anna/B-6272-2012	Wald, Anna/0000-0003-3486-6438				AGY MB, 1989, DIAGN MICR INFEC DIS, V12, P303, DOI 10.1016/0732-8893(89)90094-1; BOTTGER EC, 1991, 31ST P INT C ANT AG; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; HIRSCHEL B, 1990, NEW ENGL J MED, V323, P109, DOI 10.1056/NEJM199007123230207; MINNIKIN DE, 1985, ZBL BAKT-INT J MED M, V259, P446	5	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					586	589		10.7326/0003-4819-117-7-586	http://dx.doi.org/10.7326/0003-4819-117-7-586			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524333				2022-12-24	WOS:A1992JQ22600008
J	NERI, D; BILLETER, M; WIDER, G; WUTHRICH, K				NERI, D; BILLETER, M; WIDER, G; WUTHRICH, K			NMR DETERMINATION OF RESIDUAL STRUCTURE IN A UREA-DENATURED PROTEIN, THE 434-REPRESSOR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING DOMAIN; PHAGE-434 REPRESSOR; PROTON; SPECTROSCOPY; CONFORMATIONS; FILTERS; LEUCINE; VALINE	A nuclear magnetic resonance (NMR) structure determination is reported for the polypeptide chain of a globular protein in strongly denaturing solution. Nuclear Overhauser effect (NOE) measurements with a 7 molar urea solution of the amino-terminal 63-residue domain of the 434-repressor and distance geometry calculations showed that the polypeptide segment 54 to 59 forms a hydrophobic cluster containing the side chains of Val54, Val56, Trp58, and Leu59. This residual structure in the urea-unfolded protein is related to the corresponding region of the native, folded protein by simple rearrangements of the residues 58 to 60. Based on these observations a model for the early phase of refolding of the 434-repressor(1-63) is proposed.	SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Neri, Dario/P-4368-2016; Billeter, Martin/A-8293-2010	Neri, Dario/0000-0001-5234-7370; Wider, Gerhard/0000-0001-9366-7645				ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; BILLETER M, 1990, BIOPOLYMERS, V29, P695, DOI 10.1002/bip.360290404; BRAUN W, 1981, BIOCHIM BIOPHYS ACTA, V667, P377, DOI 10.1016/0005-2795(81)90205-1; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; FESIK SW, 1988, NATURE, V332, P865, DOI 10.1038/332865a0; GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; MONDRAGON A, 1989, J MOL BIOL, V205, P189, DOI 10.1016/0022-2836(89)90375-6; NERI D, 1992, J MOL BIOL, V223, P743, DOI 10.1016/0022-2836(92)90987-U; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NERI D, 1992, P NATL ACAD SCI USA, V89, P4397, DOI 10.1073/pnas.89.10.4397; NERI D, 1992, FEBS LETT, V303, P129, DOI 10.1016/0014-5793(92)80504-A; OTTING G, 1988, J MAGN RESON, V76, P569, DOI 10.1016/0022-2364(88)90361-7; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; RICHARDS FM, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0191-54; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; SINGH UC, 1986, AMBER30 U CAL; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WIDER G, 1991, J AM CHEM SOC, V113, P4676, DOI 10.1021/ja00012a044; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	494	498	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1559	1563		10.1126/science.1523410	http://dx.doi.org/10.1126/science.1523410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523410				2022-12-24	WOS:A1992JM57000036
J	PAN, T; UHLENBECK, OC				PAN, T; UHLENBECK, OC			A SMALL METALLORIBOZYME WITH A 2-STEP MECHANISM	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; SELF-SPLICING RNA; CLEAVAGE; HYDROLYSIS	An RNA molecule consisting of an asymmetric internal loop of six nucleotides can be rapidly and specifically cleaved by Pb2+ in the presence of Mg2+. The 5' cleavage product terminates with a 3' phosphomonoester generated from a 2',3'-cyclic phosphodiester reaction intermediate. This two-step reaction mechanism resembles that of many protein ribonucleases but has not previously been observed for reactions catalysed by RNA.			PAN, T (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.							Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1990, REV BIOCH, V59, P5543; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FARKAS WR, 1968, BIOCHIM BIOPHYS ACTA, V155, P401, DOI 10.1016/0005-2787(68)90184-6; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RUBIN JR, 1983, J BIOMOL STRUCT DYN, V1, P639, DOI 10.1080/07391102.1983.10507471; SUNDARALINGAM M, 1984, INT J QUANTUM CHEM, P355; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	19	205	216	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 13	1992	358	6387					560	563		10.1038/358560a0	http://dx.doi.org/10.1038/358560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501711				2022-12-24	WOS:A1992JH82900050
J	STRANG, J; GRIFFITHS, P; POWIS, B; GOSSOP, M				STRANG, J; GRIFFITHS, P; POWIS, B; GOSSOP, M			1ST USE OF HEROIN - CHANGES IN ROUTE OF ADMINISTRATION OVER TIME	BRITISH MEDICAL JOURNAL			English	Article											STRANG, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,NATL ADDICT CTR,DRUG TRANSIT STUDY,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				BEWLEY TH, 1967, BRIT MED J, V2, P498, DOI 10.1136/bmj.2.5550.498; BRETTLE RP, 1987, BRIT MED J, V295, P421, DOI 10.1136/bmj.295.6595.421; GOSSOP M, 1988, BRIT J ADDICT, V83, P1159; PARKER H, 1987, BRIT J ADDICT, V82, P147; 1991, STATISTICAL B MISUSE	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1222	1223		10.1136/bmj.304.6836.1222	http://dx.doi.org/10.1136/bmj.304.6836.1222			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT964	1515792	Green Published, Bronze			2022-12-24	WOS:A1992HT96400022
J	MURAKAMI, M; TSUBATA, T; OKAMOTO, M; SHIMIZU, A; KUMAGAI, S; IMURA, H; HONJO, T				MURAKAMI, M; TSUBATA, T; OKAMOTO, M; SHIMIZU, A; KUMAGAI, S; IMURA, H; HONJO, T			ANTIGEN-INDUCED APOPTOTIC DEATH OF LY-1 B-CELLS RESPONSIBLE FOR AUTOIMMUNE-DISEASE IN TRANSGENIC MICE	NATURE			English	Article							ANTIBODY-SECRETING CELLS; LYMPHOCYTES-B; RHEUMATOID-FACTOR; SOMATIC MUTATION; CLONAL DELETION; DNA; MOUSE; AUTOANTIBODIES; ENUMERATION; LINEAGE	STUDIES on transgenic mice expressing immunoglobulins against self-antigens 1-6 have shown that self-tolerance is maintained by active elimination (clonal deletion) 1-3,7, functional inactivation (clonal anergy) 4,5,8 of self-reactive B cells, or a combination of both 6. We have established and characterized a transgenic mouse line expressing an anti-erythrocyte autoantibody 6. In contrast to other autoantibody transgenic lies, about 50% of the animals of this transgenic line suffer from autoimmune disease, indicating a loss of self-tolerance. Here we show that peritoneal Ly-1 B cells (also known as B-1 cells 9) are responsible for this autoimmune disease in our transgenic mice. A few self-reactive Ly-1 B cells that have somehow escaped the deletion mechanism expand in the peritoneum because of the absence of self-antigen. These Ly-1 B cells are eliminated in vivo by apoptosis once exposed to self-antigen. On the basis of these results we propose a novel autoantibody production mechanism whereby self-reactive B cells sequestered in compartments free of self-antigens may survive, proliferate and be activated for generation of pathogenic autoantibodies in autoimmune diseases.	KYOTO UNIV, FAC MED, DEPT INTERNAL MED 2, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, CTR MOLEC BIOL & GENET, SAKYO KU, KYOTO 606, JAPAN	Kyoto University; Kyoto University	MURAKAMI, M (corresponding author), KYOTO UNIV, FAC MED, DEPT MED CHEM, SAKYO KU, KYOTO 606, JAPAN.		Tsubata, Takeshi/AAI-7489-2021; Honjo, Tasuku/N-4470-2016	Tsubata, Takeshi/0000-0003-0760-1258; 				BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; CASALI P, 1989, J IMMUNOL, V143, P3476; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GIUSTI AM, 1987, P NATL ACAD SCI USA, V84, P2926, DOI 10.1073/pnas.84.9.2926; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P30; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; HARDY RR, 1986, IMMUNOL REV, V93, P53, DOI 10.1111/j.1600-065X.1986.tb01502.x; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; MARCOS MAR, 1989, EUR J IMMUNOL, V19, P2031, DOI 10.1002/eji.1830191110; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SMITH HR, 1983, ANNU REV IMMUNOL, V1, P175, DOI 10.1146/annurev.iy.01.040183.001135; WILLIAMS JR, 1974, NATURE, V252, P754, DOI 10.1038/252754a0	32	270	270	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					77	80		10.1038/357077a0	http://dx.doi.org/10.1038/357077a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1574128				2022-12-24	WOS:A1992HT22900062
J	FARROW, DC; HUNT, WC; SAMET, JM				FARROW, DC; HUNT, WC; SAMET, JM			GEOGRAPHIC-VARIATION IN THE TREATMENT OF LOCALIZED BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPARING TOTAL MASTECTOMY; SMALL-AREA VARIATIONS; HEALTH-CARE SERVICES; CAROTID ENDARTERECTOMY; OUTCOMES MOVEMENT; NEW-MEXICO; NEW-HAVEN; AGE; RADIOTHERAPY; PATTERNS	Background. Breast-conserving surgery followed by radiation therapy is as effective as modified radical mastectomy in treating women with localized breast cancer, as demonstrated by clinical trials reported during the 1980s. The extent to which breast-conserving surgery has been adopted in various regions of the United States is not known. Methods. We assessed variations in the use of breast-conserving surgery from 1983 to 1986 in 18,399 non-Hispanic white, 324 Hispanic, and 1174 black women with breast cancer in nine areas of the United States, using data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Results. The proportion of white women with localized breast cancer who underwent breast-conserving surgery ranged from 9.2 percent (Iowa) to 32.1 percent (Seattle) in 1983-1984 and from 19.6 percent (Iowa) to 41.5 percent (Seattle) in 1985-1986. Between 1983 and 1986, the use of breast-conserving surgery increased in each area, but the relative rankings of the areas changed little. The frequency of the use of breast-conserving surgery in black and Hispanic women was comparable to that in white women. The proportion of women who received radiation therapy after breast-conserving surgery also varied geographically and increased from 1983 to 1986 in all areas. Older women in all areas and black women in Atlanta and Detroit were less likely than other women to receive radiotherapy after breast-conserving surgery. Conclusions. There is marked variation in the United States in the use of breast-conserving surgery for localized breast cancer. The variation is not explained by demographic factors, although race and age affect the use of radiotherapy after breast-conserving surgery.	UNIV NEW MEXICO,MED CTR,CTR CANC,NEW MEXICO TUMOR REGISTRY,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT FAMILY & COMMUNITY MED,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico; University of New Mexico					AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006879] Funding Source: NIH RePORTER; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005228] Funding Source: NIH RePORTER; AHRQ HHS [HS 06879] Funding Source: Medline; NCI NIH HHS [N01-CN-05228] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAQUET CR, 1986, DHHS NIH862785 PUBL; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; DAWSON JH, 1987, JAMA-J AM MED ASSOC, V258, P2570, DOI 10.1001/jama.258.18.2570; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; KLEINMAN JC, 1983, MED CARE, V21, P1232, DOI 10.1097/00005650-198312000-00010; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; LEAPE LL, 1989, NEW ENGL J MED, V321, P653, DOI 10.1056/NEJM198909073211006; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RIES LAG, 1990, DDHS NIH902789 PUBL; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SAMET JM, 1987, J NATL CANCER I, V79, P457; SHAMBAUGH EM, 1977, DHEW NIH771448 PUBL; STEINFELD AD, 1989, J AM GERIATR SOC, V37, P335, DOI 10.1111/j.1532-5415.1989.tb05501.x; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; 1985, SAS USERS GUIDE STAT; 1988, NIH882789 PUBL	35	423	424	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1097	1101		10.1056/NEJM199204233261701	http://dx.doi.org/10.1056/NEJM199204233261701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552910				2022-12-24	WOS:A1992HP80000001
J	NIEMIRA, DA				NIEMIRA, DA			A TIME TO DECIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1913	1913		10.1001/jama.267.14.1913	http://dx.doi.org/10.1001/jama.267.14.1913			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548814				2022-12-24	WOS:A1992HL67700007
J	KLAR, A; BALDASSARE, M; JESSELL, TM				KLAR, A; BALDASSARE, M; JESSELL, TM			F-SPONDIN - A GENE EXPRESSED AT HIGH-LEVELS IN THE FLOOR PLATE ENCODES A SECRETED PROTEIN THAT PROMOTES NEURAL CELL-ADHESION AND NEURITE EXTENSION	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN MALARIA PARASITE; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; SPINAL NEURONS; THROMBOSPONDIN; GLYCOPROTEIN; OUTGROWTH; PROPERDIN; SEQUENCES	The floor plate is a cell group implicated in the control of neural cell pattern and axonal growth in the developing vertebrate nervous system. To identify molecules that might mediate the functions of the floor plate, we have used subtractive hybridization techniques to isolate floor plate-enriched cDNA clones. One such clone encodes a novel secreted protein, F-spondin, which is expressed at high levels in the floor plate. The C-terminal half of the protein contains six repeats identified previously in thrombospondin and other proteins implicated in cell adhesion. F-spondin is expressed in the floor plate at the time that axons first extend and at lower levels in the peripheral nerve. Recombinant F-spondin promotes the attachment of spinal cord and sensory neuron cells and the out-growth of neurites in vitro. F-spondin may contribute to the growth and guidance of axons in both the spinal cord and the PNS.			KLAR, A (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		Klar, Avihu/AHC-4770-2022					ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1990, BLOOD S1, V76, pA445; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; CULOTTI J G, 1991, Journal of Cell Biology, V115, p122A; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1985, J NEUROSCI, V5, P3278; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GOUNDIS D, 1988, NATURE, V335, P62; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Hedgecock E.M., 1990, Seminars in the Neurosciences, V2, P159; HEDGECOCK EM, 1990, NEURON, V2, P61; HESSION C, 1991, J BIOL CHEM, V266, P6682; HOLLEY JA, 1987, DEV BIOL, V123, P375, DOI 10.1016/0012-1606(87)90396-4; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KARAGOGEOS D, 1991, DEVELOPMENT, V112, P61; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUWADA JY, 1990, J COMP NEUROL, V302, P617, DOI 10.1002/cne.903020316; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MCKANNA JA, 1989, SCIENCE, V243, P1477, DOI 10.1126/science.2928781; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OSTERHOUT DJ, 1992, IN PRESS DEV BIOL; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; PERKINS SJ, 1989, BIOCHEMISTRY-US, V28, P7176, DOI 10.1021/bi00444a007; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PLACZEK M, 1991, IN PRESS DEVELOPMENT; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH K A, 1991, Journal of Cell Biology, V115, p441A; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Romijn HJ, 1982, DEV BRAIN RES, V2, P583; Sambrook J., 1989, MOL CLONING; SANES JR, 1990, COLD SH Q B, V55, P419; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHNER M, 1990, MORPHOREGULATORY MOL, P443; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; SUN X, 1989, J BIOL CHEM, V264, P2885; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TUTTLE R, 1989, DEV NEUROSCI-BASEL, V11, P289, DOI 10.1159/000111907; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; Weber A., 1938, Bio-Morphosis Basel, V1, P30; WEHRLE B, 1990, DEVELOPMENT, V110, P401; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; YAGINUMA H, 1991, J NEUROSCI, V11, P2598; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	85	318	340	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					95	110		10.1016/0092-8674(92)90121-R	http://dx.doi.org/10.1016/0092-8674(92)90121-R			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555244				2022-12-24	WOS:A1992HM44500009
J	HUME, SE				HUME, SE			MASS VOLUNTARY IMMUNIZATION CAMPAIGNS FOR MENINGOCOCCAL DISEASE IN CANADA - MEDIA HYSTERIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1992, VANCOUVER SUN   0115, pA1; 1992, PROVINCE        0126, pA9; 1992, VANCOUVER SUN   0203, pB1; 1992, PROVINCE        0119, pA1; 1992, GLOBE MAIL      0114, pA14; 1992, VANCOUVER SUN   0121, pA1; 1992, PROVINCE        0121, pA1	7	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1833	&		10.1001/jama.267.13.1833	http://dx.doi.org/10.1001/jama.267.13.1833			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545470				2022-12-24	WOS:A1992HK67200039
J	PARVIN, JD; TIMMERS, HTM; SHARP, PA				PARVIN, JD; TIMMERS, HTM; SHARP, PA			PROMOTER SPECIFICITY OF BASAL TRANSCRIPTION FACTORS	CELL			English	Article							RNA POLYMERASE-II; ACCURATE TRANSCRIPTION; INITIATION-FACTOR; BINDING-PROTEIN; GENE-PRODUCTS; TATA; ACTIVATION; PURIFICATION; REQUIREMENT; COMPLEXES	Regulation of expression of protein-encoding genes in eukaryotes is frequently mediated by sequence-specific transcription factors that control the activities of the basal factors and RNA polymerase II. Basal factors have been considered to be essential for all polymerase II promoters. Studies of the basal factor requirements for transcription from the immunoglobulin heavy chain gene (IgH) core promoter and the adenovirus major late gene core promoter (MLP) suggest that this paradigm is too simple. Basal transcription from the IgH promoter was reconstituted by TFIID, TFIIB, TFIIF, and polymerase, whereas basal transcription from the MLP is highly dependent upon TFIIE in addition to the above factors. Two novel protein activities, referred to as 700 kd and 90 kd, further stimulated the basal reaction from the MLP. Thus, these data indicate that not all basal factors are in fact general.	MIT,DEPT BIOL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT)	PARVIN, JD (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02138, USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1988, J BIOL CHEM, V263, P10812; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KINGSTON RE, 1984, MOL CELL BIOL, V4, P1970, DOI 10.1128/MCB.4.10.1970; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0	36	108	108	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1135	1144		10.1016/0092-8674(92)90084-P	http://dx.doi.org/10.1016/0092-8674(92)90084-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547507				2022-12-24	WOS:A1992HK67400016
J	KANNEL, WB; ANDERSON, K; WILSON, PWF				KANNEL, WB; ANDERSON, K; WILSON, PWF			WHITE BLOOD-CELL COUNT AND CARDIOVASCULAR-DISEASE - INSIGHTS FROM THE FRAMINGHAM-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; LEUKOCYTE COUNTS; CORONARY; PREDICTOR; MORTALITY; RISK	Objective.-To examine the relation of white blood cell (WBC) count to the development of cardiovascular disease (CVD), including coronary heart disease, stroke, peripheral arterial disease, and cardiac failure. Traditional CVD risk factors, hematocrit, and vital capacity were considered. Design.-Prospective cohort analysis with one baseline examination of relevant risk factors and 12 years of follow-up for CVD. Participants and Methods.-A community-based sample (Framingham Offspring Study) of 1393 men and 1401 women who were free of CVD at the onset of the study and who were between the ages of 30 and 59 years at baseline. Time-dependent multiple variable logistic regression methods were used. Results.-There were 180 CVD events in men and 80 in women. The WBC count was correlated most strongly with the number of cigarettes smoked per day, hematocrit, and vital capacity. Among nonsmoking men with WBC counts within the normal range, the age-adjusted WBC count was significantly associated with CVD and coronary heart disease incidence. For each 1.0 x 10(9)/L-cell difference in WBC count, the CVD risk increased 32%. In women, each 1.0 x 10(9)/L-cell increment in WBC count was associated with a 17% increase in CVD risk, but only in smokers, and the relationship was not statistically significant after adjustment for relevant risk factors. Conclusions.-The degree of elevation of WBC count within the normal range is a marker for increased risk of CVD that is partially explained by cigarette smoking. Future-studies should include differential WBC determinations to assess their association with CVD.	NHLBI,FRAMINGHAM HEART STUDY,5 THURBER ST,FRAMINGHAM,MA 01701; BOSTON UNIV,SCH MED,EVANS MEM RES FDN,DEPT MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; CENTOCOR INC,MALVERN,PA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc			Wilson, Peter W.F./J-2455-2016		NHLBI NIH HHS [N01-HV-92922, N01-HV-52971] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DELABRY LO, 1990, J CLIN EPIDEMIOL, V43, P153, DOI 10.1016/0895-4356(90)90178-R; DESERVI S, 1991, AM J CARDIOL, V68, pB64, DOI 10.1016/0002-9149(91)90386-Y; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P1275, DOI 10.1056/NEJM197406062902302; GRIMM RH, 1985, JAMA-J AM MED ASSOC, V254, P1932, DOI 10.1001/jama.254.14.1932; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LOWE GDO, 1985, THROMB HAEMOSTASIS, V54, P700; PRENTICE RL, 1982, AM J EPIDEMIOL, V116, P496, DOI 10.1093/oxfordjournals.aje.a113434; PRENTICE RL, 1982, J CHRON DIS, V35, P703, DOI 10.1016/0021-9681(82)90094-7; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P234; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; WILSON PWF, 1983, ARTERIOSCLEROSIS, V3, P273, DOI 10.1161/01.ATV.3.3.273; ZALOKAR JB, 1981, NEW ENGL J MED, V304, P402	13	338	348	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1253	1256		10.1001/jama.267.9.1253	http://dx.doi.org/10.1001/jama.267.9.1253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538564				2022-12-24	WOS:A1992HF43900029
J	JONES, PDE; HUDSON, N; HAWKEY, CJ				JONES, PDE; HUDSON, N; HAWKEY, CJ			DEPRESSION OF SALIVARY EPIDERMAL GROWTH-FACTOR BY SMOKING	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BENOWITZ NL, 1986, ANNU REV MED, V37, P21; JONES PDE, 1990, EUR J GASTROEN HEPAT, V2, P203; MACCINI DM, 1990, AM J GASTROENTEROL, V85, P1102; OLSEN PS, 1986, GUT, V27, P1443, DOI 10.1136/gut.27.12.1443; SONTAG S, 1984, NEW ENGL J MED, V311, P689, DOI 10.1056/NEJM198409133111101	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					480	480		10.1136/bmj.304.6825.480	http://dx.doi.org/10.1136/bmj.304.6825.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547420	Green Published, Bronze			2022-12-24	WOS:A1992HF55500023
J	HUGHES, SM; BLAU, HM				HUGHES, SM; BLAU, HM			MUSCLE-FIBER PATTERN IS INDEPENDENT OF CELL LINEAGE IN POSTNATAL RODENT DEVELOPMENT	CELL			English	Article							HEAVY-CHAIN ISOFORMS; MYOSIN GENE-EXPRESSION; CEREBRAL-CORTEX; CLONAL ANALYSIS; NEURAL CONTROL; RAT; MYOBLASTS; DIFFERENTIATION; FAMILY; SLOW	Muscle fibers specialized for fast or slow contraction are arrayed in characteristic patterns within developing limbs. Clones of myoblasts analyzed in vitro express fast and slow myosin isoforms typical of the muscle from which they derive. As a result, it has been suggested that distinct myoblast lineages generate and maintain muscle fiber pattern. We tested this hypothesis in vivo by using a retrovirus to label myoblasts genetically so that the fate of individual clones could be monitored. Both myoblast clones labeled in muscle in situ and clones labeled in tissue culture and then injected into various muscles contribute progeny to all fiber types encountered. Thus, extrinsic signals override the intrinsic commitment of myoblast nuclei to particular programs of gene expression. We conclude that in postnatal development, pattern is not dictated by myoblast lineage.			HUGHES, SM (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA.		Hughes, Simon M/S-1073-2016	Hughes, Simon M/0000-0001-8227-9225	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009521, R37AG009521] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09521] Funding Source: Medline; NICHD NIH HHS [HD-18179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONNER PH, 1974, DEV BIOL, V37, P317, DOI 10.1016/0012-1606(74)90152-3; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; BUTLER J, 1982, J EXP ZOOL, V224, P65, DOI 10.1002/jez.1402240108; CONDON K, 1990, DEV BIOL, V138, P275, DOI 10.1016/0012-1606(90)90197-Q; COSSU G, 1988, DEVELOPMENT, V102, P65; DANGOOR M, 1990, J MUSCLE RES CELL M, V11, P216, DOI 10.1007/BF01843575; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GUNDERSEN K, 1988, J PHYSIOL-LONDON, V398, P177, DOI 10.1113/jphysiol.1988.sp017037; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HOH JFY, 1988, J MUSCLE RES CELL M, V9, P59; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KELLY AM, 1986, MED SCI SPORT EXER, V18, P292, DOI 10.1249/00005768-198606000-00007; LAFRAMBOISE WA, 1991, DEV BIOL, V144, P1, DOI 10.1016/0012-1606(91)90473-G; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MILLER AD, 1990, BLOOD, V76, P271; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1985, J CELL BIOL, V101, P1643, DOI 10.1083/jcb.101.5.1643; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEDROSA F, 1989, HISTOCHEMISTRY, V92, P185, DOI 10.1007/BF00500917; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PRICE J, 1988, DEVELOPMENT, V104, P473; Price J, 1989, CURR OPIN CELL BIOL, V1, P1071, DOI 10.1016/S0955-0674(89)80052-3; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SALVIATI G, 1986, NATURE, V322, P637, DOI 10.1038/322637a0; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAFER DA, 1987, CELL, V48, P659, DOI 10.1016/0092-8674(87)90244-3; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, SKELETAL MUSCLE, P440; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WESTGAARD RH, 1988, J NEUROSCI, V8, P4415	50	187	190	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					659	671		10.1016/0092-8674(92)90142-Y	http://dx.doi.org/10.1016/0092-8674(92)90142-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1531450				2022-12-24	WOS:A1992HF44000007
J	JIRIKOWSKI, GF; SANNA, PP; MACIEJEWSKILENOIR, D; BLOOM, FE				JIRIKOWSKI, GF; SANNA, PP; MACIEJEWSKILENOIR, D; BLOOM, FE			REVERSAL OF DIABETES-INSIPIDUS IN BRATTLEBORO RATS - INTRAHYPOTHALAMIC INJECTION OF VASOPRESSIN MESSENGER-RNA	SCIENCE			English	Article							BRAIN RIBONUCLEASES; PITUITARY; MOUSE; GENE; HYPOTHALAMUS; EXPRESSION; TRANSPORT; OXYTOCIN	Messenger RNAs occur within the axons of magnocellular hypothalamic neurons known to secrete oxytocin and vasopressin. In Brattleboro rats, which have a genetic mutation that renders them incapable of vasopressin expression and secretion and thus causes diabetes insipidus, injection into the hypothalamus of purified mRNAs from normal rat hypothalami or of synthetic copies of the vasopressin mRNA leads to selective uptake, retrograde transport, and expression of vasopressin exclusively in the magnocellular neurons. Temporary reversal of their diabetes insipidus (for up to 5 days) can be observed within hours of the injection. Intra-axonal mRNAs may represent an additional category of chemical signals for neurons.			JIRIKOWSKI, GF (corresponding author), Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022347] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 47680] Funding Source: Medline; NINDS NIH HHS [NS 22347-03] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCH B, 1990, NEUROSCI LETT, V109, P259, DOI 10.1016/0304-3940(90)90004-S; BROOKS PJ, 1990, SOC NEUR ABSTR, V14; CARAZANNA EJ, 1988, MOL CELL BIOL, V8, P2267; CARTER DA, 1989, J BIOL CHEM, V264, P6601; DAVIS L, 1990, J NEUROSCI, V10, P3056; FRANZONI L, 1978, ACTA PHYSIOL LAT AM, V28, P185; HAUSSLER HU, 1990, J CHEM NEUROANAT, V3, P271; IVELL R, 1984, P NATL ACAD SCI USA, V81, P1216; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; LEHMANN E, 1990, NEUROSCI LETT, V111, P170, DOI 10.1016/0304-3940(90)90363-E; LENOIR D, 1986, J NEUROSCI, V6, P522; LEVY A, 1990, J NEUROENDOCRINOL, V2, P329, DOI 10.1111/j.1365-2826.1990.tb00413.x; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MCCABE JJ, 1985, IN SITU HYBRIDIZATIO, P73; MOHR E, 1991, EMBO J, V10, P2419, DOI 10.1002/j.1460-2075.1991.tb07781.x; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; MURPHY D, 1989, P NATL ACAD SCI USA, V86, P9002, DOI 10.1073/pnas.86.22.9002; POPICK FR, 1976, LIFE SCI, V18, P197, DOI 10.1016/0024-3205(76)90025-4; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0; SCHULZHARDER B, 1988, HISTOCHEMISTRY, V88, P587, DOI 10.1007/BF00570329; STERNBERGER LA, 1978, IMMUNOCYTOCHEMISTRY; TREMBLEAU A, 1991, NEUROCYTOCHEMICAL ME, P313; ZINGG HH, 1988, J BIOL CHEM, V263, P11041	24	156	192	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					996	998		10.1126/science.1546298	http://dx.doi.org/10.1126/science.1546298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546298				2022-12-24	WOS:A1992HE60500045
J	MARAHRENS, Y; STILLMAN, B				MARAHRENS, Y; STILLMAN, B			A YEAST CHROMOSOMAL ORIGIN OF DNA-REPLICATION DEFINED BY MULTIPLE FUNCTIONAL ELEMENTS	SCIENCE			English	Article							RIBOSOMAL-PROTEIN GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; CONSENSUS SEQUENCE; BINDING PROTEIN; SILENCER; ARS; PURIFICATION; PLASMIDS; INITIATION	Although it has been demonstrated that discrete origins of DNA replication exist in eukaryotic cellular chromosomes, the detailed organization of a eukaryotic cellular origin remains to bc determined. Linker substitution mutations were constructed across the entire Saccharomyces cerevisiae chromosomal origin, ARS1. Functional studies of these mutants revealed one essential clement (A), which includes a match to the ARS consensus sequence, and three additional elements (B1, B2, and B3), which collectively are also essential for origin function. These four elements arranged exactly as in ARS1, but surrounded by completely unrelated sequence, functioned as an efficient origin. Element B3 is the binding site for the transcription factor-origin binding protein ABF1. Other transcription factor binding sites substitute for the B3 element and a trans-acting transcriptional activation domain is required. The multipartite nature of a chromosomal replication origin and the role of transcriptional activators in its function present a striking similarity to the organization of eukaryotic promoters.	SUNY STONY BROOK, GRAD PROGRAM MOLEC & CELLULAR BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	MARAHRENS, Y (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091	NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020460, R01AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DORSMAN JC, 1989, NUCLEIC ACIDS RES, V17, P4917, DOI 10.1093/nar/17.13.4917; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; MARAHRENS Y, UNPUB; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; ORRWEAVER TL, 1989, EMBO J, V8, P4153, DOI 10.1002/j.1460-2075.1989.tb08600.x; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SRIENC F, 1985, MOL CELL BIOL, V5, P1676, DOI 10.1128/MCB.5.7.1676; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	70	507	515	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					817	823		10.1126/science.1536007	http://dx.doi.org/10.1126/science.1536007			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536007				2022-12-24	WOS:A1992HD54800028
J	SPIES, T; CERUNDOLO, V; COLONNA, M; CRESSWELL, P; TOWNSEND, A; DEMARS, R				SPIES, T; CERUNDOLO, V; COLONNA, M; CRESSWELL, P; TOWNSEND, A; DEMARS, R			PRESENTATION OF VIRAL-ANTIGEN BY MHC CLASS-I MOLECULES IS DEPENDENT ON A PUTATIVE PEPTIDE TRANSPORTER HETERODIMER	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; TOXIC LYMPHOCYTES-T; HLA-B ANTIGENS; ASSOCIATION; PROTEIN; RECOGNITION; PATHWAY; INVITRO; REGION; CELLS	MAJOR histocompatibility complex (MHC) class I molecules present peptides derived from the endogenous protein pool to cytotoxic T lymphocytes, which can thus recognize intracellular antigen 1-3 . This pathway may depend on a transporter (PSF1) (refs 4-6) to mediate entry of the cytosolic peptides into a pre-Golgi compartment where they bind to class I heavy chains and promote their stable assembly with beta-2-microglobulin 7-12. There is, however, only indirect support for this function of PSF1 (ref. 6). Here we show that PSF1 is necessary for the efficient assembly of class I molecules and enables them to present a peptide epitope derived from endogenously synthesized viral antigen. Immunochemical and genetic data demonstrate that the PSF1 polypeptide is associated with a complementary transporter chain, which is polymorphic and is encoded by the PSF2 gene 13, which is closely linked to PSF1.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; IST NAZL RIC CANC,I-16132 GENOA,ITALY; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Oxford; University of Genoa; IRCCS AOU San Martino IST; Yale University; University of Wisconsin System; University of Wisconsin Madison	SPIES, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,44 BINNEY ST,BOSTON,MA 02115, USA.			Cerundolo, Vincenzo/0000-0003-0040-3793; Colonna, Marco/0000-0001-5222-4987; Townsend, Alain/0000-0002-3702-0107				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HYDE SC, 1990, NATURE, V346, P263; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEACH R, 1986, P NATL ACAD SCI USA, V83, P3909, DOI 10.1073/pnas.83.11.3909; LJUNGGREN HG, 1990, NATURE, V346, P478; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WAYS JP, 1986, J IMMUNOL, V137, P217; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	28	331	332	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					644	646		10.1038/355644a0	http://dx.doi.org/10.1038/355644a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538752				2022-12-24	WOS:A1992HD54700058
J	EDWARDS, IR; COULTER, DM; MACINTOSH, D				EDWARDS, IR; COULTER, DM; MACINTOSH, D			INTESTINAL EFFECTS OF CAPTOPRIL	BRITISH MEDICAL JOURNAL			English	Article									UNIV OTAGO,SCH MED,NATL TOXICOL GRP,DUNEDIN,NEW ZEALAND	University of Otago								BHASKAR RM, 1984, PEPTIDES, V5, P291; CHONG EKS, 1973, J PHARM PHARMACOL, V25, P170, DOI 10.1111/j.2042-7158.1973.tb10614.x; LEVENS NR, 1985, AM J PHYSIOL, V249, pG3, DOI 10.1152/ajpgi.1985.249.1.G3; PICARELLI ZP, 1954, CIRC RES, V2, P354, DOI 10.1161/01.RES.2.4.354; WALUS KM, 1981, DIGEST DIS SCI, V26, P1069, DOI 10.1007/BF01295970	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					359	360		10.1136/bmj.304.6823.359	http://dx.doi.org/10.1136/bmj.304.6823.359			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540734	Green Published, Bronze			2022-12-24	WOS:A1992HD38700025
J	YOUNGERSHEPHERD, S; VAESSIN, H; BIER, E; JAN, LY; JAN, YN				YOUNGERSHEPHERD, S; VAESSIN, H; BIER, E; JAN, LY; JAN, YN			DEADPAN, AN ESSENTIAL PAN-NEURAL GENE ENCODING AN HLH PROTEIN, ACTS AS A DENOMINATOR IN DROSOPHILA SEX DETERMINATION	CELL			English	Article							ACHAETE-SCUTE COMPLEX; LOOP-HELIX PROTEINS; PERIPHERAL NERVOUS-SYSTEM; X-A RATIO; DOSAGE COMPENSATION; DNA-BINDING; DETERMINATION SIGNAL; NEGATIVE REGULATOR; PRONEURAL CLUSTERS; NUMERATOR ELEMENT	In Drosophila, sex is determined by the X:A ratio. One major numerator element on the X chromosome is sisterless-b (sis-b), also called scute, which encodes an HLH-type transcription factor. We report here that an essential pan-neural gene, the autosomal HLH gene deadpan (dpn), acts as a denominator element. As revealed by dosage-dependent dominant interactions, males die with too high a ratio of sc+ to dpn+, caused by misexpression of Sex lethal (Sxl) in embryos, and females die with too low a ratio of sc+ to dpn+, because of altered embryonic Sxl expression. In addition, we found that the HLH gene extramacrochaetae (emc), like daughterless (da), is needed maternally for proper communication of the X:A ratio, thus supporting the idea that a set of HLH genes comprises a functional cassette that makes a sensitive and stable genetic switch used in both neural determination and sex determination.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL & BIOCHEM, SAN FRANCISCO, CA 94143 USA; OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, OHIO STATE BIOTECHNOL CTR, COLUMBUS, OH 43210 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Francisco; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California San Diego; University of California System; University of California San Diego	YOUNGERSHEPHERD, S (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL AE, 1954, GENETICS, V39, P958; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLINE TW, 1983, GENETICS, V104, P516; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CRONMILLER C, 1986, DEV GENET, V7, P205, DOI 10.1002/dvg.1020070406; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; Dobzhansky T, 1934, J GENET, V28, P349, DOI 10.1007/BF02981760; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FOE VE, 1983, J CELL SCI, V61, P31; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GERGEN JP, 1987, GENETICS, V117, P477; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; INGHAM PW, 1985, GENETICS, V111, P463; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; LINDSLEY D, 1987, DROS INF SERV, V65; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; MANGE AP, 1973, GENETICS, V73, P73; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHUPBACH T, 1985, GENETICS, V109, P529; SCHUPBACH T, 1982, DEV BIOL, V89, P117, DOI 10.1016/0012-1606(82)90300-1; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SLEE R, 1990, Q REV BIOL, V65, P175, DOI 10.1086/416718; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VAESSIN H, 1990, COLD SH Q B, V55, P239; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	76	112	114	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					911	922		10.1016/0092-8674(92)90242-5	http://dx.doi.org/10.1016/0092-8674(92)90242-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525829				2022-12-24	WOS:A1992JN78100007
J	RESCH, KL; ERNST, E; MATRAI, A; PAULSEN, HF				RESCH, KL; ERNST, E; MATRAI, A; PAULSEN, HF			FIBRINOGEN AND VISCOSITY AS RISK-FACTORS FOR SUBSEQUENT CARDIOVASCULAR EVENTS IN STROKE SURVIVORS	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; FIBRINOGEN; RHEOLOGY; CARDIOVASCULAR DISEASES; MYOCARDIAL INFARCTION	ISCHEMIC-HEART-DISEASE; PLASMA-FIBRINOGEN; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; BLOOD	Objective: To investigate whether abnormalities in blood viscosity predict a poor prognosis for subsequent cardiovascular events in stroke survivors. Design: Nested case-control study among a cohort of survivors of a first stroke, followed for an average of 2 years. Patients with a second stroke, myocardial infarction, or cardiovascular death were matched with patients who did not have such events (control patients). Setting: Buchberg-Klinik, Bad Tolz, Germany, a specialized center for stroke rehabilitation. Patients: A total of 625 consecutive patients. Twenty-one patients (3.5%) were lost to follow-up. Sixty pairs were matched. Measurements: Native and hematocrit-standardized blood viscosity at three shear rates, hematocrit, plasma viscosity, fibrinogen, erythrocyte sedimentation rate, total leukocyte count, and the matching variables. Results: Eighty-five patients had a second stroke, myocardial infarction, or died due to a cardiovascular event. Patients with re-events had higher blood viscosity and fibrinogen levels than the control patients. In the 60 matched pairs, the mean of the paired differences between patients with re-events and control patients was 5.03 mPa . s (95% Cl, 1.262 to 8.941; P = 0.01) for native blood viscosity at shear rate 0.7 s-1, for plasma viscosity, 0.044 mPa . s (CI, 0.006 to 0.083; P > 0.02), and for fibrinogen, 0.056 g/L (CI, 0.010 to 0.101; P > 0.02). Odds ratios were significantly increased only for plasma viscosity (odds ratio, 2.86; CI, 1.06 to 8.43) and fibrinogen (odds ratio, 3.67; CI, 1.31 to 11.69). Conclusions: Hyperfibrinogenemia is an independent risk factor for cardiovascular events in stroke survivors. Intervention trials with fibrinogen lowering measures may be warranted.	UNIV VIENNA, DEPT PHYS MED & REHABIL, WAHRINGER GURTEL 18-20, A-1097 VIENNA, AUSTRIA; BUCHBERG KLIN, W-8170 BAD TOLZ, GERMANY	University of Vienna								BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CHIEN S, 1987, CLIN HEMORHEOL, P125; COULL BM, 1991, STROKE, V22, P162, DOI 10.1161/01.STR.22.2.162; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; ERNST E, 1990, CLIN HEMORHEOL, V10, P525; ERNST E, 1988, STROKE, V19, P634, DOI 10.1161/01.STR.19.5.634; ERNST E, 1990, J INTERN MED, V227, P365, DOI 10.1111/j.1365-2796.1990.tb00174.x; ERNST E, 1991, BRIT MED J, V303, P596, DOI 10.1136/bmj.303.6803.596; ERNST E, 1986, HERZ KREISLAUF, V18, P30; ERNST E, 1989, HAMORHEOLOGIE THEORI, P247; ERNST E, 1992, IN PRESS J CLIN PATH; FISHER M, 1991, STROKE, V22, P1164, DOI 10.1161/01.STR.22.9.1164; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GROTTA J, 1982, STROKE, V13, P296, DOI 10.1161/01.STR.13.3.296; HIER DB, 1991, STROKE, V22, P155, DOI 10.1161/01.STR.22.2.155; International Committee for Standardization in Haematology Expert Panel on Blood Cell Sizing, 1980, J CLIN PATHOL, V33, P1; JUNGQUIST G, 1991, J CLIN EPIDEMIOL, V44, P347, DOI 10.1016/0895-4356(91)90073-I; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Lowe GDO, 1987, CLIN HEMORHEOL, P195; LOWE GOD, 1987, CEREBRAL ISCHEMIA HE, P496; MATRAD A, 1985, CLIN HEMORHEOL, V5, P622; MATRAI A, 1984, Biorheology, P99; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MERRILL EW, 1969, PHYSIOL REV, V49, P863, DOI 10.1152/physrev.1969.49.4.863; OTT EO, 1974, STROKE, V5, P330, DOI 10.1161/01.STR.5.3.330; PETERSEN WE, 1953, J LAB CLIN MED, V42, P641; RIDKER PM, 1991, CIRCULATION, V83, P1098, DOI 10.1161/01.CIR.83.3.1098; Schlesselman J. J, 1982, CASE CONTROL STUDIES, P207; SPINELLI F R, 1974, Biorheology, V11, P301; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; SYRJANEN J, 1989, J CLIN PATHOL, V42, P63, DOI 10.1136/jcp.42.1.63; THOMAS DJ, 1987, CEREBRAL ISCHEMIA HE, P301; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1984, J CLIN PATHOL, V34, P1147	36	126	130	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					371	375		10.7326/0003-4819-117-5-371	http://dx.doi.org/10.7326/0003-4819-117-5-371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503327				2022-12-24	WOS:A1992JK67800004
J	JAVIER, R; RASKA, K; SHENK, T				JAVIER, R; RASKA, K; SHENK, T			REQUIREMENT FOR THE ADENOVIRUS TYPE-9 E4 REGION IN PRODUCTION OF MAMMARY-TUMORS	SCIENCE			English	Article							E2F TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; RETINOBLASTOMA GENE-PRODUCT; TRANSFORMED RAT-CELLS; NATURAL-KILLER CELLS; INFECTED-CELLS; NUCLEOTIDE-SEQUENCE; E1A PROTEINS; CYCLIN-A; EXPRESSION	Oncogenic viruses demonstrating a strict tropism for the mammary gland provide special opportunities to study the susceptibility of this tissue to neoplasia. In rats, human adenovirus type 9 (Ad9) elicits mammary fibroadenomas that are similar to common breast tumors in women, as well as phyllodes-like tumors and mammary sarcomas. By constructing recombinant adenoviruses between Ad9 and Ad26 (a related nontumorigenic virus), it was shown that the Ad9 E4 region was absolutely required to produce these mammary tumors. This indicates that an adenovirus gene located outside the classic transforming region (E1) can significantly influence the in vivo oncogenicity of an adenovirus. Consistent with a direct role in mammary gland oncogenesis, the Ad9 E4 region also exhibited transforming properties in vitro. Therefore, the Ad9 E4 region is a viral oncogene specifically involved in mammary gland tumorigenesis.	PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,NEW BRUNSWICK,NJ 08903; ST PETERS MED CTR,NEW BRUNSWICK,NJ 08903	Howard Hughes Medical Institute; Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [P01CA041086, R01CA021196, T32CA009528] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21196, CA 41086, T32 CA09528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1984, J VIROL, V50, P847, DOI 10.1128/JVI.50.3.847-853.1984; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, VIROLOGY, V93, P481, DOI 10.1016/0042-6822(79)90251-4; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HANAHAN D, 1984, MOL CELL BIOL, V4, P302, DOI 10.1128/MCB.4.2.302; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HEMSTROM C, 1988, J VIROL, V62, P3258; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; HOGENKAMP T, 1990, NUCLEIC ACIDS RES, V18, P3065, DOI 10.1093/nar/18.10.3065; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; JANNUN R, 1987, VIRUS RES, V7, P33, DOI 10.1016/0168-1702(87)90056-6; JAVIER R, 1991, J VIROL, V65, P192; JAVIER R, UNPUB; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MELLOW GH, 1984, VIROLOGY, V134, P460, DOI 10.1016/0042-6822(84)90313-1; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SAWADA Y, 1988, VIROLOGY, V166, P281, DOI 10.1016/0042-6822(88)90175-4; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHELLABARGER C, COMMUNICATION; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; STILLMAN B, 1986, CANCER SURV, V5, P389; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986	53	54	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1267	1271		10.1126/science.1519063	http://dx.doi.org/10.1126/science.1519063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519063				2022-12-24	WOS:A1992JL05000030
J	LANKER, S; BUSHMAN, JL; HINNEBUSCH, AG; TRACHSEL, H; MUELLER, PP				LANKER, S; BUSHMAN, JL; HINNEBUSCH, AG; TRACHSEL, H; MUELLER, PP			AUTOREGULATION OF THE YEAST LYSYL-TRANSFER RNA-SYNTHETASE GENE GCD5/KRS1 BY TRANSLATIONAL AND TRANSCRIPTIONAL CONTROL MECHANISMS	CELL			English	Article							AMINO-ACID BIOSYNTHESIS; GCN4 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; PROTEIN-SYNTHESIS; MUTATIONS; DNA; SPECIFICITY; EXPRESSION; REPRESSOR	We cloned the GCD5 gene of S. cerevisiae and found it to be identical to KRS1, which encodes lysyl-tRNA synthetase (LysRS). The mutation gcd5-1 changes a conserved residue in the putative lysine-binding domain of LysRS. This leads to a defect in lysine binding and, consequently, to reduced charging of tRNA(Lys). Mutant gcd5-1 cells compensate for the defect in LysRS by increasing GCN4 expression at the translational level. GCN4 protein in turn stimulates transcription of GCD5, leading to increased LysRS activity. We propose an autoregulatory model in which uncharged tRNA(Lys) stimulates the protein kinase GCN2, a translational activator of GCN4, and thereby increases transcription of GCD5 and other genes regulated by GCN4.	NICHHD,MOLEC GENET LOWER EUKARYOTES SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	LANKER, S (corresponding author), UNIV BERN,INST BIOCHEM & MOLEC BIOL,CH-3000 BERN 9,SWITZERLAND.		Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ANSELME J, 1991, FEBS LETT, V280, P163, DOI 10.1016/0014-5793(91)80228-U; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELFORGE J, 1975, EUR J BIOCHEM, V57, P231, DOI 10.1111/j.1432-1033.1975.tb02295.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1991, TRANSLATION EUKARYOT, P243; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAST P, 1991, J MOL BIOL, V222, P99, DOI 10.1016/0022-2836(91)90740-W; MARTINEZ R, 1991, MOL GEN GENET, V227, P149, DOI 10.1007/BF00260720; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUESSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; PADDON CJ, 1989, GENETICS, V122, P543; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; THIEROS B, 1984, P NATL ACAD SCI USA, V81, P5096; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4	39	48	52	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					647	657		10.1016/0092-8674(92)90433-D	http://dx.doi.org/10.1016/0092-8674(92)90433-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505029				2022-12-24	WOS:A1992JJ88600013
J	NGUYENVANTAM, JS; BAKER, DM				NGUYENVANTAM, JS; BAKER, DM			GENERAL-PRACTICE AND ACCIDENT AND EMERGENCY DEPARTMENT CARE - DOES THE PATIENT KNOW BEST	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT ACCID & EMERGENCY,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Baker, Daryll/0000-0002-0098-405X				DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109	1	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					157	158		10.1136/bmj.305.6846.157	http://dx.doi.org/10.1136/bmj.305.6846.157			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515831	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JF06300023
J	STRATHDEE, CA; GAVISH, H; SHANNON, WR; BUCHWALD, M				STRATHDEE, CA; GAVISH, H; SHANNON, WR; BUCHWALD, M			CLONING OF CDNAS FOR FANCONIS ANEMIA BY FUNCTIONAL COMPLEMENTATION	NATURE			English	Article							EPSTEIN-BARR-VIRUS; HUMAN-CELLS; MAMMALIAN-CELLS; ANEMIA; REPLICATION; SEQUENCES; MEMBRANE; PROTEINS; REPAIR; VECTOR	Fanconi's anaemia is a rare autosomal recessive disorder characterized by progressive pancytopaenia and a cellular hypersensitivity to DNA crosslinking agents. Four genetic complementation groups have been identified so far, and here we use a functional complementation method to clone complementary DNAs that correct the defect of group C cells. The cDNAs encode alternatively processed transcripts of a new gene, designated FACC, which is mutated in group C patients. The predicted FACC polypeptide does not contain any motifs common to other proteins and so represents a new gene involved in the cellular response to DNA damage.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ALTHOFF MZ, 1953, KINDERHEIL, V72, P267; ANDERSON WF, 1991, HUM GENE THER, V2, P193, DOI 10.1089/hum.1991.2.3-193; AUERBACH AD, 1989, BLOOD, V73, P391; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BUCHWALD M, 1989, FANCONI ANEMIA CLIN, P226; COLBEREGARAPIN F, 1986, GENE, V50, P279, DOI 10.1016/0378-1119(86)90332-X; DUCKWORTHRYSIECKI G, 1985, SOMAT CELL MOLEC GEN, V11, P35, DOI 10.1007/BF01534732; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; FUJIWARA Y, 1977, J MOL BIOL, V113, P635, DOI 10.1016/0022-2836(77)90227-3; GLUCKMAN E, 1984, SEMIN HEMATOL, V21, P20; GLUCKMAN E, 1989, FANCONI ANEMIA CLIN, P60; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; JOENJE H, 1989, FANCONI ANEMIA CLIN, P174; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P131; LEEDER JS, 1989, ANAL BIOCHEM, V177, P364, DOI 10.1016/0003-2697(89)90067-5; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J., 1989, MOL CLONING LAB MANU; SASAKI MS, 1973, CANCER RES, V33, P1829; SCHROEDER TM, 1976, HUM GENET, V32, P257, DOI 10.1007/BF00295817; SCHROEDER TM, 1964, HUMANGENETIK, V1, P194, DOI 10.1007/BF00389636; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRATHDEE CA, IN PRESS NATURE GENE; Szybalski W., 1967, ANTIBIOTICS, V1, P211; THOMPSON LH, 1991, MUTAT RES, V247, P213, DOI 10.1016/0027-5107(91)90017-I; VANDUUREN BL, 1969, ANN NY ACAD SCI, V163, P633, DOI 10.1111/j.1749-6632.1969.tb24883.x; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; [No title captured]	35	529	539	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					763	767		10.1038/356763a0	http://dx.doi.org/10.1038/356763a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574115				2022-12-24	WOS:A1992HR18600040
J	GEWIRTZ, JD				GEWIRTZ, JD			A MEMORY OF BLOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2173	2173						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556784				2022-12-24	WOS:A1992HN84100009
J	CRYER, B; LEE, E; FELDMAN, M				CRYER, B; LEE, E; FELDMAN, M			FACTORS INFLUENCING GASTRODUODENAL MUCOSAL PROSTAGLANDIN CONCENTRATIONS - ROLES OF SMOKING AND AGING	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; AGING; PROSTAGLANDINS; GASTRIC MUCOSA; INTESTINAL MUCOSA	GASTRIC LUMINAL PROSTAGLANDIN-E2; ANTI-INFLAMMATORY DRUGS; SECRETION; ULCER; CYTOPROTECTION; INDOMETHACIN; INJURY; HUMANS; ACID; RAT	Objective: To evaluate behavioral, demographic, clinical, and histologic variables that independently influence gastroduodenal mucosal prostaglandin concentrations. Design: Prospective study. Setting: A clinical research laboratory located in a Department of Veterans Affairs hospital. Patients: Fifty-two healthy adults who had no history of peptic ulcer disease and who were not receiving nonsteroidal anti-inflammatory drugs. Measurements: Mucosal biopsy specimens were obtained endoscopically from the stomach (body and antrum) and the duodenum (bulb and postbulbar area). Mucosal extracts from each of these four regions were assessed by radioimmunoassay to determine prostaglandin E2 and prostaglandin F2-alpha concentrations. Specimens were also examined histologically for inflammation and the presence of Helicobacter pylori. A multivariate linear regression model was used to determine which behavioral, demographic, and histologic variables significantly and independently influenced gastroduodenal mucosal prostaglandin concentrations. Results: Smoking and older age were independently associated with lower prostaglandin concentrations in all four mucosal regions (P = 0.0001 to P = 0.05). Compared with results in young nonsmokers, mucosal prostaglandin concentrations were reduced by 70% to 80% in older smokers. Gender, alcohol use, endoscopic appearance, dyspeptic symptoms, mucosal inflammation, and the presence of H. pylori had no consistent effect on prostaglandin content. Conclusion: Smoking and older age are associated with significantly reduced gastric and duodenal prostaglandin concentrations. These observations may help explain the predisposition to ulcer disease in smokers and older persons.	DEPT VET AFFAIRS MED CTR, 4500 S LANCASTER RD, DALLAS, TX 75216 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 16816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BOCHENEK WJ, 1973, AM J DIG DIS, V18, P729; BODE C, 1988, DIGEST DIS SCI, V33, P814, DOI 10.1007/BF01550968; BODE C, 1989, ALCOHOL ALCOHOLISM, V24, P35; COHEN MM, 1989, GASTROENTEROLOGY, V96, P292, DOI 10.1016/0016-5085(89)91550-3; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; DOLL R, 1958, LANCET, V1, P657; ENDOH K, 1991, DIGEST DIS SCI, V36, P39, DOI 10.1007/BF01300085; GOTO H, 1991, GASTROENTEROLOGY, V100, P74; GREENBERG RE, 1988, GASTROENTEROLOGY, V94, pA155; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Gunst R. F., 1980, REGRESSION ANAL ITS, DOI 10.1201/9780203741054; HAWKEY CJ, 1988, GASTROENTEROLOGY, V94, P948, DOI 10.1016/0016-5085(88)90552-5; ISENBERG JI, 1986, GASTROENTEROLOGY, V91, P370, DOI 10.1016/0016-5085(86)90571-8; KONTUREK SJ, 1982, DIGEST DIS SCI, V27, P967, DOI 10.1007/BF01391740; LANZA FL, 1984, AM J MED, V77, P19, DOI 10.1016/S0002-9343(84)80014-5; MALESCI A, 1988, SCAND J GASTROENTERO, V23, P602, DOI 10.3109/00365528809093919; MCCREADY DR, 1985, GUT, V26, P1192, DOI 10.1136/gut.26.11.1192; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; MOORE JG, 1991, GASTROENTEROLOGY, V100, P1626, DOI 10.1016/0016-5085(91)90661-4; MURTHY SNS, 1977, GASTROENTEROLOGY, V73, P758; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; QUIMBY GF, 1986, ANN INTERN MED, V104, P616, DOI 10.7326/0003-4819-104-5-616; REDFERN JS, 1987, GASTROENTEROLOGY, V92, P969, DOI 10.1016/0016-5085(87)90972-3; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; SILEN W, 1987, PHYSL GASTROINTESTIN, P1055; SOMERVILLE K, 1986, LANCET, V1, P462; STEEL RGD, 1960, PRINCIPLES PROCEDURE, P157; WALT R, 1986, LANCET, V1, P489; WHITFIELD PF, 1987, GUT, V28, P557, DOI 10.1136/gut.28.5.557; WHITTLE BJR, 1987, PHYSL GASTROINTESTIN, P143; WONG SH, 1986, J PHARM PHARMACOL, V38, P537, DOI 10.1111/j.2042-7158.1986.tb04633.x	32	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					636	640		10.7326/0003-4819-116-8-636	http://dx.doi.org/10.7326/0003-4819-116-8-636			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546863				2022-12-24	WOS:A1992HN84400005
J	HILLNER, BE; SMITH, TJ; DESCH, CE				HILLNER, BE; SMITH, TJ; DESCH, CE			EFFICACY AND COST-EFFECTIVENESS OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN METASTATIC BREAST-CANCER - ESTIMATES USING DECISION-ANALYSIS WHILE AWAITING CLINICAL-TRIAL RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DOSE CHEMOTHERAPY; MANAGEMENT; PROGNOSIS; THERAPY; SUPPORT	Objective. - To assess the efficacy and cost-effectiveness of standard chemotherapy and high-dose chemotherapy with autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Design. - Decision analysis model using a Markov process. Setting. - Response and recurrence rates from the published literature for standard therapy and from case series of ABMT. Costs were based on local charges and on adjusted Medicare data. Patients. - Hypothetical cohorts of women with metastatic breast cancer who had no bone marrow involvement and no comorbid illness. Intervention. - The standard chemotherapy cohort received cyclophosphamide, doxorubicin, and fluorouracil. The ABMT cohort was treated with intense induction chemotherapy, then additional high-dose chemotherapy following a remission, with ABMT support. Main Outcome Measures. - Anticipated survival, incremental cost per year of life, and incremental cost per quality-adjusted year of life gained using a 5-year time horizon. Rigorous sensitivity analyses were done, including assessing a benefit "tail" of normal life expectancy for those free of disease after 5 years. Results. - ABMT was the preferred approach under almost all assumptions, but the size of the benefit varied greatly. ABMT had a survival benefit of 6.0 months at 5 years at an incremental cost of $115 800 per year of life saved. If patients who were free of disease after 5 years had normal survival, the benefit was 18.1 months at an incremental cost of $28 600 per year. The benefit of ABMT was primarily dependent on whether the recurrence risk was constant or decreases after a finite period of time. Conclusion. - Using reasonable assumptions, ABMT provided a substantial benefit but at a cost that may be untenable. Decision analysis highlights the limitations in the currently available data and the assumptions made for the emotional question of using ABMT in metastatic breast cancer. The model supports the need for randomized clinical trials.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University	HILLNER, BE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT INTERNAL MED,DIV GEN MED,MCV STN,BOX 170,RICHMOND,VA 23298, USA.		Hillner, Bruce/A-6852-2009	Smith, Thomas/0000-0003-3040-6434	AHRQ HHS [R01 HS 0659-O1A1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANTMAN K, 1988, ANN INTERN MED, V108, P570, DOI 10.7326/0003-4819-108-4-570; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; ANTMAN K, 1991, NEW STRATEGIES BONE, P423; BAKER MS, 1991, MED CARE, V29, P40, DOI 10.1097/00005650-199101000-00004; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BELANGER D, 1991, J CLIN ONCOL, V9, P7, DOI 10.1200/JCO.1991.9.1.7; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DJULBEGOVIC B, 1991, MED DECIS MAKING, V11, P1, DOI 10.1177/0272989X9101100101; DUNPHY FR, 1990, J CLIN ONCOL, V8, P1207, DOI 10.1200/JCO.1990.8.7.1207; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELIAS A, 1990, BLOOD S, V76, pA536; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HENDERSON IC, 1991, J NATL CANCER I, V83, P894; HENDERSON IC, 1990, CANCER, V66, P1439, DOI 10.1002/1097-0142(19900915)66:14+<1439::AID-CNCR2820661421>3.0.CO;2-M; HENDERSON IC, 1991, BREAST DIS, P604; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HOLLENBERG J, 1989, SMLTREE 2 9; JONES RB, 1990, CANCER, V66, P431, DOI 10.1002/1097-0142(19900801)66:3<431::AID-CNCR2820660305>3.0.CO;2-X; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; LEVINE MN, 1991, EFFECT CANCER QUALIT, P205; MICK R, 1989, BREAST CANCER RES TR, V13, P33, DOI 10.1007/BF01806548; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEWCOMER LN, 1990, NEW ENGL J MED, V323, P1702, DOI 10.1056/NEJM199012133232411; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; Peters W P, 1991, Important Adv Oncol, P135; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1991, JUN FOR EM TREATM BR; PETERS WP, 1991, 14TH ANN ANT TEX BRE; PETRU E, 1986, WIEN KLIN WOCHENSCHR, V98, P790; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SIMES RJ, 1989, P AM SOC CLIN ONCOL, V8, pA52; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WIESEMAN T, 1991, ONCOL ISSUES, V6, P7; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; 1990, NEWSWEEK        1210, P62; 1990, NY TIMES        1112, pA1; 1991, J NATL CANCER I, V83, P254; 1986, LANCET, V1, P786; 1991, MED LETT DRUGS THER, V33, P3940; 1990, STATISTICAL ABSTRACT, P469	47	142	143	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2055	2061		10.1001/jama.267.15.2055	http://dx.doi.org/10.1001/jama.267.15.2055			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552641				2022-12-24	WOS:A1992HM65000031
J	BEGUN, DJ; AQUADRO, CF				BEGUN, DJ; AQUADRO, CF			LEVELS OF NATURALLY-OCCURRING DNA POLYMORPHISM CORRELATE WITH RECOMBINATION RATES IN DROSOPHILA-MELANOGASTER	NATURE			English	Article							RESTRICTION-MAP VARIATION; DROSOPHILA-MELANOGASTER; MOLECULAR EVOLUTION; REGION; LOCUS; 87A	Two genomic regions with unusually low recombination rates in Drosophila melanogaster have normal levels of divergence but greatly reduced nucleotide diversity 1,2, apparently resulting from the fixation of advantageous mutations and the associated hitch-hiking effect 3,4 . Here we show that for 20 gene regions from across the genome, the amount of nucleotide diversity in natural populations of D. melanogaster is positively correlated with the regional rate of recombination. This cannot be explained by variation in mutation rates and/or functional constraint, because we observe no correlation between recombination rates and DNA sequence divergence between D. melanogaster and its sibling species, D. simulans. We suggest that the correlation may result from genetic hitch-hiking associated with the fixation of advantageous mutants. Hitch-hiking thus seems to occur over a large fraction of the Drosophila genome and may constitute a major constraint on levels of genetic variation in nature.			BEGUN, DJ (corresponding author), CORNELL UNIV, GENET & DEV SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.				NIGMS NIH HHS [R01 GM036431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADE M, 1989, MOL BIOL EVOL, V6, P123; AQUADRO CF, 1988, GENETICS, V119, P875; AQUADRO CF, 1986, GENETICS, V114, P1165; ASHBURNER M, 1991, DROSOPHILA GENETIC M, V69; BEGUN DJ, 1991, GENETICS, V129, P1147; BERRY AJ, 1991, GENETICS, V129, P1111; BIRKY CW, 1988, P NATL ACAD SCI USA, V85, P6414, DOI 10.1073/pnas.85.17.6414; BROWN AJL, 1983, P NATL ACAD SCI-BIOL, V80, P5350, DOI 10.1073/pnas.80.17.5350; BROWN AJL, 1981, NATURE, V290, P677, DOI 10.1038/290677a0; EANES WF, 1989, MOL BIOL EVOL, V6, P384; GAME AY, 1990, GENETICS, V126, P1021; Hochman B., 1976, GENET BIOL DROSOPHIL, V1b, P903; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; KAPLAN NL, 1989, GENETICS, V123, P887; Kimura M, 1985, NEUTRAL THEORY MOL E; LANGE BW, 1990, GENETICS, V126, P921; LANGLEY CH, 1982, P NATL ACAD SCI-BIOL, V79, P5631, DOI 10.1073/pnas.79.18.5631; LANGLEY CH, 1988, GENETICS, V119, P619; LANGLEY CH, POPULATION BIOL GENE, P75; Lindsley D. L., 1967, GENETIC VARIATIONS D; LINDSLEY DL, 1977, PHILOS T R SOC B, V277, P295, DOI 10.1098/rstb.1977.0019; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672300014634, 10.1017/S0016672308009579]; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MERRIAM J, 1991, SCIENCE, V254, P221, DOI 10.1126/science.1925579; MIYASHITA N, 1988, GENETICS, V120, P199; Nei M, 1987, MOL EVOLUTIONARY GEN; SCHAEFFER SW, 1988, MOL BIOL EVOL, V5, P30; SOUSA V, 1988, CHROMOSOME MAPS DROS; TAJIMA F, 1990, GENETICS, V125, P447; TAKANO TS, 1991, GENETICS, V129, P753	30	750	758	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	1992	356	6369					519	520		10.1038/356519a0	http://dx.doi.org/10.1038/356519a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560824				2022-12-24	WOS:A1992HN23100057
J	MERBS, SL; NATHANS, J				MERBS, SL; NATHANS, J			ABSORPTION-SPECTRA OF HUMAN CONE PIGMENTS	NATURE			English	Article							HUMAN COLOR-VISION; MOLECULAR-GENETICS; BOVINE RHODOPSIN; POLYMORPHISM; SENSITIVITY	HUMAN colour vision is mediated by three light-sensitive pigments, each found in a different cone-cell type 1. The absorption spectra of the human cone pigments have been sought for over a century 2 using techniques such as psychophysical colour matching 3, reflection densitometry 4, electroretinography 5, single-cell action spectra 6 and, most directly, microspectrophotometry 7,8. We report here a direct determination of the human cone pigment photobleaching difference absorption spectra after the production of each cone pigment apoprotein in tissue culture cells transfected with the corresponding complementary DNA clones 9,10. The mean values for the wavelength of maximal absorption are 426 nm for the blue pigment, 530 nm for the green pigment, and 552 nm and 557 nm for two polymorphic variants of the red pigment.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MERBS, SL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, NJ PHYSL, V266, P647; Boynton R. M., 1979, HUMAN COLOR VISION; BROWN PK, 1964, SCIENCE, V144, P45, DOI 10.1126/science.144.3614.45; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Maniatis T, 1989, DECONTAMINATION DILU; Maxwell J. C., 1860, PHILOS T R SOC LONDO, V150, P57, DOI DOI 10.1098/RSTL.1860.0005; NATHANS J, 1989, VISION RES, V29, P907, DOI 10.1016/0042-6989(89)90105-3; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; RUSHTON WAH, 1972, HDB SENSORY PHYSL, V7, P364; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	22	243	246	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					433	435		10.1038/356433a0	http://dx.doi.org/10.1038/356433a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557124				2022-12-24	WOS:A1992HL83000063
J	BOWERMAN, B; EATON, BA; PRIESS, JR				BOWERMAN, B; EATON, BA; PRIESS, JR			SKN-1, A MATERNALLY EXPRESSED GENE REQUIRED TO SPECIFY THE FATE OF VENTRAL BLASTOMERES IN THE EARLY C-ELEGANS EMBRYO	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; DNA-BINDING; GERM-LINE; CELLULAR INTERACTIONS; NUCLEOTIDE-SEQUENCE; SPLICED LEADER; DORSAL PROTEIN; LOCUS; LOCALIZATION	By the 4-cell stage of C. elegans embryogenesis, a ventral blastomere, called EMS, is already committed to producing pharyngeal and intestinal cell types. Recessive, maternal-effect mutations in the gene skn-1 prevent EMS from producing both pharyngeal and intestinal cells. In skn-1 mutant embryos, EMS instead produces hypodermal cells and body wall muscle cells, much like its sister blastomere. Genetic analysis suggests that the skn-1 gene product is also required post-embryonically for development of the intestine. We have cloned and sequenced the skn-1 gene and describe sequence similarities to the basic regions of bZIP transcription factors. We propose that the maternally expressed skn-1 gene product acts to specify the fate of the EMS blastomere.			BOWERMAN, B (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104, USA.							ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Ausubel F, 1989, MOL REPROD DEV, V1, P146; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON AR, 1986, P NATL ACAD SCI USA, V85, P4397; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DELACONCHA A, 1988, GENETICS, V118, P499; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GREENWALD IS, 1980, GENETICS, V96, P147; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREENWALD IS, 1985, CELL, V45, P583; HARI T, 1989, GENE DEV, V3, P2083; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MANSUKHANI A, 1988, MOL GEN GENET, V211, P121, DOI 10.1007/BF00338402; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MENEELY PM, 1979, GENETICS, V92, P99; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MUSSLEINVOLHARD C, 1991, DEVELOPMENT S, V1, P1; OBRIEN SJ, 1990, GENETIC MAPS, V5; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P991; WALLACE JC, 1991, IN PRESS CABIOS; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; Waterston R., 1988, NEMATODE C ELEGANS, P281; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	75	315	327	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1061	1075		10.1016/0092-8674(92)90078-Q	http://dx.doi.org/10.1016/0092-8674(92)90078-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547503				2022-12-24	WOS:A1992HK67400010
J	FU, YH; PIZZUTI, A; FENWICK, RG; KING, J; RAJNARAYAN, S; DUNNE, PW; DUBEL, J; NASSER, GA; ASHIZAWA, T; DEJONG, P; WIERINGA, B; KORNELUK, R; PERRYMAN, MB; EPSTEIN, HF; CASKEY, CT				FU, YH; PIZZUTI, A; FENWICK, RG; KING, J; RAJNARAYAN, S; DUNNE, PW; DUBEL, J; NASSER, GA; ASHIZAWA, T; DEJONG, P; WIERINGA, B; KORNELUK, R; PERRYMAN, MB; EPSTEIN, HF; CASKEY, CT			AN UNSTABLE TRIPLET REPEAT IN A GENE RELATED TO MYOTONIC MUSCULAR-DYSTROPHY	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE	Synthetic oligonucleotides containing GC-rich triplet sequences were used in a scanning strategy to identify unstable genetic sequences at the myotonic dystrophy (DM) locus. A highly polymorphic GCT repeat was identified and found to be unstable, with an increased number of repeats occurring in DM patients. In the case of severe congenital DM, the paternal triplet allele was inherited unaltered while the maternal, DM-associated allele was unstable. These studies suggest that the mutational mechanism leading to DM is triplet amplification, similar to that occurring in the fragile X syndrome. The triplet repeat sequence is within a gene (to be referred to as myotonin-protein kinase), which has a sequence similar to protein kinases.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,NIJMEGEN,NETHERLANDS; CHILDRENS HOSP EASTERN ONTARIO,DEPT GENET,OTTAWA K1H 8L1,ONTARIO,CANADA; BAYLOR COLL MED,DEPT CARDIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; University of Ottawa; Children's Hospital of Eastern Ontario; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; PIZZUTI, Antonio/0000-0003-3245-1925	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01-RR00350] Funding Source: Medline; NHGRI NIH HHS [P30-HG00210] Funding Source: Medline; NHLBI NIH HHS [P50HL42267-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GOLDSTEIN JL, 1989, METABOLIC BASIS INHE, pCH48; HALL JG, 1990, AM J HUM GENET, V46, P357; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSEN G, IN PRESS GENOMICS; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LUPSKI JR, UNPUB; Myotonic Dystrophy Foundation, 2017, VOIC PAT REP MYOT DY; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SHUTLER G, IN PRESS GENOMICS; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609	21	1275	1329	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1256	1258		10.1126/science.1546326	http://dx.doi.org/10.1126/science.1546326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546326				2022-12-24	WOS:A1992HG67700043
J	GAO, WQ; LIU, XL; HATTEN, ME				GAO, WQ; LIU, XL; HATTEN, ME			THE WEAVER GENE ENCODES A NONAUTONOMOUS SIGNAL FOR CNS NEURONAL DIFFERENTIATION	CELL			English	Article							GRANULE CELL MIGRATION; CEREBELLAR CORTEX; MOUSE CEREBELLUM; POSTNATAL-DEVELOPMENT; MUTANT MICE; RAT-BRAIN; INVITRO; DROSOPHILA; ASTROGLIA; ADHESION	In the neurological mutant mouse weaver, CNS precursor cells in the external germinal layer (EGL) of the cerebellar cortex proliferate normally, but fail to differentiate and die in the proliferative zone. To examine the autonomy of expression of the weaver gene, we carried out cell-mixing experiments in vitro. In homo-typic, reaggregate cultures, weaver EGL precursor cells expressed the general neuronal markers N-CAM, L1, and MAP2, but failed to express the late neuronal antigens TAG-1 and astrotactin, to extend neurites or to migrate on glial fibers. After reaggregation with wild-type EGL precursor cells, weaver precursor cells extended neurites equivalent in length to wild-type cells, migrated along astroglial fibers, and expressed TAG-1 and astrotactin. Rescue of neurite production was also achieved by the addition of membranes from, but not by medium conditioned by wild-type cells. These findings suggest that the weaver gene acts nonautonomously, encoding a membrane-associated ligand that induces EGL neuronal differentiation.			GAO, WQ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PATHOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015429] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15429] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BAIRD D, 1992, IN PRESS J NEUROSCI; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAJAL SR, 1889, REV TRIM HISTOL NORM; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; EDMONDSON JC, 1988, J CELL BIOL, V106, P505, DOI 10.1083/jcb.106.2.505; FISHELL G, 1991, DEVELOPMENT, V113, P755; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GOLDOWITZ D, 1989, NEURON, V2, P1565, DOI 10.1016/0896-6273(89)90045-7; GOLDOWITZ D, 1982, J NEUROSCI, V2, P1474; GREGORY WA, 1988, J NEUROSCI, V8, P1728; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1984, DEV BRAIN RES, V13, P309, DOI 10.1016/0165-3806(84)90166-4; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTEN ME, 1987, J CELL BIOL, V104, P1353, DOI 10.1083/jcb.104.5.1353; HATTEN ME, 1984, J CELL BIOL, V98, P193, DOI 10.1083/jcb.98.1.193; HATTEN ME, 1984, J NEUROSCI, V4, P1163; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HATTEN ME, 1978, EXP CELL RES, V113, P111, DOI 10.1016/0014-4827(78)90092-7; HIS W, 1989, ABHANDL MATH PHYS KO, V26, P313; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; HUBER G, 1984, J NEUROSCI, V4, P151; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Le Douarin N.M., 1982, NEURAL CREST; LUND RD, 1985, NEUROSCI LETT, V61, P221, DOI 10.1016/0304-3940(85)90428-8; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARTINEZARIAS A, 1988, NATURE, V336, P348; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RATHJEN FG, 1984, EMBO J, V3, P1; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAUER FC, 1935, J COMP NEUROL, V63, P12; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SMEYNE RJ, 1991, ANAT EMBRYOL, V183, P213; SOTELO C, 1974, BRAIN RES, V77, P484, DOI 10.1016/0006-8993(74)90636-2; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5; THIERY JP, 1977, J BIOL CHEM, V252, P6841; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; WILLINGER M, 1985, DEV BIOL, V107, P156, DOI 10.1016/0012-1606(85)90384-7; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMAMOTO M, 1986, J NEUROSCI, V6, P3676; 1970, ANAT REC, V166, P257	60	103	105	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					841	854		10.1016/0092-8674(92)90028-B	http://dx.doi.org/10.1016/0092-8674(92)90028-B			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547486				2022-12-24	WOS:A1992HH74800004
J	CHOW, RH; VONRUDEN, L; NEHER, E				CHOW, RH; VONRUDEN, L; NEHER, E			DELAY IN VESICLE FUSION REVEALED BY ELECTROCHEMICAL MONITORING OF SINGLE SECRETORY EVENTS IN ADRENAL CHROMAFFIN CELLS	NATURE			English	Article							PATCH-CLAMP TECHNIQUES; TRANSMITTER RELEASE; CALCIUM DIFFUSION; CHANNELS; MEMBRANE; FACILITATION; VOLTAMMETRY; EXOCYTOSIS; ELECTRODES; SQUID	IN synapses, a rise in presynaptic intracellular calcium leads to secretory vesicle fusion in less than a millisecond, as indicated by the short delay from excitation to postsynaptic signal 1-4 . In nonsynaptic secretory cells, studies at high time resolution have been limited by the lack of a detector as fast and sensitive as the postsynaptic membrane. Electrochemical methods may be sensitive enough to detect catecholamines released from single vesicles 5,6. Here, we show that under voltage-clamp conditions, stochastically occurring signals can be recorded from adrenal chromaffin cells using a carbon-fibre electrode as an electrochemical detector. These signals obey statistics characteristic for quantal release; however, in contrast to neuronal transmitter release, secretion occurs with a significant delay after short step depolarizations. Furthermore, we identify a pedestal or 'foot' at the onset of unitary events which may represent the slow leak of catecholamine molecules out of a narrow 'fusion pore' before the pore dilates for complete exocytosis.	MAX PLANCK INST BIOPHYS CHEM,POSTFACH 2841,W-3400 GOTTINGEN,GERMANY	Max Planck Society			Chow, Robert/B-8155-2013; Neher, Erwin/A-2109-2013					ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; ARMSTRONGJAMES M, 1979, J NEUROSCI METH, V1, P279, DOI 10.1016/0165-0270(79)90039-6; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; Crank J., 1975, MATH DIFFUSION; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DETOLEDO GA, 1990, J GEN PHYSIOL, V95, P397, DOI 10.1085/jgp.95.3.397; DUCHEN MR, 1991, J PHYSIOL-LONDON, V426, P5; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jackson J., 1975, CLASSICAL ELECTRODYN; KATZ B, 1965, J PHYSIOL-LONDON, V181, P656, DOI 10.1113/jphysiol.1965.sp007790; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARSDEN CA, 1988, NEUROSCIENCE, V25, P389, DOI 10.1016/0306-4522(88)90247-3; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	28	727	744	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					60	63		10.1038/356060a0	http://dx.doi.org/10.1038/356060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538782				2022-12-24	WOS:A1992HG60200055
J	BURATOWSKI, S; ZHOU, H				BURATOWSKI, S; ZHOU, H			TRANSCRIPTION FACTOR-IID MUTANTS DEFECTIVE FOR INTERACTION WITH TRANSCRIPTION FACTOR-IIA	SCIENCE			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; SCHIZOSACCHAROMYCES-POMBE; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; FUNCTIONAL DOMAINS; GENE; BOX	Transcription factor IID (TFIID) recognizes the TATA element of promoters transcribed by RNA polymerase II (RNAPII) and serves as the base for subsequent association by other general transcription factors and RNAPII. The carboxyl-terminal domain of TFIID is highly conserved and contains an imperfect repetition of a 60-amino acid sequence. These repeats are separated by a region rich in bask amino acids. Mutagenesis of the lysines in this region resulted in a conditional phenotype in vivo, and the mutant proteins were defective for interactions with transcription factor IIA in vitro. Binding of TFIID to DNA was unaffected. These results suggest that the basic domain of TFIID is important for protein-protein interactions.			BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [R29-GM46498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURATOWSKI S, UNPUB; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; EISENMANN DM, 1989, CELL, V58, P1193; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	40	92	93	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1130	1132		10.1126/science.1546314	http://dx.doi.org/10.1126/science.1546314			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546314				2022-12-24	WOS:A1992HF63200042
J	GRENFELL, BT; PRICE, OF; ALBON, SD; CLUTTONBROCK, TH				GRENFELL, BT; PRICE, OF; ALBON, SD; CLUTTONBROCK, TH			OVERCOMPENSATION AND POPULATION-CYCLES IN AN UNGULATE	NATURE			English	Article							ECOLOGICAL-SYSTEMS; DENSITY DEPENDENCE; MODELS; CHAOS	ALTHOUGH theoretical studies show that overcompensatory density-dependent mechanisms can potentially generate regular or chaotic fluctuations in animal numbers, the majority of realistic single-species models of invertebrate populations are not overcompensatory enough to cause sustained population cycles 1-3. The possibility that overcompensation may generate cycles or chaos in vertebrate populations has seldom been considered. Here we show that highly overcompensating density-dependent mortality can generate recurrent population crashes consistent with those observed in a naturally limited population of Soay sheep. The observed interval of three or more years between crashes points to sharp 'focusing' of mortality over a narrow range of population density.			GRENFELL, BT (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		ALBON, Stephen D/C-6304-2011; Price, Owen F/H-4033-2012	ALBON, Stephen D/0000-0002-0811-1333; Price, Owen F/0000-0001-5327-568X				ATKIN M, 1989, STATISTICAL MODELLIN; BELLOWS TS, 1981, J ANIM ECOL, V50, P139, DOI 10.2307/4037; BULMER MG, 1974, J ANIM ECOL, V43, P701, DOI 10.2307/3532; CLARK CW, 1976, J MATH BIOL, V3, P381, DOI 10.1007/BF00275067; Clutton-Brock T. H., 1989, RED DEER HIGHLANDS; CLUTTONBROCK TH, 1985, J ANIM ECOL, V54, P831, DOI 10.2307/4381; CLUTTONBROCK TH, 1991, J ANIM ECOL, V60, P593, DOI 10.2307/5300; Fowler C.W., 1987, Current Mammalogy, V1, P401; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; HASSELL MP, 1976, J ANIM ECOL, V45, P471, DOI 10.2307/3886; HASSELL MP, 1988, ECOLOGICAL CONCEPTS, P147; Holden AV., 1986, CHAOS; Hudson P.J., 1990, P5; LESLIE PH, 1948, BIOMETRIKA, V35, P213, DOI 10.2307/2332342; LESLIE PH, 1945, BIOMETRIKA, V33, P183, DOI 10.2307/2332297; PETERSON RO, 1984, SCIENCE, V224, P1350, DOI 10.1126/science.224.4655.1350; SCHAFFER WM, 1985, ECOLOGY, V66, P93, DOI 10.2307/1941309; SCHAFFER WM, 1986, TRENDS ECOL EVOL, V1, P58, DOI 10.1016/0169-5347(86)90018-2; SMITH JM, 1973, ECOLOGY, V54, P384, DOI 10.2307/1934346; Varley G.C., 1973, INSECT POPULATION EC; WATSON A, 1984, J ANIM ECOL, V53, P639, DOI 10.2307/4541; [No title captured]; [No title captured]	23	107	108	0	55	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					823	826		10.1038/355823a0	http://dx.doi.org/10.1038/355823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538761				2022-12-24	WOS:A1992HF63600055
J	MAHER, J; REILLY, M; DALY, L; HUTCHINSON, M				MAHER, J; REILLY, M; DALY, L; HUTCHINSON, M			PLANTAR POWER - REPRODUCIBILITY OF THE PLANTAR RESPONSE	BRITISH MEDICAL JOURNAL			English	Article							PURE MOTOR HEMIPLEGIA		ADELAIDE HOSP,DEPT NEUROL,DUBLIN 8,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PUBL HLTH MED & EPIDEMIOL,DUBLIN 4,IRELAND	Trinity College Dublin; University College Dublin			hutchinson, michael/H-3508-2019	Maher, John/0000-0001-8275-8488; hutchinson, michael/0000-0002-8675-1723				CHOKROVERTY S, 1975, ARCH NEUROL-CHICAGO, V32, P647, DOI 10.1001/archneur.1975.00490510103014; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; LEESTMA JE, 1976, J NEUROL NEUROSUR PS, V39, P877, DOI 10.1136/jnnp.39.9.877; MCCANCE C, 1968, J CHRON DIS, V21, P369, DOI 10.1016/0021-9681(68)90045-3; NATHAN PW, 1955, J NEUROL NEUROSUR PS, V18, P250, DOI 10.1136/jnnp.18.4.250	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					482	482		10.1136/bmj.304.6825.482	http://dx.doi.org/10.1136/bmj.304.6825.482			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547422	Bronze, Green Published			2022-12-24	WOS:A1992HF55500025
J	HU, SL; ABRAMS, K; BARBER, GN; MORAN, P; ZARLING, JM; LANGLOIS, AJ; KULLER, L; MORTON, WR; BENVENISTE, RE				HU, SL; ABRAMS, K; BARBER, GN; MORAN, P; ZARLING, JM; LANGLOIS, AJ; KULLER, L; MORTON, WR; BENVENISTE, RE			PROTECTION OF MACAQUES AGAINST SIV INFECTION BY SUBUNIT VACCINES OF SIV ENVELOPE GLYCOPROTEIN GP160	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; EXPRESSION; LENTIVIRUS	Simian immunodeficiency virus (SIV) is a primate lentivirus related to human immunodeficiency viruses and is an etiologic agent for acquired immunodeficiency syndrome (AIDS)-like diseases in macaques. To date, only inactivated whole virus vaccines have been shown to protect macaques against SIV infection. Protective immunity was elicited by recombinant subunit vaccines. Four Macaca fascicularis were immunized with recombinant vaccinia virus expressing SIVmne gpl60 and were boosted with gpl60 produced in baculovirus-infected cells. All four animals were protected against an intravenous challenge of the homologous virus at one to nine animal-infectious doses. These results indicate that immunization with viral envelope antigens alone is sufficient to elicit protective immunity against a primate immunodeficiency virus. The combination immunization regimen, similar to one now being evaluated in humans as candidate human immunodeficiency virus (HIV)-1 vaccines, appears to be an effective way to elicit such immune responses.	UNIV WASHINGTON,SEATTLE,WA 98195; DUKE UNIV,MED CTR,DURHAM,NC 27710; NCI,FREDERICK,MD 21701	University of Washington; University of Washington Seattle; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HU, SL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121, USA.		Hu, Shiu-Lok/A-3196-2008	Hu, Shiu-Lok/0000-0003-4336-7964	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028065] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [R01 AI28065, AI26503] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, UNPUB; BENVENISTE RE, 1990, J MED PRIMATOL, V19, P351; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; BENVENISTE RE, 1989, J MED PRIMATOL, V18, P287; BENVENISTE RE, UNPUB; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P1; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; COONEY EL, 1990, 6TH INT C AIDS SAN F; CRANAGE MP, IN PRESS SCIENCE; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; GARDNER MB, IN PRESS AIDS; GRAHAM BS, 1991, 7TH INT C AIDS FLOR; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; HU SL, 1988, J VIROL, V62, P176, DOI 10.1128/JVI.62.1.176-180.1988; HU SL, 1986, NATURE, V320, P537, DOI 10.1038/320537a0; HU SL, 1987, J VIROL, V61, P3617, DOI 10.1128/JVI.61.11.3617-3620.1987; HU SL, 1991, AIDS RES HUM RETROV, V7, P615, DOI 10.1089/aid.1991.7.615; HU SL, IN PRESS AIDS RES HU; HU SL, IN PRESS J MED PRIMA; KOFF WC, 1990, AIDS S1, V4, P179; KULLER LR, UNPUB; LANGLOIS AJ, 1991, AIDS RES HUM RETROV, V7, P713, DOI 10.1089/aid.1991.7.713; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; MURPHEYCORB M, 1991, AIDS, V5, P655, DOI 10.1097/00002030-199106000-00003; MURPHEYCORB M, 1990, 3RD ANN M NAT COOP V; SHAFFERMAN A, 1991, P NATL ACAD SCI USA, V88, P7126, DOI 10.1073/pnas.88.16.7126; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0	32	327	350	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					456	459		10.1126/science.1531159	http://dx.doi.org/10.1126/science.1531159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1531159				2022-12-24	WOS:A1992HA59000038
J	FERRIS, JP; ERTEM, G				FERRIS, JP; ERTEM, G			OLIGOMERIZATION OF RIBONUCLEOTIDES ON MONTMORILLONITE - REACTION OF THE 5'-PHOSPHORIMIDAZOLIDE OF ADENOSINE	SCIENCE			English	Article							BOND FORMATION; RNA; TETRAHYMENA; NUCLEOTIDES; CATALYSIS; ENZYME	The regiospecific formation of oligomers from unblocked monomers in aqueous solution is one of the central tenets in research on the.origins of life on earth. Direct experimental support for this hypothesis has been obtained in studies of the condensation of the 5'-phosphorimidazolide of adenosine (ImpA) with itself and with P1,P2-diadenosine-5',5'-pyrophosphate (AppA) in water in the presence of a montmorillonite clay. Oligomers of up to ten nucleotides in length are formed. Analysis of the trimers, tetramers, and pentamers formed from a 9:1 ImpA:AppA mixture has shown that 85% of the bonds formed are 3',5'-linked and that any 2',5'-linkages present are at the phosphodiester bond next to the 3'-terminus of the oligomers.			FERRIS, JP (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ASHIRBEKOVA DT, 1989, BIOORG KHIM+, V15, P166; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BERNAL JD, 1949, P PHYS SOC LOND A, V62, P537, DOI 10.1088/0370-1298/62/9/301; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; ERTEM G, 1990, ORIGINS LIFE EVOL BI, V20, P279; FAKHRAI H, 1981, J MOL EVOL, V17, P295, DOI 10.1007/BF01795751; FERRIS JP, 1989, ORIGINS LIFE EVOL B, V19, P609, DOI 10.1007/BF01808121; FERRIS JP, 1989, ORIGINS LIFE EVOL B, V19, P165, DOI 10.1007/BF01808150; GRZESKOWIAK K, 1986, J MOL EVOL, V23, P287, DOI 10.1007/BF02100635; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KORNBERG A, 1991, DNA REPLICATION, P310; LOHRMANN R, 1979, J MOL EVOL, V14, P243, DOI 10.1007/BF01732491; LOHRMANN R, 1978, J MOL EVOL, V11, P17, DOI 10.1007/BF01768021; LUEBKE KJ, 1991, J AM CHEM SOC, V113, P7447, DOI 10.1021/ja00019a066; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PONNAMPERUMA C, 1982, ORIGINS LIFE, V12, P98; Reid T.W., 1971, ENZYMES, V4, P373; RODRIGUEZ L, 1991, J MOL EVOL, V32, P101, DOI 10.1007/BF02515382; SAWAI H, 1975, J AM CHEM SOC, V97, P3532, DOI 10.1021/ja00845a050; SAWAI H, 1989, B CHEM SOC JPN, V62, P2018, DOI 10.1246/bcsj.62.2018; SLEEPER HL, 1979, J MOL EVOL, V12, P357, DOI 10.1007/BF01732030; SOFFHILL R, 1970, J ORG CHEM, V35, P2881; STRIBLING R, 1991, J CHROMATOGR, V338, P474; SULSTON J, 1968, P NATL ACAD SCI USA, V59, P726, DOI 10.1073/pnas.59.3.726; YOUNG B, 1989, J MOL EVOL, V29, P480, DOI 10.1007/BF02602919; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	27	210	212	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1387	1389		10.1126/science.1529338	http://dx.doi.org/10.1126/science.1529338			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529338				2022-12-24	WOS:A1992JL61200029
J	GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN				GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN			CONTROLLING CARDIAC CHAOS	SCIENCE			English	Article							DYNAMICS; CELLS	The extreme sensitivity to initial conditions that chaotic systems display makes them unstable and unpredictable. Yet that same sensitivity also makes them highly susceptible to control, provided that the developing chaos can be analyzed in real time and that analysis is then used to make small control interventions. This strategy has been used here to stabilize cardiac arrhythmias induced by the drug ouabain in rabbit ventricle. By administering electrical stimuli to the heart at irregular times determined by chaos theory, the arrhythmia was converted to periodic beating.	USN,CTR SURFACE WARFARE,SILVER SPRING,MD 20903; COLL WOOSTER,DEPT PHYS,WOOSTER,OH 44691; UNIV CALIF LOS ANGELES,DEPT MED CARDIOL,LOS ANGELES,CA 90024	United States Department of Defense; United States Navy; College of Wooster; University of California System; University of California Los Angeles	GARFINKEL, A (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90024, USA.		Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036729, K04HL001890, R01HL044880] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44880, KO4 HL01890, R01 HL36729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNSDORF MF, 1991, CURR OPIN CARDIOL, V6, P3, DOI 10.1097/00001573-199102000-00002; BOWEN R, 1971, T AM MATH SOC, V154, P377, DOI 10.2307/1995452; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; CRUTCHFIELD JP, 1986, SCI AM, V255, P46, DOI 10.1038/scientificamerican1286-46; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; GARFINKEL AJ, 1991, LIFE SCI, V48, P2189, DOI 10.1016/0024-3205(91)90153-3; GOLLUB JP, 1975, PHYS REV LETT, V35, P927, DOI 10.1103/PhysRevLett.35.927; GREBOGI C, 1988, PHYS REV A, V37, P1711, DOI 10.1103/PhysRevA.37.1711; GUCKENHEIMER J, 1983, NONLINEAR OSCILLATIO, P105; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HUNT ER, 1991, PHYS REV LETT, V67, P53; Kaplan JL, 1979, LECT NOTES MATH, P228; Moon F.C., 1987, CHAOTIC VIBRATIONS; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; ROSSLER OE, 1978, NATURE, V271, P89, DOI 10.1038/271089a0; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; SHINBROT T, 1992, PHYS REV LETT, V68, P2863, DOI 10.1103/PhysRevLett.68.2863; SHINBROT T, 1990, PHYS REV LETT, V65, P3215, DOI 10.1103/PhysRevLett.65.3215; WEISS J, 1982, AM J PHYSIOL, V243, pH318, DOI 10.1152/ajpheart.1982.243.2.H318; WEISS JN, 1987, CARDIAC ARRHYTHMIAS, P83	23	703	727	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1230	1235		10.1126/science.1519060	http://dx.doi.org/10.1126/science.1519060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519060	Green Submitted			2022-12-24	WOS:A1992JL05000019
J	LI, M; JAN, YN; JAN, LY				LI, M; JAN, YN; JAN, LY			SPECIFICATION OF SUBUNIT ASSEMBLY BY THE HYDROPHILIC AMINO-TERMINAL DOMAIN OF THE SHAKER POTASSIUM CHANNEL	SCIENCE			English	Article							MUSCLE ACETYLCHOLINE-RECEPTOR; DELAYED-RECTIFIER PROPERTIES; K+ CHANNEL; FUNCTIONAL EXPRESSION; RAT-BRAIN; XENOPUS-OOCYTES; HETEROMULTIMERIC CHANNELS; EXCITABLE CELLS; MAMMALIAN BRAIN; EPSILON SUBUNIT	The functional heterogeneity of potassium channels in eukaryotic cells arises not only from the multiple potassium channel genes and splice variants but also from the combinatorial mixing of different potassium channel polypeptides to form heteromultimeric channels with distinct properties. One structural element that determines the compatibility of different potassium channel polypeptides in subunit assembly has now been localized to the hydrophilic amino-terminal domain. A Drosophila Shaker B (ShB) potassium channel truncated polypeptide that contains only the hydrophilic amino-terminal domain can form a homomultimer; the minimal requirement for the homophilic interaction has been localized to a fragment of 114 amino acids. Substitution of the amino-terminal domain of a distantly related mammalian potassium channel polypeptide (DRK1) with that of ShB permits the chimeric DRK1 polypeptide to coassemble with ShB.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LI, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P567; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COPELAND BR, 1982, J BIOL CHEM, V257, P5065; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; DREWE JA, 1992, J NEUROSCI, V12, P538; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1991, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; LATORRE R, 1984, ANNU REV PHYSIOL, V46, P485; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Li M., UNPUB; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PAK MD, 1991, J NEUROSCI, V11, P869; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	69	413	423	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1225	1230		10.1126/science.1519059	http://dx.doi.org/10.1126/science.1519059			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519059				2022-12-24	WOS:A1992JL05000018
J	YARNELL, WS; ROBERTS, JW				YARNELL, WS; ROBERTS, JW			THE PHAGE-LAMBDA GENE-Q TRANSCRIPTION ANTITERMINATOR BINDS DNA IN THE LATE GENE PROMOTER AS IT MODIFIES RNA-POLYMERASE	CELL			English	Article							ESCHERICHIA-COLI; TERNARY COMPLEXES; BACTERIOPHAGE-LAMBDA; Q-PROTEIN; 3' END; INITIATION; SITE; TERMINATION; ELONGATION; PRODUCT	The bacteriophage lambda-gene Q transcription antiterminator modifies RNA polymerase during an extended pause in elongation at nt +16 and +17 of the phage late gene promoter transcript. We show here that Q binds a specific DNA site between the -10 and -35 elements of the promoter as it interacts with the enzyme. We show that the pause must reflect a specialized elongation structure that is receptive to modification by Q, because Q does not bind to RNA polymerase stopped artificially after transcribing 16 nt of mutant DNA that does not encode the natural pause. Footprinting shows that RNA polymerase in the paused complex makes distinctive interactions with DNA in the region where Q binds; binding of Q, in turn, changes the footprint both at the Q-binding site and in the transcription bubble. Binding of Q to the paused transcription complex is stabilized by the transcription factor NusA, as expected from the dependence of lambda-Q-mediated antitermination on NusA.			YARNELL, WS (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEVEGVAR HEN, 1986, CELL, V47, P259; Friedman DI., 1983, LAMBDA 2, P21; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1982, CELL, V30, P637, DOI 10.1016/0092-8674(82)90260-4; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GUO HC, 1991, J BACTERIOL, V173, P1554, DOI 10.1128/jb.173.4.1554-1560.1991; GUO HC, 1990, THESIS CORNELL U ITH; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SPENCER CA, 1990, ONCOGENE, V5, P777; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	32	80	80	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1181	1189		10.1016/0092-8674(92)90639-T	http://dx.doi.org/10.1016/0092-8674(92)90639-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535556				2022-12-24	WOS:A1992JA43100012
J	GAMER, J; BUJARD, H; BUKAU, B				GAMER, J; BUJARD, H; BUKAU, B			PHYSICAL INTERACTION BETWEEN HEAT-SHOCK PROTEINS DNAK, DNAJ, AND GRPE AND THE BACTERIAL HEAT-SHOCK TRANSCRIPTION FACTOR-SIGMA(32)	CELL			English	Article							ESCHERICHIA-COLI DNAK; METAL CHELATE ADSORBENT; BACTERIOPHAGE-LAMBDA; RNA-POLYMERASE; CELLULAR DEFECTS; REGULATORY GENE; SIGMA-32; REPLICATION; MUTANTS; INITIATION	Genetic evidence indicates central roles for Hsp70 chaperones in the regulation of heat shock gene expression. This regulatory function has been postulated for Escherichia coli to rely on the direct association of DnaK (Hsp70) with the heat shock transcription factor sigma-32. This report presents evidence for the physical association of DnaK, DnaJ, and GrpE chaperones with sigma-32 in vivo. Surprisingly, an interaction of DnaJ with sigma-32 exists that is distinguishable from an interaction of DnaK and GrpE with sigma-32: addition of ATP disrupts the association of DnaK and GrpE with sigma-32, but not the association of DnaJ with sigma-32. Furthermore, DnaJ-sigma-32 and DnaK-sigma-32 associations occur independent of DnaK and DnaJ, respectively. These results suggest distinct regulatory functions of DnaJ and DnaK/GrpE.			GAMER, J (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,INF 282,W-6900 HEIDELBERG,GERMANY.			Bukau, Bernd/0000-0003-0521-7199				ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANATHAN J, 1986, SCIENCE, V232, P252; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COWING DW, 1985, P NATL ACAD SCI USA, V82, P2679, DOI 10.1073/pnas.82.9.2679; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ERICKSON JW, 1987, GENE DEV, V1, P419, DOI 10.1101/gad.1.5.419; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KRUGER JH, 1984, P NATL ACAD SCI USA, V81, P1499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZER M, 1988, THESIS U HEIDELBERG; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Miller J.H., 1972, EXPT MOL GENETICS; Morimoto RI, 1990, STRESS PROTEINS BIOL; NAGAI H, 1990, J BACTERIOL, V172, P2710, DOI 10.1128/jb.172.5.2710-2715.1990; NEIDHARDT FC, 1987, CELLULAR MOL BIOL, V2, P1334; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; Silhavy T.J., 1984, EXPT GENE FUSIONS; SKELLY S, 1988, P NATL ACAD SCI USA, V85, P5497, DOI 10.1073/pnas.85.15.5497; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860	50	278	281	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					833	842		10.1016/0092-8674(92)90294-M	http://dx.doi.org/10.1016/0092-8674(92)90294-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1534276				2022-12-24	WOS:A1992HW83800013
J	ARIEFF, AI; AYUS, JC; FRASER, CL				ARIEFF, AI; AYUS, JC; FRASER, CL			HYPONATREMIA AND DEATH OR PERMANENT BRAIN-DAMAGE IN HEALTHY-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							ANTI-DIURETIC HORMONE; WATER-INTOXICATION; NORMAL INFANTS; RAT-BRAIN; HYPONATREMIA; VASOPRESSIN; PATHOGENESIS; MORBIDITY; SURGERY; SALINE	Objective - To determine if hyponatraemia causes permanent brain damage in healthy children and, if so, if the disorder is primarily limited to females, as occurs in adults. Design - Prospective clinical case study of 16 affected children and a review of 24 412 consecutive surgical admissions at one medical centre. Patients - 16 children (nine male, seven female; age 7 (SD 5) years) with generally minor illness were electively hospitalised for primary care. Consultation was obtained for the combination of respiratory arrest with symptomatic hyponatraemia (serum sodium concentration less-than-or-equal-to 128 mmol/l). Main outcome measures - Presence, gender distribution, and classification of permanent brain damage in children with symptomatic hyponatraemia in both prospective and retrospective studies. Results - By retrospective evaluation the incidence of postoperative hyponatraemia among 24 412 patients was 0.34% (83 cases) and mortality of those afflicted was 8.4% (seven deaths). In the prospective population the serum sodium concentration on admission was 138 (SD 2) mmol/l. From three to 120 inpatient hours after hypotonic fluid administration patients developed progressive lethargy, headache, nausea, and emesis with an explosive onset of respiratory arrest. At the time serum sodium concentration was 115 (7) mmol/l and arterial oxygen tension 6 (1.5) kPa. The hyponatraemia was primarily caused by extrarenal loss of electrolytes with replacement by hypotonic fluids. All 16 patients had cerebral oedema detected at either radiological or postmortem examination. All 15 patients not treated for their hyponatraemia in a timely manner either died or were permanently incapacitated by brain damage. The only patient treated in a timely manner was alive but mentally retarded. Conclusions - Symptomatic hyponatraemia can result in a high morbidity in children of both genders, which is due in large part to inadequate brain adaptation and lack of timely treatment.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; BAYLOR COLL MED,HOUSTON,TX 77030	University of California System; University of California San Francisco; Baylor College of Medicine					PHS HHS [R01 08575-01A2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abramow M, 1984, Adv Nephrol Necker Hosp, V13, P1; ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ASHRAF N, 1981, AM J MED, V70, P1163, DOI 10.1016/0002-9343(81)90822-6; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7; AYUS JC, 1991, J AM SOC NEPHROL, V2, P278; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; COWLEY D M, 1988, Australian and New Zealand Journal of Surgery, V58, P485, DOI 10.1111/j.1445-2197.1988.tb06240.x; CRAWFORD JD, 1964, PEDIATR CLIN N AM, V11, P1029; CRUMPACK.RW, 1973, NEUROLOGY, V23, P1251, DOI 10.1212/WNL.23.11.1251; DAVID R, 1981, PEDIATRICS, V68, P349; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; DELCASTILLO AR, 1987, BRAIN RES, V416, P113, DOI 10.1016/0006-8993(87)91502-2; FARACI FM, 1990, AM J PHYSIOL, V258, pR94, DOI 10.1152/ajpregu.1990.258.1.R94; FRASER CL, 1989, AM J PHYSIOL, V256, pR880, DOI 10.1152/ajpregu.1989.256.4.R880; FRASER CL, 1989, AM J PHYSIOL, V257, pE284, DOI 10.1152/ajpendo.1989.257.2.E284; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; GARCIA JH, 1980, BRAIN EDEMA PATHOLOG, P147; GROSS PA, 1987, EUR J CLIN INVEST, V17, P123, DOI 10.1111/j.1365-2362.1987.tb02391.x; GUERRA M, 1987, NEUROSCI LETT, V78, P97, DOI 10.1016/0304-3940(87)90568-4; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; JENNETT B, 1972, LANCET, V1, P734; JUDD BA, 1987, ACTA PAEDIATR SCAND, V76, P385; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; MELTON JE, 1983, AM J PHYSIOL, V244, pR724, DOI 10.1152/ajpregu.1983.244.5.R724; MELTON JE, 1987, AM J PHYSIOL, V252, pF661, DOI 10.1152/ajprenal.1987.252.4.F661; NATTIE EE, 1981, J APPL PHYSIOL, V51, P1086, DOI 10.1152/jappl.1981.51.5.1086; Rosenberg G A, 1990, Adv Neurol, V52, P149; ROSOMOFF HL, 1963, ARCH NEUROL-CHICAGO, V9, P36; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; TIEN R, IN PRESS AM J MED; VARAVITHYA W, 1967, J PEDIATR-US, V71, P269, DOI 10.1016/S0022-3476(67)80087-8; WIDDOWSON EM, 1960, BIOCHEM J, V77, P30, DOI 10.1042/bj0770030; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168; [No title captured]; 1990, STAT ABSTR US 1990, P110; 1991, AM HOSPITAL ASS HOSP, P20; 1985, SAS USERS GUIDE BASI; 1990, STAT ABSTR US 1990, P16	42	269	283	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1218	1222		10.1136/bmj.304.6836.1218	http://dx.doi.org/10.1136/bmj.304.6836.1218			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515791	Green Published, Bronze			2022-12-24	WOS:A1992HT96400021
J	HARTWIG, JH; THELEN, M; ROSEN, A; JANMEY, PA; NAIRN, AC; ADEREM, A				HARTWIG, JH; THELEN, M; ROSEN, A; JANMEY, PA; NAIRN, AC; ADEREM, A			MARCKS IS AN ACTIN FILAMENT CROSS-LINKING PROTEIN REGULATED BY PROTEIN-KINASE-C AND CALCIUM CALMODULIN	NATURE			English	Article							PROMINENT CELLULAR SUBSTRATE; MOLECULAR-CLONING; PHORBOL ESTERS; 87-KDA PROTEIN; GROWTH-FACTORS; PHOSPHORYLATION; BRAIN; MYRISTOYLATION; PURIFICATION; EXPRESSION	AGONISTS that stimulate protein kinase C (PKC) induce profound changes in cell morphology correlating with the reorganization of submembranous actin 1,2, but no direct connection between PKC and actin assembly has been identified 3. The myristoylated, alanine-rich C kinase substrate (MARCKS) binds calmodulin 4,5 and is a predominant, specific substrate of PKC which is phosphorylated during macrophage and neutrophil activation 6-8, growth factor-dependent mitogenesis 9,10 and neurosecretion 11,12; it is redistributed from plasma membrane to cytoplasm when phosphorylated 13-15 and is involved in leukocyte motility 14,15. Here we report that MARCKS is a filamentous (F) actin crosslinking protein, with activity that is inhibited by PKC-mediated phosphorylation and by binding to calcium-calmodulin. MARCKS may be a regulated crossbridge between actin and the plasma membrane, and modulation of the actin crosslinking activity of the MARCKS protein by calmodulin and phosphorylation represents a potential convergence of the calcium-calmodulin and PKC signal transduction pathways in the regulation of the actin cytoskeleton.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021; BRIGHAM & WOMENS HOSP,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Rockefeller University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Nairn, Angus/0000-0002-7075-0195				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; Berne B., 1976, DYNAMIC LIGHT SCATTE; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; CORWIN HL, 1983, DEV BIOL, V99, P61, DOI 10.1016/0012-1606(83)90254-3; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P641, DOI 10.1083/jcb.86.2.641; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHETERLINE P, 1986, J MUSCLE RES CELL M, V7, P405, DOI 10.1007/BF01753583; SNYDERMAN R, 1987, REV INFECT DIS, V9, P562; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YIN HL, 1980, J BIOL CHEM, V255, P9494	31	664	673	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					618	622		10.1038/356618a0	http://dx.doi.org/10.1038/356618a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560845				2022-12-24	WOS:A1992HP03100054
J	BAIN, JD; SWITZER, C; CHAMBERLIN, AR; BENNER, SA				BAIN, JD; SWITZER, C; CHAMBERLIN, AR; BENNER, SA			RIBOSOME-MEDIATED INCORPORATION OF A NONSTANDARD AMINO-ACID INTO A PEPTIDE THROUGH EXPANSION OF THE GENETIC-CODE	NATURE			English	Article							SITE-SPECIFIC INCORPORATION; ENZYMATIC INCORPORATION; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; BASE PAIR; RNA; DNA; ANALOG; STOP	ONE serious limitation facing protein engineers is the availability of only 20 'proteinogenic' amino acids encoded by natural messenger RNA. The lack of structural diversity among these amino acids restricts the mechanistic and structural issues that can be addressed by site-directed mutagenesis. Here we describe a new technology for incorporating non-standard amino acids into polypeptides by ribosome-based translation. In this technology, the genetic code is expanded through the creation of a 65th codon-anticodon pair from unnatural nucleoside bases having non-standard hydrogen-bonding patterns 1,2. This new codon-anticodon pair efficiently supports translation in vitro to yield peptides containing a non-standard amino acid. The versatility of the ribosome as a synthetic tool offers new possibilities for protein engineering, and compares favourably with another recently described approach in which the genetic code is simply rearranged to recruit stop codons to play a coding role 3-9.	UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND	University of California System; University of California Riverside; Swiss Federal Institutes of Technology Domain; ETH Zurich	BAIN, JD (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BAIN JD, 1991, TETRAHEDRON, V14, P2389; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FLUCK MM, 1977, MOL GEN GENET, V151, P137, DOI 10.1007/BF00338688; HECHT SM, 1978, J BIOL CHEM, V253, P4517; JUKES TH, 1991, NATURE, V352, P575, DOI 10.1038/352575a0; KAST P, 1991, THESIS ETH ZURICH; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LYTTLE MH, 1991, J ORG CHEM, V56, P4608, DOI 10.1021/jo00015a010; MANTSCH HH, 1975, BIOCHEMISTRY-US, V14, P5593, DOI 10.1021/bi00697a009; MCBRIDE LJ, 1986, J AM CHEM SOC, V108, P2040, DOI 10.1021/ja00268a052; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; ROBERTS JW, 1975, J BIOL CHEM, V250, P5530; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROESSER JR, 1986, BIOCHEMISTRY-US, V25, P6361, DOI 10.1021/bi00369a003; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; SMRT J, 1970, J BIOL CHEM, V245, P2753; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; VALLE RPC, 1988, FEBS LETT, V235, P1, DOI 10.1016/0014-5793(88)81225-0	27	260	290	2	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					537	539		10.1038/356537a0	http://dx.doi.org/10.1038/356537a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560827				2022-12-24	WOS:A1992HN23100064
J	TSIPOURAS, P; DELMASTRO, R; SARFARAZI, M; LEE, B; VITALE, E; CHILD, AH; GODFREY, M; DEVEREUX, RB; HEWETT, D; STEINMANN, B; VILJOEN, D; SYKES, BC; KILPATRICK, M; RAMIREZ, F				TSIPOURAS, P; DELMASTRO, R; SARFARAZI, M; LEE, B; VITALE, E; CHILD, AH; GODFREY, M; DEVEREUX, RB; HEWETT, D; STEINMANN, B; VILJOEN, D; SYKES, BC; KILPATRICK, M; RAMIREZ, F			GENETIC-LINKAGE OF THE MARFAN-SYNDROME, ECTOPIA LENTIS, AND CONGENITAL CONTRACTURAL ARACHNODACTYLY TO THE FIBRILLIN GENES ON CHROMOSOME-15 AND CHROMOSOME-5	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; CLASSIFICATION; MICROFIBRILS; DIAGNOSIS; DISORDERS	Background. The large glycoprotein fibrillin is a structural component of elastin-containing microfibrils found in many tissues. The Marfan syndrome has been linked to the fibrillin gene on chromosome 15, but congenital contractural arachnodactyly, which shares some of the physical features of the syndrome, has been linked to the fibrillin gene on chromosome 5. Methods. Using specific markers for the fibrillin genes, we performed genetic linkage analysis in 28 families with the Marfan syndrome and 8 families with four phenotypically related disorders - congenital contractural arachnodactyly (3 families), ectopia lentis (2), mitral-valve prolapse syndrome (2), and annuloaortic ectasia (1). Results. Genetic linkage was established between the Marfan syndrome and only the fibrillin gene on chromosome 15, with a maximum lod score of 25.6 (odds for linkage, 10(25-6):1). Ectopia lentis was also linked to the fibrillin gene on chromosome 15, whereas congenital contractural arachnodactyly was linked to the fibrillin gene on chromosome 5. There was no linkage of mitral-valve prolapse to the fibrillin gene on chromosome 5; studies of chromosome 15 were not informative. Annuloaortic ectasia was not linked to either fibrillin gene. Conclusions. The Marfan syndrome appears to be caused by mutations in a single fibrillin gene on chromosome 15. Diagnosis of the Marfan syndrome by genetic linkage and analysis is now feasible in many families.	UNIV BIRMINGHAM,DEPT CLIN GENET,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV LONDON,ST GEORGES MED SCH,DEPT CARDIOL SCI,LONDON,ENGLAND; UNIV NEBRASKA,HOLLISTER RES LABS,OMAHA,NE 68182; CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021; UNIV OXFORD,INST MOLEC MED,OXFORD,ENGLAND; UNIV ZURICH,DEPT PEDIAT,CH-8006 ZURICH,SWITZERLAND; UNIV CAPE TOWN,DEPT HUMAN GENET,CAPE TOWN,SOUTH AFRICA	University of Birmingham; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; St Georges University London; University of London; University of Nebraska System; Cornell University; University of Oxford; University of Zurich; University of Cape Town	TSIPOURAS, P (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06030, USA.		vitale, emilia/A-5282-2011; Hayward, Caroline/M-8818-2016; Ramesar, Raj S/I-6941-2015	Hayward, Caroline/0000-0002-9405-9550; Ramesar, Raj S/0000-0001-5688-1634; Vitale, Emilia/0000-0003-4651-3875; Byers, Peter H./0000-0001-7786-7030	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR038648, R01AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARROYO MAR, 1985, CLIN GENET, V27, P570; BEALS RK, 1971, J BONE JOINT SURG AM, VA 53, P987, DOI 10.2106/00004623-197153050-00013; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MCKUSICK VA, 1988, MENDELIAN INHERITANC; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; OTT J, 1983, ANN HUM GENET, V47, P311, DOI 10.1111/j.1469-1809.1983.tb01001.x; OTT J, 1974, AM J HUM GENET, V26, P588; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; TSIPOURAS P, 1991, P NATL ACAD SCI USA, V88, P4486, DOI 10.1073/pnas.88.10.4486; WEIL D, 1988, J BIOL CHEM, V263, P8561; [No title captured]	22	230	235	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					905	909		10.1056/NEJM199204023261401	http://dx.doi.org/10.1056/NEJM199204023261401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542340				2022-12-24	WOS:A1992HL26100001
J	REYNOLDS, BA; WEISS, S				REYNOLDS, BA; WEISS, S			GENERATION OF NEURONS AND ASTROCYTES FROM ISOLATED CELLS OF THE ADULT MAMMALIAN CENTRAL-NERVOUS-SYSTEM	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; RAT-BRAIN; PROLIFERATION; DIFFERENTIATION; LOCALIZATION; INVITRO	Neurogenesis in the mammalian central nervous system is believed to end in the period just after birth; in the mouse striatum no new neurons are produced after the first few days after birth. In this study, cells isolated from the striatum of the adult mouse brain were induced to proliferate in vitro by epidermal growth factor. The proliferating cells initially expressed nestin, an intermediate filament found in neuroepithelial stem cells, and subsequently developed the morphology and antigenic properties of neurons and astrocytes. Newly generated cells with neuronal morphology were immunoreactive for gamma-aminobutyric acid and substance P, two neurotransmitters of the adult striatum in vivo. Thus, cells of the adult mouse striatum have the capacity to divide and differentiate into neurons and astrocytes.	UNIV CALGARY,FAC MED,DEPT PATHOL,NEUROSCI RES GRP,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA; UNIV CALGARY,FAC MED,DEPT PHARMACOL & THERAPEUT,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary; University of Calgary								ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; BAYER SA, 1985, ANN NY ACAD SCI, V457, P163, DOI 10.1111/j.1749-6632.1985.tb20804.x; BIRECREE E, 1991, DEV BRAIN RES, V60, P145, DOI 10.1016/0165-3806(91)90043-I; CATTANEO E, 1991, TRENDS NEUROSCI, V14, P338, DOI 10.1016/0166-2236(91)90158-Q; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FREDERIKSEN K, 1988, J NEUROSCI, V8, P144; GENSBURGER C, 1987, FEBS LETT, V217, P1, DOI 10.1016/0014-5793(87)81230-9; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; JACOBSON M, 1991, DEV NEUROBIOL, P41; KAY AR, 1986, J NEUROSCI METH, V16, P227, DOI 10.1016/0165-0270(86)90040-3; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; REYNOLDS BR, UNPUB; SIMPSON DL, 1982, J NEUROSCI RES, V8, P453, DOI 10.1002/jnr.490080233; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; WILLIAMS JS, 1991, NEUROSCIENCE, V43, P437, DOI 10.1016/0306-4522(91)90306-9; [No title captured]	23	4116	4708	13	361	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1707	1710		10.1126/science.1553558	http://dx.doi.org/10.1126/science.1553558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553558				2022-12-24	WOS:A1992HK81200039
J	KTISTAKIS, NT; LINDER, ME; ROTH, MG				KTISTAKIS, NT; LINDER, ME; ROTH, MG			ACTION OF BREFELDIN-A BLOCKED BY ACTIVATION OF A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN	NATURE			English	Article							INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; RAT HEPATOCYTES; CELLS; MASTOPARAN	IN many mammalian cells brefeldin A interferes with mechanisms that keep the Golgi apparatus separate from the endoplasmic reticulum 1-8. The earliest effect of brefeldin A is release of the coat protein beta-COP from the Golgi 9-11. This release is blocked by pretreatment with GTP-gamma-S or AlF4- (ref. 12). The AlF4- ion activates heterotrimeric C proteins 13 but not proteins of the ras superfamily 14, suggesting that a heterotrimeric G protein might control membrane transfer from the endoplasmic reticulum to the Golgi. We report here that mastoparan, a peptide that activates heterotrimeric G proteins 15,16, promotes binding of beta-COP to Golgi membranes in vitro and antagonizes the effect of brefeldin A on beta-COP in perforated cells and on isolated Golgi membranes. This inhibition is greatly diminished if cells are pretreated with pertussis toxin before perforation., Thus, a heterotrimeric G protein of the G(i)/G(o) subfamily regulates association of coat components with Golgi membranes.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KTISTAKIS, NT (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Roth, Michael/0000-0002-9056-332X				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992	23	101	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1992	356	6367					344	346		10.1038/356344a0	http://dx.doi.org/10.1038/356344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549178				2022-12-24	WOS:A1992HK79400066
J	MELSKI, JW				MELSKI, JW			PRICE OF TECHNOLOGY - A BLIND SPOT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROGRESSIVE SYSTEMIC-SCLEROSIS				MELSKI, JW (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC,DEPT DERMATOL 4K5,MARSHFIELD,WI 54449, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; BLACK CM, 1990, ANN RHEUM DIS, V49, P735, DOI 10.1136/ard.49.9.735; BLOOM BS, 1988, INQUIRY-J HEALTH CAR, V25, P383; CHARLEY MR, 1983, J INVEST DERMATOL, V80, pA328; EDELSON R, 1991, PROG DERMATOL, V25, P1; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; JAMPEL RM, 1991, ARCH DERMATOL, V127, P1673, DOI 10.1001/archderm.127.11.1673; JOHNSON HA, 1991, JAMA-J AM MED ASSOC, V265, P2229, DOI 10.1001/jama.265.17.2229; KALALEH MB, 1986, CLIN EXP RHEUMATOL, V4, P367; LOHR K, 1986, MED CARE, V24, pS72; RELMAN AS, 1989, NEW ENGL J MED, V320, P33; ROOK AH, 1989, YALE J BIOL MED, V62, P639; ROOK AH, 1992, ARCH DERMATOL, V128, P1517; STEEN VD, 1982, ANN INTERN MED, V97, P652, DOI 10.7326/0003-4819-97-5-652; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; WINSLOW R, 1991, WALL STREET J   1105, P73	18	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1516	1518						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538542				2022-12-24	WOS:A1992HH48800034
J	FUHRMAN, JA; MCCALLUM, K; DAVIS, AA				FUHRMAN, JA; MCCALLUM, K; DAVIS, AA			NOVEL MAJOR ARCHAEBACTERIAL GROUP FROM MARINE PLANKTON	NATURE			English	Article							RIBOSOMAL-RNA SEQUENCES; PHYLOGENETIC ANALYSIS; SARGASSO SEA; BACTERIOPLANKTON; BACTERIA; MICROORGANISMS; FILTRATION	MARINE bacteria often dominate the plankton biomass 1,2 and are responsible for much of the cycling of organic matter 3, but bacterial diversity is poorly understood because conventional identification methods (requiring culturing) miss about 99% of the organisms 4,5. Recent advances permit characterization of microbial communities by analysis of 16S ribosomal RNA gene sequences directly from biomass without the need to culture the organisms 6; such studies from surface ocean samples have found only eubacteria 7-10, not archaebacteria (or Archaea 11), which are profoundly different 12. Here we report 16S rRNA sequences obtained from Pacific Ocean bacterioplankton samples collected from depths of 100 m and 500 m. Among these we found sequences only distantly related to those of any organisms previously characterized by 16S rRNA sequences, with similarities to the nearest such relatives (extreme thermophiles) approximately the same as those between animals and plants. We suggest that these sequences are from a previously undescribed archaebacterial group that may have diverged from the ancestors of characterized organisms very early in evolution.			FUHRMAN, JA (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA.		Fuhrman, Jed A/C-6461-2013	Fuhrman, Jed A/0000-0002-2361-1985				AMANN R, 1991, NATURE, V351, P161, DOI 10.1038/351161a0; AZAM F, 1983, MAR ECOL PROG SER, V10, P257, DOI 10.3354/meps010257; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BRITSCHGI TB, 1991, APPL ENVIRON MICROB, V57, P1707, DOI 10.1128/AEM.57.6.1707-1713.1991; CHO BC, 1988, NATURE, V332, P441, DOI 10.1038/332441a0; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FERGUSON RL, 1984, APPL ENVIRON MICROB, V47, P49, DOI 10.1128/AEM.47.1.49-55.1984; FUHRMAN JA, 1988, APPL ENVIRON MICROB, V54, P1426, DOI 10.1128/AEM.54.6.1426-1429.1988; FUHRMAN JA, 1989, MAR ECOL PROG SER, V57, P207, DOI 10.3354/meps057207; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1990, APPL ENVIRON MICROB, V56, P2572, DOI 10.1128/AEM.56.8.2572-2575.1990; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; HOLM-HANSEN OSMUND, 1965, J CONS CONS PERMS INTE EXPLOR MER, V30, P3; JANNASCH HW, 1959, LIMNOL OCEANOGR, V4, P128, DOI 10.4319/lo.1959.4.2.0128; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; LEE S, 1990, APPL ENVIRON MICROB, V56, P739, DOI 10.1128/AEM.56.3.739-746.1990; LEE SH, 1991, LIMNOL OCEANOGR, V36, P1277, DOI 10.4319/lo.1991.36.7.1277; Maniatis T., 1982, MOL CLONING; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; PACE NR, 1986, ADV MICROB ECOL, V9, P1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMIDT TM, 1991, J BACTERIOL, V173, P4371, DOI 10.1128/JB.173.14.4371-4378.1991; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	26	652	687	1	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					148	149		10.1038/356148a0	http://dx.doi.org/10.1038/356148a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545865				2022-12-24	WOS:A1992HH73100057
J	KANG, C; ZHANG, XH; RATLIFF, R; MOYZIS, R; RICH, A				KANG, C; ZHANG, XH; RATLIFF, R; MOYZIS, R; RICH, A			CRYSTAL-STRUCTURE OF 4-STRANDED OXYTRICHA TELOMERIC DNA	NATURE			English	Article							POLYINOSINIC ACID; POLYGUANYLIC ACID; FIBER DIFFRACTION; 3' TERMINUS; X-RAY	The sequence d(GGGGTTTTGGGG) from the 3' over-hang of the Oxytricha telomere has been crystallized and its three-dimensional structure solved to 2.5 angstrom resolution. The oligonucleotide forms hairpins, two of which join to make a four-stranded helical structure with the loops containing four thymine residues at either end. The guanine residues are held together by cyclic hydrogen bonding and an ion is located in the centre. The four guanine residues in each segment have a glycosyl conformation that alternates between anti and syn. There are two four-stranded molecules in the asymmetric unit showing that the structure has some intrinsic flexibility.	UNIV CALIF LOS ALAMOS SCI LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	KANG, C (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.			Kang, ChulHee/0000-0002-0693-7860				ARNOTT S, 1974, BIOCHEM J, V141, P537, DOI 10.1042/bj1410537; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, X PLOR MANUAL; CECH TR, 1988, NATURE, V332, P777, DOI 10.1038/332777a0; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARE DR, 1986, BIOCHEMISTRY-US, V25, P5341, DOI 10.1021/bi00366a053; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HOWARD FB, 1982, BIOCHEMISTRY-US, V21, P6736, DOI 10.1021/bi00269a019; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; LIPPS HJ, 1980, P NATL ACAD SCI-BIOL, V77, P4104, DOI 10.1073/pnas.77.7.4104; LIPPS HJ, 1982, P NATL ACAD SCI-BIOL, V79, P2495, DOI 10.1073/pnas.79.8.2495; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; RICH A, 1958, BIOCHIM BIOPHYS ACTA, V29, P502, DOI 10.1016/0006-3002(58)90005-2; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1991, J BIOMOLEC STRUCT DY, V8, P201; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WANG Y, IN PRESS J MOL BIOL; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZIMMERMAN SB, 1976, J MOL BIOL, V106, P663, DOI 10.1016/0022-2836(76)90257-6; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	30	547	554	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					126	131		10.1038/356126a0	http://dx.doi.org/10.1038/356126a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545863				2022-12-24	WOS:A1992HH73100049
J	NATHKE, IS; HEUSER, J; LUPAS, A; STOCK, J; TURCK, CW; BRODSKY, FM				NATHKE, IS; HEUSER, J; LUPAS, A; STOCK, J; TURCK, CW; BRODSKY, FM			FOLDING AND TRIMERIZATION OF CLATHRIN SUBUNITS AT THE TRISKELION HUB	CELL			English	Article							LIGHT-CHAINS; HEAVY-CHAIN; COATED VESICLES; BINDING; PROTEINS; INTERNALIZATION; SEQUENCE; RECEPTOR; PURIFICATION; INTERMEDIATE	The triskelion shape of the clathrin molecule enables it to form the polyhedral protein network that covers clathrin-coated pits and vesicles. Domains within the clathrin heavy chain that are responsible for maintaining triskelion shape and function were identified and localized. Sequences that mediate trimerization are distal to the carboxyl terminus and are adjacent to a domain that mediates both light chain binding and clathrin assembly. Structural modeling predicts that within this domain, the region of heavy chain-light chain interaction is a bundle of three or four a helices. These studies establish a low resolution model of clathrin subunit folding in the central portion (hub) of the triskelion, thus providing a basis for future mutagenesis experiments.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL); Princeton University; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	NATHKE, IS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.			Nathke, Inke/0000-0003-2420-4385; Brodsky, Frances/0000-0002-1334-9258	NIGMS NIH HHS [GM-29647, GM-38093, GM-26691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093, R01GM029647, P50GM026691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; BLANK GS, 1986, EMBO J, V5, P2087, DOI 10.1002/j.1460-2075.1986.tb04470.x; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FERRIN TE, 1987, J MOL GRAPHICS, V6, P2; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; JACKSON AP, 1988, J BIOL CHEM, V263, P16688; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAKELA O, 1986, HDB EXPT IMMUNOLOGY, V1; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; OHALLORAN TJ, 1992, IN PRESS DNA CELL BI; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x	45	135	136	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					899	910		10.1016/0092-8674(92)90033-9	http://dx.doi.org/10.1016/0092-8674(92)90033-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547490				2022-12-24	WOS:A1992HH74800009
J	HENDRA, TJ; MARSHALL, AJ				HENDRA, TJ; MARSHALL, AJ			INCREASED PRESCRIPTION OF THROMBOLYTIC TREATMENT TO ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION ASSOCIATED WITH AUDIT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS STREPTOKINASE; THERAPY; MORTALITY	Objectives - To assess prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction and the incidence of side effects. Design - Retrospective analysis of prescriptions during five months (first audit) followed by prospective analysis of uptake of treatment during five months after interventions in clinical management; prospective assessment of adverse events during thrombolytic treatment. Setting - Coronary care unit of large district general hospital. Patients - 110 patients aged greater-than-or-equal-to 65 with subsequently proved acute myocardial infarction admitted in first audit and 119 admitted in the second. Main outcome measures - Site of infarct, prescription of thrombolysis treatment, reasons for nonprescription, complications. Results - Before intervention thrombolytic treatment was prescribed to 13/110 (12%) patients with subsequently confirmed myocardial infarction and after intervention to 55/119 (46%) patients (p < 0.01). In the first audit no patients with angina received thrombolytic treatment whereas 13/79 (16%) were treated in the second audit. Increased prescription of thrombolytic treatment in the second audit was associated with significantly fewer exclusions owing to dyspepsia (p < 0.05) and unstated or unsatisfactory reasons (p < 0.01) Streptokinase infusions were completed uneventfully in 75% (48/64) and 77% (10/13) of patients with infarction and angina respectively. Side effects of treatment were more common in patients with inferior than with anterior infarcts (16/42 (30%) v 3/24 (13%), p < 0.05). Conclusions - Low rates of prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction were identified and corrected. Streptokinase treatment was associated with transient arrhythmias or hypotension in about a third of these patients with infarcts, particularly those with electrocardiographic changes in inferior leads.	DERRIFORD HOSP, DEPT CARDIOL, PLYMOUTH PL6 8DH, ENGLAND	Derriford Hospital								ALDRICH MS, 1985, JAMA-J AM MED ASSOC, V253, P1777, DOI 10.1001/jama.253.12.1777; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; KENNEDY JW, 1990, ANN INTERN MED, V113, P907, DOI 10.7326/0003-4819-113-12-907; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LEW AS, 1985, CIRCULATION, V72, P1321, DOI 10.1161/01.CIR.72.6.1321; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; PETCH MC, 1990, BMJ-BRIT MED J, V300, P483, DOI 10.1136/bmj.300.6723.483; SHAW C, 1990, MED AUDIT HOSPITAL H; SLEIGHT P, 1990, EUR HEART J, V11, P1; SMITH LDR, 1990, POSTGRAD MED J, V66, P263, DOI 10.1136/pgmj.66.774.263; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; WILCOX RG, 1988, LANCET, V2, P525; 1976, PUBLIC HLTH EUROPE, V5	18	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					423	425		10.1136/bmj.304.6824.423	http://dx.doi.org/10.1136/bmj.304.6824.423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547391	Green Published, Bronze			2022-12-24	WOS:A1992HE38900022
J	YIN, YX; TAINSKY, MA; BISCHOFF, FZ; STRONG, LC; WAHL, GM				YIN, YX; TAINSKY, MA; BISCHOFF, FZ; STRONG, LC; WAHL, GM			WILD-TYPE P53 RESTORES CELL-CYCLE CONTROL AND INHIBITS GENE AMPLIFICATION IN CELLS WITH MUTANT P53 ALLELES	CELL			English	Article							CHINESE-HAMSTER CELLS; DNA POLYMERASE-ALPHA; MAMMALIAN-CELLS; T-ANTIGEN; COLORECTAL TUMORIGENESIS; HIGH-SENSITIVITY; CANCER SYNDROME; OVARY CELLS; CAD GENE; PROTEIN	Loss of cell cycle control and acquisition of chromosomal rearrangements such as gene amplification often occur during tumor progression, suggesting that they may be correlated. We show here that the wild-type p53 allele is lost when fibroblasts from patients with the Li-Fraumeni syndrome (LFS) are passaged in vitro. Normal and LFS cells containing wild-type p53 arrested in G1 when challenged with the uridine biosynthesis inhibitor PALA and did not undergo PALA-selected gene amplification. The converse occurred in cells lacking wild-type p53 expression. Expression of wild-type p53 in transformants of immortal and tumor cells containing mutant p53 alleles restored G1 control and reduced the frequency of gene amplification to undetectable levels. These studies reveal that p53 contributes to a metabolically regulated G1 checkpoint, and they provide a model for understanding how abnormal cell cycle progression leads to the genetic rearrangements involved in tumor progression.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT EXPTL PEDIAT, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	YIN, YX (corresponding author), SALK INST, SAN DIEGO, CA 92186 USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P01CA34936] Funding Source: Medline; NIGMS NIH HHS [GM27754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BEISKER W, 1987, CYTOMETRY, V8, P235, DOI 10.1002/cyto.990080218; BIEDLER JL, 1988, CANCER RES, V48, P3179; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CHEN KC, 1989, HUM GENET, V82, P40, DOI 10.1007/BF00288269; CHENG J, 1992, CANCER RES, V52, P222; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Cleaver J E, 1989, Birth Defects Orig Artic Ser, V25, P61; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKI T, 1987, CANCER RES, V47, P5162; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLINTOFF WF, 1984, MOL CELL BIOL, V4, P69, DOI 10.1128/MCB.4.1.69; FULTS D, 1992, CANCER RES, V52, P674; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOZ B, 1989, MOL PHARMACOL, V36, P360; HAHN P, 1986, CANCER RES, V46, P4607; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNT JD, 1990, MOL CELL BIOL, V10, P823, DOI 10.1128/MCB.10.2.823; JAMES CD, 1988, CANCER RES, V48, P5546; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOYAMA H, 1982, MUTAT RES, V105, P433, DOI 10.1016/0165-7992(82)90190-7; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1987, CANCER RES, V47, P4229; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN WE, 1986, CHROMOSOMA, V93, P191, DOI 10.1007/BF00292737; MOYER JD, 1982, CANCER RES, V42, P4525; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P1507; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1982, TUMOR CELL HETEROGEN, P351; OTTO E, 1989, J BIOL CHEM, V264, P3390; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICE GC, 1987, P NATL ACAD SCI USA, V84, P9261, DOI 10.1073/pnas.84.24.9261; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STEIN WD, 1991, ADV CANCER RES, V56, P161; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TISTY T, 1982, GENE AMPLIFICATION, P231; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	89	1172	1183	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					937	948		10.1016/0092-8674(92)90244-7	http://dx.doi.org/10.1016/0092-8674(92)90244-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525830				2022-12-24	WOS:A1992JN78100009
J	WORMSER, GP; FORSETER, G; COOPER, D; NOWAKOWSKI, J; NADELMAN, RB; HOROWITZ, H; SCHWARTZ, I; BOWEN, SL; CAMPBELL, GL; GOLDBERG, NS				WORMSER, GP; FORSETER, G; COOPER, D; NOWAKOWSKI, J; NADELMAN, RB; HOROWITZ, H; SCHWARTZ, I; BOWEN, SL; CAMPBELL, GL; GOLDBERG, NS			USE OF A NOVEL TECHNIQUE OF CUTANEOUS LAVAGE FOR DIAGNOSIS OF LYME-DISEASE ASSOCIATED WITH ERYTHEMA MIGRANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NEEDLE ASPIRATION; BORRELIA-BURGDORFERI; CELLULITIS; LIDOCAINE; LESIONS; ADULTS	Objective.-Determining the microbial cause of cellulitis is often difficult. In this study, a novel two-needle lavage technique was used to culture Borrelia burgdorferi from the skin of suspected erythema migrans lesions. Design.-The yield of lavage cultures for B burgdorferi was compared with that of a 2-mm skin biopsy sample. Setting.-A Lyme disease diagnostic center located in an area in which Lyme disease is epidemic. Patients.-Forty-five patients with suspected erythema migrans who had not been treated with antimicrobial agents. Intervention.-Cutaneous lavage of the advancing edge of a suspected primary erythema migrans lesion was done for all 45 participants, 33 of whom also had a skin biopsy of the same lesion at an identical (14) or an adjacent (19) site. Main Outcome Measures.-Growth of B burgdorferi in in vitro culture. Results.-Lavage fluid cultures grew B burgdorferi in 13 (29%) of the 45 cases (95% confidence interval [CI], 16% to 44%). Among the 33 cases in which both lavage and skin biopsy cultures were done, the yield of lavage culture was less than that of biopsy culture (P<.09, 12/33 vs 20/33). If contaminated cultures are excluded, this difference is significant (P<.05, 12/30 vs 20/27). Conclusion.-Cutaneous lavage is a new diagnostic technique for recovery of B burgdorferi from erythema migrans lesions that has potential applicability to other types of cutaneous infections.	NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT DERMATOL,VALHALLA,NY 10595; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VECTOR BORNE INFECT DIS,FT COLLINS,CO 80522	New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center	WORMSER, GP (corresponding author), NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT MED,DIV INFECT DIS,ROOM 209SE,MACY PAVIL,VALHALLA,NY 10595, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041511] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41511] Funding Source: Medline; PHS HHS [200-91-0912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; HOOK EW, 1986, ARCH INTERN MED, V146, P295; MILLER MA, 1985, ARCH DERMATOL, V121, P1157, DOI 10.1001/archderm.121.9.1157; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NEWELL PM, 1988, J CLIN MICROBIOL, V26, P401, DOI 10.1128/JCM.26.3.401-404.1988; PAVIA CS, 1985, GENITOURIN MED, V61, P75; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; SCHMIDT RM, 1970, J INFECT DIS, V121, P597, DOI 10.1093/infdis/121.6.597; SCHWARTZ JJ, 1992, J BACTERIOL, V174, P3757, DOI 10.1128/JB.174.11.3757-3765.1992; SIGURDSSON AF, 1989, SCAND J INFECT DIS, V21, P537, DOI 10.3109/00365548909037882; UMAN SJ, 1975, ARCH INTERN MED, V135, P959, DOI 10.1001/archinte.135.7.959; 1990, MMWR, V39, P19	13	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1311	1313		10.1001/jama.268.10.1311	http://dx.doi.org/10.1001/jama.268.10.1311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507378				2022-12-24	WOS:A1992JL60800033
J	RAMAKRISHNAN, V; WHITE, SW				RAMAKRISHNAN, V; WHITE, SW			THE STRUCTURE OF RIBOSOMAL PROTEIN-S5 REVEALS SITES OF INTERACTION WITH 16S RIBOSOMAL-RNA	NATURE			English	Article							BACILLUS-STEAROTHERMOPHILUS RIBOSOME; ESCHERICHIA-COLI RIBOSOME; RNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; SUBUNITS; S5; GENES; RECONSTITUTION; MUTATIONS; SEQUENCE	UNDERSTANDING the process whereby the ribosome translates the genetic code into protein molecules will ultimately require high-resolution structural information, and we report here the first crystal structure of a protein from the small ribosomal subunit. This protein, S5, has a molecular mass of 17,500 and is highly conserved in all lifeforms1-4. The molecule contains two distinct alpha/beta-domains that have structural similarities to several other proteins that are components of ribonucleoprotein complexes. Mutations in S5 result in several phenotypes which suggest that S5 may have a role in translational fidelity and translocation. These include ribosome ambiguity or ram5, reversion from streptomycin dependence6 and resistance to spectinomycin6. Also, a cold-sensitive, spectinomycin-resistant mutant of S5 has been identified which is defective in initiation7. Here we show that these mutations map to two distinct regions of the molecule which seem to be sites of interaction with ribosomal RNA. A structure/function analysis of the molecule reveals discrepancies with current models8,9 of the 30S subunit.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	MRC Laboratory Molecular Biology; Duke University	RAMAKRISHNAN, V (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.		White, Stephen W/N-8164-2018	Ramakrishnan, V/0000-0002-4699-2194				ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; APPELT K, 1983, J BIOL CHEM, V258, P3328; ARNDT UW, 1985, METHOD ENZYMOL, V114, P472; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HELD WA, 1973, J BIOL CHEM, V248, P5720; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA M, 1984, J BIOL CHEM, V259, P1051; LAMBERT JM, 1983, BIOCHEMISTRY-US, V22, P3913, DOI 10.1021/bi00285a029; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LEIJONMARCK M, 1988, PROTEINS, V3, P243, DOI 10.1002/prot.340030405; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONTANDON PE, 1986, EMBO J, V5, P3705, DOI 10.1002/j.1460-2075.1986.tb04703.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOMURA M, 1987, COLD SPRING HARB SYM, V52, P653, DOI 10.1101/SQB.1987.052.01.075; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OSSWALD M, 1987, NUCLEIC ACIDS RES, V15, P3221, DOI 10.1093/nar/15.8.3221; PIEPERSBERG W, 1975, MOL GEN GENET, V143, P43, DOI 10.1007/BF00269419; PIEPERSBERG W, 1975, MOL GEN GENET, V140, P91, DOI 10.1007/BF00329777; RAMAKRISHNAN V, 1991, J BIOL CHEM, V266, P880; SCHOLZEN T, 1991, MOL GEN GENET, V228, P70, DOI 10.1007/BF00282450; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; WHITE SW, 1983, FEBS LETT, V163, P73, DOI 10.1016/0014-5793(83)81166-1; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; WITTMANNLIEBOLD B, 1978, FEBS LETT, V95, P91, DOI 10.1016/0014-5793(78)80059-3	33	147	155	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					768	771		10.1038/358768a0	http://dx.doi.org/10.1038/358768a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508272				2022-12-24	WOS:A1992JK69900057
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			INVESTIGATION OF LONG-TERM PROBLEMS AFTER OBSTETRIC EPIDURAL-ANESTHESIA	BRITISH MEDICAL JOURNAL			English	Article							INTRAMUSCULAR PETHIDINE; MATERNAL OPINION; ANALGESIA; LABOR; ANESTHESIA; BLOCK	Objective-To examine the association between obstetric epidural anaesthesia and subsequent long term problems. Design -Postal questionnaire on heath problems after childbirth linked to maternity case note data. Setting-Maternity hospital in Birmingham. Subjects-11 701 women who delivered their most recent child during 1978-85 and who returned completed questionnaires. Main outcome measures-Frequencies of long term symptoms after childbirth. Results-Compared with the 6935 women who did Dot have epidural anaesthesia the 4766 women who did more commonly experienced backache (903 (18.9%) with epidural v 731 (10.5%) without epidural), frequent headaches 220 (4.6%) v 199 (2.9%)), migraine (92 (1.9%) v 73 (1.1%)), neckache (116 (2.4%) v 112 (1-6%)), and tingling in hands or fingers (143 (3.0%) v 150 (2.2%)). The results could not be explained by correlated social or obstetric factors. The associations with head, neck, and hand symptoms were found only in women who reported backache. An excess of visual disturbances among women who had epidural anaesthesia (83 (1.7%) v 91 (1.3%); was present only in association with migraine, but excess of dizziness or fainting (102 (2.1%) v 109 (1.6%)) was independent of other symptoms. 26 women had numbness or tingling in the lower back, buttocks, and leg, of whom 23 had had epidural anaesthesia. Of 34 women with spinal headache, nine (five after accidental dural puncture; four after spinal block) reported long term headaches. Conclusions-These associations may indicate a causal sequence, although this cannot be proved from this type of study. Randomised trials of epidural anaesthesia are required to determine whether causal relations exist.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; CRAWFORD JS, 1985, ANAESTHESIA, V40, P1219, DOI 10.1111/j.1365-2044.1985.tb10664.x; Crawford JS, 1985, PRINCIPLES PRACTICE; HIBBARD BM, 1990, BRIT J OBSTET GYNAEC, V97, P402, DOI 10.1111/j.1471-0528.1990.tb01826.x; KITZINGER S, 1987, SOME WOMENS EXPERIEN; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1991, HLTH AFTER CHILDBIRT; MOORE J, 1974, ANAESTHESIA, V29, P537, DOI 10.1111/j.1365-2044.1974.tb00716.x; MORGAN BM, 1982, LANCET, V2, P808; PHILIPSEN T, 1990, EUR J OBSTET GYN R B, V34, P205, DOI 10.1016/0028-2243(90)90072-9; RAMANATHAN S, 1988, OBSTETRIC ANAESTHESI; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x	13	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1279	1282		10.1136/bmj.304.6837.1279	http://dx.doi.org/10.1136/bmj.304.6837.1279			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1535010	Bronze, Green Published			2022-12-24	WOS:A1992HV08600020
J	MANOLIO, TA; FURBERG, CD; WAHL, PW; TRACY, RP; BORHANI, NO; GARDIN, JM; FRIED, LP; OLEARY, DH; KULLER, LH				MANOLIO, TA; FURBERG, CD; WAHL, PW; TRACY, RP; BORHANI, NO; GARDIN, JM; FRIED, LP; OLEARY, DH; KULLER, LH			ELIGIBILITY FOR CHOLESTEROL REFERRAL IN COMMUNITY-DWELLING OLDER ADULTS - THE CARDIOVASCULAR-HEALTH-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						LIPOPROTEINS; CORONARY DISEASE; HYPERCHOLESTEROLEMIA; ANTILIPEMIC AGENTS; GERIATRICS; HEALTH SERVICES FOR THE AGED	CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RISK-FACTORS; SERUM-CHOLESTEROL; EDUCATION-PROGRAM; SOCIAL-CLASS; PREVALENCE; LEVEL	Objectives: To assess the proportion of community-dwelling adults aged 65 years or older who are eligible for referral for lipoprotein analysis and intervention according to the National Cholesterol Education Program (NCEP) guidelines. Design: Cross-sectional study based on examinations and questionnaires collected in 1989 and 1990. Setting: Four communities in the U.S. in the Cardiovascular Health Study (CHS), a study of risk factors for heart disease and stroke in older adults. Participants: A sample of 4810 men and women ages 65 to 100 randomly selected and recruited from Health Care Financing Administration Medicare eligibility lists for the four communities; not institutionalized, not wheelchair-bound, not currently receiving therapy for cancer, not currently taking lipid-lowering medications, and not having eaten in the preceding 9 hours. Measurements: Total cholesterol and lipoprotein analysis measured in all participants. Results: Total cholesterol levels were less than 5.17 mmol/L (200 mg/dL) in 37% of participants, 5.17 to 6.19 mmol/L (200 to 239 mg/dL) in 39%, and 6.20 mmol/L (240 mg/dL) or greater in 24%. Compared with their counterparts, older participants, especially those over 80 years of age, were more likely to have levels below 5.17 mmol/L, as were men, nonwhites, and those with coronary heart disease or two or more coronary heart disease risk factors (P < 0.008 for all values). Based on this screening measurement, 2174 participants were eligible for lipoprotein analysis, 80% were eligible for dietary or drug therapy using NCEP guidelines. Overall, 46% of CHS participants were eligible for lipoprotein analysis and 36% for intervention by NCEP guidelines, based on a single cholesterol measurement. Conclusion: A substantial proportion of older adults in this community sample were eligible for lipoprotein analysis and intervention. Prospective studies of elderly persons are needed to determine the risk for incident coronary heart disease according to NCEP classifications and the benefits of lipid-lowering treatments in persons in this age group so that intervention strategies may best be targeted to an appropriately high-risk group.	NHLBI, BETHESDA, MD 20892 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; GEISINGER MED CTR, DANVILLE, PA 17822 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; University of Vermont; University of California System; University of California Irvine; Johns Hopkins University; Geisinger Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MANOLIO, TA (corresponding author), UNIV WASHINGTON, CTR CARDIOVASC HLTH STUD COORDINAT, JD-30, 1107 NE 45TH ST, SUITE 530, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [N01-HC-85079, N01-HC-85081, N01-HC-85080] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085080, N01HC085079, N01HC085081] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON AJ, 1979, PREV MED, V8, P419, DOI 10.1016/0091-7435(79)90019-7; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; BURTON BT, 1985, INT J OBESITY, V9, P155; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Castelli W P, 1976, Hosp Pract, V11, P113; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DONAHUE RP, 1989, ARTERIOSCLEROSIS, V9, P656, DOI 10.1161/01.ATV.9.5.656; DRURY TF, 1985, NIH851468 PUBL, pVII1; FEINLEIB M, 1989, CIRCULATION, V79, P13; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULWOOD R, 1986, VITAL HLTH STATIS 11, V236; GARBER AM, 1991, ARCH INTERN MED, V151, P1089, DOI 10.1001/archinte.151.6.1089; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GARBER AM, 1989, GPO052003011514 OFF; HARLAN WR, 1989, PHS7 US DEP HLTH HUM; HARRIS T, 1990, CIRCULATION, V81, P714; KANNEL WB, 1986, CORONARY HEART DISEA, P60; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; Kuller L H, 1978, Adv Neurol, V19, P281; LILLIENFELD AM, 1980, F EPIDEMIOLOGY, P76; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; MANOLIO TA, 1991, IN PRESS ANN EPIDEMI; MCCALL M, 1979, ACTA MED SCAND, V206, P477; MOGADAM M, 1990, ARCH INTERN MED, V150, P1645, DOI 10.1001/archinte.150.8.1645; PALUMBO PJ, 1988, MAYO CLIN PROC, V63, P88, DOI 10.1016/S0025-6196(12)62672-X; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; 1990, VITAL STATISTICS U A, V2; 1980, NIH801257 NAT HEART, P76; 1989, DHHS PHS891232 NAT C, P102; 1989, DHHS PHS891232 NAT C, P96; 1959, STATISTICAL B METROP, V40, P1; 1987, VITAL HLTH STATIS 11, V238, P21	38	21	21	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					641	649		10.7326/0003-4819-116-8-641	http://dx.doi.org/10.7326/0003-4819-116-8-641			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546864				2022-12-24	WOS:A1992HN84400006
J	JOSHI, HC; PALACIOS, MJ; MCNAMARA, L; CLEVELAND, DW				JOSHI, HC; PALACIOS, MJ; MCNAMARA, L; CLEVELAND, DW			GAMMA-TUBULIN IS A CENTROSOMAL PROTEIN REQUIRED FOR CELL CYCLE-DEPENDENT MICROTUBULE NUCLEATION	NATURE			English	Article							LYSED MAMMALIAN-CELLS; HAMSTER OVARY CELLS; ALPHA-TUBULIN; ASPERGILLUS-NIDULANS; MITOTIC CENTERS; INITIATION; SPINDLE; IDENTIFICATION; FILAMENTS; ANTIBODY	Gamma-TUBULIN is a newly identified member of the tubulin family whose sequence is highly conserved from yeast to man. This minor microtubule protein is localized to the microtuble organizing centres 1-3 and a mutation in the gene encoding it produces a microtubuleless mitotic arrest in the filamentous fungus Aspergillus nidulans 4,5. Here we investigate the in vivo function of gamma-tubulin in mammalian cells using a synthetic peptide to generate a polyclonal antibody that binds to a highly conserved segment of gamma-tubulin. After microinjection into cultured mammalian cells, immunofluorescence localization revealed that this antibody binds to native centrosomes at all phases of the cell cycle. In the presence of the gamma-tubulin antibody, microtubules fail to regrow into cytoplasmic arrays after depolymerization induced by nocodazole or cold. Furthermore, cells injected immediately before or during mitosis fail to assemble a functional spindle. Thus in vivo gamma-tubulin is required for microtubule nucleation throughout the mammalian cell cycle.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	JOSHI, HC (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BAJER A, 1969, CHROMOSOMA, V27, P448, DOI 10.1007/BF00325682; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; ELLIOTT EM, 1986, MOL CELL BIOL, V6, P906, DOI 10.1128/MCB.6.3.906; HORIO T, 1991, J CELL SCI, V99, P693; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MCGILL M, 1975, J CELL BIOL, V67, P189, DOI 10.1083/jcb.67.1.189; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PEPPER DA, 1979, J CELL BIOL, V82, P585, DOI 10.1083/jcb.82.2.585; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER JA, 1975, J CELL BIOL, V67, P744, DOI 10.1083/jcb.67.3.744; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VENDRE DD, 1984, MOL BIOL CYTOSKELETO, P3; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	25	428	432	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					80	83		10.1038/356080a0	http://dx.doi.org/10.1038/356080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538786				2022-12-24	WOS:A1992HG60200062
J	LOMBARDI, V; PIAZZESI, G; LINARI, M				LOMBARDI, V; PIAZZESI, G; LINARI, M			RAPID REGENERATION OF THE ACTIN MYOSIN POWER STROKE IN CONTRACTING MUSCLE	NATURE			English	Article							STRIATED-MUSCLE; FIBERS; LENGTH; REFLECTIONS; DIFFRACTION; STIFFNESS; TENSION	AT the molecular level, muscle contraction is the result of cyclic interaction between myosin crossbridges, which extend from the thick filament, and the thin filament, which consists mainly of actin. The energy for work done by a single crossbridge during a cycle of attachment, generation of force, shortening and detachment is believed to be coupled to the hydrolysis of one molecule of ATP 1,2. The distance the actin filament slides relative to the myosin filament in one crossbridge cycle has been estimated as 12 nm by step-length perturbation studies on single fibres from frog muscle 3,4. The 'mechanical' power stroke of the attached crossbridge can therefore be defined as 12-nm shortening with a force profile like that shown by the quick recovery of force following a length perturbation. According to this definition, power strokes cannot be repeated faster than the overall ATPase rate. Here, however, we show that the power stroke can be regenerated much faster than expected from the ATPase rate. This contradiction can be resolved if, in the shortening muscle, the free energy of ATP hydrolysis is used in several actin-myosin interactions consisting of elementary power strokes each of 5-10 nm.			LOMBARDI, V (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,VIALE GB MORGAGNI 63,I-50134 FLORENCE,ITALY.			LINARI, MARCO/0000-0001-6512-4897				CECCHI G, 1987, PFLUG ARCH EUR J PHY, V409, P39, DOI 10.1007/BF00584747; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; CECCHI G, 1983, J PHYSIOL-LONDON, V345, pP146; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; GOLMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HOMSHER E, 1984, CONTRACTILE MECH MUS, P865; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1980, J PHYSIOL-LONDON, V305, pP15; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1980, NATURE, V284, P140, DOI 10.1038/284140a0; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P617; MATSUBARA I, 1975, NATURE, V255, P728, DOI 10.1038/255728a0; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; Woledge RC., 1985, ENERGETIC ASPECTS MU; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	20	183	185	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					638	641		10.1038/355638a0	http://dx.doi.org/10.1038/355638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538750				2022-12-24	WOS:A1992HD54700056
J	MENIKOFF, JA; SACHS, GA; SIEGLER, M				MENIKOFF, JA; SACHS, GA; SIEGLER, M			BEYOND ADVANCE DIRECTIVES - HEALTH-CARE SURROGATE LAWS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SELF-DETERMINATION ACT; LIVING WILLS; INTERVENTIONS; ATTITUDES; PROXY; LIFE				MENIKOFF, JA (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Areen J, 1991, Law Med Health Care, V19, P91; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; CAPLAN AL, 1991, GERONTOLOGIST, V31, P582; CAPRON AM, 1990, HASTINGS CENT REP, V20, P35, DOI 10.2307/3562537; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Goldman G M, 1989, Law Med Health Care, V17, P298; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HIGH DM, 1991, GERONTOLOGIST, V31, P611, DOI 10.1093/geront/31.5.611; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; Portman R M, 1991, J Health Hosp Law, V24, P311; RHODEN NK, 1988, HARVARD LAW REV, V102, P375, DOI 10.2307/1341384; Rouse F, 1991, Law Med Health Care, V19, P83; ROWLAND M, 1990, NY TIMES        1111, V3, P17; Sachs G.A., 1991, J CRIT ILLNESS, V6, P348; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	23	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1165	1169		10.1056/NEJM199210153271612	http://dx.doi.org/10.1056/NEJM199210153271612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528214				2022-12-24	WOS:A1992JT15300012
J	DITULLIO, M; SACCO, RL; GOPAL, A; MOHR, JP; HOMMA, S				DITULLIO, M; SACCO, RL; GOPAL, A; MOHR, JP; HOMMA, S			PATENT FORAMEN OVALE AS A RISK FACTOR FOR CRYPTOGENIC STROKE	ANNALS OF INTERNAL MEDICINE			English	Article						HEART SEPTAL DEFECTS, ATRIAL; CEREBROVASCULAR DISORDERS; RISK FACTORS; ECHOCARDIOGRAPHY; CEREBRAL INFARCTION	ATRIAL SEPTAL-DEFECTS; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TRANSCRANIAL DOPPLER ULTRASOUND; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSIS; EMBOLISM; EMBOLIZATION; PREVALENCE; ISCHEMIA; SHUNTS	Objective: To determine and compare the prevalence of patent foramen ovale in patients with stroke of undetermined origin (cryptogenic) and in patients with stroke of determined origin to assess the possible role of patent foramen ovale as a risk factor for cryptogenic stroke. Design: Cross-sectional study with nested case-control analysis. M Patients: A total of 146 patients (73 men, 73 women) with acute ischemic stroke referred to the echocardiography laboratory for evaluation. Setting: Neurovascular Unit and Echocardiography Laboratory, Columbia-Presbyterian Medical Center, New York, New York. Measurements: Patients were considered to have strokes of determined origin or cryptogenic strokes according to National Institute of Neurological Disorders and Stroke (NINDS) Stroke Data Bank criteria. The presence of patent foramen ovale was assessed by contrast echocardiography, performed blinded for type of stroke. The association between patent foramen ovale and type of stroke was tested after correcting for patients' demographic variables and stroke risk factors. Results: The overall prevalence of patent foramen ovale was 26 of 146 patients (18%; 95% CI, 11.4% to 24.6%). Patients with cryptogenic stroke (31%) had a significantly higher prevalence of patent foramen ovale than did patients with an identifiable cause of stroke (69%) in both the younger (< 55 years; 48% compared with 4%; P < 0.001) and the older (greater-than-or-equal-to 55 years; 38% compared with 8%; P < 0.001) age groups. Multiple logistic regression analysis was used to identify the presence of a patent foramen ovale as strongly associated with the diagnosis of cryptogenic stroke (odds ratio, 7.2; Cl, 2.4 to 21.7), irrespective of patient age and other stroke risk factors. Conclusions: Patients with cryptogenic stroke have a higher prevalence of patent foramen ovale than patients with stroke of determined cause in all age groups, even after correcting for the presence of recognized stroke risk factors. This identifies patent foramen ovale as a risk factor for cryptogenic stroke. Regardless of patient age, contrast echocardiography should be considered when the cause of stroke is unknown.	COLUMBIA PRESBYTERIAN MED CTR,DIV CARDIOL,P&S 9-441,630 W 168TH ST,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital			Mohr, J/AAO-9694-2020; Sacco, Ralph/Y-9278-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027517] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS27517] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; BILLER J, 1987, ARCH NEUROL-CHICAGO, V44, P740, DOI 10.1001/archneur.1987.00520190046016; BOMMER WJ, 1984, J AM COLL CARDIOL, V3, P6, DOI 10.1016/S0735-1097(84)80423-4; BOROW KM, 1990, NEW ENGL J MED, V323, P1698, DOI 10.1056/NEJM199012133232409; Breslow N, 1980, STATISTICAL METHODS, V32; DITULLIO M, 1991, CIRCULATION, V84, P451; DUBOURG O, 1986, ARCH MAL COEUR VAISS, V79, P193; GROSS CR, 1986, ARCH NEUROL-CHICAGO, V43, P893, DOI 10.1001/archneur.1986.00520090031012; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HART RG, 1983, STROKE, V14, P110, DOI 10.1161/01.STR.14.1.110; HARVEY JR, 1986, ANN INTERN MED, V105, P695, DOI 10.7326/0003-4819-105-5-695; HOFMANN T, 1990, LANCET, V336, P1421; JEANRENAUD X, 1990, SCHWEIZ MED WSCHR, V120, P823; JONES HR, 1983, ANN NEUROL, V13, P314, DOI 10.1002/ana.410130315; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LOSCALZO J, 1986, AM HEART J, V112, P141, DOI 10.1016/0002-8703(86)90692-7; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MOHR JP, 1988, NEW ENGL J MED, V318, P1197, DOI 10.1056/NEJM198805053181810; MOHR JP, 1984, INT ANGIOL, V3, P431; NEMEC JJ, 1991, AM J CARDIOL, V68, P1498, DOI 10.1016/0002-9149(91)90285-S; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; ROCCHINI AP, 1990, CIRCULATION, V82, P1044, DOI 10.1161/01.CIR.82.3.1044; ROSENOW EC, 1981, MAYO CLIN PROC, V56, P161; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SHUB C, 1983, J AM COLL CARDIOL, V2, P127, DOI 10.1016/S0735-1097(83)80385-4; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; TEAGUE SM, 1991, STROKE, V22, P740, DOI 10.1161/01.STR.22.6.740; VANHARE GF, 1989, J AM COLL CARDIOL, V13, P673, DOI 10.1016/0735-1097(89)90610-4; WEBSTER MWI, 1988, LANCET, V2, P11	29	447	452	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					461	465		10.7326/0003-4819-117-6-461	http://dx.doi.org/10.7326/0003-4819-117-6-461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503349				2022-12-24	WOS:A1992JN25700003
J	BECKSAGUE, C; DOOLEY, SW; HUTTON, MD; OTTEN, J; BREEDEN, A; CRAWFORD, JT; PITCHENIK, AE; WOODLEY, C; CAUTHEN, G; JARVIS, WR				BECKSAGUE, C; DOOLEY, SW; HUTTON, MD; OTTEN, J; BREEDEN, A; CRAWFORD, JT; PITCHENIK, AE; WOODLEY, C; CAUTHEN, G; JARVIS, WR			HOSPITAL OUTBREAK OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS INFECTIONS - FACTORS IN TRANSMISSION TO STAFF AND HIV-INFECTED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe transmission of multidrug-resistant (MDR) Mycobacterium tuberculosis infection among patients and health care workers (HCWs) in a ward and clinic for human immunodeficiency virus (HIV)-infected patients in a hospital, four studies were conducted. Methods.-Case patients and control patients were persons who had been treated in the HIV ward or clinic, whose clinical course was consistent with tuberculosis and who had at least one positive culture for M tuberculosis between January 1, 1988, and January 31, 1990, resistant to at least isoniazid and rifampin (case patients), or whose isolates were susceptible to all drugs tested (control patients). In the first study, case patients and control patients were compared to identify risk factors for MDR tuberculosis. In the second study, inpatient and outpatient days of MDR tuberculosis case patients were compared to determine whether acid-fast bacillus (AFB) smear-positivity or aerosolized pentamidine use was associated with higher numbers of subsequent MDR tuberculosis cases among exposed patients. In the third study, restriction fragment length polymorphism analysis was performed on available MDR and sensitive M tuberculosis isolates. In the fourth study, skin test conversion rates among HCWs in the HIV ward and clinic were compared with those of HCWs in another ward, and the strength of the associations between skin test conversions among HCWs on the HIV ward and the number of person-days that AFB smear-positive case patients and control patients were on this ward was estimated. Results.-Case patients were more likely than control patients to have been exposed on the HIV ward or clinic to an AFB smear-positive case patient (P<.001). Inpatient and outpatient days of MDR tuberculosis case patients were associated with more subsequent cases of MDR tuberculosis if exposing case patients were smear-positive or if they received aerosolized pentamidine (P less-than-or-equal-to .01). Of 13 MDR isolates, all had one of two restriction fragment length polymorphism patterns; 10 sensitive isolates had restriction fragment length polymorphism patterns that were different from each other. The HCW skin test conversion rate was higher on the HIV ward and clinic than on the comparison ward (P<.01). The risk of occupational acquisition of infection increased in direct proportion to the number of person-days that AFB smear-positive case patients were on the HIV ward (r=.75; P=.005), but did not increase in proportion to the number of person-days that AFB smear-positive control patients were there (r=-.36; P=NS). After isolation measures for AFB smear-positive tuberculosis patients were improved, MDR tuberculosis cases decreased to seven of 214 tuberculosis patients. Conclusions.-Nosocomial transmission of MDR M tuberculosis infection to patients and HCWs occurred on the HIV ward and clinic. Infectiousness of MDR tuberculosis case patients was associated with AFB sputum-smear positivity. Case patients with MDR tuberculosis created a greater risk of skin test conversion for HCWs on the HIV ward than drug-susceptible control patients.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; UNIV MIAMI,MIAMI,FL 33152; VET AFFAIRS MED CTR,MIAMI,FL; JACKSON MEM HOSP,MIAMI,FL 33136	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BECKSAGUE, C (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333, USA.			Beck-Sague, Consuelo/0000-0001-9082-0165				CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Dean A. G., 1990, EPI INFO VERSION 5 W; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; Kent PT, 1985, GUIDE LEVEL 3 LAB; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SIEGEL S, 1981, NONPARAMETRIC STAT, P184; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; 1985, MMWR, V29, P429; 1985, SAS USERS GUIDE BASI, P861; 1990, AM REV RESPIR DIS, V142, P725; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1992, MMWR, V41, P61; 1991, MMWR, V40, P129; 1990, MMWR, V39, P1	17	395	401	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1280	1286		10.1001/jama.268.10.1280	http://dx.doi.org/10.1001/jama.268.10.1280			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507374				2022-12-24	WOS:A1992JL60800028
J	FERRERA, VP; NEALEY, TA; MAUNSELL, JHR				FERRERA, VP; NEALEY, TA; MAUNSELL, JHR			MIXED PARVOCELLULAR AND MAGNOCELLULAR GENICULATE SIGNALS IN VISUAL AREA V4	NATURE			English	Article							MACAQUE STRIATE CORTEX; BROAD-BAND CHANNELS; REVERSIBLE INACTIVATION; INTRINSIC CONNECTIONS; GANGLION-CELLS; COLOR-OPPONENT; LAMINA 4C; PERCEPTION; VISION	VISUAL information from the retina is transmitted to the cerebral cortex by way of the lateral geniculate nucleus (LGN) in the thalamus. In primates, most of the retinal ganglion cells that project to the LGN belong to one of two classes, P and M, whose axons terminate in the parvocellular or magnocellular subdivisions of the LGN. These cell classes give rise to two channels that have been distinguished anatomically, physiologically and behaviourally1-3,16,17. The visual cortex also can be subdivided into two pathways, one specialized for motion processing and the other for colour and form information4. Several lines of indirect evidence have suggested a close correspondence between the subcortical and cortical pathways, such that the M channel provides input to the motion pathway and the P channel drives the colour/form pathway5-7. This hypothesis was tested directly by selectively inactivating either the magnocellular or parvocellular subdivision of the LGN and recording the effects on visual responses in the cortex. We have previously reported that, in accordance with the hypothesis, responses in the motion pathway in the cortex depend primarily on magnocellular LGN8. We now report that in the colour/form pathway, visual responses depend on both P and M input. These results argue against a simple correspondence between the subcortical and cortical pathways.	UNIV ROCHESTER,DEPT PHYSIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR VISUAL SCI,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439; Ferrera, Vincent/0000-0002-6599-7740				BLASDEL GG, 1985, J NEUROSCI, V5, P3350; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FITZPATRICK D, 1985, J NEUROSCI, V5, P3329; LACHICA EA, 1992, P NATL ACAD SCI USA, V89, P3566, DOI 10.1073/pnas.89.8.3566; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MAUNSELL JHR, 1987, MATTERS INTELLIGENCE; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, J NEUROSCI, V11, P994; NEALEY TA, 1991, INVEST OPHTH VIS SCI, V32, P1117; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SILVEIRA LCL, 1991, NEUROSCIENCE, V40, P217, DOI 10.1016/0306-4522(91)90186-R; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR	17	141	143	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					756	758		10.1038/358756a0	http://dx.doi.org/10.1038/358756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508271				2022-12-24	WOS:A1992JK69900053
J	PAPPAS, PG; POTTAGE, JC; POWDERLY, WG; FRASER, VJ; STRATTON, CW; MCKENZIE, S; TAPPER, ML; CHMEL, H; BONEBRAKE, FC; BLUM, R; SHAFER, RW; KING, C; DISMUKES, WE				PAPPAS, PG; POTTAGE, JC; POWDERLY, WG; FRASER, VJ; STRATTON, CW; MCKENZIE, S; TAPPER, ML; CHMEL, H; BONEBRAKE, FC; BLUM, R; SHAFER, RW; KING, C; DISMUKES, WE			BLASTOMYCOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						BLASTOMYCOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM INFECTIONS; AMPHOTERICIN-B; KETOCONAZOLE; HUMAN IMMUNODEFICIENCY VIRUS	DERMATITIDIS; KETOCONAZOLE; ITRACONAZOLE; INFECTIONS; PULMONARY	Objective: To describe the clinical, demographic, radiographic, diagnostic, and therapeutic aspects of blastomycosis in patients with the acquired immunodeficiency syndrome (AIDS). Design: A retrospective survey. Setting: Ten university medical centers and community hospitals, six in geographic areas endemic for Blastomyces dermatitidis, and four outside the endemic area. Patients: We identified 15 patients with blastomycosis and positive serologic test results for human immunodeficiency virus (HIV). Measurements: A diagnosis of blastomycosis was based on a positive culture (14 patients) or typical histopathologic features (one patient) for B. dermatitidis in clinical specimens. Results: Twelve of 15 patients had a previous or concomitant AIDS-defining illness at the time of diagnosis of blastomycosis, and only one patient had a CD4 lymphocyte count of greater than 200 cells/mm3. Two patterns of disease emerged: localized pulmonary involvement (seven patients), and disseminated or extrapulmonary blastomycosis (eight patients). Central nervous system involvement was common (40%). Six patients died within 21 days of presentation with blastomycosis, including four patients with disseminated and two with fulminant pulmonary disease. Among the nine patients who survived longer than 1 month, all received amphotericin B as initial antifungal therapy, and most received subsequent therapy with ketoconazole. Only two of these nine patients died with evidence of progressive blastomycosis. Conclusions: Blastomycosis is a late and frequently fatal infectious complication in a few patients with AIDS. In these patients, overwhelming disseminated disease including involvement of the central nervous system is common, and it is associated with a high early mortality. Initial therapy with amphotericin B is appropriate in patients with AIDS and presumptive blastomycosis.			PAPPAS, PG (corresponding author), UNIV ALABAMA, DIV INFECT DIS, 229 TINSLEY HARRISON TOWER, UNIV STN, BIRMINGHAM, AL 35294 USA.			Powderly, William/0000-0001-7808-3086; Fraser, Victoria/0000-0001-6251-0733	NIAID NIH HHS [N01-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARATHOON EG, 1989, MYCOSES, V32, P109, DOI 10.1111/j.1439-0507.1989.tb02300.x; BRADSHER RW, 1984, AM REV RESPIR DIS, V129, P430; BRADSHER RW, 1985, ANN INTERN MED, V103, P872, DOI 10.7326/0003-4819-103-6-872; BROWN LR, 1991, MAYO CLIN PROC, V66, P29, DOI 10.1016/S0025-6196(12)61172-0; CHERNISS EI, 1956, ANN INTERN MED, V44, P105, DOI 10.7326/0003-4819-44-1-105; CHIU J, 1988, 4 INT C AIDS STOCKH; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DISMUKES WE, 1985, ANN INTERN MED, V103, P861, DOI 10.7326/0003-4819-103-6-861; DUTTERA J, 1969, SOUTHERN MED J, V62, P295; EHNI W, 1989, AM J MED, V86, P831, DOI 10.1016/0002-9343(89)90483-X; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; ESPINELINGROFF A, 1984, ANTIMICROB AGENTS CH, V26, P5, DOI 10.1128/AAC.26.1.5; EVANS ME, 1982, AM REV RESPIR DIS, V126, P1099; FRASER VJ, 1991, J INFECT DIS, V163, P1378, DOI 10.1093/infdis/163.6.1378; GRIFFITH JE, 1979, CHEST, V75, P630, DOI 10.1378/chest.75.5.630; HERD AM, 1990, CAN MED ASSOC J, V143, P1329; KITCHEN LW, 1989, J INFECT DIS, V160, P911, DOI 10.1093/infdis/160.5.911; KLEIN BS, 1986, NEW ENGL J MED, V314, P529, DOI 10.1056/NEJM198602273140901; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P471, DOI 10.7326/0003-4819-109-6-471; LASKEY W, 1978, ANN INTERN MED, V88, P50, DOI 10.7326/0003-4819-88-1-50; ONAL E, 1976, AM REV RESPIR DIS, V113, P83; PETERSON PK, 1982, MEDICINE, V61, P360, DOI 10.1097/00005792-198211000-00002; RECHT LD, 1982, AM REV RESPIR DIS, V125, P359; ROOS KL, 1987, MEDICINE, V66, P224, DOI 10.1097/00005792-198705000-00006; SAROSI GA, 1979, AM REV RESPIR DIS, V120, P911; STEVENS DA, 1990, REV INFECT DIS, V12, pS304; Turner S, 1986, Semin Respir Infect, V1, P22; WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001; WITORSCH P, 1968, MEDICINE, V47, P169, DOI 10.1097/00005792-196805000-00001; 1987, MMWR S, V36, P1	31	158	159	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					847	853		10.7326/0003-4819-116-10-847	http://dx.doi.org/10.7326/0003-4819-116-10-847			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567099				2022-12-24	WOS:A1992HT80200011
J	HEDGES, SB; BOGART, JP; MAXSON, LR				HEDGES, SB; BOGART, JP; MAXSON, LR			ANCESTRY OF UNISEXUAL SALAMANDERS	NATURE			English	Article							JEFFERSONIANUM COMPLEX; AMBYSTOMA; ORIGIN; SEQUENCES	IN eastern North America there are populations of all-female salamanders that incorporate the nuclear genomes of two or three of four sympatric bisexual species. The hybrids can be diploid, triploid, tetraploid or pentaploid, and 18 different combinations have been reported. All hybrids require sperm from a sympatric male of one of the bisexual species to reproduce, but the sperm may or may not be incorporated in the egg. Some of the hybrids are believed to represent separate, clonal species, but little is known of the origin of this hybrid complex. Vertebrate mitochondrial DNA is inherited maternally, allowing identification of the female parent that gave rise to hybrid lineages. A portion of the cytochrome b gene was sequenced from diploid and triploid hybrids that represent combinations of all four species. Nearly all hybrids had a similar mitochondrial genome sequence, independent of nuclear genome composition and ploidy, and the sequence was distinct from that of any of the four bisexual species. The hybrids maintain a mitochondrial lineage that has evolved independently of their nuclear genome and represent the most ancient known unisexual vertebrate lineage.	UNIV GUELPH,DEPT ZOOL,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph	HEDGES, SB (corresponding author), PENN STATE UNIV,DEPT BIOL,INST MOLEC EVOLUT GENET,UNIV PK,PA 16802, USA.							ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AVISE JC, 1991, EVOLUTION, V45, P1530, DOI 10.1111/j.1558-5646.1991.tb02657.x; BOGART JP, 1986, CAN J GENET CYTOL, V28, P605, DOI 10.1139/g86-089; BOGART JP, 1989, SCIENCE, V246, P1032, DOI 10.1126/science.2587986; BOGART JP, 1980, POLYPLOIDY BIOL RELE, P341, DOI DOI 10.1007/978-1-4613-3069-1_; BOGART JP, 1989, NY STATE MUS B, V466, P209; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HEDGES SB, 1991, MOL BIOL EVOL, V8, P767; HIGHTON R, 1976, EVOLUTION, V30, P33, DOI 10.1111/j.1558-5646.1976.tb00879.x; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; JUKES T H, 1969, P21; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KRAUS F, 1990, P NATL ACAD SCI USA, V87, P2235, DOI 10.1073/pnas.87.6.2235; KRAUS F, 1985, OCCAS PAP MUS ZOOL U, V709, P1; Kraus Fred, 1989, New York State Museum Bulletin, V466, P218; LOWCOCK LA, 1989, CAN J ZOOL, V67, P350, DOI 10.1139/z89-052; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SESSIONS SK, 1982, CHROMOSOMA, V84, P599, DOI 10.1007/BF00286329; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; TAYLOR AS, 1990, GENOME, V33, P837, DOI 10.1139/g90-126; UZZELL TM, 1967, EVOLUTION, V21, P345, DOI 10.1111/j.1558-5646.1967.tb00163.x; Vrijenhoek Robert C., 1989, New York State Museum Bulletin, V466, P19	25	109	114	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					708	710		10.1038/356708a0	http://dx.doi.org/10.1038/356708a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570014				2022-12-24	WOS:A1992HQ14600059
J	DEUTSCH, JC; NEFDT, RJC				DEUTSCH, JC; NEFDT, RJC			OLFACTORY CUES INFLUENCE FEMALE CHOICE IN 2 LEK-BREEDING ANTELOPES	NATURE			English	Article							MALE MATING SUCCESS; MATE CHOICE; FALLOW DEER; LEKKING; BEHAVIOR	PRONOUNCED differences in mating success between males holding territories clustered on traditional mating grounds (leks) are commonly cited as evidence of female choice for male phenotypes 1-6, but female ungulates appear to prefer particular territories 6-12 even when no other individuals are on the lek 11,12. Female choice of territories may be influenced by spatial features 7-10,12, but observations suggest that females may also be attracted to successful territories by olfactory cues in the soil 13. Here we report that transferring the topsoil between successful and unsuccessful territories on leks of two reduncine antelope species caused the numbers of females and matings on the unsuccessful territories to increase tenfold. Females were probably attracted to the soil by smells that had accumulated from heavy use by other females. Because of this attraction, stochastic process may play an important part in generating the variance in mating success between territory holders on leks.			DEUTSCH, JC (corresponding author), DEPT ZOOL,LARGE ANIM RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							Alexander R.D., 1975, P35; APOLLONIO M, 1990, ANIM BEHAV, V39, P205, DOI 10.1016/S0003-3472(05)80864-4; BALMFORD A, 1991, TRENDS ECOL EVOL, V6, P87, DOI 10.1016/0169-5347(91)90181-V; BALMFORD A, 1990, THESIS CAMBRIDGE U; Bradbury J.W., 1985, P301; Bradbury J.W., 1983, P109; Buechner H. K., 1965, Zeitschrift fuer Tierpsychologie, V22, P209; BUECHNER HK, 1961, SCIENCE, V133, P698, DOI 10.1126/science.133.3454.698; CLUTTONBROCK TH, 1988, BEHAV ECOL SOCIOBIOL, V23, P281, DOI 10.1007/BF00300575; CLUTTONBROCK TH, 1989, NATURE, V340, P463, DOI 10.1038/340463a0; DEUTSCH JC, IN PRESS BEHAV ECOL; FLOODY O R, 1975, Zeitschrift fuer Tierpsychologie, V37, P192; FRYXELL JM, 1987, ETHOLOGY, V75, P211; Gibson RM, 1991, BEHAV ECOL, V2, P165, DOI 10.1093/beheco/2.2.165; GOSLING LM, 1987, ANIM BEHAV, V35, P620, DOI 10.1016/S0003-3472(87)80298-1; GOSLING LM, 1990, ANIM BEHAV, V40, P272, DOI 10.1016/S0003-3472(05)80922-4; HINDLE JE, 1990, J REPROD FERTIL, V90, P571; HOGANWARBURG AJ, 1966, ARDEA, V54, P111; HOGLUND J, 1990, ANIM BEHAV, V40, P23, DOI 10.1016/S0003-3472(05)80662-1; HOGLUND J, 1990, BEHAVIOUR, V114, P221, DOI 10.1163/156853990X00130; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LASLEY BL, 1985, ADV VET SCI COMP MED, V30, P209; LEUTHOLD W, 1966, BEHAVIOUR, V27, P215, DOI 10.1163/156853966X00164; MCDONALD DB, 1989, ANIM BEHAV, V37, P1007, DOI 10.1016/0003-3472(89)90145-0; MODHA KL, 1973, THESIS MAKERERE U KA; SCHUSTER RH, 1976, SCIENCE, V192, P1240, DOI 10.1126/science.192.4245.1240; WADE MJ, 1990, P NATL ACAD SCI USA, V87, P5749, DOI 10.1073/pnas.87.15.5749	27	48	48	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					596	598		10.1038/356596a0	http://dx.doi.org/10.1038/356596a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560842				2022-12-24	WOS:A1992HP03100046
J	MITTLER, JE; LENSKI, RE				MITTLER, JE; LENSKI, RE			EXPERIMENTAL-EVIDENCE FOR AN ALTERNATIVE TO DIRECTED MUTATION IN THE BGL OPERON	NATURE			English	Article							ESCHERICHIA-COLI; MUTANTS; INSERTION; SELECTION; POPULATIONS; HYPOTHESIS; EVOLUTION; SEQUENCE; ORIGIN	THE directed mutation hypothesis 1-6 suggests that some mutations occur more often when selectively advantageous than when neutral or disadvantageous, challenging the principle that the selective value of a mutation does not affect the rate of its occurrence 7-11. Mutations in the bgl operon of Escherichia coli have been reported to be a case of directed mutation 2. E. coli K12 strain chi-342LD cannot grow on salicin but derivatives with two mutations in the bgl operon, an excision of IS150 (formally called IS103; ref. 12) from bglF and a point mutation or insertion in bglR 13-15, grow rapidly on this sugar. When chi-342LD is grown on a medium containing salicin, bglF excision mutants accumulate to a frequency of > 1%, even though these mutants are reportedly 2 unable to grow on salicin, and Sal+ double mutants subsequently attain a high frequency. Comparable accumulations of excision mutants and Sal+ double mutants are not observed in the absence of salicin. As salicin is not mutagenic, it has been suggested that excision mutations in bglF might serve only to create the potential for a secondary selectively advantageous mutation 2. We show here, however, that these double mutants can be accounted for by spontaneous mutation to intermediate genotypes in non-growing populations, coupled with slow growth of some of these intermediates on salicin, which enables their populations to reach a size where secondary mutations allowing rapid growth on salicin become common.	MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824	Michigan State University	MITTLER, JE (corresponding author), UNIV CALIF IRVINE,DEPT ECOL & EVOLUT BIOL,IRVINE,CA 92717, USA.			Lenski, Richard/0000-0002-1064-8375				BENSON SA, 1991, GENETICS, V129, P647; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, P NATL ACAD SCI USA, V88, P5882, DOI 10.1073/pnas.88.13.5882; HALL BG, 1989, GENOME, V31, P265, DOI 10.1139/g89-044; HALL BG, 1990, GENETICS, V126, P5; HALL BG, 1989, GENETICS, V121, P423; LEDERBERG J, 1989, GENETICS, V121, P395; LENSKI RE, 1989, TRENDS ECOL EVOL, V4, P148, DOI 10.1016/0169-5347(89)90218-8; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; REYNOLDS AE, 1981, NATURE, V293, P625, DOI 10.1038/293625a0; REYNOLDS AE, 1985, UCLA S MOL CELL BIOL, V20, P265; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; STAHL FW, 1990, NATURE, V346, P791, DOI 10.1038/346791a0; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0	21	41	41	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					446	448		10.1038/356446a0	http://dx.doi.org/10.1038/356446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557128				2022-12-24	WOS:A1992HL83000068
J	GILL, TM				GILL, TM			ARE YOU SURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Gill, Thomas/0000-0002-6450-0368					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1750	1750						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545454				2022-12-24	WOS:A1992HK67200009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PARTICIPATES IN CLINICAL LABORATORY IMPROVEMENT REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545450				2022-12-24	WOS:A1992HK67200004
J	SATOH, MS; LINDAHL, T				SATOH, MS; LINDAHL, T			ROLE OF POLY(ADP-RIBOSE) FORMATION IN DNA-REPAIR	NATURE			English	Article							EXCISION REPAIR; ADP-RIBOSE; POLYMERASE; INVITRO; TRANSCRIPTION; INHIBITORS; MECHANISM; DOMAIN	THE abundant nuclear enzyme poly(ADP-ribose) polymerase catalyses the synthesis of poly(ADP-ribose) from nicotinamide adenine dinucleotide (NAD+) 1-5. This protein has an N-terminal DNA-binding domain containing two zinc-fingers, which is linked to the C-terminal NAD+-binding domain by a short region containing several glutamic acid residues that are sites of auto-poly(ADP-ribosyl)ation 6-8. The intracellular production of poly(ADP-ribose) is induced by agents that generate strand interruptions in DNA 7. The branched homopolymer chains may attain a size of 200-300 residues 9 but are rapidly degraded after synthesis. The function of poly(ADP-ribose) synthesis is not clear, although it seems to be required for DNA repair 10,11. Here we describe a human cell-free system that enables the role of poly(ADP-ribose) synthesis in DNA repair to be characterized. The results indicate that unmodified polymerase molecules bind tightly to DNA strand breaks; auto-poly(ADP-ribosyl)ation of the protein then effects its release and allows access to lesions for DNA repair enzymes.			SATOH, MS (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.							ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P1; BENHUR E, 1984, RADIAT RES, V97, P546, DOI 10.2307/3576146; CHAMBON P, 1966, BIOCHEM BIOPH RES CO, V25, P638, DOI 10.1016/0006-291X(66)90502-X; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EKI T, 1991, J BIOL CHEM, V266, P3087; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MIWA M, 1984, METHOD ENZYMOL, V106, P441; NDUKA N, 1980, EUR J BIOCHEM, V105, P525, DOI 10.1111/j.1432-1033.1980.tb04528.x; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; Sugimura T, 1973, Prog Nucleic Acid Res Mol Biol, V13, P127, DOI 10.1016/S0079-6603(08)60102-6; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WERNER E, 1984, EUR J BIOCHEM, V139, P81, DOI 10.1111/j.1432-1033.1984.tb07979.x; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YOSHIHARA K, 1981, J BIOL CHEM, V256, P3471; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	25	954	977	3	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					356	358		10.1038/356356a0	http://dx.doi.org/10.1038/356356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549180				2022-12-24	WOS:A1992HK79400070
J	COMAI, L; TANESE, N; TJIAN, R				COMAI, L; TANESE, N; TJIAN, R			THE TATA-BINDING PROTEIN AND ASSOCIATED FACTORS ARE INTEGRAL COMPONENTS OF THE RNA POLYMERASE-I TRANSCRIPTION FACTOR, SL1	CELL			English	Article							INITIATION FACTOR-IIB; RIBOSOMAL-RNA; PROMOTER INTERACTIONS; FUNCTIONAL-ANALYSIS; PURIFICATION; ACTIVATION; UPSTREAM; SPECIFICITY; MECHANISMS; COMPLEXES	We have previously shown that the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs) are required for regulated transcriptional initiation by RNA polymerase II. Here we report the biochemical properties of the RNA polymerase I promoter selectivity factor, SL1, and its relationship to TBP. Column chromatography and glycerol gradient sedimentation indicate that a subpopulation of TBP copurifies with SL1 activity. Antibodies directed against TBP efficiently deplete SL1 transcriptional activity, which can be restored with the SL1 fraction but not purified TBP. Thus, TBP is necessary but not sufficient to complement SL1 activity. Analysis of purified SL1 reveals a complex containing TBP and three distinct TAFs. Purified TAFs reconstituted with recombinant TBP complement SL1 activity, and this demonstrates that TBP plus novel associated factors are integral components of SL1. These findings suggest that TBP may be a universal transcription factor and that the TBP-TAF arrangement provides a unifying mechanism for promoter recognition in animal cells.			COMAI, L (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841				BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOSICK R, 1976, RNA POLYMERASE, P227; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, IN PRESS P NATL ACAD; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	37	378	384	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					965	976		10.1016/0092-8674(92)90039-F	http://dx.doi.org/10.1016/0092-8674(92)90039-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547496				2022-12-24	WOS:A1992HH74800015
J	VINCENT, JP; OFARRELL, PH				VINCENT, JP; OFARRELL, PH			THE STATE OF ENGRAILED EXPRESSION IS NOT CLONALLY TRANSMITTED DURING EARLY DROSOPHILA DEVELOPMENT	CELL			English	Article							SEGMENT POLARITY GENES; PAIR-RULE GENES; FUSHI-TARAZU; CELL LINEAGE; REGULATORY INTERACTIONS; SPATIAL-DISTRIBUTION; WINGLESS GENE; MELANOGASTER; EMBRYOS; DISK	In Drosophila embryos, boundaries of lineage restriction separate groups of cells, or compartments. engrailed is essential for specification of the posterior compartment of each segment, and its expression is thought to mark this compartment. Using a new photo-activatable lineage tracer, we followed the progeny of single embryonic cells marked at the blastoderm stage. No clones straddled the anterior edges of engrailed stripes (the parasegment border). However, posterior cells of each stripe lose engrailed expression, producing mixed clones. We suggest that stable expression of engrailed by cells at the anterior edge of the stripe reflects, not cell-intrinsic mechanisms, but proximity to cells that produce Wingless, an extracellular signal needed for maintenance of engrailed expression. If control of posterior cell fate parallels control of engrailed expression, cell fate is initially responsive to cell environment and cell fate determination is a later event.			VINCENT, JP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037193-10, R01 GM037193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BROWER DL, 1984, NATURE, V310, P496, DOI 10.1038/310496a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; HARTENSTEIN V, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P213, DOI 10.1007/BF00848248; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1988, DEVELOPMENT, V104, P61; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; Lawrence PA, 1976, INSECT DEV, P132; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SLACK JWM, 1983, DEV CELL BIOL SERIES; SZABAD J, 1979, DEV BIOL, V73, P256, DOI 10.1016/0012-1606(79)90066-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0	42	147	150	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					923	931		10.1016/0092-8674(92)90035-B	http://dx.doi.org/10.1016/0092-8674(92)90035-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547492	Green Accepted			2022-12-24	WOS:A1992HH74800011
J	FOWLER, GJS; VISSCHERS, RW; GRIEF, GG; VANGRONDELLE, R; HUNTER, CN				FOWLER, GJS; VISSCHERS, RW; GRIEF, GG; VANGRONDELLE, R; HUNTER, CN			GENETICALLY MODIFIED PHOTOSYNTHETIC ANTENNA COMPLEXES WITH BLUESHIFTED ABSORBENCY BANDS	NATURE			English	Article							RHODOPSEUDOMONAS-SPHAEROIDES; ENERGY-TRANSFER	LIGHT energy for photosynthesis is collected by the antenna system, creating an excited state which migrates energetically 'downhill'. To achieve efficient migration of energy the antenna is populated with a series of pigments absorbing at progressively redshifted wavelengths. This variety in absorbing species in vivo has been created in a biosynthetically economical fashion by modulating the absorbance behaviour of one kind of (bacterio) chlorophyll molecule. This modulation is poorly understood but has been ascribed to pigment-pigment and pigment-protein interactions. We have examined the relationship between aromatic residues in antenna polypeptides and pigment absorption, by studying the effects of site-directed mutagenesis on a bacterial antenna complex. A clear correlation was observed between the absorbance of bacteriochlorophyll a and the presence of two tyrosine residues, alpha-Tyr44 and alpha-Tyr45, in the alpha-subunit of the peripheral light-harvesting complex of Rhodobacter sphaeroides, a purple photosynthetic bacterium that provides a well characterized system for site-specific mutagenesis 1-3. By constructing single (alpha-Tyr44, alpha-Tyr45 --> PheTyr) and then double (alpha-Tyr44, alpha-Tyr45 --> PheLeu) site-specific mutants, the absorbance of bacteriochlorophyll was blueshifted by 11 and 24 nm at 77 K, respectively. The results suggest that there is a close approach of tyrosine residues to bacteriochlorophyll, and that this proximity may promote redshifts in vivo.	FREE UNIV AMSTERDAM,DEPT PHYS & ASTRON,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	FOWLER, GJS (corresponding author), UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,KREBS INST,WESTERN BANK,SHEFFIELD S10 2UH,ENGLAND.			Fowler, Gregory/0000-0002-0420-7661				Brunisholz R., 1988, PHOTOSYNTHETIC LIGHT, P103; BURGESS JG, 1989, J GEN MICROBIOL, V135, P1809; COGDELL RJ, 1990, MOL BIOL MEMBRANE BO, P211; FEHER G, 1989, NATURE, V339, P11; GUDOWSKANOWAK E, 1990, J PHYS CHEM-US, V94, P5795, DOI 10.1021/j100378a036; HUNTER CN, 1989, TRENDS BIOCHEM SCI, V14, P72; HUNTER CN, 1988, J GEN MICROBIOL, V134; JONES MR, IN PRESS MOL MICROBI; KRAMER HJM, 1984, BIOCHIM BIOPHYS ACTA, V765, P156, DOI 10.1016/0005-2728(84)90009-4; PEARLSTEIN RM, 1988, PHOTOSYNTHETIC LIGHT, P555; SIMON R, 1983, BIOTECHNOLOGY, V1, P748; SUNDSTROM V, 1990, J OPT SOC AM B, V7, P1595, DOI 10.1364/JOSAB.7.001595; VANGRONDELLE R, 1982, BIOCHIM BIOPHYS ACTA, V682, P208, DOI 10.1016/0005-2728(82)90100-1; VANMOURIK F, 1990, MOL BIOL MEMBRANE BO, P345	14	229	241	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					848	850		10.1038/355848a0	http://dx.doi.org/10.1038/355848a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538765				2022-12-24	WOS:A1992HF63600063
J	JUKES, TH				JUKES, TH			TODAYS NON-ORWELLIAN ANIMAL FARM	NATURE			English	Editorial Material											JUKES, TH (corresponding author), UNIV CALIF BERKELEY,DEPT INTEGRAT BIOL,BERKELEY,CA 94720, USA.							LASLEY FA, 1988, US BROILER IND; Lepkovsky S, 1935, Science, V82, P326, DOI 10.1126/science.82.2127.326; POND WG, 1983, SCI AM, V249, P96; SINGER P, 1991, NATURE, V353, P613, DOI 10.1038/353613a0	4	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					582	582		10.1038/355582a0	http://dx.doi.org/10.1038/355582a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538742				2022-12-24	WOS:A1992HD54700018
J	MARTIN, GA; YATANI, A; CLARK, R; CONROY, L; POLAKIS, P; BROWN, AM; MCCORMICK, F				MARTIN, GA; YATANI, A; CLARK, R; CONROY, L; POLAKIS, P; BROWN, AM; MCCORMICK, F			GAP DOMAINS RESPONSIBLE FOR RAS P21-DEPENDENT INHIBITION OF MUSCARINIC ATRIAL K+ CHANNEL CURRENTS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; GENE-PRODUCT; SRC; RECEPTORS; P21; PHOSPHORYLATION; SIMILARITY; BINDING; CLAMP	The interaction between the low molecular weight G protein ras p21 and a guanosine triphosphatase activating protein (GA-P) uncouples a heterotrimeric G protein (G(k)) from muscarinic receptors. Through the use of isolated atrial cell membranes and genetically engineered GAP deletion mutants, the src homology regions (SH2-SH3) at the amino terminus of GAP have been identified as the domains responsible for this effect. Deletion of the domain required to stimulate the guanosine triphosphatase activity of ras p21 relieves the requirement for ras p21 in this system. A model is presented that suggests that ras p21 induces a conformational change in GAP, which allows the SH2-SH3 regions of GAP to function.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine	MARTIN, GA (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.				NCI NIH HHS [CA51992-01] Funding Source: Medline; NHLBI NIH HHS [HL36930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BROWN AM, 1984, NATURE, V311, P570, DOI 10.1038/311570a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FORCE T, 1991, J BIOL CHEM, V266, P6650; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OKABE K, 1989, Biophysical Journal, V55, p586A; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RAPP UR, 1991, ONCOGENE, V6, P495; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	37	143	222	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					192	194		10.1126/science.1553544	http://dx.doi.org/10.1126/science.1553544			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553544				2022-12-24	WOS:A1992GY70400034
J	SHIRODKAR, S; EWEN, M; DECAPRIO, JA; MORGAN, J; LIVINGSTON, DM; CHITTENDEN, T				SHIRODKAR, S; EWEN, M; DECAPRIO, JA; MORGAN, J; LIVINGSTON, DM; CHITTENDEN, T			THE TRANSCRIPTION FACTOR E2F INTERACTS WITH THE RETINOBLASTOMA PRODUCT AND A P107-CYCLIN-A COMPLEX IN A CELL CYCLE-REGULATED MANNER	CELL			English	Article							ADENOVIRUS E1A PROTEINS; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; TRANS-ACTIVATION; DNA-REPLICATION; RB GENE; TRANSACTIVATION; PROMOTER; BINDING	E2F is a transcription factor believed to play a role in the activation of genes required for cellular proliferation. Its regulation is likely important for maintenance of G0 and for the initiation of cell growth. The retinoblastoma product (RB) forms a complex with E2F in G1 in primary and established human cells. As these cells enter S, a second E2F-containing complex appears. It contains p107, a nuclear "pocket" protein with similarities in structure and protein-binding properties to RB, and cyclin A, a cyclin believed to play a role in facilitating DNA replication. Hence, the regulation of E2F is carried out differently in G1 or S. The presence of cyclin A and a pocket protein, a possible cell growth regulator, in the same S phase-associated complex suggests a link between the function of E2F and the regulation of the DNA replication process.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SHIRODKAR, S (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, 1992, IN PRESS SCIENCE; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	50	587	603	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					157	166		10.1016/0092-8674(92)90214-W	http://dx.doi.org/10.1016/0092-8674(92)90214-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531040				2022-12-24	WOS:A1992GZ58300017
J	LINDGREN, S; LOKSHIN, B; STROMQUIST, A; WEINBERGER, M; NASSIF, E; MCCUBBIN, M; FRASHER, R				LINDGREN, S; LOKSHIN, B; STROMQUIST, A; WEINBERGER, M; NASSIF, E; MCCUBBIN, M; FRASHER, R			DOES ASTHMA OR TREATMENT WITH THEOPHYLLINE LIMIT CHILDRENS ACADEMIC-PERFORMANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY PATIENTS; SCHOOL PERFORMANCE; CHILDHOOD ASTHMA; UNITED-STATES; BEHAVIOR; HOSPITALIZATION; PREVALENCE; PREDNISONE; CAFFEINE; THERAPY	Background. Asthma is a major cause of morbidity in childhood, restricting activity and causing absences from school. Theophylline, although effective in managing chronic asthma, has been reported to cause deficits in cognitive functioning and school performance. We therefore examined the effect of asthma and its treatment on academic achievement in a large, representative population of school-age children; matched sibling controls were used for comparison. Methods. We identified 255 consecutive children with asthma (mean age, 12.0 years) who had taken nationally standardized scholastic achievement tests administered routinely by the schools. One hundred one of these children had siblings without asthma with whom comparisons Gould be made in reading, mathematics, and a composite measure of achievement. Results. Academic achievement among the children with asthma was similar to normative standards in Iowa and higher than national standards, as reflected in a mean composite T-score of 57.1 (expected mean [+/-SD], 50+/-10). For the 101 children with sibling controls, composite T-scores were 58.3 for the children with asthma and 57.5 for the siblings. Eighty-five of these 101 children with asthma were receiving daily maintenance medication for chronic asthma; 72 of these were receiving theophylline. The mean composite T-scores were 58.5 for the theophylline-treated patients and 58.4 for their siblings without asthma. None of the differences between the children with asthma and the sibling controls were statistically significant. Conclusions. Academic achievement among children with asthma, at least those whose status is closely monitored in a structured treatment program, generally appears to be unaffected by asthma or by its treatment with appropriate doses of theophylline.	MCFARLAND CLIN,AMES,IA; UNIV IOWA,COLL MED,DEPT PREVENT MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ENVIRONM HLTH,IOWA CITY,IA 52242; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT PEDIAT,COLUMBIA,MO 65201	University of Iowa; University of Iowa; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	LINDGREN, S (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.		Weinberger, Miles/H-6743-2019					BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BENDER B G, 1991, Annals of Allergy, V66, P65; CREER TL, 1989, J PEDIATR, V15, P850; Crowder M.J., 1990, ANAL REPEATED MEASUR; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; ELKINS RN, 1981, AM J PSYCHIAT, V138, P178; FELDT LS, 1989, IOWA TESTS ED DEV; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; GELLIS SS, 1986, PEDIATRIC NOTES, V10, P207; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471, DOI 10.1001/archpedi.1989.02150160101020; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HIERONYMUS AN, 1989, IOWA TESTS BASIC SKI; LINDGREN SD, 1985, CHILD DEV, V56, P1404, DOI 10.1111/j.1467-8624.1985.tb00206.x; MCNEMAR Q, 1969, PSYCHOL STATISTICS; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAPOPORT JL, 1984, ARCH GEN PSYCHIAT, V41, P1073; RAPPAPORT L, 1989, AM J DIS CHILD, V143, P368, DOI 10.1001/archpedi.1989.02150150126032; SCHLIEPER A, 1991, J PEDIATR-US, V118, P449, DOI 10.1016/S0022-3476(05)82167-5; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; SUESS WM, 1986, J ASTHMA, V23, P291, DOI 10.3109/02770908609073175; TWAROG FJ, 1987, PEDIATR ALERT, V12, P17; WEINBERGER M, 1987, J PEDIATR-US, V111, P471, DOI 10.1016/S0022-3476(87)80483-3; WEINBERGER M, 1990, MANAGING ASTHMA; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOLKOWITZ OM, 1990, AM J PSYCHIAT, V147, P1297; 1962, AM REV RESPIR DIS, V85, P762	32	60	60	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					926	930		10.1056/NEJM199209243271305	http://dx.doi.org/10.1056/NEJM199209243271305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP014	1513349				2022-12-24	WOS:A1992JP01400005
J	SAWYERS, CL; CALLAHAN, W; WITTE, ON				SAWYERS, CL; CALLAHAN, W; WITTE, ON			DOMINANT NEGATIVE MYC BLOCKS TRANSFORMATION BY ABL ONCOGENES	CELL			English	Article							HUMAN C-MYC; CHRONIC MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE-ACTIVITY; DNA-BINDING; PHILADELPHIA-CHROMOSOME; LYMPHOID-CELLS; V-SRC; RAS; SEQUENCES	A link between ABL oncogenes and MYC is suggested by the transformation synergy that is observed when MYC is expressed at high levels. Dominant negative MYC proteins were overexpressed in fibroblasts to determine if MYC complements ABL oncogene transformation or is essential for this process. Transformation by both v-abl and BCR-ABL oncogenes was reduced 5- to 10-fold, whereas transformation by the serine/threonine kinase oncogene v-mos was unaffected. Using a retrovirus construct modified to express BCR-ABL and MYC genes simultaneously, we show that dominant negative MYC suppressed transformation of primary mouse bone marrow pre-B cells by BCR-ABL. These observations demonstrate that c-MYC is essential for transformation and help define the pathway by which these proteins cause transformation.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MOLEC GENET, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MED, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLICK M, 1987, CANCER GENET CYTOGEN, V27, P349, DOI 10.1016/0165-4608(87)90018-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEAN M, 1987, ONCOGENE RES, V1, P279; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCCARTHY DM, 1984, LANCET, V2, P1362; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1978, J EXP MED, V147, P1126, DOI 10.1084/jem.147.4.1126; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608	43	359	369	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					901	910		10.1016/0092-8674(92)90241-4	http://dx.doi.org/10.1016/0092-8674(92)90241-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525828				2022-12-24	WOS:A1992JN78100006
J	BUCCI, C; PARTON, RG; MATHER, IH; STUNNENBERG, H; SIMONS, K; HOFLACK, B; ZERIAL, M				BUCCI, C; PARTON, RG; MATHER, IH; STUNNENBERG, H; SIMONS, K; HOFLACK, B; ZERIAL, M			THE SMALL GTPASE RAB5 FUNCTIONS AS A REGULATORY FACTOR IN THE EARLY ENDOCYTIC PATHWAY	CELL			English	Article							CELL-FREE SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; RECOMBINANT VACCINIA VIRUS; BINDING YPT1 PROTEIN; COATED VESICLES; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTORS; VESICULAR TRANSPORT; GOLGI TRANSPORT; FUSION INVITRO	We have investigated the in vivo functional role of rab5, a small GTPase associated with the plasma membrane and early endosomes. Wild-type rab5 or rab5ile133, a mutant protein defective in GTP binding, was overexpressed in baby hamster kidney cells. In cells expressing the rab5ile133 protein, the rate of endocytosis was decreased by 50% compared with normal, while the rate of recycling was not significantly affected. The morphology of early endosomes was also drastically changed by the mutant protein, which induced accumulation of small tubules and vesicles at the periphery of the cell. Surprisingly, overexpression of wild-type rab5 accelerated the uptake of endocytic markers and led to the appearance of atypically large early endosomes. We conclude that rab5 is a rate-limiting component of the machinery regulating the kinetics of membrane traffic in the early endocytic pathway.	UNIV MARYLAND,DEPT ANIM SCI,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park	BUCCI, C (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Parton, Robert G/C-5673-2009; Stunnenberg, Hendrik G./D-6875-2012; HOFLACK, Bernard/AAZ-6668-2020; Bucci, Cecilia/F-6699-2012	Parton, Robert G/0000-0002-7494-5248; Stunnenberg, Hendrik G./0000-0002-0066-1576; Bucci, Cecilia/0000-0002-6232-6183; Simons, Kai/0000-0002-9231-9996				BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SAHAGIAN GG, 1985, J BIOL CHEM, V260, P9838; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	70	1152	1177	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					715	728		10.1016/0092-8674(92)90306-W	http://dx.doi.org/10.1016/0092-8674(92)90306-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516130	hybrid			2022-12-24	WOS:A1992JL66300004
J	ERICKSON, MA; ROBINSON, P; LISMAN, J				ERICKSON, MA; ROBINSON, P; LISMAN, J			DEACTIVATION OF VISUAL TRANSDUCTION WITHOUT GUANOSINE TRIPHOSPHATE HYDROLYSIS BY G-PROTEIN	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; LIGHT-ACTIVATED PHOSPHODIESTERASE; FROG PHOTORECEPTOR-MEMBRANES; RETINAL RODS; CGMP PHOSPHODIESTERASE; MECHANISM; SUBUNIT; GDP	G proteins couple receptors to their target enzymes in many signal transduction cascades. It has generally been thought that deactivation of such cascades cannot occur without the hydrolysis of guanosine triphosphate (GTP) by G protein. This requirement has now been reexamined in both vertebrate and invertebrate phototransduction. Results indicate that GTP hydrolysis is not required for deactivation. Evidence is presented for an alternative model in which the target enzyme is deactivated by an inhibitory factor that is available even when GTP hydrolysis is blocked.	BRANDEIS UNIV,DEPT BIOCHEM,BIOPHYS PROGRAM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University					NATIONAL EYE INSTITUTE [R01EY001496, R37EY001496] Funding Source: NIH RePORTER; NEI NIH HHS [EY 01496] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADOLPH AR, 1964, J GEN PHYSIOL, V48, P297, DOI 10.1085/jgp.48.2.297; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BOLSOVER SR, 1982, J PHYSIOL-LONDON, V332, P325, DOI 10.1113/jphysiol.1982.sp014416; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FATHI M, 1991, J CHROMATOGR-BIOMED, V563, P356, DOI 10.1016/0378-4347(91)80042-B; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HOFFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60; HURLEY JB, 1982, J BIOL CHEM, V257, P8188; HURLEY JM, UNPUB; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KIRKWOOD A, 1989, P NATL ACAD SCI USA, V86, P3872, DOI 10.1073/pnas.86.10.3872; KONDO H, 1988, P NATL ACAD SCI USA, V85, P1322, DOI 10.1073/pnas.85.4.1322; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAMB TD, 1988, J PHYSIOL-LONDON, V407, P463, DOI 10.1113/jphysiol.1988.sp017426; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LISMAN J, 1985, J GEN PHYSIOL, V85, P171, DOI 10.1085/jgp.85.2.171; MIKI N, 1975, J BIOL CHEM, V250, P6320; ROBINSON PH, UNPUB; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; STRYER L, 1981, TRENDS BIOCHEM SCI, V6, P245, DOI 10.1016/0968-0004(81)90089-X; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WHEELER GL, 1977, P NATL ACAD SCI USA, V74, P4238, DOI 10.1073/pnas.74.10.4238; YAMANAKA G, 1986, BIOCHEMISTRY-US, V25, P6149, DOI 10.1021/bi00368a048; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YEE R, 1978, J BIOL CHEM, V253, P8902	37	37	37	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1255	1258		10.1126/science.1519062	http://dx.doi.org/10.1126/science.1519062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519062				2022-12-24	WOS:A1992JL05000026
J	MEZARD, C; POMPON, D; NICOLAS, A				MEZARD, C; POMPON, D; NICOLAS, A			RECOMBINATION BETWEEN SIMILAR BUT NOT IDENTICAL DNA-SEQUENCES DURING YEAST TRANSFORMATION OCCURS WITHIN SHORT STRETCHES OF IDENTITY	CELL			English	Article							DOUBLE-STRAND BREAKS; HUMAN ARGININOSUCCINATE LYASE; AMINO-ACID-SEQUENCES; MISMATCH REPAIR GENE; MOUSE L-CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; HOMOLOGOUS RECOMBINATION	Interactions between similar but not identical (homeologous) DNA sequences play an important biological role in the evolution of genes and genomes. To gain insight into the underlying molecular mechanism(s) of genetic recombination, we have studied inter- and intramolecular homeologous recombination in S. cerevisiae during transformation. We found that homeologous DNAs recombine efficiently. Hybrid sequences were obtained between two mammalian cytochrome P450 cDNAs, sharing 73% identity, and between the yeast ARG4 gene and its human homeologous cDNA, sharing 52% identity. Sequencing data showed that the preferred recombination events are those corresponding to the overall alignment of the DNA sequences and that the junctions are within stretches of identity of variable length (2-21 nt). We suggest that these events occur by a conventional homologous recombination mechanism.	UNIV PIERRE & MARIE CURIE,PROPRE ASSOCIE LAB,CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	MEZARD, C (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE.							AHN BY, 1988, MOL CELL BIOL, V8, P2442, DOI 10.1128/MCB.8.6.2442; AUASUBEL FM, 1987, CURRENT PROTOCOLS MO; BAILIS AM, 1990, GENETICS, V126, P535; BAUER GA, 1988, J BIOL CHEM, V263, P917; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BURGERS PMJ, 1988, J BIOL CHEM, V263, P8099; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHEVALLIER MR, 1979, FEBS LETT, V108, P179, DOI 10.1016/0014-5793(79)81204-1; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DOUTRIAUX MP, 1986, P NATL ACAD SCI USA, V83, P2576, DOI 10.1073/pnas.83.8.2576; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; ERNST JF, 1981, P NATL ACAD SCI-BIOL, V78, P6334, DOI 10.1073/pnas.78.10.6334; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GOGUEL V, 1992, MOL CELL BIOL, V12, P696, DOI 10.1128/MCB.12.2.696; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; IOANNIDES C, 1990, DRUG METAB REV, V22, P1, DOI 10.3109/03602539008991444; JACOBSEN H, 1974, EUR J BIOCHEM, V45, P623, DOI 10.1111/j.1432-1033.1974.tb03588.x; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KARIMOVA GA, 1985, MOL GENET MIKROBIOL, V10, P29; KIMURA S, 1984, J BIOL CHEM, V259, P705; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; KUNES S, 1984, COLD SPRING HARB SYM, V49, P617, DOI 10.1101/SQB.1984.049.01.070; LAU PP, 1979, NUCLEIC ACIDS RES, V6, P331, DOI 10.1093/nar/6.1.331; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LISKAY RM, 1987, GENETICS, V115, P161; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MATUO S, 1988, FEBS LETT, V234, P395, DOI 10.1016/0014-5793(88)80124-8; MAUTNER V, 1984, VIROLOGY, V139, P43, DOI 10.1016/0042-6822(84)90328-3; Miller J.H., 1972, EXPT MOL GENETICS; MUNZ P, 1981, A BENZON S, V16, P264; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1990, BIOCHIMIE, V73, P371; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; RUBNITZ J, 1984, MOL CELL BIOL, V5, P529; RUDIN N, 1989, GENETICS, V122, P519; RUDOLPH H, 1985, GENE, V36, P87, DOI 10.1016/0378-1119(85)90072-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Sherman F., 1986, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4766; WHEELER CJ, 1990, NATURE, V347, P192, DOI 10.1038/347192a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	72	110	124	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					659	670		10.1016/0092-8674(92)90434-E	http://dx.doi.org/10.1016/0092-8674(92)90434-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505030				2022-12-24	WOS:A1992JJ88600014
J	KEE, F; WILSON, RH; GILLILAND, R; SLOAN, JM; ROWLANDS, BJ; MOOREHEAD, RJ				KEE, F; WILSON, RH; GILLILAND, R; SLOAN, JM; ROWLANDS, BJ; MOOREHEAD, RJ			CHANGING SITE DISTRIBUTION OF COLORECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article									NO HLTH & SOCIAL SERV BOARD,DEPT PUBL HLTH MED,BALLYMENA BT42 1QB,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT SURG,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT SMALL ANIM MED & SURG,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast; Queens University Belfast								ARMITAGE P, 1987, STATISTICAL METHODS; BEART RW, 1983, DIS COLON RECTUM, V26, P393, DOI 10.1007/BF02553382; JASS JR, 1991, DIS COLON RECTUM, V34, P56, DOI 10.1007/BF02050208; KEE F, 1990, ULSTER MED J, V59, P155; MUIR C, 1987, CANCER INCIDENCE 5 C, V5	5	65	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					158	158		10.1136/bmj.305.6846.158	http://dx.doi.org/10.1136/bmj.305.6846.158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515832	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JF06300024
J	STRANG, JR; PUGH, EJ				STRANG, JR; PUGH, EJ			MENINGOCOCCAL INFECTIONS - REDUCING THE CASE FATALITY RATE BY GIVING PENICILLIN BEFORE ADMISSION TO HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To determine whether parenteral penicillin given before admission to hospital reduces the case fatality rate in patients with meningococcal disease. Design-Retrospective analysis of 46 consecutive patients admitted to hospital with meningococcal disease from january 1986 to March 1991. Setting-District general hospital. Main outcome measure-Hospital case fatality rate. Results-None of the 13 patients given parenteral penicillin by the referring doctor before admission died, compared with eight deaths (24%) in 33 patients admitted without such treatment. Conclusion-Parenteral penicillin given before admission probably contributed to a reduction in the case fatality rate from meningococcal disease, and primary care physicians should be encouraged to give such treatment immediately on suspicion of the diagnosis before transferring the patient to hospital. Public health physicians are well placed to inform and alert general practitioners of the potential benefit of this action.	MEM HOSP DARLINGTON,PUBL HLTH MED,DARLINGTON DL3 6HX,ENGLAND									BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; CARTWRIGHT KAV, 1986, LANCET, V2, P558; GEDDE-DAHL T W, 1990, NIPH (National Institute of Public Health) Annals (Oslo), V13, P45; HAVENS PL, 1989, PEDIATR INFECT DIS J, V8, P8, DOI 10.1097/00006454-198901000-00003; HOPKIN D A B, 1978, Lancet, V2, P1193; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; WELSBY PD, 1990, BRIT MED J, V300, P1150, DOI 10.1136/bmj.300.6733.1150; 1980, INFECTIONS DISEASES; 1989, COMMUNICABLE DISEASE, V8, P3; 1960, IMMUNISATION INFECTI, P166; 1988, MENINGOCOCCAL INFECT	12	117	119	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					141	143		10.1136/bmj.305.6846.141	http://dx.doi.org/10.1136/bmj.305.6846.141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515826	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1992JF06300018
J	LETOURNEUR, F; KLAUSNER, RD				LETOURNEUR, F; KLAUSNER, RD			A NOVEL DI-LEUCINE MOTIF AND A TYROSINE-BASED MOTIF INDEPENDENTLY MEDIATE LYSOSOMAL TARGETING AND ENDOCYTOSIS OF CD3 CHAINS	CELL			English	Article							CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; TRANSMEMBRANE PROTEINS; INTERLEUKIN-2 RECEPTOR; MOLECULAR-CLONING; ACID-PHOSPHATASE; INTERNALIZATION; DEGRADATION	Partial complexes of the T cell antigen receptor lacking zeta-chains are delivered to lysosomes. Chimeric proteins composed of the Tac antigen fused to the cytoplasmic domains of each CD3 chain has allowed the identification of lysosomal targeting sequences. Tac-gamma and Tac-delta chimeras are retained in the endoplasmic reticulum because of the presence of basic residues reminiscent of sequences responsible for the localization of endoplasmic reticulum resident proteins. Truncation of these retention motifs revealed lysosomal targeting of both Tac-gamma and delta-chimeras. A di-leucine- and a tyrosine-based motif are individually sufficient to induce both endocytosis and delivery to lysosomes of Tac. In contrast with chimeras containing only one of these motifs, the chimera containing both was predominantly delivered directly to lysosomes without going through the cell surface. These two sequences may represent two families of targeting motifs that determine the fate of proteins within the peripheral membrane system.			LETOURNEUR, F (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Letourneur, Francois/0000-0003-2232-6127				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANIYASH M, 1988, J BIOL CHEM, V263, P449; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P708, DOI 10.1093/oxfordjournals.jbchem.a122921; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON K F, 1991, Journal of Cell Biology, V115, p244A; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SELDIN RF, 1990, CURRENT PROTOCOLS MO, P921; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIES RS, 1990, J BIOL CHEM, V265, P10132; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VEGA MA, 1991, J BIOL CHEM, V266, P16269; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; WHITE J, 1989, J IMMUNOL, V143, P1822; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	59	515	528	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1143	1157		10.1016/0092-8674(92)90636-Q	http://dx.doi.org/10.1016/0092-8674(92)90636-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535555				2022-12-24	WOS:A1992JA43100009
J	MOHR, G; ZHANG, AX; GIANELOS, JA; BELFORT, M; LAMBOWITZ, AM				MOHR, G; ZHANG, AX; GIANELOS, JA; BELFORT, M; LAMBOWITZ, AM			THE NEUROSPORA CYT-18 PROTEIN SUPPRESSES DEFECTS IN THE PHAGE-T4 TD INTRON BY STABILIZING THE CATALYTICALLY ACTIVE STRUCTURE OF THE INTRON CORE	CELL			English	Article							TRANSFER RNA-SYNTHETASE; GROUP-I INTRONS; MESSENGER-RNA; YEAST; GENE; MITOCHONDRIA; TETRAHYMENA; INVOLVEMENT; SEQUENCES; EXCISION	The Neurospora CYT-18 protein, a tyrosyl-tRNA synthetase, which functions in splicing group I introns in mitochondria, promotes splicing of mutants of the distantly related bacteriophage T4 td intron. In an in vivo assay, wild-type CYT-18 protein expressed in E. coli suppressed mutations in the td intron's catalytic core. CYT-18-suppressible mutations were also suppressed by high Mg2+ or spermidine in vitro, suggesting they affect intron structure. Both the N- and C-terminal domains of CYT-18 are required for efficient splicing, but CYT-18 with a large C-terminal truncation retains some activity. Our results indicate that CYT-18 interacts with conserved structural features of group I introns, and they provide direct evidence that a protein promotes splicing by stabilizing the catalytically active structure of the intron RNA.	OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LAB & RES,MOLEC GENET PROGRAM,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12222	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	MOHR, G (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.			Belfort, Marlene/0000-0002-1592-5618; Mohr, Georg/0000-0002-6411-0685	NIGMS NIH HHS [GM39422, GM44844, GM37951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037951, R37GM039422, R01GM039422, R37GM037951, R01GM044844] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BEDOUELLE H, 1990, BIOCHIMIE, V72, P589, DOI 10.1016/0300-9084(90)90122-W; BELFORT M, 1990, METHOD ENZYMOL, V181, P521; BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BELFORT M, 1990, ANNU REV GENET, V24, P363; BELLPEDERSEN D, 1991, J BACTERIOL, V173, P1193, DOI 10.1128/jb.173.3.1193-1200.1991; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; CHERNIACK AD, 1991, THESIS OHIO STATE U; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; EHRENMAN K, 1989, NUCLEIC ACIDS RES, V17, P9147, DOI 10.1093/nar/17.22.9147; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUO QB, 1991, J BIOL CHEM, V266, P1809; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HILL J, 1985, J BIOL CHEM, V260, P3235; KAMPER U, 1992, MOL CELL BIOL, V12, P499; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	102	105	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					483	494		10.1016/0092-8674(92)90449-M	http://dx.doi.org/10.1016/0092-8674(92)90449-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1533818				2022-12-24	WOS:A1992HT07800010
J	SCHIER, AF; GEHRING, WJ				SCHIER, AF; GEHRING, WJ			DIRECT HOMEODOMAIN DNA INTERACTION IN THE AUTOREGULATION OF THE FUSHI-TARAZU GENE	NATURE			English	Article							DROSOPHILA; PROTEINS; SPECIFICITY; BINDING; TRANSCRIPTION; ACTIVATION; REPRESSION; ELEMENTS; COMPLEX; SITE	A MAJOR problem in the elucidation of the molecular mechanisms governing development is the distinction between direct and indirect regulatory interactions among developmental control genes 1-5. In vivo studies have indicated that the Drosophila segmentation gene fushi tarazu (ftz) directly or indirectly autoregulates its expression 6. Here we describe a generally applicable experimental approach which establishes a direct in vivo interaction of the homeodomain protein ftz with the ftz cis-autoregulatory control region. In vitro studies have shown that the DNA-binding specificity of the ftz homeodomain can be changed by a single amino-acid substitution in the recognition helix (Gln 50 --> Lys) 7. Whereas wild-type ftz homeodomain binds preferentially to a CCATTA motif, the mutant homeodomain (ftzQ50K) recognizes a GGATTA motif. We now find that the in vivo activity of an ftz autoregulatory enhancer element is reduced by mutations of putative ftz-binding sites to GGATTA. This down-regulatory effect is specifically suppressed in vivo by the DNA-binding specificity mutant ftzQ50K. These results establish a direct positive autoregulatory feedback mechanism in the regulation of this homeobox gene.			SCHIER, AF (corresponding author), UNIV BASEL,BIOZENTRUM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Schier, Alexander Franz/0000-0001-7645-5325				AFFOLTER M, 1990, CURR OPINION CELL BI, V2, P1485; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EBRIGHT RH, 1991, METHOD ENZYMOL, V208, P620; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARRISON SD, 1988, NUCLEIC ACIDS RES, V16, P11403, DOI 10.1093/nar/16.24.11403; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MAIER D, 1990, EMBO J, V9, P3957, DOI 10.1002/j.1460-2075.1990.tb07616.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRIS NR, 1979, CELL, V16, P437; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1992, EMBO J, V11, P382; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; TREISMAN J, 1989, CELL, V59, P553	30	144	144	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					804	807		10.1038/356804a0	http://dx.doi.org/10.1038/356804a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574120				2022-12-24	WOS:A1992HR18600054
J	WONG, I; LOHMAN, TM				WONG, I; LOHMAN, TM			ALLOSTERIC EFFECTS OF NUCLEOTIDE COFACTORS ON ESCHERICHIA-COLI REP HELICASE DNA-BINDING	SCIENCE			English	Article							GENE-PRODUCT; PROTEIN; REPLICATION; PURIFICATION; UVRD; ENZYME; RHO; MUTATIONS; MECHANISM; COMPONENT	The Escherichia coli Rep helicase unwinds duplex DNA during replication. The functional helicase appears to be a dimer that forms only on binding DNA. Both protomers of the dimer can bind either single-stranded or duplex DNA. Because binding and hydrolysis of adenosine triphosphate (ATP) are essential for helicase function, the energetics of DNA binding and DNA-induced Rep dimerization were studied quantitatively in the presence of the nucleotide cofactors adenosine diphosphate (ADP) and the nonhydrolyzable ATP analog AMPP(NH)P. Large allosteric effects of nucleotide cofactors on DNA binding to Rep were observed. Binding of ADP favored Rep dimers in which both protomers bound single-stranded DNA, whereas binding of AMPP(NH)P favored simultaneous binding of both single-stranded and duplex DNA to the Rep dimer. A rolling model for the active unwinding of duplex DNA by the dimeric Rep helicase is proposed that explains vectorial unwinding and predicts that helicase translocation along DNA is coupled to ATP binding, whereas ATP hydrolysis drives unwinding of multiple DNA base pairs for each catalytic event.			WONG, I (corresponding author), WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.				NIGMS NIH HHS [GM45948, GM30498, R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030498, R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI N, 1981, J BIOL CHEM, V256, P5294; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BRIDGES BA, 1981, MUTAT RES, V82, P229, DOI 10.1016/0027-5107(81)90152-4; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; FASSLER JS, 1985, J BACTERIOL, V161, P609, DOI 10.1128/JB.161.2.609-614.1985; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LANE D, 1988, NATURE, V334, P478, DOI 10.1038/334478a0; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1989, P NATL ACAD SCI USA, V86, P4430, DOI 10.1073/pnas.86.12.4430; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATTHEWS BW, 1973, ANNU REV BIOPHYS BIO, V2, P257, DOI 10.1146/annurev.bb.02.060173.001353; RAY BK, 1985, J BIOL CHEM, V260, P7651; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, UNPUB; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEO YS, 1991, J BIOL CHEM, V266, P13161; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WONG I, 1992, J BIOL CHEM, V267, P7596; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	45	177	180	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					350	355		10.1126/science.256.5055.350	http://dx.doi.org/10.1126/science.256.5055.350			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1533057				2022-12-24	WOS:A1992HP03200028
J	KABACK, DB; GUACCI, V; BARBER, D; MAHON, JW				KABACK, DB; GUACCI, V; BARBER, D; MAHON, JW			CHROMOSOME SIZE-DEPENDENT CONTROL OF MEIOTIC RECOMBINATION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENETIC-MAP; MOLECULAR-CLONING; I DNA; YEAST; SEQUENCES	Smaller chromosomes have higher rates of meiotic reciprocal recombination (centimorgans per kilobase pair) than larger chromosomes. This report demonstrates that decreasing the size of Saccharomyces cerevisiae chromosomal DNA molecules increases rates of meiotic recombination and increasing chromosome size decreases recombination rates. These results indicate that chromosome size directly affects meiotic reciprocal recombination.			KABACK, DB (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103, USA.		Kaback, David/G-9973-2016	Kaback, David/0000-0002-5420-3335				BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COLEMAN KG, 1986, MOL CELL BIOL, V6, P4516, DOI 10.1128/MCB.6.12.4516; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; FASULLO MT, 1987, P NATL ACAD SCI USA, V84, P6215, DOI 10.1073/pnas.84.17.6215; GUACCI V, 1991, GENETICS, V127, P475; KABACK DB, 1984, GENETICS, V108, P67; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, UNPUB; KING JD, COMMUNICATION; LAMBIE EJ, 1986, GENETICS, V109, P303; LINK AJ, 1991, GENETICS, V127, P681; MAHON J, UNPUB; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NICOLAS A, 1989, NATURE, V338, P85; PERKINS DD, 1974, GENETICS, V77, P459; PERKINS DD, 1949, GENETICS, V34, P607; PETES TD, 1977, P NATL ACAD SCI USA, V74, P5091, DOI 10.1073/pnas.74.11.5091; STEENSMA HY, 1989, CURR GENET, V16, P131; SUROSKY RT, 1988, GENETICS, V119, P273; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; WHYTE W, 1990, GENE, V95, P65, DOI 10.1016/0378-1119(90)90414-M	26	132	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					228	232		10.1126/science.1566070	http://dx.doi.org/10.1126/science.1566070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566070				2022-12-24	WOS:A1992HM89600031
J	DRICKAMER, MA; LACHS, MS				DRICKAMER, MA; LACHS, MS			SHOULD PATIENTS WITH ALZHEIMERS-DISEASE BE TOLD THEIR DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									YALE UNIV,SCH MED,NEW HAVEN,CT 06510	Yale University	DRICKAMER, MA (corresponding author), W HAVEN VET AFFAIRS MED CTR,W HAVEN,CT 06516, USA.							BOK S, 1978, LYING MORAL CHOICE P, P220; CASSEL CK, 1985, TEACHING NURSING HOM, P109; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; ERDE EL, 1988, J FAM PRACTICE, V26, P401; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; HOWELL T, 1990, J GEN INTERN MED, V5, P431, DOI 10.1007/BF02599434; JONAS H, 1978, HASTINGS CENT REP, V8, P31, DOI 10.2307/3560975; KATZMAN R, 1991, J AM GERIATR SOC, V39, P5516; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; PARFIT D, 1986, REASONS PERSONS, P236; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; REISER SJ, 1980, ANN INTERN MED, V92, P837, DOI 10.7326/0003-4819-92-6-837; van Oosten F F, 1991, Med Law, V10, P31; VANDIJK PTM, 1991, J AM GERIATR SOC, V39, P603, DOI 10.1111/j.1532-5415.1991.tb03602.x; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; WINOGRAD CH, 1988, TREATMENTS ALZHEIMER, P3; 1991, CAN MED ASSOC J, V144, P425; 1987, GUIDELINES TERMINATI; 1983, SUMMING UP FINAL REP, P65	23	109	109	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					947	951		10.1056/NEJM199204023261410	http://dx.doi.org/10.1056/NEJM199204023261410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542346				2022-12-24	WOS:A1992HL26100010
J	ROWLEY, R; HUDSON, J; YOUNG, PG				ROWLEY, R; HUDSON, J; YOUNG, PG			THE WEE1 PROTEIN-KINASE IS REQUIRED FOR RADIATION-INDUCED MITOTIC DELAY	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; DNA DAMAGE; MITOSIS; GENE; CELLS; MUTATION; DIVISION; MUTANTS	CELLULAR feedback or 'checkpoint' mechanisms maintain the order of completion of essential, cell-cycle related functions 1-3. In the budding yeast, for example, the RAD9 gene product is required to delay progression into mitosis in response to DNA damage 2,4-6. Similarly, in fission yeast, the cdc25 and cdc2 gene products influence the ability of cells to delay mitosis in response to the inhibition of DNA synthesis 7. Because these two checkpoint controls regulate the same event, mitosis, we observed the effect of gamma-irradiation on cell cycle progression in fission yeast, to test whether the two controls require the same cell-cycle regulatory elements. We show that gamma-radiation-induced mitotic delay requires functional wee1 protein kinase but does not seem to involve the cdc25 pathway. Mitotic delay in response to DNA damage is thus distinct from the delay induced by inhibition of DNA synthesis, which involves cdc25 but is not dependent on wee1.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada	ROWLEY, R (corresponding author), UNIV UTAH,MED CTR,DEPT RADIOL,SALT LAKE CITY,UT 84132, USA.							DOIDA Y, 1969, RADIAT RES, V38, P513, DOI 10.2307/3572611; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; Fantes P.A., 1989, MOL BIOL FISSION YEA, P127; FEATHERSTONE C, 1991, NATURE, V349, P508; FEILOTTER H, 1991, GENETICS, V127, P309; FLEIG UN, 1991, MOL GEN GENET, V226, P432, DOI 10.1007/BF00260656; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Gutz H., 1974, HDB GENETICS, V1, P395; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUDSON JD, 1990, GENETICS, V126, P309; KRAKOFF IH, 1968, CANCER RES, V28, P1559; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEEPER DB, 1973, RADIAT RES, V53, P326, DOI 10.2307/3573538; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1980, GENETICS, V96, P627; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; WEINERT T, 1989, J CELL SCI S, V12, P145; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554	32	128	134	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					353	355		10.1038/356353a0	http://dx.doi.org/10.1038/356353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549179				2022-12-24	WOS:A1992HK79400069
J	OLEARY, MP				OLEARY, MP			ELIMINATING HIV FROM SEMINAL FLUID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											OLEARY, MP (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.							ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; KIESSLING AA, 1989, P NATL ACAD SCI USA, V86, P5109, DOI 10.1073/pnas.86.13.5109; KILEGER IN, 1991, J INFECT DIS, V163, P386; PORTIS JL, 1990, HETEROSEXUAL TRANSMI, P107	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542180				2022-12-24	WOS:A1992HJ59700040
J	GAUL, U; MARDON, G; RUBIN, GM				GAUL, U; MARDON, G; RUBIN, GM			A PUTATIVE RAS GTPASE ACTIVATING PROTEIN ACTS AS A NEGATIVE REGULATOR OF SIGNALING BY THE SEVENLESS RECEPTOR TYROSINE KINASE	CELL			English	Article							DEVELOPING DROSOPHILA EYE; CELL-CELL-INTERACTION; SACCHAROMYCES-CEREVISIAE; P21 GTPASE; GENE; DOMAIN; GAP; MELANOGASTER; ENCODES; RETINA	A Drosophila gene with similarity to the mammalian Ras GTPase activating protein has been isolated in screens for mutations that affect eye development. Inactivation of the locus, Gap1, mimics constitutive activation of the Sevenless receptor tyrosine kinase and eliminates the need for a functional Sevenless protein in the R7 cell. Our results suggest that Gap1 acts as a negative regulator of signaling by Sevenless by down-regulating the activity of the Ras1 protein, which has been shown to be a key element in signaling by Sevenless.			GAUL, U (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; ENGELS W, 1989, MOBILE DNA, P375; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FRANCESCHINI N, 1971, KYBERNETIK, V9, P152; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1991, METHODS NEUROSCIENCE, V9; MONTELL C, 1987, J NEUROSCI, V7, P1558; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P407; READY DF, 1989, TRENDS NEUROSCI, V12, P101; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VAESSIN A, 1987, GENETICS, V116, P433; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	63	276	278	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1007	1019		10.1016/0092-8674(92)90073-L	http://dx.doi.org/10.1016/0092-8674(92)90073-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547500				2022-12-24	WOS:A1992HK67400005
J	NAIR, BC; DEVICO, AL; NAKAMURA, S; COPELAND, TD; CHEN, Y; PATEL, A; ONEIL, T; OROSZLAN, S; GALLO, RC; SARNGADHARAN, MG				NAIR, BC; DEVICO, AL; NAKAMURA, S; COPELAND, TD; CHEN, Y; PATEL, A; ONEIL, T; OROSZLAN, S; GALLO, RC; SARNGADHARAN, MG			IDENTIFICATION OF A MAJOR GROWTH-FACTOR FOR AIDS KAPOSIS-SARCOMA CELLS AS ONCOSTATIN-M	SCIENCE			English	Article							YOUNG HOMOSEXUAL MEN; LONG-TERM CULTURE; REGULATOR; LESIONS; PROTEIN	Conditioned medium from human T cell leukemia virus type 2 (HTLV-II)-infected T cells supports the growth and long-term culture of cells derived from acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma lesions (AIDS-KS cells). A protein of 30 kilodaltons was purified from conditioned medium that supports the growth of AIDS-KS cells. The amino-terminal sequence of this protein was identical to the amino-terminal sequence of Oncostatin M, a glycoprotein that inhibits the growth of a variety of cancer cells. Oncostatin M from conditioned medium stimulated a twofold increase in the growth of AIDS-KS cells at a concentration of less than 1 nanogram of the protein per milliliter of medium.	ADV BIOSCIENCE LABS INC,DEPT CELL BIOL,KENSINGTON,MD 20895; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP073723] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-73723, N01-CO-74101] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARILLARI G, UNPUB; BROWN TJ, 1987, J IMMUNOL, V139, P2977; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MCNUTT NS, 1983, AM J PATHOL, V111, P62; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	16	225	233	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1430	1432		10.1126/science.1542792	http://dx.doi.org/10.1126/science.1542792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542792				2022-12-24	WOS:A1992HH74400055
J	GILBERT, CD; WIESEL, TN				GILBERT, CD; WIESEL, TN			RECEPTIVE-FIELD DYNAMICS IN ADULT PRIMARY VISUAL-CORTEX	NATURE			English	Article							SOMATOSENSORY CORTEX; DIGIT AMPUTATION; STRIATE CORTEX; NERVE INJURY; REORGANIZATION; CAT; ORGANIZATION; CONNECTIONS; LESIONS; RESPONSES	THE adult brain has a remarkable ability to adjust to changes in sensory input. Removal of afferent input to the somatosensory, auditory, motor or visual cortex results in a marked change of cortical topography 1-10. Changes in sensory activity can, over a period of months, alter receptive field size and cortical topography 11. Here we remove visual input by focal binocular retinal lesions and record from the same cortical sites before and within minutes after making the lesion and find immediate striking increases in receptive field size for cortical cells with receptive fields near the edge of the retinal scotoma. After a few months even the cortical areas that were initially silenced by the lesion recover visual activity, representing retinotopic loci surrounding the lesion. At the level of the lateral geniculate nucleus, which provides the visual input to the striate cortex, a large silent region remains. Furthermore, anatomical studies show that the spread of geniculocortical afferents is insufficient to account for the cortical recovery. The results indicate that the topographic reorganization within the cortex was largely due to synaptic changes intrinsic to the cortex, perhaps through the plexus of long-range horizontal connections.			GILBERT, CD (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; CRANE HD, 1983, SCIENCE, V221, P1078, DOI 10.1126/science.221.4615.1078; CUSICK CG, 1990, BRAIN RES, V537, P355, DOI 10.1016/0006-8993(90)90385-O; DEVOR M, 1978, NATURE, V276, P75, DOI 10.1038/276075a0; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P479; EYSEL UT, 1981, EXP BRAIN RES, V41, P256; FENDICK M, 1983, VISION RES, V23, P145, DOI 10.1016/0042-6989(83)90137-2; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; Kanizsa G., 1979, ESSAYS GESTALT PERCE; KRAUSKOPF J, 1961, AM J PSYCHOL, V80, P632; MARTIN KAC, 1984, J PHYSL, V353, P4463; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P25; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PARADISO MA, 1991, VISION RES, V31, P1221, DOI 10.1016/0042-6989(91)90047-9; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; Rockland KS, 1982, BRAIN RES, V169, P19; SANES JN, 1990, EXP BRAIN RES, V79, P479; SANES JN, 1988, P NATL ACAD SCI USA, V85, P2003, DOI 10.1073/pnas.85.6.2003; TSO DY, 1988, J NEUROSCI, V8, P1712; TSO DY, 1986, J NEUROSCI, V6, P1160; YARBUS A. L., 1957, BIOFIZIKA [TRANSL], V2, P683	32	649	653	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					150	152		10.1038/356150a0	http://dx.doi.org/10.1038/356150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545866				2022-12-24	WOS:A1992HH73100058
J	STEVENS, ME; SUMMERFIELD, GP; HALL, AA; BECK, CA; HARDING, AJ; COVESMITH, JR; PATERSON, AD				STEVENS, ME; SUMMERFIELD, GP; HALL, AA; BECK, CA; HARDING, AJ; COVESMITH, JR; PATERSON, AD			COST-BENEFITS OF LOW-DOSE SUBCUTANEOUS ERYTHROPOIETIN IN PATIENTS WITH ANEMIA OF END STAGE RENAL-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; PERITONEAL-DIALYSIS; ANEMIA; FAILURE	Objective - To assess the cost benefits of low dose subcutaneous recombinant human erythropoietin in correcting the anaemia of end stage renal disease. Design - Three year retrospective study. Setting - Subregional nephrology service serving a mixed urban and rural population of 800 000. Subjects - 60 patients with symptoms of anaemic end stage renal disease treated with erythropoietin (43 receiving haemodialysis; 11 receiving continuous ambulatory peritoneal dialysis; two with predialysis end stage renal disease; four with failing renal transplants). Main outcome measures - Costs and savings of achieving and maintaining a haemoglobin concentration of 85-105 g/l with erythropoietin. Results - All patients treated with erythropoietin achieved the target haemoglobin concentration at median induction doses of 97 (95% confidence interval 95 to 108) units/kg/week, and this was maintained with 79 (75 to 95) units/kg/week at an average annual cost per patient of L2260. Admissions related to anaemia were virtually eliminated (246 v 1 inpatient days for 12 months before and after starting erythropoietin). 54 patients required no blood transfusions after starting erythropoietin, and the total requirements fell from 230 to 21 units in the 12 months before and after starting erythropoietin. Iron stores were maintained with oral or intravenous iron. All patients reported increased wellbeing, appetite, and exercise capacity. Hypertension developed or worsened in 30 patients, resulting in hospital admissions in five patients, one of whom had seizures. Conclusion - Low dose subcutaneous erythropoietin restores haemoglobin concentrations sufficiently to abolish blood transfusion requirements and reduce morbidity. The net cost of erythropoietin prescribed in this way (L2260/patient/year) was largely offset by savings in costs of hospital admissions. The true annual cost to the NHS was around L1200 per patient.	MIDDLESBROUGH GEN HOSP, DEPT BLOOD TRANSFUS, MIDDLESBROUGH, ENGLAND		STEVENS, ME (corresponding author), S CLEVELAND HOSP, NEPHROL & GEN MED, MIDDLESBROUGH TS4 3BW, ENGLAND.							BOMMER J, 1988, LANCET, V2, P406; CASATI S, 1987, BMJ-BRIT MED J, V295, P1017, DOI 10.1136/bmj.295.6605.1017; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1988, AM J KIDNEY DIS, V11, P203, DOI 10.1016/S0272-6386(88)80150-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; GABRIEL R, 1991, BRIT MED J, V302, P248, DOI 10.1136/bmj.302.6771.248; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LEESE B, 1971, COSTS BENEFITS USE E; MACDOUGALL IC, 1990, LANCET, V335, P489, DOI 10.1016/0140-6736(90)90733-L; MACDOUGALL IC, 1990, BMJ-BRIT MED J, V300, P655, DOI 10.1136/bmj.300.6725.655; POLLOK M, 1989, CONTRIB NEPHROL, V76, P201; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SINAITRIEMAN L, 1989, J PEDIATR-US, V114, P550, DOI 10.1016/S0022-3476(89)80692-4; STEVENS JM, 1989, LANCET, V1, P1388; TAYLOR JE, 1991, BMJ-BRIT MED J, V302, P272, DOI 10.1136/bmj.302.6771.272-a; WINEARLS CG, 1989, NEPHROL DIAL TRANSPL, V4, P323, DOI 10.1093/oxfordjournals.ndt.a091884; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; 1990, RECOMMENDATIONS USE	19	43	43	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1992	304	6825					474	477		10.1136/bmj.304.6825.474	http://dx.doi.org/10.1136/bmj.304.6825.474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547417	Green Published			2022-12-24	WOS:A1992HF55500020
J	SMYTHE, C; NEWPORT, JW				SMYTHE, C; NEWPORT, JW			COUPLING OF MITOSIS TO THE COMPLETION OF S PHASE IN XENOPUS OCCURS VIA MODULATION OF THE TYROSINE KINASE THAT PHOSPHORYLATES P34CDC2	CELL			English	Article							CYCLE CONTROL GENE; MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; DNA-REPLICATION; MITOTIC CONTROL; MESSENGER-RNA; EGGS; ACTIVATION	In cell-free extracts derived from Xenopus eggs which oscillate between S phase and mitosis, incompletely replicated DNA blocks the activation of p34cdc2-cyclin by maintaining p34cdc2 in a tyrosine-phosphorylated form. We used a recombinant cyclin fusion protein to generate a substrate to measure the ability of the tyrosine kinase(s) to phosphorylate and inactivate p34cdc2 in the absence of tyrosine phosphatase activity. p34cdc2 tyrosine phosphorylation is highly regulated during the cell cycle, being elevated in S phase and attenuated in mitosis. The elevation in p34cdc2 tyrosine phosphorylation rate occurs in response to the presence of incompletely replicated DNA. Moreover, okadaic acid and caffeine, which uncouple the dependence of mitosis on the completion of S phase, increase unphosphorylated p34cdc2 by attenuating tyrosine kinase function. These data indicate that the control system, which monitors the state of DNA replication, modulates the function of the tyrosine kinase by a phosphorylation/dephosphorylation mechanism, ensuring that mitosis occurs only when S phase is complete.			SMYTHE, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,B-022,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33523-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUTCHISON C, 1989, J CELL SCI, V93, P605; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P287; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; OHKURA H, 1989, CEYCELL, V57, P998; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	42	214	221	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					787	797		10.1016/0092-8674(92)90153-4	http://dx.doi.org/10.1016/0092-8674(92)90153-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1531451				2022-12-24	WOS:A1992HF44000018
J	BERG, AT; SHINNAR, S; HAUSER, WA; ALEMANY, M; SHAPIRO, ED; SALOMON, ME; CRAIN, EF				BERG, AT; SHINNAR, S; HAUSER, WA; ALEMANY, M; SHAPIRO, ED; SALOMON, ME; CRAIN, EF			A PROSPECTIVE-STUDY OF RECURRENT FEBRILE SEIZURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM DIAZEPAM PROPHYLAXIS; NATIONAL COHORT; CONVULSIONS; EPILEPSY; PREDICTORS; CHILDHOOD; LIFE; RISK	Background. Febrile seizures occur in 2 to 4 percent of all children, approximately one third of whom will have recurrent febrile seizures. Little is known about predictors of recurrence. Methods. In this prospective study, we identified 347 children (1 month to 10 years of age) who presented with a first febrile seizure at one of four pediatric emergency departments. Information about these children was collected from medical records and interviews with the parents, and the children were followed for a median of 20 months to ascertain whether febrile seizures recurred. Results. Recurrent febrile seizures occurred in 94 of the 347 children (27 percent) with a cumulative risk of 25 percent at one year and 30 percent at two years. The duration of fever before the initial seizure was associated with the risk of recurrence at one year: for fever lasting less than 1 hour, the risk of recurrence was 44 percent; for fever lasting 1 to 24 hours, 23 percent; and for fever lasting more than 24 hours, 13 percent (P<0.001). With each degree of increase in temperature (in degrees Fahrenheit), from 101-degrees-F (38.3-degrees-C) to greater-than-or-equal-to 105-degrees-F (40.6-degrees-C), the risk of recurrence at one year declined, from 35 percent to 30, 26, 20, and 13 percent (P for trend = 0.024). An age of less than 18 months and a family history of febrile seizures were also associated with an increased risk of recurrence. A family history of epilepsy, complex febrile seizures, and neurodevelopmental abnormalities did not increase the risk of recurrent febrile seizures. Conclusions. A shorter duration of fever before the initial febrile seizure and a lower temperature are associated with an increased risk of recurrence in children who have febrile seizures.	MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT NEUROL, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, MONTEFIORE EINSTEIN EPILEPSY MANAGEMENT, BRONX, NY 10467 USA; COLUMBIA UNIV COLL PHYS & SURG, GERTRUDE SERGIEVSKY CTR, NEW YORK, NY 10032 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Columbia University	BERG, AT (corresponding author), YALE UNIV, SCH MED, DEPT PEDIAT, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.		Hauser, W Allen/AAB-5277-2020		NINDS NIH HHS [1R01 NS26151, 1R29 NS27728] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027728, R01NS026151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1990, EPILEPSY RES, V5, P209, DOI 10.1016/0920-1211(90)90040-3; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1980, Pediatrics, V66, P1009; Berg A T, 1992, Paediatr Perinat Epidemiol, V6, P145, DOI 10.1111/j.1365-3016.1992.tb00756.x; BERG A T, 1991, Epilepsia, V32, P84; BERG AT, 1992, EPILEPSIA, V33, P661, DOI 10.1111/j.1528-1157.1992.tb02344.x; BERG AT, 1990, J PEDIATR-US, V116, P329, DOI 10.1016/S0022-3476(05)82816-1; BREG W R, 1962, Pediatr Clin North Am, V9, P101; CAMFIELD CS, 1979, J PEDIATR-US, V95, P361, DOI 10.1016/S0022-3476(79)80507-7; CAMFIELD PR, 1980, J PEDIATR-US, V97, P16, DOI 10.1016/S0022-3476(80)80122-3; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1985, BMDP STATISTICAL SOF, P555; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELRADHI AS, 1986, CLIN PEDIATR, V25, P311; FREEMAN JM, 1990, PEDIATRICS, V86, P624; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, MONOGRPAHS EPIDEMIOL, V1, P293; KNUDSEN FU, 1985, ARCH DIS CHILD, V60, P1045, DOI 10.1136/adc.60.11.1045; KNUDSEN FU, 1985, J PEDIATR-US, V106, P487, DOI 10.1016/S0022-3476(85)80688-0; Lennox MA, 1946, RES PUBL ASSOC RES N, V26, P342; LENNOX WG, 1953, PEDIATRICS, V11, P341; LENNOXBUCHTHAL MA, 1975, ACTA NEUROL SCAND, P77; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; OFFRINGA M, 1992, DEV MED CHILD NEUROL, V34, P15; POLLACK MA, 1978, AM J DIS CHILD, V132, P87, DOI 10.1001/archpedi.1978.02120260089021; PRUITT AW, 1985, PEDIATRICS, V76, P644; ROSMAN NP, 1992, CONT PEDIATR, V9, P12; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; SHINNAR S, 1990, CURRENT THERAPY NEUR, P29; SHIRTS SB, 1987, EPILEPSIA, V28, P625; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; WOLF SM, 1978, PEDIATRICS, V61, P728; WOLF SM, 1989, ACTA PAEDIATR SCAND, V78, P291, DOI 10.1111/j.1651-2227.1989.tb11072.x; WOLF SM, 1977, PEDIATRICS, V59, P378	37	169	174	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1122	1127		10.1056/NEJM199210153271603	http://dx.doi.org/10.1056/NEJM199210153271603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528207	Bronze			2022-12-24	WOS:A1992JT15300003
J	POWELL, SM; ZILZ, N; BEAZERBARCLAY, Y; BRYAN, TM; HAMILTON, SR; THIBODEAU, SN; VOGELSTEIN, B; KINZLER, KW				POWELL, SM; ZILZ, N; BEAZERBARCLAY, Y; BRYAN, TM; HAMILTON, SR; THIBODEAU, SN; VOGELSTEIN, B; KINZLER, KW			APC MUTATIONS OCCUR EARLY DURING COLORECTAL TUMORIGENESIS	NATURE			English	Article							GENES; IDENTIFICATION; CHROMOSOME-5Q21; CANCERS; LOCUS; FAP	HUMAN tumorigenesis is associated with the accumulation of mutations both in oncogenes and in tumour suppressor genes1-3. But in no common adult cancer have the mutations that are critical in the early stages of the tumorigenic process been defined. We have attempted to determine if mutations of the APC gene play such a role in human colorectal tumours, which evolve from small benign tumours (adenomas) to larger malignant tumours (carcinomas) over the course of several decades. Here we report that sequence analysis of 41 colorectal tumours revealed that the majority of colorectal carcinomas (60%) and adenomas (63%) contained a mutated APC gene. Furthermore, the APC gene met two criteria of importance for tumour initiation. First, mutations of this gene were found in the earliest tumours that could be analysed, including adenomas as small as 0.5 cm in diameter. Second, the frequency of such mutations remained constant as tumours progressed from benign to malignant stages. These data provide strong evidence that mutations of the APC gene play a major role in the early development of colorectal neoplasms.	JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55905	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Mayo Clinic			Pillay, Nischalan/F-9536-2012; Bryan, Tracy M/B-8468-2014	Bryan, Tracy/0000-0002-7990-5501				BAKER SJ, 1990, CANCER RES, V50, P7717; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TURNBULL RB, 1967, ANN SURG, V166, P420; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIJNEN J, 1991, NUCLEIC ACIDS RES, V19, P6965, DOI 10.1093/nar/19.24.6965-a	22	1589	1636	0	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					235	237		10.1038/359235a0	http://dx.doi.org/10.1038/359235a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528264				2022-12-24	WOS:A1992JN94400061
J	BASU, TN; GUTMANN, DH; FLETCHER, JA; GLOVER, TW; COLLINS, FS; DOWNWARD, J				BASU, TN; GUTMANN, DH; FLETCHER, JA; GLOVER, TW; COLLINS, FS; DOWNWARD, J			ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS	NATURE			English	Article							GENE; MUTATIONS; GAP; TRANSFORMATION; DELETIONS; SEQUENCE; RECEPTOR; ENCODES; LOCUS	DEFECTS in the NF1 gene have been implicated in the inherited disorder neurofibromatosis type 1, which is characterized by several developmental abnormalities including an increased frequency of benign and malignant tumours of neural crest origin (neurofibromas and neurofibrosarcomas respectively) 1. The NF1 gene encodes a ubiquitous protein homologous to p120GAP, the GTPase-activating protein (GAP) for the products of the ras protooncogenes 2-6. When expressed in non-mammalian systems, the region of the NF1 gene homologous to p120GAP produces a protein with GAP-like activity 7-9. Here we present evidence that the ras proteins in malignant tumour cell lines from patients with type 1 neurofibromatosis are in a constitutively activated state, as judged by the guanine nucleotide bound to them, and are necessary for cellular proliferation. These cells contain p21ras and p120GAP that are both functionally wild type, but barely any functional NF1 protein. Our results show that the NF1 protein is normally essential for correct negative regulation of ras proteins in the cell, even in the presence of normal p120GAP, and they support the hypothesis that NF1 is a tumour-suppressor gene whose product acts upstream of ras.	IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	Cancer Research UK; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Downward, Julian/A-3251-2012	Gutmann, David/0000-0002-3127-5045; Downward, Julian/0000-0002-2331-4729				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CANTRELL DA, 1988, IMMUNOLOGY, V65, P343; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	22	569	582	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					713	715		10.1038/356713a0	http://dx.doi.org/10.1038/356713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570015	Green Published			2022-12-24	WOS:A1992HQ14600061
J	FREYTAG, SO; GEDDES, TJ				FREYTAG, SO; GEDDES, TJ			RECIPROCAL REGULATION OF ADIPOGENESIS BY MYC AND C/EBP-ALPHA	SCIENCE			English	Article							ENHANCER BINDING-PROTEIN; TUMOR SUPPRESSOR GENES; C-MYC; CELL-DIFFERENTIATION; DNA-BINDING; EXPRESSION; SENESCENCE	3T3-L1 adipoblasts that express large amounts of c-Myc cannot terminally differentiate, raising the possibility that Myc inhibits the expression of genes that promote adipogenesis. The CCAAT/enhancer binding protein (C/EBP-alpha) is induced during 3T3-L1 adipogenesis when cells commit to the differentiation pathway. Transfection of 3T3-L1 adipoblasts with the gene that encodes C/EBP-alpha caused overt expression of the adipocyte morphology. Expression of Myc prohibited the normal induction of C/EBP-alpha and prevented adipogenesis. Enforced expression of C/EBP-alpha overcame the Myc-induced block to differentiation. These results provide a molecular basis for the regulation of adipogenesis and implicate Myc and C/EBP-alpha as pivotal controlling elements.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	FREYTAG, SO (corresponding author), HENRY FORD HOSP,MOLEC BIOL RES PROGRAM,DETROIT,MI 48202, USA.				NATIONAL CANCER INSTITUTE [R01CA051748] Funding Source: NIH RePORTER; NCI NIH HHS [CA51748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEAN M, 1986, J BIOL CHEM, V261, P9161; DHAR R, 1980, P NATL ACAD SCI USA, V77, P3938; FREYTAG S, UNPUB; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	34	282	286	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					379	382		10.1126/science.256.5055.379	http://dx.doi.org/10.1126/science.256.5055.379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566086				2022-12-24	WOS:A1992HP03200037
J	OAKLEY, K; GOOCH, C; COCKCROFT, A				OAKLEY, K; GOOCH, C; COCKCROFT, A			REVIEW OF MANAGEMENT OF INCIDENTS INVOLVING EXPOSURE TO BLOOD IN A LONDON TEACHING HOSPITAL, 1989-91	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-B; ZIDOVUDINE; INFECTION; INJURY; VIRUS	Objective-To review management of incidents involving exposure to blood reported to an occupational health unit. Design-Analysis of all reported incidents from january 1989 to June 1991. Setting-London teaching hospital. Subjects-447 health care workers and students. Main outcome measures-Immunisation against hepatitis B virus before exposure, proportion of known source patients tested for hepatitis B surface antigen and HIV antibodies, and reasons for not testing known source patients. Results-447 incidents were reported: 337 sharps injuries and 110 other exposures. 310 staff reporting incidents (205 (82%) nurses) were already immune to hepatitis B virus, nearly always because of immunisation. 345 source patients were identified, 77 of whom had already been tested for hepatitis B surface antigen (28 positive results) and 58 for HIV antibodies (18 positive results). Of those not previously tested, 145 of 266 were subsequently tested for hepatitis B surface antigen (two positive) and 149 of 287 for HIV antibodies (none positive). The main reasons for not testing source patients were that the incident was not considered a risk, that the patient had gone home, and that the clinical team were unwilling to ask the patient. Specific hepatitis B immunoglobulin was given to 18 staff who were not immune and was avoided in 11 cases by a negative result for the patient. Prophylactic zidovudine was discussed but not given to any staff member. Conclusions-Management of exposure to blood is improved by widespread immunisation against hepatitis B virus and by knowledge of source patients' hepatitis B virus and HIV status.	ROYAL FREE HAMSTEAD NHS TRUST,OCCUPAT HLTH UNIT,LONDON NW3 2QG,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								ASTBURY C, 1990, J SOC OCCUP MED, V40, P92; BOR R, 1991, BRIT MED J, V303, P905, DOI 10.1136/bmj.303.6807.905; BROWN EM, 1991, BRIT MED J, V303, P990, DOI 10.1136/bmj.303.6808.990; BURDEN AD, 1991, POSTGRAD MED J, V67, P256, DOI 10.1136/pgmj.67.785.256; JEFFRIES DJ, 1991, BRIT MED J, V302, P1349, DOI 10.1136/bmj.302.6789.1349; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; MILLER PJ, 1989, J OCCUP ENVIRON MED, V31, P524, DOI 10.1097/00043764-198906000-00008; MILLER R, 1988, AIDS GUIDE CLIN COUN; PORTEOUS MJL, 1990, BRIT MED J, V301, P167, DOI 10.1136/bmj.301.6744.167; TAIT DR, 1991, BRIT MED J, V303, P581; YASSI A, 1990, BRIT J IND MED, V47, P645; 1989, MMWR, V38, pS6; 1990, GUIDANCE CLIN HLTH C; 1990, CODE PRACTICE SAFE U; 1990, HIV CAUSATIVE AGENT	16	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					949	951		10.1136/bmj.304.6832.949	http://dx.doi.org/10.1136/bmj.304.6832.949			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1530692	Green Published, Bronze			2022-12-24	WOS:A1992HP06400020
J	EVAN, GI; WYLLIE, AH; GILBERT, CS; LITTLEWOOD, TD; LAND, H; BROOKS, M; WATERS, CM; PENN, LZ; HANCOCK, DC				EVAN, GI; WYLLIE, AH; GILBERT, CS; LITTLEWOOD, TD; LAND, H; BROOKS, M; WATERS, CM; PENN, LZ; HANCOCK, DC			INDUCTION OF APOPTOSIS IN FIBROBLASTS BY C-MYC PROTEIN	CELL			English	Article							PROGRAMMED CELL-DEATH; RAT VENTRAL PROSTATE; DNA-BINDING; GROWTH; DIFFERENTIATION; TRANSFORMATION; TRANSCRIPTION; EXPRESSION; EVENTS; G1	Although Rat-1 fibroblasts expressing c-myc constitutively are unable to arrest growth in low serum, their numbers do not increase in culture because of substantial cell death. We show this cell death to be dependent upon expression of c-myc protein and to occur by apoptosis. Regions of the c-myc protein required for induction of apoptosis overlap with regions necessary for cotransformation, autoregulation, and inhibition of differentiation, suggesting that the apoptotic function of c-myc protein is related to its other functions. Moreover, cells with higher levels of c-myc protein are more prone to cell death upon serum deprivation. Finally, we demonstrate that deregulated c-myc expression induces apoptosis in cells growth arrested by a variety of means and at various points in the cell cycle.	UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh	EVAN, GI (corresponding author), IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Penn, Linda/0000-0001-8133-5459				ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; COTTER TG, 1990, ANTICANCER RES, V10, P1153; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FIELD JK, 1990, ANTICANCER RES, V10, P1; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KYPRIANOU N, 1991, CANCER RES, V51, P162; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ormerod M.G., 1990, FLOW CYTOMETRY PRACT, P69; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATERS CM, 1991, ONCOGENE, V6, P797; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1987, ARCH TOXICOL, P3; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	42	2964	3042	2	95	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					119	128		10.1016/0092-8674(92)90123-T	http://dx.doi.org/10.1016/0092-8674(92)90123-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555236				2022-12-24	WOS:A1992HM44500011
J	HENKEL, T; ZABEL, U; VANZEE, K; MULLER, JM; FANNING, E; BAEUERLE, PA				HENKEL, T; ZABEL, U; VANZEE, K; MULLER, JM; FANNING, E; BAEUERLE, PA			INTRAMOLECULAR MASKING OF THE NUCLEAR LOCATION SIGNAL AND DIMERIZATION DOMAIN IN THE PRECURSOR FOR THE P50 NF-KAPPA-B SUBUNIT	CELL			English	Article							ENHANCER-BINDING-PROTEIN; TRANSCRIPTION FACTOR; REL ONCOGENE; 65-KD SUBUNIT; DNA; HOMOLOGY; RECEPTOR; CELLS; ACTIVATION; ANTIBODIES	We show that the non-DNA-binding precursor for the p50 subunit (p110), like NF-kappa-B, is subject to control of nuclear uptake. In contrast to p50, p110 was excluded from nuclei and unable to associate detectably with p50 or p65 NF-kappa-B subunits. The nuclear location signal in the N-terminal half of p110 was not accessible for monospecific antibodies. Removal of only 191 amino acids from the C-terminus of p110 restored antibody accessibility as well as nuclear uptake. The C-terminal half of p110, which is linked to the p50 portion via a glycine-rich hinge, could also noncovalently bind to p50. This helps to explain why p50, after cleavage of the precursor in intact cells, was still retained in an inactive form in the cytoplasm. Our study describes a novel mechanism of nuclear uptake control by masking of a nuclear location signal through a remote domain within a precursor molecule.	INST BIOCHEM,W-8000 MUNICH 2,GERMANY		HENKEL, T (corresponding author), UNIV MUNICH,GENZENTRUM,MOLEK BIOL LAB,KLOPFERSPITZ,W-8033 MARTINSRIED,GERMANY.							ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V344, P36; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P398; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Graessmann A, 1980, Methods Enzymol, V65, P816; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, TRENDS CELL BIOL, V10, P3805; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANZEE K, 1991, MOL CELL BIOL, V11, P5137, DOI 10.1128/MCB.11.10.5137; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	48	368	375	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1121	1133		10.1016/0092-8674(92)90083-O	http://dx.doi.org/10.1016/0092-8674(92)90083-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547506				2022-12-24	WOS:A1992HK67400015
J	SCHOFIELD, AE; REARDON, DM; TANNER, MJA				SCHOFIELD, AE; REARDON, DM; TANNER, MJA			DEFECTIVE ANION TRANSPORT ACTIVITY OF THE ABNORMAL BAND-3 IN HEREDITARY OVALOCYTIC RED-BLOOD-CELLS	NATURE			English	Article							HUMAN-ERYTHROCYTES; MALARIA PARASITES; PROTEIN; MELANESIANS; MEMBRANES; INVASION; EXCHANGE; INVITRO; CARRIER	HEREDITARY ovalocytosis is common in some areas of Melanesia and South East Asia where malaria is endemic. These red cells resist invasion by malarial parasites in vitro 1,2 and ovalocytic individuals are less parasitized than normal 3. This has been attributed to the greater rigidity of ovalocytic red cells 4,5. It has been suggested that South East Asian ovalocytosis results from the heterozygous presence of an altered membrane anion transporter (band 3) 6,7. We have used the polymerase chain reaction to clone the abnormal band 3 complementary DNA from an ovalocytic of Indian origin 8 and found two changes from the normal protein: a point mutation (Lys 56 --> Glu) and the deletion of the sequence AFSPQVLAA (residues 400-408), but no evidence for an N-terminal extension 7. The deletion is also found in the abnormal band 3 of South East Asian ovalocytes 9 and seems to be responsible for the unusual properties of the ovalocytic red cell. We show here that the membrane domain of the abnormal ovalocyte band 3 has a substantially altered structure and that the protein is defective in anion transport activity. The changed transport properties of the red cells may have a role in the reduced parasitaemia of ovalocytic individuals.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; ADDENBROOKES HOSP,DEPT HAEMATOL,CAMBRIDGE CB2 2QQ,ENGLAND	University of Bristol; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMATO D, 1977, PAPUA NEW GUINEA MED, V20, P26; CABANTCHIK ZI, 1983, MOL PHARMACOL, V23, P92; CATTANI JA, 1987, T ROY SOC TROP MED H, V81, P705, DOI 10.1016/0035-9203(87)90001-0; HADLEY T, 1983, J CLIN INVEST, V71, P780, DOI 10.1172/JCI110827; HALESTRAP AP, 1976, BIOCHEM J, V156, P193, DOI 10.1042/bj1560193; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JONES GL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P33; KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; MOHANDAS N, 1984, BLOOD, V63, P1385; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; SAUL A, 1984, J CELL BIOL, V98, P1348, DOI 10.1083/jcb.98.4.1348; SCHOFIELD AE, IN PRESS J MOL BIOL; SERJEANTSON S, 1977, HUM GENET, V37, P161, DOI 10.1007/BF00393579; SHEARMAN MS, 1984, BIOCHEM J, V223, P673, DOI 10.1042/bj2230673; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1991, BLOOD, V78, P2785; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WEITH JO, 1982, PHILOS T R SOC LON B, V299, P383	21	154	155	1	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					836	838		10.1038/355836a0	http://dx.doi.org/10.1038/355836a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538763				2022-12-24	WOS:A1992HF63600059
J	RINI, JM; SCHULZEGAHMEN, U; WILSON, IA				RINI, JM; SCHULZEGAHMEN, U; WILSON, IA			STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; BINDING; COMPLEX; PEPTIDE; PROTEIN; FAB; RESOLUTION; REFINEMENT	The three-dimensional structure of a specific antibody (Fab 17/9) to a peptide immunogen from influenza virus hemagglutinin [HA1(75-110)] and two independent crystal complexes of this antibody with bound peptide (Tyr(P100)-Leu(P108) have been determined by x-ray crystallographic techniques at 2.0 angstrom, 2.9 angstrom, and 3.1 angstrom resolution, respectively. The nonapeptide antigen assumes a type I beta-turn in the antibody combining site and interacts primarily with the Fab hypervariable loops L3, H2, and H3. Comparison of the bound and unbound Fab structures shows that a major rearrangement in the H3 loop accompanies antigen binding. This conformational change results in the creation of a binding pocket for the beta-turn of the peptide, allowing Tyr(P105) to be accommodated. The conformation of the peptide bound to the antibody shows similarity to its cognate sequence in the HA1, suggesting a possible mechanism for the cross-reactivity of this Fab with monomeric hemagglutinin. The structures of the free and antigen bound antibodies demonstrate the flexibility of the antibody combining site and provide an example of induced fit as a mechanism for antibody-antigen recognition.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIAID NIH HHS [AI-23498] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Colman PM, 1991, CURR OPIN STRUC BIOL, V1, P232, DOI 10.1016/0959-440X(91)90067-4; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; COLMAN PM, 1989, PHILOS T R SOC B, V323, P511, DOI 10.1098/rstb.1989.0028; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GETZOFF ED, 1987, NATURE, V326, P358; GEYSEN HM, UNPUB; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOPE H, 1989, ACTA CRYSTALLOGR B, V45, P190, DOI 10.1107/S0108768188013710; HOUGHTEN RA, 1986, VACCINES 86 NEW APPR, P21; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JANIN J, 1990, J BIOL CHEM, V265, P16027; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOHLER H, 1989, METHOD ENZYMOL, V178, P3; LERNER RA, 1988, BIOESSAYS, V9, P107, DOI 10.1002/bies.950090402; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PINILLA C, 1991, PEPTIDES, P538; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON IA, 1991, CIBA F SYMP, V159, P13; YEATES TO, 1988, J APPL CRYSTALLOGR, V21, P925, DOI 10.1107/S0021889888007927	49	511	524	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					959	965		10.1126/science.1546293	http://dx.doi.org/10.1126/science.1546293			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546293				2022-12-24	WOS:A1992HE60500033
J	LUND, E; DAHLBERG, JE				LUND, E; DAHLBERG, JE			CYCLIC 2',3'-PHOSPHATES AND NONTEMPLATED NUCLEOTIDES AT THE 3' END OF SPLICEOSOMAL U6 SMALL NUCLEAR RNAS	SCIENCE			English	Article							HELA-CELL EXTRACT; LUPUS ANTIGEN-LA; POLYMERASE-III; TRANSCRIPTION TERMINATION; 3'-TERMINAL PHOSPHATE; CAP STRUCTURE; INVITRO; U4; PROTEIN; YEAST	Spliceosomal U6 small nuclear RNA (U6 RNA) in species as diverse as man, frog, fruitfly, and soybean have at their 3' ends a cyclic 2',3'-phosphate (> p) apparently derived from uridylic acid residues that were added post-transcriptionally. The 3' ends of U6 RNA's from various sources may be processed in different ways, or to different extents, depending on the organism or stage of development. The presence of a > p terminus on U6 RNA may influence the activity of U6 RNA either directly during splicing or indirectly by ensuring that the RNA has a defined length or proper conformation (or both).			LUND, E (corresponding author), UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1986, P NATL ACAD SCI USA, V83, P221, DOI 10.1073/pnas.83.2.221; BARRELL BG, 1971, PROCEDURES NUCLEIC A, V2, P751; BASS BL, 1991, NATURE, V352, P283, DOI 10.1038/352283a0; BINDEREIF A, 1990, EMBO J, V9, P251, DOI 10.1002/j.1460-2075.1990.tb08102.x; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHOUDHURY K, 1988, J CELL PHYSIOL, V137, P529, DOI 10.1002/jcp.1041370319; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; Deutscher M P, 1973, Prog Nucleic Acid Res Mol Biol, V13, P51, DOI 10.1016/S0079-6603(08)60100-2; DEUTSCHER MP, 1990, METHOD ENZYMOL, V181, P434; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FIELD D, COMMUNICATION; FILIPOWICZ W, 1985, P NATL ACAD SCI USA, V82, P1316, DOI 10.1073/pnas.82.5.1316; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARADA F, 1980, BIOCHEM BIOPH RES CO, V95, P1332, DOI 10.1016/0006-291X(80)91620-4; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HIRAI H, 1988, J BIOCH, V164, P991; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; HUTCHINS CJ, 1990, METHOD ENZYMOL, V181, P583; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LUND E, 1987, GENE DEV, V1, P39, DOI 10.1101/gad.1.1.39; LUND E, 1985, SCIENCE, V229, P1271, DOI 10.1126/science.2412294; LUND E, UNPUB; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; NEU HC, 1964, J BIOL CHEM, V239, P2927; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; OHSHIMA Y, 1981, NUCLEIC ACIDS RES, V9, P5145, DOI 10.1093/nar/9.19.5145; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; REDDY R, 1983, J BIOL CHEM, V258, P8352; REDDY R, 1987, J BIOL CHEM, V262, P75; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TERNS MP, UNPUB; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WOLFF T, IIN PRESS EMBO J; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0	56	120	121	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					327	330		10.1126/science.1549778	http://dx.doi.org/10.1126/science.1549778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549778				2022-12-24	WOS:A1992GZ69500041
J	DUHAMEL, JR; COLBY, CL; GOLDBERG, ME				DUHAMEL, JR; COLBY, CL; GOLDBERG, ME			THE UPDATING OF THE REPRESENTATION OF VISUAL SPACE IN PARIETAL CORTEX BY INTENDED EYE-MOVEMENTS	SCIENCE			English	Article							MECHANISMS; PRIMATE; MACAQUE; MEMORY	Every eye movement produces a shift in the visual image on the retina. The receptive field, or retinal response area, of an individual visual neuron moves with the eves so that after an eye movement it covers a new portion of visual space. For some parietal neurons, the location of the receptive field is shown to shift transiently before an eve movement. In addition, nearly all parietal neurons respond when an eye movement brings the site of a previously flashed stimulus into the receptive field. Parietal cortex both anticipates the retinal consequences of eye movements and updates the retinal coordinates of remembered stimuli to generate a continuously accurate representation of visual space.	NEI,SENSORIMOTOR RES LAB,BLDG 10,ROOM 10C 101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			Duhamel, Jean-René/M-4723-2017	Duhamel, Jean-René/0000-0003-0210-1027				ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; [Anonymous], 1962, TREATISE PHYSL OPTIC; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; DROULEZ J, 1990, MOTOR CONTROL CONCEP, P137; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1990, COLD SPRING HARB SYM, V55, P729; GOLDBERG ME, 1990, J NEUROPHYSIOL, V64, P489, DOI 10.1152/jn.1990.64.2.489; GOLDENBERG DH, 1983, J FUTURES MARKETS, V3, P225, DOI 10.1002/fut.3990030210; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P745, DOI 10.1152/jn.1976.39.4.745; WURTZ RH, 1969, J NEUROPHYSIOL, V32, P727, DOI 10.1152/jn.1969.32.5.727; YIN TCT, 1977, SCIENCE, V197, P1381, DOI 10.1126/science.408924	13	1321	1325	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					90	92						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553535				2022-12-24	WOS:A1992GX79100045
J	LETOURNEUR, F; KLAUSNER, RD				LETOURNEUR, F; KLAUSNER, RD			ACTIVATION OF T-CELLS BY A TYROSINE KINASE ACTIVATION DOMAIN IN THE CYTOPLASMIC TAIL OF CD3-EPSILON	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; HYBRIDOMAS; PROTEIN	The multichain T cell antigen receptor functions by interacting with and activating one or more nonreceptor tyrosine kinases. The cytoplasmic tail of the zeta-chain can activate T cells independently of the rest of the receptor complex. The function of the remaining invariant CD3 chains remains unknown. A 22-amino acid region of the cytoplasmic tail of CD3-epsilon was also able to independently activate T cells. Stimulation of T cells by means of the cytoplasmic tails of either zeta or CD3-epsilon resulted in quantitatively distinct patterns of tyrosine phosphorylation, suggesting activation of different biochemical pathways.			LETOURNEUR, F (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Letourneur, Francois/0000-0003-2232-6127				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR F, UNPUB; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; REITH M, 1983, NATURE, V338, P383; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SELDIN RF, 1990, CURRENT PROTOCOLS MO, V1, P921; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WHITE J, 1989, J IMMUNOL, V143, P1822	23	425	444	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					79	82		10.1126/science.1532456	http://dx.doi.org/10.1126/science.1532456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532456				2022-12-24	WOS:A1992GX79100041
J	SOLARO, CR; LINGLE, CJ				SOLARO, CR; LINGLE, CJ			TRYPSIN-SENSITIVE, RAPID INACTIVATION OF A CALCIUM-ACTIVATED POTASSIUM CHANNEL	SCIENCE			English	Article							CA-2+-ACTIVATED K+ CHANNELS; PITUITARY CELL-LINE; RAT MUSCLE; DROSOPHILA MUSCLE; SMALL CONDUCTANCE; SODIUM-CHANNEL; CURRENTS; BLOCKADE; NEURONS; SECRETION	Most calcium-activated potassium channels couple changes in intracellular calcium to membrane excitability by conducting a current with a probability that depends directly on submembrane calcium concentration. In rat adrenal chromaffin cells, however, a large conductance, voltage- and calcium-activated potassium channel (BK) undergoes rapid inactivation, suggesting that this channel has a physiological role different than that of other BK channels. The inactivation of the BK channel, like that of the voltage-gated Shaker B potassium channel, is removed by trypsin digestion and channels are blocked by th Shaker B amino-terminal inactivating domain. Thus, this BK channel shares functional and possibly structural homologies with other inactivating voltage-gated potassium channels.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Lingle, Christopher/0000-0002-9916-3795				ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P567; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; CHUNG S K, 1991, Society for Neuroscience Abstracts, V17, P777; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; FINDLAY I, 1985, FEBS LETT, V185, P4, DOI 10.1016/0014-5793(85)80729-8; GOH JW, 1987, J PHYSIOL-LONDON, V394, P315, DOI 10.1113/jphysiol.1987.sp016872; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUGERS ARCH, V393, P254; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IKEMOTO Y, 1989, BIOPHYS J, V56, P207, DOI 10.1016/S0006-3495(89)82665-7; IWATSUKI N, 1985, BIOCHIM BIOPHYS ACTA, V819, P249, DOI 10.1016/0005-2736(85)90180-4; KIDOKORO Y, 1980, J PHYSIOL-LONDON, V307, P199, DOI 10.1113/jphysiol.1980.sp013431; LANCASTER B, 1987, J PHYSIOL-LONDON, V387, P519, DOI 10.1113/jphysiol.1987.sp016587; LANG DG, 1990, J PHYSIOL-LONDON, V425, P117, DOI 10.1113/jphysiol.1990.sp018095; LANG DG, 1987, PFLUG ARCH EUR J PHY, V410, P614, DOI 10.1007/BF00581321; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LATTORE R, 1990, ANN REV PHYSL, V51, P385; MACDERMOTT AB, 1982, NATURE, V300, P185, DOI 10.1038/300185a0; MARTY A, 1983, TRENDS NEUROSCI, V6, P262, DOI 10.1016/0166-2236(83)90115-7; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MILLER C, 1987, J GEN PHYSIOL, V90, P427, DOI 10.1085/jgp.90.3.427; MURRELLLAGNADO R, COMMUNICATION; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NOHMI M, 1984, BRAIN RES, V301, P146, DOI 10.1016/0006-8993(84)90412-8; PALLOTTA BS, 1985, J PHYSIOL-LONDON, V363, P501, DOI 10.1113/jphysiol.1985.sp015724; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; ROMEY G, 1984, BIOCHEM BIOPH RES CO, V118, P669, DOI 10.1016/0006-291X(84)91355-X; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; TORO L, 1992, Biophysical Journal, V61, pA379; VERGARA C, 1983, J GEN PHYSIOL, V82, P543, DOI 10.1085/jgp.82.4.543; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	43	100	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1694	1698		10.1126/science.1529355	http://dx.doi.org/10.1126/science.1529355			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529355				2022-12-24	WOS:A1992JN50100034
J	DERVAN, PB				DERVAN, PB			REAGENTS FOR THE SITE-SPECIFIC CLEAVAGE OF MEGABASE DNA	NATURE			English	Article							TRIPLE-HELIX FORMATION; RECOGNITION; MOTIF				DERVAN, PB (corresponding author), CALTECH, DEPT CHEM & CHEM ENGN, PASADENA, CA 91125 USA.							BEAL PA, 1992, J AM CHEM SOC, V114, P4976, DOI 10.1021/ja00039a004; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; Home D. A., 1990, J AM CHEM SOC, V112, P2435; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1992, J AM CHEM SOC, V114, P5934, DOI 10.1021/ja00041a005; RADHAKRISHNAN I, 1991, BIOCHEMISTRY-US, V30, P9022, DOI 10.1021/bi00101a016; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SINGLETON SF, IN PRESS J AM CHEM S; STOBEL SA, 1991, SCIENCE, V254, P1639; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0	20	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					87	88		10.1038/359087a0	http://dx.doi.org/10.1038/359087a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522894				2022-12-24	WOS:A1992JL66200063
J	JOHNSON, NA; PEREZ, DE; CABOT, EL; HOLLOCHER, H; WU, CI				JOHNSON, NA; PEREZ, DE; CABOT, EL; HOLLOCHER, H; WU, CI			A TEST OF RECIPROCAL X-Y INTERACTIONS AS A CAUSE OF HYBRID STERILITY IN DROSOPHILA	NATURE			English	Article							HALDANE RULE; CHROMOSOME; PSEUDOOBSCURA; MELANOGASTER; PERSIMILIS	ELUCIDATION of the nature of the gene interactions that underly the sterility of interspecific hybrids is important in evolutionary biology1,2. The interactions between the heterospecific X and Y (or Z and W) chromosomes are often used as an explanation for two reasons. First, the fertility of the hybrids of the heterogametic sex is much more often affected than that of the homogametic sex (Haldane's rule3) and X-Y interactions are specific to the heterogametic sex. Second, sex chromosomes, especially the X chromosome, are often considered to be of special importance in determining the fertility of hybrids1,2,4. X-Y interactions have been addressed in studies of males with a heterospecific Y chromosome in a mixed genetic background5-8. A more stringent test of the X-Y interaction model requires each X chromosome sterility factor to be tested separately for its interaction with the Y chromosome in a homogeneous background of the pure species. Here we report such a test of the X-Y interaction model and conclude that X-Y interactions should not be assumed to be the only or even the most common cause of hybrid sterility.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Chicago; University of Rochester								CLARK AG, 1987, GENETICS, V115, P143; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; COYNE JA, 1989, HEREDITY, V62, P97, DOI 10.1038/hdy.1989.13; COYNE JA, 1989, SPECIATION ITS CONSE, P181; Dobzhansky T, 1936, GENETICS, V21, P113; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; HENNIG W, 1977, ADV ENZYME REGUL, V15, P363, DOI 10.1016/0065-2571(77)90025-5; JOHNSON NA, 1992, GENETICS, V130, P507; JONES JS, 1985, NATURE, V314, P668, DOI 10.1038/314668a0; LIVAK KJ, 1984, GENETICS, V107, P611; Muller HJ., 1940, NEW SYSTEMATICS, P185; OKA HI, 1974, GENETICS, V77, P521; ORR HA, 1987, GENETICS, V116, P555; PANTAZIDIS AC, 1988, HEREDITY, V60, P299, DOI 10.1038/hdy.1988.46; WU CI, 1983, GENETICS, V105, P71; WU CI, IN PRESS MOL PALEOPO	16	47	47	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					751	753		10.1038/358751a0	http://dx.doi.org/10.1038/358751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508270				2022-12-24	WOS:A1992JK69900051
J	SODERSTROM, CA; DISCHINGER, PC; SMITH, GS; MCDUFF, DR; HEBEL, JR; GORELICK, DA				SODERSTROM, CA; DISCHINGER, PC; SMITH, GS; MCDUFF, DR; HEBEL, JR; GORELICK, DA			PSYCHOACTIVE SUBSTANCE DEPENDENCE AMONG TRAUMA CENTER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; RECOGNITION; PREVALENCE; ABUSE; SEVERITY	Introduction.-The practice of assessing only trauma patients with elevated blood alcohol concentrations (BACs) or positive drug screens for psychoactive substance use disorders (PSUDs) was evaluated. Methods.-Twenty-four BAC-negative (BAC-) (BAC, 0) and 21 BAC-positive (BAC+) (BAC, greater-than-or-equal-to 22 mmol/L or 100 mg/dL; mean, 41 mmol/L; range, 24.3 to 79 mmol/L) adult trauma patients were evaluated for alcoholism and other PSUDs using the Structured Clinical Interview (SCI) from the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R). Approximately half were vehicular crash victims and 78% were men. Results.-A total of 64 PSUDs were diagnosed in 31 (68.9%) of the 45 patients; all but one was for dependence (vs abuse). Of the BAC+ patients, 14 (66.7%) met DSM-III-R criteria for alcohol dependence, 11 (78.6%) of whom also had other PSUDs not related to alcohol. Two other BAC+ patients had nonalcohol PSUDs. Of the BAC- patients, 11 (45.8%) had alcohol dependence, six (54.5%) of whom also had nonalcohol PSUDs. Another four BAC- patients had nonalcohol PSUDs. Overall, 76.2% of the BAC+ patients and 62.5% of the BAC- patients had a diagnosis of psychoactive substance dependence. Conclusion.-All patients admitted to trauma centers should be assessed for alcoholism and other PSUDs.	CHARLES MATHIAS NATL STUDY CTR TRAUMA & EMERGENCY, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY PREVENT, BALTIMORE, MD 21218 USA; UNIV MARYLAND, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, BALTIMORE, MD 21201 USA; NIDA, BETHESDA, MD USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	SODERSTROM, CA (corresponding author), MARYLAND INST EMERGENCY MED SERV SYST, R ADAMS COWLEY SHOCK TRAUMA CTR, DEPT SURG, 22 S GREENE ST, BALTIMORE, MD 21201 USA.		Gorelick, David/ABF-4941-2021	Smith, Gordon/0000-0002-2911-3071	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA007700] Funding Source: NIH RePORTER; NIAAA NIH HHS [R29AA07700] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CLARK DE, 1985, ANN EMERG MED, V14, P274, DOI 10.1016/S0196-0644(85)80456-X; CLEARY PD, 1988, AM J MED, V85, P466; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; HOFFMANN N G, 1989, Advances in Alcohol and Substance Abuse, V8, P119; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; Ramzy A I, 1988, Md Med J, V37, P517; REDMOND AD, 1987, ALCOHOL ALCOHOLISM, V22, P341; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SILVERMAN JJ, 1985, J TRAUMA, V25, P544, DOI 10.1097/00005373-198506000-00014; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON J, 1980, J STUD ALCOHOL, V41, P583, DOI 10.15288/jsa.1980.41.583; Spitzer R. L., 1987, STRUCTURED CLIN INTE; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; YERSIN B, 1989, ARCH INTERN MED, V149, P2071, DOI 10.1001/archinte.149.9.2071; 1990, US DHHS901656 PUBL; 1987, DIAGNOSTIC STATISTIC; 1989, INJURY PREVENTION M; 1991, ALCOHOL ALERT, P1; [No title captured]; 1990, MMWR, V39, P173; 1986, JAMA-J AM MED ASSOC, V255, P522; 1991, HS807693 US DEP TRAN; 1988, MMWR, V37, P753; 1991, ALCOHOL ALERT, V12, P1; 1990, RESOURCES OPTIMAL CA; 1987, MMWR, V36, P437	38	103	105	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2756	2759		10.1001/jama.267.20.2756	http://dx.doi.org/10.1001/jama.267.20.2756			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578594				2022-12-24	WOS:A1992HV26500022
J	KINTNER, C				KINTNER, C			REGULATION OF EMBRYONIC-CELL ADHESION BY THE CADHERIN CYTOPLASMIC DOMAIN	CELL			English	Article							XENOPUS EMBRYOS; MOLECULE UVOMORULIN; N-CAM; EXPRESSION; PROTEIN; CDNAS; JUNCTIONS; ECTODERM; REGION	Differential adhesion between embryonic cells has been proposed to be mediated by a family of closely related glycoproteins called the cadherins. The cadherins mediate adhesion in part through an interaction between the cadherin cytoplasmic domain and intracellular proteins, called the catenins. To determine whether these interactions could regulate cadherin function in embryos, a form of N-cadherin was generated that lacks an extracellular domain. Expression of this mutant in Xenopus embryos causes a dramatic inhibition of cell adhesion. Analysis of the mutant phenotype shows that at least two regions of the N-cadherin cytoplasmic domain can inhibit adhesion and that the mutant cadherin can inhibit catenin binding to E-cadherin. These results suggest that cadherin-mediated adhesion can be regulated by cytoplasmic interactions and that this regulation may contribute to morphogenesis when emerging tissues coexpress several cadherin types.			KINTNER, C (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, POB 85800, SAN DIEGO, CA 92186 USA.							ANGRES B, 1991, DEVELOPMENT, V111, P829; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; CHOI YS, 1989, J CELL BIOL, V108, P2449, DOI 10.1083/jcb.108.6.2449; CHOI YS, 1990, J CELL BIOL, V110, P1575, DOI 10.1083/jcb.110.5.1575; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GINSBERG D, 1991, DEVELOPMENT, V111, P315; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KELLER RE, 1980, J EMBRYOL EXP MORPH, V60, P201; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOCH PJ, 1991, DIFFERENTIATION, V47, P29, DOI 10.1111/j.1432-0436.1991.tb00218.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEVI G, 1991, DEVELOPMENT, V111, P159; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NILLES LA, 1991, J CELL SCI, V99, P809; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; Sambrook J., 1989, MOL CLONING LAB MANU; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796	42	370	386	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					225	236		10.1016/0092-8674(92)90404-Z	http://dx.doi.org/10.1016/0092-8674(92)90404-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568244				2022-12-24	WOS:A1992HQ18300003
J	PULLMAN, WE; BODMER, WF				PULLMAN, WE; BODMER, WF			CLONING AND CHARACTERIZATION OF A GENE THAT REGULATES CELL-ADHESION	NATURE			English	Article							DIFFERENTIATION; INTEGRINS; SURFACE; CANCER; FAMILY	MOLECULES of the cadherin and integrin families involved in cell-cell and cell-matrix adhesion have been implicated in epithelial differentiation, carcinogenesis and metastasis 1-6. Having observed that a colon cancer cell line bound avidly to collagen type I, inducing integrin-triggered glandular differentiation 7, We investigated the regulation of integrin function in these cells. We modified a mammalian expression cloning system 8 that used monoclonal antibody selection to clone cell surface molecules. Using attachment to collagen type I to select for adhesive phenotype, we isolated a complementary DNA clone that increases cell adhesion to components of the extracellular matrix. The corresponding gene (cell adhesion regulator, CAR) is located on the long arm of chromosome 16 (16q) and encodes a protein of 142 amino acids, which has an N-terminal myristoylation motif and a consensus tyrosine-kinase phosphorylation site at the C terminus. Removal of this tyrosine residue abolishes enhancement of cell-matrix adhesion. This gene may encode an adhesion signal transduction molecule that functions in the suppression of tumour invasion.			PULLMAN, WE (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Bodmer, Walter/0000-0001-6244-9792				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BICKNELL DC, 1991, GENOMICS, V10, P186, DOI 10.1016/0888-7543(91)90499-5; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HUSCHTSCHA LI, 1989, IN VITRO CELL DEV B, V25, P105, DOI 10.1007/BF02624419; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIGNATELLI M, 1990, J PATHOL, V162, P95, DOI 10.1002/path.1711620202; PIGNATELLI M, 1988, P NATL ACAD SCI USA, V85, P5561, DOI 10.1073/pnas.85.15.5561; RESH MD, 1990, ONCOGENE, V5, P1437; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAMBROOK J, 1991, MOL CLONING LABORATO, V3, P215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, CANCER RES, V50, P7184; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	25	93	95	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					529	532		10.1038/356529a0	http://dx.doi.org/10.1038/356529a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560826				2022-12-24	WOS:A1992HN23100061
J	KELLEHER, DJ; KREIBICH, G; GILMORE, R				KELLEHER, DJ; KREIBICH, G; GILMORE, R			OLIGOSACCHARYLTRANSFERASE ACTIVITY IS ASSOCIATED WITH A PROTEIN COMPLEX COMPOSED OF RIBOPHORIN-I AND RIBOPHORIN-II AND A 48KD PROTEIN	CELL			English	Article							ROUGH MICROSOMAL-MEMBRANES; ENDOPLASMIC-RETICULUM; N-GLYCOSYLATION; SUBSTRATE RECOGNITION; RIBOSOME BINDING; YEAST GENE; DOLICHOL; TRANSLOCATION; TRANSFERASE; SEQUENCE	Oligosaccharyltransferase catalyzes the N-linked glycosylation of asparagine residues on nascent polypeptides in the lumen of the rough endoplasmic reticulum (RER). A protein complex composed of 66, 63, and 48 kd subunits copurified with oligosaccharyltransferase from canine pancreas. The 66 and 63 kd subunits were shown by protein immunoblotting to be identical to ribophorin I and II, two previously identified RER glycoproteins that colocalize with membrane-bound ribosomes. The transmembrane segment of ribophorin I was found to be homologous to a recently proposed dolichol recognition consensus sequence. Based on a revision of the consensus sequence, we propose a model for the interaction of dolichol with the glycosyltransferases that catalyze the assembly and transfer of lipid-linked oligosaccharides.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	New York University	KELLEHER, DJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768, R01GM021971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21971, GM 43768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; AUBERT JP, 1982, BIOPHYS RES COMMUN, V144, P1550; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CHALIFOUR RJ, 1988, J BIOL CHEM, V263, P15673; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GLABE CG, 1980, J BIOL CHEM, V255, P9236; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KIRKEGAARD LH, 1973, BIOCHEMISTRY-US, V12, P3627, DOI 10.1021/bi00743a009; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LIU T, 1979, J BIOL CHEM, V254, P4554; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MURGOLO NJ, 1989, BIOCHEMISTRY-US, V28, P253, DOI 10.1021/bi00427a035; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; Stewart JM, 1984, SOLID PHASE PEPTIDE; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931; ZHU XY, 1990, J BIOL CHEM, V265, P14250	43	238	245	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					55	65		10.1016/0092-8674(92)90118-V	http://dx.doi.org/10.1016/0092-8674(92)90118-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555242				2022-12-24	WOS:A1992HM44500006
J	LENO, GH; DOWNES, CS; LASKEY, RA				LENO, GH; DOWNES, CS; LASKEY, RA			THE NUCLEAR-MEMBRANE PREVENTS REPLICATION OF HUMAN G2 NUCLEI BUT NOT G1 NUCLEI IN XENOPUS EGG EXTRACT	CELL			English	Article							PERMEABILIZED CHROMAFFIN CELLS; SYNCHRONIZED HELA-CELLS; STREPTOLYSIN-O; DNA-REPLICATION; TETANUS TOXIN; CATECHOLAMINE SECRETION; PURIFIED DNA; INITIATION; ENVELOPE; RELEASE	We have used synchronized HeLa cells to investigate the role of the nuclear membrane in preventing rereplication in a single cell cycle. Nuclei were prepared with intact nuclear membranes using streptolysin-O or digitonin and assayed for replication in Xenopus egg extracts. Intact G1 nuclei replicate semiconservatively, but intact G2 nuclei do not replicate in egg extract. However, permeabilizing the nuclear membranes of G2 nuclei by treatment with NP-40 allows them all to replicate in egg extract under cell cycle control, suggesting that integrity of the nuclear membrane is required to distinguish G2 from G1 human nuclei and to prevent rereplication within a single cell cycle. The results are discussed in terms of the previously proposed licensing factor model.	UNIV CAMBRIDGE, CRC MAMMALIAN DNA REPAIR GRP, CAMBRIDGE CB2 3EJ, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	University of Cambridge; University of Cambridge	LENO, GH (corresponding author), UNIV CAMBRIDGE, WELLCOME CRC INST CANC & DEV BIOL, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BROWN DB, 1985, EXP CELL RES, V156, P251, DOI 10.1016/0014-4827(85)90279-4; DEROEPER A, 1977, NATURE, V265, P469, DOI 10.1038/265469a0; DOWNES CS, 1982, NUCLEIC ACIDS RES, V10, P5357, DOI 10.1093/nar/10.17.5357; DOWNES CS, 1979, BIOPHYS J, V25, P129, DOI 10.1016/S0006-3495(79)85282-0; DOWNES CS, 1987, ANAL BIOCHEM, V165, P56, DOI 10.1016/0003-2697(87)90200-4; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; JOST E, 1981, J CELL SCI, V47, P25; LAZAROVICI P, 1989, FEBS LETT, V253, P121, DOI 10.1016/0014-5793(89)80943-3; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; PAINE PL, 1975, J CELL BIOL, V66, P652, DOI 10.1083/jcb.66.3.652; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; PRIGENT D, 1976, BIOCHIM BIOPHYS ACTA, V443, P288, DOI 10.1016/0005-2736(76)90511-3; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; WILSON SP, 1983, J BIOL CHEM, V258, P4994; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944	33	125	128	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					151	158		10.1016/0092-8674(92)90126-W	http://dx.doi.org/10.1016/0092-8674(92)90126-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555238				2022-12-24	WOS:A1992HM44500014
J	DONEHOWER, LA; HARVEY, M; SLAGLE, BL; MCARTHUR, MJ; MONTGOMERY, CA; BUTEL, JS; BRADLEY, A				DONEHOWER, LA; HARVEY, M; SLAGLE, BL; MCARTHUR, MJ; MONTGOMERY, CA; BUTEL, JS; BRADLEY, A			MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS	NATURE			English	Article							CELL-CYCLE CONTROL; WILD-TYPE P53; MONOCLONAL-ANTIBODY; T-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; PROTO-ONCOGENE; MOUSE; GENE; EXPRESSION	Mutations in the p53 tumour-suppressor gene are the most frequently observed genetic lesions in human cancers. To investigate the role of the p53 gene in mammalian development and tumorigenesis, a null mutation was introduced into the gene by homologous recombination in murine embryonic stem cells. Mice homozygous for the null allele appear normal but are prone to the spontaneous development of a variety of neoplasms by 6 months of age. These observations indicate that a normal p53 gene is dispensable for embryonic development, that its absence predisposes the animal to neoplastic disease, and that an oncogenic mutant form of p53 is not obligatory for the genesis of many types of tumours.	BAYLOR COLL MED, CTR COMPARAT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	DONEHOWER, LA (corresponding author), BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA.			Butel, Janet/0000-0002-6876-3245; Bradley, Allan/0000-0002-2349-8839				ALISON RH, 1987, VET PATHOL, V24, P226, DOI 10.1177/030098588702400305; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DAVID YB, 1988, ONCOGENE, V3, P179; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JARVIS DL, 1984, VIROLOGY, V134, P168, DOI 10.1016/0042-6822(84)90282-4; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1990, NATURE, V64, P313; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAITA K, 1988, TOXICOL PATHOL, V16, P340, DOI 10.1177/019262338801600305; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOWAT M, 1985, NATURE, V61, P2777; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SLAGLE BL, 1984, CANCER RES, V44, P2155; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUSSI T, 1990, ONCOGENE, V5, P945; SQUIRE RA, 1978, PATHOLOGY LABORATORY, P1054; SRIVASTAVA S, 1990, NATURE, V348, P757; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STUTMAN O, 1974, FED PROC, V33, P2028; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YANDELL D W, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P459; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	4046	4170	4	197	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					215	221		10.1038/356215a0	http://dx.doi.org/10.1038/356215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552940				2022-12-24	WOS:A1992HJ94400048
J	WANNAMETHEE, G; SHAPER, AG				WANNAMETHEE, G; SHAPER, AG			PHYSICAL-ACTIVITY AND STROKE IN BRITISH MIDDLE-AGED MEN	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; HEART-DISEASE; QUESTIONNAIRE; HEALTH; DEATH	Objectives - To assess the relation between physical activity and stroke and to determine the overall benefit of physical activity for all major cardiovascular events. Design - Prospective study of a cohort of men followed up for 9-5 years. Setting - General practices in 24 towns in England, Wales, and Scotland (British regional heart study). Subjects - 7735 men aged 40-59 at screening, selected at random from one general practice in each of 24 towns. Main outcome measures - Fatal and non-fatal strokes and heart attacks. Results - 128 major strokes (fatal and non-fatal) occurred. Physical activity was inversely associated with risk of stroke independent of coronary risk factors, heavy drinking, and pre-existing ischaemic heart disease or stroke (relative risk 1.0 for inactivity, 0.6 moderate activity, and 0.3 vigorous activity; test for trend p = 0.008). The association remained after excluding men reporting regular sporting (vigorous) activity. However, vigorous physical activity was associated with a marginally significant increased risk of heart attack compared with moderate or moderately vigorous activity in men with no pre-existing ischaemic heart disease or stroke (relative risk 1.6; 95% confidence interval 0.96 to 2.8). In men with symptomatic ischaemic heart disease or stroke those doing moderately vigorous or vigorous activity had a risk of heart attack slightly higher than that in inactive men (relative risk = 1.6; 0.8 to 3.3). Conclusions - Moderate physical activity significantly reduces the risk of stroke and heart attacks in men both with and without pre-existing ischaemic heart disease. More vigorous activity did not confer any further protection. Moderate activity, such as frequent walking and recreational activity or weekly sporting activity, should be encouraged without restriction.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977				BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; HERMAN B, 1982, STROKE, V13, P334, DOI 10.1161/01.STR.13.3.334; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; PAFFENBA.RS, 1967, LANCET, V1, P753, DOI 10.1016/S0140-6736(67)91367-0; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SLATTERY ML, 1989, CIRCULATION, V79, P3104; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	15	179	182	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					597	601		10.1136/bmj.304.6827.597	http://dx.doi.org/10.1136/bmj.304.6827.597			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559088	Bronze, Green Published			2022-12-24	WOS:A1992HH73300020
J	HENDERSON, RA; MICHEL, H; SAKAGUCHI, K; SHABANOWITZ, J; APPELLA, E; HUNT, DF; ENGELHARD, VH				HENDERSON, RA; MICHEL, H; SAKAGUCHI, K; SHABANOWITZ, J; APPELLA, E; HUNT, DF; ENGELHARD, VH			HLA-A2.1-ASSOCIATED PEPTIDES FROM A MUTANT-CELL LINE - A 2ND PATHWAY OF ANTIGEN PRESENTATION	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; VIRAL PEPTIDES; LYMPHOCYTE-T; PROTEIN; BINDING; INVITRO; GENE	Peptides extracted from HLA-A2.1 class I major histocompatibility complex (MHC) molecules expressed on the antigen processing mutant CEMx721.174.T2 were characterized by electrospray ionization-tandem mass spectrometry. Only seven dominant peptides were found, in contrast to over 200 associated with HLA-A2.1 on normal cells. These peptides were derived from the signal peptide domains of normal cellular proteins, were usually larger than nine residues, and were also associated with HLA-A2.1 in normal cells. These results suggest that proteolysis of signal peptide domains in the endoplasmic reticulum is a second mechanism for processing and presentation of peptides for association with class I molecules.	UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903; NCI,CELL BIOL LAB,BETHESDA,MD 20892	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HENDERSON, RA (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908, USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sakaguchi, Kazuyasu/0000-0002-8434-4171; Engelhard, Victor/0000-0002-1741-0925	NIAID NIH HHS [AI20963] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020963, R37AI020963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEMARS R, 1991, NATURE, V351, P323; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ENGELHARD VH, 1991, J IMMUNOL, V146, P1226; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P25122; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1260; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHEL HV, UNPUB; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0	32	511	533	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1264	1266		10.1126/science.1546329	http://dx.doi.org/10.1126/science.1546329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546329				2022-12-24	WOS:A1992HG67700046
J	CHENEVERT, J; CORRADO, K; BENDER, A; PRINGLE, J; HERSKOWITZ, I				CHENEVERT, J; CORRADO, K; BENDER, A; PRINGLE, J; HERSKOWITZ, I			A YEAST GENE (BEM1) NECESSARY FOR CELL POLARIZATION WHOSE PRODUCT CONTAINS 2 SH3 DOMAINS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE; SEQUENCE; PROTEIN; SIGNAL; FUSION; VIRUS	CELL polarization requires that a cellular axis or cell-surface site be chosen and that the cytoskeleton be organized with respect to it. Details of the link between the cytoskeleton and the chosen axis or site are not clear 1. Cells of the yeast Saccharomyces cerevisiae exhibit cell polarization in two phases of their life cycle, during vegetative growth and during mating, which reflects responses to intracellular and extracellular signals, respectively. Here we describe the isolation of two mutants defective specifically in cell polarization in response to peptide mating pheromones. The mutants carry special alleles (denoted bem1-s) of the BEM1 gene required for cell polarization during vegetative growth 2,3. Unlike other bem1 mutants, the bem1-s mutants are normal for vegetative growth. Complete deletion of BEM1 leads to the defect in polarization of vegetative cells seen in bem1 mutants 2,3. The predicted sequence of the BEM1 protein (Bem1p) reveals two copies of a domain (denoted SH3) that is found in many proteins associated with the cortical cytoskeleton and which may mediate binding to actin or some other component of the cell cortex 4,5. The sequence of Bem1p and the properties of mutants defective in this protein indicate that it may link the cytoskeleton to morphogenetic determinants on the cell surface.	UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	CHENEVERT, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUGGIERI R, IN PRESS MOL CELL BI; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	23	188	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					77	79		10.1038/356077a0	http://dx.doi.org/10.1038/356077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538785	Green Published			2022-12-24	WOS:A1992HG60200061
J	MORRIS, JK; COOK, DG; SHAPER, AG				MORRIS, JK; COOK, DG; SHAPER, AG			NONEMPLOYMENT AND CHANGES IN SMOKING, DRINKING, AND BODY-WEIGHT	BRITISH MEDICAL JOURNAL			English	Article							AGED BRITISH MEN; CARDIOVASCULAR RISK-FACTORS; ALCOHOL-CONSUMPTION; SOCIAL-CLASS; UNEMPLOYMENT; HEALTH; MORTALITY; BEHAVIOR; BRITAIN	Objective - To assess the effect of unemployment and early retirement on cigarette smoking, alcohol consumption, and body weight in middle aged British men. Design - Prospective cohort study (British regional heart study.) Setting - One general practice in 24 towns in Britain. Subjects - 6057 men aged 40-59 who had been continuously employed for five years before the initial screening. Five years after screening 4412 men had been continuously employed and 1645 had experienced some unemployment or retired. Main outcome measures - Numbers of cigarettes smoked and units of alcohol consumed per week and body mass index (kg/m2). Results - At initial screening significantly higher percentages of men who subsequently experienced non-employment smoked or had high alcohol consumption than of men who remained continuously employed: 43.0% versus 37.0% continuously employed for cigarette smoking (95% confidence interval for difference 3.2% to 9.0%) and 12.1% versus 9.0% for heavy drinking (1.3% to 5.1%). There was no evidence that men increased their smoking or drinking on becoming non-employed. Men non-employed through illness were significantly more likely to reduce their smoking and drinking than men who remained continuously employed. Men who experienced non-employment were significantly more likely to gain over 10% in weight than men who remained continuously employed: 7.5% versus 5.0% continuously employed (0.9% to 4.0%). Conclusions - Loss of employment was not associated with increased smoking or drinking but was associated with an increased likelihood of gaining weight. The long term effects of the higher levels of smoking and alcohol consumption before nonemployment should be taken into account when comparing mortality and morbidity in groups of unemployed and employed people.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Cook, Derek/0000-0002-9723-5759; Morris, Joan/0000-0002-7164-612X				[Anonymous], 1970, CLASSIFICATION OCCUP; BRAY GA, 1978, INT J OBESITY, V2, P99; COOK DG, 1982, LANCET, V1, P1290; CRAWFORD A, 1987, BRIT J ADDICT, V82, P1007; CUMMINS RO, 1981, BRIT MED J, V283, P1497, DOI 10.1136/bmj.283.6305.1497; HAMMARSTROM A, 1988, SOC SCI MED, V26, P1025, DOI 10.1016/0277-9536(88)90220-1; HEADY P, 1989, LIVING STANDARDS UNE; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; IVERSEN L, 1986, SOC SCI MED, V22, P107, DOI 10.1016/0277-9536(86)90314-X; KASL SV, 1972, INT J EPIDEMIOL, V1, P111, DOI 10.1093/ije/1.2.111; KENDELL RE, 1983, BRIT MED J, V287, P809, DOI 10.1136/bmj.287.6395.809; KESSLER RC, 1987, J HEALTH SOC BEHAV, V28, P51, DOI 10.2307/2137140; Kirby H D, 1986, Health Visit, V59, P312; LEE AJ, 1990, BRIT J ADDICT, V85, P1165; MATTIASSON I, 1990, BRIT MED J, V301, P461, DOI 10.1136/bmj.301.6750.461; MOSER KA, 1984, LANCET, V2, P1324; NARENDRANTHAN W, 1985, J R STAT SOC A STAT, V148, P254, DOI 10.2307/2981970; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMART RG, 1979, J OCCUP ENVIRON MED, V21, P731, DOI 10.1097/00043764-197911000-00005; WALDRON I, 1989, AM J PREV MED, V3, P142; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WARR P, 1983, J APPL SOC PSYCHOL, V13, P206, DOI 10.1111/j.1559-1816.1983.tb01735.x; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; 1985, SAS USERS GUIDE STAT; 1984, GENERAL HOUSEHOLD SU; 1986, GENERAL HOUSEHOLD SU; 1980, GENERAL HOUSEHOLD SU; 1986, SUGI SUPPLEMENTAL LI; 1988, GENERAL HOUSEHOLD SU; 1990, GENERAL HOUSEHOLD SU	33	101	101	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					536	541		10.1136/bmj.304.6826.536	http://dx.doi.org/10.1136/bmj.304.6826.536			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG599	1559056	Green Published, Bronze			2022-12-24	WOS:A1992HG59900018
J	EPSTEIN, NR				EPSTEIN, NR			FRAME AND FOCUS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ALZHEIMERS DISEASE; PHYSICIAN-PATIENT RELATIONS		A physician meets with an Alzheimer patient and the patient's wife. In the process, an examination is done, and the wife and physician discuss her ability to cope with her difficult responsibilities. They digress into her memories of past travels with her husband, and of the onset of his disease. The physician grapples with questions of bis own vulnerability and ponders some disquieting possibilities.											0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					690	690		10.7326/0003-4819-117-8-690	http://dx.doi.org/10.7326/0003-4819-117-8-690			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530201				2022-12-24	WOS:A1992JR86100011
J	SEIDEL, HM; POMPLIANO, DL; KNOWLES, JR				SEIDEL, HM; POMPLIANO, DL; KNOWLES, JR			EXONS AS MICROGENES	SCIENCE			English	Editorial Material							SPLICE JUNCTIONS; EVOLUTION; TETRAHYMENA; CODONS; INTRON; GENES		HARVARD UNIV, DEPT CHEM, 12 OXFORD ST, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University								Anfinsen C.B., 1971, ENZYMES, V4; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; GALAKATOS NG, 1987, BIOCHEMISTRY-US, V26, P8475, DOI 10.1021/bi00399a066; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; Hori T., 1984, BIOCH NATURAL C P CO; LI CH, 1976, P NATL ACAD SCI USA, V73, P1476, DOI 10.1073/pnas.73.5.1476; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; ORGEL LE, 1987, COLD SPRING HARB SYM, V52, P9, DOI 10.1101/SQB.1987.052.01.004; OSAWA S, 1990, P ROY SOC B-BIOL SCI, V241, P19, DOI 10.1098/rspb.1990.0060; RICHARDS FM, 1971, ENZYMES, V4, P647; SEIDEL HM, 1992, BIOCHEMISTRY-US, V31, P2598, DOI 10.1021/bi00124a021; SENAPATHY P, 1988, P NATL ACAD SCI USA, V85, P1129, DOI 10.1073/pnas.85.4.1129; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; [No title captured]	21	29	31	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1489	1490		10.1126/science.1523407	http://dx.doi.org/10.1126/science.1523407			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523407				2022-12-24	WOS:A1992JM57000019
J	SMITH, JL; WILSON, JE; MACDONALD, PM				SMITH, JL; WILSON, JE; MACDONALD, PM			OVEREXPRESSION OF OSKAR DIRECTS ECTOPIC ACTIVATION OF NANOS AND PRESUMPTIVE POLE CELL-FORMATION IN DROSOPHILA EMBRYOS	CELL			English	Article							POSTERIOR DETERMINANT NANOS; MATERNAL-EFFECT MUTATIONS; DOUBLE-ABDOMEN EMBRYOS; GAP GENE GIANT; GERM PLASM; MESSENGER-RNA; ANTEROPOSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; SEQUENCE SIMILARITY; BODY PATTERN	In Drosophila, a small group of maternal effect genes, including oskar, defines a shared pathway leading to the provision of two determinants at the posterior pole of the embryo. One determinant is the posterior body patterning morphogen nanos, and the other directs germ cell formation. Overexpression of oskar causes the shared pathway to be hyperactivated, with excess nanos activity present throughout the embryo and a superabundance of posterior pole cells. In addition, presumptive pole cells appear at a novel anterior position. Strikingly, formation of these ectopic pole cells is enhanced in nanos mutants. This observation may reflect competition between nanos and the germ cell determinant for a shared and limiting precursor.			SMITH, JL (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042612] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42612] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; KERR JB, 1974, J EMBRYOL EXP MORPH, V32, P573; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NIKI Y, 1986, DEV BIOL, V113, P255, DOI 10.1016/0012-1606(86)90127-2; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wieschaus E., 1986, P199	50	174	175	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					849	859		10.1016/0092-8674(92)90318-7	http://dx.doi.org/10.1016/0092-8674(92)90318-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516136				2022-12-24	WOS:A1992JL66300016
J	HENRY, MF; CRONAN, JE				HENRY, MF; CRONAN, JE			A NEW MECHANISM OF TRANSCRIPTIONAL REGULATION - RELEASE OF AN ACTIVATOR TRIGGERED BY SMALL MOLECULE-BINDING	CELL			English	Article							FATTY-ACID DEGRADATION; ESCHERICHIA-COLI K-12; POSITIVE CONTROL; PRIMARY SEQUENCE; OPERON FUSION; DNA FRAGMENTS; GENE; CLONING; PROTEIN; SYSTEM	The FadR protein of E. coli activates transcription of the fabA gene, a key enzyme of fatty acid synthesis. We report that FadR binds to a DNA sequence positioned at -40 relative to the start site of the FadR-regulated fabA transcript (the location favored by positive activators). This binding was found to be specifically antagonized by long chain acyl-CoAs. The chain length specificity of the disassociation of the FadR-DNA complex by acyl-CoAs observed in vitro reflects that seen in the repression of fabA transcription observed upon addition of fatty acids to bacterial cultures. Acyl-CoA antagonism of FadR-DNA interactions is readily reversible. These data indicate that repression of fabA transcription by fatty acids is the first reported example of a repression system mediated by positive control.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; ARPS PJ, 1987, J BACTERIOL, V169, P1061, DOI 10.1128/jb.169.3.1061-1070.1987; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; CASADABAN MJ, 1975, P NATL ACAD SCI USA, V72, P809, DOI 10.1073/pnas.72.3.809; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CRONAN JE, 1984, J BACTERIOL, V159, P773, DOI 10.1128/JB.159.2.773-775.1984; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1984, J BACTERIOL, V158, P357, DOI 10.1128/JB.158.1.357-361.1984; CRONAN JE, 1987, CELLULAR MOL BIOL, V1, P474; Davis R., 1980, ADV BACTERIAL GENETI; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; HENRY MF, 1989, J BACTERIOL, V171, P5254, DOI 10.1128/jb.171.10.5254-5261.1989; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HILL FF, 1972, MOL GEN GENET, V117, P143, DOI 10.1007/BF00267611; HUGHES KT, 1988, J BACTERIOL, V170, P1666, DOI 10.1128/jb.170.4.1666-1671.1988; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEWIN B, 1990, GENES, V4, P257; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937, DOI 10.1093/nar/18.16.4937; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; NUNN WD, 1987, CELLULAR MOL BIOL, V1, P31; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; SALLUS L, 1983, J BACTERIOL, V155, P1450, DOI 10.1128/JB.155.3.1450-1454.1983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGEAU MA, 1989, THEORETICAL BIOLOGY, P42; SAVAGEAU MA, 1979, BIOL REGUL DEV, V1, P57; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; STRUHL K, 1989, CURRENT PROTOCOLS MO, V2; TABOR S, 1987, CURRENT PROTOCOLS MO, V1; TAKETA K, 1966, J BIOL CHEM, V241, P720; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	52	134	136	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					671	679		10.1016/0092-8674(92)90435-F	http://dx.doi.org/10.1016/0092-8674(92)90435-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505031				2022-12-24	WOS:A1992JJ88600015
J	LAI, ZC; RUBIN, GM				LAI, ZC; RUBIN, GM			NEGATIVE CONTROL OF PHOTORECEPTOR DEVELOPMENT IN DROSOPHILA BY THE PRODUCT OF THE YAN GENE, AN ETS DOMAIN PROTEIN	CELL			English	Article							CELL-CELL-INTERACTION; TYROSINE-KINASE; DNA-BINDING; SEVENLESS PROTEIN; FATE; EYE; EXPRESSION; RECEPTOR; MELANOGASTER; ONCOGENE	Loss-of-function mutations in the yan gene result in the differentiation of supernumerary photoreceptors in the Drosophila eye. The yan gene encodes a protein with an ETS DNA-binding domain that accumulates in the nuclei of undifferentiated cells during the early stages of eye development. Our data suggest that yan functions as a cell-autonomous negative regulator of photoreceptor development; in the presumptive R7 and cone cells, yan appears to act antagonistically to the proneural signal mediated by sevenless and Ras1.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	LAI, ZC (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FREEMAN M, 1992, IN PRESS DEVELOPMENT; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	50	235	238	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					609	620		10.1016/0092-8674(92)90430-K	http://dx.doi.org/10.1016/0092-8674(92)90430-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505027				2022-12-24	WOS:A1992JJ88600010
J	BAGASRA, O; HAUPTMAN, SP; LISCHNER, HW; SACHS, M; POMERANTZ, RJ				BAGASRA, O; HAUPTMAN, SP; LISCHNER, HW; SACHS, M; POMERANTZ, RJ			DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRUS IN MONONUCLEAR-CELLS BY INSITU POLYMERASE CHAIN-REACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GLIAL-CELLS; PERIPHERAL-BLOOD; HTLV-III; T-CELL; INFECTED INDIVIDUALS; HIV INFECTION; SYNDROME AIDS; DNA; EXPRESSION; HYBRIDIZATION	Background. Studies of human immunodeficiency virus type 1 (HIV-1) infection have attempted to quantitate the viral load and correlate it with the degree of immune deficiency. In one study, only about 1 in 10,000 peripheral-blood mononuclear cells (PBMC) expressed HIV-1, but in other studies, at least 1 in 100 CD4-positive cells was infected and harbored the HIV-1 provirus. Methods. We developed a new, highly sensitive in situ polymerase-chain-reaction (PCR) method that amplifies selected genetic regions within intact single cells. We used this technique to determine the proportion of PBMC carrying HIV-1 provirus in infected patients in different stages of disease. Results. None of the PBMC from 11 HIV-1-seronegative patients were found to be positive for HIV-1 provirus by the in situ PCR method. In 56 patients infected with HIV-1, the percentage of PBMC with HIV-1 ranged from 0.1 percent to 13.5 percent. The mean percentage of infected mononuclear cells was greater in 13 patients with persistent generalized adenopathy (mean, 6.6 percent) and 19 with the acquired immunodeficiency syndrome (Stages IV-A to IV-C) (4.6 percent) than in 19 patients with asymptomatic HIV-1 infection (0.9 percent) (P < 0.001). However, in five patients with Kaposi's sarcoma (Stage IV-D), an average of only 1.6 percent of mononuclear cells were infected Conclusions. In HIV-1 infection, the proportion of PBMC that are infected appears to be at least 10 times higher than previously described. It is likely that most infected cells contain HIV-1 provirus in a latent or defective form that was not detected in some earlier studies.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; ST CHRISTOPHERS HOSP CHILDREN,DEPT PEDIAT,PHILADELPHIA,PA 19133; TEMPLE UNIV,PHILADELPHIA,PA 19122	Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	BAGASRA, O (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,1025 WALNUT ST,SUITE 813,PHILADELPHIA,PA 19107, USA.				NIAID NIH HHS [AI-00930] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000930] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BORKOWSKY W, 1987, LANCET, V1, P1168; BRINCHMANN JE, 1991, J VIROL, V65, P2019, DOI 10.1128/JVI.65.4.2019-2023.1991; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEWLEY JP, 1989, J VIROL METHODS, V25, P179, DOI 10.1016/0166-0934(89)90031-1; CLOUSE KA, 1989, J IMMUNOL, V142, P431; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEFRANCHIS R, 1988, NUCLEIC ACIDS RES, V16, P10355, DOI 10.1093/nar/16.21.10355; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; DICKOVER RE, 1990, J CLIN MICROBIOL, V28, P2130, DOI 10.1128/JCM.28.9.2130-2133.1990; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENESCA J, 1990, J INFECT DIS, V162, P1025, DOI 10.1093/infdis/162.5.1025; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HORSBURGH RC, 1990, J INFECT DIS, V152, P542; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; IKEUCHI K, 1990, J VIROL, V64, P4226, DOI 10.1128/JVI.64.9.4226-4231.1990; JACKSON JB, 1988, JAMA-J AM MED ASSOC, V260, P2236; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; KELLER GH, 1989, ANAL BIOCHEM, V177, P27, DOI 10.1016/0003-2697(89)90007-9; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; KWOK S, 1989, PCR PROTOCOLS GUIDE, P142; LEWIS DE, 1990, J INFECT DIS, V162, P1373, DOI 10.1093/infdis/162.6.1373; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LOCHE M, 1988, LANCET, V2, P418; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MONTAGNIER L, 1984, SCIENCE, V225, P63, DOI 10.1126/science.6328661; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POZNANSKY MC, 1991, J ACQ IMMUN DEF SYND, V4, P368; PYUN KH, 1987, NEW ENGL J MED, V317, P611, DOI 10.1056/NEJM198709033171006; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SALAHUDDIN SZ, 1985, P NATL ACAD SCI USA, V82, P5530, DOI 10.1073/pnas.82.16.5530; SALAHUDDIN SZ, 1986, BLOOD, V68, P281; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TSUBOTA H, 1989, J IMMUNOL, V143, P858; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; [No title captured]	56	276	293	2	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1385	1391		10.1056/NEJM199205213262103	http://dx.doi.org/10.1056/NEJM199205213262103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569974				2022-12-24	WOS:A1992HU89000003
J	HUSSAIN, SF; WATURA, R; CASHMAN, B; CAMPBELL, IA; EVANS, MR				HUSSAIN, SF; WATURA, R; CASHMAN, B; CAMPBELL, IA; EVANS, MR			AUDIT OF A TUBERCULOSIS CONTACT TRACING CLINIC	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the efficiency of tuberculosis contact tracing in South Glamorgan 1987-9. Design - Review of records of contact tracing clinic and of data from the Mycobacterium Reference Unit. The clinic's practice was compared with 1983 British Thoracic Society's recommendations. Setting - Health authority tuberculosis control programme. Main outcome measures - Proportion of contacts screened, follow up attendance rates, number of secondary cases detected, and quality of record keeping. Results - 101 index patients and 611 contacts were identified. 596 (97.5%) contacts were screened, of whom 139 should not have been. Of 356 contacts requiring a Heaf test, 237 were tested, seven refused the test, and 112 had chest radiography without a Heaf test. 95 contacts were unnecessarily tested. 87 contacts had chest radiography unnecessarily and seven should have had radiography but did not. 34 contacts were given follow up appointments inappropriately and seven were overlooked for follow up. Tuberculosis was diagnosed in five asymptomatic contacts, all at initial screening and all close contacts of index patients with pulmonary disease. Conclusion - Inadequacy of data, non-adherence to contact tracing guidelines, and failure to define the term highly infectious index case resulted in many contacts being unnecessarily screened or followed up. Implications - The efficiency of tracing contacts would be improved by specifying smear results and ethnic origin of the index case on the notification form, clearly classifying contacts as close or casual, and clearly defining the term highly infectious.	LLANDOUGH HOSP,DEPT CHEST MED,CARDIFF CF6 1XX,WALES; TEMPLE PEACE & HLTH,CTR APPL PUBL HLTH,CARDIFF CF1 3NW,WALES; TEMPLE PEACE & HLTH,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,WALES				Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				[Anonymous], 1978, Tubercle, V59, P245; ESMONDE TFG, 1991, RESP MED, V85, P421, DOI 10.1016/S0954-6111(06)80188-5; JONES JS, 1983, LANCET, V1, P232; SELBY CD, 1988, THORAX, V43, pP834; 1990, BMJ, V300, P995; 1983, BMJ, V287, P1118	6	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1213	1215		10.1136/bmj.304.6836.1213	http://dx.doi.org/10.1136/bmj.304.6836.1213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515789	Green Published, Bronze			2022-12-24	WOS:A1992HT96400019
J	CAMMAROTA, G; SCHEIRLE, A; TAKACS, B; DORAN, DM; KNORR, R; BANNWARTH, W; GUARDIOLA, J; SINIGAGLIA, F				CAMMAROTA, G; SCHEIRLE, A; TAKACS, B; DORAN, DM; KNORR, R; BANNWARTH, W; GUARDIOLA, J; SINIGAGLIA, F			IDENTIFICATION OF A CD4 BINDING-SITE ON THE BETA-2-DOMAIN OF HLA-DR MOLECULES	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CELL-SURFACE-ANTIGENS; CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; MHC CLASS; COMPLEX; RECEPTOR; RECOGNITION; ACTIVATION	THE CD4 and CD8 molecules are transmembrane glycoproteins expressed by functionally distinct subsets of mature T cells. CD4+ and CD8+ T cells recognize antigens on major histocompatibility complex (MHC) class II-bearing and class I-bearing target cells respectively 1-3. The ability of monoclonal antibodies against CD4 and CD8 to block antigen recognition by T cells, as well as cell-cell adhesion assays 4-7, indicate that CD4 and CD8 bind to non-polymorphic determinants of class II or class I MHC. Here we demonstrate that soluble recombinant HLA-DR4 molecules from insect cells and HLA-DR-derived peptides bind to immobilized recombinant soluble CD4. CD4 binds recombinant soluble DR4 heterodimers, as well as the soluble DR4-beta-chain alone. Furthermore, two out of twelve DR4-beta-peptides could interact specifically with CD4. These findings show that CD4 interacts with a region of MHC class II molecules analogous to a previously identified loop in class I MHC proteins that binds CD8 (refs 8,9).	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Roche Holding; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Cammarota, Giovanni/AAD-1732-2022	Cammarota, Giovanni/0000-0002-3626-6148				AUTIERO M, 1991, VIROLOGY, V185, P820, DOI 10.1016/0042-6822(91)90553-N; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DEGLIANTONI G, 1985, J EXP MED, V161, P1152, DOI 10.1084/jem.161.5.1152; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GORGA JC, 1987, J BIOL CHEM, V262, P16087; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOSCICKI RA, 1983, J IMMUNOL, V131, P743; NOLLI ML, 1986, THROMB HAEMOSTASIS, V56, P214; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SINIGAGLIA F, 1992, METHOD ENZYMOL, V203, P370; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	25	272	281	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					799	801		10.1038/356799a0	http://dx.doi.org/10.1038/356799a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574119				2022-12-24	WOS:A1992HR18600052
J	JAIN, J; MCCAFFREY, PG; VALGEARCHER, VE; RAO, A				JAIN, J; MCCAFFREY, PG; VALGEARCHER, VE; RAO, A			NUCLEAR FACTOR OF ACTIVATED T-CELLS CONTAINS FOS AND JUN	NATURE			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; INTERLEUKIN-2 GENE; DNA-BINDING; PROTEIN; ENHANCER; ELEMENT; AP-1	THE nuclear factor NF-AT (ref. 1) is induced in T cells stimulated through the T-cell receptor/CD3 complex, and is required for interleukin-2 (IL-2) gene induction. Although NF-AT has not been cloned or purified, there is evidence that it is a major target for immunosuppression by cyclosporin A (CsA) and FK506 (refs 2-7). NF-AT induction may require two activation-dependent events: the CsA-sensitive translocation of a pre-existing component and the CsA-resistant synthesis of a nuclear component 8. Here we report that the newly synthesized nuclear component of NF-AT is the transcription factor AP-1. We show that the inducible nuclear form of NF-AT contains Fos and Jun proteins. Furthermore, we identify a pre-existing NF-AT-binding factor that is present in hypotonic extracts of unstimulated T cells. On the basis of binding, reconstitution and cotransfection experiments, we propose that activation of NF-AT occurs in at least two stages: a CsA-sensitive stage involving modification and/or translocation of the pre-existing NF-AT complex, and a CsA-insensitive stage involving the addition of newly synthesized Fos or Fos/Jun proteins to the pre-existing complex.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)								BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; POGNONEC P, 1989, ONCOGENE, V4, P691; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	26	492	503	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					801	804		10.1038/356801a0	http://dx.doi.org/10.1038/356801a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1533441				2022-12-24	WOS:A1992HR18600053
J	SEONG, RH; CHAMBERLAIN, JW; PARNES, JR				SEONG, RH; CHAMBERLAIN, JW; PARNES, JR			SIGNAL FOR T-CELL DIFFERENTIATION TO A CD4 CELL LINEAGE IS DELIVERED BY CD4 TRANSMEMBRANE REGION AND OR CYTOPLASMIC TAIL	NATURE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; TYROSINE-PROTEIN-KINASE; TRANSGENIC MICE; RECEPTOR DETERMINE; CD4/CD8 PHENOTYPE; LYMPHOCYTES-T; MOLECULES; EXPRESSION; THYMUS; PHOSPHORYLATION	MATURE T cells express either CD4 or CD8 on their surface. Most helper T cells express CD4, which binds to class II major histocompatibility complex (MHC) proteins, and most cytotoxic T cells express CD8, which binds to class I MHC proteins. In the thymus, mature CD4+CD8- and CD4- CD8+ T cells expressing alpha-beta-T-cell antigen receptors (TCR) develop from immature thymocytes through CD4+CD8+ alpha-beta-TCR+ intermediates 1. Experiments using mice transgenic for alpha-beta-TCR 2-5 suggest that the specificity of the TCR determines the CD4/CD8 phenotype of mature T cells. These results, however, do not indicate how a T cell differentiates into the CD4 or CD8 lineage. Here we show that the CD4 transmembrane region and/or cytoplasmic tail mediates the delivery of a specific signal that directs differentiation of T cells to a CD4 lineage. We generated transgenic mice expressing a hybrid molecule composed of the CD8-alpha extracellular domains linked to the CD4 transmembrane region and cytoplasmic tail. We predicted that this hybrid molecule would bind to class I MHC proteins through the extracellular domains but deliver the intracellular signals characteristic of CD4. By crossing our transgenic mice with mice expressing a transgenic alpha-beta-TCR specific for a particular antigen plus class I MHC protein, we were able to express the hybrid molecule in developing thymocytes expressing the class I MHC-restricted TCR. Our results show that the signal transduced by the hybrid molecule results in the differentiation of immature thymocytes expressing a class I-restricted TCR into mature T cells expressing CD4.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA	Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Seong, Rho/0000-0001-5699-0718				BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GORMAN SD, 1987, P NATL ACAD SCI USA, V84, P7644, DOI 10.1073/pnas.84.21.7644; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAPPLER JW, 1978, J EXP MED, V148, P1510, DOI 10.1084/jem.148.6.1510; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1978, P NATL ACAD SCI USA, V75, P2434; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	22	83	83	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1992	356	6371					718	720		10.1038/356718a0	http://dx.doi.org/10.1038/356718a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1533274				2022-12-24	WOS:A1992HQ14600063
J	KIM, S; LANDY, A				KIM, S; LANDY, A			LAMBDA-INT PROTEIN BRIDGES BETWEEN HIGHER-ORDER COMPLEXES AT 2 DISTANT CHROMOSOMAL LOCI ATTL AND ATTR	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; INTEGRATION HOST FACTOR; BACTERIOPHAGE-LAMBDA; EXCISIVE RECOMBINATION; GENE-PRODUCT; ATTACHMENT SITE; BINDING-SITES; DNA COMPLEX; PURIFICATION; SEQUENCE	The excisive recombination reaction of bacteriophage lambda involves a specific and efficient juxtaposition of two distant higher order protein-DNA complexes on the chromosome of Escherichia coli. These complexes, which mediate synapsis and strand exchange, consist of two DNA sequences, attL and attR, the bivalent DNA binding protein Int, and the sequence-specific DNA bending proteins, IHF, Xis, and Fis. The protein-protein and protein-DNA interactions within, and between, these complexes were studied by various biochemical techniques and the patterns of synergism among pairs of mutants with marginally impaired recombination function were analyzed. The DNA bending proteins facilitated long-range tethering of high- and low-affinity DNA sites by the bivalent Int protein, and a specific map is proposed for the resulting Int bridges. These structural motifs provide a basis for postulating the mechanisms of site-specific recombination and may also be relevant to other pathways in which two distant chromosomal sites become associated.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Brown University			Kim, Sunghoon/AAE-8314-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033928, R01GM062723] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 13544] Funding Source: Medline; NIGMS NIH HHS [R01 GM062723, R01 GM033928, GM 33928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1982, J BIOL CHEM, V257, P9658; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BALL CA, 1991, J BACTERIOL, V173, P4027, DOI 10.1128/jb.173.13.4027-4031.1991; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BUSHMAN W, 1985, SCIENCE, V230, P906, DOI 10.1126/science.2932798; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KOTEWICZ M, 1980, J BIOL CHEM, V255, P2433; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LANDY A, 1977, SCIENCE, V197, P1147, DOI 10.1126/science.331474; LANDY A, UNPUB; NASH HA, 1981, J BIOL CHEM, V256, P9246; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUMRYCH TE, 1990, NUCLEIC ACIDS RES, V18, P3953, DOI 10.1093/nar/18.13.3953; NUNESDUBY S, UNPUB; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X; THOMPSON JF, 1987, CELL, V50, P901, DOI 10.1016/0092-8674(87)90516-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THOMPSON JF, 1986, J BACTERIOL, V168, P1343, DOI 10.1128/jb.168.3.1343-1351.1986; THOMPSON JF, 1988, DNA BENDING CURVATUR, P119; THOMPSON JF, 1989, MOBILE DNA, P1; WINOTO A, 1986, J MOL BIOL, V192, P677, DOI 10.1016/0022-2836(86)90286-X; YIN S, 1985, P NATL ACAD SCI USA, V82, P1040, DOI 10.1073/pnas.82.4.1040; ZAHN K, UNPUB	45	113	124	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					198	203		10.1126/science.1533056	http://dx.doi.org/10.1126/science.1533056			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1533056	Green Accepted			2022-12-24	WOS:A1992HM89600022
J	PIL, PM; LIPPARD, SJ				PIL, PM; LIPPARD, SJ			SPECIFIC BINDING OF CHROMOSOMAL PROTEIN-HMG1 TO DNA DAMAGED BY THE ANTICANCER DRUG CISPLATIN	SCIENCE			English	Article							PLATINUM COMPLEXES; CIS-DIAMMINEDICHLOROPLATINUM(II); TRANS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS; REPLICATION; CELLS	The mechanism of action of the anticancer compound cis-diamminedichloroplatinum(II) (cisplatin) involves covalent binding to DNA. In an effort to understand the tumor-specific cytotoxicity of such DNA damage, the interactions of these lesions with cellular proteins have been studied. One such protein has been identified as the high-mobility group protein HMG1. Recombinant rat HMG1 binds specifically (dissociation constant 3.7 +/- 2.0 x 10(-7) molar) to DNA containing cisplatin d(GpG) or d(ApG) intrastrand cross-links, which unwind and bend DNA in a specific manner, but not to DNA modified by therapeutically inactive platinum analogs. These results suggest how HMG1 might bind to altered DNA structures and may be helpful in designing new antitumor drugs.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PA, 1991, CANCER COMMUN, V3, P1; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BIANCHI ME, 1991, GENE, V104, P271, DOI 10.1016/0378-1119(91)90261-9; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CHAO CCK, 1991, BIOCHEM J, V277, P875, DOI 10.1042/bj2770875; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CICCARELLI RB, 1985, BIOCHEMISTRY-US, V24, P7533, DOI 10.1021/bi00347a005; Cleare, 1973, BIOINORG CHEM, V2, P187, DOI DOI 10.1016/S0006-3061(00)80249-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KECK MV, IN PRESS J AM CHEM S; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; MAREKOV LN, 1984, BIOCHIM BIOPHYS ACTA, V789, P63, DOI 10.1016/0167-4838(84)90061-X; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; SCOVELL WM, 1989, J MACROMOL SCI CHEM, VA26, P455, DOI 10.1080/00222338908051987; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TREIBER DK, UNPUB; VISSE R, 1991, J BIOL CHEM, V266, P7609; 1991, CANCER FACTS FIGURES	29	530	540	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					234	237		10.1126/science.1566071	http://dx.doi.org/10.1126/science.1566071			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566071				2022-12-24	WOS:A1992HM89600033
J	FEDSON, DS; WAJDA, A; NICOL, JP; ROOS, LL				FEDSON, DS; WAJDA, A; NICOL, JP; ROOS, LL			DISPARITY BETWEEN INFLUENZA VACCINATION RATES AND RISKS FOR INFLUENZA-ASSOCIATED HOSPITAL DISCHARGE AND DEATH IN MANITOBA IN 1982-1983	ANNALS OF INTERNAL MEDICINE			English	Article						HEALTH SERVICES FOR THE AGED; INFLUENZA; GERIATRICS; VACCINATION; PULMONARY DISEASE; PNEUMONIA	ACUTE RESPIRATORY-DISEASE; UNITED-STATES; PNEUMOCOCCAL IMMUNIZATION; EPIDEMIOLOGIC RATIONALE; ADMINISTRATIVE DATA; EXCESS MORTALITY; EPIDEMICS; PHYSICIANS; SHENANDOAH; ENGLAND	Objective: To determine, in a defined population, the percentage of persons who were discharged from a hospital or died of influenza-associated respiratory conditions who had a health care contact during the preceding vaccination season and to determine the relation between risk status for influenza-associated hospitalization and death and influenza vaccination rates. Design: An observational study using linked-record analysis of medical claims data. Setting and Patients: A probability sample of 100 000 noninstitutionalized adults living in Manitoba in 1982 to 1983. Measurements: Analysis of medical claims for influenza vaccination and hospital discharges and deaths for influenza-associated respiratory conditions during the 1982-83 influenza vaccination season and influenza outbreak period. Results: For the population as a whole, 50% to 60% of elderly persons (greater-than-or-equal-to 65 years of age ) and 30% to 40% of younger persons had one or more health care contacts during the influenza vaccination season but fewer than 10% of all persons had been discharged from a hospital. In contrast, for elderly persons hospitalized with respiratory conditions during the influenza outbreak period, approximately 80% had at least one health care contact during the vaccination season. Among the elderly, 39% to 46% of all those discharged for influenza-associated respiratory conditions and 62% to 67% of those who died had been discharged from hospital during the previous vaccination season. Persons discharged with high-risk conditions during the vaccination season were at greater risk for hospitalization with influenza-associated respiratory conditions but were less likely to be vaccinated than were those at lower risk. Conclusions: Most persons who were hospitalized with influenza-associated respiratory conditions had contact with health care providers during the preceding influenza vaccination season. Among elderly patients, previous hospital care was common, especially among those who died. The disparity between influenza vaccination rates and risks for influenza-associated hospital discharge and death supports a strategy of hospital-based influenza vaccination.	UNIV MANITOBA, MANITOBA CTR HLTH POLICY & EVALUAT, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Manitoba	FEDSON, DS (corresponding author), UNIV VIRGINIA, MED CTR, SCH MED, BOX 494, CHARLOTTESVILLE, VA 22908 USA.			Roos, Leslie L./0000-0002-4215-8346	NIA NIH HHS [5-R01 AG 09145] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009145] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; AOKI FY, 1990, CLIN INVEST MED, V13, pB58; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BARON RC, 1988, PUBLIC HEALTH REP, V103, P120; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P511, DOI 10.1164/arrd.1982.125.5.511; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; FEDSON DS, 1983, AM J PUBLIC HEALTH, V73, P442, DOI 10.2105/AJPH.73.4.442; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FEDSON DS, 1990, INFECT CONT HOSP EP, V11, P357; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; HARWARD MP, 1987, CLIN RES, V35, pA8; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; LIU KJ, 1987, AM J PUBLIC HEALTH, V77, P712; Mackenzie S G, 1991, Can Dis Wkly Rep, V17, P128; NICHOL KL, 1990, AM J MED, V89, P156, DOI 10.1016/0002-9343(90)90293-M; NICHOL KL, 1991, AM J MED, V91, P584, DOI 10.1016/0002-9343(91)90210-O; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; ROOS LL, 1982, MED CARE, V20, P266, DOI 10.1097/00005650-198203000-00003; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; ROOS LL, 1979, EVALUATION QUART, V3, P236, DOI 10.1177/0193841X7900300204; Roos N P, 1989, J Aging Health, V1, P411, DOI 10.1177/089826438900100401; Schoenbaum S C, 1990, Infect Dis Clin North Am, V4, P199; SHAPIRO E, 1984, GERONTOLOGIST, V24, P610, DOI 10.1093/geront/24.6.610; SPRENGER MJW, 1990, LANCET, V336, P382, DOI 10.1016/0140-6736(90)91929-5; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; WAJDA A, 1987, COMPUT BIOL MED, V17, P239, DOI 10.1016/0010-4825(87)90010-2; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1988, CANADA YB 1988; 1989, 1988 89 MAN HLTH SER; 1989, MMWR, V38, P129; 1989, MMWR, V38, P124; 1988, NAITONAL HTLH EXPEND; 1989, CANADIAN IMMUNIZATIO, P59; 1990, MMWR, V39, P1	36	57	60	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					550	555		10.7326/0003-4819-116-7-550	http://dx.doi.org/10.7326/0003-4819-116-7-550			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543309				2022-12-24	WOS:A1992HL25800005
J	GIMENO, CJ; LJUNGDAHL, PO; STYLES, CA; FINK, GR				GIMENO, CJ; LJUNGDAHL, PO; STYLES, CA; FINK, GR			UNIPOLAR CELL DIVISIONS IN THE YEAST SACCHAROMYCES-CEREVISIAE LEAD TO FILAMENTOUS GROWTH - REGULATION BY STARVATION AND RAS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; CAENORHABDITIS-ELEGANS; PROLINE UTILIZATION; GENES; INDUCTION; SELECTION; GENETICS; PROTEINS; MUTANTS	Diploid S. cerevisiae strains undergo a dimorphic transition that involves changes in cell shape and the pattern of cell division and results in invasive filamentous growth in response to starvation for nitrogen. Cells become long and thin and form pseudohyphae that grow away from the colony and invade the agar medium. Pseudohyphal growth allows yeast cells to forage for nutrients. Pseudohyphal growth requires the polar budding pattern of a/alpha-diploid cells; haploid axially budding cells of identical genotype cannot undergo this dimorphic transition. Constitutive activation of RAS2 or mutation of SHR3, a gene required for amino acid uptake, enhance the pseudohyphal phenotype; a dominant mutation in RSR1/BUD1 that causes random budding suppresses pseudohyphal growth.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	GIMENO, CJ (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540	NIGMS NIH HHS [GM35010, GM40266, GM12038-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266, R01GM035010, R37GM035010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BISSON LF, 1991, 1991 P INT S NNITR G, P136; BRANDRISS MC, 1979, J BACTERIOL, V140, P498, DOI 10.1128/JB.140.2.498-503.1979; BRANDRISS MC, 1980, J BACTERIOL, V143, P1403, DOI 10.1128/JB.143.3.1403-1410.1980; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROWN CM, 1965, NATURE, V206, P676, DOI 10.1038/206676a0; CHAFFIN WL, 1984, J GEN MICROBIOL, V130, P431; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DABROWA N, 1976, INFECT IMMUN, V13, P830, DOI 10.1128/IAI.13.3.830-835.1976; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EUBANKS VL, 1982, J FOOD SCI, V47, P1717, DOI 10.1111/j.1365-2621.1982.tb05019.x; Evans EG, 1989, MED MYCOLOGY PRACTIC; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GUILLIERMOND A, 1920, YEASTS; Gunning B.E.S., 1982, DEV ORDER ITS ORIGIN, P379; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HICKS JB, 1977, GENETICS, V85, P395; HOLMES AR, 1987, J GEN MICROBIOL, V133, P3219; HUANG Z, 1989, AM J ENOL VITICULT, V40, P135; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; INGLEDEW WM, 1987, AM J ENOL VITICULT, V38, P246; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson M.H., 1986, EXPT APPROACHES MAMM, P35; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KULKARNI RK, 1981, EXP MYCOL, V5, P148, DOI 10.1016/0147-5975(81)90015-3; LAND GA, 1975, INFECT IMMUN, V11, P1014, DOI 10.1128/IAI.11.5.1014-1023.1975; Lodder J, 1970, YEASTS TAXONOMIC STU; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Odds FC., 1988, CANDIDA CANDIDOSIS; OUGH CS, 1974, AM J ENOL VITICULT, V25, P7; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, LIFE CYCLE INHERITAN, P97; RAYNER ADM, 1991, MYCOLOGIA, V83, P48, DOI 10.2307/3759832; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; Shepherd M G, 1988, Curr Top Med Mycol, V2, P278; Sherman F., 1986, METHODS YEAST GENETI; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH D, 1969, CAN J BOTANY, V47, P1061, DOI 10.1139/b69-151; Soll D. R., 1991, The fungal spore and disease initiation in plants and animals., P503; SUTHERLAND AE, 1990, DEV BIOL, V137, P13, DOI 10.1016/0012-1606(90)90003-2; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X	58	993	1014	2	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1077	1090		10.1016/0092-8674(92)90079-R	http://dx.doi.org/10.1016/0092-8674(92)90079-R			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547504				2022-12-24	WOS:A1992HK67400011
J	SULSTON, J; DU, Z; THOMAS, K; WILSON, R; HILLIER, L; STADEN, R; HALLORAN, N; GREEN, P; THIERRYMIEG, J; QIU, L; DEAR, S; COULSON, A; CRAXTON, M; DURBIN, R; BERKS, M; METZSTEIN, M; HAWKINS, T; AINSCOUGH, R; WATERSTON, R				SULSTON, J; DU, Z; THOMAS, K; WILSON, R; HILLIER, L; STADEN, R; HALLORAN, N; GREEN, P; THIERRYMIEG, J; QIU, L; DEAR, S; COULSON, A; CRAXTON, M; DURBIN, R; BERKS, M; METZSTEIN, M; HAWKINS, T; AINSCOUGH, R; WATERSTON, R			THE C-ELEGANS GENOME SEQUENCING PROJECT - A BEGINNING	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; EMBRYONIC CELL LINEAGES; SIMPLEX VIRUS TYPE-1; DNA-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MESSENGER-RNA; GENE	The long-term goal of this project is the elucidation of the complete sequence of the Caenorhabditis elegans genome. During the first year methods have been developed and a strategy implemented that is amenable to large-scale sequencing. The three cosmids sequenced in this initial phase are surprisingly rich in genes, many of which have mammalian homologues.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; CTR RECH BIOCHIM MACROMOLEC & PHYS MATH,CNRS,F-34044 MONTPELLIER,FRANCE	Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS)	SULSTON, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		THIERRY-MIEG, Jean/F-1975-2017; Wilson, Richard K./AAF-4139-2019; Durbin, Richard/AAE-7178-2019	THIERRY-MIEG, Jean/0000-0002-0396-6789; Wilson, Richard K./0000-0002-1992-1358; Durbin, Richard/0000-0002-9130-1006				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CANTOR CR, 1990, SCIENCE, V248, P49, DOI 10.1126/science.2181666; CHEN CM, 1986, J BIOL CHEM, V261, P5030; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; CRAXTON M, 1992, DNA SEQUENCING LABOR; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DOGNIN MJ, 1980, EUR J BIOCHEM, V112, P131, DOI 10.1111/j.1432-1033.1980.tb04995.x; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EDGLEY ML, 1990, GENETIC MAPS, V5, P3; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRENKEL M, 1991, M63263 GENB ACC NUMB; FUKAO T, 1989, J BIOCHEM-TOKYO, V106, P197, DOI 10.1093/oxfordjournals.jbchem.a122832; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HAWKINS TL, 1991, NUCLEIC ACIDS RES, V19, P2784, DOI 10.1093/nar/19.10.2784; HAWKINS TL, UNPUB ELECTROPHORESI; HEINE U, 1986, J MOL BIOL, V188, P301, DOI 10.1016/0022-2836(86)90156-7; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; Hillier L, 1991, PCR Methods Appl, V1, P124; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LENDAHL U, 1984, CELL, V36, P1027, DOI 10.1016/0092-8674(84)90052-7; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OLSON M, 1991, GENOME DYNAMICS PROT, P1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; PRASAD SS, 1991, GENOME, V34, P6, DOI 10.1139/g91-002; ROBERTS L, 1990, SCIENCE, V249, P1497, DOI 10.1126/science.2218490; ROBERTS L, 1990, SCIENCE, V248, P1310, DOI 10.1126/science.2356467; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SASAOKA T, 1989, NEUROCHEM INT, V15, P555, DOI 10.1016/0197-0186(89)90176-9; SAUER N, 1991, X55350 GENB ACC NUMB; SCHRIEFER LA, 1990, NUCLEIC ACIDS RES, V18, P7455, DOI 10.1093/nar/18.24.7455; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLS N, 1983, CELL, V33, P575, DOI 10.1016/0092-8674(83)90438-5; Wood WB, 1988, NEMATODE CAENORHABDI; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	70	470	520	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					37	41		10.1038/356037a0	http://dx.doi.org/10.1038/356037a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538779				2022-12-24	WOS:A1992HG60200046
J	MCCONNELL, RJ				MCCONNELL, RJ			ABNORMAL THYROID-FUNCTION TEST-RESULTS IN PATIENTS TAKING SALSALATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THYROXINE-BINDING; HUMAN SERUM; SALICYLATE; INHIBITION	Objective.-To evaluate how the nonsteroidal anti-inflammatory agent salsalate affects the results of routine thyroid function tests. Design.-In a cohort of patients taking salsalate for various rheumatic conditions, thyroid function tests were performed with patients on and off the drug. Setting.-Primary care of ambulatory patients in a university medical center. Patients.-A convenience sample of 14 euthyroid subjects, none of whom was taking thyroid hormone or other medication recognized to alter thyroid function. Intervention. -Treatment with therapeutic doses of salsalate for a mean period of 44 weeks. Main Outcome Measures.-Serum levels of thyroxine (T4), free T4, thyroid hormone binding ratio, free T4 index (the product of T4 and the thyroid hormone binding ratio), triiodothyronine, and thyrotropin. Results.-Serum T4 dropped from a mean baseline level of 96.7 nmol/L off salsalate to 53.4 nmol/L on it (P < .001), and the free T4 index showed a parallel decline from 85.9 to 50.4 (P < .001), with both values falling into the hypothyroid range. Similarly, free T4 levels and total triiodothyronine concentrations were low in several patients treated with salsalate. Serum thyrotropin levels declined transiently, falling from a mean of 3.2 to 1.7 mU/L (P < .02) in patients treated for less than 3 weeks. Patients treated for longer periods had levels comparable to baseline. Despite these changes in the thyroid function test results, all subjects remained clinically euthyroid. Conclusion.-Salsalate commonly produces abnormalities in routine thyroid function test results similar to those found in central hypothyroidism.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University								AUSTEN FK, 1958, J CLIN INVEST, V37, P1131, DOI 10.1172/JCI103703; CHOPRA IJ, 1980, ENDOCRINOLOGY, V106, P1728, DOI 10.1210/endo-106-6-1728; DUSSAULT JH, 1976, J CLIN ENDOCR METAB, V43, P232, DOI 10.1210/jcem-43-1-232; HAMADA S, 1970, J CLIN ENDOCR METAB, V31, P166, DOI 10.1210/jcem-31-2-166; KABADI UM, 1987, J AM GERIATR SOC, V35, P255, DOI 10.1111/j.1532-5415.1987.tb02319.x; LARSEN PR, 1972, J CLIN INVEST, V51, P1125, DOI 10.1172/JCI106905; MCCONNELL RJ, 1989, ARTHRITIS RHEUM, V32, P1344, DOI 10.1002/anr.1780321031; RAMEY JN, 1976, J CLIN ENDOCR METAB, V43, P107, DOI 10.1210/jcem-43-1-107; SCHUSSLER GC, 1986, WERNERS THYROID, P381; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; WITHERSPOON LR, 1984, CLIN CHEM, V30, P778; WOEBER KA, 1964, J CLIN INVEST, V43, P931, DOI 10.1172/JCI104979	12	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1242	1243		10.1001/jama.267.9.1242	http://dx.doi.org/10.1001/jama.267.9.1242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538562				2022-12-24	WOS:A1992HF43900027
J	GUNNELL, DJ				GUNNELL, DJ			MYSTERIOUS SLAPPED FACE RASH AT HOLIDAY CENTER	BRITISH MEDICAL JOURNAL			English	Article							CONTACT-DERMATITIS; SOAPS	Objective - To discover the cause of an outbreak of facial rash in a holiday centre. Design - Questionnaire survey of those with rash; analysis of samples of linen. Setting - Holiday centre in south west England. Patients - 98 holidaymakers presenting to the first aid post with a facial rash. Intervention - Replacement of bed linen with new linen in selected parts of the site. Results - The attack rate was 7.0-14.2/1000 for most accommodation areas in the centre, but in one accommodation area the rate was zero. The pH of rinse water from sheets varied from 7.4 to 9.0. Those parts of the accommodation provided with new linen had zero attack rates. Conclusion - The facial rash resulted from irritation from washing powder retained owing to insufficient rinsing during laundering. Modifications to the rinsing process led to a gradual disappearance of the rash.			GUNNELL, DJ (corresponding author), SOMERSET HLTH AUTHOR,PUBL HLTH MED,TAUNTON TA2 7PQ,ENGLAND.		Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470				DOEGLAS HMG, 1965, ARCH DERMATOL, V83, P175; DOOMSGOOSSENS AE, 1986, J AM ACAD DERMATOL, V15, P1, DOI 10.1016/S0190-9622(86)70135-7; HARPIN VA, 1983, J PEDIATR-US, V102, P419, DOI 10.1016/S0022-3476(83)80669-6; Kligman A M, 1978, Curr Probl Dermatol, V7, P1; MALTEN KE, 1981, CONTACT DERMATITIS, V7, P238, DOI 10.1111/j.1600-0536.1981.tb04059.x; MATHIAS CGT, 1986, OCCUP MED, V1, P205; OSMUNDSE.PE, 1969, BRIT J DERMATOL, V81, P799, DOI 10.1111/j.1365-2133.1969.tb15947.x; RYCROFT RJG, 1986, TXB DERMATOLOGY, P533; RYECROFT R, 1986, TXB DERMATOLOGY, P437; STRUBE DD, 1987, CUTIS, V39, P544	10	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					477	479		10.1136/bmj.304.6825.477	http://dx.doi.org/10.1136/bmj.304.6825.477			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547418	Green Published, Bronze			2022-12-24	WOS:A1992HF55500021
J	SMITH, RC; PREZELIN, BB; BAKER, KS; BIDIGARE, RR; BOUCHER, NP; COLEY, T; KARENTZ, D; MACINTYRE, S; MATLICK, HA; MENZIES, D; ONDRUSEK, M; WAN, Z; WATERS, KJ				SMITH, RC; PREZELIN, BB; BAKER, KS; BIDIGARE, RR; BOUCHER, NP; COLEY, T; KARENTZ, D; MACINTYRE, S; MATLICK, HA; MENZIES, D; ONDRUSEK, M; WAN, Z; WATERS, KJ			OZONE DEPLETION - ULTRAVIOLET-RADIATION AND PHYTOPLANKTON BIOLOGY IN ANTARCTIC WATERS	SCIENCE			English	Review							UV-B RADIATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOUTHEASTERN BERING SEA; GREAT-BARRIER-REEF; ICE-EDGE ZONE; NATURAL-WATERS; PRIMARY PRODUCTIVITY; MARINE-PHYTOPLANKTON; AQUATIC ENVIRONMENT; ABSORBING-SUBSTANCE	The springtime stratospheric ozone (O3) layer over the Antarctic is thinning by as much as 50 percent, resulting in increased midultraviolet (UVB) radiation reaching the surface of the Southern Ocean. There is concern that phytoplankton communities confined to near-surface waters of the marginal ice zone will be harmed by increased UVB irradiance penetrating the ocean surface, thereby altering the dynamics of Antarctic marine ecosystems. Results from a 6-week cruise (Icecolors) in the marginal ice zone of the Bellingshausen Sea in austral spring of 1990 indicated that as the O3 layer thinned: (i) sea surface- and depth-dependent ratios of UVB irradiance (280 to 320 nanometers) to total irradiance (280 to 700 nanometers) increased and (ii) UVB inhibition of photosynthesis increased. These and other Icecolors findings suggest that O3-dependent shifts of in-water spectral irradiances alter the balance of spectrally dependent phytoplankton processes, including photoinhibition, photo-reactivation, photoprotection, and photosynthesis. A minimum 6 to 12 percent reduction in primary production associated with O3 depletion was estimated for the duration of the cruise.	UNIV CALIF SANTA BARBARA, UNIV CALIF MARINE BIOOPT, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, CTR REMOTE SENSING & ENVIRONM OPT, COMP SYST LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, INST MARINE SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SAN DIEGO, UNIV CALIF MARINE BIOOPT, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, LA JOLLA, CA 92093 USA; UNIV HAWAII, DEPT OCEANOG, HONOLULU, HI 96822 USA; MOSS LANDING MARINE LABS, MOSS LANDING, CA 95039 USA; UNIV CALIF SAN FRANCISCO, RADIOBIOL & ENVIRONM HLTH LAB, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Hawaii System; Moss Landing Marine Laboratories; University of California System; University of California San Francisco	SMITH, RC (corresponding author), UNIV CALIF SANTA BARBARA, DEPT GEOG, SANTA BARBARA, CA 93106 USA.		Ondrusek, Michael/F-5617-2010	Ondrusek, Michael/0000-0002-5311-9094				Ainley D.G., 1988, P140; AINLEY DG, 1986, SCIENCE, V232, P847, DOI 10.1126/science.232.4752.847; ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; BIDIGARE RR, 1989, PHOTOCHEM PHOTOBIOL, V50, P469, DOI 10.1111/j.1751-1097.1989.tb05551.x; BIDIGARE RR, 1985, LIMNOL OCEANOGR, V30, P432, DOI 10.4319/lo.1985.30.2.0432; BIDIGARE RR, 1989, MAR ECOL PROG SER, V56, P177, DOI 10.3354/meps056177; BOOTH C, COMMUNICATION; BRASSEUR G, 1987, ENVIRONMENT, V29, P6, DOI 10.1080/00139157.1987.9928845; BUHLMANN B, 1987, J PLANKTON RES, V9, P935, DOI 10.1093/plankt/9.5.935; CALDWELL MM, 1968, ECOL MONOGR, V38, P243, DOI 10.2307/1942430; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; CALKINS J, 1980, NATURE, V283, P563, DOI 10.1038/283563a0; CARRETO JI, 1990, J PLANKTON RES, V12, P909, DOI 10.1093/plankt/12.5.909; CRAWFORD M, 1987, SCIENCE, V237, P1557, DOI 10.1126/science.237.4822.1557; CULLEN JJ, 1991, MAR BIOL, V111, P183, DOI 10.1007/BF01319699; DAMKAER DM, 1981, OECOLOGIA, V48, P178, DOI 10.1007/BF00347960; DAMKAER DM, 1983, OECOLOGIA, V60, P169, DOI 10.1007/BF00379518; DILLON TM, 1982, J GEOPHYS RES-OCEANS, V87, P9601, DOI 10.1029/JC087iC12p09601; DOHLER G, 1984, MAR BIOL, V83, P247, DOI 10.1007/BF00397456; DUNLAP WC, 1986, CORAL REEFS, V5, P155, DOI 10.1007/BF00298182; DUNLAP WC, 1986, J EXP MAR BIOL ECOL, V104, P239, DOI 10.1016/0022-0981(86)90108-5; ELSAYED SZ, 1971, BIOL ANTARCTIC SEAS, V4, P301; ELSAYED SZ, 1977, POLAR OCEANS, P463; FRASER WR, 1986, BIOSCIENCE, V36, P258, DOI 10.2307/1310216; FREDERICK JE, 1988, SCIENCE, V241, P438, DOI 10.1126/science.241.4864.438; FREDERICK JE, 1989, PHOTOCHEM PHOTOBIOL, V50, P443, DOI 10.1111/j.1751-1097.1989.tb05548.x; Fryxell G.A., 1984, Antarctic Journal of the United States, V19, P107; GARRISON DL, 1987, J PHYCOL, V23, P564; GIESKES WW, 1983, LIMNOL OCEANOGR, V28, P757, DOI 10.4319/lo.1983.28.4.0757; GIESKES WWC, 1983, MAR BIOL, V75, P179, DOI 10.1007/BF00406000; GORDON HR, 1985, APPL OPTICS, V24, P4172, DOI 10.1364/AO.24.004172; GRAN H. H., 1931, Conseil Perm. Internat. pour I'Explor. de la Mer. Rapp. et Proces-Verb., V75, P37; HADER DP, 1988, ARCH MICROBIOL, V150, P20, DOI 10.1007/BF00409712; HAXO FT, 1985, J PHYCOL, V21, P282; HIROSAWA T, 1983, ARCH MICROBIOL, V135, P98, DOI 10.1007/BF00408016; HOBSON LA, 1983, J PLANKTON RES, V5, P325, DOI 10.1093/plankt/5.3.325; HOLMHANSEN O, 1977, 3RD P SCAR S ANT BIO, P11; Hunter J. R., 1982, ROLE SOLAR ULTRAVIOL, P459; HUNTER JR, 1979, PHOTOCHEM PHOTOBIOL, V29, P325, DOI 10.1111/j.1751-1097.1979.tb07055.x; JEFFERY WR, 1990, DEV BIOL, V140, P388, DOI 10.1016/0012-1606(90)90088-Z; JERLOV NG, 1950, NATURE, V166, P111, DOI 10.1038/166111a0; JOKIEL PL, 1984, LIMNOL OCEANOGR, V29, P192, DOI 10.4319/lo.1984.29.1.0192; KARANAS JJ, 1979, LIMNOL OCEANOGR, V24, P1104, DOI 10.4319/lo.1979.24.6.1104; KARENTZ D, 1991, MAR BIOL, V108, P157, DOI 10.1007/BF01313484; KARENTZ D, 1991, J PHYCOL, V27, P326, DOI 10.1111/j.0022-3646.1991.00326.x; KARENTZ D, 1991, ANTARCT SCI, V3, P3, DOI 10.1017/S0954102091000032; KARENTZ D, 1990, LIMNOL OCEANOGR, V35, P549, DOI 10.4319/lo.1990.35.3.0549; KARENTZ S, 1991, NATURE, V350, P28, DOI 10.1038/350028b0; KRUEGER AP, COMMUNICATION; LARKUM AWD, 1983, ADV BOT RES, V10, P1, DOI 10.1016/S0065-2296(08)60260-8; LENOBLE J, 1956, ANN GEOPHYS, V12, P16; LUBIN D, IN PRESS J GEOPHYS R; MANTOURA RFC, 1983, ANAL CHIM ACTA, V151, P297, DOI 10.1016/S0003-2670(00)80092-6; MARSHALL PT, 1957, J CONS CONS INT EXPL, V23, P173; MASKE H, 1984, J PLANKTON RES, V6, P351, DOI 10.1093/plankt/6.2.351; MOLINA LT, 1986, J GEOPHYS RES-ATMOS, V91, P14501, DOI 10.1029/JD091iD13p14501; MOROWITZ HJ, 1950, SCIENCE, V111, P229; NELSON DM, 1989, DEEP-SEA RES, V36, P191, DOI 10.1016/0198-0149(89)90133-7; NELSON DM, 1987, J GEOPHYS RES-OCEANS, V92, P7181, DOI 10.1029/JC092iC07p07181; NIEBAUER HJ, 1985, CONT SHELF RES, V4, P367, DOI 10.1016/0278-4343(85)90001-9; PERRIN RA, 1987, HYDROBIOLOGIA, V146, P33, DOI 10.1007/BF00007575; PREZELIN BB, 1991, AQUAT SCI, V53, P136, DOI 10.1007/BF00877058; PREZELIN BB, 1987, MAR BIOL, V96, P563, DOI 10.1007/BF00397975; PREZELIN BB, 1991, J PLANKTON RES, V13, pS45; RINGELBERG J, 1984, HYDROBIOLOGIA, V112, P217, DOI 10.1007/BF00008087; ROBERTS L, 1989, SCIENCE, V244, P288, DOI 10.1126/science.244.4902.288; SCHOEBERL MR, 1991, SCIENCE, V251, P46, DOI 10.1126/science.251.4989.46; SHIBATA K, 1969, PLANT CELL PHYSIOL, V10, P325; SHICK JM, 1991, SYMBIOSIS, V10, P145; SIEBECK O, 1978, VERH INT VEREIN LIMN, V20, P2469; SIVALINGAM PM, 1974, BOT MAR, V17, P23, DOI 10.1515/botm.1974.17.1.23; Smith K. C., 1989, SCI PHOTOBIOLOGY, DOI DOI 10.1007/978-1-4615-8061-4; Smith R. C., 1982, ROLE SOLAR ULTRAVIOL, P509; SMITH RC, 1984, P SOC PHOTO-OPT INST, V489, P119; SMITH RC, 1981, APPL OPTICS, V20, P177, DOI 10.1364/AO.20.000177; SMITH RC, 1980, PHOTOCHEM PHOTOBIOL, V31, P585, DOI 10.1111/j.1751-1097.1980.tb03750.x; SMITH RC, 1980, SCIENCE, V208, P592, DOI 10.1126/science.208.4444.592; SMITH RC, 1989, PHOTOCHEM PHOTOBIOL, V50, P459, DOI 10.1111/j.1751-1097.1989.tb05550.x; SMITH RC, 1979, PHOTOCHEM PHOTOBIOL, V29, P311, DOI 10.1111/j.1751-1097.1979.tb07054.x; SMITH RC, 1984, APPL OPTICS, V23, P2791, DOI 10.1364/AO.23.002791; SMITH RC, 1987, MAR BIOL, V96, P575, DOI 10.1007/BF00397976; SMITH RC, 1986, P SPIE OCEAN OPT 8, V637, P95; SMITH RC, 1978, PHOTOCHEM PHOTOBIOL, V17, P471; SMITH RC, 1981, 8117 SCRIPPS I OC VI; SMITH RC, IN PRESS J GEOPHYS R; SMITH RC, 1989, OCEANOGRAPHY, V2, P4, DOI DOI 10.5670/0CEAN0G.1989.01; SMITH SL, 1986, CONT SHELF RES, V5, P215, DOI 10.1016/0278-4343(86)90016-6; Smith W. O. J., 1985, ANTARCTIC NUTR CYCLE, P70; SMITH WO, 1991, NATURE, V352, P514, DOI 10.1038/352514a0; SMITH WO, 1986, BIOSCIENCE, V36, P251, DOI 10.2307/1310215; SMITH WO, 1985, SCIENCE, V227, P163, DOI 10.1126/science.227.4683.163; SMITH WO, 1987, OCEANOGR MAR BIOL, V25, P11; SMITH WO, 1988, ANTARCTIC OCEAN RESO, P131, DOI DOI 10.1007/978-3-642-73724-4_10; SMITH WO, 1990, POLAR OCEANOGRAPHY B, P427; SOLOMON S, 1988, REV GEOPHYS, V26, P131, DOI 10.1029/RG026i001p00131; SOLOMON S, 1990, NATURE, V347, P347, DOI 10.1038/347347a0; Strickland J.D.H., 1972, PRACTICAL HDB SEWATE, DOI [10.2307/1979241, DOI 10.2307/1979241]; THORPE SA, 1977, PHILOS T R SOC A, V286, P125, DOI 10.1098/rsta.1977.0112; Torres A, COMMUNICATION; Voss K., 1986, P OCEAN OPT 8 SPIE, VVIII, P186; VOYTEK MA, 1990, AMBIO, V19, P52; WALSH JJ, 1986, CONT SHELF RES, V5, P259, DOI 10.1016/0278-4343(86)90018-X; Waters K J, 1990, OCEANOGRAPHY, V3, P18, DOI DOI 10.5670/OCEANOG.1990.03; WATSON R, 1988, OZONE TRENDS PANEL; WILSON DL, 1986, DEEP-SEA RES, V33, P1375, DOI 10.1016/0198-0149(86)90041-5; Worrest R. C., 1986, EFFECTS CHANGES STRA, P175; WORREST RC, 1981, PHOTOCHEM PHOTOBIOL, V33, P223, DOI 10.1111/j.1751-1097.1981.tb05328.x; WORREST RC, 1978, LIMNOL OCEANOGR, V17, P471; ZEPP RG, 1977, ENVIRON SCI TECHNOL, V11, P359, DOI 10.1021/es60127a013; [No title captured]; [No title captured]; 1984, CAUSES EFFECTS STRAT; 1987, STRATOSPHERIC OZONE	113	767	814	8	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					952	959		10.1126/science.1546292	http://dx.doi.org/10.1126/science.1546292			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546292				2022-12-24	WOS:A1992HE60500032
J	BODE, J; KOHWI, Y; DICKINSON, L; JOH, T; KLEHR, D; MIELKE, C; KOHWISHIGEMATSU, T				BODE, J; KOHWI, Y; DICKINSON, L; JOH, T; KLEHR, D; MIELKE, C; KOHWISHIGEMATSU, T			BIOLOGICAL SIGNIFICANCE OF UNWINDING CAPABILITY OF NUCLEAR MATRIX ASSOCIATING DNAS	SCIENCE			English	Article							SCAFFOLD-ATTACHED REGIONS; CHROMOSOMAL LOOP ANCHORAGE; DROSOPHILA-MELANOGASTER; TOPOISOMERASE-II; SUPERCOILED DNA; SITES; GENE; TRANSCRIPTION; CHROMATIN; CELLS	Matrix attachment regions (MARs) are thought to separate chromatin into topologically constrained loop domains. A MAR located 5' of the human beta-interferon gene becomes stably base-unpaired under superhelical strain, as do the MARs flanking the immunoglobulin heavy chain gene enhancer; in both cases a nucleation site exists for DNA unwinding. Concatemerized oligonucleotides containing the unwinding nucleation site exhibited a strong affinity for the nuclear scaffold and augmented SV40 promoter activity in stable transformants. Mutated concatemerized oligonucleotides resisted unwinding, showed weak affinity for the nuclear scaffold, and did not enhance promoter activity. These results suggest that the DNA feature capable of relieving superhelical strain is important for MAR functions.	GESELL BIOTECHNOL FORSCH GMBH,MASCHERODER WEG 1,W-3300 BRAUNSCHWEIG,GERMANY; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Gesellschaft fur Biotechnologische Forschung mbH; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA039681, R01CA051377] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA39681, R0I CA51377] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; CLARK P, 1991, EMBO J, V10, P387; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KAY V, UNPUB; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOCHETKOV N K, 1971, Tetrahedron Letters, V22, P1993; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, UNPUB; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MIZUTANI M, 1991, P NATL ACAD SCI USA, V88, P718, DOI 10.1073/pnas.88.3.718; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PROBST H, 1985, EUR J BIOCHEM, V146, P167, DOI 10.1111/j.1432-1033.1985.tb08634.x; SINDEN RR, 1987, J CHEM EDUC, V64, P294, DOI 10.1021/ed064p294; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	42	395	415	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					195	197		10.1126/science.1553545	http://dx.doi.org/10.1126/science.1553545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553545				2022-12-24	WOS:A1992GY70400035
J	COX, J; NAYLOR, CD				COX, J; NAYLOR, CD			THE CANADIAN-CARDIOVASCULAR-SOCIETY GRADING SCALE FOR ANGINA-PECTORIS - IS IT TIME FOR REFINEMENTS	ANNALS OF INTERNAL MEDICINE			English	Review						ANGINA PECTORIS; SEVERITY OF ILLNESS INDEX; CANADIAN-CARDIOVASCULAR-SOCIETY; CHEST PAIN; CLINIMETRICS	CORONARY-ARTERY DISEASE; CHRONIC STABLE ANGINA; SILENT MYOCARDIAL ISCHEMIA; HEART-DISEASE; CHEST PAIN; UNSTABLE ANGINA; NATURAL-HISTORY; ELECTROCARDIOGRAPHIC CHANGES; PROGNOSTIC IMPORTANCE; FUNCTIONAL STATUS	Objective: To appraise the measurement properties of the Canadian Cardiovascular Society (CCS) classification of stable angina pectoris. Data Sources: Relevant articles were identified through a MEDLINE search (1976 to November 1991). Bibliographies of retrieved articles were also reviewed. Study Selection: Studies chosen directly addressed the validity and reliability of the CCS scale. Recent studies and reviews of related topics (for example, silent ischemia) are selectively cited. Data Synthesis: No data address the scale's applicability, that is, how clinicians typically assign angina grades in practice. Comprehensiveness would be improved by coverage of the patient's perceptions of symptom burden; mixed exertional and rest symptoms; episodic or changing symptoms; and modifying factors. Reliability was assessed in one study with two clinicians; the interobserver, chance-corrected agreement on patient grading was 60%. Content validity (the ability of the scale to measure what it claims) is threatened by the unproven assumption of symptomatic or physiologic equivalence among diverse levels of different activities within any given grade of angina. Construct validity is uncertain, given weak relations between angina grade and noninvasive markers of ischemia, anatomical disease, or prognosis. The scale's responsiveness (the ability to detect the smallest clinically important changes) is limited by the reliance on four coarse gradations based on only ambulation or stair-climbing. Conclusions: The CCS scale for stable angina might be made more useful by developing measurements for patients' self-rated symptom burden and the changes they deem important; by adding items on clinical instability (that is, progressive symptoms or pain at rest); and by empirically testing the current scale to eliminate redundant or inconsistent elements.	SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, A443, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; DALHOUSIE UNIV, HALIFAX B3H 4H2, NS, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Dalhousie University; University of Toronto				Cox, Jafna/0000-0001-7908-5323				ALLISON RB, 1963, CIRCULATION, V27, P170, DOI 10.1161/01.CIR.27.2.170; ASSEY ME, 1988, AM J CARDIOL, V61, pF19; BIAGINI A, 1981, CLIN CARDIOL, V4, P315, DOI 10.1002/clc.4960040602; BURGGRAF GW, 1975, CIRCULATION, V51, P146, DOI 10.1161/01.CIR.51.1.146; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALLAHAM PR, 1989, J AM COLL CARDIOL, V14, P1175, DOI 10.1016/0735-1097(89)90413-0; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHASSIN MR, 1986, INDICATIONS SELECTED; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; COHN PF, 1981, AM J CARDIOL, V47, P233, DOI 10.1016/0002-9149(81)90391-X; COHN PF, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90971-X; COLE JP, 1978, AM J CARDIOL, V41, P227, DOI 10.1016/0002-9149(78)90161-3; DEHMER GJ, 1982, CURRENT PROBLEMS CAR, V12, P213; DETRE K, 1981, CIRCULATION, V63, P1329, DOI 10.1161/01.CIR.63.6.1329; DEYO RA, 1984, CONTROL CLIN TRIALS, V5, P223, DOI 10.1016/0197-2456(84)90026-6; DUNCAN B, 1976, BRIT MED J, V1, P981, DOI 10.1136/bmj.1.6016.981; EGSTRUP K, 1987, ACTA MED SCAND, V222, P301; EPSTEIN SE, 1988, NEW ENGL J MED, V318, P1038, DOI 10.1056/NEJM198804213181606; FARHI JI, 1986, AM J CARDIOL, V58, P547, DOI 10.1016/0002-9149(86)90031-7; FEINSTEIN AR, 1986, ANN INTERN MED, V105, P413, DOI 10.7326/0003-4819-105-3-413; FEINSTEIN AR, 1977, AM HEART J, V93, P172, DOI 10.1016/S0002-8703(77)80308-6; Feinstein AR, 1987, CLINIMETRICS; FINDLAY I N, 1988, European Heart Journal, V9, P2; GARBER CE, 1991, J AM COLL CARDIOL, V17, P1256, DOI 10.1016/S0735-1097(10)80132-9; GOLDMAN L, 1982, J CHRON DIS, V35, P763, DOI 10.1016/0021-9681(82)90087-X; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOTTLIEB S O, 1987, American Journal of Cardiology, V60, p33J, DOI 10.1016/0002-9149(87)90681-3; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P403, DOI 10.1016/0895-4356(89)90128-5; HAGMAN M, 1977, ACTA MED SCAND, V201, P571; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HAUSMANN D, 1991, AM J CARDIOL, V67, P465, DOI 10.1016/0002-9149(91)90005-6; HEYDEN S, 1971, ARCH INTERN MED, V128, P961, DOI 10.1001/archinte.128.6.961; HLATKY MA, 1989, J CLIN EPIDEMIOL, V42, P381, DOI 10.1016/0895-4356(89)90125-X; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HUMPHRIE.JO, 1974, CIRCULATION, V49, P489, DOI 10.1161/01.CIR.49.3.489; ISKANDRIAN AS, 1984, AM J CARDIOL, V53, P1239, DOI 10.1016/0002-9149(84)90071-7; JAFFE MD, 1980, LANCET, V2, P934; JOHNSON SM, 1982, AM HEART J, V103, P4, DOI 10.1016/0002-8703(82)90522-1; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KOSSMANN CE, 1964, DISEASES HEART BLOOD, P112; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; MAHMARIAN JJ, 1990, CIRCULATION, V82, P1305, DOI 10.1161/01.CIR.82.4.1305; MARK DB, 1989, J AM COLL CARDIOL, V14, P885, DOI 10.1016/0735-1097(89)90459-2; MASERI A, 1980, BRIT HEART J, V43, P648; MASERI A, 1986, AM J MED, V80, P48, DOI 10.1016/0002-9343(86)90452-3; MCLENACHAN JM, 1991, CIRCULATION, V83, P1263, DOI 10.1161/01.CIR.83.4.1263; MEDALIE JH, 1973, AM J MED, V55, P583, DOI 10.1016/0002-9343(73)90179-4; MIRANDA CP, 1991, ANN INTERN MED, V114, P649, DOI 10.7326/0003-4819-114-8-649; MYERS WO, 1989, J THORAC CARDIOV SUR, V97, P487; MYERS WO, 1987, ANN THORAC SURG, V44, P471, DOI 10.1016/S0003-4975(10)62104-2; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NIXON PGF, 1987, AM HEART J, V114, P1542, DOI 10.1016/0002-8703(87)90583-7; PERMANYERMIRALDA G, 1991, J CLIN EPIDEMIOL, V44, P779, DOI 10.1016/0895-4356(91)90130-2; PROUDFIT W L, 1986, Canadian Journal of Cardiology, V2, P62; PROUDFIT WL, 1978, PROG CARDIOVASC DIS, V21, P53, DOI 10.1016/S0033-0620(78)80004-8; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; PUPITA G, 1989, AM HEART J, V118, P539, DOI 10.1016/0002-8703(89)90270-6; QUYYUMI AA, 1985, BRIT HEART J, V54, P22; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P123; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SELZER A, 1972, AM J CARDIOL, V30, P306, DOI 10.1016/0002-9149(72)90079-3; SHUB C, 1990, MAYO CLIN PROC, V65, P233, DOI 10.1016/S0025-6196(12)65018-6; SMITH WCS, 1990, BRIT HEART J, V64, P295; SPIEKERMAN RE, 1962, CIRCULATION, V25, P57, DOI 10.1161/01.CIR.25.1.57; TAKARO T, 1982, CIRCULATION, V65, P60, DOI 10.1161/01.CIR.65.7.60; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; VASSILIADIS IV, 1991, AM HEART J, V121, P1403, DOI 10.1016/0002-8703(91)90145-8; WARTAK J, 1984, AM HEART J, V107, P402, DOI 10.1016/0002-8703(84)90401-0; WATERS DD, 1985, J AM COLL CARDIOL, V6, P1011, DOI 10.1016/S0735-1097(85)80302-8; WEBSTER JS, 1974, AM J CARDIOL, V33, P195, DOI 10.1016/0002-9149(74)90274-4; WEINBLATT E, 1968, J CHRON DIS, V21, P231, DOI 10.1016/0021-9681(68)90060-X; WEINER DA, 1987, AM J CARDIOL, V59, P725, DOI 10.1016/0002-9149(87)91081-2; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINER DA, 1978, AM HEART J, V96, P458, DOI 10.1016/0002-8703(78)90155-2; WIKLUND I, 1991, CLIN CARDIOL, V14, P204, DOI 10.1002/clc.4960140306	82	54	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					677	683		10.7326/0003-4819-117-8-677	http://dx.doi.org/10.7326/0003-4819-117-8-677			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530200				2022-12-24	WOS:A1992JR86100009
J	EDLIN, BR; STCLAIR, MH; PITHA, PM; WHALING, SM; KING, DM; BITRAN, JD; WEINSTEIN, RA				EDLIN, BR; STCLAIR, MH; PITHA, PM; WHALING, SM; KING, DM; BITRAN, JD; WEINSTEIN, RA			INVITRO RESISTANCE TO ZIDOVUDINE AND ALPHA-INTERFERON IN HIV-1 ISOLATES FROM PATIENTS - CORRELATIONS WITH TREATMENT DURATION AND RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Article						INTERFERON-ALPHA; HUMAN IMMUNODEFICIENCY VIRUS; ZIDOVUDINE; DRUG RESISTANCE; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; AIDS; SENSITIVITY; INFECTION; TYPE-1; THERAPY	Objective: To measure in-vitro antiviral drug susceptibilities of human immunodeficiency virus type 1 (HIV-1) isolates recovered from patients treated with alpha-interferon or zidovudine and patients not treated with these drugs and to examine the relation of these susceptibility measurements to duration of therapy, disease stage, and response to alpha-interferon therapy. Design: Cross-sectional study. Setting: Outpatient HIV clinic. Patients: Twenty-six ambulatory HIV-1-infected patients: Fifteen of these patients were receiving alpha-interferon therapy, and 11 had never received such therapy. Nine patients were participating in a clinical trial of combination therapy with zidovudine and alpha-interferon. Measurements: The 50% inhibitory concentration (IC50) of zidovudine and alpha-interferon was determined for HIV-1 isolates recovered from each patient. Plasma concentrations of HIV-1 p24 antigen in the nine patients in the clinical trial were measured monthly after alpha-interferon was added to zidovudine monotherapy. Results: Zidovudine IC50 (range, 0.01 to 4.87-mu-M) increased steadily with duration of zidovudine therapy (r = 0.57, P = 0.003). In contrast, alpha-interferon IC50 (range, 0.8 to 415 units/mL) was not related to duration of alpha-interferon treatment; in fact, high IC50s were found in isolates from patients who had never received exogenous alpha-interferon therapy. Resistance to alpha-interferon was greater in isolates from the 15 patients with the acquired immunodeficiency syndrome (AIDS) (median, 104 units/mL) than in those from the 10 patients without AIDS (median, 50 units/mL). Interferon activity was detected in plasma samples from 23 of 24 patients and was also at higher levels in patients with AIDS than in HIV-infected patients without AIDS. Reductions in plasma concentrations of HIV-1 p24 antigen in nine patients after beginning alpha-interferon therapy were greater in those with more susceptible isolates (r = -0.72, P = 0.03). Conclusions: Interferon resistance, possibly due to endogenous interferon, is not related to duration of interferon therapy but may limit the effectiveness of interferon therapy. Determinations of interferon susceptibility may identify patients most likely to benefit from this agent.			EDLIN, BR (corresponding author), CTR DIS CONTROL, DIV HIV AIDS, 1600 CLIFTON RD, E-45, ATLANTA, GA 30333 USA.		Edlin, Brian R/F-2966-2018	Edlin, Brian R/0000-0001-8172-8797				BERGLUND O, 1991, J INFECT DIS, V163, P710, DOI 10.1093/infdis/163.4.710; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; DESTEFANO E, 1982, J INFECT DIS, V146, P451, DOI 10.1093/infdis/146.4.451; DEWIT R, 1988, LANCET, V2, P1214; DEWIT R, 1991, J INTERN MED, V229, P35; EDLIN BR, 1989, LANCET, V1, P156; EDLIN BR, 1992, J INFECT DIS, V165, P793, DOI 10.1093/infdis/165.5.793; EVANS LA, 1987, J IMMUNOL, V138, P3415; FISCHL MA, 1991, J ACQ IMMUN DEF SYND, V4, P1; FRANCIS ML, 1992, AIDS RES HUM RETROV, V8, P199, DOI 10.1089/aid.1992.8.199; HARPER HD, 1973, BIOCHEM BIOPH RES CO, V53, P1220, DOI 10.1016/0006-291X(73)90595-0; HO DD, 1985, LANCET, V1, P602; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOKLIK WK, 1985, VIROLOGY, P283; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LANE HC, 1988, LANCET, V2, P1218; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; PITHA PM, 1991, J INTERFERON RES, V11, P313, DOI 10.1089/jir.1991.11.313; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X	25	36	36	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					457	460		10.7326/0003-4819-117-6-457	http://dx.doi.org/10.7326/0003-4819-117-6-457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503348				2022-12-24	WOS:A1992JN25700002
J	MATCHAR, DB; DIVINE, GW; HEYMAN, A; FEUSSNER, JR				MATCHAR, DB; DIVINE, GW; HEYMAN, A; FEUSSNER, JR			THE INFLUENCE OF HYPERGLYCEMIA ON OUTCOME OF CEREBRAL INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERGLYCEMIA; CEREBRAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); BLOOD GLUCOSE; CEREBROVASCULAR DISORDERS	ACUTE STROKE; DIABETES-MELLITUS; BLOOD-GLUCOSE; PROGNOSTIC VALUE; CEREBROVASCULAR ACCIDENT; GLYCOSYLATED HEMOGLOBIN; NATURAL-HISTORY; BARTHEL INDEX; RECOVERY; ISCHEMIA	Objective: To determine whether hyperglycemia in the acute stroke period is associated with worse survival and functional outcome after accounting for acute stress response and chronic hyperglycemia. Design: Prospective, county-wide, multicenter cohort study. Setting: A community hospital, a university hospital, and a Veterans Affairs hospital. Patients: A cohort of 146 patients hospitalized with new atherothrombotic stroke. Measurements: Admission blood glucose concentration, demographic characteristics of patients, 24-hour urinary catecholamine, serum cortisol, and glycosylated hemoglobin levels; outcomes included mortality and functional outcome (Barthel index and Fugl-Meyer score) at 5, 30, 90, and 180 days after stroke. Results: Of the 996 patients with possible acute stroke who were screened, 146 (15%) were eligible for and consented to participate in the study; in most cases, exclusion from study was based on the absence of acute, atherothrombotic stroke. Overall, no evidence was found of a significant univariate association between admission blood glucose level and survival (relative risk, 1.02; 95% CI, 0.94 to 1.09) or functional outcome (univariate regression coefficient for adjusted Fugl-Meyer score at day 30, - 0.36; CI, - 1.08 to 0.27). This absence of an association persisted after adjustment for significant predictors of outcome in a multivariate model. Conclusions: These data do not support an association between level of glycemia and outcome from acute stroke.	DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GEN INTERNAL MED, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, DURHAM, NC USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	MATCHAR, DB (corresponding author), DUKE UNIV, CTR HLTH POLICY RES & EDUC, SUITE 125, OLD CHEM BLDG, DURHAM, NC 27706 USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108	NINDS NIH HHS [NS 06233] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006233] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUZEID HAH, 1978, ARCH NEUROL-CHICAGO, V35, P213, DOI 10.1001/archneur.1978.00500280031005; ACHESON J, 1971, Q J MED, V40, P25; ARONSON SM, 1973, J NEUROPATH EXP NEUR, V32, P183, DOI 10.1097/00005072-197304000-00001; ASPLUND K, 1980, ACTA MED SCAND, V207, P417; BARNES AJ, 1977, LANCET, V2, P789; BENTSEN N, 1975, STROKE, V6, P497, DOI 10.1161/01.STR.6.5.497; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; BUTTERFIELD WJH, 1955, LANCET, V1, P489; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; COX NH, 1986, POSTGRAD MED J, V62, P7, DOI 10.1136/pgmj.62.723.7; CRUICKSHANK JM, 1974, BRIT HEART J, V36, P697; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; ENTMACHER PS, 1964, DIABETES, V13, P373, DOI 10.2337/diab.13.4.373; FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FULLERTON KJ, 1988, Q J MED, V66, P147; GINSBERG MD, 1987, STROKE, V18, P570, DOI 10.1161/01.STR.18.3.570; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GIROUD M, 1987, PRESSE MED, V16, P1079; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; GRAY CS, 1987, DIABETIC MED, V4, P237, DOI 10.1111/j.1464-5491.1987.tb00870.x; GRAY CS, 1989, POSTGRAD MED J, V65, P720, DOI 10.1136/pgmj.65.768.720; GRUNNET ML, 1963, NEUROLOGY, V13, P486, DOI 10.1212/WNL.13.6.486; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; Huff TA, 1972, STROKE, V3, P543, DOI 10.1161/01.STR.3.5.543; JACHUCK SJ, 1975, BRIT MED J, V1, P242, DOI 10.1136/bmj.1.5952.242; Kannel WB, 1971, STROKE, V2, P295, DOI 10.1161/01.STR.2.4.295; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LAVY S, 1968, J NEUROL SCI, V7, P409, DOI 10.1016/0022-510X(68)90049-X; LAVY S, 1974, STROKE, V5, P775, DOI 10.1161/01.STR.5.6.775; LEBOVITZ HE, 1969, CIRCULATION, V39, P171, DOI 10.1161/01.CIR.39.2.171; MAHONEY F I, 1965, Md State Med J, V14, P61; MARSH WR, 1986, J NEUROSURG, V65, P693, DOI 10.3171/jns.1986.65.5.0693; MATCHAR DB, 1989, CLIN RES, V37, pA84; MCDONALD L, 1969, LANCET, V2, P1021; MCMILLAN DE, 1978, DIABETES, V27, P895, DOI 10.2337/diab.27.9.895; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; MIAH K, 1983, J CHRON DIS, V36, P279, DOI 10.1016/0021-9681(83)90063-2; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; MYERS RE, 1976, NEUROLOGY, V26, P345; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; POWER MJ, 1988, AGE AGEING, V17, P164, DOI 10.1093/ageing/17.3.164; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RIDDLE MC, 1982, STROKE, V13, P356, DOI 10.1161/01.STR.13.3.356; SCHOENBERG BS, 1980, ANN NEUROL, V8, P101; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; SIEMKOWICZ E, 1981, ACTA NEUROL SCAND, V64, P207; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; SILBERBAUER K, 1979, NEW ENGL J MED, V300, P366; TOMOMATSU T, 1964, JPN CIRC J, V28, P884; TOPIC E, 1989, DIABETIC MED, V6, P12, DOI 10.1111/j.1464-5491.1989.tb01131.x; WAUTIER JL, 1981, NEW ENGL J MED, V305, P237, DOI 10.1056/NEJM198107303050501; WEIDLER DJ, 1974, STROKE, V5, P759, DOI 10.1161/01.STR.5.6.759; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; [No title captured]	64	60	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					449	456		10.7326/0003-4819-117-6-449	http://dx.doi.org/10.7326/0003-4819-117-6-449			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503347				2022-12-24	WOS:A1992JN25700001
J	PEARSON, M; BJORNSON, R; PEARSON, G; ROHRMANN, G				PEARSON, M; BJORNSON, R; PEARSON, G; ROHRMANN, G			THE AUTOGRAPHA-CALIFORNICA BACULOVIRUS GENOME - EVIDENCE FOR MULTIPLE REPLICATION ORIGINS	SCIENCE			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; HOMOLOGOUS DNA; SEQUENCE; REGIONS; GENE	The Autographa californica multinucleocapsid nuclear polyhedrosis virus (AcMNPV), which is used for the overexpression of eukaryotic genes and is being engineered for possible use as a viral insecticide, has a circular, supercoiled genome of approximately 128 kilobases. Despite its widespread use, little is known about the mechanism by which AcMNPV replicates. Evidence is presented in this report that AcMNPV origins of DNA replication are repeated sequences each containing several closely related imperfect palindromes that are present in six regions distributed around the genome. Although AcMNPV infection-dependent plasmid replication was initiated by a single complete palindrome, the amount of replication was substantially increased in plasmids containing six or eight palindromes.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University; Oregon State University					NIAID NIH HHS [AI21973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COCHRAN MA, 1983, J VIROL, V45, P961, DOI 10.1128/JVI.45.3.961-970.1983; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GLOCKER B, 1992, J VIROL, V66, P3476, DOI 10.1128/JVI.66.6.3476-3484.1992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Kornberg A., 1992, DNA REPLICATION; LIU AF, 1986, J GEN VIROL, V67, P2565, DOI 10.1099/0022-1317-67-11-2565; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; Sambrook J., 1989, MOL CLONING LAB MANU; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; [No title captured]	14	156	165	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1382	1384		10.1126/science.1529337	http://dx.doi.org/10.1126/science.1529337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529337				2022-12-24	WOS:A1992JL61200027
J	WHEELER, CJ; VONHOEGEN, P; PARNES, JR				WHEELER, CJ; VONHOEGEN, P; PARNES, JR			AN IMMUNOLOGICAL ROLE FOR THE CD8 BETA-CHAIN	NATURE			English	Article							TYROSINE-PROTEIN-KINASE; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECEPTOR; MHC CLASS; MONOCLONAL-ANTIBODIES; ALPHA-3 DOMAIN; LYMPHOCYTES-T; EXPRESSION; MOLECULES; P56LCK	MATURE T cells can be functionally divided into two categories distinguished by surface expression of either CD4 or CD8, which in turn corresponds to restriction by and binding to class II or class I major histocompatibility complex proteins, respectively 1-8. CD8 can be expressed as a homodimer of the alpha-chain, or as a heterodimer of alpha- and beta-chains on human and mouse T cells, although most peripheral T cells seem to express CD8-alpha-beta heterodimers exclusively (reviewed in ref. 9). Functional characterization of CD8 has focused primarily on the effect of the alpha-chain, which enhances or reconstitutes T-cell responses in homodimeric form 10,11 and may play a specific role in thymic selection 12-14. In contrast, no role has been ascribed to CD8-beta or alpha-beta heterodimers specifically. Here we show that CD8-alpha-beta transfectants produce more interleukin-2 than CD8-alpha transfectants in response to specific stimuli. Increased interleukin-2 is also observed in cells expressing hybrid CD8-beta-alpha molecules (extracellular CD8-beta plus CD8-alpha transmembrane and cytoplasmic regions) on their surface. These results indicate that external portions of CD8-beta could be critical and that they may act independently of CD8-alpha in mediating their augmentation effect.	STANFORD UNIV, MED CTR, DEPT MED, DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA	Stanford University								BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, 1984, J IMMUNOGENET, V11, P197; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GELIEBTER J, 1988, MOL CELL BIOL, V8, P4342, DOI 10.1128/MCB.8.10.4342; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LEWIS J, 1988, J IMMUNOL, V141, P728; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PORTOLES P, 1989, J IMMUNOL, V142, P4169; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P7101, DOI 10.1073/pnas.78.11.7101; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	33	80	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					247	249		10.1038/357247a0	http://dx.doi.org/10.1038/357247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1534146				2022-12-24	WOS:A1992HV19500056
J	MCMAHON, AP; JOYNER, AL; BRADLEY, A; MCMAHON, JA				MCMAHON, AP; JOYNER, AL; BRADLEY, A; MCMAHON, JA			THE MIDBRAIN HINDBRAIN PHENOTYPE OF WNT-1--WNT-1- MICE RESULTS FROM STEPWISE DELETION OF ENGRAILED-EXPRESSING CELLS BY 9.5 DAYS POSTCOITUM	CELL			English	Article							SEGMENT-POLARITY GENE; MAMMARY ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; MOUSE DEVELOPMENT; TUMOR VIRUS; STEM-CELLS; HOMEO BOX; DROSOPHILA; PROTEIN	Mice homozygous for null alleles of the putative signaling molecule Wnt-1 have a reproducible phenotype: loss of the midbrain and adjacent cerebellar component of the metencephalon. By examining embryonic expression of the mouse engrailed (En) genes, from 8.0 to 9.5 days postcoitum, we demonstrate that Wnt-1 primarily regulates midbrain development. The midbrain itself is required for normal development of the metencephalon. Thus, the observed neonatal phenotype is explained by a series of early events, within 48 hr of neural plate induction, that leads to a complete loss of En domains in the anterior central nervous system. Wnt-1 and a related gene, Wnt-3a, are coexpressed from early somite stages in dorsal aspects of the myelencephalon and spinal cord. We suggest that functional redundancy between these two genes accounts for the lack of a caudal central nervous system phenotype.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Baylor College of Medicine	MCMAHON, AP (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT CELL & DEV BIOL, NUTLEY, NJ 07110 USA.			Bradley, Allan/0000-0002-2349-8839				ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; ALVARADOMALLART RM, 1984, DEV BIOL, V103, P378, DOI 10.1016/0012-1606(84)90326-9; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cowan W.M., 1982, NEURONAL DEV, P377; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GARDNER CA, 1991, DEVELOPMENT, V113, P1037; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; ICHIJO H, 1990, DEVELOPMENT, V110, P331; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; MARTINEZ S, 1990, DEV BIOL, V139, P432, DOI 10.1016/0012-1606(90)90312-7; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; NAKAMURA H, 1990, BRAIN RES, V511, P122, DOI 10.1016/0006-8993(90)90231-Y; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; TAM PPL, 1986, J EMBRYOL EXP MORPH, V92, P269; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	56	518	527	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					581	595		10.1016/0092-8674(92)90222-X	http://dx.doi.org/10.1016/0092-8674(92)90222-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1534034				2022-12-24	WOS:A1992HV08900003
J	HENGARTNER, MO; ELLIS, RE; HORVITZ, HR				HENGARTNER, MO; ELLIS, RE; HORVITZ, HR			CAENORHABDITIS-ELEGANS GENE CED-9 PROTECTS CELLS FROM PROGRAMMED CELL-DEATH	NATURE			English	Article							C-ELEGANS; MOTOR NEURONS; X-CHROMOSOME; NEMATODE; SURVIVAL; MUTANTS; ACTIVATION; LINEAGES	The gene ced-9 of the nematode Caenorhabditis elegans acts to protect cells from programmed cell death. A mutation that abnormally activates ced-9 prevents the cell deaths that occur during normal C. elegans development. Conversely, mutations that inactivate ced-9 cause cells that normally live to undergo programmed cell death; these mutations result in embryonic lethality, indicating that ced-9 function is essential for development. The ced-9 gene functions by negatively regulating the activities of other genes that are required for the process of programmed cell death.			HENGARTNER, MO (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,ROOM 56-629,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRENNER S, 1974, GENETICS, V77, P71; CASSADA R, 1981, DEV BIOL, V84, P193, DOI 10.1016/0012-1606(81)90383-3; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; COHEN JJ, 1984, J IMMUNOL, V132, P38; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS HM, 1991, GENETICS, V129, P79; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, REV CELL BIOL, V7, P663; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GREENWALD IS, 1980, GENETICS, V96, P147; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MENEELY PM, 1979, GENETICS, V92, P99; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; ROSENBLUTH RE, 1981, GENETICS, V99, P415; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE JG, 1986, PHILOS T R SOC LON B, V311, P1; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	40	708	747	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					494	499		10.1038/356494a0	http://dx.doi.org/10.1038/356494a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560823				2022-12-24	WOS:A1992HN23100048
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW APPROVED ORPHAN DRUG TO TREAT PRECOCIOUS PUBERTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545450				2022-12-24	WOS:A1992HK67200005
J	MCGURL, B; PEARCE, G; OROZCOCARDENAS, M; RYAN, CA				MCGURL, B; PEARCE, G; OROZCOCARDENAS, M; RYAN, CA			STRUCTURE, EXPRESSION, AND ANTISENSE INHIBITION OF THE SYSTEMIN PRECURSOR GENE	SCIENCE			English	Article							INDUCED PROTEINASE-INHIBITORS; INDUCED TRYPSIN-INHIBITOR; DEDUCED PRIMARY STRUCTURE; PLANT-LEAVES; ALFALFA LEAVES; TOMATO PLANTS; DEFENSE; RESISTANCE; MECHANISM; INSECTS	A gene that encodes systemin, a mobile 18-amino acid polypeptide inducer of proteinase inhibitor synthesis in tomato and potato leaves, has been isolated from tomato, Lycopersicon esculentum. Induction of proteinase inhibitors in plants is a response to insect or pathogen attacks. The gene has 10 introns and 11 exons, ten of which are organized as five homologous pairs with an unrelated sequence in the eleventh, encoding systemin. Systemin is proteolytically processed from a 200-amino acid precursor protein, prosystemin. Prosystemin messenger RNA was found in all organs of the plant except the roots and was systemically wound-inducible in leaves. Tomato plants transformed with an antisense prosystemin complementary DNA exhibited greatly suppressed systemic wound induction of proteinase Inhibitor I and II synthesis in leaves.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University								BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BRADSTOCK M, 1989, AUST LIT STUD, V14, P51; BROWN WE, 1985, BIOCHEMISTRY-US, V24, P2105, DOI 10.1021/bi00330a002; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; CHESSIN M, 1990, BOT REV, V56, P193, DOI 10.1007/BF02858325; DAVIES E, 1987, PLANT CELL ENVIRON, V10, P623, DOI 10.1111/j.1365-3040.1987.tb01844.x; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DREYER DL, 1987, PLANT CELL ENVIRON, V10, P353; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; JUNG LJ, 1991, SCIENCE, V251, P1130; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MCGURL B, IN PRESS PLANT MOL B; MCGURL B, UNPUB; NARVAEZVASQUEZ J, 1991, THESIS WASHINGTON ST; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, UNPUB; PENACORTES H, 1989, P NATL ACAD SCI USA, V86, P9851, DOI 10.1073/pnas.86.24.9851; ROBY D, 1987, PHYSL MOL PL PATH, V30, P6453; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; RYAN CA, 1978, TRENDS BIOCHEM SCI, V3, P148, DOI 10.1016/S0968-0004(78)90098-1; RYAN CA, 1967, ANAL BIOCHEM, V19, P434, DOI 10.1016/0003-2697(67)90233-3; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; RYAN CA, 1968, PLANT PHYSIOL, V43, P1880, DOI 10.1104/pp.43.11.1880; SAMBROOK J, 1989, MOL CLONING LAB MANU, pCH9; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; THAIN JF, 1990, PLANT CELL ENVIRON, V13, P569, DOI 10.1111/j.1365-3040.1990.tb01074.x; TRAUTMAN R, 1971, IMMUNOCHEMISTRY, V8, P901, DOI 10.1016/0019-2791(71)90429-0	35	312	350	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1570	1573		10.1126/science.1549783	http://dx.doi.org/10.1126/science.1549783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549783				2022-12-24	WOS:A1992HJ80900040
J	OESTERHELD, M; SALA, OE; MCNAUGHTON, SJ				OESTERHELD, M; SALA, OE; MCNAUGHTON, SJ			EFFECT OF ANIMAL HUSBANDRY ON HERBIVORE-CARRYING CAPACITY AT A REGIONAL SCALE	NATURE			English	Article							COMMUNITY STRUCTURE; ECOSYSTEM; RAINFALL; BIOMASS	ALL significant properties of the herbivore trophic level, including biomass, consumption and productivity, are significantly correlated with primary productivity across a broad range of terrestrial ecosystems 1,2. Here we show that livestock biomass in South American agricultural ecosystems across a 25-fold gradient of primary productivity exhibited a relationship with a slope essentially identical to unmanaged ecosystems, but with a substantially greater y-intercept. Therefore the biomass of herbivores supported per unit of primary productivity is about an order of magnitude greater in agricultural than in natural ecosystems, for a given level of primary production. We also present evidence of an increase in livestock body size with primary productivity, a pattern previously characterized in natural ecosystems 3. To our knowledge this is the first quantitative documentation at a regional scale of the impact of animal husbandry practices, such as herding, stock selection and veterinary care, on the biomass and size-structure of livestock herds compared with native herbivores.	SYRACUSE UNIV,BIOL RES LABS,SYRACUSE,NY 13244	Syracuse University	OESTERHELD, M (corresponding author), UNIV BUENOS AIRES,FAC AGRON,DEPT ECOL,AV SAN MARTIN 4453,RA-1417 BUENOS AIRES,ARGENTINA.			Sala, Osvaldo/0000-0003-0142-9450; Oesterheld, Martin/0000-0001-8462-0087				COE MJ, 1976, OECOLOGIA, V22, P341, DOI 10.1007/BF00345312; COUGHENOUR MB, 1985, SCIENCE, V230, P619, DOI 10.1126/science.230.4726.619; Darwin C, 1872, ORIGIN SPECIES; EAST R, 1984, AFR J ECOL, V22, P245, DOI 10.1111/j.1365-2028.1984.tb00700.x; ERRINGTON PL, 1956, SCIENCE, V124, P304, DOI 10.1126/science.124.3216.304; GOLLEY FB, 1961, ECOLOGY, V42, P581, DOI 10.2307/1932247; Lauenroth W. K., 1979, Perspectives in grassland ecology., P3; MCNAUGHTON SJ, 1983, ECOL MONOGR, V53, P291, DOI 10.2307/1942533; MCNAUGHTON SJ, 1984, AM NAT, V124, P863, DOI 10.1086/284321; MCNAUGHTON SJ, 1989, NATURE, V341, P142, DOI 10.1038/341142a0; MCNAUGHTON SJ, 1991, COMPARATIVE ANALYSES OF ECOSYSTEMS, P120; MCNAUGHTON SJ, IN PRESS BIOL RELATI; MILCHUNAS DG, 1988, AM NAT, V132, P87, DOI 10.1086/284839; MOEN J, 1991, NATURE, V353, P510, DOI 10.1038/353510a0; SALA OE, 1986, VEGETATIO, V67, P27; SCARNECCHIA DL, 1990, J RANGE MANAGE, V43, P553, DOI 10.2307/4002363; Sharkey M. J., 1970, Mammalia, V34, P564, DOI 10.1515/mamm.1970.34.4.564; WESTOBY M, 1985, AM NAT, V126, P870, DOI 10.1086/284460; 1987, PRODUCTION YB 1986; 1980, CENSO GENERAL AGROPE; 1974, EMPADRONAMIENTO NACI	21	157	168	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					234	236		10.1038/356234a0	http://dx.doi.org/10.1038/356234a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552941				2022-12-24	WOS:A1992HJ94400055
J	WILLIAMS, TM; FRIEDL, WA; FONG, ML; YAMADA, RM; SEDIVY, P; HAUN, JE				WILLIAMS, TM; FRIEDL, WA; FONG, ML; YAMADA, RM; SEDIVY, P; HAUN, JE			TRAVEL AT LOW ENERGETIC COST BY SWIMMING AND WAVE-RIDING BOTTLE-NOSED DOLPHINS	NATURE			English	Article							LOCOMOTION	OVER the past 50 years there has been much speculation about the energetic cost of swimming and wave-riding by dolphins 1-11. When aligned properly in front of the bow of moving ships 1-3, in the stern wake of small boats 4,5, on wind waves 6, and even in the wake of larger cetaceans 7-9, the animals appear to move effortlessly through the water without the benefit of propulsive strokes by the flukes. Theoretically, body streamlining as well as other anatomical and behavioural adaptations contribute to low transport costs in these animals. The economy of movement permitted by wave-riding has been perceived as an energetic advantage for the swimming dolphin 2,310, but has been hard to prove in the absence of physiological data for exercising cetaceans. Here we determine the aerobic and anaerobic costs of swimming and wave-riding in bottlenose dolphins and find that the minimum cost of transport for swimming dolphins is 1.29 +/- 0.05 J kg-1 m-1 at a cruising speed of 2.1 m s-1. Aerobic costs are nearly twice as high for swimming 12. seals and sea lions, and 8-12 times higher for human swimmers Wave-riding by dolphins provides additional benefits in terms of speed. The results indicate that behavioural, physiological and morphological factors make swimming an economical form of high-speed travel for dolphins.			WILLIAMS, TM (corresponding author), USN,CTR OCEANS SYST,HAWAII LAB,POB 997,CODE 511,KAILUA,HI 96734, USA.							Aleyev Y.G, 1977, NEKTON; AU D, 1980, NATURE, V284, P548, DOI 10.1038/284548a0; BARTHOLOMEW G. A., 1977, ANIMAL PHYSL PRINCIP, P57; BLAKE RW, 1983, J MAR BIOL ASSOC UK, V63, P61, DOI 10.1017/S0025315400049808; BRETT JR, 1964, J FISH RES BOARD CAN, V21, P1183, DOI 10.1139/f64-103; Fedak M.A., 1986, DIVING ANIMALS MAN, P11; Goforth H.W. Jr, 1990, P559; Gray J, 1936, J EXP BIOL, V13, P192; Hertel H., 1969, P31; HOMER I, 1972, J APPL PHYSIOL, V33, P502; LANG TG, 1966, SCIENCE, V152, P531, DOI 10.1126/science.152.3721.531; LANG TG, 1966, WHALES DOLPHINS PORP, P410; MCBRIDE AF, 1951, J MAMMAL, V32, P251, DOI 10.2307/1375657; NORRIS KENNETH S., 1961, UNIV CALIFORNIA PUBL ZOOL, V63, P291; PONGANIS PJ, 1990, J COMP PHYSIOL B, V160, P473; Ridgway S.H., 1972, P590; RIDGWAY SH, 1969, SCIENCE, V166, P1651, DOI 10.1126/science.166.3913.1651; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; SCHOLANDER PF, 1959, SCIENCE, V129, P1085, DOI 10.1126/science.129.3356.1085; SHANE SH, 1986, MAR MAMMAL SCI, V2, P34, DOI 10.1111/j.1748-7692.1986.tb00026.x; WILLIAMS T L, 1991, Journal of the Marine Biological Association of the United Kingdom, V71, P727; WILLIAMS TM, 1991, J COMP PHYSIOL B, V160, P637, DOI 10.1007/BF00571261; WILLIAMS TM, 1989, J COMP PHYSIOL A, V164, P815, DOI 10.1007/BF00616753; WILLIAMS TM, 1985, PHYSIOL ZOOL, V58, P576, DOI 10.1086/physzool.58.5.30158584; WOODCOCK AH, 1951, J EXP BIOL, V28, P215; WURSIG B, 1979, FISH B-NOAA, V77, P399; Zar JH, 1974, BIOSTATISTICAL ANAL	27	118	124	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					821	823		10.1038/355821a0	http://dx.doi.org/10.1038/355821a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538760				2022-12-24	WOS:A1992HF63600054
J	KROLL, DM; GOMPPER, G				KROLL, DM; GOMPPER, G			THE CONFORMATION OF FLUID MEMBRANES - MONTE-CARLO SIMULATIONS	SCIENCE			English	Article							TRIANGULATED RANDOM SURFACES; SELF-AVOIDING SURFACES; THERMAL FLUCTUATIONS; ELASTICITY; DIMENSIONS; CURVATURE; TENSION; MODEL	The conformation and scaling properties of self-avoiding fluid membranes with an extrinsic bending rigidity-kappa were studied with the use of Monte Carlo methods. For kappa = 0, the results are consistent with branched polymer behavior at large length scales. There is a smooth crossover from a crumpled to an extended state with increasing kappa, with a peak in the specific heat when the persistence length reaches the system size. The scale-dependent effective bending rigidity is a decreasing function of system size for all bare rigidities. These results indicate that fluid membranes are always crumpled at sufficiently long length scales.	FORSCHUNGSZENTRUM JULICH, INST FESTKORPERFORSCH, W-5170 JULICH 1, GERMANY; UNIV MUNICH, SEKT PHYS, W-8000 MUNICH, GERMANY	Helmholtz Association; Research Center Julich; University of Munich	KROLL, DM (corresponding author), UNIV MINNESOTA, AHPCRC, MINNEAPOLIS, MN 55455 USA.		Gompper, Gerhard/I-4886-2012	Gompper, Gerhard/0000-0002-8904-0986				AMBJORN J, 1985, NUCL PHYS B, V257, P433, DOI 10.1016/0550-3213(85)90356-6; AMBJORN J, 1986, NUCL PHYS B, V275, P161, DOI 10.1016/0550-3213(86)90594-8; BAILLIE CF, 1990, NUCL PHYS B, V335, P469, DOI 10.1016/0550-3213(90)90504-7; BAUMGARTNER A, 1990, PHYS REV A, V41, P5747, DOI 10.1103/PhysRevA.41.5747; BILLOIRE A, 1986, NUCL PHYS B, V275, P617, DOI 10.1016/0550-3213(86)90577-8; BOULATOV DV, 1986, NUCL PHYS B, V275, P641, DOI 10.1016/0550-3213(86)90578-X; BROCHARD F, 1975, J PHYS-PARIS, V36, P1035, DOI 10.1051/jphys:0197500360110103500; CATES ME, 1985, PHYS LETT B, V161, P363, DOI 10.1016/0370-2693(85)90779-8; DAVID F, 1991, J PHYS II, V1, P959, DOI 10.1051/jp2:1991120; DEGENNES PG, 1982, J PHYS CHEM-US, V86, P2294, DOI 10.1021/j100210a011; DIMIGLIO JM, 1985, PHYS REV LETT, V54, P1686; DUWE HP, 1990, J PHYS-PARIS, V51, P945, DOI 10.1051/jphys:019900051010094500; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; FORSTER D, 1986, PHYS LETT A, V114, P115, DOI 10.1016/0375-9601(86)90536-0; FORSTER D, 1986, PHYS LETT A, V116, P57; FUJIKAWA K, 1983, NUCL PHYS B, V226, P437, DOI 10.1016/0550-3213(83)90202-X; GLAUS U, 1988, J STAT PHYS, V50, P1141, DOI 10.1007/BF01019158; GLAUS U, 1986, PHYS REV LETT, V56, P1996, DOI 10.1103/PhysRevLett.56.1996; GOMPPER G, 1991, J PHYS I, V1, P1411, DOI 10.1051/jp1:1991211; HO JS, 1990, EUROPHYS LETT, V12, P295, DOI 10.1209/0295-5075/12/4/002; Itzykson C, 1986, P GIFT SEMINAR JACA, V85, P130; KLEINERT H, 1986, PHYS LETT A, V114, P263, DOI 10.1016/0375-9601(86)90219-7; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; MUTZ M, 1990, J PHYS-PARIS, V51, P991, DOI 10.1051/jphys:019900051010099100; NELSON DR, 1989, STATISTICAL MECHANIC; PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690; SEUNG HS, 1988, PHYS REV A, V38, P1005, DOI 10.1103/PhysRevA.38.1005	27	104	104	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					968	971		10.1126/science.1546294	http://dx.doi.org/10.1126/science.1546294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546294				2022-12-24	WOS:A1992HE60500035
